UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 20-F

(Mark One)

[X] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

[   ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended _________________________________________________________

OR

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______

OR

[   ] SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

Commission file number

TRILLIUM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)

Province of Ontario, Canada
(Jurisdiction of Incorporation or Organization)

96 Skyway Avenue, Toronto, Ontario M9W 4Y9, Canada
(Address of Principal Executive Offices)

James Parsons
Chief Financial Officer
96 Skyway Avenue
Toronto, Ontario, Canada M9W 4Y9
Telephone: (416) 595-0627
Email: james@trilliumtherapeutics.com
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class Name of each exchange on which registered
Common Shares, no par value NASDAQ Stock Market LLC
Rights to Purchase Common Shares NASDAQ Stock Market LLC
   

Securities registered or to be registered pursuant to section 12(g) of the Act: None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None .

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common shares as of the close of the period covered by the annual report. Not Applicable.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes [   ]      No [X]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [   ]      No [X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes [   ]      No [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [   ] Accelerated filer [   ] Non-accelerated filer [X]

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP [   ] International Financial Reporting Standards as issued Other [   ]
  by the International Accounting Standards Board [X]  

If “Other” has been checked in response to previous question, indicate by check mark which financial statement item the registrant has elected to follow.
Item 17 [   ]      Item 18 [   ]

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes [   ]      No [   ]


TABLE OF CONTENTS

Introduction   1
     
Currency Translation   1
     
Forward-Looking Statements   1
     
Item 1. Identity of Directors, Senior Management and Advisers 4
     
Item 2. Offer Statistics and Expected Timetable 5
     
Item 3. Key Information 5
     
Item 4. Information on the Company 23
     
Item 4A. Unresolved Staff Comments 36
     
Item 5. Operating and Financial Review and Prospects 36
     
Item 6. Directors, Senior Management & Employees 45
     
Item 7. Major Shareholders and Related Party Transactions 61
     
Item 8. Financial Information 62
     
Item 9. The Offer and Listing 64
     
Item 10. Additional Information 66
     
Item 11. Quantitative & Qualitative Disclosures About Market Risk 92
     
Item 12. Description of Securities Other Than Equity Securities 94
     
PART II   95
     
Item 13. Defaults, Dividend Arrearages and Delinquencies 95
     
Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds. 95
     
Item 15. Control and Procedures 95
     
Item 16A. Audit Committee Financial Expert 95
     
Item 16B. Code of Ethics 95
     
Item 16C. Principal Accountant Fees and Services 95
     
Item 16D. Exemptions from the Listing Standards for Audit Committees 95
     
Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 95



Item 16F. Change in Registrant’s Certifying Accountant 95
     
Item 16G. Corporate Governance 95
     
Item 16H. Mine Safety Disclosure 96
     
PART III   97
     
Item 17. Financial Statements 97
     
Item 18. Financial Statements 97
     
Item 19. Exhibits 98


INTRODUCTION

All references in this Form 20-F to “the Company”, “Trillium”, “we”, “us”, or “our” refer to Trillium Therapeutics Inc. and the subsidiaries through which it conducts its business, unless otherwise indicated.

CURRENCY TRANSLATION

Unless otherwise indicated, all references to “dollars” or the use of the symbol “$” are to Canadian dollars, and all references to “U.S. dollars” or “US$” are to United States dollars. See “Exchange Rate Data” under Item 1 for relevant information about the rates of exchange between Canadian dollars and United States dollars.

FORWARD-LOOKING STATEMENTS

This registration statement contains forward-looking statements within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate”, “believe”, “expect”, “estimate”, “may”, “will”, “could”, “leading”, “intend”, “contemplate”, “shall” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements in this registration statement include, but are not limited to, statements with respect to:

1


All forward-looking statements are based on our beliefs and assumptions based on information available at the time the assumption was made. These forward-looking statements are not based on historical facts but rather on management’s expectations regarding future activities, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections or other forward-looking statements will not occur. Factors which could cause future outcomes to differ materially from those set forth in the forward-looking statements include, but are not limited to:

all as further and more fully described under the heading “Item 3.D. Risk Factors”.

2


Although the forward looking statements contained in this registration statement are based upon what our management believes to be reasonable assumptions, we cannot assure readers that actual results will be consistent with these forward looking statements. We undertake no obligation to update any forward looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events, except as may be required by securities legislation.

Any forward-looking statements represent our estimates only as of the date of this registration statement and should not be relied upon as representing our estimates as of any subsequent date.

3


PART I

ITEM 1.                     IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

A. Directors and Senior Management.

The name, office and function of our directors and senior management are set forth in the following table.

Name and Office
Function
Calvin Stiller
Director, Chair of the
Board

As an independent director, Dr. Stiller supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Luke Beshar
Director

As an independent director, Mr. Beshar supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Henry Friesen
Director

As an independent director, Dr. Friesen supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Robert Kirkman
Director

As an independent director, Dr. Kirkman supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Michael Moore
Director

As an independent director, Dr. Moore supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Thomas Reynolds
Director

As an independent director, Dr. Reynolds supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Niclas Stiernholm
President & Chief
Executive Officer, Director

As President & Chief Executive Officer, Dr. Stiernholm is responsible for overseeing our strategic direction, executing business development plans and ensuring that our scientific programs remain funded and advance on schedule. As a director, Dr. Stiernholm participates in management oversight and helps to ensure compliance with our corporate governance policies and standards.

Robert Uger
Chief Scientific Officer

As Chief Scientific Officer, Dr. Uger is responsible for developing and implementing our scientific direction, and oversees both internal product development and external research and development programs.

James Parsons
Chief Financial Officer

As Chief Financial Officer, Mr. Parsons is responsible for financial and risk management, investor relations, corporate governance and administration.

Penka Petrova
Vice President, Drug
Development

As Vice President, Drug Development, Dr. Petrova is responsible for managing our formal drug development efforts, including all outsourced activities to contract manufacturers and contract research organizations.

The business address for our directors and senior management is Trillium Therapeutics Inc., 96 Skyway Avenue, Toronto, Ontario, Canada, M9W 4Y9.

B. Advisers.

Our legal advisers are Borden Ladner Gervais LLP with a business address at Scotia Plaza, 40 King Street West, Toronto, Ontario, Canada, M5H 3Y4 and Dorsey & Whitney LLP with a business address at Suite 1605 – 777 Dunsmuir Street, Vancouver, British Columbia, Canada V7Y 1K4.

4


C. Auditors.

Our auditors Ernst & Young LLP are independent registered chartered accountants. The address for Ernst & Young LLP is Ernst & Young Tower, 222 Bay Street, Toronto, Ontario, Canada, M5K 1J7. Ernst & Young LLP have been our auditors since our inception on March 31, 2004.

ITEM 2.                     OFFER STATISTICS AND EXPECTED TIMETABLE

Not Applicable

ITEM 3.                     KEY INFORMATION

A. Selected Financial Data

The following tables summarize selected financial data as at and for the six months ended June 30, 2014 and 2013, and for the fiscal years ended December 31, 2013, 2012, 2011, and 2010 prepared in accordance with International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standards Board (“ IASB ”). The financial information in the tables below as at December 31, 2013, 2012 and 2011 and for the years then ended has been derived from our audited consolidated financial statements and related notes included in this Form 20-F. The financial information in the tables below as at December 31, 2010 and for the year then ended has been derived from our audited consolidated financial statements and related notes for that year. The financial information in the tables below as at June 30, 2014 and for the six months ended June 30, 2014 and 2013 has been derived from our unaudited interim condensed consolidated financial statements included in this Form 20-F.

The selected financial data below should be read in conjunction with the financial statements included in this registration statement beginning on page F-1 and with the information appearing in “Item 5. Operating and Financial Review and Prospects”. Our historical results do not necessarily indicate results expected for any future period.


Consolidated statement of
loss and comprehensive
loss data
Six months
ended
June 30,
2014
Six months
ended
June 30,
2013
Year
ended
December
31, 2013
Year
ended
December
31, 2012
Year
ended
December
31, 2011
Year
ended
December
31, 2010
Net sales - - - - - -
Net loss and comprehensive loss $6,140,431 $1,712,265 $4,289,308 $1,061,502 $3,173,947 $4,305,867
Loss from continuing operations per share $0.05 $0.06 $0.11 $0.06 $0.17 $0.27
Net loss per common share $0.05 $0.06 $0.11 $0.06 $0.17 $0.27
Fully diluted net loss per common share $0.05 $0.06 $0.11 $0.06 $0.17 $0.27

5




Consolidated statement of
financial position data

As at June
30, 2014
As at
December
31, 2013
As at
December
31, 2012
As at
December
31, 2011
As at
December
31, 2010
Total assets $31,981,662 $35,087,386 $1,567,728 $2,763,580 $3,904,256
Net assets $30,420,985 $33,908,447 $1,382,470 $2,409,466 $3,568,240
Capital stock - common $48,579,360 $47,191,303 $31,388,959 $31,388,959 $30,212,225
Number of common shares outstanding 126,427,031 121,752,380 18,661,936 18,661,936 16,833,754
Capital stock - preferred $11,002,583 $11,292,525 - - -
Number of preferred shares outstanding 75,895,165 77,895,165 - - -
Dividends declared per share - - - - -

Exchange Rate Data

The following table sets forth, for each period indicated, the high, low and average exchange rates for Canadian dollars expressed in United States dollars, provided by the Bank of Canada. The exchange rates set forth below demonstrate trends in exchange rates, but the actual exchange rates used throughout this registration statement may vary. The average exchange rate is calculated by using the average of the closing prices on the last day of each month during the relevant period. On August 11, 2014, the noon exchange rate for 1 Canadian dollar expressed in United States dollars as reported by the Bank of Canada, was Cdn$1.00 = US$0.9145.

$1 Canadian dollar equivalent in U.S. dollars High (1) Low (1) Average
Year ended December 31, 2009 0.9755 0.7653 0.8798
Year ended December 31, 2010 1.0069 0.9218 0.9657
Year ended December 31, 2011 1.0630 0.9383 1.0217
Year ended December 31, 2012 1.0371 0.9576 1.0010
Year ended December 31, 2013 1.0188 0.9314 0.9662
Six months ended June 30, 2014 0.9444 0.8866 0.9239
February 2014 0.9141 0.8932  
March 2014 0.9128 0.8866  
April 2014 0.9210 0.9046  
May 2014 0.9247 0.9085  
June 2014 0.9393 0.9122  
July 2014 0.9416 0. 9149  
August 2014 (through August 11) 0.9187 0.9103  

Notes:

  (1)

The high and low exchange rates are intra-day values rather than noon or closing rates.

B. Capitalization and Indebtedness

The table below sets forth our total indebtedness and shows our capitalization as at June 30, 2014. You should read this table in conjunction with our consolidated financial statements included in this Form 20-F, together with the accompanying notes and the other information appearing under the heading “Item 5. Operating and Financial Review and Prospects”.

6



  As at June 30, 2014
Liabilities  
Accounts payable and accrued liabilities $1,012,226
Other current liabilities (1) $120,452
         Total current liabilities $1,132,678
   
Loan payable (2) $311,565
Long-term liability (3) $116,434
         Total non-current liabilities $427,999
   
Equity  
Common shares (4) $48,579,360
Preferred shares (4) $11,002,583
Warrants (4) $9,283,332
Contributed surplus (5)(6) $5,370,357
Deficit $(43,814,647)
   
Total equity $30,420,985

Notes:

  (1)

The current portions of the Loan payable and Long-term liability are included in Other current liabilities.

     
  (2)

We are indebted under a contribution agreement with the Federal Economic Development Agency for Southern Ontario (“ FedDev ”). The period of contribution ended on December 31, 2013. As at June 30, 2014, we have repayable contributions of $575,139 representing the outstanding principal balance, repayable in equal monthly installments for 60 months beginning on December 1, 2014. The loan payable bears no interest. On acquisition of the private company Trillium Therapeutics Inc. (“ Trillium Privateco ”) in April 2013, the fair value of the loan payable was determined by discounting the loan payable using an estimated market interest rate of 15%. Interest expense accretes on the discounted loan amount until it reaches its face value at maturity.

     
  (3)

We have a long-term liability of $169,784 related to certain discontinued technologies. This liability has been discounted using an estimated market interest rate of 15% and interest expense is accreting.

     
  (4)

As at June 30, 2014, 126,427,031 common shares, 75,895,165 Series I First Preferred shares, and 138,724,781 common share purchase warrants were outstanding.

     
  (5)

As at June 30, 2014, there were 17,727,275 stock options outstanding. Share-based compensation expense recognized as stock options vest is recorded in contributed surplus.

     
  (6)

As at June 30, 2014, there were 863,310 deferred share units (“ DSUs ”) issued. Share-based compensation expense recorded on the issuance of DSUs is recorded in contributed surplus.

C. Reasons for the Offer and Use of Proceeds

Not Applicable.

D. Risk Factors

An investment in our common shares involves a high degree of risk and should be considered speculative. An investment in our common shares should only be undertaken by those persons who can afford the total loss of their investment. You should carefully consider the risks and uncertainties described below, as well as other information contained in this Form 20-F. The risks and uncertainties below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business. If any of the following risks occur, our business, financial condition and results of operations could be seriously harmed and you could lose all or part of your investment. Further, if we fail to meet the expectations of the public market in any given period, the market price of our common shares could decline. We operate in a highly competitive environment that involves significant risks and uncertainties, some of which are outside of our control.

7


Risks Related to our Business and our Industry

We expect to incur future losses and we may never become profitable.

We have incurred losses of $4.3 million, $1.1 million and $3.2 million during 2013, 2012 and 2011, respectively, and expect to incur an operating loss in 2014. We have an accumulated deficit since inception through June 30, 2014 of over $43 million. We believe that operating losses will continue in and beyond 2014 because we are planning to incur significant costs associated with the preclinical and clinical development of SIRPaFc. Our net losses have had and will continue to have an adverse effect on, among other things, our shareholders' equity, total assets and working capital. We expect that losses will fluctuate from quarter to quarter and year to year, and that such fluctuations may be substantial. We cannot predict when we will become profitable, if at all.

We currently have no product revenue and will not be able to maintain our operations and research and development without additional funding.

To date, we have generated no product revenue and cannot predict when and if we will generate product revenue. Our ability to generate product revenue and ultimately become profitable depends upon our ability, alone or with partners, to successfully commercialize products, including any of our current product candidates, or other product candidates that we may develop, in-license or acquire in the future. We do not anticipate generating revenue from the sale of products for the foreseeable future. We expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates into clinical trials. We will also require significant additional funds if we expand the scope of our current clinical plans for the SIRPaFc program or if we were to acquire any new assets and advance those towards clinical testing.

We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates.

As a research and development company, our operations have consumed substantial amounts of cash since inception. We expect to spend substantial funds to continue the research, development and testing of our products that are in the preclinical and clinical testing stages of development, and to prepare to commercialize products in anticipation of U.S. Food and Drug Administration (“ FDA ”) approval in the U.S. and similar approvals in other jurisdictions. Therefore, for the foreseeable future, we will have to fund all of our operations and development expenditures from cash on hand, equity or debt financings, through collaborations with other biotechnology or pharmaceutical companies or through financings from other sources. Additional financing will be required to meet our long term liquidity needs. If we do not succeed in raising additional funds on acceptable terms, we might not be able to complete planned preclinical and clinical trials or obtain approval of any product candidates from the FDA and other regulatory authorities. It is possible that future financing will not be available or, if available, may not be on favorable terms. The availability of financing will be affected by the achievement of our corporate goals, the results of scientific and clinical research, the ability to obtain regulatory approvals, the state of the capital markets generally and with particular reference to drug development companies, the status of strategic alliance agreements and other relevant commercial considerations. If adequate funding is not available, we may be required to delay, reduce or eliminate one or more of our product development programs, or obtain funds through corporate partners or others who may require us to relinquish

8


significant rights to product candidates or obtain funds on less favorable terms than we would otherwise accept. To the extent that external sources of capital become limited or unavailable or available on onerous terms, our intangible assets and our ability to continue our clinical development plans may become impaired, and our assets, liabilities, business, financial condition and results of operations may be materially or adversely affected.

Our prospects depend on the success of our product candidates which are at early stages of development, and we may not generate revenue for several years, if at all, from these products.

Given the early stage of our product development, we can make no assurance that our research and development programs related to SIRPaFc, CD200 or others will gain regulatory approval or result in commercially viable products. To achieve profitable operations, we, alone or with others, must successfully develop, gain regulatory approval and market our future products. We currently have no products that have been approved by the FDA, Health Canada (“ HC ”) or any similar regulatory authority. To obtain regulatory approvals for our product candidates being developed and to achieve commercial success, clinical trials must demonstrate that the product candidates are safe for human use and that they demonstrate efficacy. While SIRPaFc has entered formal Investigational New Drug (“ IND ”) enabling studies, we have not yet completed manufacturing, initiated formal toxicology studies, a phase I clinical study or subsequent required clinical trials. Our CD200 program is ready to enter formal preclinical studies, but we have yet to initiate these and under current circumstances are not contemplating doing so without a development partner to share in the cost and responsibility of the program.

Many product candidates never reach the stage of clinical testing and even those that do have only a small chance of successfully completing clinical development and gaining regulatory approval. Product candidates may fail for a number of reasons, including being unsafe for human use or due to the failure to provide therapeutic benefits equal to or better than the standard of treatment at the time of testing. Unsatisfactory results obtained from a particular study relating to a research and development program may cause us or our collaborators to abandon commitments to that program. Positive results of early preclinical research may not be indicative of the results that will be obtained in later stages of preclinical or clinical research. We can make no assurance that any future studies, if undertaken, will yield favorable results.

The early stage of our product development makes it particularly uncertain whether any of our product development efforts will prove to be effective, meet applicable regulatory standards, receive the requisite regulatory approvals, be capable of being manufactured at a reasonable cost or successfully marketed. If successful in developing our current and future product candidates into approved products, we will still experience many potential obstacles such as the need to develop or obtain manufacturing, marketing and distribution capabilities. If we are unable to successfully commercialize any of our products, our financial condition and results of operations may be materially and adversely affected.

We rely on third parties to plan, conduct and monitor our preclinical and clinical studies, and their failure to perform as required would interfere with our product development.

We rely on third parties to conduct a significant portion of our preclinical and clinical development activities. Preclinical activities include in vivo studies providing access to specific disease models, pharmacology and toxicology studies, and assay development. Clinical development activities include trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. If there is any dispute or disruption in our relationship with third parties, of if they are unable to provide quality services in a timely manner and at a feasible cost, our active development programs will face delays. Further, if any of these third parties fails to perform as we expect or if their work fails to meet regulatory standards, our testing could be delayed, cancelled or rendered ineffective.

9


We rely on contract manufacturers over whom we have limited control. If we are subject to quality, cost or delivery issues with the preclinical and clinical grade materials supplied by contract manufacturers, our business operations could suffer significant harm.

We have limited manufacturing experience and rely on contract manufacturing organizations (“ CMOs ”), to manufacture our product candidates for larger preclinical and clinical studies. We produce small quantities of our product candidates at bench scale in our laboratory facilities for use in smaller studies. We rely on CMOs for manufacturing, filling, packaging, storage and shipping of drug product in compliance with current Good Manufacturing Practice (“cGMP”) regulations applicable to our products.

We have contracted with Catalent Pharma Solutions (“ Catalent ”) for the manufacture of the SIRPaFc protein needed for our pre-IND toxicology and pharmacology studies and to supply drug for our phase I clinical trial. The manufacture of recombinant proteins uses well established processes including a protein expression system. Catalent is producing SIRPaFc using their proprietary GPEx® expression system which, according to Catalent, has been used to produce more than 100 product candidates for phase I and II clinical trials. According to Catalent, there are three commercial products manufactured using this expression system, although none in North America. We believe that Catalent has the capacity, the systems and the experience to supply SIRPaFc for our planned phase I clinical trial and they may be considered for manufacturing for later clinical trials. Since the Catalent manufacturing facility where SIRPaFc is being produced was only recently established it has not been inspected by the FDA. Any manufacturing failures or delays or compliance issues could cause delays in the completion of our preclinical studies of SIRPaFc, and delays in the submission or approval of our IND and the initiation of our phase I trial.

There can be no assurances that CMOs will be able to meet our timetable and requirements. We have not contracted with alternate suppliers in the event Catalent is unable to scale production, or if we otherwise experience any other significant problems with them. If we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner, we may be delayed in the development of our product candidates. Further, contract manufacturers must operate in compliance with cGMP and failure to do so could result in, among other things, the disruption of product supplies. Our dependence upon third parties for the manufacture of our products may adversely affect our profit margins and our ability to develop and deliver products on a timely and competitive basis.

If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials in humans to demonstrate the safety and efficacy of the product candidates. Clinical testing is expensive and difficult to design and implement, can take many years to complete and has uncertain outcomes. The outcome of preclinical studies and early clinical trials may not predict the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. We do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of our product candidates as approved products in any jurisdiction. A product candidate may fail for safety or efficacy reasons at any stage of the testing process. A major risk we face is the possibility that none of our product candidates under development will successfully complete the testing process to final approval for marketing and sale, resulting in us being unable to derive any commercial revenue from them after investing significant amounts of capital in multiple stages of preclinical and clinical testing.

10


If we experience delays in clinical testing, we will be delayed in commercializing our product candidates, our costs may increase and our business may be harmed.

We cannot predict whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Our product development costs will increase if we experience delays in clinical testing. Significant clinical trial delays could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before us, which would impair our ability to successfully commercialize our product candidates and may harm our financial condition, results of operations and prospects. The commencement and completion of clinical studies for our products, including our planned SIRPaFc phase I clinical trial, may be delayed for a number of reasons, including delays related, but not limited to:

  • failure by regulatory authorities to grant permission to proceed or placing the clinical study on hold;
  • patients failing to enroll or remain in our trials at the rate we expect;
  • suspension or termination of clinical trials by regulators for many reasons, including concerns about patient safety or failure of our contract manufacturers to comply with cGMP requirements;
  • any changes to our manufacturing process that may be necessary or desired;
  • delays or failure to obtain clinical supply from contract manufacturers of our products necessary to conduct clinical trials;
  • product candidates demonstrating a lack of efficacy during clinical trials;
  • patients choosing an alternative treatment for the indications for which we are developing any of our products or participating in competing clinical studies;
  • patients failing to complete clinical trials due to dissatisfaction with the treatment, side effects or other reasons;
  • reports of clinical testing on similar technologies and products raising safety and/or efficacy concerns;
  • competing clinical trials and scheduling conflicts with participating clinicians;
  • clinical investigators not performing our clinical trials on their anticipated schedule, dropping out of a trial, or employing methods not consistent with the clinical trial protocol, regulatory requirements or other third parties not performing data collection and analysis in a timely or accurate manner;

11


  • failure of our contract research organizations (“ CROs ”) to satisfy their contractual duties or meet expected deadlines;
  • inspections of clinical study sites by regulatory authorities or Institutional Review Boards (“ IRBs ”) finding regulatory violations that require us to undertake corrective action, resulting in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study;
  • one or more IRBs rejecting, suspending or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; and
  • reaching agreement on acceptable terms with prospective clinical trial sites.

Our product development costs will increase if we experience delays in testing or approval or if we need to perform more or larger clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to regulatory authorities or IRBs for re-examination, which may impact the cost, timing or successful completion of that study. Delays or increased product development costs may have a material adverse effect on our business, financial condition and prospects.

If we have difficulty enrolling patients in clinical trials, the completion of the trials may be delayed or cancelled.

As our product candidates advance from preclinical testing to clinical testing, and then through progressively larger and more complex clinical trials, we will need to enroll an increasing number of patients that meet our eligibility criteria. There is significant competition for recruiting cancer patients in clinical trials, and we may be unable to enroll the patients we need to complete clinical trials on a timely basis or at all. The factors that affect our ability to enroll patients are largely uncontrollable and include, but are not limited to, the following:

  • size and nature of the patient population;
  • eligibility and exclusion criteria for the study;
  • design of the study protocol;
  • competition with other companies for clinical sites or patients;
  • the perceived risks and benefits of the therapy under study;
  • the patient referral practices of physicians; and
  • the number, availability and accessibility of clinical trial sites.

If we are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience significant delays in doing so, we may not achieve marketing approval or realize the full commercial potential of our therapeutic product candidates.

We plan to develop companion diagnostics for our therapeutic product candidates. We expect that, at least in some cases, regulatory authorities may require the development and regulatory approval of a companion diagnostic as a condition to approving our therapeutic product candidates. We have limited experience and capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. We do not currently have any agreement in place with any third party to develop or commercialize companion diagnostics for any of our therapeutic product candidates.

12


Companion diagnostics are subject to regulation by the FDA, HC and comparable foreign regulatory authorities as medical devices and may require separate regulatory approval prior to commercialization. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience delays in doing so:

  • the development of our therapeutic product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials;

  • our therapeutic product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and

  • and we may not realize the full commercial potential of any therapeutic product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with cancers that are most likely to respond to treatment with our therapeutic products.

If any of these events were to occur, our business would be harmed, possibly materially.

Regulatory approval processes are lengthy, expensive and inherently unpredictable. Our inability to obtain regulatory approval for our product candidates would substantially harm our business.

Our development and commercialization activities and product candidates are significantly regulated by a number of governmental entities, including the FDA, HC and by comparable authorities in other countries. Regulatory approvals are required prior to each clinical trial and we may fail to obtain the necessary approvals to commence or continue clinical testing. We must comply with regulations concerning the manufacture, testing, safety, effectiveness, labeling, documentation, advertising and sale of products and product candidates and ultimately must obtain regulatory approval in all of these areas before we can commercialize the product candidate. The time required to obtain approval by such regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials. Any analysis we perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any future product candidates will ever obtain regulatory approval.

We could fail to receive regulatory approval for our product candidates for many reasons, including, but not limited to:

  • disagreement with the design or implementation of our clinical trials;

  • failure to demonstrate that a product candidate is safe and effective for its proposed indication;

  • failure of clinical trials to meet the level of statistical significance required for approval;

  • failure to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

  • disagreement with our interpretation of data from preclinical studies or clinical trials;

13


  • the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a Biologics License Application (“ BLA ”) or other submission or to obtain regulatory approval;

  • failure to obtain approval of the manufacturing processes or facilities of CMOs with whom we contract for clinical and commercial supplies; or

  • or changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.

A regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate.

We face competition from other biotechnology and pharmaceutical companies and our financial condition and operations will suffer if we fail to effectively compete.

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our competitors include large, well-established pharmaceutical companies, biotechnology companies, and academic and research institutions developing cancer therapeutics for the same indications we are targeting and competitors with existing marketed therapies. Many other companies are developing or commercializing therapies to treat the same diseases or indications for which our product candidates may be useful. Although there are no approved therapies that specifically target the CD47 pathway, some competitors use therapeutic approaches that may compete directly with our product candidates. For example, SIRPaFc is in direct competition with CD47 blocking antibodies from Stanford University, Celgene Corporation and Novimmune SA. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer.

Many of our competitors have substantially greater financial, technical and human resources than we do and have significantly greater experience than us in conducting preclinical testing and human clinical trials of product candidates, scaling up manufacturing operations and obtaining regulatory approvals of products and manufacturing facilities. Accordingly, our competitors may succeed in obtaining regulatory approval for products more rapidly than we do. Our ability to compete successfully will largely depend on:

  • the efficacy and safety profile of our product candidates relative to marketed products and other product candidates in development;

  • our ability to develop and maintain a competitive position in the product categories and technologies on which we focus;

  • the time it takes for our product candidates to complete clinical development and receive marketing approval;

14


  • our ability to obtain required regulatory approvals;

  • our ability to commercialize any of our product candidates that receive regulatory approval;

  • our ability to establish, maintain and protect intellectual property rights related to our product candidates; and

  • acceptance of any of our product candidates that receive regulatory approval by physicians and other healthcare providers and payers.

We heavily rely on the capabilities and experience of our key executives and scientists and the loss of any of them could affect our ability to develop our products.

The loss of Dr. Niclas Stiernholm, our President and Chief Executive Officer, or other key members of our staff, including Dr. Robert Uger, our Chief Scientific Officer, James Parsons, our Chief Financial Officer, or Dr. Penka Petrova, our Vice President, Drug Development, could harm us. We have employment agreements with Drs. Stiernholm, Uger and Petrova and Mr. Parsons although this does not guarantee their retention. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside commitments that may limit their availability to us. In addition, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled scientific, managerial, medical, clinical and regulatory personnel, particularly as we expand our activities and seek regulatory approvals for clinical trials. We routinely enter into consulting agreements with our scientific and clinical collaborators and advisors, key opinion leaders and academic partners in the ordinary course of our business. We also enter into contractual agreements with physicians and institutions who recruit patients into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for these types of personnel from other companies, research and academic institutions, government entities and other organizations. We cannot predict our success in hiring or retaining the personnel we require for continued growth. The loss of the services of any of our executive officers or other key personnel could potentially harm our business, operating results or financial condition.

We may expand our business through the acquisition of companies or businesses or by entering into collaborations or by in-licensing product candidates that could disrupt our business and harm our financial condition.

We have in the past and may in the future seek to expand our pipeline and capabilities by acquiring one or more companies or businesses, entering into collaborations or in-licensing one or more product candidates. For example, in April 2013 we acquired Trillium Privateco to acquire novel cancer therapeutics, an experienced scientific management team and internal development capabilities. In April 2013, we also in-licensed tigecycline which was subsequently returned to the University Health Network (“ UHN ”) in 2014. Acquisitions, collaborations and in-licenses involve numerous risks, including:

  • substantial cash expenditures;

  • technology development risks;

  • potentially dilutive issuances of equity securities;

15


  • incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition;

  • difficulties in assimilating the operations of the acquired companies;

  • potential disputes regarding contingent consideration;

  • diverting our management’s attention away from other business concerns;

  • entering markets in which we have limited or no direct experience; and

  • potential loss of our key employees or key employees of the acquired companies or businesses.

We have experience in making acquisitions, entering collaborations and in-licensing product candidates, however, we cannot provide assurance that any acquisition, collaboration or in-license will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired company or business or in-licensed product candidate. In addition, our future success would depend in part on our ability to manage the rapid growth associated with some of these acquisitions, collaborations and in-licenses. We cannot assure you that we would be able to successfully combine our business with that of acquired businesses, manage a collaboration or integrate in-licensed product candidates. Furthermore, the development or expansion of our business may require a substantial capital investment by us.

Negative results from clinical trials or studies of others and adverse safety events involving the targets or active ingredients of our products may have an adverse impact on our future commercialization efforts.

From time to time, studies or clinical trials on various aspects of biopharmaceutical products, including a product’s active ingredient, are conducted by academic researchers, competitors or others. The results of these studies or trials, when published, may have a significant effect on the market for the biopharmaceutical product that is the subject of the study. The publication of negative results of studies or clinical trials or adverse safety events related to our product candidates and active ingredient in our product candidates, or the therapeutic areas in which our product candidates compete, could adversely affect our share price and our ability to finance future development of our product candidates, and our business and financial results could be materially and adversely affected.

We face the risk of product liability claims, which could exceed our insurance coverage, and produce recalls, each of which could deplete our cash resources.

We are exposed to the risk of product liability claims alleging that use of our product candidates caused an injury or harm. These claims can arise at any point in the development, testing, manufacture, marketing or sale of our product candidates and may be made directly by patients involved in clinical trials of our product candidates, by consumers or healthcare providers or by individuals, organizations or companies selling our products. Product liability claims can be expensive to defend, even if the product or product candidate did not actually cause the alleged injury or harm.

Insurance covering product liability claims becomes increasingly expensive as a product candidate moves through the development pipeline to commercialization. We currently maintain clinical trial liability insurance coverage of $10 million. However, there can be no assurance that such insurance coverage is or will continue to be adequate or available to us at a cost acceptable to us or at all. We may choose or find it necessary under our collaborative agreements to increase our insurance coverage in the future. We may not be able to secure greater or broader product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any liability for damages resulting from a product liability claim could exceed the amount of our coverage, require us to pay a substantial monetary award from our own cash resources and have a material adverse effect on our business, financial condition and results of operations. Moreover, a product recall, if required, could generate substantial negative publicity about our products and business and inhibit or prevent commercialization of other products and product candidates.

16


In addition, some of our licensing and other agreements with third parties require or might require us to maintain product liability insurance. If we cannot maintain acceptable amounts of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material adverse impact on our operations.

We may not achieve our publicly announced milestones according to schedule.

From time to time, we may announce the timing of certain events we expect to occur, such as the anticipated timing of results from our clinical trials. These statements are forward-looking and are based on the best estimates of management at the time relating to the occurrence of such events. However, the actual timing of such events may differ from what has been publicly disclosed. The timing of events such as initiation or completion of a clinical trial, filing of an application to obtain regulatory approval, or announcement of additional clinical trials for a product candidate may ultimately vary from what is publicly disclosed. For example, we cannot provide assurances that the SIRPaFc phase I clinical trial will be initiated on schedule, or that we will make regulatory submissions or receive regulatory approvals as planned. These variations in timing may occur as a result of different events, including the nature of the results obtained during a clinical trial or during a research phase, problems with a CMO or a CRO or any other event having the effect of delaying the publicly announced timeline. We undertake no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as otherwise required by law. Any variation in the timing of previously announced milestones could have a material adverse effect on our business plan, financial condition or operating results and the trading price of common shares.

We are exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates.

We may be adversely affected by foreign currency fluctuations. To date, we have been primarily funded through issuances of equity, proceeds from the exercise of warrants and stock options and from interest income on funds available for investment, which are all denominated in Canadian dollars. A growing portion of our expenditures are in U.S. dollars, however, and we are, therefore, subject to foreign currency fluctuations which may, from time to time, impact our financial position and results of operations.

17


Risks Related to Intellectual Property

If we are unable to adequately protect and enforce our intellectual property, our competitors may take advantage of our development efforts or acquired technology and compromise our prospects of marketing and selling our key products.

We own or hold licenses to a number of U.S.-issued patents and U.S. and Canadian pending patent applications, as well as foreign patents and foreign counterparts. In the U.S., we have our own rights to ten issued patents and four pending patents. In addition, we have numerous patent applications pending in Europe, Australia and Japan. Our success will depend in part upon our ability to protect our intellectual property and proprietary technologies and upon the nature of the intellectual property protection we receive. For example, some of our patent portfolio covers primarily method of use but not composition of matter. The ability to compete effectively and to achieve partnerships will depend on our ability to develop and maintain proprietary aspects of our technology and to operate without infringing on the proprietary rights of others. The presence of such patents could severely limit our ability to develop and commercialize our products, to conduct our existing research and/or require financial resources to defend litigation, which may be in excess of our ability to raise such funds. There is no assurance that our pending patent applications or those that we intend to acquire will be approved in a form that will be sufficient to protect our proprietary technology and gain or keep our competitive advantage.

The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved. Patents issued to us or our respective licensors may be challenged, invalidated or circumvented. To the extent our intellectual property, including licensed intellectual property, offers inadequate protection, or is found to be invalid or unenforceable, we are exposed to a greater risk of direct competition. If our intellectual property does not provide adequate protection against our competitors’ products, our competitive position could be adversely affected, as could our business, financial condition and results of operations. Both the patent application process and the process of managing patent disputes can be time consuming and expensive, and the laws of some foreign countries may not protect our intellectual property rights to the same extent as do the laws of Canada and the United States.

We will be able to protect our intellectual property from unauthorized use by third parties only to the extent that our proprietary technologies, key products and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets and provided we have the funds to enforce our rights, if necessary.

If we lose our licenses from third-party owners we may be unable to continue a substantial part of our business.

We are party to a number of licenses that give us rights to intellectual property that is necessary or useful for a substantial part of our business. Pursuant to our exclusive license agreement with UHN and the Hospital for Sick Children (“ HSC ”) under which we license certain patent rights for our key products and their uses, we are required to use commercially reasonable efforts to commercialize products based on the licensed rights and pay certain royalties and sublicensing revenue to UHN and HSC. These licenses require that we pay development milestone payments, regulatory milestone payments, royalties on net and sublicensing revenues as well as annual maintenance fees.

18


We have also entered in to an agreement allowing us to manufacture SIRPaFc using Catalent’s proprietary GPEx ® expression system. The consideration for this includes payments at the time we successfully reach a series of development and sales milestones. We may also enter into licenses in the future to access additional third-party intellectual property.

If we fail to pay annual maintenance fees, development and sales milestones, or it is determined that we did not use commercially reasonable efforts to commercialize licensed products, we could lose our licenses which could have a material adverse effect on our business and financial condition.

We may require additional third-party licenses to effectively develop and manufacture our key products and are currently unable to predict the availability or cost of such licenses.

A substantial number of patents have already been issued to other biotechnology and pharmaceutical companies. To the extent that valid third-party patent rights cover our products or services, we or our strategic collaborators would be required to seek licenses from the holders of these patents in order to manufacture, use or sell these products and services, and payments under them would reduce our profits from these products and services. We are currently unable to predict the extent to which we may wish or be required to acquire rights under such patents and the availability and cost of acquiring such rights, or whether a license to such patents will be available on acceptable terms or at all. There may be patents in the U.S. or in foreign countries or patents issued in the future that are unavailable to license on acceptable terms. Our inability to obtain such licenses may hinder or eliminate our ability to manufacture and market our products.

Changes in patent law and its interpretation could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors’ or collaborators’ ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the U.S. Patent and Trademark Office (“ USPTO ”), the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors’ or collaborators’ ability to obtain new patents or to enforce existing patents and patents we and our licensors or collaborators may obtain in the future.

Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors’ or collaborators’ patent applications and the enforcement or defense of our or our licensors’ or collaborators’ issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors’ or collaborators’ patent applications and the enforcement or defense of our or our licensors’ or collaborators’ issued patents, all of which could have a material adverse effect on our business and financial condition.

19


Litigation regarding patents, patent applications and other proprietary rights may be expensive, time consuming and cause delays in the development and manufacturing of our key products.

Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. The pharmaceutical industry is characterized by extensive patent litigation. Other parties may have, or obtain in the future, patents and allege that the use of our technologies infringes these patent claims or that we are employing their proprietary technology without authorization.

In addition, third parties may challenge or infringe upon our existing or future patents. Proceedings involving our patents or patent applications or those of others could result in adverse decisions regarding:

  • the patentability of our inventions relating to our key products; and/or
  • the enforceability, validity or scope of protection offered by our patents relating to our key products.

If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. For example, in 2012 we received a favorable settlement in a patent interference case initiated by the U.S. Patent & Trademark Office after which we agreed to withdraw certain pending and issued patents related to Parkinson’s disease treatment in exchange for a payment of U.S.$250,000 from NeuroNova AB. Regardless of the outcome, patent litigation is costly and time consuming. In some cases, we may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may:

  • incur substantial monetary damages;
  • encounter significant delays in bringing our key products to market; and/or
  • be precluded from participating in the manufacture, use or sale of our key products or methods of treatment requiring licenses.

Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them.

Because we rely on third parties to develop our products, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs which may require us to share trade secrets under the terms of research and development collaboration or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor's discovery of our trade secrets would impair our competitive position and could have a material adverse effect on our business and financial condition.

20


Risks Related to Our Common Shares

Our common share price has been volatile in recent years.

The market prices for securities of biopharmaceutical companies have been historically volatile, including ours. In the year ended December 31, 2013, our common shares traded on TSXV at a low of $0.140 and a high of $0.600. In the quarter ended June 30, 2014, on the TSX our common shares traded at a high of $0.520 and a low of $0.265. A number of factors could influence the volatility in the trading price of our common shares, including changes in the economy or in the financial markets, industry related developments, the results of product development and commercialization, government regulations, and developments concerning proprietary rights, litigation and cash flow. Our quarterly losses may vary because of the timing of costs for manufacturing and initiating and completing preclinical and clinical trials. Also, the reporting of adverse safety events involving our products and public rumors about such events could cause our stock price to decline or experience periods of volatility. Each of these factors could lead to increased volatility in the market price of our common shares. In addition, changes in the market prices of the securities of our competitors may also lead to fluctuations in the trading price of our common shares.

Consolidation of our outstanding common shares could significantly reduce liquidity and could cause a decline in our market capitalization.

We intend to apply for a listing on the NASDAQ Stock Exchange which would require us to consolidate our outstanding common shares to meet the minimum share price requirement of the exchange. We have received approval from our shareholders to consolidate our issued and outstanding common shares on a ratio of one post-consolidation common share for each 10 to 30 outstanding pre-consolidation common shares, with the final ratio to be determined by the Board of Directors in their sole discretion.

There are numerous factors and contingencies that could affect the prices of pre-consolidation common shares and the post-consolidation common shares, including our reported financial results in future periods, and general economic, geopolitical, stock market and industry conditions. Accordingly, the market price of the post-consolidation common shares may not be sustainable at the direct arithmetic result of the share consolidation, and may be lower. If the market price of the post-consolidation common shares is lower than it was before the share consolidation on an arithmetic equivalent basis, our total market capitalization (the aggregate value of all common shares at the then market price) after the share consolidation may be lower than before the share consolidation. If the share consolidation is implemented and the market price of the post-consolidation common shares declines, the percentage decline may be greater than would occur in the absence of the share consolidation. Furthermore, the liquidity of the post-consolidation common shares could be adversely affected by the reduced number of consolidated common shares that would be outstanding after the share consolidation.

21


We have never paid dividends and do not expect to do so in the foreseeable future.

We have not declared or paid any cash dividends on our common or preferred shares to date. The payment of dividends in the future will be dependent on our earnings and financial condition in addition to such other factors as our Board of Directors considers appropriate. Unless and until we pay dividends, shareholders may not receive a return on their shares. There is no present intention by our Board of Directors to pay dividends on our shares.

Future sales or issuances of equity securities and the conversion of outstanding securities to common shares could decrease the value of the common shares, dilute investors’ voting power and reduce our earnings per share.

We may sell additional equity securities in future offerings, including through the sale of securities convertible into equity securities, to finance operations, acquisitions or projects, and issue additional common shares if outstanding warrants or stock options are exercised, or preferred shares are converted to common shares, which may result in dilution. See the information under the heading “Item 10.A. Share Capital” for details of our outstanding securities convertible into common shares. We filed a base shelf prospectus with securities commissions in Canada on May 26, 2014 that provides that we may sell under the prospectus from time to time over the following 25 months up to $50 million, in one or more offerings, of common shares, First Preferred shares, warrants to purchase common shares, or units comprising common shares, First Preferred shares and warrants. Subject to receipt of any required regulatory approvals, subscribers of the December 2013 private placement who purchased a minimum of 10% of the securities sold under the offering received rights to purchase our securities in future financings to enable each such shareholder to maintain their percentage holding in our common shares for so long as the subscriber holds at least 10% of the outstanding common shares on a fully-diluted basis. Shareholders who do not have this future financing participation right may be disadvantaged in participating in such financings.

Our Board of Directors has the authority to authorize certain offers and sales of additional securities without the vote of, or prior notice to, shareholders. Based on the need for additional capital to fund expected expenditures and growth, it is likely that we will issue additional securities to provide such capital. Such additional issuances may involve the issuance of a significant number of common shares at prices less than the current market price for our common shares.

Sales of substantial amounts of our securities, or the availability of such securities for sale, as well as the issuance of substantial amounts of our common shares upon conversion of outstanding convertible equity securities, could adversely affect the prevailing market prices for our securities and dilute investors’ earnings per share. A decline in the market prices of our securities could impair our ability to raise additional capital through the sale of securities should we desire to do so.

22


Judgments based upon the civil liability provisions of the United States federal securities laws may be difficult to enforce.

The ability of investors to enforce judgments of United States courts based upon the civil liability provisions of the United States federal securities laws against us, our directors and our officers may be limited due to the fact that we are incorporated outside of the United States and that certain directors and officers reside outside of the United States and their assets may be located outside the United States. There is uncertainty as to whether foreign courts would either enforce judgments of United States courts obtained against us, our directors or our officers predicated upon the civil liability provisions of the United States federal securities laws or entertain original actions brought in Canadian courts against us or such persons predicated upon the federal securities laws of the United States, as such laws may conflict with Canadian laws.

We are likely a “passive foreign investment company”, which may have adverse U.S. federal income tax consequences for U.S. shareholders.

U.S. investors should be aware that we believe we were classified as a passive foreign investment company (“ PFIC ”) during the tax year ended December 31, 2013, and based on current business plans and financial expectations, we expect that we will be a PFIC for the current tax year and may be a PFIC in future tax years. If we are a PFIC for any year during a U.S. shareholder’s holding period, then such U.S. shareholder generally will be required to treat any gain realized upon a disposition of our common shares, or any so-called “excess distribution” received on common shares, as ordinary income, and to pay an interest charge on a portion of such gain or distributions, unless the shareholder makes a timely and effective “qualified electing fund” election (“ QEF Election ”) or a “mark-to-market” election with respect to our shares. A U.S. shareholder who makes a QEF Election generally must report on a current basis its share of our net capital gain and ordinary earnings for any year in which we are a PFIC, whether or not we distribute any amounts to our shareholders. A U.S. shareholder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the common shares over the shareholder’s basis therein. There is no assurance that we will provide U.S. investors with the information required in order to make a QEF Election. This paragraph is qualified in its entirety by the discussion below under the heading “Item 6.E. United States Federal Income Taxation.” Each U.S. shareholder should consult its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership, and disposition of our common shares.

ITEM 4.                     INFORMATION ON THE COMPANY

A. History and Development of the Company

Name, Address and Incorporation

We were incorporated under the Business Corporations Act (Alberta) on March 31, 2004 as Neurogenesis Biotech Corp. On October 19, 2004, we amended our articles of incorporation to change our name from Neurogenesis Biotech Corp. to Stem Cell Therapeutics Corp. (“ SCT ”). On November 7, 2013 SCT was continued under the Business Corporations Act (Ontario) (“ OBCA ”). On June 1, 2014 we filed articles of amalgamation to amalgamate SCT with our wholly-owned subsidiary, Trillium Privateco, and renamed the combined company Trillium Therapeutics Inc. We are a company domiciled in Ontario, Canada. Our head office and registered office is located at 96 Skyway Avenue, Toronto, Ontario, Canada M9W 4Y9. Our telephone number is (416) 595-0627.

23


Intercorporate Relationships

Stem Cell Therapeutics Inc. is a wholly-owned subsidiary of ours incorporated under the Business Corporations Act (Alberta) on December 22, 1999 and was continued under the Business Corporations Act (Ontario) on November 12, 2003 and then extra-provincially registered in Alberta on January 11, 2005. We have initiated the process to dissolve this inactive subsidiary.

Trillium Privateco was incorporated as an Ontario corporation on July 23, 1996, under the name Xeno Transplantation Inc. It subsequently amended its articles of incorporation to change its name to Transplantation Technologies Inc. and then to Trillium Therapeutics Inc. Trillium Privateco merged with 2364556 Ontario Inc., a special purpose wholly-owned subsidiary of ours incorporated solely to effect the acquisition of Trillium Privateco on April 9, 2013 to become a wholly-owned subsidiary of ours. Trillium Privateco amalgamated with us on June 1, 2014.

General Development of the Business

We are an immuno-oncology company developing novel and innovative cancer therapies. Our current primary objective is to advance our preclinical SIRPaFc program into a first-in-human phase I trial in patients with Acute Myeloid Leukemia (“ AML ”), expected to begin in the second half of 2015. We are also investigating SIRPaFc in other oncology indications, including other hematological and solid tumors, as well as combinations with other immunotherapies, in preclinical models.

During 2013, we refocused our product pipeline through the strategic acquisition of Trillium Privateco on April 9, 2013, which included the SIRPaFc and CD200 preclinical cancer programs. See the description of a description of SIRPaFc and CD200 under “Item 3.B. Business Overview – Products in Development”.

Acquisition of Trillium Privateco

On April 9, 2013, we completed a merger with Trillium Privateco, a private biopharmaceutical company specializing in immune regulation and the development of cancer therapeutics. We applied the acquisition method of accounting for the business combination and the losses were consolidated from the acquisition date. The consideration was allocated to the underlying assets acquired and liabilities assumed based upon their fair values at the date of acquisition. The purchase price allocation was assigned to the net identifiable assets based on their estimated fair values. The final purchase price allocation was as follows:

24



Fair value of consideration paid  
         Cash $1,200,000
         2,779,180 common shares and 3,300,000 units $1,380,836
Subtotal $2,580,836
   
Assets acquired  
         Cash and marketable securities $1,182,714
         Amounts receivable $820,944
         Prepaid expenses $44,300
         Equipment $91,000
         Acquired technology $1,018,037
Subtotal $3,156,995
   
Liabilities assumed  
           Accounts payable and accrued liabilities $282,178
           Loan payable $293,981
Subtotal $576,159
   
Net identifiable assets acquired $2,580,836

As consideration, we paid $1,200,000 in cash and issued 2,779,180 common shares and 3,300,000 units. Each unit consisted of one common share and one common share purchase warrant, with each common share purchase warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018. The fair value of the unit was determined based on the stand-alone value of the common share and the common share purchase warrant, in accordance with IFRS 13, Fair value measurement and IFRS 3, Business combinations . Accordingly, the fair value of the aggregate 6,079,180 common shares issued was based on the closing price of our common shares of $0.20 on April 9, 2013. The fair value of the 3,300,000 common share purchase warrants was determined using the Black-Scholes option pricing model. Assumptions used to determine the value of the common share purchase warrant were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 68%; and average expected life of 3 years. Cash used in the investment of $647,996 was determined by subtracting cash acquired of $552,004 from cash consideration of $1,200,000. Post-closing, Trillium Privateco shareholders held approximately 16% of the issued and outstanding common shares, and Trillium Privateco became our wholly-owned subsidiary.

Financings

On December 13, 2013, we completed a private placement of 79,247,693 common share units (each common share unit consisting of one common share and three-quarters of a common share purchase warrant) at a price of $0.21 per unit and 77,895,165 preferred share units (each preferred share unit consisting of one Series 1 First Preferred Share and three-quarters of a common share purchase warrant) at a price of $0.21 per unit for gross proceeds of $32,866,025 ($30,713,841 net of issuance costs). Each whole warrant entitles the holder to purchase one common share at a price of $0.28 at any time prior to expiry on December 13, 2018. Proceeds from the private placement will be used primarily for the advancement of our SIRPaFc program through IND-enabling studies, manufacturing and phase I clinical trials. In the first quarter of fiscal 2014 we assembled a small team of experienced manufacturing, toxicology, clinical and regulatory employees and consultants to support this program.

In March 2013, we completed an offering pursuant to a base shelf prospectus and prospectus supplement and in the U.S. pursuant to a private placement memorandum for a total of 12,735,000 units at a price of $0.25 per unit, for aggregate gross proceeds to us of $3,185,080. Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.40 per share at any time prior to expiry on March 15, 2018 (12,315,000 warrants) and March 27, 2018 (420,000 warrants). In connection with the financing, we issued 814,051 compensation warrants entitling the holder to acquire one common share at an exercise price of $0.25 per share prior to expiry on March 16, 2015.

25


In March 2011, we completed an offering pursuant to a base shelf prospectus and a prospectus supplement. An aggregate of 18,181,819 units were issued at a price of $0.11 per unit, representing gross proceeds of $2 million. Each unit consisted of one common share and one-half of one common share purchase warrant. Each whole warrant entitled the holder to purchase one common share at a price of $1.60 at any time prior to expiry on March 14, 2014.

Board of Director Changes

In the previous three years, we restructured our product pipeline and acquired the necessary financial resources to advance our lead SIRPaFc program forward. Over this period, our Board of Directors has evolved as our focus has changed. Recent changes to the Board include the retirement of Mr. David Allan, Dr. James DeMesa and Mr. Dean Peterson, and the appointment of Dr. Michael Moore in April 2013, Dr. Robert Kirkman in December 2013, and Dr. Calvin Stiller as Chair in January 2014. On March 10, 2014, Mr. Luke Beshar and Dr. Thomas Reynolds joined the Board of Directors.

Share Consolidation, TSXV and TSX

Our Board of Directors authorized the implementation of a share consolidation at a ratio of one post-consolidation common share for 10 pre-consolidation common shares and on February 6, 2013, our common shares began trading on the TSXV on a post-consolidation basis. On April 22, 2014, our common shares began trading on the TSX and were simultaneously delisted from the TSXV.

OTCQX

Our stock began trading on the OTCQX International over-the-counter marketplace under the symbol “SCTPF” on May 20, 2013.

Tigecycline License

On April 16, 2013, we signed an agreement with UHN to gain rights to intellectual property related to the use of tigecycline for the treatment of leukemia which included a UHN sponsored, open label phase I multicenter dose-escalation tigecycline trial in patients with relapsed or refractory AML, which continues to enroll patients. The initial consideration for the UHN license of $1,085,714 was satisfied by the issuance of 5,028,571 common shares and 1,600,000 common share purchase warrants, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018. Additional consideration under the UHN license included an annual license maintenance fee and future development milestones. The fair value of the common shares issued was based on the closing price of our common shares of $0.20 on April 16, 2013 and $0.25 per unit based on the fair value of the common share and common share purchase warrant components as of the date of acquisition.

Since acquiring these rights, we monitored the results of the phase I trial and assessed alternate development strategies for the technology. In August 2014, we completed an evaluation of this program with respect to its scientific merit, commercial potential, strength of intellectual property, as well as its overall fit with our current focus and expertise. We concluded that we should focus our business plan on expanding the SIRPaFc program, rather than continue development of tigecycline, and returned the licensed rights to UHN.

26


Capital Expenditures

Prior to the April 2013 merger with Trillium Privateco, we incurred minimal capital expenditures in 2012 and 2011. Capital expenditures are required mainly for laboratory equipment, office equipment, computers and leasehold improvements. Capital expenditures in the last three fiscal years and the six months ended June 30, 2014 are set out in the following table.


Six months ended
June 30, 2014
Year ended
December 31, 2013
Year ended
December 31, 2012
Year ended
December 31, 2011
Capital expenditures $139,997 $34,017 - -

B. Business Overview

General

We are an immuno-oncology company developing innovative therapies for the treatment of cancer. We have two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (“ mAb ”), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in AML and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. Our oncology product pipeline is as follows:

Our lead program is SIRPaFc, a novel antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on cancer cells to evade the host immune system. SIRPaFc is initially being developed as a treatment for AML. However, recent data suggest that CD47 is highly expressed by a variety of liquid and solid tumors, and CD47 blockade has demonstrated efficacy in numerous xenograft models. Furthermore, CD47 blockade has been reported to synergize with several marketed anti-cancer antibodies, raising the possibility that SIRPaFc can be used as a combination therapy. SIRPaFc may therefore have potential in the treatment of other malignancies, in addition to AML. We are currently developing two distinct SIRPaFc fusion proteins, TTI-621 and TTI-622, differing in their Fc regions. One is envisioned to be used as monotherapy, following debulking by conventional chemotherapy, and the other used in combination with other targeted anti-cancer treatments, such as monoclonal antibodies. SIRPaFc entered formal IND enabling studies in 2013 and is being developed initially as a treatment for AML, with potential applications in other hematological and solid tumors. Contract manufacturing for two SIRPaFc fusion proteins has been secured to generate product for formal toxicology studies and a subsequent phase I clinical study.

27


Our CD200 mAb program also targets a key immunoregulatory pathway that tumor cells exploit to evade the host immune system. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. This asset is ready to enter a formal preclinical program which we anticipate will only commence once a development partner has been secured. In the meantime we will continue to accommodate requests for research material from third parties in order to further our understanding of the CD200 immunoregulatory pathway and how to best exploit it for the treatment of cancer.

Products in Development

SIRPaFc

SIRPaFc is an antibody-like recombinant fusion protein that binds to CD47 and activates macrophages to eliminate cancer cells. The rationale for the SIRPaFc program is based on three main observations:

CD47, by binding the SIRPa receptor, delivers a “do not eat” signal to macrophages;

   

CD47 is upregulated by many different types of tumors and high CD47 expression correlates with poor clinical outcome, consistent with tumor cells exploiting this pathway to evade immune-mediated attack; and

   

Genetic experiments establish that disruption of the CD47-SIRPa axis leads to elimination of tumor cells in vivo.

Through a series of optimization studies, human SIRPaFc clinical development candidates were identified. These fusion proteins bind to CD47 with high (nanomolar) affinity and block its interaction with SIRPa. In vitro , SIRPaFc treatment enables macrophages to destroy AML tumor cells while sparing normal cord blood- or peripheral blood-derived mononuclear cells. This selectivity for tumor cells may be due to the differential expression of pro-phagocytic signals (such as calreticulin) on malignant cells relative to normal cells. In AML xenograft studies, treatment with SIRPaFc results in anti-leukemic activity, significantly reducing the leukemic burden in the bone marrow and impairing disease dissemination. These results are further validated by an independent body of work demonstrating similar activity when CD47 is blocked using monoclonal antibodies.

28


Since human SIRPaFc does not cross-react with murine CD47, mouse SIRPaFc surrogate fusion proteins were generated. These incorporated the SIRPa sequence from the NOD mouse strain, which has the unusual property of binding both mouse and human CD47, and thus can be used in the xenograft model. The mouse surrogates were shown to be well tolerated in mice and could mediate anti-leukemic activity in the AML xenograft model, even at relatively low doses (<1 mg/kg).

Data from non-Good Laboratory Practice preclinical studies in non-human primates, using several variants of our high-affinity CD47 antagonist, provided supportive safety and pharmacokinetic data to advance this program into formal pre-IND studies.

In April 2014, we presented data at the 105 th American Association of Cancer Research (“ AACR ”) Annual Meeting demonstrating that our SIRPaFc fusion proteins, which incorporate wild type (non-mutated) SIRPa sequences and bind effectively to CD47 with low nanomolar affinity, bind very poorly to human red blood cells (“ RBCs ”) compared to both commercial anti-CD47 monoclonal antibodies and proprietary CD47-blocking agents. We did not see this difference in binding with other cell types, including AML tumor cells, suggesting it may be an RBC-specific phenomenon. We believe the lack of significant SIRPaFc binding to erythrocytes is unique to humans, since SIRPaFc bound strongly to mouse and non-human primate RBCs. These results are consistent with independently published reports documenting differences in binding between CD47-specific antibodies and the natural CD47 ligand, SIRPa. While the mechanism behind this observation is still under investigation, our preliminary data suggest that it may relate to unique structural features of CD47 in the human RBC membrane. Importantly, these results suggest that our SIRPaFc proteins may have a preferable RBC binding profile compared to competing approaches, which we believe may predict a lower risk of hematological toxicity and a more favorable pharmacokinetic profile in patients.

SIRPaFc is initially being developed as a therapy to eradicate cancer cells in AML patients. Beyond AML, there is potential to apply SIRPaFc therapy to other malignancies. Recent data has suggested that the CD47 “do not eat” signal is highly expressed by many hematopoietic tumors, including acute lymphoblastic leukemia, diffuse large cell B lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Elevated CD47 has been reported in solid tumors, including breast, colon, ovarian, brain, liver and prostate cancers and leiomyosarcoma. There is evidence in a number of these cancers that high CD47 expression has negative clinical consequences, correlating with more aggressive disease and poor survival, and antibody blockade of CD47 has demonstrated efficacy across numerous xenograft models. In addition, there is evidence from the literature that SIRPaFc may be useful in combination with approved anti-cancer antibodies (e.g., rituximab). Since many cancer antibodies work at least in part through antibody-dependent cellular cytotoxicity, it may be possible to enhance the potency of these agents by blocking the negative “do not eat” CD47 signal on tumor cells. We therefore plan to explore SIRPaFc in combination studies using preclinical xenograft models.

Our SIRPaFc program originated from leading researchers in the field, including Drs. John Dick and Jean Wang of the UHN and Dr. Jayne Danska of HSC. Exclusive rights to SIRPaFc have been licensed from UHN and HSC pursuant to a license agreement amended and restated as of June 1, 2012. The licensed intellectual property relates to methods and compounds used in the modulation of SIRPa-CD47 interaction for therapeutic cancer applications. The license includes commitments to pay an annual maintenance fee of $25,000, as well as payments on patent issuances, development milestone payments ranging from $100,000 to $300,000 on the initiation of phase I, II and III clinical trials, and payments on the achievement of certain regulatory milestones as well as low single digit royalties on commercial sales.

29


We are also required to pay 20% of any sublicensing revenues to the licensors on the first $50 million of sublicensing revenues received, and 15% thereafter.

Products for Development with Partners

CD200 mAb

We have developed fully human monoclonal antibodies that block the activity of CD200, an immunosuppressive molecule that many tumors exploit to evade attack from the immune system. Although immune regulation by CD200 was first explored in the context of transplantation and autoimmunity, it has become clear that this molecule may play an important role in tumor immunity. There is abundant evidence that CD200 is overexpressed by many different types of hematological and solid tumors, and in numerous cases this overexpression correlates with disease progression and poor clinical outcome. This is consistent with tumor cells using CD200 as a means of evading immune-mediated destruction. Indeed, tumor-expressed CD200 can modulate anti-tumor responses in vitro and in vivo , and antibodies that block CD200 have been shown to promote anti-tumor immunity in animal models of cancer.

Our antibodies bind to human CD200 with high affinity, potently neutralizing CD200 function in vitro , and have anti-tumor activity in a human xenograft model. We are seeking a development partner to advance this program into formal preclinical IND-enabling studies.

TTI-1612

TTI-1612 is a recombinant soluble form of heparin-binding epidermal-growth-factor-like growth factor. It is being developed as a treatment for interstitial cystitis/bladder pain syndrome (“ IC/BPS ”), a chronic bladder disease characterized by low urinary HB-EGF levels and a dysfunctional, "leaky" bladder epithelium. TTI-1612 stimulates the proliferation of bladder epithelial cells and reduces their permeability. Unlike the current IC therapeutics, which are largely palliative in nature, TTI-1612 is designed to target the root cause of IC, the dysfunction of the bladder urothelium caused by low levels of HB-EGF.

Our phase I study of TTI-1612 in 28 patients with IC/BPS was completed in 2013. The study was designed to assess the safety and tolerability of single ascending doses of TTI-1612 in IC/BPS patients. Pharmacokinetics and changes in disease symptoms were also evaluated. Clinical data indicate that TTI-1612 was well tolerated and exhibited a favorable pharmacokinetic profile.

This project is outside of our core interest in immuno-oncology, and we are therefore seeking to out-license or divest the entire program.

While we may seek to out-license certain development products there can be no assurance that we will be successful at partnering these products. Where ongoing patent and other maintenance costs exceed expected proceeds of out-licensing, certain non-core technologies may be abandoned.

Previously-held Regenerative Stem Cell Technologies

Prior to the April 2013 merger with Trillium Privateco, we were focused for the previous three years on regenerative stem cell technologies. During that time we considered two agents, Human Chorionic Gonadotrophin (“ hCG ”) and Epoeitin Alpha (“ EPO ”), to be therapeutically attractive as they allowed for a repurposing of two approved drugs to be used for a new indication. This unique combination of therapeutic compounds was called NTx®-265. From 2008 to 2010, NTx®-265 was tested in several phase II acute ischemic stroke trials. In April 2011, we announced the enrollment of the first patient in a company-supported open label, single centre, phase IIa trial investigating NTx®-265 in traumatic brain injury. The trial was designed to enroll 10 patients, however patient recruitment was extremely slow.

30


In the fourth quarter of 2012, we settled a patent interference case initiated by the United States Patent and Trademark Office by concluding an arrangement with NeuroNova AB. We agreed to withdraw certain pending and issued patents to treat Parkinson's disease in return for a US$250,000 payment from NeuroNova AB.

In July 2013, we ceased all activities associated with our pre-merger historic regenerative neurology programs, including terminating the phase IIa study in traumatic brain injury, and abandoned all related intellectual property filings.

AML/ Competitive Environment

AML is the most common type of acute leukemia in adults, with approximately 13,000 new cases diagnosed each year in the United States. The majority of AML patients receive induction chemotherapy. In patients under 60 years of age, remission rates of up to 75% can be achieved, and patients with good-risk or standard-risk cytogenetics will typically receive post-remission therapy with high dose cytarabine. However, relapses are common, and the majority of patients will die from their disease. AML in patients over 60 years of age is notoriously difficult to treat, with five-year survival rates reportedly of less than 10%. There is ample evidence that AML is sustained by leukemic stem cells (“ LSCs ”), and the failure to eradicate these LSCs using conventional chemotherapy is thought to be responsible for disease relapse. CD47 is overexpressed by both bulk AML cancer cells as well as LSCs.

While there is significant clinical activity in AML, there are a limited number of agents in development targeting AML LSCs. Similar to our targeting of CD47, we believe other agents in development targeting AML LSCs are largely focused on cell surface antigens such as CD123 and CD44. SIRPaFc is in direct competition with a CD47 blocking antibody from Stanford University which is in preclinical development and expected to enter clinical development soon. Although both agents target the same pathway, we understand each are structurally distinct entities with unique properties. We are also aware that Celgene Corporation and Novimmune SA have CD47 antibody programs.

We believe that our approach of using the natural ligand to CD47 may have advantages over treatment with CD47-specific antibodies. In April 2014, we presented data at the 105 th AACR Annual Meeting demonstrating that our wild type SIRPaFc fusion protein, which binds effectively to CD47 with low nanomolar affinity, binds very poorly to human red blood cells (“ RBCs ”) compared to both commercial anti-CD47 monoclonal antibodies and proprietary CD47-blocking agents. This difference in binding was not seen with other cell types, including AML tumor cells, suggesting it is an RBC-specific phenomenon. In addition, the lack of significant SIRPaFc binding to erythrocytes is unique to humans, since SIRPaFc bound strongly to mouse and non-human primate RBCs. Overall, the data suggest that a wild type SIRPaFc fusion protein may have advantages as a CD47-blocking agent to reduce the potential antigen sink effect caused by RBCs and to minimize hematological toxicity in patients, while maintaining potent anti-tumor effects.

31


Business Strategy

Our goal is to use our patented and licensed technologies to establish us as a leader in the development and commercialization of immunotherapies for cancer and related diseases.

Clinical Development Collaborations

We plan to advance the clinical development of our lead product candidates to create shareholder value by establishing their clinical and commercial potential as therapies for cancer. We intend to supplement our in-house clinical and regulatory capabilities in the design, performance and oversight of clinical trials by working with external consultants, collaborators and CROs.

Commercialization Partnerships and Other Strategic Initiatives

We will evaluate strategic partnerships or other strategic initiatives with established pharmaceutical and biotechnology companies to continue the development of our technologies through later stage clinical trials and commercialization.

Financial Strategy

Our financial strategy is to maintain sufficient liquidity such that we can continue the development of our programs. To accomplish this we will seek to raise additional funds through issuances of equity and/or debt, and from sources of non-dilutive funding including grants and matching funding programs, and government tax credits.

Intellectual Property

We own or control patent rights covering our key products and their therapeutic end uses. The patents and patent applications are either granted or pending in major pharmaceutical markets. In all, the patent estate includes seven patent families, including 10 issued patents and four pending patents in the U.S. and various other patent applications pending in Europe, Canada, Australia and Japan. These include five granted patents in the U.S. relating to the immune modulating use of CD200 mAbs, and a granted patent in the U.S. for an assay useful to detect CD200 in cancer patients, as well as a filing for novel human antibodies to CD200. We also control three granted patents in the U.S. covering the use of HB-EGF in treating interstitial cystitis, and a patent family based on more recent results with the active drug.

We also own and control patents relating to SIRPaFc, including a patent family covering the anti-cancer use of SIRPa, and a further international filing relating to a specific form of SIRPaFc. The first SIRPa patents begin to expire in the year 2029.

We intend to protect additional intellectual property developed by us through the filing of patent applications within the appropriate jurisdictions throughout the world.

Regulatory Process

Securing final regulatory approval for the manufacture and sale of human therapeutic products in the U.S., Europe, Canada and other commercial territories, is a long and costly process that is controlled by that particular territory’s national regulatory agency. The national regulatory agency in the United States is the FDA, in Canada it is HC, and in Europe it is the European Medicines Agency or (“ EMA ”). Other national regulatory agencies have similar regulatory approval processes, but each national regulatory agency has its own approval processes. Approval in U.S., Canada or Europe does not assure approval by other national regulatory agencies, although often test results from one country may be used in applications for regulatory approval in another country.

32


None of our products have been completely developed or tested and, therefore, we are not yet in a position to seek final regulatory approval to market any of our products.

U.S. Approval Process

In the U.S., the FDA, a federal government agency, is responsible for the drug approval process. The FDA’s mission is to protect human health by ensuring that all medications on the market are safe and effective. The FDA’s approval process examines potential drugs and only those that meet strict requirements are approved.

The U.S. food and drug regulations require licensing of manufacturing facilities, carefully controlled research and testing of products, governmental review and approval of test results prior to marketing of therapeutic products, and adherence to cGMP. The drug approval process begins with the discovery of a potential drug. Pharmaceutical companies then test the drug extensively. A description of the different stages in the drug approval process in the U.S. follows.

Stage 1: Preclinical Research. After an experimental drug is discovered, research is conducted to help determine its potential for treating or curing an illness. This is called preclinical research. Animal studies are conducted to determine if there are any harmful effects of the drug and to help understand how the drug works. Information from these experiments is submitted in an IND application to the FDA for review, to decide if the drug is safe to proceed for study in humans.

Stage 2: Clinical Research. In Stage 2, the experimental drug is studied in humans in clinical trials. Clinical trials are carefully designed and controlled experiments in which the experimental drug is administered to patients to test its safety and to determine the effectiveness of an experimental drug. The four general phases of clinical research are described below.

Phase I . Phase I includes the initial introduction of an investigational new drug into humans. Phase I studies are typically conducted in patients or healthy volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During phase I, sufficient information about the drug's pharmacokinetic and pharmacological effects is obtained to permit the design of well-controlled, scientifically valid, phase II studies. Phase I studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes.

Phase II. Phase II includes the controlled clinical studies to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug.

33


Phase III . Phase III studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

Phase IV . Phase IV studies are undertaken after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Stage 3: FDA Review for Approval. Following Phase III, the pharmaceutical company prepares reports of all studies conducted on the drug and a complete dossier on the manufacturing of the product and submits the reports to the FDA in a New Drug Application (“NDA”) or Biologic License Application. The FDA reviews the information in the NDA/BLA to determine if the drug is safe and effective for its intended use. If the FDA determines that the drug is safe and effective, the drug will be approved.

Stage 4: Marketing. After the FDA has approved the drug, the pharmaceutical company can make it available to physicians and their patients. A company may also continue to conduct research to discover new uses for the drug. Each time a new use for a drug is discovered, the drug is once again subject to the entire FDA approval process before it can be marketed for that purpose.

European Approval Process

The EMA process is roughly parallel to that of the FDA in terms of the strict requirements. The EMA was set up in 1995 in an attempt to harmonize (but not replace) the work of existing national medicine regulatory bodies in individual European countries. As with the FDA, the EMA drug review and approval process follows different stages from preclinical testing through clinical testing in phases I, II and III. There are also some differences between the FDA and EMA review process, and specifically the review process in individual European countries. Such differences may allow certain drug products to be tested in patients at an earlier stage of development.

Manufacturing and Supply

We have limited experience in manufacturing products for clinical or commercial purposes. We produce small quantities of SIRPaFc and CD200 mAb in our laboratories for internal use.

We have established a contract manufacturing relationship for the supply of SIRPaFc that we believe will provide sufficient material for early clinical trials. In addition, we are establishing the basis for long-term commercial production capabilities. However, there can be no assurance that our contract manufacturer will be successful at scaling up and producing our product with the required quality and in the quantities and timelines that we will need for clinical and/or commercial purposes.

We expect to similarly rely on contract manufacturing relationships for any products that we may further develop, or in-license or acquire in the future. However, there can be no assurance that we will be able to successfully contract with such manufacturers on terms acceptable to us, or at all.

Contract manufacturers are subject to ongoing periodic and unannounced inspections by the FDA, the U.S. Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other state and federal regulations. We do not have control over third-party manufacturers’ compliance with these regulations and standards, other than through contractual obligations and periodic auditing. If they are deemed out of compliance with and such regulations, approvals could be delayed, product recalls could result, inventory could be destroyed, production could be stopped and supplies could be delayed or otherwise disrupted.

34


If we need to change manufacturers after commercialization, the FDA and corresponding foreign regulatory agencies must approve these new manufacturers in advance, which will involve testing and additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay, and disruption of supply. Furthermore, switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly or on terms acceptable to us, or at all.

Seasonality

We have not had revenue in the previous three fiscal years. We do not expect our business to be affected by seasonality. The amount and timing of expenditures and therefore liquidity and capital resources vary substantially from period to period depending on the number of research and development programs being undertaken at any one time, the stage of the development programs, the timing of significant expenditures for manufacturing, toxicology and pharmacology studies and clinical trials, and the availability of funding from investors and prospective commercial partners.

Raw Materials

We believe that sources of raw materials pertinent to our laboratory operations and for manufacturing of our SIRPaFc product by our CMO are generally available.

Plan of Operations

Over the next 12-18 months, our primary focus is the advancement of our SIRPaFc development program to the initiation of phase I clinical studies. The major tasks to be performed to accomplish this include: complete cGMP manufacturing of preclinical and phase I quantities, initiate and complete Good Laboratory Practice toxicology and pharmacology studies, prepare for and attend a pre-IND meeting with the FDA, prepare and submit our IND documents for FDA approval to start the trial, and complete the establishment of relationships with a CRO, clinical sites and investigators and make all preparations for the clinical trial.

C. Organizational Structure

We have one wholly-owned subsidiary, Stem Cell Therapeutics Inc. (“ SCTI ”), which was incorporated under the Business Corporations Act (Alberta) on December 22, 1999 and was continued under the Business Corporations Act (Ontario) on November 12, 2003 and then extra-provincially registered in Alberta on January 11, 2005. The office address of SCTI is 96 Skyway Avenue, Toronto, Ontario, Canada, M9W 4Y9. We have initiated the process to dissolve this inactive subsidiary.

35


D. Property, Plants and Equipment

We operate from approximately 10,000 square feet of leased laboratory and office space at 96 Skyway Avenue, Toronto, Ontario, Canada, M9W 4Y9. We perform research and development in our facility and use qualified vendors and collaborators to conduct research and development and manufacturing on our behalf. We incur capital expenditures mainly for laboratory equipment, office equipment, computer equipment and leaseholds in the operation of our business. As at June 30, 2014 the net carrying value of our property and equipment was $228,874.

ITEM 4A.                  UNRESOLVED STAFF COMMENTS

Not Applicable.

ITEM 5.                     OPERATING AND FINANCIAL REVIEW AND PROSPECTS

The following discussion and analysis of our financial condition and results of operations for the six months ended June 30, 2014 and 2013, the years ended December 31, 2013 and 2012, and the years ended December 31, 2012 and 2011, should be read in conjunction with our consolidated financial statements and related notes included in this registration statement in accordance with “Item 8. Financial Information”. Our consolidated financial statements were prepared in accordance with IFRS as issued by the IASB.

See “Item 17. Financial Statements” and the notes to the financial statements included as part of this registration statement for a discussion of the significant accounting policies and significant estimates and judgments required to be made by management.

A. Operating Results

For the three and six months ended June 30, 2014 and 2013

Net loss for the three months ended June 30, 2014 of $4,100,371 exceeded the loss of $1,376,687 for the same period in 2013 due mainly to higher SIRPaFc development costs, higher share-based compensation on the issuance of stock options and DSU units, due to the impairment loss on the return of the tigecycline rights to UHN, and higher share listing and professional fees. Net loss for the six months ended June 30, 2014 of $6,140,431 exceeded the loss of $1,712,265 for the same period in 2013 due mainly to the inclusion of Trillium Privateco results for six months in 2014, including personnel and the SIRPaFc program costs, compared to approximately three months in 2013, higher share-based compensation on the issuance of stock options and DSU units, and due to an impairment loss on the return of the tigecycline rights to UHN.

Research and Development

Components of research and development expenses for the three months ended June 30 were as follows:

36



    2014     2013  
    $     $  
Research and development programs excluding the below   900,461     308,458  
Salaries, fees and short-term benefits   532,228     430,532  
Share-based compensation   1,097,360     153,801  
Amortization of intangible assets   220,551     209,257  
Impairment of intangible assets   429,763     -  
Depreciation of property and equipment   13,878     4,425  
Tax credits   (88,839 )   (47,410 )
    3,105,402     1,059,063  

Components of research and development expenses for the six months ended June 30 were as follows:

    2014     2013  
    $     $  
Research and development programs excluding the below   1,823,075     413,836  
Salaries, fees and short-term benefits   1,049,376     482,683  
Share-based compensation   1,123,277     158,441  
Amortization of intangible assets   441,102     209,757  
Impairment of intangible assets   429,763     -  
Depreciation of property and equipment   20,130     4,425  
Tax credits   (215,839 )   (47,410 )
    4,670,884     1,221,732  

Our research and development expenses consist primarily of personnel-related costs, manufacturing and preclinical study services costs for external service providers, patent fees, share-based compensation and amortization of intangible assets.

The increase in program costs in the three months ended June 30, 2014 was due mainly to an increase in SIRPaFc expenses of $515,864 related to manufacturing and preclinical studies and an increase in tigecycline costs of $138,763, partially offset by lower patent costs due to discontinued technologies. Personnel costs increased due to higher staffing and salaries compared to 2013. Share-based compensation was higher due to a larger number of options outstanding in 2014 compared to the prior year. After a review of the tigecycline program, we returned the rights to UHN and recorded an impairment loss of $429,763 in the second quarter of 2014. R&D tax credits recorded were $88,839 for the second quarter of 2014 commensurate with the higher level of development activity compared to the prior period.

The increase in research and development expenses for the six months ended June 30, 2014 over the prior year period was due mainly to the inclusion of Trillium Privateco in 2014 for six months compared to just under three months in 2013. Program costs increased for the six months ended June 30, 2014 due mainly to an increase in SIRPaFc expenses of $935,380 related to manufacturing and preclinical studies, an increase in tigecycline costs of $288,763, an increase of $158,525 of sublicense fees and costs for our laboratory and office space for three additional months. Personnel costs increased due to mainly to Trillium Privateco’s research and development staff for six months in 2014 compared to three months in 2013. Share-based compensation was higher due to a larger number of options outstanding in 2014 year-to-date compared to the comparable period last year. Non-cash intangible asset related costs were higher from six months of amortization in 2014 compared to three months in 2013, and the recording of the impairment loss of $429,763 in the second quarter of 2014 related to the return of tigecycline rights. R&D tax credits recorded were $215,839 for the six months ended June 30, 2014 commensurate with the higher level of development activity compared to the prior period.

37


General and Administrative

Components of general and administrative expenses for the three months ended June 30 were as follows:

    2014     2013  
    $     $  
             
General and administrative, excluding the below   569,493     182,077  
Salaries, fees and short-term benefits   86,173     72,528  
DSU units issued for director compensation   240,000     -  
Share-based compensation   180,295     75,111  
    1,075,961     329,716  

Components of general and administrative expenses for the six months ended June 30 were as follows:

    2014     2013  
    $     $  
             
General and administrative, excluding the below   763,637     306,722  
Salaries, fees and short-term benefits   310,626     125,281  
DSU units issued for director compensation   240,000     -  
Share-based compensation   323,279     75,598  
    1,637,542     507,601  

General and administrative expenses consist mainly of professional fees, personnel costs related to corporate activities including directors’ fees, costs for shareholder related activities including investor relations, stock exchange fees and share-based compensation.

General and administrative costs for the three and six months ended June 30, 2014 were higher than the comparable prior year periods due mainly to listing fees on graduation to the TSX of $162,000 and higher professional fees. Personnel costs increased due mainly to higher directors’ fees and full-time administrative staff in 2014. Share-based compensation was higher than the comparable periods due mainly to a larger number of options outstanding in 2014 and payment of directors’ fees in the form of DSUs in 2014.

Finance Income and Costs

Finance income for the three and six months ended June 30, 2014 was higher than the prior year comparable period due mainly to investment income earned on  higher cash and marketable securities balances in 2014.

Finance costs for the three and six months ended June 30, 2014 were higher than the comparable period due mainly to interest accretion related to the loan payable and long-term liability.

For the years ended December 31, 2013 and 2012

Net loss for the year ended December 31, 2013 of $4,289,308 exceeded the loss of $1,061,502 for the year ended December 31, 2012 due mainly to higher personnel and facility costs with the inclusion of Trillium Privateco results from April 9, 2013 with a staff of 12 people, higher research and development program costs mainly due to the SIRPaFc program, higher professional fees and shareholder relations costs, higher amortization of intangible assets acquired with Trillium Privateco, and higher share-based compensation expenses.

38


Research and Development

Components of research and development expenses for the years ended December 31 were as follows:

    2013     2012  
    $     $  
Research and development programs excluding the below   1,411,264     418,479  
Salaries, fees and short-term benefits   1,299,055     209,588  
Share-based compensation   211,419     38,011  
Amortization of intangible assets   632,779     2,000  
Depreciation of property and equipment   16,010     4,382  
Tax credits   (233,821 )   (48,912 )
    3,336,706     623,548  

The increase in research and development expenses for the year ended December 31, 2013 over the prior year was due mainly to the inclusion of the Trillium Privateco results from April 9, 2013. Program costs increased with preclinical and lab expenses for the SIRPaFc program of $402,558 compared to $139,110 in the prior year for legacy programs, higher patent fees of $230,126 due in part to a favorable patent interference settlement which provided gross proceeds of US$250,000 in Q4-2012 related to legacy programs (which lowered program expenses), and lab and office facility costs of $192,155 not in the prior year. Personnel costs increased due to Trillium Privateco’s research and development staff and amortization of intangible assets increased due to the Trillium Privateco and UHN intangible assets acquired in Q2-2013.

39


General and Administrative

Components of general and administrative expenses for the years ended December 31 were as follows:

    2013     2012  
    $     $  
             
General and administrative, excluding the below   599,785     269,849  
Salaries, fees and short-term benefits   254,952     199,943  
Share-based compensation   107,463     (3,505 )
    962,200     466,287  

General and administrative costs for the year ended December 31, 2013 were higher than the comparable prior year due mainly to higher professional fees related to the Trillium Privateco merger and UHN license agreements, stock exchange and transfer agent fees related to the issuances of shares and warrants related to the merger and UHN license, higher share-based compensation expenses, costs of participating on the OTCQX International, and slightly higher personnel costs.

Finance Income and Costs

Finance income for the year ended December 31, 2013 was higher than the prior year due mainly to investment income earned on the $33 million financing proceeds received in December 2013. Finance costs for the year ended December 31, 2013 were higher than the comparable period due mainly to interest accretion on the loan payable and long-term liability.

For the years ended December 31, 2012 and 2011

Net loss for the year ended December 31, 2012 was $1,061,502 compared to a loss of $3,173,947 for the year ended December 31, 2011. The decrease in 2012 resulted mainly due to a cost reduction plan initiated in the second half of 2011 which reduced staff and overhead, and due to lower non-cash costs for amortization and impairment of intangible assets and share-based compensation. The net loss was also lower due to a favorable patent interference settlement which provided gross proceeds of US$250,000 to us.

Research and Development

Components of research and development expenses for the years ended December 31 were as follows:

    2012     2011  
    $     $  
Research and development programs excluding the below   418,479     703,828  
Salaries, fees and short-term benefits   209,588     466,495  
Termination costs   -     132,615  
Share-based compensation   38,011     171,603  
Impairment of intangible assets   -     665,416  
Amortization of intangible assets   2,000     243,117  
Depreciation of property and equipment   4,382     9,295  
Tax credits   (48,912 )   (56,968 )
    623,548     2,335,401  

40



The decrease in research and development expense for the year ended December 31, 2012 from the 2011 year was due mainly to a US$250,000 favorable patent interference settlement in 2012 where we withdrew certain pending and issued patents to treat Parkinson's disease (which lowered program expenses), lower personnel and overhead costs in 2012 as we terminated three employees and sourced external management for our clinical program in the fourth quarter of 2011, and the recognition of an impairment loss in 2011 of $665,416 related to acquired technology no longer being pursued and certain patents with limited or no benefit within our development plans, and consequently determined to have no future value. Research and development expenses also decreased due to lower amortization of intangible assets, and lower share-based compensation due to fewer stock options issued in the period.

General and Administrative

Components of general and administrative expenses for the years ended December 31 were as follows:

    2012     2011  
    $     $  
             
General and administrative, excluding the below   269,849     343,861  
Salaries, fees and short-term benefits   199,943     296,016  
Termination costs   -     56,000  
Share-based compensation   (3,505 )   161,555  
Depreciation of property and equipment   -     3,198  
    466,287     860,630  

General and administrative costs for the year ended December 31, 2012 decreased significantly from the prior year’s comparable period due to the impact of lower administrative staffing in 2012, reduced office overhead and the closure of our Calgary office in early 2012 to establish further cost savings. Share-based compensation was also lower in 2012 reflecting a net year-to-date reversal of expense due to forfeitures and no option grants to administrative staff in 2012.

Finance Income and Costs

Finance income was down in 2012 due mainly to lower investment income on lower average cash balances in the year, partially offset by a small net foreign currency gain on U.S. dollar balances. Finance costs were lower due mainly to a net foreign exchange loss in 2011 whereas there was a small net gain in 2012.

B. Liquidity and Capital Resources

Since inception, we have financed our operations primarily from sales of equity, proceeds from the exercise of warrants and stock options, and from interest income on funds available for investment.

Our primary capital needs are for funds to support our scientific research and development activities including manufacturing, preclinical and clinical trials, administrative costs and for working capital.

41


We have experienced operating losses and cash outflows from operations since incorporation, will require ongoing financing in order to continue our research and development activities, and we have not earned significant revenue or reached successful commercialization of our products. Our future operations are dependent upon our ability to finance our cash requirements which will allow us to continue our research and development activities and the commercialization of our products. There can be no assurance that we will be successful in continuing to finance our operations.

We filed a base shelf prospectus with the British Columbia, Alberta, Manitoba, Ontario and Nova Scotia securities commissions in Canada on May 26, 2014 that provides that we may sell under the prospectus from time to time over the following 25 months up to $50 million, in one or more offerings, of common shares, First Preferred shares, warrants to purchase common shares, or units comprising common shares, First Preferred shares and warrants.

We believe we have sufficient resources available to support our activities for at least the next 12 months of operations.

There are a significant number of warrants outstanding, some of which are in-the-money and may provide future liquidity. See “Item 10.A Warrants”.

June 30, 2014 Compared to December 31, 2013

Our cash and marketable securities totaled $30,544,979 at June 30, 2014 compared to $32,983,104 at December 31, 2013. As at June 30, 2014, our working capital of $30,017,503 was comparable to the amount of $32,772,281 at December 31, 2013. Accounts payable and accrued liabilities as at June 30, 2014 were $1,012,226 compared to $669,860 at December 31, 2013. The increase in accounts payable was due mainly to higher development costs and professional fees. Amounts receivable as at June 30, 2014 were $487,319 compared to $427,234 at December 31, 2013. The increase in amounts receivable was due mainly to recording of expected refundable scientific research and development tax credits for the six months ended June 30, 2014 partly offset by harmonized sales tax refunds received in the period.

We are indebted to FedDev under a non-interest-bearing contribution agreement dated February 1, 2012 which supported the clinical development of TTI-1612. The period of contribution ended on December 31, 2013. As at December 31, 2013, we had repayable contributions of $575,139 representing the outstanding principal balance, repayable in equal monthly installments for 60 months beginning on December 1, 2014. The loan payable bears no interest. On the acquisition of Trillium Privateco, the fair value of the loan payable was determined by discounting the loan payable using an estimated market interest rate of 15%. Interest expense accretes on the discounted loan amount until it reaches its face value at maturity.

We have a long-term liability of $169,784 related to certain discontinued technologies. This liability has been discounted using an estimated market interest rate of 15% and interest expense is accreting.

As at June 30, 2013 and in the normal course of business, we had obligations to make future payments, representing research and development contracts and other commitments that are known and committed in the amount of $2,207,000 over the next 12 months, $97,000 from 12 to 24 months, $55,000 from 24-36 months, and $25,000 each year thereafter.

We enter into research, development and license agreements in the ordinary course of business where we receive research services and rights to proprietary technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain.

42


We periodically enter into research and license agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require us to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken by or on our behalf. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents us from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, we have not made any indemnification payments under such agreements and no amount has been accrued in our financial statements with respect to these indemnification obligations.

December 31, 2013 Compared to December 31, 2012

Our cash and marketable securities totaled $32,983,104 at December 31, 2013 compared to $1,375,015 at December 31, 2012. The increase in our cash resources resulted from two financings in 2013 where we raised gross proceeds of $36 million.

As at December 31, 2013 our working capital was $32,772,281. Accounts payable and accrued liabilities as at December 31, 2013 were $669,860 compared to $185,258 at December 31, 2012. The increase in accounts payable was due mainly to the addition of the Trillium Privateco operations.

December 31, 2012 Compared to December 31, 2011

Our cash and cash equivalents totaled $1,375,015 at December 31, 2012 compared to $2,696,764 at December 31, 2011. As at December 31, 2012 our working capital was $1,379,970 compared to $2,400,584 at December 31, 2011. The decrease in our cash resources and working capital was due mainly to operating expenditures in 2012 as no new funding was received.

C. Research and Development, Patents and Licenses, etc.

During 2013, we refocused our product pipeline through the strategic acquisition of Trillium Privateco on April 9, 2013, which included the SIRPaFc and CD200 mAb preclinical cancer programs, and the TTI-1612 IC program which is available for out-license. On April 16, 2013, we completed a license agreement with UHN to gain rights to intellectual property related to the use of tigecycline for the treatment of leukemia. In August 2014, we returned these rights to UHN and expanded our SIRPaFc research and development program to include preclinical work on additional cancer indications and combinations with other therapies. Substantially all of our research and development resources are focused on the SIRPaFc program.

Prior to the April 2013 merger with Trillium Privateco, we were developing regenerative stem cell products and sought new technologies to develop. In July 2013, we ceased all activities associated with our pre-merger regenerative medicine neurology programs and abandoned all related intellectual property filings.

43


Research and development expenditures for the preceding three years were as follows:


Program
Year ended
December 31, 2013
($)
Year ended
December 31, 2012
($)
Year ended
December 31, 2011
($)
SIRPaFc $1,913,051 - -
Tigecycline $642,879 - -
TTI-1612 $328,459 - -
Regenerative medicine programs discontinued in 2013 $409,278 $623,548 $2,335,401
Other programs $43,039 - -
Total $3,336,706 $623,548 $2,335,401

Notes:

(1)

Research and development expenditures in the above table include all direct and indirect costs for the programs, personnel costs, intellectual property related costs net of recoveries, share-based compensation and research and development overhead, and is net of government assistance.

We rely on patents and licenses to enable the commercialization of our novel technologies. See “Item 4. Information on the Company” and “Item 4.B. Information on the Company – Intellectual Property”.

D. Trend Information

Historical patterns of expenditures cannot be taken as an indication of future expenditures. The amount and timing of expenditures and therefore liquidity and capital resources vary substantially from period to period depending on the number of research and development programs being undertaken at any one time, the stage of the development programs, the timing of significant expenditures for manufacturing, toxicology and pharmacology studies and clinical trials, and the availability of funding from investors and prospective commercial partners.

Expenses for the three months ended March 31, 2013 were lower due to low development activity levels while we sought new products for development. Subsequent to the April 9, 2013 Trillium Privateco merger, expenses increased significantly as we acquired twelve personnel and an approximately 10,000 square foot leased laboratory and office facility, and thereafter licensed additional technology assets from UHN. In December 2013, we completed a private placement raising gross proceeds of $33 million to advance our SIRPaFc program through phase I clinical trials. Management expects 2014 expenditures will increase significantly from 2013 levels as we advance our SIRPaFc program through IND-enabling studies and incur increased manufacturing costs.

E. Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

F. Tabular Disclosure of Contractual Obligations

Other than as disclosed below, we did not have any contractual obligations as at December 31, 2013 relating to long-term debt obligations, capital (finance) lease obligations, operating lease obligations, purchase obligations or other long-term liabilities reflected on our balance sheet as at December 31, 2013:

44


Contractual Obligations (1)

Payments due by period ($)

Total
Less than 1
Year
1 to 3
Years
3 to 5
Years
More than
5 Years
Long-Term Debt Obligations (2) $575,139 $9,586 $230,064 $335,489 -
Capital (Finance) Lease Obligations - - - - -
Operating Lease Obligations (3) $194,192 $73,959 $71,511 $48,722 -
Purchase Obligations (4) $63,317 $63,317 - - -
Other Long-Term Liabilities Reflected on our Balance Sheet under IFRS (5) $212,720 $53,180 $106,360 $53,180 -
Total $1,045,368 $200,042 $407,935 $437,391 -

Notes:

  (1)

Contractual obligations in the above table do not include amounts in accounts payable and accrued liabilities on our balance sheet as at December 31, 2013. Annual technology license fees currently approximating $60,000 are not included in the above table.

  (2)

Amounts due to FedDev repayable in equal monthly installments for 60 months beginning on December 1, 2014.

  (3)

Operating lease obligations for laboratory and office facilities currently expire in August 2016.

  (4)

Amounts for research and development service agreements. As at June 30, 2014, purchase obligations were $2,133,000 which included contracts for manufacturing and preclinical studies.

  (5)

Long-term liability related to the cessation of the development of our regenerative medicine products.

G. Safe harbor

Not Applicable.

ITEM 6.                     DIRECTORS, SENIOR MANAGEMENT & EMPLOYEES

A. Directors and Senior Management

The following table and summary of business experience set forth the name, office held, and functions and areas of experience in the Company, principal business activities and other principal directorships of each of our Directors and senior management:

Name
Present Office Held
Position
Held
Since
Principal Business Activities and
Other Principal Directorships
Luke Beshar
Director (1)
March 10, 2014

Mr. Beshar is the EVP and CFO, NPS Pharmaceuticals, Inc. a global biopharmaceutical company since January 2012 and was the SVP and CFO, NPS Pharmaceuticals, Inc. from November 2007 to December 2011.

Henry Friesen
Director (1) (2)
June 28, 2011

Dr. Friesen is a Distinguished University Professor Emeritus, University of Manitoba since October 2000.

Robert Kirkman
Director (1) (3)
December 17, 2013

Dr. Kirkman is President and CEO and director of Oncothyreon Inc., an oncology-focused biotechnology company since September 2006.

45



Michael Moore
Director (2) (3)
April 9, 2013

Dr. Moore is the Executive Chair of MISSION Therapeutics Ltd. since 2012 and a Board Chair or Director of several private biopharmaceutical companies in the UK. From 2004 to 2013, Dr. Moore was the Chair of Trillium Privateco, and from 2003 to 2008, Dr. Moore was the CEO and Director, PIramed Ltd, a UK-based oncology company sold to Roche in 2008.

Thomas Reynolds
Director (2)(3)
March 10, 2014

Dr. Reynolds is an independent biotechnology consultant since February 2013, and was Chief Medical Officer, Seattle Genetics, Inc., a biotechnology company focused on antibody-based therapies for the treatment of cancer from March 2007 to January 2013. Dr. Reynolds also sits on the board of MEI Pharma, Inc.

Calvin Stiller
Director, Chair of the Board
July 18, 2011

Dr. Stiller is the Chair, Ontario Institute for Cancer Research, and Professor Emeritus, Western University. Dr. Stiller also sits on the board of Revera Corporation and Magor Corporation.

Niclas Stiernholm
President and Chief
Executive Officer, Director
Director since July 18, 2011; President and CEO since April 9, 2013

Dr. Stiernholm is the President and Chief Executive Officer of Trillium since April 9, 2013 and was the President and Chief Executive Officer of Trillium Privateco since 2002. He joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer.

Robert Uger
Chief Scientific Officer
April 9, 2013

Dr. Uger is the Chief Scientific Officer of Trillium since April 9, 2013 and was the Vice President, Research of Trillium Privateco since 2003. He joined Trillium from Aventis Pasteur where he was a Senior Research Scientist involved in cancer vaccine research.

James Parsons
Chief Financial Officer
August 25, 2011

Mr. Parsons is the Chief Financial Officer of Trillium since August 25, 2011 and was also the Director, Finance of Trillium Privateco. He was previously the Vice President, Finance of DiaMedica Inc. from October 2010 to May 2014, and Chief Financial Officer of Amorfix Life Sciences Ltd. from 2006 to 2010. Mr. Parsons sits on the board of Sernova Corp.

Penka Petrova
Vice-President, Drug Development
April 9, 2013

Dr. Petrova is the Vice President, Drug Development of Trillium since April 9, 2013 and was the Director, Drug Development of Trillium Privateco from June 2011 to March 2013. Dr. Petrova joined Trillium Privateco from Prescient Neuropharma in 2003.

Notes:

  (1)

Member of the Audit Committee.

  (2)

Member of the Corporate Governance and Nominating Committee.

  (3)

Member of the Compensation Committee.

Summary of Business Experience and Functions within the Company

Luke Beshar, CPA - Director, Chair of the Audit Committee

Mr. Beshar is Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals. He joined NPS Pharmaceuticals in 2007 and has been responsible for financial management, investor relations, information technology, technical operations, supply-chain management, facilities, project management, contracts and outsourcing and strategic and alliance management. Prior to joining NPS, Mr. Beshar served as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a global life sciences company. Mr. Beshar began his career with Arthur Andersen & Co. and is a certified public accountant.

46


He obtained his bachelor's degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia.

Dr. Henry Friesen - Director

Dr. Friesen was the President of the Canadian Government's Medical Research Council, and the architect and lead champion for the creation the Canadian Institutes for Health Research, President of the National Cancer Institute of Canada and President of the Canadian Society for Clinical Investigation. He is the Past Founding Chair of Genome Canada. A Fellow of the Royal Society of Canada, Dr. Friesen was named a Companion of the Order of Canada and was inducted into the Canadian Medical Hall of Fame in 2001 and, later the Order of Manitoba. He was also awarded the Gairdner Foundation Wightman Award, the McLaughlin Medal of the Royal Society of Canada, and the Koch Medal, the highest award of the Endocrine Society. He was presented with the Frederic Newton Gisborne Starr Award by the Canadian Medical Association, the association's highest award, in 2006. Dr. Friesen also holds eight Honorary Doctorates from Canadian universities.

Dr. Robert Kirkman - Director

Dr. Kirkman has served as Oncothyreon's President and Chief Executive Officer since September 2006. From 2005 to 2006, he was acting President and Chief Executive Officer of Xcyte Therapies, which concluded a merger with Cyclacel Pharmaceuticals, both development-stage biopharmaceutical companies, in March of 2006. From 2004 to 2005, Dr. Kirkman was Chief Business Officer and Vice President of Xcyte. From 1998 to 2003, Dr. Kirkman was Vice President, Business Development and Corporate Communications of Protein Design Labs, a biopharmaceutical company. Dr. Kirkman holds a M.D. degree from Harvard Medical School and a B.A. in economics from Yale University.

Dr. Michael Moore - Director

Dr. Moore is currently Executive Chairman, MISSION Therapeutics Limited, a UK drug discovery company targeting deubiquitinating enzymes for multiple disease indications. He also holds non-executive positions with other UK biopharmaceutical companies. From 2004-2013, Dr Moore was non-executive chair of Trillium Privateco and from 2003-2008 Chief Executive Officer and Director of PIramed Ltd, a UK-based biotechnology company developing small molecule drugs against the PI-3 kinase superfamily, which was acquired by Roche. Prior to PIramed, he held several progressive positions at Xenova Group plc (1988-2003), including Chief Scientific Officer and Research Director. Dr. Moore held a tenured Cancer Research Campaign position (1980) at the Paterson Institute for Cancer Research, was Honorary Reader in Immunology and Oncology at the University of Manchester Medical School (1986), and Editor-in-chief, British Journal of Cancer (1983). Dr. Moore received his PhD (Faculty of Pure Science) and DSc (Faculty of Medicine) from Nottingham University and has more than 150 scientific publications.

Dr. Thomas Reynolds - Director

Dr. Reynolds served as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February, 2013. While at Seattle Genetics, he was responsible for building and leading an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of ADCETRIS. From 2002 to 2007, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM. Previously, he was Vice President, Clinical Affairs at Targeted Genetics, and before that he was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds received his M.D., and Ph.D. in Biophysics, from Stanford University and a B.A. in Chemistry from Dartmouth College.

47


Dr. Calvin Stiller - Director, Chair of the Board of Directors

Dr. Stiller is a Member of the Order of Canada and the Order of Ontario, was the recipient of the Canada Gairdner Wightman Award in 2011 (awarded to a Canadian who has demonstrated outstanding leadership in medicine and medical science) and was inducted into the Canadian Medical Hall of Fame in 2010. Dr. Stiller is chair of the Ontario Institute for Cancer Research, the former chair of Genome Canada and is Professor Emeritus in the Departments of Medicine, and Immunology and Bacteriology at the University of Western Ontario. Dr. Stiller founded the J. Allyn Taylor International Prize in Medicine, co-founded the Medical and Related Sciences Research District (“ MaRS ”), was the Chair of the Ontario Research and Development Challenge Fund Board and was the co-founder of four venture capital funds of over $500 million. He serves on the boards of a number of private and public companies, was founding Chair of Trillium Privateco and was chair of Verio Therapeutics, a Canadian stem cell company that was acquired in 2010 by Fate Corporation, a California-based regeneration company. Together with Robert Klein (the founder of the California Institute of Regenerative Medicine, a state agency responsible for granting approximately $3 billion in stem cell research funding), he co-founded the Cancer Stem Cell Initiative, a Canada-California consortium that has been productive in the search for and identification of cancer stem cells. He serves on the board of Revera Corporation, one of the nation’s largest healthcare and seniors company.

Dr. Niclas Stiernholm - President and Chief Executive Officer, Director

Dr. Stiernholm became the President and Chief Executive Officer on our merger with Trillium Privateco in April 2013. Previously, as President and Chief Executive Officer of Trillium Privateco since 2002, Dr. Stiernholm spearheaded the in-licensing of our development technologies, raised over $23 million in venture capital financing, and raised non-dilutive funding from several out-licensing transactions with pharmaceutical partners. Dr. Stiernholm joined Trillium Privateco from YM BioSciences where he was Executive Vice President and Chief Scientific Officer. While there, he played a significant role in the success of their Initial Public Offering in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals' business development office. He currently serves on the boards of the Ontario Genomics Institute, AvidBiologics and Vasomune Therapeutics. He received his Ph.D. in Immunology from the University of Toronto, where he also completed his postdoctoral training.

Dr. Robert Uger - Chief Scientific Officer

Dr. Uger became the Chief Scientific Officer on our merger with Trillium Privateco in April 2013. Dr. Uger is responsible for developing and implementing our scientific direction, and overseeing both internal product development and external research discovery programs. He also acts as our scientific liaison with respect to global collaborations with academic and hospital research scientists. Dr. Uger joined Trillium Privateco in 2003 from Aventis Pasteur where he was a Senior Research Scientist involved in cancer vaccine research. He received his Ph.D. in Immunology from the University of Toronto.

48


James Parsons, CPA-CA - Chief Financial Officer

Mr. Parsons joined us in August 2011 and Trillium Privateco in 2003 on a part-time basis, and became full-time in June 2014. Mr. Parsons has an extensive background in the life sciences industry and over 25 years of financial management experience. Mr. Parsons was the Vice-President, Finance for DiaMedica Inc. from October 2010 to May 2014, and the Chief Financial Officer and Corporate Secretary for Amorfix Life Sciences Ltd. from 2006 to 2010 where his responsibilities included finance, administration, commercialization, risk management, and corporate governance. Mr. Parsons has been a CFO and advisor in the life sciences industry since 2000 with early-stage to late-clinical stage biotechnology companies across many therapeutic, diagnostic and device areas. Mr. Parsons has a Master of Accounting degree from the University of Waterloo and is a Chartered Professional Accountant and Chartered Accountant.

Dr. Penka Petrova - Vice President, Drug Development

Dr. Petrova became the Vice President, Drug Development on our merger with Trillium Privateco in April 2013. Dr. Petrova is responsible for managing our formal drug development efforts, including all outsourced activities to contract research organizations. In addition, she continues to serve as the Head of Trillium’s cell biology group and oversees all the in vivo studies. Dr. Petrova joined Trillium Privateco from Prescient Neuropharma in 2003, where she was a Research Scientist and was involved in identifying and characterizing novel proteins involved in neuroprotection. Dr. Petrova received her Ph.D. in Microbiology from Saarland University in Saarbruecken, Germany, where she also conducted her post doctoral studies.

Family Relationships

There are no family relationships among our directors and senior management.

Other Arrangements

There are no arrangements or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or member of senior management.

B. Compensation

For the year ended December 31, 2013, our directors and members of our administrative, supervisory or management bodies received compensation for services, as follows:

49






Name and Principal Position
Salary/
Fees
earned (1)
($)
Share-
based
awards
($)
Option-
based
awards (2)
($)
Non-equity
incentive plan
compensation (3)
($)


Total
($)
Niclas Stiernholm (4)
President & Chief Executive Officer
and Director
222,500

Nil

262,679

120,000

605,179

Robert Uger (4)
Chief Scientific Officer
137,750
Nil
52,536
47,500
237,786
James Parsons (5)    106,042              Nil 26,268 25,000  157,310
Chief Financial Officer          
Luke Beshar (6)
Director
Nil
Nil
Nil
Nil
Nil
Henry Friesen
Director
20,000
Nil
27,810
Nil
47,810
Robert Kirkman (6)
Director
Nil
Nil
Nil
Nil
Nil
Michael Moore (6)
Director
15,000
Nil
24,720
Nil
39,720
Thomas Reynolds (6)
Director
Nil
Nil
Nil
Nil
Nil
Calvin Stiller
Director, Chair
20,000
Nil
24,720
Nil
44,720
David Allan (7)
Executive Chair and Director
161,250
Nil
30,900
Nil
192,150
James DeMesa (8)
Director
20,000
Nil
20,600
Nil
40,600
Dean Peterson (8)
Director
20,000
Nil
20,600
Nil
40,600

Notes:

  (1)

For the year ended December 31, 2013, we compensated each director with an annual retainer of $20,000 and the chair with an additional annual retainer of $10,000.

  (2)

The option-based awards value is the grant date fair value of stock options granted in the year calculated in accordance with IFRS using the Black-Scholes option pricing model.

  (3)

These payments reflect cash bonuses on the achievement of the 2013 corporate objectives.

  (4)

Prior to becoming the President and CEO, Dr. Stiernholm was a director of ours and received $5,000 in fees for the first quarter of 2013. Dr. Stiernholm and Dr. Uger joined us upon the acquisition of Trillium Privateco on April 9, 2013 and the salaries paid were for the period from this date to the end of 2013. Dr. Stiernholm’s annual salary for 2013 was $300,000 and Dr. Uger’s salary for 2013 was $190,000. Subsequent to the Trillium Privateco merger Dr. Stiernholm was not compensated as a director.

  (5)

Mr. Parsons worked on a part-time basis in 2013.

  (6)

Michael Moore, Robert Kirkman, Luke Beshar and Thomas Reynolds were appointed to the Board of Directors on April 9, 2013, December 17, 2013, March 10, 2014, and March 10, 2014, respectively.

  (7)

Mr. Allan was an officer of ours to May 31, 2013, and a consultant thereafter. Mr. Allan also received compensation as a director beginning Q2-2013. David Allan resigned as a director on January 25, 2014.

  (8)

Dr. DeMesa resigned as a director on March 7, 2014. Mr. Peterson resigned as a director on March 6, 2014.

Employment Agreements

Effective June 3, 2014, we entered into an employment agreement with Niclas Stiernholm which has an indefinite term and provides for his employment as President and Chief Executive Officer. The agreement provides for compensation with respect to Dr. Stiernholm’s annual base salary of $390,000 and participation in our bonus plan and stock option plan. Dr. Stiernholm’s agreement provides for severance pay of 15 months salary plus bonus if terminated without cause and 18 months salary plus bonus if terminated on a change in control. If the severance is as a result of a change in control, all unvested stock options will also immediately vest.

50


Effective June 3, 2014, we entered into an employment agreement with Robert Uger which has an indefinite term and provides for his employment as Chief Scientific Officer. The agreement provides for compensation with respect to Dr. Uger’s annual base salary of $270,000 and participation in our bonus plan and stock option plan. Dr. Uger’s agreement provides for severance pay of nine months base salary remuneration. If the severance is as a result of a change in control, all unvested stock options will also immediately vest.

Effective June 3, 2014, we entered into an employment agreement with James Parsons which has an indefinite term and provides for his employment as Chief Financial Officer. The agreement provides for compensation with respect to Mr. Parsons annual base salary of $250,000 and participation in our bonus plan and stock option plan. Mr. Parsons’ agreement provides for severance pay of nine months base salary remuneration. If the severance is as a result of a change in control, all unvested stock options will also immediately vest.

Effective June 3, 2014, we entered into an employment agreement with Penka Petrova which has an indefinite term and provides for her employment as Vice President, Drug Development. The agreement provides for compensation with respect to Dr. Petrova’s annual base salary of $205,000 and participation in our bonus plan and stock option plan. Dr. Petrova’s agreement provides for severance pay of six months base salary remuneration. If the severance is as a result of a change in control, all unvested stock options will also immediately vest.

Stock Option Plan

We have adopted a stock option plan (the “ 2014 Stock Option Plan ”) that provides for the granting of stock options to officers, directors, employees and consultants of ours and our affiliates. The purpose of the 2014 Stock Option Plan is to advance our interests by encouraging our directors, officers and key employees and consultants retained to acquire common shares, thereby: (a) increasing the proprietary interests of such persons in us; (b) aligning the interests of such persons with the interests of our shareholders generally; (c) encouraging such persons to remain associated with us; and (d) furnishing such persons with an additional incentive in their efforts on behalf of us. As at June 30, 2014, pursuant to the 2014 Stock Option Plan, we are entitled to issue an additional 1,641,635 options.

The following is a summary only, and is qualified in its entirety by the terms and conditions of the 2014 Stock Option Plan, which is attached as an exhibit to this Form 20-F.

Administration by the Board of Directors

The 2014 Stock Option Plan is administered by our Board of Directors which has final authority and discretion, subject to the express provisions of the 2014 Stock Option Plan, to interpret the 2014 Stock Option Plan, to prescribe, amend and rescind rules and regulations relating to it and to make all other determinations deemed necessary or advisable for the administration of the 2014 Stock Option Plan. This includes the discretion of the Board of Directors to decide who will participate in the 2014 Stock Option Plan, including directors, officers, employees or consultants (the “ Participants ”). The Board of Directors also has authority to delegate its duties to the Compensation Committee.

Expiry

Options granted under the 2014 Stock Option Plan (the “ Options ”) are non-transferable, expire not later than ten years from the date of issuance and are exercisable as determined by the Board of Directors. In addition, notwithstanding the expiration date applicable to any Option, if an Option would otherwise expire during or immediately after a Blackout Period (as defined in the 2014 Stock Option Plan), then the expiration date of such Option shall be the 10th business day following the expiration of the Blackout Period, provided that in no event shall the period during which said Option is exercisable be extended beyond 10 years from the date such Option is granted to the Participant.

51


Exercise Price

The exercise price payable in respect of each Option may not be lower than the volume weighted average trading price of the common shares on the TSX over a period of five days preceding the date of grant.

Insider Participation Limit

The aggregate number of common shares issuable (or reserved for issuance) to Insider Participants under the 2014 Stock Option Plan or any other security-based compensation arrangement of ours and our affiliates (including, without limitation, our 2014 Deferred Share Unit Plan (the “ 2014 DSU Plan ”), may not at any time exceed 10% of the combined total number of common shares issued and outstanding (on a non-diluted basis) and the total number of common shares into which the outstanding Series I First Preferred Shares may be converted. Common shares issued to Insider Participants under the 2014 Stock Option Plan or any other security-based arrangement of ours within a one-year period may not exceed 10% of the total number of common shares issued and outstanding (on a non-diluted basis) plus 10% of the total number of common shares into which the outstanding Series I First Preferred Shares may be converted.

Amendment Provisions

The Board of Directors has the discretion to make amendments to the 2014 Stock Option Plan and any Options granted thereunder which it may deem necessary, without having to obtain shareholder approval. Such changes include, without limitation:

  • minor changes of a “housekeeping” nature;

  • amending Options under the 2014 Stock Option Plan, including with respect to the Option Period (provided that the period during which an Option is exercisable does not exceed ten years from the date the Option is granted and that such Option is not held by an Insider Participant), vesting period, exercise method and frequency, exercise price of an Option (provided that such Option is not held by an Insider Participant) and method of determining the exercise price, assignability and effect of termination of a Participant’s employment or cessation of the Participant’s directorship;

  • changing the class of Participants eligible to participate under the 2014 Stock Option Plan;

  • accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an Insider Participant), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted;

  • changing the terms and conditions of any financial assistance which may be provided by us to Participants to facilitate the purchase of common shares under the 2014 Stock Option Plan; and

  • adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying common shares from the 2014 Stock Option Plan reserve.

52


Shareholder approval will be required in the case of: (i) any amendment to the amendment provisions of the 2014 Stock Option Plan; (ii) any increase in the maximum number of common shares issuable under the 2014 Stock Option Plan; and (iii) any reduction in the exercise price or extension of the Option Period benefiting an Insider Participant, in addition to such other matters that may require Shareholder approval under the rules and policies of the TSX.

Termination, Resignation, Death, etc.

Options granted under the 2014 Stock Option Plan are, and will be, evidenced by an option agreement entered between us and the Participant. Options granted under the plan terminate immediately if a Participant is dismissed with cause. If a Participant ceases to hold any position as a Participant, by reason of retirement, resignation or disability, the vested options terminate within 120 days from cessation. Under the 2014 Stock Option Plan, the Board of Directors has been provided with discretion to extend the time to termination for cessation beyond 120 days but no longer than the normal expiry of the Option. Under the 2014 Stock Option Plan, if a Participant dies, his options may be exercised by his legal representatives during the period of (and they shall terminate) one year following the date to the extent they were exercisable on the date of death. If a Participant ceases to be a director, officer or employee of, or consultant to, the Company or of one of our subsidiaries as a result of disability or illness preventing the Participant from performing the duties routinely performed by such Participant, vested options terminate 180 days from the date that the Participant ceases to serve in such capacities (or until the normal expiry date of the Options if earlier).

Change of Control

The 2014 Stock Option Plan provides that any Options outstanding immediately prior to the occurrence of a Change of Control (as defined in the plan), but which are not then exercisable, shall immediately vest and become fully exercisable upon the occurrence of a Change of Control.

Maximum Limit

The 2014 Stock Option Plan is a “rolling” and “reloading” stock option plan, meaning that Options may be granted for no more than 10% of the total number of common shares issued and outstanding (on a non-diluted basis) plus 10% of the total number of common shares into which the outstanding Series I First Preferred Shares may be converted in accordance with their terms less the number of any common shares reserved for issuance to insiders of ours pursuant to the 2014 DSU Plan. Each exercise of Options will result in a corresponding increase in the number of Options available for granting under the 2014 Stock Option Plan, up to the 10% aggregate maximum limit. There are additional restrictions in the 2014 Stock Option Plan with regard to the number of Options that may be granted which include the restriction that the aggregate number of Options granted in any 12 month period to any one person cannot exceed 5% of the aggregate total number of issued and outstanding common shares (on a non-diluted basis) and common shares into which the outstanding Series I First Preferred Shares may be converted in accordance with their terms.

53


Other Terms

Any consolidation or subdivision of common shares will be reflected in an adjustment to the stock options.

Deferred Share Unit Plan

Our shareholders approved the 2014 DSU Plan on May 27, 2014. The 2014 DSU Plan is intended to promote a greater alignment of long-term interests between non-executive directors and executive officers of ours and its shareholders through the issuance of deferred share units (“ DSUs ”). Since the value of a DSU increases or decreases with the market price of the common shares, DSUs reflect a philosophy of aligning the interests of directors and executive officers with those of the shareholders by tying compensation to share price performance. The Board of Directors intends to use DSUs issued under the 2014 DSU Plan, as well as Options issued under the 2014 Stock Option Plan, as part of our overall director and executive officer compensation program. A total of 863,310 units were issued and outstanding as at June 30, 2014.

Overview of the 2014 DSU Plan

The 2014 DSU Plan provides that, subject to the terms of the 2014 DSU Plan and such other conditions as the Board of Directors (or Compensation Committee of the Board of Directors after delegation by authority from the Board of Directors) may impose, an executive officer or director of ours (an “ Eligible Person ”) shall receive his or her Total Compensation in the form of DSUs. The term, “ Total Compensation ” includes annual and special bonuses payable to directors and executive officers and, in the case of directors, directors fees (including annual board retainers, fees for serving as Chair of the Board of Directors and/or as a Chair or member of any committee of the Board of Directors, for attending meetings of the Board of Directors or any committee thereof, and any other fees payable to directors) in the form of DSUs. The Board of Directors may use DSUs to pay bonuses and directors fees either alone or in conjunction with cash, or any combination of DSUs and cash.

The number of DSUs (including fractional DSUs, computed to three digits) to be credited to an Eligible Person for services will be determined by dividing the Awarded Amount by the Fair Market Value as at the last trading day before the date the Awarded Amount is declared by the Board of Directors. “ Fair Market Value ” of the Common Shares is the volume weighted average trading price of the Common Shares on the TSX for the five days immediately preceding the date in question.

An Eligible Person who has ceased to be a director or executive officer (other than as a result of death) may elect to receive one common share in respect of each whole DSU credited to the Eligible Person’s account by filing with us a notice of redemption in the form and by the time stipulated in the 2014 DSU Plan.

If the Eligible Person does not make the election on a timely basis, the Eligible Person will be deemed to have elected to redeem all of his or her DSUs.

The issuance of the common shares will be made by us as soon as reasonably possible following the election to redeem the DSUs, or being deemed to have been made, by the Eligible Person.

54


Maximum Number of Shares issuable under the Plan

The “ Outstanding Issue ” means the combined total of the number of common shares outstanding and the number of common shares into which the Series I First Preferred Shares outstanding (on a non-diluted basis) may be converted in accordance with their terms. The maximum number of common shares reserved for issuance under the 2014 DSU Plan is 2,000,000, which is approximately 1.0% of the current Outstanding Issue.

The 2014 DSU Plan provides that the maximum number of common shares that may be reserved for issuance to Insiders (as that term is defined in the TSX’s rules) pursuant to the 2014 DSU Plan, together with any common shares issuable pursuant to any other securities-based compensation arrangement of ours (including the 2014 Stock Option Plan), will not exceed 10% of the Outstanding Issue.

In addition, the maximum number of common shares that may be issued to Insiders under the 2014 DSU Plan, together with any common shares issued to Insiders pursuant to any other securities-based compensation arrangement of ours (including the 2014 Stock Option Plan), within any one year period, will not exceed 10% of the Outstanding Issue. Also, in no event, may the number of common shares reserved for issuance to any one person pursuant to the 2014 DSU Plan and the 2014 Stock Option Plan exceed 5% of the Outstanding Issue.

Transferability

DSUs and any other rights, benefits or interests in the 2014 DSU Plan are non-transferable, except that if the Eligible Person dies, the legal representatives of the Eligible Person will be entitled to receive the amount of any payment otherwise payable to the Eligible Person in accordance with the provisions 2014 DSU Plan.

Amendments to the 2014 DSU Plan

The Board of Directors has the discretion to make amendments to the 2014 DSU Plan and any DSUs granted thereunder which it may deem necessary, without having to obtain shareholder approval. Such changes may include, without limitation:

  a)

minor changes of a “housekeeping” nature;

     
  b)

amending the terms of DSUs under the 2014 DSU Plan and method of determining the Awarded Amount and the number of DSUs that may be issued to an Eligible Person, and the assignability and effect of Terminated Service of an Eligible Person;

     
  c)

changing the class of Eligible Persons; and

     
  d)

changing the method and procedures to be followed with regard to the issuance of DSUs under the 2014 DSU Plan.

Shareholder approval will be required in the case of: (i) any amendment to the amendment provisions of the 2014 DSU Plan; (ii) any increase in the maximum number of common shares issuable under the 2014 DSU Plan; and (iii) such other matters that may require shareholder approval under the rules and policies of the TSX.

55


Termination of Service

An Eligible Person who has Terminated Service may elect to receive one common share in respect of each whole DSU credited to the Eligible Person's account, by filing a notice of redemption in the form prescribed from time to time by us on or before December 15 of the first calendar year commencing after the date on which the Eligible Person has Terminated Service. If the Eligible Person fails to file such notice on or before that December 15, the Eligible Person will be deemed to have filed a notice of redemption on that December 15 and will be deemed to have elected to redeem all of his or her DSUs. The date on which a notice is filed or deemed to be filed with the Secretary of the Company is the “Filing Date”. We may defer the Filing Date to any other date if such deferral is, in the sole opinion of ours, desirable to ensure compliance the 2014 DSU Plan. There are no causes of cessation of entitlement under the 2014 DSU Plan, including termination for or without cause.

In the event of the death of an Eligible Person, we will, within two months of the Eligible Person's death, pay cash equal to the Fair Market Value of the Shares which would be deliverable to the Eligible Person if the Eligible Person had Terminated Service in respect of the Deferred Share Units credited to the deceased Eligible Person's account (net of any Applicable Withholding Tax) to or for the benefit of the legal representative of the Eligible Person. The Fair Market Value will be calculated on the date of death of the Eligible Person.

The foregoing is a summary only, and is qualified in its entirety by the terms and conditions of the 2014 DSU Plan which is attached as an exhibit to this Form 20-F.

Termination and Change of Control Benefits

Except as disclosed above, we have no plans or arrangements in respect of remuneration received or that may be received by our directors and senior management in respect of compensating such person in the event of termination of employment (as a result of, for example, resignation, retirement, change of control) or a change in responsibilities.

Pension, Retirement or Similar Benefits

We have not set aside or accrued any amounts to provide pension, retirement or similar benefit for our directors or senior management.

C. Board Practices Term of Office

The term of office of directors expires annually at the time of the annual meeting. The directors were elected at the annual meeting of shareholders on May 27, 2014. The term of office of the officers expires at the discretion of the directors.

Service Contracts

See the disclosure under the heading “Item 6.B. Employment Agreements” for particulars of Dr. Stiernholm’s service contract. Other than as disclosed herein, we do not have any service contracts with directors which provide for benefits upon termination of employment.

56


Committees

We have an Audit Committee, a Corporate Governance and Nominating Committee and a Compensation Committee. Each of our committee charters is available on our website at www.trilliumtherapeutics.com.

Audit Committee

Our Audit Committee is comprised of a minimum of three members, each of whom, in the determination of the Board of Directors, satisfies the independence, financial literacy and experience requirements of applicable U.S. and Canadian securities laws, rules and guidelines, any applicable stock exchange requirements or guidelines and any other applicable regulatory rules.

In particular:

  • each member shall be (a) an “Independent Director,” as defined in Nasdaq Marketplace Rule 5605(a)(2), and (b) “independent” within the meaning of Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), and the determination of independence will be affirmatively made by the Board annually, provided that the Board may elect to take advantage of any exemption from such requirements provided in the rules of the NASDAQ Stock Market LLC (“ NASDAQ ”) or the Exchange Act;

  • each member shall meet the independence and financial literacy requirements set forth in Canadian National Instrument 52-110 Audit Committees ;

  • each member shall not have participated in the preparation of the financial statements of ours (or any then current subsidiary of ours) at any time during the past three years;

  • each member shall be able to read and understand fundamental financial statements in accordance with the audit committee requirements for companies listed on Nasdaq in Nasdaq Marketplace Rule 5605(c)(2)(A)(iv); and

  • at least one (1) member shall, in the judgment of the Board, be an “audit committee financial expert” within the meaning of such term in Item 407(d) of Regulation S-K under the U.S. Securities Act of 1933, as amended.

Our Audit Committee members are Mr. Luke Beshar (Chair), Dr. Henry Friesen and Dr. Robert Kirkman each of whom is a non-executive member of our Board of Directors. Our Board of Directors has determined that each of the members of the Audit Committee is financially literate and has sufficient financial expertise, and is independent within the meaning of such term in the rules of NASDAQ, the U.S. Securities and Exchange Commission (“ SEC ”) and Canadian provincial securities regulatory authorities. The Board of Directors has determined that Mr. Luke Beshar is a financial expert in accordance with the rules and regulations of the SEC.

The purpose of the Audit Committee is to assist the Board of Directors in:

  • overseeing the integrity of our financial statements and our accounting and financial reporting processes and financial statement audits;

  • overseeing our compliance with legal and regulatory requirements;

57


  • overseeing the qualifications and independence of our registered public accounting firm (independent auditor);

  • overseeing the performance of our independent auditor; and

  • overseeing the design, implementation and ongoing effectiveness of our systems of disclosure controls and procedures, risk management systems, internal control over financial reporting and compliance with ethical standards adopted by us.

Corporate Governance and Nominating Committee

The Corporate Governance and Nominating Committee shall be composed of at least two members of the Board, all of whom are “independent directors” within the meaning of Nasdaq Rule 5605(a)(2). In affirmatively determining the independence of any member of the Corporate Governance and Nominating Committee, the Board must consider all factors specifically relevant to determining whether a director has a relationship to us that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

All members of the Corporate Governance and Nominating Committee shall be "independent" as contemplated in National Instrument 58-101 – Disclosure of Corporate Governance Practices ("NI 58-101"), such that all members of the Corporate Governance and Nominating Committee will have no direct or indirect relationship with us that could, in the view of the Board of Directors, be reasonably expected to interfere with the exercise of his or her independent judgment.

The purpose of the Corporate Governance and Nominating Committee is to:

  • Assist the Board of Directors in identifying prospective director nominees and recommend to the Board of Directors the director nominees for each annual meeting of shareholders;

  • Recommend members for each Board committee;

  • Ensure that the Board of Directors is properly constituted to meet its fiduciary obligations to the Company and its shareholders and that the Company follows appropriate governance standards;

  • Develop and recommend to the Board of Directors governance principles applicable to the Company;

  • Oversee the succession planning for senior management; and

  • Oversee the evaluation of the Board of Directors and management.

Our Corporate Governance and Nomination Committee members are Dr. Henry Friesen (Chair), Dr. Michael Moore and Dr. Thomas Reynolds. Our Board of Directors has determined that each member of our Corporate Governance and Nomination Committee is independent within the meaning of such term in the rules of NASDAQ and Canadian provincial securities regulatory authorities.

58


Compensation Committee

The Compensation Committee shall be composed of at least two members of the Board, all of whom are considered “independent” of the management of the Company in accordance with the provisions of Rule 10C-1(b)(1) under the Exchange Act and NASDAQ Rule 5605(a)(2). In affirmatively determining the independence of any member of the Compensation Committee, the Board of Directors must consider all factors specifically relevant to determining whether a director has a relationship to the Company that is material to that director's ability to be independent from management in connection with the duties of a Compensation Committee member, including, but not limited to: (i) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the Company to such director; and (ii) whether such director is affiliated with the Company, a subsidiary of the Company or an affiliate of a subsidiary of the Company.

The purpose of the Compensation Committee shall be to ensure that the compensation programs and values transferred to management through cash pay, stock and stock-based awards, whether immediate, deferred, or contingent are fair and appropriate to attract, retain and motivate management and are reasonable in view of company economics and of the relevant practices of other similar companies. The Compensation Committee will also recommend to the Board of Directors compensation arrangements for Board members.

Our Compensation Committee members are Dr. Michael Moore (Chair), Dr. Robert Kirkman and Dr. Thomas Reynolds. Our Board of Directors has determined that each member of our Compensation Committee is independent within the meaning of such term in the rules of NASDAQ and Canadian provincial securities regulatory authorities.

D. Employees

As at August 11, 2014, we had fourteen full-time employees including four senior management, nine research and development staff and one administrative staff. All employees are located at our head office and lab facilities in Toronto, Ontario, Canada.

We also use consultants and outside contractors to carry on many of our activities, including preclinical testing and validation, formulation, assay development, manufacturing, clinical and regulatory affairs, toxicology and clinical trials.

On December 31, 2013, we employed 11 full-time staff and one part-time staff. During 2012 and just prior to the merger with Trillium Privateco, we had two personnel, the Executive Chair and the Chief Financial Officer who each worked part-time. During 2011, the Company employed two full-time staff and three part-time staff. In December 2011, two full-time staff and one part-time staff were terminated on the closure of our Calgary office.

E. Share Ownership

As at August 11, 2014, our directors and senior management beneficially owned the following common shares and deferred share units of our Company:

59





Name and Office Held

Number of
Common Shares


% of Class (1)
Number of
Deferred Share
Units (2)
Niclas Stiernholm Nil n/a Nil
President & Chief Executive Officer and
Director



Robert Uger
Chief Scientific Officer
Nil
n/a
Nil
James Parsons
Chief Financial Officer
Nil
n/a
Nil
Penka Petrova
Vice President, Drug Development
Nil
n/a
Nil
Luke Beshar
Director
Nil
n/a
143,885
Henry Friesen
Director
Nil
n/a
143,885
Robert Kirkman
Director
Nil
n/a
143,885
Michael Moore
Director
Nil
n/a
143,885
Thomas Reynolds
Director
Nil
n/a
143,885
Calvin Stiller (3)
Director, Chair
890,000
0.70
143,885

Notes:

  (1)

Based on 126,427,031 common shares issued and outstanding as at August 11, 2014.

  (2)

Deferred share units are redeemable on a one-for-one basis for common shares only after termination of service with us.

  (3)

Total of direct, indirect and other holdings where Dr. Stiller exercises control or direction.

The following table sets forth the outstanding option-based awards outstanding for each of our directors and officers as at August 11, 2014:

60









Name and Office Held
Option-based Awards
Number of
securities
underlying
unexercised
options
(#)



Option
exercise price
($)




Option
expiration date

Value of
unexercised in-
the-money
options (1)
($)
Niclas Stiernholm
President & Chief Executive Officer
and Director
50,000
1,275,141
4,793,025
4,045,444
1.00
0.25
0.345
0.278
Jul 18, 2016
Apr 8, 2023
Apr 27, 2024
May 27, 2024
Nil
51,006
Nil
48,545
Robert Uger
Chief Scientific Officer
255,028
1,262,013
1,011,361
0.25
0.345
0.278
Apr 8, 2023
Apr 27, 2024
May 27, 2024
10,201
Nil
12,136
James Parsons
Chief Financial Officer

12,500
127,514
1,086,119
809,089
1.00
0.25
0.345
0.278
Aug 25, 2016
Apr 8, 2023
Apr 27, 2024
May 27, 2024
Nil
5,101
Nil
9,709
Penka Petrova
Vice President, Drug Development
127,514
782,711
606,816
0.25
0.345
0.278
Apr 8, 2023
Apr 27, 2024
May 27, 2024
5,101
Nil
7,282
Luke Beshar
Director
200,000
0.63
Mar 6, 2024
Nil
Henry Friesen
Director
50,000
135,000
1.00
0.25
Jun 28, 2016
Apr 8, 2023
Nil
5,400
Robert Kirkman
Director
200,000
0.51
Jan 29, 2024
Nil
Michael Moore
Director
120,000
0.25
Apr 8, 2023
4,800
Thomas Reynolds
Director
200,000
0.63
Mar 6, 2024
Nil
Calvin Stiller
Director, Chair
50,000
120,000
1.00
0.25
Jul 18, 2016
Apr 8, 2023
Nil
4,800

Notes:

  (1)

The value of the unexercised “in-the-money” options as at August 11, 2014 has been determined based on the excess of the closing price of the common shares on the TSX of $0.29 per common share over the exercise price of such options.

Our employees are eligible to participate in the 2014 Stock Option Plan. A summary of the Stock Option Plan is given under the heading “Item 6.B. – Stock Option Plan”.

ITEM 7.                     MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A. Major Shareholders

To our knowledge, there are no persons or company who beneficially own, directly or indirectly, or exercise control or direction over, securities carrying more than 5% of the voting rights attached to any class of voting securities of ours as at August 11, 2014, except as follows:


Shareholder

# of Common Shares
% of Total Outstanding
Common Shares
Merlin Nexus IV, LP 12,145,238 9.6%
Special Situations (various L.P.s) 12,145,238 9.6%
Opaleye L.P. 10,000,000 7.9%

These shareholders in the above table purchased common shares from us in our December 2013 private placement financing. On the acquisition of Trillium Privateco, we issued 6,079,180 common shares to the shareholders of Trillium Privateco representing at the time approximately 16% ownership of our outstanding shares. Other than the December 2013 private placement and the Trillium Privateco transaction more fully described in Item 4.A. – Information on the Company, there has otherwise been no significant change in percentage ownership level by any major shareholders during the past three years.

All shareholders have the same voting rights.

As at June 30, 2014, approximately 56% of common shares and 100% of Series I First Preferred shares were held by shareholders in the United States and there were 24 registered shareholders in the United States.

61


B. Related Party Transactions

Other than as disclosed in this registration statement, since the beginning of our preceding three financial years, there have been no transactions or loans between us and:

  (a)

enterprises that directly or indirectly through one or more intermediaries, control or are controlled by, or are under common control with, us;

     
  (b)

associates, meaning unconsolidated enterprises in which we have a significant influence or which have significant influence over us;

     
  (c)

individuals owning, directly or indirectly, an interest in the voting power of us that gives them significant influence over our us, and close members of any such individual’s family;

     
  (d)

key management personnel, that is, those persons having authority and responsibility for planning, directing and controlling the activities of ours, including directors and senior management of us and close members of such individuals’ families; and

     
  (e)

enterprises in which a substantial interest in the voting power is owned, directly or indirectly, by any person described in (c) or (d) or over which such a person is able to exercise significant influence, including enterprises owned by directors or major shareholders of us and enterprises that have a member of key management in common with us.

For the six months ended June 30, 2014 and 2013, $7,916 and $7,916, respectively, was paid to the former Executive Chair, a director, for consulting fees. These transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.

Compensation

For information regarding compensation for our directors and senior management, see the information under the heading “Item 6.B. Compensation”.

C. Interests of Experts and Counsel

Not Applicable.

ITEM 8.                     FINANCIAL INFORMATION

A. Financial Statements and Other Financial Information

The following financial statements and notes thereto (as applicable) in Canadian dollars are filed with and incorporated herein as part of this registration statement:

  • audited consolidated financial statements of the Company for the years ended December 31, 2013 and 2012, prepared in accordance with IFRS as issued by the IASB, including: consolidated statements of financial position, consolidated statements of loss and comprehensive loss, consolidated statements of changes in equity, consolidated statements of cash flows, and notes to the consolidated financial statements.

62


  • audited consolidated financial statements of the Company for the years ended December 31, 2012 and 2011, prepared in accordance with IFRS as issued by the IASB, including: consolidated statements of financial position, consolidated statements of loss and comprehensive loss, consolidated statements of changes in equity, consolidated statements of cash flows, and notes to the consolidated financial statements.

  • unaudited interim condensed consolidated financial statements of the Company for the six months ended June 30, 2014 and 2013, prepared in accordance International Accounting Standard 34, Interim Financial Reporting including: consolidated statements of financial position, consolidated statements of loss and comprehensive loss, consolidated statements of changes in equity, consolidated statements of cash flows, and notes to the unaudited interim condensed consolidated financial statements.

  • audited financial statements of Trillium Privateco for the years ended June 30, 2012 and 2011, prepared in accordance with Canadian Accounting Standards for Private Enterprises (“ ASPE ”), including: balance sheets, statements of operations and deficit and statements of cash flows, and notes to the financial statements, including note 16 - Differences between Canadian and United States Generally Accepted Accounting Principles (“ U.S. GAAP ”).

  • unaudited interim condensed financial statements of Trillium Privateco for the nine months ended March 31, 2013 and 2012, prepared in accordance with ASPE, including: balance sheets, statements of operations and deficit and statements of cash flows, and notes to the unaudited interim condensed financial statements, including note 13 - Differences between Canadian and United States Generally Accepted Accounting Principles.

  • pro forma unaudited consolidated statement of loss and comprehensive loss of the Company for the year ended December 31, 2013, assuming the acquisition of Trillium Privateco occurred on January 1, 2013 rather than April 9, 2013, with explanatory notes describing the pro forma adjustments.

These financial statements can be found beginning on page F-1 of this registration statement.

Export Sales

We have no sales.

Legal Proceedings

To our knowledge, there have not been any legal or arbitration proceedings, including those relating to bankruptcy, receivership or similar proceedings, those involving any third party, and governmental proceedings pending or known to be contemplated, which may have, or have had in the recent past, significant effect our financial position or profitability.

63


Also, to our knowledge, there have been no material proceedings in which any director, any member of senior management, or any of our affiliates is either a party adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.

Policy on Dividend Distributions

We have not declared any dividends since our inception and do not anticipate that we will do so in the foreseeable future. We currently intend to retain future earnings, if any, to finance the development of our business. Any future payment of dividends or distributions will be determined by our Board of Directors on the basis of our earnings, financial requirements and other relevant factors.

B. Significant Changes

We are not aware of any significant change that has occurred since June 30, 2014 included in this Form 20-F and that has not been disclosed elsewhere in this Form 20-F.

ITEM 9.                     THE OFFER AND LISTING

A. Offer and Listing Details

Price History

We were listed on the TSXV until April 22, 2014 when we delisted from the TSXV and began trading on the TSX. We traded under the symbol “SSS” until June 6, 2014 when the symbol was changed to “TR”. We are also currently traded on the OTCQX International under the symbol “SCTPF”.

Five Most Recent Financial Years

The annual high and low market prices of our common shares for the five most recent full financial years on the TSXV/ TSX and since May 20, 2013 on the OTCQX International were as follows:


Year ended
TSXV in $ (1) OTCQX International in US$ (2)
High Low High Low
December 31, 2013 0.600 0.140 0.476 0.139
December 31, 2012 0.600 0.150    
December 31, 2011 1.400 0.400    
December 31, 2010 5.500 0.450    
December 31, 2009 2.100 0.400    

Note:

  (1)

Our common shares began trading on the TSX on April 22, 2014.

  (2)

Our common shares began trading on the OTCQX International on May 20, 2013.

Full Financial Quarters

The high and low market prices of our common shares for each full financial quarter for the two most recent full financial years on the TSXV/TSX and the OTCQX Marketplace were as follows:

64




Quarter ended
TSXV/TSX in $ (1) OTCQX International in US$ (2)  
High Low High Low
June 30, 2014 0.520 0.265 0.475 0.238
March 31, 2014 0.740 0.380 0.653 0.354
December 31, 2013 0.440 0.260 0.414 0.242
September 30, 2013 0.495 0.220 0.476 0.218
June 30, 2013 0.250 0.140 0.241 0.139
March 31, 2013 0.600 0.185    
December 31, 2012 0.500 0.150    
September 30, 2012 0.350 0.150    

Note:

(1)

Our common shares began trading on the TSX on April 22, 2014.

   
(2)

Our common shares began trading on the OTCQX International on May 20, 2013.

Most Recent Six Months

The high and low market prices of our common shares for each month for the most recent six months on the TSXV/TSX and the OTCQX Marketplace were as follows:


Month ended
TSXV/TSX in $ Canadian (1) OTCQX International
High Low High Low
August 1 - 11, 2014 0.295 0.280 0.276 0.252
July 31, 2014 0.345 0.280 0.332 0.254
June 30, 2014 0.410 0.270 0.383 0.243
May 31, 2014 0.405 0.265 0.377 0.238
April 30, 2014 0.520 0.325 0.475 0.290
March 31, 2014 0.740 0.420 0.653 0.369
February 28, 2014 0.600 0.490 0.549 0.440

Note:

  (1)

Our common shares began trading on the TSX on April 22, 2014.

Transfers of Common Shares

Our common shares, with no par value, are in registered form and the transfer of our common shares is managed by our transfer agent, Computershare Investor Services Inc., 8 th floor, University Avenue, Toronto, Ontario, Canada (Tel: (800) 564-6253).

B. Plan of Distribution

Not Applicable.

C. Markets

Our common shares are traded on the TSX under the symbol “TR” and on the OTCQX International Marketplace under the symbol “SCTPF”.

We currently plan to apply to have our common shares traded on the NASDAQ Capital Market upon the effectiveness of this registration statement. We cannot provide our investors with any assurance that our common shares will be listed on the NASDAQ Capital Market, or, if traded, that a public market in the United States will materialize. If our common shares are not quoted on the NASDAQ Capital Market then investors in the United States may have difficulty reselling our common shares.

65


D. Selling Shareholders

Not Applicable.

E. Dilution

Not Applicable.

F. Expenses of the Issue

Not Applicable.

ITEM 10.                  ADDITIONAL I NFORMATION

A. Share Capital

Our authorized share capital consists of an unlimited number of common shares, Class B Shares and First Preferred Shares, in each case without nominal or par value.

The holders of common shares are entitled to receive notice of and to attend all annual and special meetings of our shareholders and to one vote per share held at each such meeting, and they are entitled to receive dividends as determined and declared by our Board of Directors.

Subject to the rights of the holders of any other class of our shares entitled to receive dividends in priority to or concurrently with the holders of the common shares, our Board of Directors may in its sole discretion declare dividends on the common shares to the exclusion of any other class of shares of the Company.

In the event of our liquidation, dissolution or winding up or other distribution of our assets among our shareholders for the purpose of winding up our affairs, the holders of the common shares shall, subject to the rights of the holders of any other class of shares entitled to receive our assets upon such a distribution in priority to or concurrently with the holders of the common shares, be entitled to participate in the distribution. Such distribution shall be made in equal amounts per share on all the common shares at the time outstanding without preference or distinction.

The holders of the Class B Shares are entitled to receive notice of and to attend any meeting of our shareholders but shall not be entitled to vote any of their Class B Shares at any such meeting. Each issued and fully paid Class B Share may at any time be converted, at the option of the holder, into one common share.

The First Preferred Shares may at any time and from time to time be issued in one or more series and our the Board of Directors may before the issue thereof fix the number of shares in, and determine the designation, rights, privileges, restrictions and conditions attaching to the shares of, each series of First Preferred Shares.

The First Preferred Shares shall be entitled to priority over the common shares and Class B Shares and all other shares ranking junior to the First Preferred Shares with respect to the payment of dividends and the distribution of our assets in the event of our liquidation, dissolution or winding up or other distribution of our assets among our shareholders for the purpose of winding up our affairs.

66


The First Preferred Shares of each series rank on a parity with the First Preferred Shares of every other series with respect to priority in the payment of dividends and in the distribution of our assets in the event of our liquidation, dissolution or winding up or other distribution of our assets among our shareholders for the purpose of winding up our affairs.

During 2013, we created a new series of First Preferred Shares designated as Series I Non-Voting Convertible First Preferred Shares (“ Series I Preferred Shares ”). The holders of Series I Preferred Shares are not entitled to vote at any meeting of our shareholders (except in limited circumstances provided for in the Business Corporations Act (Ontario)), and they are entitled to receive dividends as determined and declared at the discretion of the Board of Directors equally on a one-for-one basis with the holders of shares of the other series of First Preferred Shares. Each issued and fully paid Series I Preferred Share may at any time be converted, at the option of the holder, into one common share, subject to adjustment.

As at August 11, 2014, 126,427,031 common shares and 75,895,165 Series I Preferred Shares were outstanding and no Class B Shares were outstanding. As at August 11, 2014, 138,724,781 common share purchase warrants were outstanding at a weighted average exercise price of $0.29 per share.

As at August 11, 2014, there were 17,727,275 stock options outstanding to purchase common shares. The terms and conditions of such stock options are contained in the 2014 Stock Option Plan. A summary of the 2014 Stock Option Plan, is given under the heading “Item 6.E. Share Ownership – Stock Option Plan”.

As at August 11, we have issued 863,310 deferred share units. The terms and conditions of such deferred share units are contained in the 2014 DSU Plan. A summary of 2014 DSU Plan is given under the heading “Item 6.B. Compensation Deferred Share Unit Plan”.

Warrants

Our Board of Directors authorized or ratified the issuances of the warrants set forth in the tables below and the issuance of one common share upon the due exercise of each warrant in accordance with its terms and the receipt by us of the designated exercise price payable in respect of the share prior to the time of expiry on the designated expiry date.

As at December 31, 2013, we had the following outstanding warrants:

Number of Warrants
Outstanding
Exercise Price
Expiry Date
909,091 $1.60 March 14, 2014
814,051 $0.25 March 16, 2015
5,014,839 $0.21 December 13, 2015
17,215,000 $0.40 March 15, 2018
420,000 $0.40 March 27, 2018
117,857,142 $0.28 December 13, 2018
Total: 142,230,123      

67


As at August 11, 2014, we had the following outstanding warrants:

Number of Warrants
Outstanding
Exercise Price
Expiry Date
202,800 $0.25 March 16, 2015
5,014,839 $0.21 December 13, 2015
15,230,000 $0.40 March 15, 2018
420,000 $0.40 March 27, 2018
117,857,142 $0.28 December 13, 2018
Total: 138,724,781    

Stock Options

Our Board of Directors authorized or ratified the issuances of the options set forth in the tables below and the issuance of one common share upon the due exercise of each option in accordance with its terms and the receipt by us of the designated exercise price payable in respect of the share prior to the time of expiry on the designated expiry date.

As at December 31, 2013 we had the following outstanding stock options:

Number of Stock
Options Outstanding
Number Exercisable
Exercise Price
Expiry Date
12,000 12,000 $1.00 February 24, 2014
20,000 20,000 $0.25 June 24, 2014
3,000 3,000 $1.20 August 28, 2014
20,000 20,000 $1.70 November 24, 2014
8,400 8,400 $0.25 March 15, 2015
40,000 40,000 $1.00 August 27, 2015
50,000 50,000 $1.00 June 28, 2016
150,000 150,000 $1.00 July 18, 2016
12,500 9,722 $1.00 August 25, 2016
10,000 10,000 $1.00 June 1, 2017
2,560,197 855,106 $0.25 April 8, 2023
35,000 11,690 $0.25 May 23, 2023
Total: 2,921,097 Total: 1,189,918    

As at August 11, we had the following outstanding stock options:

68



Number of Stock
Options Outstanding
Number Exercisable
Exercise Price
Expiry Date
3,000 3,000 $1.20 August 28, 2014
20,000 20,000 $1.70 November 24, 2014
40,000 40,000 $1.00 March 7, 2015
50,000 50,000 $1.00 June 28, 2016
50,000 50,000 $1.00 March 6, 2015
100,000 100,000 $1.00 July 18, 2016
12,500 11,806 $1.00 August 25, 2016
10,000 10,000 $1.00 June 1, 2017
100,000 100,000 $0.25 March 6, 2015
100,000 100,000 $0.25 March 7, 2015
2,210,197 1,105,099 $0.25 April 8, 2023
35,000 17,500 $0.25 May 23, 2023
200,000 66,667 $0.51 January 30, 2024
400,000 133,334 $0.63 March 6, 2024
7,923,868 2,641,290 $0.345 April 17, 2024
6,472,710 2,157,569 $0.278 May 27, 2024
Total: 17,727,275 Total: 6,606,265    

Deferred Share Units

As at December 31, 2013 , we had not issued any deferred share units which are convertible into common shares. A total of 863,310 DSUs were issued during the six months ended June 30, 2014 for payment of directors fees. As at August 11, 2014, we had 863,310 issued and outstanding deferred share units which are convertible into common shares.

Issuances of Common Shares

Share capital issued – for the six months ended June 30, 2014

During the six months ended June 30, 2014, 2,596,251 warrants were exercised for proceeds of $946,813 and 78,400 stock options were exercised for proceeds of $19,600. Also, 909,091 warrants issued March 14, 2011 with an exercise price of $1.60 expired unexercised.

During the six months ended June 30, 2014, 2,000,000 First Preferred Shares were converted to common shares.

Share capital issued – for the year ended December 31, 2013

We consolidated our outstanding common shares issuing one post-consolidated share for each 10 pre-consolidated shares and the common shares began trading on a post-consolidated basis on February 6, 2013.

In March 2013, we completed an offering pursuant to a base shelf prospectus and prospectus supplement and in the U.S. pursuant to a private placement memorandum for a total of 12,735,000 units at a price of $0.25 per unit, for aggregate gross proceeds of $3,185,080 ($2,615,240 net of issuance costs). Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.40 per share at any time prior to expiry on March 15, 2018 (12,315,000 warrants) and March 27, 2018 (420,000 warrants). In connection with the financing, we issued 814,051 compensation warrants having an aggregate fair value of $48,843 estimated using the Black-Scholes option pricing model. Each compensation warrant entitles the holder to acquire one common share at an exercise price of $0.25 per share prior to expiry on March 16, 2015.

The allocation of the $0.25 common share unit issue price to the common shares and unit warrants was based on the relative fair values of the common shares and the warrants. The fair value of the warrants was determined using the Black-Scholes option pricing model. The common shares were allocated a price of $0.20 per share and the warrants were allocated a price of $0.05 per warrant. The costs of the issue were allocated on a pro rata basis to the common shares and warrants. Accordingly, $2,092,192 was allocated to common shares and $523,048 to warrants, net of issuance costs. Assumptions used to determine the value of the unit warrants were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 64%; and average expected life of 3 years. Assumptions used to determine the value of the compensation warrants were: dividend yield of 0%; risk-free interest rate of 1.0%; expected volatility of 80%; and average expected life of 2 years.

69


On April 9, 2013, we issued 6,079,180 common shares and 3,300,000 common share purchase warrants for partial consideration for the acquisition of Trillium Privateco.

On April 16, 2013, we issued 5,028,571 common shares and 1,600,000 common share purchase warrants as consideration for the acquisition of certain rights related to tigecycline from UHN.

On December 13, 2013, we completed a private placement of 79,247,693 common share units (each common share unit consisting of one common share and three-quarters of a common share purchase warrant) at a price of $0.21 per unit and 77,895,165 preferred share units (each preferred share unit consisting of one Series 1 First Preferred Share and three-quarters of a common share purchase warrant) at a price of $0.21 per unit for gross proceeds of $32,866,025 ($30,713,841 net of issuance costs). Each whole warrant entitles the holder to purchase one common share at a price of $0.28 at any time prior to expiry on December 13, 2018. In connection with the financing, we issued 5,014,839 compensation warrants having an aggregate fair value of $651,929 estimated using the Black-Scholes option pricing model. Each compensation warrant entitles the holder to acquire one common share at an exercise price of $0.21 per share prior to expiry on December 13, 2015.

The allocation of the $0.21 unit issue price to the common shares, Series 1 First Preferred Shares and unit warrants was based on the relative fair values of the common shares, Series 1 First Preferred Shares and the warrants. The fair value of the warrants was determined using the Black-Scholes option pricing model. The common shares were allocated a price of $0.16 per share, the Series 1 First Preferred Shares were allocated a price of $0.16 per share, and the warrants were allocated a price of $0.05 per three-quarter warrant. The costs of the issue were allocated on a pro rata basis. Accordingly, $11,488,602 was allocated to common shares, $11,292,525 to the Series 1 First Preferred Shares and $7,932,714 to warrants, net of issuance costs. Assumptions used to determine the value of the unit warrants were: dividend yield of 0%; risk-free interest rate of 1.2%; expected volatility of 70%; and average expected life of 3 years. Assumptions used to determine the value of the compensation warrants were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 66%; and average expected life of 2 years.

All securities issued under the offering (including the compensation warrants), in Canada were subject to a four month hold and resale restrictions under Canadian securities law, and in the United States are subject to statutory resale restrictions under U.S. securities laws.

In the December 2013 private placement, subscribers who purchased preferred share units and certain subscribers who purchased common share units were subject to restrictions on the conversion and exercise of securities of ours convertible in common shares. Such subscribers cannot convert or exercise securities of ours convertible or exercisable into common shares if, after giving effect to the exercise of conversion, the subscriber and its joint actors would have beneficial ownership or direction or control over common shares in excess of 4.99% of the then outstanding common shares. This limit may be increased at the option of the subscriber on 61 days prior written notice: (i) up to 9.99%, (ii) up to 19.99%, subject to stock exchange clearance of a personal information form submitted by the subscriber, and (iii) above 19.99%, subject to stock exchange approval and shareholder approval.

70


Subject to receipt of any required regulatory approvals, subscribers who purchased a minimum of 10% of the securities sold under the offering have been given rights to purchase securities of ours in future financings to enable each such subscriber to maintain its percentage holding in us for so long as the subscriber holds at least 10% of the outstanding common shares on a fully-diluted basis.

Share capital issued – for the year ended December 31, 2012

There were no common or preferred shares issued in the year ended December 31, 2012.

Share capital issued – for the year ended December 31, 2011

On March 24, 2011, we completed an offering pursuant to a base shelf prospectus and prospectus supplement of 18,181,819 units at a price of $0.11 per unit, for aggregate gross proceeds of $2,000,000 ($1,580,379 net of issuance costs). Each unit consisted of one common share and one-half common share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of $0.16 per share at any time prior to expiry on March 24, 2014. In connection with the financing, we issued 1,272,727 compensation warrants having an aggregate fair value of $91,636 estimated using the Black-Scholes option pricing model. Each whole compensation warrant entitles the holder to acquire one common share at an exercise price of $0.11 per share prior to expiry on March 24, 2013.

The allocation of the $0.11 common share unit issue price to the common shares and warrants was based on the relative fair values of the common shares and the warrants. The fair value of the warrants was determined using the Black-Scholes option pricing model. The common shares were allocated a price of $0.081 per share and the warrants were allocated a price of $0.029 per warrant. The costs of the issue were allocated on a pro rata basis to the common shares and warrants. Accordingly, $1,163,734 was allocated to common shares and $416,645 to warrants, net of issuance costs. Assumptions used to determine the value of the warrants and the compensation warrants were: dividend yield of 0%; risk-free interest rate of 2.8%; expected volatility of 130%; and average expected life of 36 and 24 months, respectively.

During the year ended December 31, 2011, 100,000 common shares were issued on the exercise of stock options for gross proceeds of $10,000.

Shareholder Rights Plan

On October 17, 2013 our shareholders adopted a shareholder rights plan (the “ 2013 Rights Plan ”) and approved certain amendments on May 27, 2014 (the “ Rights Plan Amendment ” which together with the 2013 Rights Plan may be referred to as the “ Rights Plan ”).

Purpose of the Rights Plan

Many public companies in Canada have shareholder rights plans in effect. While securities legislation in Canada requires a take-over bid to be open for at least 35 days, the Board of Directors is concerned that this is too short a time for companies that are subject to unsolicited take-over bids to be able to respond to ensure that shareholders are offered full and fair value for their shares. The Rights Plan is designed to give our shareholders sufficient time to properly assess a take-over bid without undue pressure and to give the Board of Directors time to consider alternatives designed to allow our shareholders to receive full and fair value for their common shares.

71


The Board of Directors is also concerned that current Canadian take-over bid rules permit a person or company to obtain control or effective control of the Company without treating all shareholders equally. The Rights Plan is not intended to prevent a take-over bid or deter offers for common shares. It is designed to encourage any bidder to provide shareholders with equal treatment and full and fair value for their common shares.

Summary of the Rights Plan

The following is a summary of the principal terms of the Rights Plan, which is qualified in its entirety by reference to the text of the Rights Plan which is filed as an exhibit to this Form 20-F. All capitalized terms used in this summary without definition have the meanings attributed to them in the Rights Plan.

Effective Date and Term

The 2013 Rights Plan came into effect on September 16, 2013 and the Rights Plan Amendment was approved by the shareholders on May 27, 2014. Subject to periodic confirmation by shareholders as discussed below, the Rights Plan will remain in effect until the termination of our annual meeting in the year 2016.

Issue of Rights

Immediately upon the Rights Plan coming into effect, one right (“ Right ”) was issued and attached to each common share outstanding and will attach to each common share subsequently issued.

Rights Exercise Privilege

The Rights will separate from the common shares and will be exercisable on the close of business on the tenth trading day (the “ Separation Time ”) after the earlier of the date on which a person has acquired 20% or more of, or a person commences or announces a take-over bid for, our outstanding common shares, other than by an acquisition pursuant to a Permitted Bid or a Competing Permitted Bid. The acquisition by a person (an “ Acquiring Person ”) of 20% or more of the common shares is referred to as a “ Flip-in Event ”. When a Flip-in Event occurs each Right (except for Rights beneficially owned by an Acquiring Person or certain transferees of an Acquiring Person, which Rights will be void pursuant to the Rights Plan) becomes a right to purchase from us, upon exercise thereof in accordance with the terms of the Rights Plan, that number of common shares having an aggregate market price on the date of consummation or occurrence of such Flip-in Event equal to twice the Exercise Price for an amount in cash equal to the Exercise Price. The Exercise Price for the Rights provided for in the Rights Plan is $100. As an example, if at the time of the Flip-in Event the common shares have a market price of $25.00, the holder of each Right would be entitled to receive $200 (twice the Exercise Price) in market value of the common shares (8 common shares) for $100, i.e. at a 50% discount.

72


The issue of the Rights is not initially dilutive. However, upon a Flip-in Event occurring and the Rights separating from the common shares, reported earnings per share may be affected. Holders of Rights not exercising their Rights upon the occurrence of a Flip-in Event may suffer substantial dilution.

Any Rights held by an Acquiring Person will become void upon the occurrence of a Flip-in Event. Any offer other than a Permitted Bid, a competing Permitted Bid or a bid for which the Board of Directors has waived the application of the Rights Plan to a particular Flip-in Event (see “ Waiver ” below) will become prohibitively expensive for the Acquiring Person. The Rights Plan is therefore designed to require any person interested in acquiring more than 20% of the common shares to do so by way of a Permitted Bid or a Competing Permitted Bid or to make an offer which the Board of Directors considers to represent the full and fair value of the common shares.

Exemptions for Portfolio Managers, etc.

Portfolio managers (for fully managed accounts), mutual funds and their managers, trust companies (acting in their capacities as trustees and administrators), statutory bodies whose business includes the management of funds, administrators of registered pension plans and crown agents acquiring greater than 20% of the common shares are exempted from triggering a Flip-in Event, provided that they are not making, and are not part of a group making, a take-over bid.

Grandfathered Person

A person (a “ Grandfathered Person ”) who was the beneficial owner of more than 20% of the outstanding common shares on September 16, 2013 is deemed not to be an Acquiring Person until it ceases to own more than 20% of the common shares or increases its beneficial ownership by more than 1% of the outstanding common shares on September 16, 2013 except in specified circumstances. To the knowledge of our senior officers, we do not have any Grandfathered Person.

Certificates and Transferability

Prior to the Separation Time, the Rights will be evidenced by a legend imprinted on our common share certificates and will not be transferable separately from the common shares. Common share certificates do not need to be exchanged to entitle a Shareholder to these Rights. The legend will be on all new certificates we issue after the Effective Date. From and after the Separation Time, the Rights will be evidenced by Rights certificates and will be transferable separately from the common shares.

Permitted Bid Requirements

The Permitted Bid requirements include the following:

  (a)

the take-over bid must be made by way of a take-over bid circular;

     
  (b)

the take-over bid must be made to all holders of common shares (other than the bidder);

     
  (c)

the take-over bid provides that no common shares tendered pursuant to the take-over bid may be taken up prior to the expiry of a 60 day period following the date of the bid and unless at such date more than 50% of the common shares held by the Independent Shareholders (i.e. the shareholders, other than the bidder, its affiliates and persons acting jointly or in concert and certain other persons), have been tendered to the take-over bid and not withdrawn;

73



  (d)

the take-over bid must be open for acceptance for a minimum period of 60 days;

     
  (e)

the common shares deposited pursuant to the bid may be withdrawn until taken up or paid for; and

     
  (f)

if the minimum deposit condition described in (iii) above has been satisfied, the bidder must make a public announcement of that fact and the take-over bid must remain open for deposits of common shares for an additional 10 business days from the date of such public announcement.

The Rights Plan allows for a competing Permitted Bid (a “ Competing Permitted Bid ”) to be made while a Permitted Bid is in existence. A Competing Permitted Bid must satisfy all of the requirements of a Permitted Bid except that no Common Shares will be taken up or paid for pursuant to the Competing Permitted Bid prior to the close of business on a date that is no earlier than the later of:

  (a)

35 days after the date of the Competing Permitted Bid; and

     
  (b)

the 60th day after the earliest date on which any other Permitted Bid that is then in existence was made.

Waiver

The Board of Directors, acting in good faith may, prior to the occurrence of a Flip-in Event, waive the application of the Rights Plan to a particular Flip-in Event (an “ Exempt Acquisition ”) where the take-over bid is made by a take-over bid circular to all holders of common shares. Where the Board of Directors exercises the waiver power for one take-over bid, the waiver will also apply to any other take-over bid for us made by a take-over bid circular to all holders of common shares prior to the expiry of any other bid for which the Rights Plan has been waived.

Redemption

The Board of Directors, with the approval of the majority of votes cast by Shareholders (or the holders of the Rights if the Separation Time has occurred) voting in person and by proxy, at a meeting duly called for that purpose, may redeem all of the then outstanding Rights at $0.000001 per Right as adjusted by the terms of the Rights Plan. Rights shall be automatically redeemed following completion of a Permitted Bid, Competing Permitted Bid or Exempt Acquisition.

Protection Against Dilution

The Rights Plan contains detailed provisions regarding adjustments to the Exercise Price and the number and nature of the securities that may be purchased upon exercise of Rights outstanding to prevent dilution in the event of certain declarations of dividends, or consolidation of outstanding common shares, issuances of common shares (or other securities or rights) in respect of or in lieu of an exchange for existing common shares or other changes in the common shares.

74


Amendment

The Board of Directors may amend the Rights Plan with the approval of a majority of votes cast by Shareholders (or the holders of the Rights if the Separation Time has occurred) voting in person and by proxy at a meeting duly called for that purpose. The Board of Directors, without such approval, may correct clerical or typographical errors and, subject to the subsequent approval as noted above at the next meeting of the Shareholders (or holders of Rights, as the case may be), may make amendments to the Rights Plan to maintain its validity due to changes in applicable legislation.

B. Memorandum and Articles of Association

Incorporation

On November 7, 2013 we were continued, and we became a corporation subsisting, under the Business Corporations Act (Ontario) (“ OBCA ”). Our Ontario corporation number is 1916667 and our business number is 864092275. A copy of our articles of incorporation has been filed as an exhibit to this Form 20-F.

Objects and Purposes of Our Company

Our articles of incorporation do not contain and are not required to contain a description of our objects and purposes. There is no restriction contained in our articles of incorporation on the business that we may carry on.

Voting on Certain Proposal, Arrangement, Contract or Compensation by Directors

Other than as disclosed below, neither our articles nor our corporate by-laws restrict our directors’ power to (a) vote on a proposal, arrangement or contract in which the directors are materially interested or (b) to vote with regard to compensation payable to themselves or any other members of their body in the absence of an independent quorum.

Our corporate by-laws provide that a director or officer who: (a) is a party to; or (b) is a director or an officer of, or has a material interest in, any person who is a party to; a material contract or transaction or proposed material contract or transaction with us shall disclose the nature and extent of such director's or officer's interest at the time and in the manner provided by the OBCA. Any such contract or transaction or proposed material contract or transaction shall be referred to our Board of Directors or shareholders for approval in accordance with the OBCA even if such contract or proposed material contract or transaction is one that in the ordinary course of our business would not require approval by our Board of Directors or shareholders, and a director interested in a contract or transaction so referred to our Board of Directors shall not attend any part of a meeting of our Board of Directors during which the contract or transaction is discussed and shall not vote on any resolution to approve such contract or transaction except as provided by the OBCA.

Subject to our articles and any unanimous shareholder agreement, our directors shall be paid such remuneration for their services as our Board of Directors may from time to time determine. Our directors shall also be entitled to be reimbursed for travelling and other expenses properly incurred by them in attending meetings of our Board of Directors or any committee thereof.

75


The OBCA provides that a director who holds a disclosable interest in a contract or transaction into which we have entered or propose to enter shall not attend any part of a meeting of directors during which the contract or transaction is discussed and shall not vote on any resolution to approve the contract or transaction unless it is a contract or transaction: (i) relating primarily to such director's remuneration as a director of the company or one of our affiliates; (ii) for indemnity or insurance for the benefit of such director in his/her capacity as a director; or (iii) with one of our affiliates.

A director or officer who holds a disclosable interest in a contract or transaction into which we have entered or propose to enter is not accountable to us or our shareholders for any profit or gain realized from the contract or transaction and the contract or transaction is neither void nor voidable by reason only of that relationship or by reason only that the director is present at or is counted to determine the presence of a quorum at the meeting of directors that authorized the contract or transaction, if the director or officer disclosed his or her interest in accordance with the OBCA and the contract or transaction was reasonable and fair to us at the time it was approved.

The OBCA provides that a director or officer generally holds a disclosable interest in a contract or transaction if either (a) the director or officer is a party to the contract or transaction with us and such contract or transaction is material to us; or (b) the director or officer is a director or an officer of, or has a material interest in, any person who is a party to a material contract or transaction or proposed material contract or transaction with us.

Borrowing Powers of Directors

Our corporate by-laws provide that, if authorized by our directors, we may:

  • borrow money upon our credit;
  • issue, reissue, sell or pledge debt obligations, including bonds, debentures, notes or other evidences of indebtedness or guarantees, whether secured or unsecured;
  • give a guarantee on our behalf to secure performance of an obligation of any person; and
  • mortgage, hypothecate, pledge or otherwise create a security interest in all or any currently owned or subsequently acquired real or personal, movable or immovable, property of the Company including book debts, rights, powers, franchises and undertakings, to secure any such bonds, debentures, notes or other evidences of indebtedness or guarantee or any other present or future indebtedness, liability or obligation of the Company.

Amendment to the borrowing powers described above requires an amendment to our corporate by-laws. Our corporate by-laws do not contain any provisions in connection with amending the by-laws. The OBCA provides that our Board of Directors may by resolution, make, amend or repeal any by-laws that regulate our business and affairs and that the Board of Directors will submit such by-law, amendment or repeal to our shareholders at the next meeting of shareholders and the shareholders may, by ordinary resolution, confirm, reject or amend the by-law, amendment or repeal.

Qualifications of Directors

Under our articles and corporate by-laws, a director is not required to hold a share in our capital as qualification for his or her office but must be qualified as required by the OBCA to become, act or continue to act as a director. The OBCA provides that the following persons are disqualified from being a director of a corporation: (i) a person who is less than 18 years of age; (ii) a person who has been found under the Substitute Decisions Act, 1992 or under the Mental Health Act to be incapable of managing property or who has been found to be incapable by a court in Canada or elsewhere; (iii) a person who is not an individual; and (iv) a person who has the status of a bankrupt.

76


Share Rights

See the discussion under the heading “Item 10.A. Share Capital” for a summary of our authorized capital and the rights attached to our common shares and preferred shares.

Procedures to Change the Rights of Shareholders

The rights, privileges, restrictions and conditions attaching to our shares are contained in our articles and such rights, privileges, restrictions and conditions may be changed by amending our articles. In order to amend our articles, the OBCA requires a resolution to be passed by a majority of not less than two-thirds of the votes cast by the shareholders entitled to vote thereon. In addition, if we resolve to make particular types of amendments to our articles, a holder of our shares may dissent with regard to such resolution and, if such shareholder so elects, we would have to pay such shareholder the fair value of the shares held by the shareholder in respect of which the shareholder dissents as of the close of business on the day before the resolution was adopted. The types of amendments that would be subject to dissent rights include without limitation: (i) to add, remove or change restrictions on the issue, transfer or ownership of shares of a class or series of our shares; and (ii) to add, remove or change any restriction upon the business that we may carry on or upon the powers that we may exercise.

Meetings

Each director holds office until our next annual general meeting or until his office is earlier vacated in accordance with our articles or with the provisions of the OBCA. A director appointed or elected to fill a vacancy on our board also holds office until our next annual general meeting.

Annual meetings of our shareholders must be held at such time in each year not more than 15 months after the last annual meeting, as the Board of Directors may determine.

Meetings of our shareholders shall be held at our registered office or, if our Board of Directors shall so determine, at some other place in Ontario or, at some place outside Ontario if all the shareholders entitled to vote at the meeting so agree.

Our Board of Directors, the Chair of our Board, our Chief Executive Officer, or our President shall have power to call a special meeting of our shareholders at any time.

The OBCA provides that our shareholders may requisition a special meeting in accordance with the OBCA. The OBCA provides that the holders of not less than five percent of our issued shares that carry the right to vote at a meeting may requisition our directors to call a special meeting of shareholders for the purposes stated in the requisition.

Under our by-laws, the quorum for the transaction of business at a meeting of our shareholders is two or more persons, present in person or by proxy and holding in aggregate not less than 33 1/3% of our issued shares entitled to vote at such meeting.

77


Limitations on Ownership of Securities

Except as provided in the Investment Canada Act (Canada), there are no limitations specific to the rights of non-Canadians to hold or vote our shares under the laws of Canada or Ontario, or in our charter documents.

Change in Control

We refer you to the Rights Plan described under the heading “Item 6.E. Share Ownership – Shareholder Rights Plan”. There are no provisions in our articles or by-laws that would have the effect of delaying, deferring or preventing a change in control of our Company, and that would operate only with respect to a merger, acquisition or corporate restructuring involving our Company or our subsidiaries.

Ownership Threshold

Neither our by-laws nor our articles contain any provisions governing the ownership threshold above which shareholder ownership must be disclosed. In addition, securities legislation in Canada requires that we disclose in our proxy information circular for our annual meeting and certain other disclosure documents filed by us under such legislation, holders who beneficially own more than 10% of our issued and outstanding shares.

Upon the effectiveness of this registration statement on Form 20-F, United States federal securities laws will require us to disclose, in our annual reports on Form 20-F, holders who own 5% or more of our issued and outstanding voting shares.

C. Material Contracts

There are no other contracts, other than those disclosed in this registration statement and those entered into in the ordinary course of our business, that are material to us and which were entered into in the last two completed fiscal years or which were entered into before the two most recently completed fiscal years but are still in effect as of the date of this registration statement:

  1.

License Agreement between Trillium Privateco, UHN and The Hospital for Sick Children dated February 1, 2010 pursuant to which we licensed intellectual property relating to methods and compounds for the modulation of the SIRPa-CD47 interaction for therapeutic cancer applications. We paid an up-front license fee of $150,000 and committed to pay an annual maintenance fee of $25,000, as well as payments on patent issuances, development milestone payments ranging from $100,000 to $300,000 on the initiation of phase I, II and III clinical trials respectively, and payments upon the achievement of certain regulatory milestones as well as royalties of either 3% or 1% of net revenues on commercial sales. The regulatory milestone payments amount to $1 million on each of the submission of a first BLA in the U.S. and receipt of first regulatory approval in the U.S. and proportionate payments in other territories worldwide. Under the license agreement, Trillium is required to pay 20% of any sublicensing revenues to the licensors on the first $50 million of sublicensing revenues, and pay 15% of any sublicensing revenues to the licensors after the first $50 million of sublicensing revenue received.

     
  2.

Debenture Purchase Agreement and Merger Agreement between the Company, Trillium Privateco, 2364556 Ontario Limited, and the holders of debentures issued by Trillium Privateco debenture holders dated March 25, 2013 pursuant to which we acquired Trillium Privateco. See the disclosure of the terms of the merger with Trillium Privateco under the heading “Item 4.A General Development of the Business – Acquisition of Trillium Privateco”.

78



  3. GPEx®-Derived Cell Line Sale Agreement between Trillium Therapeutics Inc. and Catalent Pharma Solutions, LLC dated August 12, 2014 pursuant to which we acquired the right to use the GPEx® expression system for the manufacture of TTI-621 (SIRPaFc). Consideration for the license includes potential pre-marketing approval milestones of up to U.S. $875,000 and aggregate sales milestone payments of up to U.S. $7.5 million.
     
  4. GPEx®-Derived Cell Line Sale Agreement between Trillium Therapeutics Inc. and Catalent Pharma Solutions, LLC dated August 12, 2014 pursuant to which we acquired the right to use the GPEx® expression system for the manufacture of TTI-622 (SIRPaFc). Consideration for the license includes potential pre-marketing approval milestones of up to U.S. $875,000 and aggregate sales milestone payments of up to U.S. $7.5 million.
     
  5.

Shareholder rights plan between Trillium and Computershare Investor Services Inc. dated September 16, 2013 and amended June 3, 2014. This plan was approved by our shareholders on May 27, 2014. See the discussion under the heading “Item 6.E. Share Ownership – Shareholder Rights Plan”.

     
  6.

2014 Stock Option Plan that was approved by our shareholders on May 27, 2014. See the discussion under the heading “Item 6.B. Compensation –Stock Option Plan”.

     
  7.

2014 DSU Plan that was approved by our shareholders on May 27, 2014. See the discussion under the heading “Item 6.B. Compensation –Deferred Share Unit Plan”.

     
  8.

Warrant Indenture between the Company and Computershare Trust Company of Canada (“ Computershare ”) dated March 15, 2013. This indenture provides that Computershare will act as the trust agent for the administration of the issued warrants.

     
  9.

Warrant Indenture between the Company and Computershare Trust Company of Canada dated April 8, 2013. This indenture provides that Computershare will act as the trust agent for the administration of the issued warrants.

     
  10.

Warrant Indenture between the Company and Computershare Trust Company of Canada dated December 13, 2013. This indenture provides that Computershare will act as the trust agent for the administration of the issued warrants.

     
  11.

Agency Agreement between the Company, Bloom Burton & Co. Inc. and Roth Capital Partners, LLC dated December 13, 2013. Bloom Burton & Co. Inc. and Roth Capital Partners acted as the sole and exclusive agents in our December 2013 private placement to solicit, on a commercially reasonable best efforts basis, orders for the Offered Units from Purchasers resident in the Offering Jurisdictions (capitalized terms having their meaning as set out in the agreement which is attached as an exhibit to this Form 20-F). For their services, the agents received a commission equal to 6% of the total proceeds of the offering sold by the agents, and compensation warrants equal to 6% of the number of units sold by the agents, with an exercise price of $0.21 and a term of two years.

79


D. Exchange Controls

There are no government laws, decrees or regulations in Canada that restrict the export or import of capital or that affect the remittance of dividends, interest or other payments to non-resident holders of our common shares. Any remittances of dividends to United States residents and to other non-residents are, however, subject to withholding tax. See the discussion under the heading “Item 16.E. Taxation – United States Federal Income Taxation”.

E. Taxation

Canadian Federal Income Taxation

We consider that the following general summary fairly describes the principal Canadian federal income tax consequences applicable to a holder of our common shares who is a resident of the United States, who is not, will not be and will not be deemed to be a resident of Canada for purposes of the Income Tax Act (Canada) and any applicable tax treaty and who does not use or hold, and is not deemed to use or hold, his, her or its common shares in the capital of our Company in connection with carrying on a business in Canada (a “ non-resident holder ”).

This summary is based upon the current provisions of the Income Tax Act (Canada), the regulations thereunder (the “ Regulations ”), the current publicly announced administrative and assessing policies of the Canada Revenue Agency and the Canada-United States Tax Convention as amended by the Protocols thereto (the “ Treaty ”). This summary also takes into account the amendments to the Income Tax Act (Canada) and the Regulations publicly announced by the Minister of Finance (Canada) prior to the date hereof (the “ Tax Proposals ”) and assumes that all such Tax Proposals will be enacted in their present form. However, no assurances can be given that the Tax Proposals will be enacted in the form proposed, or at all. This summary is not exhaustive of all possible Canadian federal income tax consequences applicable to a holder of our common shares and, except for the foregoing, this summary does not take into account or anticipate any changes in law, whether by legislative, administrative or judicial decision or action, nor does it take into account provincial, territorial or foreign income tax legislation or considerations, which may differ from the Canadian federal income tax consequences described herein.

This summary is of a general nature only and is not intended to be, and should not be construed to be, legal, business or tax advice to any particular holder or prospective holder of our common shares, and no opinion or representation with respect to the tax consequences to any holder or prospective holder of our common shares is made. Accordingly, holders and prospective holders of our common shares should consult their own tax advisors with respect to the income tax consequences of purchasing, owning and disposing of our common shares in their particular circumstances.

Dividends

Dividends paid on our common shares to a non-resident holder will be subject under the Income Tax Act (Canada) to withholding tax at a rate of 25% subject to a reduction under the provisions of an applicable tax treaty, which tax is deducted at source by our Company. The Treaty provides that the Income Tax Act (Canada) standard 25% withholding tax rate is reduced to 15% on dividends paid on shares of a corporation resident in Canada (such as our Company) to residents of the United States, and also provides for a further reduction of this rate to 5% where the beneficial owner of the dividends is a corporation resident in the United States that owns at least 10% of the voting shares of the corporation paying the dividend.

80


Capital Gains

A non-resident holder is not subject to tax under the Income Tax Act (Canada) in respect of a capital gain realized upon the disposition of a common share of our Company unless such share represents “taxable Canadian property”, as defined in the Income Tax Act (Canada), to the holder thereof. Our common shares generally will be considered taxable Canadian property to a non-resident holder if:

  • the non-resident holder;
  • persons with whom the non-resident holder did not deal at arm’s length; or
  • the non-resident holder and persons with whom such non-resident holder did not deal at arm’s length,

owned, or had an interest in an option in respect of, not less than 25% of the issued shares of any class of our capital stock at any time during the 60 month period immediately preceding the disposition of such shares. In the case of a non-resident holder to whom shares of our Company represent taxable Canadian property and who is resident in the United States, no Canadian taxes will generally be payable on a capital gain realized on such shares by reason of the Treaty unless the value of such shares is derived principally from real property situated in Canada.

Rights Plan

The following commentary summarizes certain Canadian federal income tax consequences of the issuance of the Rights. It is of a general nature only and is not intended to constitute nor should it be construed to constitute legal or tax advice to any particular holder of common shares. Such shareholders are advised to consult their own tax advisors regarding the consequences of acquiring, holding, exercising or otherwise disposing of their Rights, taking into account their own particular circumstances and any applicable foreign, provincial or territorial legislation.

The Company did not receive any income for the purposes of the Income Tax Act (Canada) (the “ ITA ”) as a result of the issuance of the Rights. The ITA provides that the value of a right to acquire additional shares of a corporation is not a taxable benefit which must be included in computing income of a shareholder, and is not subject to non-resident withholding tax, if the right is conferred on all holders of common shares. Although the Rights are to be so conferred, the Rights could become void in the hands of certain holders of common shares upon certain triggering events occurring (such as a Flip-in Event) and, consequently, whether or not the issuance of the Rights is a taxable event is not entirely free from doubt. In any event, only the amount or value of such benefit must be included in computing income of a shareholder. We consider that the Rights have negligible monetary value because there is only a remote possibility that the Rights will ever be exercised. If the Rights are disposed of (except on exercise thereof), a holder of Rights may be subject to tax in respect of the proceeds of disposition of such Rights.

Eligibility for Investment in Canada

Provided that at all material times we remain a “public corporation” for purposes of the ITA and deal at arm’s length with each person who is an annuitant, a beneficiary, an employer or a subscriber, as the case may be, under a registered retirement savings plan, a registered retirement income fund, a deferred profit sharing plan or a registered education savings plan (collectively, the “Plans”), the Rights will be qualified investments under the ITA for the Plans.

81


United States Federal Income Taxation

The following is a general summary of material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership, and disposition of our common shares.

This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of common shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder, including specific tax consequences to a U.S. Holder under an applicable tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of common shares. Except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each U.S. Holder should consult its own tax advisor regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of common shares.

No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the “ IRS ”) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the positions taken in this summary.

Scope of this Summary

Authorities

This summary is based on the Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended, or the Canada-U.S. Tax Convention, and U.S. court decisions that are applicable and, in each case, as in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive or prospective basis which could affect the U.S. federal income tax considerations described in this summary. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.

82


U.S. Holders

For purposes of this summary, the term “U.S. Holder” means a beneficial owner of common shares that is for U.S. federal income tax purposes:

  • an individual who is a citizen or resident of the U.S.;

  • a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) organized under the laws of the U.S., any state thereof or the District of Columbia;

  • an estate whose income is subject to U.S. federal income taxation regardless of its source; or

  • a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.

Non-U.S. Holders

For purposes of this summary, a “non-U.S. Holder” is a beneficial owner of common shares that is not a U.S. Holder. This summary does not address the U.S. federal income tax consequences to non-U.S. Holders arising from and relating to the acquisition, ownership, and disposition of common shares. Accordingly, a non-U.S. Holder should consult its own tax advisor regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences (including the potential application of and operation of any income tax treaties) relating to the acquisition, ownership, and disposition of common shares.

U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed

This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, the following: (a) U.S. Holders that are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) U.S. Holders that are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) U.S. Holders that are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) U.S. Holders that have a “functional currency” other than the U.S. dollar; (e) U.S. Holders that own common shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) U.S. Holders that acquired common shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) U.S. Holders that hold common shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); or (h) U.S. Holders that own or have owned (directly, indirectly, or by attribution) 10% or more of the total combined voting power of our outstanding shares. This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Income Tax Act (Canada) (the “Tax Act”); (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold common shares in connection with carrying on a business in Canada; (d) persons whose common shares constitute “taxable Canadian property” under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisor regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of common shares.

83


If an entity or arrangement that is classified as a partnership (or “pass-through” entity) for U.S. federal income tax purposes holds common shares, the U.S. federal income tax consequences to such partnership and the partners of such partnership generally will depend on the activities of the partnership and the status of such partners (or owners). This summary does not address the tax consequences to any such partnership or partner. Partners of entities or arrangements that are classified as partnerships for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership, and disposition of common shares.

Passive Foreign Investment Company Rules

If we were to constitute a “passive foreign investment company” under the meaning of Section 1297 of the Code, or a PFIC, for any year during a U.S. Holder’s holding period, then different and potentially adverse rules will affect the U.S. federal income tax consequences to a U.S. Holder resulting from the acquisition, ownership and disposition of common shares. In addition, in any year in which we are classified as a PFIC, such holder may be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621.

PFIC Status of the Company

We generally will be a PFIC if, for a tax year, (a) 75% or more of our gross income is passive income (the “income test”) or (b) 50% or more of the value of our assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the “asset test”). “Gross income” generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and “passive income” generally includes, for example, dividends, interest, rents and royalties, gains from the sale of stock and securities, and gains from commodities transactions.

For purposes of the PFIC income test and asset test described above, if we own, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, we will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and asset test described above, and assuming certain other requirements are met, “passive income” does not include interest, dividends, rents, or royalties that are received or accrued by us from “related persons” (as defined in Section 954(d)(3) of the Code), to the extent such items are properly allocable to the income of such related person that is not passive income.

In addition, under attribution rules, if we are a PFIC, U.S. Holders will be deemed to own their proportionate share of the stock of any subsidiary of ours that is also a PFIC, or a Subsidiary PFIC, and will be subject to U.S. federal income tax on their proportionate share of (a) a distribution on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC.

84


We believe that we were classified as a PFIC during the tax year ended December 31, 2013, and may be a PFIC in future tax years. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by us (or a Subsidiary PFIC) concerning its PFIC status. Each U.S. Holder should consult its own tax advisor regarding the PFIC status of the Company and any Subsidiary PFIC.

Default PFIC Rules Under Section 1291 of the Code

If we are a PFIC, the U.S. federal income tax consequences to a U.S. Holder of the acquisition, ownership, and disposition of common shares will depend on whether such U.S. Holder makes an election to treat us and each Subsidiary PFIC, if any, as a “qualified electing fund” or “QEF” under Section 1295 of the Code, or a QEF Election, or a mark-to-market election under Section 1296 of the Code, or a Mark-to-Market Election. A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a “Non-Electing U.S. Holder.” A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code with respect to (a) any gain recognized on the sale or other taxable disposition of common shares and (b) any excess distribution received on our common shares. A distribution generally will be an “excess distribution” to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder’s holding period for our common shares, if shorter).

Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of common shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any “excess distribution” received on common shares, must be ratably allocated to each day in a Non-Electing U.S. Holder’s holding period for the respective common shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income. The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as “personal interest,” which is not deductible.

If we are a PFIC for any tax year during which a Non-Electing U.S. Holder holds common shares, we will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether we cease to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such common shares were sold on the last day of the last tax year for which we were a PFIC.

85


QEF Election

A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which its holding period of its common shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its common shares. A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder’s pro rata share of (a) our net capital gain, which will be taxed as long-term capital gain to such U.S. Holder, and (b) our ordinary earnings, which will be taxed as ordinary income to such U.S. Holder. Generally, “net capital gain” is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and “ordinary earnings” are the excess of (a) “earnings and profits” over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which we are a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by us. However, for any tax year in which we are a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as “personal interest,” which is not deductible.

A U.S. Holder that makes a timely and effective QEF Election with respect to us generally (a) may receive a tax-free distribution from us to the extent that such distribution represents “earnings and profits” of ours that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder’s tax basis in our common shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of common shares.

The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as “timely” if such QEF Election is made for the first year in the U.S. Holder’s holding period for our common shares in which we were a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder’s holding period for our common shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder also makes a “purging” election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such common shares were sold for their fair market value on the day the QEF Election is effective.

A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, we cease to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which we are not a PFIC. Accordingly, if we become a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which we qualify as a PFIC.

U.S. Holders should be aware that there can be no assurance that we will satisfy the record keeping requirements that apply to a QEF Election, or that we will supply U.S. Holders with information that such U.S. Holders require to report under the QEF Election rules, in event that we are a PFIC and a U.S. Holder wishes to make a QEF Election. Thus, U.S. Holders may not be able to make a QEF Election with respect to their common shares. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a QEF Election.

86


Mark-to-Market Election

A U.S. Holder may make a Mark-to-Market Election only if the common shares are marketable stock. Our common shares generally will be “marketable stock” if our common shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and meets other requirements and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange ensure active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be “regularly traded” for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter.

A U.S. Holder that makes a Mark-to-Market Election with respect to its common shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such common shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder’s holding period for our common shares or such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to dispositions of, and distributions on, our common shares.

A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which we are a PFIC, an amount equal to the excess, if any, of (a) the fair market value of our common shares, as of the close of such tax year over (b) such U.S. Holder’s tax basis in such common shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder’s adjusted tax basis in our common shares, over (b) the fair market value of such common shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).

A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder’s tax basis in our common shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of common shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years).

A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless our common shares cease to be “marketable stock” or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a Mark-to-Market Election.

87


Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to our common shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to eliminate the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or distributions from a Subsidiary PFIC.

Other PFIC Rules

Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon transfers of common shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which common shares are transferred.

Additional adverse rules will apply with respect to a U.S. Holder if we are a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example under Section 1298(b)(6) of the Code, a U.S. Holder that uses common shares as security for a loan will, except as may be provided in future Treasury Regulations, be treated as having made a taxable disposition of such common shares.

Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with their own tax advisor regarding the availability of the foreign tax credit with respect to distributions by a PFIC.

The PFIC rules are complex, and each U.S. Holder should consult its own tax advisor regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares.

Ownership and Disposition of Common Shares

The following discussion is subject to the rules described above under the heading “Passive Foreign Investment Company Rules”.

Distributions on Common Shares

Subject to the PFIC rules discussed above, a U.S. Holder that receives a distribution, including a constructive distribution, with respect to an Offered Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current or accumulated “earnings and profits” of ours, as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if we are a PFIC. To the extent that a distribution exceeds the current and accumulated “earnings and profits” of ours, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder's tax basis in our common shares and thereafter as gain from the sale or exchange of such common shares. (See “Sale or Other Taxable Disposition of Common Shares” below). However, we may not maintain the calculations of earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder should therefore assume that any distribution by us with respect to our common shares will constitute ordinary dividend income. Dividends received on common shares generally will not be eligible for the “dividends received deduction”. Provided we are eligible for the benefits of the Canada-U.S. Tax Convention, dividends paid by us to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided holding period and other conditions are satisfied, including that we not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisor regarding the application of such rules.

88


Sale or Other Taxable Disposition of Common Shares

Subject to the PFIC rules discussed above, upon the sale or other taxable disposition of common shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount of cash plus the fair market value of any property received and such U.S. Holder's tax basis in such common shares sold or otherwise disposed of. Subject to the PFIC rules discussed above, gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, our common shares have been held for more than one year. Preferential tax rates apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.

Additional Considerations

Additional Tax on Passive Income

Individuals, estates and trusts whose income exceeds specified thresholds will be required to pay a 3.8% surtax on “net investment income” including, among other things, dividends and net gain from disposition of property (other than property held in specified trades or businesses). U.S. Holders should consult with their own tax advisors regarding the effect, if any, of this tax on their ownership and disposition of common shares.

Receipt of Foreign Currency

The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of common shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.

Foreign Tax Credit

Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the common shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Holder’s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder’s income subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year.

89


Complex limitations apply to the foreign tax credit, including the general limitation that the credit cannot exceed the proportionate share of a U.S. Holder’s U.S. federal income tax liability that such U.S. Holder’s “foreign source” taxable income bears to such U.S. Holder’s worldwide taxable income. In applying this limitation, a U.S. Holder’s various items of income and deduction must be classified, under complex rules, as either “foreign source” or “U.S. source.” Generally, dividends paid by a foreign corporation should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign corporation by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an applicable income tax treaty, and if an election is properly made under the Code. However, the amount of a distribution with respect to the common shares that is treated as a “dividend” may be lower for U.S. federal income tax purposes than it is for Canadian federal income tax purposes, resulting in a reduced foreign tax credit allowance to a U.S. Holder. In addition, this limitation is calculated separately with respect to specific categories of income. The foreign tax credit rules are complex, and each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.

Rights Plan

The adoption of the Rights Plan, and the attachment of one Right to each common share, generally should not result in U.S. federal income tax consequences to U.S. Holders. Subsequent events, however, such as the separation of the Rights from the common shares, or the exercise of a Right and receipt of additional common shares, may result in U.S. federal income tax consequences to U.S. Holders. Each U.S. Holder should consult its own tax advisors regarding the tax consequences to such holder of the separation of the Rights from the common shares or the exercise of Rights for additional common shares.

Backup Withholding and Information Reporting

Payments made within the U.S. or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, common shares will generally be subject to information reporting and backup withholding tax, at the rate of 28%, if a U.S. Holder (a) fails to furnish such U.S. Holder’s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder’s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner.

Under U.S. federal income tax law and Treasury Regulations, U.S. Holders must generally file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold specified foreign financial assets in excess of threshold amounts. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their common shares are held in an account at financial institutions meeting specified requirements. Penalties for failure to file information returns can be substantial. U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.

90


The discussion of reporting requirements set forth above is not intended to constitute an exhaustive description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy reporting requirements may result in an extension of the time period during which the IRS can assess a tax, and under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.

F. Dividends and Paying Agents

There is no dividend restriction; however, we have not declared any dividends since our inception and do not anticipate that we will do so in the foreseeable future. We currently intend to retain future earnings, if any, to finance the development of our business. Any future payment of dividends or distributions will be determined by our Board of Directors on the basis of our earnings, financial requirements and other relevant factors. There is no special procedure for non-resident holders to claim dividends. Any remittances of dividends to United States residents and to other non-residents are, however, subject to withholding tax. See the discussion under the heading “Item 16.E. Taxation – United States Federal Income Taxation”.

G. Statement by Experts

Our consolidated financial statements as at and for the years ended December 31, 2013 and 2012, and for the years ended December 31, 2012 and 2011 included in this registration statement have been audited by Ernst & Young LLP, Independent Registered Public Accounting Firm, as stated in their report appearing in this registration statement and have been so included in reliance upon the report of such firm given their authority as experts in accounting and auditing.

The financial statements of Trillium Privateco as at and for the years ended June 30, 2012 and 2011 included in this registration statement have been audited by Ernst & Young LLP, Independent Auditors, as stated in their report appearing in this registration statement and have been so included in reliance upon the report of such firm given their authority as experts in accounting and auditing.

H. Documents on Display

Upon the effectiveness of this registration statement, we will be subject to the informational requirements of the Securities Exchange Act of 1934, and we will thereafter file reports and other information with the Securities and Exchange Commission. You may read and copy any of our reports and other information at, and obtain copies upon payment of prescribed fees from, the Public Reference Room maintained by the SEC at 100 F Street, N.E., Washington, DC 20549. In addition, the Securities and Exchange Commission maintains a web site that contains reports and other information regarding registrants that file electronically with the Securities and Exchange Commission at http://www.sec.gov. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.

91


We are also subject to the full informational requirements of the securities commissions in all provinces of Canada, and you are also invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the Canadian provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com, the Canadian equivalent of the SEC’s electronic document gathering and retrieval system.

I. Subsidiary Information

We own 100% of the voting securities Stem Cell Therapeutics Inc., a wholly-owned subsidiary incorporated under the Business Corporations Act (Alberta) on December 22, 1999 and continued under the Business Corporations Act (Ontario) on November 12, 2003 and then extra-provincially registered in Alberta on January 11, 2005. We have initiated the process to dissolve this inactive subsidiary.

ITEM 11.                  QUANTITATIVE & QUALITATIVE DISCLOSURES ABOUT MARKET RISK Fair Value

IFRS 13, Fair Value Measurement , provides a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs are those which reflect market data obtained from independent sources, while unobservable inputs reflects our assumptions with respect to how market participants would price an asset or liability. These two inputs used to measure fair value fall into the following three different levels of the fair value hierarchy:

  Level 1

Quoted prices in active markets for identical instruments that are observable.

     
Level 2

Quoted prices in active markets for similar instruments; inputs other than quoted prices that are observable and derived from or corroborated by observable market data.

     
Level 3

Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

The hierarchy requires the use of observable market data when available.

We have classified cash, marketable securities, amounts receivable, accounts payable and accrued liabilities, other current liabilities, loan payable and long-term liability as Level 1.

Cash, marketable securities, amounts receivable, accounts payable and accrued liabilities, and other current liabilities, due within one year, are all short-term in nature and, as such, their carrying values approximate fair values. The fair value of the non-current loan payable and long-term liability is estimated by discounting the expected future cash flows at the cost of money to us, which is equal to its carrying value.

92


Risks

We are exposed to credit risk, liquidity risk, interest rate risk and currency risk. Our Board of Directors has overall responsibility for the establishment and oversight of our risk management framework. The Audit Committee is responsible for reviewing our risk management policies.

Credit risk

Credit risk is the risk of financial loss to us if a counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from our cash and cash equivalents and amounts receivable. The carrying amount of these financial assets represents the maximum credit exposure. We follow an investment policy to mitigate against the deterioration of principal and to enhance our ability to meet its liquidity needs. Cash and cash equivalents are on deposit with a major Canadian chartered bank. Amounts receivable are primarily comprised of amounts due from the federal government.

Liquidity risk

Liquidity risk is the risk that we will not be able to meet its financial obligations as they fall due. We are a development stage company and are reliant on external fundraising to support its operations. Once funds have been raised, we manage our liquidity risk by investing in cash and cash equivalents to provide regular cash flow for current operations. We also manage liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves our operating and capital budgets, as well as any material transactions not in the ordinary course of business. The majority of our accounts payable and accrued liabilities have maturities of less than three months.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Our cash and cash equivalents are highly liquid holdings in bank accounts or high interest savings accounts which have a variable rate of interest. We manage our interest rate risk by holding highly liquid short-term instruments and by holding its investments to maturity, where possible. For the years ended December 31, 2013 and 2012, we earned interest income of $44,113 and $25,740, respectively. Therefore, a 1% change in the average interest rate for the year would have a net impact on finance income of $441.

Currency risk

We are exposed to currency risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. Currency risk is limited to the portion of our business transactions denominated in currencies other than the Canadian dollar which are primarily expenses in U.S. dollars. We manage our exposure to currency fluctuations by holding cash and cash equivalents denominated in U.S. dollars in amounts approximating current U.S. dollar financial liabilities and U.S. dollar planned expenditures. As at December 31, 2013 and 2012, we held U.S. dollar cash and cash equivalents in the amount of US$493,031 and US$157,383, respectively, and had U.S. dollar denominated accounts payable and accrued liabilities in the amount of US$88,063 and US$30,396, respectively. Therefore, a 1% change in the foreign exchange rate would have had a net impact on finance costs of $4,050 in 2013 and $1,270 in 2012.

93


U.S. dollar expenses for the years ended December 31, 2013 and 2012 were approximately US$518,000 and US$532,000, respectively. Varying the US exchange rate for the year to reflect a 5% strengthening of the Canadian dollar would have decreased the net loss by approximately $26,000 in 2013 and $27,000 in 2012 assuming that all other variables remained constant.

ITEM 12.                  DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

None.

94


PART II

ITEM 13.                  DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.

ITEM 14.                  MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.

We have a shareholder rights plan pursuant to an agreement between us and Computershare Investor Services Inc. dated September 16, 2013 and amended on June 3, 2014. This plan was approved by our shareholders on May 27, 2014 and by the TSX on June 5, 2014. The primary objective of the Rights Plan is to ensure that all of our shareholders are treated fairly in connection with any take-over bid for our Company by (a) providing shareholders with adequate time to properly assess a take-over bid without undue pressure and (b) providing the Board of Directors with more time to fully consider an unsolicited take-over bid, and, if applicable, to explore other alternatives to maximize shareholder value. One right has been issued in respect of each issued common share of ours. See the discussion under the heading “Item 6.E. Share Ownership – Shareholder Rights Plan”.

ITEM 15.                  CONTROL AND PROCEDURES

Not Applicable.

ITEM 16A.                AUDIT COMMITTEE FINANCIAL EXPERT

Not Applicable.

ITEM 16B.                CODE OF ETHICS

Not Applicable.

ITEM 16C.                PRINCIPAL ACCOUNTANT FEES AND SERVICES

Not Applicable.

ITEM 16D.                EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Not Applicable.

ITEM 16E.                PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

Not Applicable.

ITEM 16F.                CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

None.

95


ITEM 16G.                CORPORATE GOVERNANCE

Not Applicable.

ITEM 16H.                MINE SAFETY DISCLOSURE

Not Applicable.

96


PART III

ITEM 17.                  FINANCIAL STATEMENTS

The following financial statements and notes thereto (as applicable) in Canadian dollars are filed with and incorporated herein as part of this Form 20-F, beginning on page F-1 following the signature page of this Form 20-F:

  • audited consolidated financial statements of the Company for the years ended December 31, 2013 and 2012, prepared in accordance with IFRS as issued by the IASB, including: consolidated statements of financial position, consolidated statements of loss and comprehensive loss, consolidated statements of changes in equity, consolidated statements of cash flows, and notes to the consolidated financial statements.

  • audited consolidated financial statements of the Company for the years ended December 31, 2012 and 2011, prepared in accordance with IFRS as issued by the IASB, including: consolidated statements of financial position, consolidated statements of loss and comprehensive loss, consolidated statements of changes in equity, consolidated statements of cash flows, and notes to the consolidated financial statements.

  • unaudited interim condensed consolidated financial statements of the Company for the six months ended June 30, 2014 and 2013, prepared in accordance with International Accounting Standard 34, Interim Financial Reporting including: consolidated statements of financial position, consolidated statements of loss and comprehensive loss, consolidated statements of changes in equity, consolidated statements of cash flows, and notes to the unaudited interim condensed consolidated financial statements.

  • audited financial statements of Trillium Privateco for the years ended June 30, 2012 and 2011, prepared in accordance with ASPE, including: balance sheets, statements of operations and deficit and statements of cash flows, and notes to the financial statements, including note 16 - Differences between Canadian and United States Generally Accepted Accounting Principles.

  • unaudited interim condensed financial statements of Trillium Privateco for the nine months ended March 31, 2013 and 2012, prepared in accordance with ASPE, including: balance sheets, statements of operations and deficit and statements of cash flows, and notes to the unaudited interim condensed financial statements, including note 13 - Differences between Canadian and United States Generally Accepted Accounting Principles.

  • pro forma unaudited consolidated statement of loss and comprehensive loss of the Company for the year ended December 31, 2013, assuming the acquisition of Trillium Privateco occurred on January 1, 2013 rather than April 9, 2013, with explanatory notes describing the pro forma adjustments.

ITEM 18.                  FINANCIAL STATEMENTS

We have elected to provide financial statements pursuant to Item 17. See the Index to the Financial Statements on page F-1 following the signature page of this Form 20-F.

97


ITEM 19.                  EXHIBITS

Exhibit    
Number   Description
     
1.1   Articles of Incorporation dated March 31, 2004
     
1.2   Articles of Amendment dated October 19, 2004
     
1.3   Articles of Amendment dated February 6, 2013
     
1.4  

Articles of Continuance dated November 7, 2013

     
1.5  

Articles of Amendment dated December 12, 2013

     
1.6  

Articles of Amalgamation dated June 1, 2014

     
1.7  

By-law No.1 of Trillium Therapeutics Inc. amended and restated as of May 27, 2014

     
2.1  

Rights Agreement between Trillium Therapeutics Inc. and Computershare Investor Services Inc. dated September 16, 2013 and amended on June 3, 2014 including the form of rights certificate

     
4.1  

Amended and restated License Agreement between Trillium Privateco, the University Health Network and The Hospital for Sick Children effective February 1, 2010 and amended June 1, 2012

     
4.2  

Debenture Purchase Agreement and Merger Agreement among Stem Cell Therapeutics Corp., Trillium Privateco, 2364556 Ontario Limited, and the Trillium Privateco debenture holders dated March 25, 2013

     
4.3*  

GPEx ® -Derived Cell Line Sale Agreement between Trillium Therapeutics Inc. and Catalent Pharma Solutions, LLC dated August 12, 2014 for TTI-621

     
4.4*  

GPEx ® -Derived Cell Line Sale Agreement between Trillium Therapeutics Inc. and Catalent Pharma Solutions, LLC dated August 12, 2014 for TTI-622

     
4.5  

2014 Stock Option Plan

     
4.6  

2014 Deferred Share Unit Plan

     
4.7  

Warrant Indenture between Stem Cell Therapeutics Corp. and Computershare Trust Company of Canada dated March 15, 2013

     
4.8  

Warrant Indenture between Stem Cell Therapeutics Corp. and Computershare Trust Company of Canada dated April 8, 2013

     
4.9  

Warrant Indenture between Stem Cell Therapeutics Corp. and Computershare Trust Company of Canada dated December 13, 2013

     
4.10  

Agency Agreement among Stem Cell Therapeutics Corp. and Bloom Burton & Co. Inc. and Roth Capital Partners, LLC dated December 13, 2013

     
15.1  

Consent of Ernst & Young LLP

     
15.2  

Consent of Ernst & Young LLP

* to be filed by amendment.

98


SIGNATURES

            The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this registration statement on its behalf on August 12, 2014.

  TRILLIUM THERAPEUTICS INC.
   
   
  /s/ Niclas Stiernholm
  Niclas Stiernholm
   
  President & Chief Executive Officer

99


INDEX TO THE FINANCIAL STATEMENTS

 

Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.)

For the three and six months ended June 30, 2014 and 2013

Consolidated Statements of Financial Position F-2
Consolidated Statements of Loss and Comprehensive Loss F-3
Consolidated Statements of Changes in Equity F-4
Consolidated Statements of Cash Flows F-5
Notes to the Interim Condensed Consolidated Financial Statements F-6

Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.)

For the years ended December 31, 2013 and 2012

Report of Independent Registered Public Accounting Firm F-22
Consolidated Statements of Financial Position F-23
Consolidated Statements of Loss and Comprehensive Loss F-24
Consolidated Statements of Changes in Equity F-25
Consolidated Statements of Cash Flows F-26
Notes to the Consolidated Financial Statements F-27

100


Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.)

For the years ended December 31, 2012 and 2011

Report of Independent Registered Public Accounting Firm F-48
Consolidated Statements of Financial Position F-50
Consolidated Statements of Loss and Comprehensive Loss F-51
Consolidated Statements of Changes in Equity F-52
Consolidated Statements of Cash Flows F-53
Notes to the Consolidated Financial Statements F-54

      Trillium Therapeutics Inc. (Trillium Privateco)

For the nine months ended March 31, 2013 and 2012

Balance Sheets F-70
Statements of Operations and Deficit F-71
Statements of Cash Flows F-72
Notes to the Interim Condensed Financial Statements F-73

Trillium Therapeutics Inc. (Trillium Privateco)

For the years ended June 30, 2012 and 2011

Report of Independent Registered Public Accounting Firm F-83
Balance Sheets F-84
Statements of Operations and Deficit F-85
Statements of Cash Flows F-86
Notes to the Interim Condensed Financial Statements F-87

101


Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.)

For the year ended December 31, 2013

Pro forma Consolidated Statement of Loss and Comprehensive Loss F-107

102



(formerly Stem Cell Therapeutics Corp.)

INTERIM CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS

 

FOR THE THREE AND SIX MONTHS ENDED
JUNE 30, 2014 AND 2013

(UNAUDITED)

 

 

96 Skyway Avenue
Toronto, Ontario M9W 4Y9
www.trilliumtherapeutics.com

F-1



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Interim Consolidated Statements of Financial Position
Amounts in Canadian Dollars
(Unaudited)

      As at     As  
  Note   June 30, 2014     December 31, 2013  
      $     $  
               
               
ASSETS              
               
Current              
Cash     30,041,001     32,456,506  
Marketable securities     503,978     526,598  
Amounts receivable 5   487,319     427,234  
Prepaid expenses     117,883     94,569  
               
Total current assets     31,150,181     33,504,907  
               
Property and equipment 6   228,874     109,007  
Intangible assets 7   602,607     1,473,472  
               
Total non-current assets     831,481     1,582,479  
               
Total assets     31,981,662     35,087,386  
               
LIABILITIES              
               
Current              
Accounts payable and accrued liabilities 8   1,012,226     669,860  
Other current liabilities 9   120,452     62,766  
               
Total current liabilities     1,132,678     732,626  
               
Loan payable 9   311,565     341,884  
Long-term liability 9   116,434     104,429  
               
Total non-current liabilities     427,999     446,313  
               
Total liabilities     1,560,677     1,178,939  
               
EQUITY              
Common shares 10   48,579,360     47,191,303  
Preferred shares 10   11,002,583     11,292,525  
Warrants 10   9,283,332     9,818,179  
Contributed surplus 10   5,370,357     3,280,656  
Deficit     (43,814,647 )   (37,674,216 )
               
Total equity     30,420,985     33,908,447  
               
Total liabilities and equity     31,981,662     35,087,386  
Commitments and contingencies [note 14]              

Approved by the Board and authorized for issue on August 11, 2014:

(signed) Luke Beshar, Director (signed) Henry Friesen, Director

See accompanying notes to the interim condensed consolidated financial statements

F-2



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Interim Consolidated Statements of Loss and Comprehensive Loss
Amounts in Canadian Dollars
(Unaudited)

 

    Three months ended     Three months ended     Six months ended     Six months ended  

 

Note   June 30, 2014     June 30, 2013     June 30, 2014     June 30, 2013  

 

    $     $     $     $  

 

                         

EXPENSES

                         

Research and development

11   3,105,402     1,059,063     4,670,884     1,221,732  

General and administrative

12   1,075,961     329,716     1,637,542     507,601  

 

                         

Operating expenses

    4,181,363     1,388,779     6,308,426     1,729,333  

 

                         

Finance income

13   (102,455 )   (13,361 )   (211,047 )   (19,285 )

Finance costs

13   21,463     1,269     43,052     2,217  

 

                         

Net finance income

    (80,992 )   (12,092 )   (167,995 )   (17,068 )

 

                         

Net loss and comprehensive loss for the period

    4,100,371     1,376,687     6,140,431     1,712,265  

 

                         

Basic and diluted loss per share

10 (c)   (0.03 )   (0.03 )   (0.05 )   (0.06 )

See accompanying notes to the interim condensed consolidated financial statements

F-3



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Interim Consolidated Statements of Changes in Equity
Amounts in Canadian Dollars
(Unaudited)

 

  Common shares     Preferred shares     Warrants     Contributed              

 

  Number     Amount     Number     Amount     Number     Amount     surplus     Deficit     Total  

 

  #     $     #     $     #     $     $     $     $  

      (note 10) (Restated note 16)         (note 10 )       (note 10) (Restated note 16)     (note 10 )        

Balance, December 31, 2013

  121,752,380     47,191,303     77,895,165     11,292,525     142,230,123     9,818,179     3,280,656     (37,674,216 )   33,908,447  

Net loss and comprehensive loss for the period

  -     -     -     -     -     -     -     (6,140,431 )   (6,140,431 )

Transactions with owners of the Company, recognized directly in equity

                                   

Exercise of warrants

  2,596,251     1,065,015     -     -     (2,596,251 )   (118,202 )   -     -     946,813  

Exercise of stock options

  78,400     33,100     -     -     -     -     (13,500 )   -     19,600  

Conversion of preferred shares

  2,000,000     289,942     (2,000,000 )   (289,942 )   -     -     -     -     -  

Expiry of warrants

  -     -     -     -     (909,091 )   (416,645 )   416,645     -     -  

Share-based compensation

  -     -     -     -     -     -     1,686,556     -     1,686,556  

Total transactions with owners of the Company

  4,674,651     1,388,057     (2,000,000 )   (289,942 )   (3,505,342 )   (534,847 )   2,089,701     -     2,652,969  

Balance, June 30, 2014

  126,427,031     48,579,360     75,895,165     11,002,583     138,724,781     9,283,332     5,370,357     (43,814,647 )   30,420,985  

 

  Common shares     Preferred shares     Warrants     Contributed              

 

  Number     Amount     Number     Amount     Number     Amount     surplus     Deficit     Total  

 

  #     $     #     $     #     $     $     $     $  

 

                                                     

Balance, December 31, 2012

  18,661,936     31,388,959     -     -     1,036,364     508,281     2,870,138     (33,384,908 )   1,382,470  

 

                                                     

Net loss and comprehensive loss for the period

  -     -     -     -     -     -     -     (1,712,265 )   (1,712,265 )

Transactions with owners of the Company, recognized directly in equity

                                   

Share units issued, net of issue costs

  12,735,000     2,092,192     -     -     12,735,000     523,048     -     -     2,615,240  

Compensation warrants

  -     -     -     -     814,051     48,843     -     -     48,843  

Issued to acquire Trillium Privateco (notes 4 and 10)

  6,079,180     1,215,836     -     -     3,300,000     165,000     -     -     1,380,836  

Issued to acquire technology rights (notes 7 and 10)

  5,028,571     1,005,714     -     -     1,600,000     80,000     -     -     1,085,714  

Expiry of warrants

  -     -     -     -     (127,273 )   (91,636 )   91,636     -     -  

Share-based compensation

  -     -     -     -     -     -     234,039     -     234,039  

Total transactions with owners of the Company

  23,842,751     4,313,742     -     -     18,321,778     725,255     325,675     -     5,364,672  

Balance, June 30, 2013

  42,504,687     35,702,701     -     -     19,358,142     1,233,536     3,195,813     (35,097,173 )   5,034,877  

See accompanying notes to the interim condensed consolidated financial statements

F-4



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Interim Consolidated Statements of Cash Flows
Amounts in Canadian Dollars
(Unaudited)

 

        Six months ended     Six months ended  

 

  Note     June 30, 2014     June 30, 2013  

 

        $     $  

 

                 

OPERATING ACTIVITIES

                 

Net loss for the period

        (6,140,431 )   (1,712,265 )

Adjustments for items not affecting cash

                 

   Share-based compensation

  10     1,686,556     234,039  

   Interest accretion

  9,13     39,138     -  

   Amortization of intangible assets

  7     441,102     209,757  

   Impairment of intangible assets

  7     429,763     -  

   Depreciation of property and equipment

  6     20,130     4,425  

 

        (3,523,742 )   (1,264,044 )

Changes in non-cash working capital balances

                 

   Amounts receivable

        (60,085 )   101,464  

   Prepaid expenses

        (23,314 )   (12,995 )

   Accounts payable and accrued liabilities

        342,366     (32,673 )

   Other current liabilities

        57,686     -  

Cash used in operating activities

        (3,207,089 )   (1,208,248 )

 

                 

FINANCING ACTIVITIES

                 

Change in loan payable

  9     (57,516 )   21,946  

Increase in long-term liability

  9     64     -  

Issue of share capital, net of issuance costs

  10     966,413     2,664,083  

Cash provided by financing activities

        908,961     2,686,029  

 

                 

INVESTING ACTIVITIES

                 

Purchase of property and equipment

  6     (139,997 )   (11,571 )

Net change in marketable securities

        22,620     (1,170 )

Acquisition of Trillium Privateco, net of cash acquired 4

    -     (647,996 )

Cash used in investing activities

        (117,377 )   (660,737 )

 

                 

Net increase (decrease) in cash during the period

        (2,415,505 )   817,044  

 

                 

Cash, beginning of period

        32,456,506     1,375,015  

 

                 

Cash, end of period

        30,041,001     2,192,059  

 

                 

Supplemental cash flow information

                 

Common share purchase warrants issued as agent’s compensation (note 10)

      -     48,843  

Common shares and warrants issued on acquisition of Trillium Privateco (note 4)

      -     1,380,836  

Common shares and warrants issued on acquisition of technology rights (note 7)

      -     1,085,546  

Preferred shares converted to common (note 10)

        289,942     -  

See accompanying notes to the interim condensed consolidated financial statements

F-5



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

1.

Corporate information

   

Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) (the “Company” or “Trillium”) is a Canadian public immuno-oncology company developing innovative therapies for the treatment of cancer. The Company was incorporated under the laws of the Province of Alberta on March 31, 2004 with nominal share capital. On October 19, 2004, the Company changed its name from Neurogenesis Biotech Corp. to Stem Cell Therapeutics Corp. On November 7, 2013, the Company filed Articles of Continuance to change its jurisdiction to Ontario. On June 1, 2014, the Company amalgamated with its wholly-owned subsidiary Trillium Therapeutics Inc. (“Trillium Privateco”) and changed its name to Trillium Therapeutics Inc.

   

The Company’s head office is located at 96 Skyway Avenue, Toronto, Ontario, M9W 4Y9 and is listed on the Toronto Stock Exchange under the symbol TR.

   
2.

Basis of presentation


(a)

Statement of compliance

   

These unaudited interim condensed consolidated financial statements have been prepared in compliance with International Accounting Standard 34 Interim Financial Reporting (“IAS 34”). The notes presented in these unaudited interim condensed consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements.

   

The policies applied in these unaudited interim condensed consolidated financial statements are based on International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The Board of Directors approved the interim condensed consolidated financial statements on August 11, 2014. Any subsequent changes to IFRS or their interpretation, that are given effect in the Company’s annual consolidated financial statements for the year ending December 31, 2014 could result in a restatement of these unaudited interim condensed consolidated financial statements.

   
(b)

Basis of measurement

   

These consolidated financial statements have been prepared on the historical cost basis, except for held-for-trading financial assets which are measured at fair value.

   
(c)

Functional and presentation currency

   

These consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency.

   
(d)

Use of significant estimates and assumptions

   

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, revenue and expenses and the related disclosures of contingent assets and liabilities and the determination of the Company’s ability to continue as a going concern. Actual results could differ materially from these estimates and assumptions. The Company reviews its estimates and underlying assumptions on an ongoing basis. Revisions are recognized in the period in which the estimates are revised and may impact future periods.

   

Management has applied significant estimates and assumptions to the following:

   

Valuation of share-based compensation and warrants

   

Management measures the costs for share-based compensation and warrants using market-based option valuation techniques. Assumptions are made and estimates are used in applying the valuation techniques. These include estimating the future volatility of the share price, expected dividend yield, expected risk-free interest rate, future employee turnover rates, future exercise behaviours and corporate performance. Such estimates and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates of share-based payments and warrants.

F-6



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

Impairment of long-lived assets

   

Long-lived assets are reviewed for impairment upon the occurrence of events or changes in circumstances indicating that the carrying value of the asset may not be recoverable. For the purpose of measuring recoverable amounts, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use (being the present value of the expected future cash flows of the relevant asset or cash-generating unit). An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. Management evaluates impairment losses for potential reversals when events or circumstances warrant such consideration.

   

Intangible assets

   

The Company estimates the useful lives of intangible assets from the date they are available for use in the manner intended by management and periodically reviews the useful lives to reflect management's intent about developing and commercializing the assets.

   
3.

Significant accounting policies

   

The Company's principal accounting policies were outlined in the Company’s annual audited consolidated financial statements for the year ended December 31, 2013 and have been applied consistently to all periods presented in these unaudited interim condensed consolidated financial statements, except as described below in new standards and interpretations adopted during 2014. These statements should be read in conjunction with the annual audited consolidated financial statements for the year ended December 31, 2013.


(a)

Basis of consolidation

   

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Stem Cell Therapeutics Inc., and Trillium Privateco from April 9, 2013, the date of acquisition (see note 4) to the date of its amalgamation with the Company on June 1, 2014.

   
(b)

New standards and interpretations adopted during 2014

   

IAS 32 Financial Instruments: Presentation

   

The amendments to IAS 32, Financial Instruments: Presentation (“IAS 32”), clarify the criteria that should be considered in determining whether an entity has a legally enforceable right of set off in respect of its financial instruments. Amendments to IAS 32 are applicable to annual periods beginning on or after January 1, 2014, with retrospective application required. The adoption of these amendments did not have a material impact on the consolidated financial statements.

   

IFRIC 21 Levies

   

In May 2013, International Financial Reporting Standards Interpretations Committee Interpretation 21, Levies ("IFRIC 21") was issued. IFRIC 21 provides guidance on when to recognize a liability to pay a levy imposed by a government that is accounted for in accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets . IFRIC 21 is effective for annual periods beginning on or after January 1, 2014 and is to be applied retrospectively. The Company adopted IFRIC 21 in its consolidated financial statements for the annual period beginning on January 1, 2014. The adoption did not have a material impact on the consolidated financial statements.

   

IAS 36 Impairment of Assets

   

In May 29, 2013, IASB published amendments to IAS 36, Impairment of Assets which reduce the circumstances in which the recoverable amount of cash-generating units is required to be disclosed and clarifies the disclosures required when an impairment loss has been recognized or reversed in the period. This amendment is effective for annual periods beginning on or after January 1, 2014. The Company adopted the IAS 36 amendments in its consolidated financial statements for the annual period beginning on January 1, 2014. The adoption did not have a material impact on the consolidated financial statements.

F-7



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

(c)

New standards and interpretations not yet effective

   

IFRS 9 Financial Instruments

   

In October 2010, the IASB published amendments to IFRS 9 which provides added guidance on the classification and measurement of financial liabilities. IFRS 9 will replace IAS 39 and will be completed in three phases: classification and measurement of financial assets and liabilities, impairment of financial assets, and general hedge accounting. This was the first phase of the project on classification and measurement of financial assets and liabilities. The IASB is discussing proposed limited amendments related to this phase of the project. The standard on general hedge accounting was issued and included as part of IFRS 9 in November 2013. The accounting for macro hedging is expected to be issued as a separate standard outside of IFRS 9. The impairment of financial assets phase of the project is currently in development. In November 2013, the mandatory effective date of IFRS 9 of January 1, 2015 was removed and the effective date will be determined when the remaining phases of IFRS 9 are finalized. The Company is currently monitoring the developments of this standard and assessing the impact that the adoption of this standard may have on the consolidated financial statements.

   

Annual Improvements to IFRS (2010 – 2012) and (2011-2013) cycles

   

In December 2013, the IASB issued narrow-scope amendments to a number of standards as part of its annual improvements process. The IASB uses the annual improvements process to make non-urgent but necessary amendments to IFRS. Amendments were made to clarify the following in their respective standards:


IFRS version that a first-time adopter can apply in IFRS 1 First-time Adoption of International Financial Reporting Standards ;

 

Definition of “vesting condition” in IFRS 2 Share-based payment ;

Classification and measurement of contingent consideration; and scope exclusion for the formation of joint arrangements in IFRS 3 Business Combinations ;

 

Disclosures on the aggregation of operating segments in IFRS 8 Operating segments ;

Measurement of short-term receivables and payables; and scope of portfolio exception in IFRS 13 Fair Value Measurement ;

Restatement of accumulated depreciation (amortization) on revaluation in IAS 16 Property, Plant and Equipment and IAS 38 Intangible Assets ;

 

Definition of “related party” in IAS 24 Related Party Disclosures ; and

 

Inter-relationship of IFRS 3 and IAS 40 in IAS 40 Investment Property .

Special transitional requirements have been set for amendments to IFRS 2, IAS 16, IAS 38 and IAS 40.

Most amendments will apply prospectively for annual periods beginning on or after July 1, 2014; earlier application is permitted, in which case, the related consequential amendments to other IFRS would also apply. The Company intends to adopt these amendments in its financial statements for the annual period beginning on January 1, 2015. The extent of the impact of adoption of the amendments has not yet been determined.

IFRS 15 Revenue from Contracts with Customers

In May 2014, the IASB issued IFRS 15, which covers principles for reporting about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. IFRS 15 is effective for annual periods beginning on or after January 1, 2017. The Company is reviewing the standard to determine the impact on the consolidated financial statements.

Other accounting standards or amendments to existing accounting standards that have been issued, but have future effective dates, are either not applicable or are not expected to have a significant impact on the Company’s consolidated financial statements. The Company assesses the impact of adoption of future standards on its consolidated financial statements, but does not anticipate significant changes in 2014.

F-8



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

4.

Acquisition of Trillium Privateco

   

On April 9, 2013, the Company completed a merger with Trillium Privateco, a private biopharmaceutical company specializing in immune regulation and the development of cancer therapeutics. The Company applied the acquisition method of accounting for the business combination and the losses have been consolidated from the acquisition date. The consideration was allocated to the underlying assets acquired and liabilities assumed based upon their fair values at the date of acquisition. The purchase price allocation was assigned to the net identifiable assets based on their estimated fair values. The final purchase price allocation was as follows:


  Fair value of consideration paid:      
                 Cash $  1,200,000  
                 2,779,180 common shares and 3,300,000 units   1,380,836  
      2,580,836  
         
  Assets acquired:      
                 Cash and marketable securities $  1,182,714  
                 Amounts receivable   820,944  
                 Prepaid expenses   44,300  
                 Equipment   91,000  
                 Acquired technology   1,018,037  
      3,156,995  
         
  Liabilities assumed:      
                 Accounts payable and accrued liabilities $  282,178  
                 Loan payable   293,981  
      576,159  
  Net identifiable assets acquired $  2,580,836  

As consideration, the Company paid $1,200,000 in cash and issued 2,779,180 common shares and 3,300,000 units. Each unit consisted of one common share and one common share purchase warrant, with each common share purchase warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018. The fair value of the unit was determined based on the stand-alone value of the common share and the common share purchase warrant, in accordance with IFRS 13, Fair value measurement and IFRS 3, Business combinations . Accordingly, the fair value of the aggregate 6,079,180 common shares issued was based on the closing price of the Company’s common shares of $0.20 on April 9, 2013. The fair value of the 3,300,000 common share purchase warrants was determined using the Black-Scholes option pricing model. Assumptions used to determine the value of the common share purchase warrant were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 68%; and average expected life of 3 years. Post-closing, Trillium Privateco shareholders held approximately 16% of the issued and outstanding common shares, and Trillium Privateco became a wholly-owned subsidiary of the Company.

Cash used in the investment was determined as follows:

      $  
         
  Cash consideration   1,200,000  
  Less cash acquired   552,004  
      647,996  

Acquisition costs incurred by the Company and included in general and administrative expenses for the year ended December 31, 2013, were approximately $113,000. From the date of the acquisition to December 31, 2013, Trillium Privateco contributed revenue of nil and a loss of $2,236,262.

F-9



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

5.

Amounts receivable


      June 30,     December 31,  
      2014     2013  
      $     $  
               
  Government programs receivable   487,319     426,946  
  Other amounts receivable   -     288  
      487,319     427,234  

6.

Property and equipment


            Computer     Office        
      Lab     equipment     equipment and        
      equipment     and software     leaseholds     Total  
      $     $     $      
                           
  Cost                        
  Balance, December 31, 2012   -     13,500     -     13,500  
  Additions   111,025     4,611     9,381     125,017  
  Balance, December 31, 2013   111,025     18,111     9,381     138,517  
  Additions   128,373     11,624     -     139,997  
  Balance, June 30, 2014   239,398     29,735     9,381     278,514  
                           
  Accumulated depreciation                        
  Balance, December 31, 2012   -     13,500     -     13,500  
  Depreciation   14,723     504     783     16,010  
  Balance, December 31, 2013   14,723     14,004     783     29,510  
  Depreciation   16,050     2,472     1,608     20,130  
  Balance June 30, 2014   30,773     16,476     2,391     49,640  
                           
  Net carrying amounts                        
  December 31, 2013   96,302     4,107     8,598     109,007  
  June 30, 2014   208,625     13,259     6,990     228,874  

In the second quarter of 2013, the Company acquired lab equipment with a fair value of $91,000 on its acquisition of Trillium Privateco.

F-10



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

7.

Intangible assets


      Total  
       
         
  Cost      
  Balance, December 31, 2012   2,431,279  
  Additions   2,103,751  
  Disposals   (2,431,279 )
  Balance December 31, 2013   2,103,751  
  Disposals   (1,085,714 )
  Balance June 30, 2014   1,018,037  
         
  Accumulated amortization      
  Balance, December 31, 2012   2,428,779  
  Amortization   632,779  
  Disposals   (2,431,279 )
  Balance, December 31, 2013   630,279  
  Amortization   441,102  
  Disposals   (655,951 )
  Balance, June 30, 2014   415,430  
         
  Net carrying amounts      
  December 31, 2013   1,473,472  
  June 30, 2014   602,607  

On April 9, 2013, acquired in-process research and development assets of Trillium Privateco amounted to $1,018,037 (see note 4).

   

On April 16, 2013, the Company signed an agreement with the University Health Network (“UHN”) to gain rights to intellectual property related to the use of tigecycline for the treatment of leukemia. The initial consideration for the UHN license of $1,085,714 was satisfied by the issuance of 5,028,571 common shares and 1,600,000 common share purchase warrants, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018. Additional consideration under the UHN license included an annual license maintenance fee and future development milestones. The fair value of the common shares issued was based on the closing price of the Company’s common shares of $0.20 on April 16, 2013 and $0.25 per unit based on the fair value of the common share and common share purchase warrant components as of the date of acquisition. Subsequent to June 30, 2014, the Company returned the rights back to UHN and recorded an impairment loss of $429,763 in Q2 2014.

   

During the third quarter of 2013, the Company ceased all activities related to the regenerative stem cell products and retired the fully amortized assets in the amount of $2,431,279.

   
8.

Accounts payable and accrued liabilities


      June 30,     December 31,  
      2014     2013  
           
               
  Trade and other payables   546,794     113,003  
  Accrued liabilities   432,087     221,580  
  Due to related parties (note 15)   33,345     335,277  
      1,012,226     669,860  

F-11



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

9.

Non-current liabilities


(a)

Trillium is indebted to the Federal Economic Development Agency for Southern Ontario under a non-interest-bearing contribution agreement dated February 1, 2012. The period of contribution ended on December 31, 2013. As at June 30, 2014, we have repayable contributions of $575,139 representing the outstanding principal balance, repayable in equal monthly installments for 60 months beginning on December 1, 2014. The loan payable bears no interest. The fair value of the loan payable was determined by discounting the loan payable using an estimated market interest rate of 15%. Interest expense accretes on the discounted loan amount until it reaches its face value at maturity.

   
(b)

The Company has a long-term liability of $169,784 related to certain discontinued technologies. This liability has been discounted using an estimated market interest rate of 15% and interest expense is accreting.

   

The current portions of the loan payable and long-term liability are included in other current liabilities in the interim consolidated statements of financial position.


10.

Share capital


(a)

Authorized

   

The authorized share capital of the Company consists of an unlimited number of common shares, Class B shares and First Preferred Shares, in each case without nominal or par value. Common shares are voting and may receive dividends as declared at the discretion of the Board of Directors. Class B shares are non-voting and convertible to common shares at the holder’s discretion, on a one-for-one basis. Upon dissolution or wind-up of the Company, Class B shares participate rateably with the common shares in the distribution of the Company’s assets. Preferred shares have voting rights as decided upon by the Board of Directors at the time of grant. Upon dissolution or wind-up of the Company, First Preferred Shares are entitled to priority over common and Class B shares.

   

In December 2013, the Company created the Series I First Preferred Shares that are non-voting, may receive dividends as declared at the discretion of the Board of Directors, and are convertible to common shares at the holder’s discretion, on a one-for-one basis.

   
(b)

Share capital issued – six months ended June 30, 2014

   

During the six months ended June 30, 2014, 2,596,251 warrants were exercised for proceeds of $946,813 and 78,400 stock options were exercised for proceeds of $19,600. Also, 909,091 warrants issued in March 2011 with an exercise price of $1.60 expired unexercised.

   

During the six months ended June 30, 2014, 2,000,000 First Preferred Shares were converted to common shares.

   

Share capital issued – year ended December 31, 2013

   

The Company consolidated its outstanding common shares issuing one post-consolidated share for each 10 pre-consolidated shares and the common shares began trading on a post-consolidated basis on February 6, 2013. All references in these interim condensed consolidated financial statements and notes to the number of common shares, warrants and stock options have been adjusted to the post-consolidation amounts.

   

In March 2013, we completed an offering pursuant to a base shelf prospectus and prospectus supplement and in the U.S. pursuant to a private placement memorandum for a total of 12,735,000 units at a price of $0.25 per unit, for aggregate gross proceeds to the Company of $3,185,080 ($2,615,240 net of issuance costs). Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.40 per share at any time prior to expiry on March 15, 2018 (12,315,000 warrants) and March 27, 2018 (420,000 warrants). In connection with the financing, the Company issued 814,051 compensation warrants having an aggregate fair value of $48,843 estimated using the Black-Scholes option pricing model. Each compensation warrant entitles the holder to acquire one common share at an exercise price of $0.25 per share prior to expiry on March 16, 2015.

F-12



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

10.

Share capital (continued)

   

The allocation of the $0.25 common share unit issue price to the common shares and unit warrants was based on the relative fair values of the common shares and the warrants. The fair value of the warrants was determined using the Black-Scholes option pricing model. The common shares were allocated a price of $0.20 per share and the warrants were allocated a price of $0.05 per warrant. The costs of the issue were allocated on a pro rata basis to the common shares and warrants. Accordingly, $2,092,192 was allocated to common shares and $523,048 to warrants, net of issuance costs. Assumptions used to determine the value of the unit warrants were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 64%; and average expected life of 3 years. Assumptions used to determine the value of the compensation warrants were: dividend yield of 0%; risk-free interest rate of 1.0%; expected volatility of 80%; and average expected life of 2 years.

   

On April 9, 2013, the Company issued 6,079,180 common shares and 3,300,000 common share purchase warrants for partial consideration for the acquisition of Trillium Privateco (see note 4).

   

On April 16, 2013, the Company issued 5,028,571 common shares and 1,600,000 common share purchase warrants as consideration for the acquisition of certain rights related to tigecycline from UHN (see note 7).

   

On December 13, 2013, the Company completed a private placement of 79,247,693 common share units (each common share unit consisting of one common share and three-quarters of a common share purchase warrant) at a price of $0.21 per unit and 77,895,165 preferred share units (each preferred share unit consisting of one Series 1 First Preferred Share and three-quarters of a common share purchase warrant) at a price of $0.21 per unit for gross proceeds of $32,866,025 ($30,713,841 net of issuance costs). Each whole warrant entitles the holder to purchase one common share at a price of $0.28 at any time prior to expiry on December 13, 2018. In connection with the financing, the Company issued 5,014,839 compensation warrants having an aggregate fair value of $651,929 estimated using the Black-Scholes option pricing model. Each compensation warrant entitles the holder to acquire one common share at an exercise price of $0.21 per share prior to expiry on December 13, 2015.

   

The allocation of the $0.21 unit issue price to the common shares, Series 1 First Preferred Shares and unit warrants was based on the relative fair values of the common shares, Series 1 First Preferred Shares and the warrants. The fair value of the warrants was determined using the Black-Scholes option pricing model. The common shares were allocated a price of $0.16 per share, the Series 1 First Preferred Shares were allocated a price of $0.16 per share, and the warrants were allocated a price of $0.05 per three-quarter warrant. The costs of the issue were allocated on a pro rata basis. Accordingly, $11,488,602 was allocated to common shares, $11,292,525 to the Series 1 First Preferred Shares and $7,932,714 to warrants, net of issuance costs. Assumptions used to determine the value of the unit warrants were: dividend yield of 0%; risk-free interest rate of 1.2%; expected volatility of 70%; and average expected life of 3 years. Assumptions used to determine the value of the compensation warrants were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 66%; and average expected life of 2 years.

   

All securities issued under the offering (including the compensation warrants), in Canada are subject to a four month hold and resale restrictions under Canadian securities law, and in the United States are subject to statutory resale restrictions under U.S. securities laws.

   

In the December 2013 private placement, subscribers who purchased preferred share units and certain subscribers who purchased common share units are subject to restrictions on the conversion and exercise of securities of the Company convertible in common shares. Such subscribers cannot convert or exercise securities of the Company convertible or exerciseable into common shares if, after giving effect to the exercise of conversion, the subscriber and its joint actors would have beneficial ownership or direction or control over common shares in excess of 4.99% of the then outstanding common shares. This limit can be raised at the option of the subscriber on 61 days prior written notice: (i) up to 9.99%, (ii) up to 19.99%, subject to stock exchange clearance of a personal information form submitted by the subscriber, and (iii) above 19.99%, subject to stock exchange approval and shareholder approval.

F-13



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

10.

Share capital (continued)

   

Subject to receipt of any required regulatory approvals, subscribers who purchased a minimum of 10% of the securities sold under the offering were given rights to purchase securities of the Company in future financings to enable each such subscriber to maintain its percentage holding in the Company for so long as the subscriber holds at least 10% of the outstanding common shares on a fully-diluted basis.


(c)

Weighted average number of common shares

   

The weighted average number of common shares outstanding for six months ended June 30, 2014 and 2013 was 124,520,987 and 41,019,305, respectively.

   
(d)

Warrants

   

Warrants outstanding at June 30, 2014 were as follows:


      Number of     Exercise  
  Expiry dates   warrants     price  
               
  March 16, 2015   202,800   $ 0.25  
  December 13, 2015   5,014,839   $ 0.21  
  March 15, 2018   15,230,000   $ 0.40  
  March 27, 2018   420,000   $ 0.40  
  December 13, 2018   117,857,142   $ 0.28  
      138,724,781        

All warrants were exercisable on issuance. Changes in the number of warrants outstanding during the six months ended June 30 were as follows:

            2014           2013  
                           
            Weighted           Weighted  
            average           average  
      Number of     exercise     Number of     exercise  
      warrants     price     warrants     price  
                           
  Balance, beginning of year   142,230,123   $  0.30     1,036,364   $  1.54  
  Issued   -     -     18,449,051     0.39  
  Exercised   (2,596,251 )   0.36     -     -  
  Expired   (909,091 )   1.60     (127,273 )   1.10  
                           
  Balance, end of period   138,724,781   $  0.29     19,358,142   $  0.45  

F-14



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

10.

Share capital (continued)


(e)

Stock option plan

   

The Company has a 10% rolling stock option plan (the “2014 Stock Option Plan”) that was approved by the Company’s shareholders at its annual general meeting held on May 27, 2014. Pursuant to the 2014 Stock Option Plan, the Company may grant stock options to purchase up to an aggregate of 10% of the Company’s issued and outstanding common shares plus 10% of the total number of common shares into which the outstanding Series I Preferred Shares may be converted.

   

Changes in the number of options outstanding during the six months ended June 30 were as follows:


            2014           2013  
                           
            Weighted           Weighted  
            average           average  
      Number of     exercise     Number of     exercise  
      options     price     options     price  
                           
  Balance, beginning of year   2,921,097   $  0.33     700,000   $  1.03  
  Granted   14,996,578     0.33     2,615,197     0.25  
  Exercised   (78,400 )   0.25     -     -  
  Cancelled/forfeited   (112,000 )   0.33     (402,500 )   1.02  
                           
  Balance, end of period   17,727,275   $  0.33     2,912,697   $  0.33  
                           
  Options exercisable, end of period   6,606,265   $  0.34     1,179,435   $  0.45  

The following table reflects stock options outstanding at June 30, 2014:

    Stock options outstanding       Stock options exercisable  
      Weighted average        
    Number remaining Weighted average   Exercisable Weighted average
  Exercise prices outstanding contractual life exercise price   number exercise price
               
  $0.25 2,445,197 8.1 years $0.25   1,322,599 $0.25
  $0.278 6,472,710 9.9 years $0.278   2,157,569 $0.278
  $0.345 7,923,868 9.8 years $0.345   2,641,290 $0.345
  $0.51 200,000 9.6 years $0.51   66,667 $0.51
  $0.63 400,000 9.7 years $0.63   133,334 $0.63
  $1.00 262,500 1.6 years $1.00   261,806 $1.00
  $1.20 3,000 0.2 years $1.20   3,000 $1.20
  $1.70 20,000 0.4 years $1.70   20,000 $1.70
               
               
    17,727,275 9.5 years $0.33   6,606,265 $0.34

F-15



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

10.

Share capital (continued)

   

Share-based compensation expense was determined based on the fair value of the options at the date of measurement using the Black-Scholes option pricing model with the weighted average assumptions for the six months ended June 30 as follows:


    2014 2013
  Expected option life 7.0 years 9.9 years
  Risk-free interest rate 2.0% 1.7%
  Dividend yield 0% 0%
  Expected volatility 75% 118%

The Black-Scholes option pricing model was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which significantly differs from the Company's stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and average option life, which significantly affect the calculated values.

   

The risk-free interest rate is based on the implied yield on a Government of Canada zero-coupon issue with a remaining term equal to the expected term of the option. The volatility is based solely on historical volatility equal to the expected life of the option. The life of the options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past. The forfeiture rate is an estimate based on historical evidence and future expectations. The dividend yield was excluded from the calculation since it is the present policy of the Company to retain all earnings to finance operations and future growth.

   

During the six months ended June 30, 2014 and 2013, the Company issued 14,996,578 and 2,615,197 stock options with a fair value of $3,427,955 and $534,681 and a weighted average grant date fair value of $0.23 and $0.20, respectively.

   
(f)

Deferred Share Units Plan

   

The shareholders of the Company approved the 2014 Deferred Share Unit Plan (the “2014 DSU Plan”) on May 27, 2014. The 2014 DSU Plan is intended to promote a greater alignment of long-term interests between non-executive directors and executive officers of the Company and its shareholders through the issuance of deferred share units (“DSUs”). Since the value of a DSU increases or decreases with the market price of the common shares, DSUs reflect a philosophy of aligning the interests of directors and executive officers with those of the shareholders by tying compensation to share price performance. The Board of Directors intends to use DSUs issued under the 2014 DSU Plan, as well as stock options issued under the 2014 Stock Option Plan, as part of the Corporation’s overall director and executive officer compensation program. A total of 863,310 units were issued during the six months ended June 30, 2014 for payment of directors fees and were outstanding as at June 30, 2014. The Company has reserved for issuance up to 2,000,000 common shares under the 2014 DSU Plan.

   
(g)

Shareholder Rights Plan

   

On October 17, 2013 our shareholders adopted a shareholder rights plan (the “2013 Rights Plan”) and approved certain amendments on May 27, 2014 (the “Rights Plan Amendment” which together with the 2013 Rights Plan may be referred to as the “Rights Plan”). The Rights Plan is designed to provide adequate time for the Board of Directors and the shareholders to assess an unsolicited takeover bid for the Company, to provide the Board of Directors with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, and to provide shareholders with an equal opportunity to participate in a takeover bid and receive full and fair value for their common shares. The Rights Plan will expire at the close of the Company's annual meeting of shareholders in 2016.

F-16



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

10.

Share capital (continued)

   

The rights issued under the Rights Plan initially attach to and trade with the common shares and no separate certificates will be issued unless an event triggering these rights occurs. The rights will become exercisable only when a person, including any party related to it, acquires or attempts to acquire 20 percent or more of the outstanding common shares without complying with the "Permitted Bid" provisions of the Rights Plan or without approval of the Board of Directors. Should such an acquisition occur or be announced, each right would, upon exercise, entitle a rights holder, other than the acquiring person and related persons, to purchase common shares at an approximate 50 percent discount to the market price at the time.

   

Under the Rights Plan, a Permitted Bid is a bid made to all holders of the common shares and which is open for acceptance for not less than 60 days. If at the end of 60 days at least 50 percent of the outstanding common shares, other than those owned by the offeror and certain related parties have been tendered, the offeror may take up and pay for the common shares but must extend the bid for a further 10 days to allow other shareholders to tender. The issuance of common shares upon the exercise of the rights is subject to receipt of certain regulatory approvals.

   
11.

Research and development

   

Components of research and development expenses for the three months ended June 30 were as follows:


      2014     2013  
      $     $  
               
  Research and development programs excluding the below   900,461     308,458  
  Salaries, fees and short-term benefits   532,228     430,532  
  Share-based compensation   1,097,360     153,801  
  Amortization of intangible assets   220,551     209,257  
  Impairment of intangible assets   429,763     -  
  Depreciation of property and equipment   13,878     4,425  
  Investment tax credits   (88,839 )   (47,410 )
      3,105,402     1,059,063  

Components of research and development expenses for the six months ended June 30 were as follows:

      2014     2013  
      $     $  
               
  Research and development programs excluding the below   1,823,075     413,836  
  Salaries, fees and short-term benefits   1,049,376     482,683  
  Share-based compensation   1,123,277     158,441  
  Amortization of intangible assets   441,102     209,757  
  Impairment of intangible assets   429,763     -  
  Depreciation of property and equipment   20,130     4,425  
  Investment tax credits   (215,839 )   (47,410 )
      4,670,884     1,221,732  

F-17



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

12.

General and Administrative

   

Components of general and administrative expenses for the three months ended June 30 were as follows:


      2014     2013  
      $     $  
               
  General and administrative expenses excluding the below   569,493     182,077  
  Salaries, fees and short-term benefits   86,173     72,528  
  DSU units issued for director compensation   240,000     -  
  Share-based compensation   180,295     75,111  
      1,075,961     329,716  

Components of general and administrative expenses for the six months ended June 30 were as follows:

      2014     2013  
      $     $  
               
  General and administrative expenses excluding the below   763,637     306,722  
  Salaries, fees and short-term benefits   310,626     125,281  
  DSU units issued for director compensation   240,000     -  
  Share-based compensation   323,279     75,598  
      1,637,542     507,601  

13.

Finance income and finance costs

   

Finance income for the three months ended June 30 was as follows:


      2014     2013  
      $     $  
               
  Interest income   96,438     8,052  
  Net foreign currency gain   6,017     5,309  
      102,455     13,361  

Finance income for the six months ended June 30 was as follows:

      2014     2013  
      $     $  
               
  Interest income   192,541     11,406  
  Net foreign currency gain   18,506     7,879  
      211,047     19,285  

F-18



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

13.

Finance income and finance costs (continued)

   

Finance costs for the three months ended June 30 were as follows:


      2014     2013  
      $     $  
               
  Bank charges   1,609     1,269  
  Accreted interest   19,854     -  
      21,463     1,269  

Finance costs for the six months ended June 30 were as follows:

      2014     2013  
      $     $  
               
  Bank charges   3,914     2,217  
  Accreted interest   39,138     -  
      43,052     2,217  

14.

Commitments and contingencies

   

As at June 30, 2014 and in the normal course of business, the Company had obligations to make future payments, representing research and development contracts and other commitments that are known and committed in the amount of $2,207,000 over the next 12 months, $97,000 from 12 to 24 months, $55,000 from 24 to 36 months, and $25,000 each year thereafter.

   

The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain.

   

The Company periodically enters into research and license agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken by or on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the consolidated financial statements with respect to these indemnification obligations.

F-19



TRILLIUM THERAPEUTICS INC.
(formerly Stem Cell Therapeutics Corp.)
Notes to the Interim Condensed Consolidated Financial Statements
June 30, 2014
Amounts in Canadian Dollars
(Unaudited)

15.

Related parties

   

For the six months ended June 30, 2014 and 2013, the key management personnel of the Company were the Board of Directors, Executive Chairman, Chief Executive Officer, Chief Financial Officer, Chief Scientific Officer and Vice- President Drug Development.

   

Compensation for key management personnel of the Company for the three months ended June 30 was as follows:


      2014     2013  
      $     $  
               
  Salaries, fees and short-term benefits   292,681     250,601  
  Share-based compensation   1,511,574     220,048  
  Total   1,804,255     470,649  

Compensation for key management personnel of the Company for the six months ended June 30 was as follows:

      2014     2013  
      $     $  
               
  Salaries, fees and short-term benefits   961,077     355,505  
  Share-based compensation   1,666,682     225,175  
  Total   2,627,759     580,680  

Executive officers and directors participate in the 2014 Stock Option Plan and the 2014 DSU Plan, and officers participate in the Company’s benefit plans. Directors receive annual fees for their services. As at June 30, 2014, the key management personnel controlled approximately 1% of the voting shares of the Company.

   

Outstanding balances with related parties at the period-end are unsecured, interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. For the six months ended June 30, 2014 and 2013, $7,916 and $7,916, respectively, was paid to a former director for consulting fees.

   
16.

Comparative financial statements

   

The comparative financial statements have been restated from interim statements previously presented to correct for the March 2013 prospectus bifurcation amounts between common shares, warrants and compensation warrants and the bifurcation amounts between common shares and warrants of the April 2013 Trillium Privateco and technology rights acquisitions. The restatement of the prospectus bifurcation resulted in an increase to common shares of $727,687 and a decrease to warrants and compensation warrants in the amount of $686,984 and $40,703, respectively. The restatement of the Trillium Privateco bifurcation resulted in an increase to common shares and a decrease to warrants of $221,100. The restatement of the technology rights bifurcation resulted in an increase to common shares and a decrease to warrants of $107,200. Accordingly, there has been no impact on retained earnings or earnings per share.

F-20


TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
 
CONSOLIDATED FINANCIAL STATEMENTS
 
FOR THE YEARS ENDED
DECEMBER 31, 2013 AND 2012

96 Skyway Avenue
Toronto, Ontario M9W 4Y9
www.trilliumtherapeutics.com

F-21


INDEPENDENT AUDITORS’ REPORT OF REGISTERED PUBLIC ACCOUNTING FIRM

To the Directors of
Trillium Therapeutics Inc.

We have audited the accompanying consolidated financial statements of T rillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp. ), which comprise the consolidated statements of financial position as at December 31, 2013 and 2012, and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for the years then ended, and a summary of significant accounting policies and other explanatory information.

Management's responsibility for the consolidated financial statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Trillium Therapeutics Inc. as at December 31, 2013 and 2012 and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board.

  /s/ Ernst & Young LLP
Toronto, Canada Chartered Accountants
March 27, 2014 Licensed Public Accountants

F-22



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Consolidated Statements of Financial Position
Amounts in Canadian Dollars

          As at     As at  
    Note     December 31, 2013     December 31, 2012  
        $   $  
                   
                   
ASSETS                  
                   
Current                  
Cash         32,456,506     1,375,015  
Marketable securities         526,598     -  
Amounts receivable   5     427,234     161,208  
Prepaid expenses         94,569     29,005  
                   
Total current assets         33,504,907     1,565,228  
                   
Property and equipment   6     109,007     -  
Intangible assets   7     1,473,472     2,500  
                   
Total non-current assets         1,582,479     2,500  
                   
Total assets         35,087,386     1,567,728  
                   
LIABILITIES                  
                   
Current                  
Accounts payable and accrued liabilities   8     669,860     185,258  
Other current liabilities   9     62,766     -  
                   
Total current liabilities         732,626     185,258  
                   
Loan payable   9     341,884     -  
Long-term liability   9     104,429     -  
                   
Total non-current liabilities         446,313     -  
                   
Total liabilities         1,178,939     185,258  
                   
EQUITY                  
Common shares   10     47,191,303     31,388,959  
Preferred shares   10     11,292,525     -  
Warrants   10     9,818,179     508,281  
Contributed surplus   10     3,280,656     2,870,138  
Deficit         (37,674,216 )   (33,384,908 )
                   
Total equity         33,908,447     1,382,470  
                   
Total liabilities and equity         35,087,386     1,567,728  

Commitments and contingencies [note 15]

Approved by the Board and authorized for issue on March 27, 2014:

(signed) Henry Friesen, Director (signed) Calvin Stiller, Director

See accompanying notes to the consolidated financial statements

F-23



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Consolidated Statements of Loss and Comprehensive Loss
Amounts in Canadian Dollars

          Year ended     Year ended  
                                                                                                                          Note     December 31, 2013     December 31, 2012  
        $   $  
                   
EXPENSES                  
Research and development   12     3,336,706     623,548  
General and administrative   13     962,200     466,287  
Operating expenses         4,298,906     1,089,835  
Finance income   14     (54,028 )   (30,730 )
Finance costs   14     44,430     2,397  
Net finance income         (9,598 )   (28,333 )
Net loss and comprehensive loss for the year         4,289,308     1,061,502  
Basic and diluted loss per common share   10 (c)   (0.11 )   (0.06 )

See accompanying notes to the consolidated financial statements

F-24



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Consolidated Statements of Changes in Equity
Amounts in Canadian Dollars

    Common shares     Preferred shares     Warrants     Contributed              
    Number     Amount     Number     Amount     Number     Amount     surplus     Deficit     Total  
    #    $     #    $     #    $    $    $    $  
          (note 10 )         (note 10 )         (note 10 )   (note 10 )            
                                                       

Balance, December 31, 2012

  18,661,936     31,388,959     -     -     1,036,364     508,281     2,870,138     (33,384,908 )   1,382,470  

 

                                                     

Net loss and comprehensive loss for the year

  -     -     -     -     -     -     -     (4,289,308 )   (4,289,308 )

Transactions with owners of the Company, recognized directly in equity

                          -     -      

Share units issued, net of issue costs

  91,982,693     13,580,794     77,895,165     11,292,525     130,592,142     8,455,762     -     -     33,329,081  

Compensation warrants

  -     -     -     -     5,828,890     700,772     -     -     700,772  

To acquire Trillium Privateco (notes 4 and 10)

  6,079,180     1,215,836     -     -     3,300,000     165,000     -     -     1,380,836  

To acquire technology rights (notes 7 and 10)

  5,028,571     1,005,714     -     -     1,600,000     80,000     -     -     1,085,714  

Expiry of warrants

  -     -     -     -     (127,273 )   (91,636 )   91,636     -     -  

Share-based compensation

  -     -     -     -     -     -     318,882     -     318,882  

Total transactions with owners of the Company

  103,090,444     15,802,344     77,895,165     11,292,525     141,193,759     9,309,898     410,518           36,815,285  
Balance, December 31, 2013   121,752,380     47,191,303     77,895,165     11,292,525     142,230,123     9,818,179     3,280,656     (37,674,216 )   33,908,447  

    Common shares     Preferred shares     Warrants     Contributed              
    Number     Amount     Number     surplus     Number     Amount     surplus     Deficit     Total  
    #    $     #    $     #    $    $    $    $  
                                                       

Balance, December 31, 2011

  18,661,936     31,388,959     -     -     1,036,364     508,281     2,835,632     (32,323,406 )   2,409,466  

 

                                                     

Net loss and comprehensive loss for the year

  -     -     -     -     -     -     -     (1,061,502 )   (1,061,502 )

Transactions with owners of the Company, recognized directly in equity

          -     -                      

Share-based compensation

  -     -     -     -     -     -     34,506     -     34,506  

Total transactions with owners of the Company

  -     -     -     -     -     -     34,506     -     34,506  

Balance, December 31, 2012

  18,661,936     31,388,959     -     -     1,036,364     508,281     2,870,138     (33,384,908 )   1,382,470  

See accompanying notes to the consolidated financial statements

F-25



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Consolidated Statements of Cash Flows
Amounts in Canadian Dollars

 

        Year ended     Year ended  

 

  Note     December 31, 2013     December 31, 2012  

 

        $    $  

 

                 

OPERATING ACTIVITIES

                 

Net loss for the year

        (4,289,308 )   (1,061,502 )

Adjustments for items not affecting cash

                 

   Share-based compensation

  10     318,882     34,506  

   Interest accretion

  9     40,133     -  

   Amortization of intangible assets

  7     632,779     2,000  

   Depreciation of property and equipment

  6     16,010     4,382  

 

        (3,281,504 )   (1,020,614 )

Changes in non-cash working capital balances

                 

   Amounts receivable

        554,918     (119,594 )

   Prepaid expenses

        (21,264 )   (12,685 )

   Other current liabilities

        62,766     -  

   Accounts payable and accrued liabilities

        202,424     (168,856 )

Cash used in operating activities

        (2,482,660 )   (1,321,749 )

 

                 

FINANCING ACTIVITIES

                 

Increase in loan payable

  9     13,284     -  

Increase in long-term liability

  9     98,915     -  

Issue of share capital, net of issuance costs

  10     34,029,853     -  

Cash provided by financing activities

        34,142,052     -  

 

                 

INVESTING ACTIVITIES

                 

Purchase of property and equipment

  6     ( 34,017 )   -  

Net change in marketable securities

        104,112     -  

Acquisition of Trillium Privateco , net of cash acquired

  4     (647,996 )   -  

Cash used in investing activities

        (577,901 )   -  

 

                 

Net increase (decrease) in cash during the year

        31,081,491     (1,321,749 )

 

                 

Cash, beginning of year

        1,375,015     2,696,764  

 

                 

Cash, end of year

        32,456,506     1,375,015  

 

                 

Supplemental cash flow information

                 

Common share purchase warrants issued as agent’s compensation (note 10)

      700,772     -  

Common shares and warrants issued on acquisition of Trillium Privateco (note 10)

      1,380,836     -  

Common shares and warrants issued on acquisition of technology rights (note 10)

      1,085,714     -  

See accompanying notes to the consolidated financial statements

F-26



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

1.

Corporate information

 

 

Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) (the “Company” or “Trillium”) is a Canadian public immuno-oncology company advancing cancer stem cell discoveries into novel and innovative cancer therapies.

The Company was incorporated under the laws of the Province of Alberta on March 31, 2004 with nominal share capital. On October 19, 2004, the Company changed its name from Neurogenesis Biotech Corp. to Stem Cell Therapeutics Corp. On November 7, 2013, the Company filed Articles of Continuance to change its jurisdiction to Ontario. On June 1, 2014, the Company amalgamated with its wholly-owned subsidiary Trillium Therapeutics Inc. (“Trillium Privateco”) and changed its name to Trillium Therapeutics Inc.

 

The Company’s head office is located at 96 Skyway Avenue, Toronto, Ontario, M9W 4Y9 and is listed on the TSX Venture Exchange under the symbol SSS.

 

2.

Basis of presentation

 

(a)

Statement of compliance   

 

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”).

 

The policies applied in these consolidated financial statements are based on IFRS issued and in effect as of March 27, 2014, the date the Board of Directors approved the consolidated financial statements.

 

(b)

Basis of measurement   

 

These consolidated financial statements have been prepared on the historical cost basis, except for held-for-trading financial assets which are measured at fair value.

 

(c)

Functional and presentation currency   

 

 

These consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency.

 

(d)

Use of significant estimates and assumptions   

 

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, revenue and expenses and the related disclosures of contingent assets and liabilities and the determination of the Company’s ability to continue as a going concern. Actual results could differ materially from these estimates and assumptions. The Company reviews its estimates and underlying assumptions on an ongoing basis. Revisions are recognized in the period in which the estimates are revised and may impact future periods.

 

 

Management has applied significant estimates and assumptions to:

 

 

Valuation of share-based compensation and warrants

 

Management measures the costs for share-based compensation and warrants using market-based option valuation techniques. Assumptions are made and estimates are used in applying the valuation techniques. These include estimating the future volatility of the share price, expected dividend yield, expected risk-free interest rate, future employee turnover rates, future exercise behaviours and corporate performance. Such estimates and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates of share-based payments and warrants.

 

 

Impairment of long lived assets

 

Long-lived assets are reviewed for impairment upon the occurrence of events or changes in circumstances indicating that the carrying value of the asset may not be recoverable. For the purpose of measuring recoverable amounts, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use (being the present value of the expected future cash flows of the relevant asset or cash-generating unit.) An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. We evaluate impairment losses for potential reversals when events or circumstances warrant such consideration.

F-27



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

Intangible assets

   

The Company estimates the useful lives of intangible assets from the date they are available for use in the manner intended by management and periodically reviews the useful lives to reflect management's intent about developing and commercializing the assets.

   
3.

Significant accounting policies

   

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

   
(a)

Basis of consolidation

   

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Stem Cell Therapeutics Inc, and Trillium Privateco (“Trillium”) from April 9, 2013, the date of acquisition (see note 4).

   

Investments in other entities where the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee, are considered subsidiaries due to the control exercised over the investee by the Company. Subsidiaries are fully consolidated from the date at which control is determined to have occurred and are de-consolidated from the date that the Company no longer controls the entity.

   

Intercompany transactions, balances and unrealized gains and losses on transactions between subsidiaries are eliminated.

   

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies.

   
(b)

Foreign currency

   

Transactions in foreign currencies are translated to the functional currency at the rate on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the spot rate of exchange as at the reporting date. All differences are taken to profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rate at the date when the fair value was determined.

   

The functional currency of each entity is separately determined. The assets and liabilities of each entity are translated at the rate of exchange in effect as at the year-end while revenue and expense items, including depreciation and amortization, are translated at the rates of exchange prevailing at the dates of the transactions. Foreign exchange gains and losses from the translation of such financial statements are deferred and recognized in other comprehensive income. On disposal of a foreign operation, the foreign currency translation reserve relating to that foreign operation is taken to profit or loss.

   

Financial instruments

   
(c)

Financial assets

   

A financial asset is classified at fair value through profit or loss if it is held for trading or is designated as such upon initial recognition. Attributable transaction costs are recognized in profit or loss as incurred. Financial assets at fair value through profit or loss are measured at fair value and changes therein are recognized in profit or loss.

   

Marketable securities

   

Marketable securities are comprised of short-term debt instruments with an original maturity of less than 90 days on purchase.

   

Loans and receivables

   

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus transaction costs and subsequently measured at amortized cost using the effective interest rate method less any impairment losses. The Company has classified its amounts receivable as loans and receivables.

F-28



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

Derecognition

A financial asset is derecognized when the rights to receive cash flows from the asset have expired or when the Company has transferred its rights to receive cash flows from the asset.

Financial liabilities

Financial liabilities are recognized initially at fair value plus any directly attributable transaction costs, and subsequently at amortized cost using the effective interest method. The Company has classified its accounts payable and accrued liabilities, other current liabilities, loan payable and long-term liability as financial liabilities.

Derecognition

A financial liability is derecognized when its contractual obligations are discharged or cancelled or expire.

Equity

Common shares, preferred shares and warrants to purchase common shares are classified as equity. Incremental costs directly attributable to the issue of common shares, preferred shares and warrants are recognized as a deduction from equity, net of any tax effects.

(d)

Property and equipment

   

Recognition and measurement

   

Items of property and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes the expenditure that is directly attributable to the acquisition of the asset. When parts of an item of property and equipment have different useful lives, they are accounted for as separate items (major components) of property and equipment. Gains and losses on disposal of an item of property and equipment are determined by comparing the proceeds from disposal with the carrying amount of property and equipment, and are recognized in profit or loss.

   

Subsequent costs

   

The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company, and its cost can be measured reliably. The carrying amount of the replaced part is then derecognized. The costs of the day-to-day servicing of property and equipment are recognized in profit or loss as incurred.

   

Depreciation

   

The estimated useful lives and the methods of depreciation for the current and comparative periods are as follows:


  Asset Basis
     
  Lab equipment 20% declining balance
  Computer equipment Straight-line over 3 years
  Office equipment Straight-line over 5 years
  Leaseholds Straight-line over lease term

Estimates for depreciation methods, useful lives and residual values are reviewed at each reporting period-end and adjusted if appropriate. Depreciation expense is recognized in research and development expenses.

(e)

Intangible assets

   

Research and development

   

Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred.

   

Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. No internal development costs have been capitalized to date.

F-29



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.

Intangible assets

Intangible assets that are acquired separately and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognized in profit or loss as incurred.

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date they are available for use in the manner intended by management. The period that the technologies acquired in the Trillium Privateco acquisition are available for use is estimated at three years, and the period that the technologies acquired from the University Health Network (“UHN”) are available for use is estimated at two years, which reflects management's intent about developing and commercializing the assets.

The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in research and development expenses.

(f)

Impairment

   

Financial assets

   

A financial asset not carried at fair value through profit or loss is assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

   

An impairment test is performed, on an individual basis, for each material financial asset. Other individually non-material financial assets are tested as groups of financial assets with similar risk characteristics. Impairment losses are recognized in profit or loss.

   

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in net profit or loss and reflected in an allowance account against the respective financial asset. Interest on the impaired asset continues to be recognized through the unwinding of the discount. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss.

   

Non-financial assets

   

The carrying amounts of the Company's non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If such an indication exists, the recoverable amount is estimated.

   

The recoverable amount of an asset or a cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or cash-generating unit. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of cash inflows of other assets or cash-generating units. An impairment loss is recognized if the carrying amount of an asset or its related cash-generating unit exceeds its estimated recoverable amount. Impairment losses for intangible assets are recognized in research and development expenses.

   

Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

F-30



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

(g)

Provisions

   

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are assessed by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount on provisions is recognized in finance costs. No provisions have been recognized.

   
(h)

Government assistance

   

Government assistance relating to research and development is recorded as a reduction of expenses when the related expenditures are incurred.

   
(i)

Share-based compensation

   

The grant-date fair value of share-based payment awards granted to employees is recognized as personnel costs, with a corresponding increase in contributed surplus, over the period that the employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that met the related service and non-market performance conditions at the vesting date.

   

For equity-settled share-based payment transactions, the Company measures the goods or services received, and the corresponding increase in contributed surplus, directly, at the fair value of the goods or services received, unless that fair value cannot be estimated reliably. If the Company cannot estimate reliably the fair value of the goods or services received, it measures their value by reference to the fair value of the equity instruments granted. Transactions measured by reference to the fair value of the equity instruments granted have their fair values remeasured at each vesting and reporting date until fully vested.

   
(j)

Income taxes

   

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable income or loss.

   

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax assets and liabilities, and they relate to income taxes levied by the same tax authority on the same taxable entity.

   

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences whey they reverse, based on the laws that have been enacted or substantively enacted at the reporting date. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized.

   

Investment tax credits earned from scientific research and development expenditures are recorded when collectability is reasonably assured.

   
(k)

Loss per share

   

Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the reporting period. Diluted loss per share is computed similar to basic loss per share except that the weighted average number of shares outstanding are increased to include additional shares for the assumed exercise of stock options and warrants and conversion of preferred shares, if dilutive. The number of additional shares is calculated by assuming that outstanding preferred shares would convert to common shares and that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the reporting period. The inclusion of the Company's stock options, warrants and preferred shares in the computation of diluted loss per share has an anti-dilutive effect on the loss per share and therefore, they have been excluded from the calculation of diluted loss per share.

F-31



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

(l)   New standards and interpretations adopted during 2013
   
  IFRS 10 Consolidated Financial Statements
   

IFRS 10 requires an entity to consolidate an investee when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. IFRS 10 supersedes SIC-12 Consolidations – Special Purpose Entities and replaces parts of IAS 27 Consolidated and Separate Financial Statements . The effective date of this amendment is for annual periods beginning on or after January 1, 2013. The Company adopted IFRS 10, including the amendments issued in June 2012, in its financial statements for the annual period beginning on January 1, 2013. The adoption did not have a material impact on the consolidated financial statements.

   
  IFRS 12 Disclosure of Interests in Other Entities
   

IFRS 12 establishes disclosure requirements for interest in other entities such as subsidiaries, joint arrangements, associates and unconsolidated structured entities. The standard carries forward existing disclosures and also introduces significant additional disclosure requirements that address the nature of, and risks associated with, an entity’s interest in other entities. IFRS 12 replaces the previous disclosure requirements included in IAS 27 Consolidated and Separate Financial Statements , IAS 31 Joint Ventures and IAS 28 Investment in Associates . The effective date of this amendment is for annual periods beginning on or after January 1, 2013. The Company adopted IFRS 12 in its consolidated financial statements for the annual period beginning on January 1, 2013. The adoption did not have a material impact on the consolidated financial statements.

   
  IFRS 13 Fair Value Measurement
   

IFRS 13 is a comprehensive standard for fair value measurement and disclosure requirements for use across all IFRS standards. IFRS 13 defines fair value and establishes disclosures about fair value measurement. The effective date of this amendment is for annual periods beginning on or after January 1, 2013. The Company adopted IFRS 13 in its consolidated financial statements for the annual period beginning on January 1, 2013. The adoption did not have a material impact on the consolidated financial statements.

   
  IAS 1 Presentation of Financial Statements
   

The IASB amended IAS 1 by revising how certain items are presented in other comprehensive income (“OCI”). Items within OCI that may be reclassified to income will be separated from items that will not. The standard is effective for fiscal years beginning on or after July 1, 2012 with early adoption permitted. The Company has adopted IAS 1 retrospectively and there are minimal disclosure differences.

   
  Annual Improvements to IFRSs 2009-2011 Cycle – various standards
   

In May 2012, the IASB published Annual Improvements to IFRSs – 2009-2011 Cycle as part of its annual improvements process to make non-urgent but necessary amendments to IFRS. These amendments are effective for annual periods beginning on or after January 1, 2013 with retrospective application. The Company adopted the amendments to the standards in its consolidated financial statements for the annual period beginning on January 1, 2013. The adoption did not have a material impact on the consolidated financial statements.

   
(m)   New standards and interpretations not yet effective
   
  IFRS 9 Financial Instruments
   

In October 2010, the IASB published amendments to IFRS 9 which provides added guidance on the classification and measurement of financial liabilities. IFRS 9 will replace IAS 39 and will be completed in three phases: classification and measurement of financial assets and liabilities, impairment of financial assets, and general hedge accounting. This was the first phase of the project on classification and measurement of financial assets and liabilities. The IASB is discussing proposed limited amendments related to this phase of the project. The standard on general hedge accounting was issued and included as part of IFRS 9 in November 2013. The accounting for macro hedging is expected to be issued as a separate standard outside of IFRS 9. The impairment of financial assets phase of the project is currently in development. In November 2013, the mandatory effective date of IFRS 9 of January 1, 2015 was removed and the effective date will be determined when the remaining phases of IFRS 9 are finalized. The Company is currently monitoring the developments of this standard and assessing the impact that the adoption of this standard may have on the consolidated financial statements.

F-32



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

IFRIC 21 Levies

In May 2013, International Financial Reporting Standards Interpretations Committee Interpretation 21, Levies ("IFRIC 21") was issued. IFRIC 21 provides guidance on when to recognize a liability to pay a levy imposed by a government that is accounted for in accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets . IFRIC 21 is effective for annual periods beginning on or after January 1, 2014 and is to be applied retrospectively. The Company is currently assessing the impact the adoption of this interpretation may have on the consolidated financial statements.

IAS 36 Impairment of Assets

In May 29, 2013, IASB published amendments to IAS 36, Impairment of Assets which reduce the circumstances in which the recoverable amount of cash-generating units is required to be disclosed and clarifies the disclosures required when an impairment loss has been recognized or reversed in the period. This amendment is effective for annual periods beginning on or after January 1, 2014. The Company does not expect the adoption of this amendment to have a material impact on its consolidated financial statements.

4.

Acquisition of Trillium Privateco

   

On April 9, 2013, the Company completed a merger with Trillium Privateco, a private biopharmaceutical company specializing in immune regulation and the development of cancer stem cell-related therapeutics. The Company applied the acquisition method of accounting for the business combination and the losses have been consolidated from the acquisition date. The consideration was allocated to the underlying assets acquired and liabilities assumed based upon their fair values at the date of acquisition. The purchase price allocation was assigned to the net identifiable assets based on their estimated fair values. The final purchase price allocation is listed below:


  Fair value of consideration paid:        
    Cash   $  1,200,000  
    2,779,180 common shares and 3,300,000 units     1,380,836  
          2,580,836  
             
  Assets acquired:        
    Cash and marketable securities   $  1,182,714  
    Amounts receivable     820,944  
    Prepaid expenses     44,300  
    Equipment     91,000  
    Acquired technology     1,018,037  
          3,156,995  
             
  Liabilities assumed:        
    Accounts payable and accrued liabilities     282,178  
    Loan payable     293,981  
          576,159  
  Net identifiable assets acquired   $  2,580,836  

F-33



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

4.

Acquisition of Trillium Privateco (continued)

   
As consideration, the Company paid $1,200,000 in cash and issued 2,779,180 common shares and 3,300,000 units. Each unit consisted of one common share and one common share purchase warrant, with each common share purchase warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018. The fair value of the unit was determined based on the stand-alone value of the common share and the common share purchase warrant, in accordance with IFRS 13, Fair value measurement and IFRS 3, Business combinations. Accordingly, the fair value of the aggregate 6,079,180 common shares issued was based on the closing price of the Company’s common shares of $0.20 on April 9, 2013. The fair value of the 3,300,000 common share purchase warrants was determined using the Black-Scholes option pricing model. Assumptions used to determine the value of the common share purchase warrant were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 68%; and average expected life of 3 years. Post-closing, Trillium Privateco shareholders held approximately 16% of the issued and outstanding common shares, and Trillium Privateco became a wholly-owned subsidiary of the Company.
   

Cash used in the investment is determined as follows:


     $  
         
  Cash consideration   1,200,000  
  Less cash acquired   552,004  
      647,996  

Acquisition costs incurred by the Company for the Trillium Privateco merger, and included in general and administrative expenses for the year ended December 31, 2013, were approximately $113,000. From the date of the acquisition to December 31, 2013, Trillium Privateco contributed revenue of nil and a loss of $2,236,262. If the acquisition had occurred on January 1, 2013, management estimates that consolidated revenue would have been nil, and consolidated loss for the year would have been $5,368,637. In determining these amounts, management has assumed that the fair value adjustments that arose on the date of acquisition would have been the same if the acquisition had occurred on January 1, 2013.

The acquisition gave rise to a deferred tax liability related to the acquired technology and a deferred tax asset related to the tax effect of the Trillium Privateco non-capital losses and the scientific research and experimental development tax pools. The Company has offset the tax liabilities and tax assets as it has a legally enforceable right to set them off. A net residual tax asset has not been recognized as it is not probable that future taxable profits will be available against which the accumulated tax assets can be utilized.

5.

Amounts receivable


      December 31,     December 31,  
      2013     2012  
      $    $  
               
  Government programs receivable   426,946     83,458  
  Other amounts receivable   288     77,750  
      427,234     161,208  

F-34



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

6.

Property and equipment


                  Office        
      Lab     Computer     equipment and        
      equipment     equipment     leaseholds     Total  
     $    $    $    $  
                           
  Cost                        
  Balance, December 31, 2011   -     154,706     33,889     188,595  
  Disposals   -     (141,206 )   (33,889 )   (175,095 )
  Balance, December 31, 2012   -     13,500     -     13,500  
  Additions   111,025     4,611     9,381     125,017  
  Balance, December 31, 2013   111,025     18,111     9,381     138,517  
                           
  Accumulated depreciation                        
  Balance, December 31, 2011   -     150,324     33,889     184,213  
  Disposals   -     (141,206 )   (33,889 )   (175,095 )
  Depreciation   -     4,382     -     4,382  
  Balance, December 31, 2012   -     13,500     -     13,500  
  Depreciation   14,723     504     783     16,010  
  Balance December 31, 2013   14,723     14,004     783     29,510  
                           
  Net carrying amounts                        
  December 31, 2012   -     -     -     -  
  December 31, 2013   96,302     4,107     8,598     109,007  

During the first quarter of 2012, the Company closed its Calgary office and retired computer and office equipment that was fully depreciated in the amount of $175,095. In the second quarter of 2013, the Company acquired lab equipment in its merger with Trillium Privateco with a fair value of $91,000.

7.

Intangible assets


      Total  
     $  
         
  Cost      
  Balance, December 31, 2011 and December 31, 2012   2,431,279  
  Additions   2,103,751  
  Disposals   (2,431,279 )
  Balance December 31, 2013   2,103,751  
         
  Accumulated amortization      
  Balance, December 31, 2011   2,426,779  
  Amortization   2,000  
  Balance, December 31, 2012   2,428,779  
  Amortization   632,779  
  Disposals   (2,431,279 )
  Balance, December 31, 2013   630,279  
         
  Net carrying amounts      
  December 31, 2012   2,500  
  December 31, 2013   1,473,472  

F-35



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

7.

Intangible assets (continued)

   

On April 9, 2013, the Company completed a merger with Trillium Privateco. In-process research and development assets of Trillium Privateco acquired amounted to $1,018,037 (see note 4).

   

On April 16, 2013, the Company signed an agreement with UHN for an exclusive world-wide license to an innovative cancer stem cell program. The initial consideration for the UHN license of $1,085,714 was satisfied by the issuance of 5,028,571 common shares and 1,600,000 common share purchase warrants, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018. Additional consideration under the UHN license includes an annual license maintenance fee and future development milestones. The fair value of the common shares issued was based on the closing price of the Company's common shares of $0.20 on April 16, 2013 and $0.25 per unit based on the fair value of the common share and common share purchase warrant components as of the date of acquisition.

   

During the third quarter of 2013, the Company ceased all activities related to the regenerative stem cell products and retired the fully amortized assets in the amount of $2,431,279.


8.

Accounts payable and accrued liabilities


      December 31,     December 31,  
      2013     2012  
      $    $  
               
  Trade and other payables   113,003     55,548  
  Accrued liabilities   221,580     95,484  
  Due to related parties (note 16)   335,277     34,226  
      669,860     185,258  

9.    Non-current liabilities
   
(a)

On February 1, 2012, Trillium Privateco entered into a contribution agreement with the Federal Economic Development Agency for Southern Ontario where it received a repayable contribution to support the clinical development of its TTI-1612 program. The period of contribution ended on December 31, 2013. As at December 31, 2013, Trillium Privateco has repayable contributions of $575,139 representing the outstanding principal balance, repayable in equal monthly installments for 60 months beginning on December 1, 2014. The loan payable bears no interest. On acquisition of Trillium Privateco, the fair value of the loan payable was determined by discounting the loan payable using an estimated market interest rate of 15%. Interest expense will accrete on the discounted loan amount until it reaches its face value at maturity.

   
(b)

The Company incurred a discounted long-term liability of $157,609 related to the cessation of the development of its regenerative medicine products. This liability has been discounted using an estimated market interest rate of 15% and interest expense is accreting.

   
The current portions of the loan payable and long-term liability are included in other current liabilities in the statements of financial position.

F-36



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

10.   Share capital
   
(a)   Authorized
   

The authorized share capital of the Company consists of an unlimited number of common shares, Class B shares and First Preferred Shares, in each case without nominal or par value. Common shares are voting and may receive dividends as declared at the discretion of the Board of Directors. Class B shares are non-voting and convertible to common shares at the holder’s discretion, on a one-for-one basis. Upon dissolution or wind-up of the Company, Class B shares participate rateably with the common shares in the distribution of the Company’s assets. Preferred shares have voting rights as decided upon by the Board of Directors at the time of grant. Upon dissolution or wind-up of the Company, First Preferred Shares are entitled to priority over common and Class B shares.

   

During 2013, the Company created a new series of preferred shares being the Series I Non-Voting Convertible First Preferred Shares. These shares are non-voting, may receive dividends as declared at the discretion of the Board of Directors, and are convertible to common shares at the holder’s discretion, on a one-for-one basis.

   
(b)   Common and preferred shares issued – year ended December 31, 2013
   

The Company consolidated its outstanding common shares issuing one post-consolidated share for each 10 pre-consolidated shares and the common shares began trading on a post-consolidated basis on February 6, 2013. All references in the consolidated financial statements and notes to the number of common shares, warrants and stock options have been adjusted to the post-consolidation amounts.

   

In March 2013, the Company completed a capital raise as part of a shelf prospectus supplement and a U.S. private placement for a total of 12,735,000 units at a price of $0.25 per unit, for aggregate gross proceeds to the Company of $3,185,080 ($2,615,240 net of issuance costs). Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.40 per share at any time prior to expiry on March 15, 2018 (12,315,000 warrants) and March 27, 2018 (420,000 warrants). In connection with the financing, the Company issued 814,050 compensation warrants having an aggregate fair value of $48,843 estimated using the Black- Scholes option pricing model. Each compensation warrant entitles the holder to acquire one common share at an exercise price of $0.25 per share prior to expiry on March 16, 2015.

   

The allocation of the $0.25 common share unit issue price to the common shares and unit warrants was based on the relative fair values of the common shares and the warrants. The fair value of the warrants was determined using the Black-Scholes option pricing model. The common shares were allocated a price of $0.20 per share and the warrants were allocated a price of $0.05 per warrant. The costs of the issue were allocated on a pro rata basis to the common shares and warrants. Accordingly, $2,092,192 was allocated to common shares and $523,048 to warrants, net of issuance costs. Assumptions used to determine the value of the unit warrants were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 64%; and average expected life of 3 years. Assumptions used to determine the value of the compensation warrants were: dividend yield of 0%; risk-free interest rate of 1.0%; expected volatility of 80%; and average expected life of 2 years.

   
On April 9, 2013, the Company issued 6,079,180 common shares and 3,300,000 common share purchase warrants for partial consideration for the acquisition of Trillium Privateco (see note 4).
   
On April 16, 2013, the Company issued 5,028,571 common shares and 1,600,000 common share purchase warrants on the acquisition of certain cancer stem cell assets from UHN (see note 7).

F-37



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

10.   Share capital (continued)
   

On December 13, 2013, the Company completed a private placement financing issuing 79,247,693 common share units (each common share unit consisting of one common share and three-quarters of a common share purchase warrant) at a price of $0.21 per unit and 77,895,165 preferred share units (each preferred share unit consisting of one Series 1 Non-Voting First Preferred Share and three-quarters of a common share purchase warrant) at a price of $0.21 per unit for gross proceeds of $32,866,025 ($30,713,841 net of issuance costs). Each whole warrant entitles the holder to purchase one common share at a price of $0.28 at any time prior to expiry on December 13, 2018. In connection with the financing, the Company issued 5,014,839 compensation warrants having an aggregate fair value of $651,929 estimated using the Black-Scholes option pricing model. Each compensation warrant entitles the holder to acquire one common share at an exercise price of $0.21 per share prior to expiry on December 13, 2015.

   

The allocation of the $0.21 unit issue price to the common shares, Series 1 Non-Voting First Preferred Shares and unit warrants was based on the relative fair values of the common shares, Series 1 Non-Voting First Preferred Shares and the warrants. The fair value of the warrants was determined using the Black-Scholes option pricing model. The common shares were allocated a price of $0.16 per share, the Series 1 Non-Voting First Preferred Shares were allocated a price of $0.16 per share, and the warrants were allocated a price of $0.05 per three-quarter warrant. The costs of the issue were allocated on a pro rata basis. Accordingly, $11,488,602 was allocated to common shares, $11,292,525 to the Series 1 Non-Voting First Preferred Shares and $7,932,714 to warrants, net of issuance costs. Assumptions used to determine the value of the unit warrants were: dividend yield of 0%; risk-free interest rate of 1.2%; expected volatility of 70%; and average expected life of 3 years. Assumptions used to determine the value of the compensation warrants were: dividend yield of 0%; risk-free interest rate of 1.1%; expected volatility of 66%; and average expected life of 2 years.

   

All securities issued under the offering (including the compensation warrants), in Canada are subject to a four month hold and resale restrictions under Canadian securities law, and in the United States are subject to statutory resale restrictions under U.S. securities laws. All securities issued under the offering are also subject to a four month hold imposed under the policies of the TSX Venture Exchange.

   

In the December 2013 private placement, subscribers who purchased Preferred Share Units and certain subscribers who purchased Common Share Units are subject to restrictions on the conversion and exercise of securities of the Company convertible in common shares. Such subscribers cannot convert or exercise securities of the Company convertible or exerciseable into common shares if, after giving effect to the exercise of conversion, the subscriber and its joint actors would have beneficial ownership or direction or control over common shares in excess of 4.99% of the then outstanding common shares. This limit can be raised at the option of the subscriber on 61 days prior written notice: (i) up to 9.99%, (ii) up to 19.99%, subject to stock exchange clearance of a personal information form submitted by the subscriber, and (iii) above 19.99%, subject to stock exchange approval and shareholder approval.

   

Subject to receipt of any required regulatory approvals, subscribers who purchased a minimum of 10% of the securities sold under the offering have been given rights to purchase securities of the Company in future financings to enable each such subscriber to maintain its percentage holding in the Company for so long as the subscriber holds at least 10% of the outstanding common shares on a fully-diluted basis.

   
  There were no common or preferred shares issued in the year ended December 31, 2012.
   
(c)    Weighted average number of common shares
   

The weighted average number of common shares outstanding for the purposes of calculating earnings per share have been adjusted for 2013 and 2012 to the post-consolidated number. The post-consolidated weighted average number of common shares outstanding for year ended December 31, 2013 was 40,707,868 (2012 – 18,661,936).

F-38



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

10. Share capital (continued)   
   
(d) Warrants

Warrants outstanding at December 31, 2013 were as follows:

    Number of Exercise
  Expiry dates warrants price
       
  March 14, 2014 909,091 $1.60
  March 16, 2015 814,051 $0.25
  December 13, 2015 5,014,839 $0.21
  March 15, 2018 17,215,000 $0.40
  March 27, 2018 420,000 $0.40
  December 13, 2018 117,857,142 $0.28
    142,230,123  

All warrants were exercisable on issuance. Changes in the number of warrants outstanding during the years ended December 31 were as follows:

      2013     2012  
                           
            Weighted           Weighted  
            average           average  
      Number of     exercise     Number of     exercise  
      warrants     price     warrants     price  
                           
  Balance, beginning of year   1,036,364   $  1.54     1,036,364   $  1.54  
  Issued   141,321,032     0.29     -     -  
  Expired   (127,273 )   1.10     -     -  
                           
  Balance, end of year   142,230,123   $  0.30     1,036,364   $  1.54  

(e)

Stock option plan

   

The Company has a 10% rolling stock option plan (the “Plan”) that was approved by the Company’s shareholders at its annual general meeting held on October 17, 2013. Pursuant to the Plan, the Company may grant stock options to purchase up to an aggregate of 10% of the Company’s issued and outstanding share capital. As at December 31, 2013, the Company was entitled to issue an additional 9,254,141 stock options under the Plan.

F-39



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

10.

Share capital (continued)

Changes in the number of options outstanding during the years ended December 31 were as follows:

      2013     2012  
                           
            Weighted           Weighted  
            average           average  
      Number of     exercise     Number of     exercise  
      options     price     options     price  
                           
  Balance, beginning of year   700,000   $  1.03     1,110,194   $  1.39  
  Granted   2,623,597     0.25     10,000     1.00  
  Cancelled/forfeited   (402,500 )   1.02     (420,194 )   1.98  
                           
  Balance, end of year   2,921,097   $  0.33     700,000   $  1.03  
                           
  Options exercisable, end of year   1,189,918   $  0.45     596,806   $  1.04  

The following table reflects stock options outstanding at December 31, 2013:

    Stock options outstanding     Stock options exercisable
      Weighted average        
    Number remaining Weighted average   Exercisable Weighted average
  Exercise prices outstanding contractual life exercise price   number exercise price
               
  $0.25 2,623,597 9.2 years $0.25   895,196 $0.25
  $1.00 274,500 2.3 years $1.00   271,722 $1.00
  $1.20 3,000 0.7 years $1.20   3,000 $1.20
  $1.70 20,000 0.9 years $1.70   20,000 $1.70
               
               
   2,921,097 8.5 years  $0.33    1,189,918  $0.45

Share-based compensation expense was determined based on the fair value of the options at the date of measurement using the Black-Scholes option pricing model with the weighted average assumptions for the years ended December 31 as follows:

    2013 2012
  Expected option life 10 years 5 years
  Risk-free interest rate 1.7% 1.1%
  Forfeiture rate 11% 10%
  Dividend yield 0% 0%
  Expected volatility 118% 137%

The Black-Scholes option pricing model was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which significantly differs from the Company's stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and average option life, which significantly affect the calculated values.

F-40



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

10.    Share capital (continued)
   

The risk-free interest rate is based on the implied yield on a Government of Canada zero-coupon issue with a remaining term equal to the expected term of the option. The volatility is based solely on historical volatility equal to the expected life of the option. The life of the options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past. The forfeiture rate is an estimate based on historical evidence and future expectations. The dividend yield was excluded from the calculation since it is the present policy of the Company to retain all earnings to finance operations and future growth.

   

During the year ended December 31, 2013, the Company issued 2,623,597 (2012 – 10,000) stock options with a fair value of $535,781 (2012 – $2,300). The weighted average grant date fair value of the stock options granted during the year ended December 31, 2013 was $0.20 (2012 - $0.02).

   
(f)   Deferred Share Units Plan
   

The shareholders of the Company approved the adoption of a deferred share units plan (the “DSU Plan”) on October 17, 2013 reserving for issuance up to 2,000,000 common shares under the DSU Plan. The purpose of the DSU Plan is to provide an alternative form of compensation to satisfy director fees and annual and special bonuses payable to senior officers and directors of the Company. No units have been issued to date.

   
(g)   Shareholder Rights Plan
   

The shareholders of the Company approved the adoption of a shareholder rights plan agreement (the “SRP Plan”) on October 17, 2013. The SRP Plan is designed to provide adequate time for the Board of Directors and the shareholders to assess an unsolicited takeover bid for the Company, to provide the Board of Directors with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, and to provide shareholders with an equal opportunity to participate in a takeover bid and receive full and fair value for their common shares. The SRP Plan will expire at the close of the Company's annual meeting of shareholders in 2016.

   

The rights issued under the SRP Plan initially attach to and trade with the common shares and no separate certificates will be issued unless an event triggering these rights occurs. The rights will become exercisable only when a person, including any party related to it, acquires or attempts to acquire 20 percent or more of the outstanding common shares without complying with the "Permitted Bid" provisions of the SRP Plan or without approval of the Board of Directors. Should such an acquisition occur or be announced, each right would, upon exercise, entitle a rights holder, other than the acquiring person and related persons, to purchase common shares at a approximate 50 percent discount to the market price at the time.

   

Under the SRP Plan, a Permitted Bid is a bid made to all holders of the common shares and which is open for acceptance for not less than 60 days. If at the end of 60 days at least 50 percent of the outstanding common shares, other than those owned by the offeror and certain related parties have been tendered, the offeror may take up and pay for the common shares but must extend the bid for a further 10 days to allow other shareholders to tender. The issuance of common shares upon the exercise of the rights is subject to receipt of certain regulatory approvals.

F-41



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

11. Income taxes   
   
The Company recognized no income taxes in the consolidated statements of loss and comprehensive loss, as it has been incurring losses since inception, and it is not probable that future taxable profits will be available against which the accumulated tax losses can be utilized.
   
(a) Unrecognized deferred tax assets:
   
  As at December 31, 2013 and 2012, deferred tax assets have not been recognized with respect to the following items:

      2013     2012  
               
  Non-capital losses carried forward $   8,515,351   $  6,130,941  
  Federal investment tax credits carryforward   1,515,626     947,496  
  Carrying value of property and equipment and intangible assets in excess of accounting basis   1,138,196     961,313  
  Scientific research and experimental development expenditures   4,101,322     1,100,271  
  Share issue costs and other   540,886     53,975  
               
    $   15,811,381   $  9,193,996  

(b)

As at December 31, 2013, the Company has available research and development expenditures of approximately $15,477,000 (2012 - $4,152,000), for income tax purposes which may be carried forward indefinitely to reduce future years’ taxable income. As at December 31, 2013, the Company also has unclaimed Canadian federal scientific research and development investment tax credits of $2,062,000 (2012 – $1,287,000) which are available to reduce future federal taxes payable with expiries from 2014 through 2033. The benefit of these expenditures and investment tax credits has not been recorded in the accounts.

   
(c)

As at December 31, 2013, the Company has accumulated non-capital losses for federal and provincial income tax purposes in Canada which are available for application against future taxable income. The benefit of these losses has not been recorded in the accounts.

   

The non-capital tax losses expire as follows:


      Federal  
     $  
         
  2014   971,000  
  2015   2,968,000  
  2026   3,320,000  
  2027   6,645,000  
  2028   4,659,000  
  2029   4,144,000  
  2030   3,736,000  
  2031   1,819,000  
  2032   1,387,000  
  2033   2,450,000  
      32,099,000  

F-42



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

11. Income taxes (continued)   
   
(d) The reconciliation of the Canadian statutory income tax rate applied to the net loss for the year to the income tax recovery is  as follows:

      2013     2012  
               
 

Statutory income tax rate

  26.5%     26.5%  
 

 

           
 

Income tax recovery based on statutory income tax rate

$   (1,136,667 ) $  (281,298 )
 

Change in income tax rates

  -     (431,758 )
 

Investment tax credits

  (207,850 )   (23,188 )
 

Share-based compensation and other

  84,902     9,429  
 

Change in valuation allowance

  1,259,615     726,815  
 

 

           
 

Income tax recovery

$  -   $  -  

12.

Research and development

Components of research and development expenses for the years ended December 31 were as follows:

      2013     2012  
      $    $  
               
 

Research and development, excluding the below

  1,411,264     418,479  
 

Salaries, fees and short-term benefits

  1,299,055     209,588  
 

Share-based compensation

  211,419     38,011  
 

Amortization of intangible assets

  632,779     2,000  
 

Depreciation of property and equipment

  16,010     4,382  
 

Investment tax credits

  (233,821 )   (48,912 )
      3,336,706     623,548  

13.

General and Administrative

Components of general and administrative expenses for the years ended December 31 were as follows:

      2013     2012  
      $    $  
               
 

General and administrative, excluding the below

  599,785     269,849  
 

Salaries, fees and short-term benefits

  254,952     199,943  
 

Share-based compensation

  107,463     (3,505 )
 

 

  962,200     466,287  

F-43



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

14.

Finance income and finance costs

   

Finance income for the years ended December 31 was as follows:


      2013     2012  
      $    $  
               
  Interest income   44,113     25,740  
  Net foreign currency gain   9,915     4,990  
      54,028     30,730  

Finance costs for the years ended December 31 were as follows:

      2013     2012  
      $    $  
               
  Bank charges   4,297     2,397  
  Accreted interest   40,133     -  
      44,430     2,397  

15.

Commitments and contingencies

   

As at December 31, 2013 and in the normal course of business, the Company had obligations to make future payments, representing research and development contracts and other commitments that are known and committed in the amount of $247,000 over the next 12 months, $182,000 from 12 to 24 months, $127,000 from 24-36 months, and $78,000 each year thereafter.

   

The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain.

   

The Company periodically enters into research and license agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken by or on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the consolidated financial statements with respect to these indemnification obligations.

F-44



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

16.

Related parties

   

For the years ended December 31, 2013 and 2012, the key management personnel of the Company were the Board of Directors, the Executive Chairman, the Chief Executive Officer, the Chief Financial Officer, the Chief Scientific Officer and the Vice-President Drug Development.

   

Compensation for key management personnel of the Company for the years ended December 31 was as follows:


      2013     2012  
      $    $  
               
  Salaries, fees and short-term benefits   844,425     396,400  
  Share-based compensation   316,069     55,272  
  Total   1,160,494     451,672  

Executive officers and directors participate in the stock option plan and officers participate in the Company’s benefit plans. Directors receive annual fees for their services. As at December 31, 2013, the key management personnel controlled approximately 4% of the voting shares of the Company.

Outstanding balances with related parties at the year-end are unsecured, interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. For the year ended December 31, 2013, $138,750 was paid to a director for consulting fees (2012 - nil).

17.

Operating segment

   

The Company has a single operating segment, the research and development of immunotherapy drugs for the treatment of cancer. Substantially all of the Company’s operations, assets, and employees are in Canada.

   
18.

Management of capital

   

The Company defines its capital as share capital, warrants and contributed surplus. The Company’s objectives when managing capital are to ensure there are sufficient funds available to carry out its research and development programs. To date, these programs have been funded primarily through the sale of equity securities and the exercise of common share purchase warrants. The Company also sources non-dilutive funding by accessing grants, government assistance and tax incentives, and through partnerships with corporations and research institutions. The Company uses budgets and purchasing controls to manage its costs.

   

The Company is not exposed to any externally imposed capital requirements.

   
19.

Financial instruments

Fair value

IFRS 13 , Fair Value Measurement, provides a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs are those which reflect market data obtained from independent sources, while unobservable inputs reflects the Company’s assumptions with respect to how market participants would price an asset or liability. These two inputs used to measure fair value fall into the following three different levels of the fair value hierarchy:

  Level 1 Quoted prices in active markets for identical instruments that are observable.
Level 2

Quoted prices in active markets for similar instruments; inputs other than quoted prices that are observable and derived from or corroborated by observable market data.

  Level 3 Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

The hierarchy requires the use of observable market data when available.

F-45



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2013
Amounts in Canadian Dollars

19.   

Financial instruments (continued)

 

The Company has classified cash, marketable securities, amounts receivable, accounts payable and accrued liabilities, other current liabilities, loan payable and long-term liability as Level 1.

 

Cash, marketable securities, amounts receivable, accounts payable and accrued liabilities, and other current liabilities, due within one year, are all short-term in nature and, as such, their carrying values approximate fair values. The fair value of the non-current loan payable and long-term liability is estimated by discounting the expected future cash flows at the cost of money to the Company, which is equal to its carrying value.

 

 

Risks

 

The Company has exposure to credit risk, liquidity risk, interest rate risk and currency risk. The Company’s Board of Directors has overall responsibility for the establishment and oversight of the Company’s risk management framework. The Audit Committee of the Board is responsible to review the Company’s risk management policies.

 

(a)   

Credit risk

 

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s cash and cash equivalents and amounts receivable. The carrying amount of these financial assets represents the maximum credit exposure. The Company follows an investment policy to mitigate against the deterioration of principal and to enhance the Company’s ability to meet its liquidity needs. Cash and cash equivalents are on deposit with a major Canadian chartered bank. Amounts receivable are primarily comprised of amounts due from the federal government.

 

(b)   

Liquidity risk

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company is a development stage company and is reliant on external fundraising to support its operations. Once funds have been raised, the Company manages its liquidity risk by investing in cash and cash equivalents to provide regular cash flow for current operations. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Company’s operating and capital budgets, as well as any material transactions not in the ordinary course of business. The majority of the Company’s accounts payable and accrued liabilities have maturities of less than three months.

 

(c)   

Interest rate risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s cash and cash equivalents are highly liquid holdings in bank accounts or high interest savings accounts which have a variable rate of interest. The Company manages its interest rate risk by holding highly liquid short-term instruments and by holding its investments to maturity, where possible. For the year ended December 31, 2013, the Company earned interest income of $44,113 (2012 - $25,740). Therefore, a 1% change in the average interest rate for the year would have a net impact on finance income of $441.

 

(d)   

Currency risk

 

The Company is exposed to currency risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. Currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the Canadian dollar which are primarily expenses in US dollars. The Company manages its exposure to currency fluctuations by holding cash and cash equivalents denominated in US dollars in amounts approximating current US dollar financial liabilities and US dollar planned expenditures. As at December 31, 2013, the Company held US dollar cash and cash equivalents in the amount of US$493,031 (2012 - US$157,383) and had US dollar denominated accounts payable and accrued liabilities in the amount of US$88,063 (2012 - US$30,396). Therefore, a 1% change in the foreign exchange rate would have a net impact on finance costs of $4,050 (2012 – $1,270).

 

US dollar expenses for the year ended December 31, 2013 were approximately US$518,000 (2012 – US$532,000). Varying the US exchange rate for the year to reflect a 5% strengthening of the Canadian dollar would have decreased the net loss by approximately $26,000 (2012 - $27,000) assuming that all other variables remained constant.

F-46


TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)

CONSOLIDATED FINANCIAL STATEMENTS

      FOR THE YEARS ENDED
DECEMBER 31, 2012 AND 2011

 

96 Skyway Avenue
Toronto, Ontario M9W 4Y9
www.trilliumtherapeutics.com

F-47


INDEPENDENT AUDITORS’ REPORT OF REGISTERED PUBLIC ACCOUNTING FIRM

To the Directors of
Trillium Therapeutics Inc.

We have audited the accompanying consolidated financial statements of Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.), which comprise the consolidated statements of financial position as at December 31, 2012 and 2011, and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for the years then ended, and a summary of significant accounting policies and other explanatory information.

Management's responsibility for the consolidated financial statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Trillium Therapeutics Inc. as at December 31, 2012 and 2011 and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board.

F-48


Emphasis of matter

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2(b) to the consolidated financial statements, the Company has recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2(b). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

  /s/ Ernst & Young LLP
Toronto, Canada Chartered Accountants
April 29, 2013 Licensed Public Accountants

F-49



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Consolidated Statements of Financial Position
Amounts in Canadian Dollars
(See note 2 – Basis of presentation)

 

        As at     As at  

 

  Note     December 31, 2012     December 31, 2011  

 

      $      

 

                 

ASSETS

                 

 

                 

Current

                 

Cash and cash equivalents

        1,375,015     2,696,764  

Amounts receivable

  4     161,208     41,614  

Prepaid expenses

        29,005     16,320  

Total current assets

        1,565,228     2,754,698  

Property and equipment

  5     -     4,382  

Intangible assets

  6     2,500     4,500  

Total non-current assets

        2,500     8,882  

Total assets

        1,567,728     2,763,580  

LIABILITIES

                 

Current

                 

Accounts payable and accrued liabilities

  7     185,258     354,114  

Total liabilities

        185,258     354,114  

EQUITY

                 

Share capital

  8     31,388,959     31,388,959  

Warrants

  8     508,281     508,281  

Contributed surplus

  8     2,870,138     2,835,632  

Deficit

        (33,384,908 )   (32,323,406 )

Total equity

        1,382,470     2,409,466  

Total liabilities and equity

        1,567,728     2,763,580  

Going concern [note 2(b)]
Commitments and contingencies [note 13]
Events after the balance sheet date [note 18]

Approved by the Board and authorized for issue on April 29, 2013:

(signed) David Allan, Director (signed) James DeMesa, Director

 

See accompanying notes to the consolidated financial statements

F-50



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Consolidated Statements of Loss and Comprehensive Loss
Amounts in Canadian Dollars

 

        Year ended     Year ended  

                                                                                                                       

    Note     December 31, 2012     December 31, 2011  

 

         

 

                 

EXPENSES

                 

Research and development

  10     623,548     2,335,401  

General and administrative

  11     466,287     860,630  

 

        1,089,835     3,196,031  

Finance income

  12     (30,730 )   (36,410 )

Finance costs

  12     2,397     14,326  

 

        (28,333 )   (22,084 )

Net loss and comprehensive loss for the year

        1,061,502     3,173,947  

Basic and diluted loss per common share

  8(c)   (0.06 )   (0.17 )

See accompanying notes to the consolidated financial statements

F-51



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Consolidated Statements of Changes in Equity
Amounts in Canadian Dollars

 

  Share capital     Warrants     Contributed              

 

  Number     Amount     Number     Amount     surplus     Deficit     Total  

 

  #   $     #   $   $   $   $  

 

        (note 8 )         (note 8 )   (note 8 )            

 

                                         

Balance, December 31, 2011

  186,619,359     31,388,959     10,363,636     508,281     2,835,632     (32,323,406 )   2,409,466  

Net loss and comprehensive loss for the year

- - - - - (1,061,502 ) (1,061,502 )

Transactions with owners of the Company, recognized directly in equity

Share-based compensation

  -     -     -     -     34,506     -     34,506  

Total transactions with owners of the Company

- - - - 34,506 - 34,506

Balance, December 31, 2012

  186,619,359     31,388,959     10,363,636     508,281     2,870,138     (33,384,908 )   1,382,470  

 

  Share capital     Warrants     Contributed              

 

  Number     Amount     Number     Amount     surplus     Deficit     Total  

 

  #   $     #   $   $   $   $  

 

                                         

Balance, December 31, 2010

  168,337,540     30,212,225     -     -     2,505,474     (29,149,459 )   3,568,240  

 

                                         

Net loss and comprehensive loss for the year

- - - - - (3,173,947 ) (3,173,947 )

Transactions with owners of the Company, recognized directly in equity

Share units issued, net of issue costs

  18,181,819     1,163,734     9,090,909     416,645     -     -     1,580,379  

Compensation warrants issued

  -     -     1,272,727     91,636     -     -     91,636  

Shares issued on exercise of stock options

100,000 13,000 - - (3,000 ) - 10,000

Share-based compensation

  -     -     -     -     333,158     -     333,158  

Total transactions with owners of the Company

18,281,819 1,176,734 10,363,636 508,281 330,158 - 2,015,173

Balance, December 31, 2011

  186,619,359     31,388,959     10,363,636     508,281     2,835,632     (32,323,406 )   2,409,466  

See accompanying notes to the consolidated financial statements

F-52



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Consolidated Statements of Cash Flows
Amounts in Canadian Dollars

 

        Year ended     Year ended  

 

  Note     December 31, 2012     December 31, 2011  

 

        $   $  

 

                 

OPERATING ACTIVITIES

                 

Net loss for the year

        (1,061,502 )   (3,173,947 )

Adjustments for items not affecting cash

                 

   Share-based compensation

  8     34,506     333,158  

   Amortization of intangible assets

  6     2,000     243,117  

   Impairment of intangible assets

  6     -     665,416  

   Depreciation of property and equipment

  5     4,382     12,493  

 

        (1,020,614 )   (1,919,763 )

Changes in non-cash working capital balances

                 

   Amounts receivable

        (119,594 )   (21,726 )

   Prepaid expenses

        (12,685 )   29,168  

   Accounts payable and accrued liabilities

        (168,856 )   18,098  

 

                 

Cash used in operating activities

        ( 1,321,749 )   (1,894,223 )

 

                 

FINANCING ACTIVITIES

                 

Issue of share capital, net of issuance costs

  8     -     1,682,015  

Cash provided by financing activities

        -     1,682,015  

 

                 

INVESTING ACTIVITIES

                 

Disposal of property and equipment

        -     1,804  

Decrease in restricted cash

        -     20,135  

 

                 

Cash provided by investing activities

        -     21,939  

 

                 

Net decrease in cash and cash equivalents during the year

(1,321,749 ) (190,269 )

 

                 

Cash and cash equivalents, beginning of year

        2,696,764     2,887,033  

 

                 

Cash and cash equivalents, end of year

        1,375,015     2,696,764  

 

                 

Cash and cash equivalents are comprised of

                 

Cash in bank and Guaranteed Investment Certificates

        1,375,015     2,696,764  

 

                 

Supplemental cash flow information

                 

Common share purchase warrants issued as agent’s compensation (note 8)

        -     91,636  

See accompanying notes to the consolidated financial statements

F-53



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

1.

Corporate information

Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) (the “Company” or “Trillium”) is a Canadian public company developing stem cell-based therapies for cell therapy and regenerative medicine from academic sources for the purpose of commercialization.

The Company was incorporated under the laws of the Province of Alberta on March 31, 2004 with nominal share capital. On October 19, 2004, the Company changed its name from Neurogenesis Biotech Corp. to Stem Cell Therapeutics Corp. On November 7, 2013, the Company filed Articles of Continuance to change its jurisdiction to Ontario. On June 1, 2014, the Company amalgamated with its wholly-owned subsidiary Trillium Therapeutics Inc. (“Trillium Privateco”) and changed its name to Trillium Therapeutics Inc.

The Company’s head office is located at MaRS Centre, Heritage Building, 101 College Street, Suite 200, Toronto, Ontario, M5G 1L7 and is listed on the TSX Venture Exchange under the symbol SSS.

2. Basis of presentation
   
(a)  Statement of compliance

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”).

The policies applied in these consolidated financial statements are based on IFRS issued and in effect as of April 29, 2013, the date the Board of Directors approved the statements.

(b)

Basis of measurement and going concern

These consolidated financial statements have been prepared on the historical cost basis, except for held-for-trading financial assets which are measured at fair value. These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Cell Therapeutics Inc. All intercompany transactions and balances are eliminated on consolidation.

These consolidated financial statements have been prepared using IFRS that are applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business for the foreseeable future. The Company has experienced operating losses and cash outflows from operations since incorporation, it will require ongoing financing in order to continue its research and development activities, and it has not earned significant revenue or reached successful commercialization of its products. The factors noted above indicate the existence of a material uncertainty that raise substantial doubt on the ability of the Company to continue as a going concern.

The Company's future operations are dependent upon its ability to finance its cash requirements which will allow it to continue its research and development activities and the commercialization of its products. There can be no assurance that the Company will be successful in continuing to finance its operations or for the Company to continue as a going concern.

These consolidated financial statements do not reflect adjustments in the carrying values of the Company’s assets and liabilities, expenses, and the balance sheet classification used, that would be necessary if the going concern assumption was not appropriate. Such adjustments could be material.

(c)

Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency.

(d)

Use of significant estimates and assumptions

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, revenue and expenses and the related disclosures of contingent assets and liabilities and the determination of the Company’s ability to continue as a going concern. Actual results could differ materially from these estimates and assumptions. The Company reviews its estimates and underlying assumptions on an ongoing basis. Revisions are recognized in the period in which the estimates are revised and may impact future periods.

Management has applied significant estimates and assumptions to the measurement of share-based compensation and warrants as well as estimates of the future cash flows for assessing the support of the going concern uncertainty.

Valuation of share-based compensation and warrants

Management measures the costs for share-based compensation and warrants using market-based option valuation techniques. Assumptions are made and estimates are used in applying the valuation techniques. These include estimating the future volatility of the share price, expected dividend yield, expected risk-free interest rate, future employee turnover rates, future exercise behaviours and corporate performance. Such estimates and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates of share-based payments and warrants. These assumptions are reviewed annually.

F-54



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

3.

Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

(a)

Basis of consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary Stem Cell Therapeutics Inc. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial statements of subsidiaries, including entities which the Company controls, are included in the consolidated financial statements from the date that control commences until the date that control ceases. The financial statements of the subsidiary are prepared for the same reporting period as the Company, using consistent accounting policies. All significant intercompany transactions and balances have been eliminated.

(b)

Foreign currency

Transactions in foreign currencies are translated to the functional currency at the rate on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the spot rate of exchange as at the reporting date. All differences are taken to profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rate at the date when the fair value was determined.

The functional currency of each entity is separately determined. The assets and liabilities of each entity are translated at the rate of exchange in effect at the year-end while revenue and expense items, including depreciation and amortization, are translated at the rates of exchange prevailing at the dates of the transactions. Foreign exchange gains and losses from the translation of such financial statements are deferred and recognized in other comprehensive income. On disposal of a foreign operation, the foreign currency translation reserve relating to that foreign operation is taken to profit or loss.

(c)

Financial instruments

Financial assets

A financial asset is classified at fair value through profit or loss if it is held for trading or is designated as such upon initial recognition. Attributable transaction costs are recognized in profit or loss as incurred. Financial assets at fair value through profit or loss are measured at fair value and changes therein are recognized in profit or loss. The Company has classified cash and cash equivalents as fair value through profit or loss.

Cash and cash equivalents
Cash and cash equivalents include cash on deposit and guaranteed investment certificates that can be redeemed at any time without penalty.

Loans and receivables
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus transaction costs and subsequently measured at amortized cost using the effective interest rate method less any impairment losses. The Company has classified its amounts receivable as loans and receivables.

Derecognition
A financial asset is derecognized when the rights to receive cash flows from the asset have expired or when the Company has transferred its rights to receive cash flows from the asset.

F-55



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

Financial liabilities

Financial liabilities are recognized initially at fair value plus any directly attributable transaction costs, and subsequently at amortized cost using the effective interest method. The Company has classified its accounts payable and accrued liabilities as financial liabilities.

Derecognition
A financial liability is derecognized when its contractual obligations are discharged or cancelled or expire.

Equity

Common shares and warrants to purchase common shares are classified as equity. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects.

(d)

Property and equipment

Recognition and measurement
Items of property and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes the expenditure that is directly attributable to the acquisition of the asset. When parts of an item of property and equipment have different useful lives, they are accounted for as separate items (major components) of property and equipment. Gains and losses on disposal of an item of property and equipment are determined by comparing the proceeds from disposal with the carrying amount of property and equipment, and are recognized in profit or loss.

Subsequent costs
The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property and equipment are recognized in profit or loss as incurred.

Depreciation
The estimated useful lives and the methods of depreciation for the current and comparative periods are as follows:

  Asset Basis
  Computer software Straight-line over 2 years
  Computer equipment Straight-line over 3 years
  Office equipment Straight-line over 5 years

Estimates for depreciation methods, useful lives and residual values are reviewed at each reporting period-end and adjusted if appropriate. Depreciation expense is recognized in research and development expenses.

(e)

Intangible assets

Research and development

Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred.

Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. No development costs have been capitalized to date.

Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.

F-56



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

Intangible assets

Intangible assets that are acquired separately and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognized in profit or loss as incurred.

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date they are available for use in the manner intended by management. The period that the Company’s technologies are available for use is estimated at ten years which reflects management's intent about developing and commercializing the assets.

The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in research and development expenses.

(f)

Impairment

Financial assets

A financial asset not carried at fair value through profit or loss is assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

An impairment test is performed, on an individual basis, for each material financial asset. Other individually non-material financial assets are tested as groups of financial assets with similar risk characteristics. Impairment losses are recognized in profit or loss.

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in net profit or loss and reflected in an allowance account against the respective financial asset. Interest on the impaired asset continues to be recognized through the unwinding of the discount. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss.

Non-financial assets

The carrying amounts of the Company's non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If such an indication exists, the recoverable amount is estimated.

The recoverable amount of an asset or a cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or cash-generating unit. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of cash inflows of other assets or cash-generating units. An impairment loss is recognized if the carrying amount of an asset or its related cash-generating unit exceeds its estimated recoverable amount. Impairment losses for intangible assets are recognized in research and development expenses.

Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

F-57



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

(g)

Provisions

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are assessed by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount on provisions is recognized in finance costs. No provisions have been recognized.

(h)

Government assistance

Government assistance relating to research and development is recorded as a reduction of expenses when the related expenditures are incurred.

(i)

Share-based compensation

The grant-date fair value of share-based payment awards granted to employees is recognized as personnel costs, with a corresponding increase in contributed surplus, over the period that the employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that met the related service and non-market performance conditions at the vesting date.

For equity-settled share-based payment transactions, the Company measures the goods or services received, and the corresponding increase in contributed surplus, directly, at the fair value of the goods or services received, unless that fair value cannot be estimated reliably. If the Company cannot estimate reliably the fair value of the goods or services received, it measures their value by reference to the fair value of the equity instruments granted. Transactions measured by reference to the fair value of the equity instruments granted have their fair values remeasured at each vesting and reporting date until fully vested.

(j)

Income taxes

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable income or loss.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax assets and liabilities, and they relate to income taxes levied by the same tax authority on the same taxable entity.

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences whey they reverse, based on the laws that have been enacted or substantively enacted at the reporting date. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized.

Investment tax credits earned from scientific research and development expenditures are recorded when collectability is reasonably assured.

(k)

Loss per share

Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the reporting period. Diluted loss per share is computed similar to basic loss per share except that the weighted average number of shares outstanding are increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the reporting period. The inclusion of the Company's stock options and warrants in the computation of diluted loss per share has an anti-dilutive effect on the loss per share and therefore, they have been excluded from the calculation of diluted loss per share.

F-58



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

New standards and interpretations not yet effective

IFRS 9 Financial Instruments

In November 2009, the IASB issued IFRS 9, which covers classification and measurement as the first part of its project to replace IAS 39. In October 2010, the IASB also incorporated new accounting requirements for liabilities. The standard introduces new requirements for measurement and eliminates the current classification of loans and receivables, available-for-sale and held-to-maturity, currently in IAS 39. There are new requirements for the accounting of financial liabilities as well as a carryover of requirements from IAS 39. The Company does not anticipate early adoption and will adopt the standard when it is mandated by the IASB, which is for annual periods beginning or after January 1, 2015. The Company is in the process of reviewing the standard to determine the impact on the consolidated financial statements.

IFRS 10 Consolidated Financial Statements

IFRS 10 requires an entity to consolidate an investee when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. IFRS 10 supersedes SIC-12 Consolidations – Special Purpose Entities and replaces parts of IAS 27 Consolidated and Separate Financial Statements . The effective date of this amendment is for annual periods beginning on or after January 1, 2013. The Company is in the process of reviewing the standards to determine the impact on the consolidated financial statements. IFRS 12 Disclosure of Interests in Other Entities IFRS 12 establishes disclosure requirements for interest in other entities such as subsidiaries, joint arrangements, associates and unconsolidated structured entities. The standard carries forward existing disclosures and also introduces significant additional disclosure requirements that address the nature of, and risks associated with, an entity’s interest in other entities. IFRS 12 replaces the previous disclosure requirements included in IAS 27 Consolidated and Separate Financial Statements , IAS 31 Joint Ventures and IAS 28 Investment in Associates . The effective date of this amendment is for annual periods beginning on or after January 1, 2013. The Company expects the adoption of this standard will not have a significant impact on the consolidated financial statements.

IFRS 13 Fair Value Measurement

IFRS 13 is a comprehensive standard for fair value measurement and disclosure requirements for use across all IFRS standards. IFRS 13 defines fair value and establishes disclosures about fair value measurement. The effective date of this amendment is for annual periods beginning on or after January 1, 2013. The Company expects the adoption of this standard will not have a significant impact on the consolidated financial statements.

Annual Improvements to IFRSs 2009-2011 Cycle – various standards

In May 2012, the IASB published Annual Improvements to IFRSs – 2009-2011 Cycle as part of its annual improvements process to make non-urgent but necessary amendments to IFRS. These amendments are effective for annual periods beginning on or after January 1, 2013 with retrospective application. The Company intends to adopt the amendments to the standards in its financial statements for the annual period beginning on January 1, 2013. The Company expects the adoption of the amendments will not have a significant impact on the consolidated financial statements.

4.

Amounts receivable


      December 31,     December 31,  
      2012     2011  
    $   $  
               
  Sales tax receivable   83,458     25,560  
  Other amounts receivable   77,750     16,054  
      161,208     41,614  

F-59



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

5.

Property and equipment


      Computer software     Office        
      and equipment     equipment     Total  
    $   $   $  
                     
  Cost                  
  Balance, December 31, 2010   156,510     33,889     190,399  
  Disposals   (1,804 )   -     (1,804 )
  Balance, December 31, 2011   154,706     33,889     188,595  
  Disposals   (141,206 )   (33,889 )   (175,095 )
  Balance, December 31, 2012   13,500     -     13,500  
  Accumulated depreciation                  
  Balance, December 31, 2010   138,292     33,428     171,720  
  Depreciation   12,032     461     12,493  
  Balance, December 31, 2011   150,324     33,889     184,213  
  Disposals   (141,206 )   (33,889 )   (175,095 )
  Depreciation   4,382     -     4,382  
  Balance, December 31, 2012   13,500     -     13,500  
  Net carrying amounts                  
  December 31, 2011   4,382     -     4,382  
  December 31, 2012   -     -     -  

During the first quarter of 2012, the Company closed its Calgary office and retired computer and office equipment that was fully depreciated in the amount of $175,095.

6.

Intangible assets


      Total  
    $  
         
  Cost      
  Balance, December 31, 2010, December 31, 2011 and December 31, 2012   2,431,279  
  Accumulated amortization      
  Balance, December 31, 2010   1,518,246  
  Amortization   243,117  
  Impairment   665,416  
  Balance, December 31, 2011   2,426,779  
  Amortization   2,000  
  Balance, December 31, 2012   2,428,779  
  Net carrying amounts      
  December 31, 2011   4,500  
  December 31, 2012   2,500  

As part of the ongoing review of the Company’s portfolio of intellectual property, an impairment loss was recognized in 2011 on acquired technology of $665,416. The impairment recognized certain applications no longer being pursued and certain patents with limited or no benefit within the Company’s current development plans and consequently determined to have no future value.

F-60



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

7.

Accounts payable and accrued liabilities


      December 31,     December 31,  
      2012     2011  
    $   $  
               
  Trade and other payables   55,548     115,268  
  Accrued liabilities   95,484     220,811  
  Due to related parties (note 14)   34,226     18,035  
      185,258     354,114  

8. Share capital
   
(a) Authorized

The authorized share capital of the Company consists of an unlimited number of common shares, Class B shares and First Preferred Shares, in each case without nominal or par value. Common shares are voting and may receive dividends as declared at the discretion of the directors. Class B shares are non-voting and convertible to common shares at the holder’s discretion, on a one-for-one basis. Upon dissolution or wind-up of the Company, Class B shares participate rateably with the common shares in the distribution of the Company’s assets. Preferred shares have voting rights as decided upon by the Board of Directors at the time of grant. Upon dissolution or wind-up of the Company, First Preferred Shares are entitled to priority over common and Class B shares.

(b)

Common shares issued – year ended December 31, 2011

On March 24, 2011, the Company completed a capital raise as part of a shelf prospectus supplement of 18,181,819 Units at a price of $0.11 per Unit, for aggregate gross proceeds to the Company of $2,000,000 ($1,580,379 net of issuance costs). Each Unit consisted of one common share and one-half common share purchase warrant ("Warrant"). Each whole Warrant entitles the holder to purchase one common share at a price of $0.16 per share at any time prior to expiry on March 24, 2014. In connection with the financing, the Company issued 1,272,727 Compensation Warrants having an aggregate fair value of $91,636 estimated using the Black-Scholes option pricing model. Each whole Compensation Warrant entitles the holder to acquire one common share at an exercise price of $0.11 per share prior to expiry on March 24, 2013.

The allocation of the $0.11 common share unit issue price to the common shares and Warrants was based on the relative fair values of the common shares and the Warrants. The fair value of the Warrants was determined using the Black-Scholes option pricing model. The common shares were allocated a price of $0.081 per share and the Warrants were allocated a price of $0.029 per Warrant. The costs of the issue were allocated on a pro rata basis to the common shares and Warrants. Accordingly, $1,163,734 was allocated to common shares and $416,645 to Warrants, net of issuance costs. Assumptions used to determine the value of the Warrants and the Compensation Warrants were: dividend yield of 0%; risk-free interest rate of 2.8%; expected volatility of 130%; and average expected life of 36 and 24 months, respectively.

The March 1, 2011 shelf prospectus provides that the Company may sell under the prospectus from time to time over the following 25 months up to $15 million, in one or more offerings, of common shares, warrants to purchase common shares, or units comprising common shares and warrants.

During the year ended December 31, 2011, 100,000 common shares were issued on the exercise of stock options for gross proceeds of $10,000. No stock options were exercised for the year ended December 31, 2012.

F-61



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

8. Share capital (continued)
   
(c) Weighted average number of common shares

The Company consolidated its common shares outstanding using a ratio of 10 – 1 and the Company’s common shares began trading on the TSX Venture Exchange on a post-consolidated basis on February 6, 2013. Accordingly, the weighted average number of common shares outstanding for the purposes of calculating earnings per share have been adjusted for 2012 and 2011 to the post-consolidated number. The post-consolidated weighted average number of common shares outstanding for the year ended December 31, 2012 was 18,661,936 (2011 – 18,247,938). The Company has not adjusted its weighted average number of common shares outstanding for the purpose of calculating the diluted loss per share as any adjustment related to stock options or warrants would be anti-dilutive.

(d)

Stock option plan

The Company has a 10% rolling stock option plan (the “Plan”) that was approved by the Company’s shareholders at its annual general meeting held on July 18, 2012. Pursuant to the Plan, the Company may grant stock options to purchase up to an aggregate of 10% of the Company’s issued and outstanding share capital. As at December 31, 2012, the Company was entitled to issue an additional pre-consolidated 11,661,936 stock options under the Plan.

Changes in the number of options outstanding on a pre-consolidated basis during the years ended December 31 were as follows:

            2012           2011  
                           
            Weighted           Weighted  
            average           average  
      Number of     exercise     Number of     exercise  
      options     price     options     price  
                           
  Balance, beginning of period   11,101,944   $  0.14     11,512,500   $  0.17  
  Granted   100,000     0.10     5,975,000     0.10  
  Exercised   -     -     (100,000 )   0.10  
  Cancelled/forfeited   (4,201,944 )   0.20     (6,285,556 )   0.17  
                           
  Balance, end of period   7,000,000   $  0.10     11,101,944   $  0.14  
                           
  Options exercisable, end of period   5,968,056   $  0.10     7,454,166   $  0.16  

The weighted average remaining contractual life for the stock options outstanding as at December 31, 2012 was 1.7 years (2011 - 2.1 years). The range of exercise prices for options outstanding as at December 31, 2012 was $0.10 to $0.17 (2011 - $0.10 to $0.58) .

Share-based compensation expense was determined based on the fair value of the options at the date of measurement using the Black-Scholes option pricing model with the weighted average assumptions for the year ended December 31 as follows:

    2012 2011
  Expected option life 5 years 3.1 years
  Risk-free interest rate 1.1% 1.7%
  Expected forfeiture rate 0% 10%
  Dividend yield 0% 0%
  Expected volatility 137% 140%

The Black-Scholes option pricing model used by the Company to calculate option values was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which significantly differs from the Company's stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and average option life, which significantly affect the calculated values.

F-62



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

8.

Share capital (continued)

The risk-free interest rate is based on the implied yield on a Government of Canada zero-coupon issue with a remaining term equal to the expected term of the option. The volatility is based solely on historical volatility equal to the expected life of the option. The life of the options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past. The forfeiture rate is an estimate based on historical evidence and future expectations. The dividend yield was excluded from the calculation since it is the present policy of the Company to retain all earnings to finance operations and future growth.

During the year ended December 31, 2012, the Company issued pre-consolidated 100,000 (2011 – pre-consolidated 5,975,000) stock options with a fair value of $2,300 (2011 – $312,725). The weighted average grant date fair value of the stock options granted during the year ended December 31, 2012 was $0.02 (2011 - $0.05) .

9.

Income taxes

The Company recognized no income taxes in the consolidated statements of loss and comprehensive loss, as it has been incurring losses since inception, and it is not probable that future taxable profits will be available against which the accumulated tax losses can be utilized.

(a)

Unrecognized deferred tax assets:

As at December 31, 2012 and 2011, deferred tax assets have not been recognized with respect to the following items:

      2012     2011  
               
  Non-capital losses carried forward $  6,130,941   $  5,635,613  
  Federal investment tax credits carryforward   947,496     943,172  
  Carrying value of property and equipment and intangible assets in excess of accounting basis 961,313 815,990
  Scientific research and experimental development expenditures   1,100,271     960,566  
  Share issue costs   53,975     68,181  
               
    $  9,193,996   $  8,423,522  

(b)

As at December 31, 2012, the company has available research and development expenditures for income tax purposes of approximately $4,152,000 (2011 - $4,007,000), which may be carried forward indefinitely to reduce future years’ taxable income.

   
(c)

As at December 31, 2012, the Company has accumulated non-capital losses for federal and provincial income tax purposes in Canada which are available for application against future taxable income. As at December 31, 2012, the Company also has unclaimed Canadian federal scientific research and development investment tax credits which are available to reduce future federal taxes payable. The benefit of these losses and investment tax credits has not been recorded in the accounts.

F-63



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

9.

Income taxes (continued)

The non-capital tax losses and investment tax credits expire as follows:

            Investment  
      Federal     tax credits  
    $   $  
               
  2014   1,004,000     72,000  
  2015   2,968,000     131,000  
  2026   3,320,000     87,000  
  2027   4,267,000     253,000  
  2028   3,993,000     305,000  
  2029   3,048,000     166,000  
  2030   2,690,000     134,000  
  2031   1,252,000     104,000  
  2032   593,000     35,000  
      23,135,000     1,287,000  

(d)

The reconciliation of the Canadian statutory income tax rate applied to the net loss for the year to the income tax recovery is as follows:


      2012     2011  
               
  Statutory income tax rate   26.5%     26.5%  
               
  Income tax recovery based on statutory income tax rate $  (281,298 ) $  (841,096 )
  Change in income tax rates   (431,758 )   29,406  
  Share-based compensation   9,429     89,128  
  Share issue costs   -     (81,997 )
  Investment tax credits   (23,188 )   (80,921 )
  Change in valuation allowance   726,815     885,480  
  Income tax recovery $  -   $  -  

F-64



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

10.

Research and development

Components of research and development expenses for the years ended December 31 were as follows:

      2012     2011  
    $   $  
               
  Research and development, excluding the below   418,479     703,828  
  Salaries, fees and short-term benefits   209,588     466,495  
  Termination costs   -     132,615  
  Share-based compensation   38,011     171,603  
  Amortization of intangible assets   2,000     243,117  
  Impairment of intangible assets   -     665,416  
  Depreciation of property and equipment   4,382     9,295  
  Investment tax credits   (48,912 )   (56,968 )
      623,548     2,335,401  

11.

General and Administrative

Components of general and administrative expenses for the years ended December 31 were as follows:

      2012     2011  
    $   $  
               
  General and administrative, excluding the below   269,849     343,861  
  Salaries, fees and short-term benefits   199,943     296,016  
  Termination costs   -     56,000  
  Share-based compensation   (3,505 )   161,555  
  Depreciation of property and equipment   -     3,198  
      466,287     860,630  

12.

Finance income and finance costs

Finance income for the years ended December 31 was as follows:

      2012     2011  
    $   $  
               
  Interest income   25,740     36,410  
  Net foreign currency gain   4,990     -  
      30,730     36,410  

Finance costs for the years ended December 31 were as follows:

      2012     2011  
    $   $  
               
  Bank charges   2,397     4,194  
  Net foreign currency loss   -     10,132  
      2,397     14,326  

F-65



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

13. Commitments and contingencies
   

(a)

Pursuant to a 2006 cross licensing agreement, the Company is obligated to pay an annual license maintenance fee of US$50,000 during the term of the agreement. The Company is also obligated to make future payments on the successful completion of a Phase II clinical trial and on commercialization of the referenced product.

   

(b)

Pursuant to a share purchase agreement with Transition Therapeutics Inc., royalty payments may become due and payable on realization of sales or licensing of certain patent rights. At December 31, 2012 royalty payments are not due and are not payable.

   
(c) The Company has an operating lease for premises with a future remaining commitment of $9,400 over the next 12 months.
   

(d)

The Company periodically enters into research and license agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken by or on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the consolidated financial statements with respect to these indemnification obligations.


14.

Related parties

For the year ended December 31, 2012 and 2011, the key management personnel of the Company were the Directors, the Executive Chairman, the Chief Executive Officer, the Chief Scientific Officer, and the Chief Financial Officer.

Compensation for key management personnel of the Company for the years ended December 31 was as follows:

      2012     2011  
    $   $  
               
  Salaries, fees and short-term benefits   396,400     459,470  
  Termination costs   -     136,000  
  Share-based compensation   55,272     311,880  
  Total   451,672     907,350  

Executive officers and directors participate in the stock option plan and certain officers participate in the Company’s health plan. Directors receive annual fees for their services. As at December 31, 2012, the key management personnel controlled approximately 11% of the voting shares of the Company.

During the year ended December 31, 2012, the Company incurred $nil (2011 - $30,000) in expenses for consulting services to a former director of the Company.

Outstanding balances with related parties at the year-end are unsecured, interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables.

15.

Operating segment

The Company has a single operating segment, the research and development of stem cell therapeutic technologies. Substantially all of the Company’s operations, assets, and employees are in Canada.

F-66



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

16.

Management of capital

The Company defines its capital as share capital, warrants and contributed surplus. The Company’s objectives when managing capital are to ensure there are sufficient funds available to carry out its research and development programs. To date, these programs have been funded primarily through the sale of equity securities and the conversion of common share purchase warrants. The Company also sources non-dilutive funding by accessing grants, government assistance and tax incentives, and through partnerships with corporations and research institutions. The Company uses budgets and purchasing controls to manage its costs.

The Company is not exposed to any externally imposed capital requirements.

17.

Financial instruments

Fair value

Certain of the Company’s accounting policies and disclosures require the determination of fair value for both financial and non-financial assets and liabilities. Financial instruments of the Company consist of cash and cash equivalents, amounts receivable and accounts payable and accrued liabilities. As at December 31, 2012, there were no significant differences between the carrying values of these amounts and their estimated fair values due to their short-term nature. The Company has classified its cash and cash equivalents as Level 1 as fair values are determined by quoted prices of identical assets in active markets.

Risks

The Company has exposure to credit risk, liquidity risk, interest rate risk and currency risk. The Company’s Board of Directors has overall responsibility for the establishment and oversight of the Company’s risk management framework. The Audit Committee of the Board is responsible to review the Company’s risk management policies.

(a)

Credit risk

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s cash and cash equivalents and amounts receivable. The carrying amount of these financial assets represents the maximum credit exposure. The Company follows an investment policy to mitigate against the deterioration of principal and to enhance the Company’s ability to meet its liquidity needs. Cash and cash equivalents are on deposit with a major Canadian chartered bank. Amounts receivable are primarily comprised of amounts due from the federal government.

(b)

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company is a development stage company and is reliant on external fundraising to support its operations. Once funds have been raised, the Company manages its liquidity risk by investing in cash and cash equivalents to provide regular cash flow for current operations. It also manages liquidity risk by continuously monitoring actual and projected cash flows [note 2(b)]. The Board of Directors reviews and approves the Company’s operating and capital budgets, as well as any material transactions not in the ordinary course of business. The majority of the Company’s accounts payable and accrued liabilities have maturities of less than three months.

(c)

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s cash and cash equivalents are highly liquid holdings in bank accounts or high interest savings accounts which have a variable rate of interest. The Company manages its interest rate risk by holding highly liquid short-term instruments and by holding its investments to maturity, where possible. For the year ended December 31, 2012, the Company earned interest income of $25,740 (2011 - $36,410). Therefore, a 1% change in the average interest rate for the year would have a net impact on finance income of $257.

F-67



TRILLIUM THERAPEUTICS INC.
(formerly STEM CELL THERAPEUTICS CORP.)
Notes to the Consolidated Financial Statements
December 31, 2012
Amounts in Canadian Dollars

(d)

Currency risk

The Company is exposed to currency risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. Currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the Canadian dollar which are primarily expenses in US dollars. The Company manages its exposure to currency fluctuations by holding cash and cash equivalents denominated in US dollars in amounts approximating current US dollar financial liabilities and US dollar planned expenditures. As at December 31, 2012, the Company held US dollar cash and cash equivalents in the amount of US$157,383 (2011 - US$5,353) and had US dollar denominated accounts payable in the amount of US$30,396 (2011 - US$90,192). Therefore, a 1% change in the foreign exchange rate would have a net impact on finance costs of $1,270 (2011 – $848).

US dollar expenses for the year ended December 31, 2012 were approximately US$532,000 (2011 – US$739,000). Varying the US exchange rate for the year to reflect a 5% strengthening of the Canadian dollar would have decreased the net loss by approximately $27,000 (2011 - $37,000) assuming that all other variables remained constant.

18.

Events after the balance sheet date

On February 6, 2013 the Company’s common shares began trading on the TSX Venture Exchange on a post-consolidation basis of a ratio of 1 common share for every 10 pre-consolidation common shares. The following events after the balance sheet date have been prepared on a post-share consolidation basis.

In March 2013, the Company completed a capital raise as part of a shelf prospectus supplement and a U.S. private placement for a total of 12,735,000 units at a price of $0.25 per unit, for aggregate gross proceeds to the Company of $3,185,080. Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.40 per share at any time prior to expiry on March 15, 2018 (12,315,000 warrants) and March 27, 2018 (420,000 warrants). In connection with the financing, the Company issued 814,050 compensation warrants entitling the holder to acquire one common share at an exercise price of $0.25 per share prior to expiry on March 16, 2015.

On April 9, 2013, the Company completed a merger with Trillium Privateco, a private biopharmaceutical company specializing in immune regulation and cytoprotection. As consideration, the Company paid $1,200,000 in cash and issued 6,079,181 common shares and 3,300,000 common share purchase warrants, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018.

On April 16, 2013 the Company signed a definitive license agreement with University Health Network (“UHN”) providing the Company with an exclusive world-wide license to an innovative cancer stem cell program. The initial consideration for the UHN license was satisfied by the issuance of 5,028,571 common shares and 1,600,000 common share purchase warrants, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018. Additional consideration under the UHN license includes an annual license maintenance fee and development milestones.

F-68


TRILLIUM THERAPEUTICS INC.
[A development stage company]


INTERIM FINANCIAL STATEMENTS


FOR THE NINE MONTHS ENDED
MARCH 31, 2013 AND 2012



(UNAUDITED)

96 Skyway Avenue,
Toronto, Ontario M9W 4Y9
www.trilliumtherapeutics.com

F-69



TRILLIUM THERAPEUTICS INC.
 
[A development stage company]
Incorporated under the laws of Ontario
 
Balance Sheets
 
[See note 1 – Basis of presentation]
Amounts in Canadian Dollars
(Unaudited)

As at            
             
    March 31,     June 30,  
    2013     2012  
     
             
ASSETS            
Current            
Cash and cash equivalents   633,845     118,953  
Marketable securities   630,486     1,807,471  
Accounts receivable   140,538     154,945  
Prepaid expenses   25,045     57,508  
Tax credits receivable   499,509     1,315,000  
Contract research deposits   8,333     15,974  
Total current assets   1,937,756     3,469,851  
Property and equipment, net [note 3]   115,681     139,820  
    2,053,437     3,609,671  
             
LIABILITIES AND SHAREHOLDERS' DEFICIENCY            
Current            
Accounts payable and accrued liabilities   198,581     203,186  
Deferred revenue       3,786  
Total current liabilities   198,581     206,972  
Loan payable [note 4]   530,154     292,363  
Convertible debentures [note 5]   10,000,000     9,710,122  
Interest payable [note 6]   5,014,337     22,650,198  
Preference share liability [note 6]   4     13,500,000  
Total liabilities   15,743,076     46,359,655  
             
Shareholders' deficiency            
Common shares [note 7]   15,139,864     1,639,868  
Stock-based compensation [note 8]   613,534     607,899  
Contributed surplus [notes 5, 6 and 9]   32,783,141     11,885,765  
Deficit   (62,226,178 )   (56,883,516 )
Total shareholders' deficiency   (13,689,639 )   (42,749,984 )
    2,053,437     3,609,671  

Commitments and contingencies [note 11]
Subsequent event [note 12]
Differences between Canadian and United States Generally Accepted Accounting Principles [note 13]


See accompanying notes to the interim financial statements

F-70



TRILLIUM THERAPEUTICS INC.
 
Statements of Operations and Deficit
 
 
Amounts in Canadian Dollars
(Unaudited)

    For the nine     For the nine  
    months ended     months ended  
    March 31,     March 31,  
    2013     2012  
     
             
REVENUES            
Licensing   3,786     11,359  
Contract        
Investment income   14,796     27,334  
    18,582     38,693  
             
EXPENSES            
Research and development, net [notes 2 and 11]   1,420,498     1,643,681  
General and administrative   307,034     148,569  
Interest accretion on convertible debentures   289,878     1,220,839  
Accrued interest on convertible debentures   1,293,190     1,102,919  
Interest accretion on preference share liability        
Accrued interest on preference share liability   1,968,325     2,094,872  
Sublicense   58,180     127,512  
Amortization   24,139     121,475  
    5,361,244     6,459,867  
Loss before income taxes   (5,342,662 )   (6,421,174 )
Provision for income taxes        
Net loss for the period   (5,342,662 )   (6,421,174 )
             
Deficit, beginning of period   (56,883,516 )   (48,418,833 )
Sale of technology rights in exchange for common shares        
Deficit, end of period   (62,226,178 )   (54,840,007 )

See accompanying notes to the interim financial statements

F-71



TRILLIUM THERAPEUTICS INC.
 
Statements of Cash Flows
 
Amounts in Canadian Dollars
(Unaudited)

    For the nine     For the nine  
    months ended     months ended  
    March 31,     March 31,  
    2013     2012  
     
             
OPERATING ACTIVITIES            
Net loss for the period   (5,342,662 )   (6,421,174 )
Add (deduct) items not affecting cash            
   Amortization of property and equipment   24,139     33,975  
   Amortization of technology rights       87,500  
   Amortization of deferred revenue   (3,786 )   (11,359 )
   Stock-based compensation   5,635     10,202  
   Interest accretion on convertible debentures   289,878     1,220,839  
   Accrued interest on convertible debentures   1,293,190     1,102,919  
   Interest accretion on preference share liability        
   Accrued interest on preference share liability   1,968,325     2,094,872  
   Write-down of technology rights        
   Loss on disposal of property and equipment        
   Gain on sale of marketable securities        
    (1,765,281 )   (1,882,226 )
Net change in non-cash working capital balances related to operations [note 10] 865,397 12,720
Cash used in operating activities   (899,884 )   (1,869,506 )
             
INVESTING ACTIVITIES            
Purchase of property and equipment       (11,149 )
Purchase of technology rights        
Purchase of marketable securities   (1,000,000 )   (1,500,000 )
Proceeds from sale of marketable securities   2,176,985     (6,684 )
Cash provided by (used in) investing activities   1,176,985     (1,517,833 )
             
FINANCING ACTIVITIES            
Issuance of common shares        
Issuance of convertible debentures, net of costs       1,993,634  
Issuance of Class A preference shares, net of costs        
Increase in loan payable   237,791     108,133  
Cash provided by financing activities   237,791     2,101,767  
             
Net increase (decrease) in cash and cash equivalents during the period 514,892 (1,285,572 )
Cash and cash equivalents, beginning of period   118,953     1,906,787  
Cash and cash equivalents, end of period   633,845     621,215  

See accompanying notes to the interim financial statements

F-72



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

1.

Corporate information and basis of presentation

Trillium Therapeutics Inc. ["Trillium" or the "Company"] is a privately held biotechnology company specializing in the discovery and development of innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, cancer and viral disease.

The Company has earned product licensing revenues as a result of agreements with development partners. Given the early stage of the technologies under these development agreements and risks associated with continued development of individual technologies in the biotechnology industry in general, the Company is considered to be in the development stage.

The success of the Company is dependent on completing product development and commercializing or entering into agreements with third parties to commercialize its products, and obtaining financing for its ongoing operations. It is not possible to predict either the commercial success of the Company's products or the Company's ability to fund these programs going forward. The Company incurred a net loss of $5,342,662 for the nine months ended March 31, 2013 and has a deficit of $62,226,178 as at March 31, 2013 and, without an additional source of funding, it will have inadequate funds to continue its existing operations for the coming year. These circumstances raise substantial doubt as to the ability of the Company to continue as a going concern. The Company's ability to continue as a going concern is dependent on receipt of additional convertible debenture financing, sourcing alternative financing or its ability to generate revenues from its products through licensing activities; however, there can be no assurance that these activities will be successful.

These financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. These financial statements do not include adjustments that would be necessary should the Company be unable to continue as a going concern.

2.

Significant accounting policies

These financial statements were prepared in accordance with Part II of the Canadian Institute of Chartered Accountants [“CICA”] Accounting Handbook - Accounting Standards for Private Enterprises, which sets out generally accepted accounting principles for non-publicly accountable enterprises in Canada [“Canadian GAAP”].

The Company's principal accounting policies were outlined in the Company’s annual audited financial statements for the year ended June 30, 2012 and have been applied consistently to all periods presented in these financial statements. The notes presented in these financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited financial statements. These statements should be read in conjunction with the annual audited financial statements for the year ended June 30, 2012.

Research and development costs

Research and development costs are charged to income as incurred, net of grants or related tax credits, unless they meet the criteria under Canadian GAAP for deferral and amortization. No development costs have been deferred to date.

The Company records investment tax credits when there is reasonable assurance that the assistance will be realized. Government assistance recognized as a credit to research and development costs for the nine months ended March 31, 2013 was $595,787 [2012 - $967,147].

F-73



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

3.

Property and equipment

Property and equipment consist of the following:

            March 31,                 June 30,        
            2013                 2012        
            Accumulated     Net           Accumulated     Net book  
      Cost     amortization     book value     Cost     amortization     value  
               
                                       
  Research equipment   865,203     762,557     102,646     865,203     744,282     120,921  
  Computer hardware and software 70,555 63,897 6,658 70,555 61,946 8,609
  Office equipment   38,574     33,871     4,703     38,574     33,034     5,540  
  Leasehold improvements   52,452     50,778     1,674     52,452     47,702     4,750  
      1,026,784     911,103     115,681     1,026,784     886,964     139,820  

During the year ended June 30, 2012, the Company revised its estimate of the remaining useful life of certain research equipment and computer hardware and recognized $40,977 of additional depreciation expense. The Company also wrote off $20,118 of research equipment and $50,754 of computer hardware which was fully depreciated and no longer in use.

4.

Loan payable

On February 1, 2012 the Company entered into a contribution agreement with the Federal Economic Development Agency for Southern Ontario where the Company can receive a repayable contribution of up to $965,000 to support the clinical development of its TTI-1612 program. The period of contribution is up to December 31, 2013. As at March 31, 2013, the Company has repayable contributions of $530,154 representing the outstanding principal balance, repayable in monthly installments of $16,083 for 60 months beginning on December 1, 2014. The loan payable bears no interest.

5.

Convertible debentures


      Amount  
     
  Balance at July 1, 2011   6,786,593  
  Debt portion of convertible debentures issued   1,293,712  
  Accreted interest   1,629,817  
  Balance at June 30, 2012   9,710,122  
  Accreted interest   289,878  
  Balance at March 31, 2013   10,000,000  

On September 15, 2011, the Company issued $2,000,000 of 12% convertible debentures with a maturity date of August 31, 2012 and received net proceeds of $1,993,634 after cash issue costs. The debentures plus accrued and unpaid interest are convertible at any time at the option of the holder, and under certain conditions, into Class A preference shares of the Company at the Class A Conversion Price, established by the Company's shareholders' agreement, divided by 1.5. Under the terms of the debentures subscription agreement, the Company issued 451,128 Class A preference share purchase warrants entitling the holders to purchase one Class A preference share at a price of $1.33 per share, subject to adjustment at any time up to September 16, 2016.

Consistent with CICA Handbook Part II Section 3856, the debentures were split into separate debt and equity components on the balance sheet. The fair value of the debt, initially determined to be $1,293,712 and described as "convertible debentures" on the balance sheet, has been estimated as the present value of future payments based on the Company's estimated incremental borrowing rates for similar debt agreements. The fair value of the equity portion of the debentures of $699,922 was included in contributed surplus and was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions for 2012: risk-free interest rate of 0.9%; dividend yield of 0%; expected volatility of 93%; and an expected life of 1.0 year. The warrants were issued for nominal consideration.

F-74



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

In the first quarter, the debenture holders unanimously extended the maturity date of all outstanding convertible debentures to October 31, 2013. Subsequent to March 31, 2013, Trillium merged with Stem Cell Therapeutics Corp. which does not intend to call the debentures in the next 12 months (see note 12).

6.

Preference share liability

The Company is authorized to issue an unlimited number of Class A preference shares. Based on the terms of these shares, the consideration received on their issuance was split into debt and equity components.

Continuity of issued preference shares

      Shares     Amount  
      #    
               
  Balance at June 30, 2011 and 2012   10,150,377     13,500,000  
  Converted to common shares   (10,150,374 )   (13,499,996 )
  Balance at March 31, 2013   3     4  

The equity component of the issued preference shares of $7,610,125 is included in contributed surplus.

The Class A preference shares are convertible into common shares at the Class A Conversion Price, initially at $1.33 per share, which is subject to adjustment. Each holder of a Class A preference share is entitled to vote for each common share into which the holder's Class A preference shares are convertible. Dividends on these shares are cumulative at 8% per annum.

The preference shareholders converted all but 3 preference shares to common shares on March 20, 2013. The undeclared and unpaid cumulative dividends on the Class A preference shares of $15,209,062 and the Part VI.1 tax liability on these dividends of $5,688,314 on March 20, 2013 was reversed and recognized as contributed surplus at the time of the conversion to common shares. This amount of cumulative dividends was described as "interest payable" on the balance sheet. Included in the "interest payable" balance as at March 31, 2013 is $nil [June 30, 2012 – 13,663,608] cumulative preference share dividends, the Part VI.1 tax liability on these dividends of $nil [June 30, 2012 - $5,265,443] and accrued interest on the Debentures of $5,014,337 [June 30, 2012 - $3,721,147].

Warrants

The Company issued Class A preference share purchase warrants in connection with its Class A preference share and convertible debentures financings. Each warrant is exercisable into one Class A preference share at a price of $1.33 per share, subject to adjustment. As at March 31, 2013, there were 5,300,752 [June 30, 2012 - 5,300,752] warrants issued and outstanding. All warrants issued to purchase Class A preference shares were issued for nominal consideration and all warrants expire on September 16, 2016.

F-75



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

7.

Share capital

Authorized
The Company is authorized to issue an unlimited number of common shares and an unlimited number of Class A preference shares [note 6] .

Continuity of issued common shares

      Shares     Amount  
      #    
               
  Balance at June 30, 2011 and 2012   6,116,667     1,639,868  
  Issued on conversion of Class A Preference shares [note 6]   10,150,374     13,499,996  
               
  Balance at March 31, 2013   16,267,041     15,139,864  

8.

Stock-based compensation

Under the Company's stock option plan enacted April 10, 2003, options may be granted to directors, officers, employees and consultants of the Company to purchase up to 2,429,129 common shares. Options are granted at the fair market value of the common shares on the date of grant. Options vest at various rates and have a term not exceeding 10 years.

For the nine months ended March 31, 2013 no options were granted, cancelled or expired. For the nine months ended March 31, 2012, 20,000 stock options were granted with an exercise price of $0.43 and a fair value of $0.38. For the nine months ended March 31, 2013 the Company recorded stock-based compensation expense of $5,635 (2012 - $10,202).

At March 31, 2013, there were 2,236,673 (June 30, 2012 – 2,236,673) stock options outstanding with a weighted average exercise price of $0.76, and 2,204,280 (June 30, 2012 – 2,173,339) stock options exercisable with a weighted average exercise price of $0.77.

9.

Contributed surplus


      Amount  
     
  Balance at June 30, 2011   11,185,843  
  Equity portion of convertible debentures issued [note 5]   699,922  
  Balance at June 30, 2012   11,885,765  
  Recognized on conversion of Class A Preference shares [note 6]   20,897,376  
  Balance at March 31, 2013   32,783,141  

F-76



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

10.

Statements of cash flows

The net change in non-cash working capital balances related to operations consists of the following:

      2013     2012  
       
               
  Decrease (increase) in current assets            
  Accounts receivable   14,407     (82,397 )
  Prepaid expenses   32,463     (51,822 )
  Tax credits receivable   815,491     355,000  
  Contract research deposits   7,641     47,294  
      870,002     268,075  
               
  Increase (decrease) in current liabilities            
  Accounts payable and accrued liabilities   (4,605 )   (255,355 )
      (4,605 )   (255,355 )
      865,397     12,720  

11. Commitments and contingencies
     

[a]

The Company enters into research, development and license agreements with various parties in the ordinary course of business whereby the Company receives research services and rights to proprietary technologies. The agreements require compensation to be paid by the Company, typically by a combination of the following methods:

     

[i]

Fees comprising amounts due initially upon entering into the agreements as well as additional amounts due either on specified timelines or defined services to be provided.

     

[ii]

Milestone payments that are dependent on products developed under the agreements proceeding towards specified plans of clinical trials and commercial development.

     

[iii]

Royalty payments calculated as a percentage of net sales commencing upon commercial sales of any product candidates developed from the technologies.

As at March 31, 2013, the Company has commitments under agreements to fund research, pre-clinical studies and manufacturing in the amount of $57,000 over the next year [June 30, 2012 - $497,000]. Included in these commitments is $nil [June 30, 2012 - $100,000] to the University Health Network [“UHN”] which is a shareholder. During the nine months ended March 31, 2013, the Company incurred $75,000 [2012 - $233,334] in expenses to shareholders for research and scientific advisory services and license fees which were recorded at the agreed upon exchange amount.

Milestone and royalty-related amounts that may become due under various agreements are dependent on, among other factors, pre-clinical safety and efficacy, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which are uncertain. Amounts due per the various agreements for milestone payments will be accrued once the occurrence of a milestone is likely. Amounts due as royalty payments will be accrued as commercial revenues from the product are earned.

  [i]

On February 1, 2010, the Company entered into a license agreement with UHN and The Hospital For Sick Children to acquire intellectual property relating to the methods and compounds for the modulation of the SIRP±-CD47 interaction for use in therapeutic cancer applications. The Company paid an up-front license fee of $150,000 and committed to pay annual maintenance fees of $25,000 in addition to patent issuance, development and regulatory milestones, and royalties on commercial sales. As at March 31, 2013, no future contingent consideration had been paid. These technology rights have been fully amortized.

F-77



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

  [ii]

On March 26, 2008, the Company entered into a license agreement with the University of Maryland, Baltimore ["UMB"] wherein UMB granted the Company an exclusive license and non-exclusive license under the UMB patent rights and a non-exclusive sublicense under the Children's Medical Center Corporation ["CMCC"] patent rights related to the Company's TTI-1612 technology.

     
 

The Company has a commitment to pay U.S.$10,000 in annual maintenance fees and there is future contingent consideration in the form of milestone payments of up to $760,000, and royalties. During the year ended June 30, 2012, the Company paid a $25,000 milestone fee to UMB on the initiation of its Phase I trial for TTI-1612. As at March 31, 2013, no other future contingent consideration had been paid. These technology rights have been fully amortized.


[b]

The Company's future commitments under operating leases for premises and equipment are $27,500 for 2013.

   
[c]

The Company enters into license agreements with third parties that include indemnification provisions in the ordinary course of business that are customary in the industry. Those guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of third-party claims or damages arising from these transactions. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions is unlimited. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount that it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the accompanying financial statements with respect to these indemnification obligations.


12.

Subsequent event

On April 9, 2013, the Company was merged into Stem Cell Therapeutics Corp. (“SCT”) by way of an amalgamation with a newly-created SCT subsidiary. On closing of the transaction, the security holders of Trillium received an aggregate consideration of $2,850,000 comprised of $1.2 million in cash and $1.65 million in SCT common shares.

13.

Differences between Canadian and United States Generally Accepted Accounting Principles

The financial statements have been prepared in accordance with Canadian GAAP, which differ in certain respects from those principles that the Company would have followed if its financial statements had been prepared in accordance with generally accepted accounting principles in the United States (US GAAP).

F-78



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

13.

Differences between Canadian and United States Generally Accepted Accounting Principles (continued)

A reconciliation of net earnings from Canadian GAAP to conform with US GAAP is as follows:

            March 31,     March 31,  
      Note     2013     2012  
             
                     
  Net loss for the period based on Canadian GAAP         (5,342,662 )   (6,421,174 )
  Acquired research and development   B     -     87,500  
  Preference shares – accrued dividends   C     1,545,454     1,496,337  
  Preference shares – part VI.1 tax (interest expense)   C     422,871     -  
  Preference shares – income tax recovery   C     5,265,443     -  
  Convertible debentures – accreted interest expense   D     289,878     1,220,839  
  Convertible debentures – issue costs   D     (13,043 )   (22,769 )
  Net income (loss) and comprehensive income (loss) for the period based on US GAAP 2,167,941 (3,639,267 )

A reconciliation of shareholders’ deficiency from Canadian GAAP to conform with US GAAP is as follows:

            March 31,     June 30,  
      Note     2013     2012  
             
                     
  Shareholders’ deficiency based on Canadian GAAP         (13,689,639 )   (42,749,984 )
  Preference shares – accreted interest   C     7,610,125     7,610,125  
  Preference shares – equity component   C     (7,610,125 )   (7,610,125 )
  Convertible debentures – accreted interest   D     4,480,421     4,190,543  
  Convertible debentures – equity component   D     (4,275,640 )   (4,275,640 )
  Convertible debentures – issue costs   D     7,134     20,178  
  Shareholders’ deficiency based on US GAAP         (13,477,724 )   (42,814,903 )

Reconciling items

A) Government assistance – investment tax credits

Under Canadian GAAP, the Company records investment tax credits arising from research and development activities on a net basis against costs to which they relate. Under US GAAP, the Company recognizes investment tax credits as a reduction of tax expense. Accordingly, to reconcile to US GAAP, research and development costs would increase and income tax recovery would increase for the nine months ended March 31, 2013 and 2012 by $595,787 and $967,147, respectively. Since both adjustments are on the statement of operations and deficit, there is no impact on net loss.

B) Acquired research and development

Under Canadian GAAP, the Company capitalized acquired research and development assets on the balance sheet as technology rights and amortized these assets over their estimated useful lives. Under US GAAP, these research and development assets are expensed at the time of acquisition because they do not have alternative uses. Accordingly, the amount of technology rights would be nil as at March 31, 2013 and June 30, 2012 and the amortization reflected in the statement of operations and deficit for the nine months ended March 31, 2013 and 2012 would be lower by $0 and $87,500, respectively.

F-79



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

13.

Differences between Canadian and United States Generally Accepted Accounting Principles (continued)

C) Preference shares

Under Canadian GAAP, the preference shares are initially bifurcated into debt and equity components. Interest is accreted on the debt component up to the original subscription amount of the shares and both accrued cumulative dividends and Part IV.1 tax are recognized as interest expense and included in interest payable. Since the shares have reached their redemption date, they are recorded at their original subscription amount in the financial statements. Upon conversion, the pro rata share of the debt component was reclassified to common shares and the pro rata share of the accrued cumulative dividends and related Part IV.1 tax was reclassified to contributed surplus. Under US GAAP, the preference shares are classified as temporary equity and adjusted to their maximum redemption amount each balance sheet date once they become redeemable. Accrued cumulative dividends are recorded as a charge to equity and included in temporary equity and Part VI.1 tax is recognized as income tax expense and included in taxes payable. Upon conversion, the pro rata share of the amount recorded in temporary equity is reclassified to common shares and the cumulative Part VI.1 tax payable is reversed as an income tax recovery.

To reconcile to US GAAP as at and for the nine-months ended March 31, 2013 (a) the $4 recorded as the preference share liability under Canadian GAAP (which is equal to the shares’ maximum redemption amount) is reclassified to temporary equity, (b) the $7,610,125 set up in contributed surplus on the original bifurcation under Canadian GAAP is deducted from shareholders’ deficiency and $7,610,125 of cumulative accreted interest included in the deficit is added back to shareholders’ deficiency, (c) the $15,209,062 of accrued cumulative dividends classified as contributed surplus under Canadian GAAP is reclassified to common shares and the $1,545,454 of accrued cumulative dividends recognized as interest expense is added back to net loss, and (d) the $5,688,314 of Part VI.1 tax liability classified as contributed surplus under Canadian GAAP is reclassified to the deficit, the $422,871 of Part VI.1 tax recognized as interest expense is reversed and $5,265,443 of income tax recovery is recorded.

To reconcile to US GAAP as at June 30, 2012 and for the nine-months ended March 31, 2012 (a) the $13,500,000 recorded as a non-current liability under Canadian GAAP (which is currently equal to the shares’ maximum redemption amount) is reclassified to temporary equity, (b) the $7,610,125 set up in contributed surplus on the original bifurcation under Canadian GAAP is deducted from shareholders’ deficiency and $7,610,125 of cumulative accreted interest included in the deficit is added back to shareholders’ deficiency, (c) the $13,663,608 of accrued cumulative dividends classified as interest payable under Canadian GAAP is reclassified to temporary equity under US GAAP and the $1,496,337 of accrued cumulative dividends recognized as interest expense is added back to net loss, and (d) the $5,265,443 of Part VI.1 tax liability classified as interest payable under Canadian GAAP is reclassified to taxes payable and the $598,535 of Part VI.1 tax recognized as interest expense is reclassified to income tax expense.

Preference share subscribers also received warrants exercisable into preference shares. Under Canadian GAAP, the Company did not account for the warrants in the financial statements as it was determined that the fair value of the warrants at the time of issuance is nominal. Under US GAAP, the warrants are classified as a liability and carried at fair value, both initially and on an on-going basis. Consistent with Canadian GAAP, the Company determined the initial fair value of the warrants to be nominal. The Company also determined that the fair value of the warrants has remained nominal since the time of issuance, resulting in no measurement difference between Canadian and US GAAP.

D) Convertible debentures

Under Canadian GAAP, the convertible debentures are initially bifurcated into debt and equity components and interest is accreted on the debt component up to its face amount of the shares. Under US GAAP, the convertible debenture is classified as debt and carried at amortized cost. Accordingly, to reconcile to US GAAP, accreted interest expense recorded of $4,480,421 and $4,190,543 as at March 31, 2013 and June 30, 2012, respectively, must be added back to shareholders’ deficiency and the amount set up in equity on the original bifurcation of the convertible debt under Canadian GAAP needs to be deducted from shareholders’ deficiency and added to the convertible debt liability in the amounts of $4,275,640 and $4,275,640 as at March 31, 2013 and June 30, 2012, respectively.

F-80



TRILLIUM THERAPEUTICS INC.
 
Notes to the Financial Statements
March 31, 2013
 
Amounts in Canadian Dollars
(Unaudited)

13.

Differences between Canadian and United States Generally Accepted Accounting Principles (continued)

Similarly, accreted interest expense recorded under Canadian GAAP would need to be added back to the net loss under US GAAP in the amounts of $289,878 and $1,220,839 for the nine months ended March 31, 2013 and 2012, respectively.

There is also a balance sheet classification difference related to the costs incurred to issue the convertible debt. Under Canadian GAAP the costs were allocated to the debt and equity components on initial bifurcation and only the portion allocated to the debt component was subsequently amortized, whereas US GAAP requires all of the costs to be set up as a separate asset and amortized. Accordingly, the issue costs allocated to equity under Canadian GAAP are amortized under US GAAP, resulting in a decrease in net income of $13,043 and $22,769 for the nine months ended March 31, 2013 and 2012, respectively. Additionally, the total balance of unamortized issue costs is reclassified to deferred financing costs, including the unamortized portion of the issue costs allocated to equity under Canadian GAAP in the amounts of $7,134 and 20,178 as at March 31, 2013 and June 30, 2012, respectively.

Convertible debt subscribers also received warrants exercisable into preference shares. Under Canadian GAAP, the Company did not account for the warrants in the financial statements as it was determined that the fair value of the warrants at the time of issuance is nominal. Under US GAAP, the warrants are classified as a liability and carried at fair value, both initially and on an on-going basis. Consistent with Canadian GAAP, the Company determined the initial fair value of the warrants to be nominal. The Company also determined that the fair value of the warrants has remained nominal since the time of issuance, resulting in no measurement difference between Canadian and US GAAP

Cash flow

In addition to the differences between Canadian and US GAAP related to the recognition and measurement of transactions by the Company, there are differences in the manner in which items are classified in the statement of cash flows. These classification differences have no impact on cash used in operating, investing and financing activities.

F-81


Financial Statements

Trillium Therapeutics Inc.
[A development stage company]
June 30, 2012

F-82


REPORT OF INDEPENDENT AUDITORS

To the Directors of
Trillium Therapeutics Inc.

We have audited the accompanying financial statements of Trillium Therapeutics Inc. , which comprise the balance sheets as of June 30, 2012 and 2011, and July 1, 2010, and the related statements of operations and deficit and cash flows for the years ended June 30, 2012 and 2011. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Trillium Therapeutics Inc. at June 30, 2012 and 2011, and July 1, 2010, and the results of its operations and its cash flows for the years ended June 30, 2012 and 2011 in conformity with Canadian accounting standards for private enterprises.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company incurred a net loss of $8,464,683 during the year ended June 30, 2012 and, as at that date the Company has a deficit of $56,883,516. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters also are described in Note 1. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

  /s/ Ernst & Young LLP
Toronto, Canada, Chartered Accountants
September 27, 2012, except as to note 16, which is as of August 11, 2014. Licensed Public Accountants

F-83



Trillium Therapeutics Inc.
[A development stage company]
Incorporated under the laws of Ontario

BALANCE SHEETS
[See note 1 - Basis of Presentation]

As at

                 

 

                 

 

  June 30,     June 30,     July 1,  

 

  2012     2011     2010  

 

$   $   $  

 

                 

ASSETS

                 

Current

                 

Cash and cash equivalents

  118,953     1,906,787     1,527,621  

Marketable securities [note 2]

  1,807,471     400,148     400,148  

Accounts receivable

  154,945     67,680     67,070  

Prepaid expenses

  57,508     33,325     38,703  

Tax credits receivable

  1,315,000     1,275,000     970,000  

Contract research deposits

  15,974     66,068     33,333  

Total current assets

  3,469,851     3,749,008     3,036,875  

Property and equipment, net [note 3]

  139,820     216,213     267,439  

Technology rights, net [note 4]

      87,500     249,811  

 

  3,609,671     4,052,721     3,554,125  

 

                 

LIABILITIES AND SHAREHOLDERS' DEFICIENCY

           

Current

                 

Accounts payable and accrued liabilities

  203,186     427,228     239,809  

Deferred revenue

  3,786     15,145     269,993  

Total current liabilities

  206,972     442,373     509,802  

Deferred revenue

      3,786     29,208  

Loan payable [note 5]

  292,363          

Convertible debentures [note 6]

  9,710,122     6,786,593     3,861,425  

Interest payable [note 7]

  22,650,198     18,319,309     14,693,493  

Preference share liability [note 7]

  13,500,000     13,500,000     13,500,000  

Total liabilities

  46,359,655     39,052,061     32,593,928  

 

                 

Shareholders' deficiency

                 

Share capital [note 8]

  1,639,868     1,639,868     1,639,868  

Stock-based compensation [note 9]

  607,899     593,782     566,368  

Contributed surplus [notes 6, 7 and 10]

  11,885,765     11,185,843     9,851,922  

Deficit

  (56,883,516 )   (48,418,833 )   (41,097,961 )

Total shareholders' deficiency

  (42,749,984 )   (34,999,340 )   (29,039,803 )

 

  3,609,671     4,052,721     3,554,125  

Commitments and contingencies [notes 4 and 13]
Subsequent event [note 15]
Differences between Canadian and United States Generally Accepted Accounting Principles [note 16]
See accompanying notes

On behalf of the Board:

Director _______________________ Director __________________________

F-84


Trillium Therapeutics Inc.
[A development stage company]

STATEMENTS OF OPERATIONS AND DEFICIT

Year ended June 30

 

  2012     2011  

 

$   $  

 

           

REVENUES

           

Licensing

  15,145     280,270  

Contract

      10,092  

Investment income

  38,902     29,751  

 

  54,047     320,113  

 

           

EXPENSES

           

Research and development, net [notes 2 and 13]

  2,042,205     2,194,408  

General and administrative

  213,265     207,163  

Interest accretion on convertible debentures

  1,629,817     1,311,257  

Accrued interest on convertible debentures

  1,507,278     1,018,768  

Interest accretion on preference share liability

       

Accrued interest on preference share liability

  2,823,611     2,607,048  

Sublicense [note 13[a]]

  127,512     83,114  

Amortization

  175,042     219,227  

 

  8,518,730     7,640,985  

Loss before income taxes

  (8,464,683 )   (7,320,872 )

Provision for income taxes

       

Net loss for the period

  (8,464,683 )   (7,320,872 )

 

           

Deficit, beginning of period

  (48,418,833 )   (41,097,961 )

Sale of technology rights in exchange for common shares

       

Deficit, end of period

  (56,883,516 )   (48,418,833 )

See accompanying notes

F-85


Trillium Therapeutics Inc.
[A development stage company]

STATEMENTS OF CASH FLOWS

Year ended June 30

 

  2012     2011  

 

$   $  

 

           

OPERATING ACTIVITIES

           

Net loss for the period

  (8,464,683 )   (7,320,872 )

Add (deduct) items not affecting cash

           

   Amortization of property and equipment

  87,542     56,916  

   Amortization of technology rights

  87,500     162,311  

   Amortization of deferred revenue

  (3,786 )   (25,422 )

   Stock-based compensation [note 9]

  14,117     27,414  

   Interest accretion on convertible debentures

  1,629,817     1,311,257  

   Accrued interest on convertible debentures

  1,507,278     1,018,768  

   Interest accretion on preference share liability

       

   Accrued interest on preference share liability

  2,823,611     2,607,048  

   Write-down of technology rights

       

   Loss on disposal of property and equipment

       

   Gain on sale of marketable securities

  (1,500 )    

 

  (2,320,104 )   (2,162,580 )

Net change in non-cash working capital balances related to operations [note 12]

  (336,755 )   (400,396 )

Cash used in operating activities

  (2,656,859 )   (2,562,976 )

 

           

INVESTING ACTIVITIES

           

Purchase of property and equipment

  (11,149 )   (5,690 )

Purchase of technology rights

       

Purchase of marketable securities

  (1,500,000 )   (400,000 )

Proceeds from sale of marketable securities

  94,177     400,000  

Cash used in investing activities

  (1,416,972 )   (5,690 )

 

           

FINANCING ACTIVITIES

           

Issuance of common shares

       

Issuance of convertible debentures, net of costs

  1,993,634     2,947,832  

Issuance of Class A preference shares, net of costs

       

Increase in loan payable

  292,363      

Cash provided by financing activities

  2,285,997     2,947,832  

 

           

Net increase (decrease) in cash and cash equivalents during the year

  (1,787,834 )   379,166  

Cash and cash equivalents, beginning of year

  1,906,787     1,527,621  

Cash and cash equivalents, end of year

  118,953     1,906,787  

See accompanying notes

F-86


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

1. BASIS OF PRESENTATION

Trillium Therapeutics Inc. ["Trillium" or the "Company"] is a privately held biotechnology company specializing in the discovery and development of innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, cancer and viral disease.

The Company has earned product licensing revenues as a result of agreements with development partners. Given the early stage of the technologies under these development agreements and risks associated with continued development of individual technologies in the biotechnology industry in general, the Company is considered to be in the development stage.

The success of the Company is dependent on completing product development and commercializing or entering into agreements with third parties to commercialize its products, and obtaining financing for its ongoing operations. It is not possible to predict either the commercial success of the Company's products or the Company's ability to fund these programs going forward. The Company incurred a loss of $8,464,683 for the year ended June 30, 2012 and has a deficit of $56,883,516 as at June 30, 2012 and, without an additional source of funding, it will have inadequate funds to continue its existing operations for the coming year. These circumstances raise substantial doubt as to the ability of the Company to continue as a going concern. The Company's ability to continue as a going concern is dependent on receipt of additional convertible debenture financing, sourcing alternative financing or its ability to generate revenues from its products through licensing activities; however, there can be no assurance that these activities will be successful.

These financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. These financial statements do not include adjustments that would be necessary should the Company be unable to continue as a going concern.

F-87


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND FIRST-TIME ADOPTION OF ACCOUNTING STANDARDS FOR PRIVATE ENTERPRISES

These financial statements were prepared in accordance with Part II of the Canadian Institute of Chartered Accountants ["CICA"] Accounting Handbook − Accounting Standards for Private Enterprises ["Part II"], which sets out generally accepted accounting principles for non-publicly accountable enterprises in Canada ["Canadian GAAP"] and include the significant accounting policies described hereafter:

Use of estimates

The preparation of financial statements in conformity with Canadian GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates include tax credits receivable, the valuation allowance for future income tax assets, and the fair values used to account for equity and convertible debt transactions including stock-based compensation expense, and the fair values determined in connection with acquiring technology rights. Actual results could differ from those estimates.

Cash equivalents, marketable securities and investment income

Trillium invests in high-quality government and corporate issuers with low credit risk. Cash equivalents consist of highly liquid investments with a maturity of 90 days or less at the time of purchase.

Marketable securities consist of fixed income securities with a maturity date beyond 90 days from the date of purchase and are recorded at their accreted value as they are held-to-maturity instruments. The estimated market value of marketable securities as at June 30, 2012 was $1,813,471 [2011 - $402,148]. Investment income includes interest income on marketable securities. Interest income is accrued as earned.

F-88


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

Property and equipment

Property and equipment are recorded at cost less accumulated amortization. Amortization is provided at rates that are expected to charge operations with the cost of the assets over their estimated useful lives as follows:

Research and office equipment 20% declining balance
Computer hardware 30% declining balance
Computer software 100% declining balance
Leasehold improvements Straight-line over lease term

Each year, the Company assesses its property and equipment to determine if there has been an impairment in their value. There is an impairment loss when the carrying value of an asset exceeds the sum of the undiscounted cash flow expected from this asset. An impairment loss is measured as the amount by which the carrying amount of the asset exceeds its fair value.

Technology rights

At the time of acquisition of intangible assets, the Company makes an assessment to determine if they have an estimated useful life or whether they have an indefinite life. The Company has determined that the technology rights have finite lives and, accordingly, they are being amortized over their estimated useful lives, from two to four years, on a straight-line basis.

The Company annually reviews the carrying value of the technology rights for evidence of facts or changes in circumstance that might indicate a condition of impairment. An impairment loss would be recognized when estimates of undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than the carrying amount. An impairment loss is measured as the amount by which the carrying amount of the asset exceeds its fair value.

Revenue recognition

Research and development funding and license fees

Non-refundable, up-front fees received for access to the Company's proprietary technology are deferred and recognized as revenue on a systematic basis over the term of the research collaboration with the development partner. Research and development funding is recognized as an offset to research and development expenses on a systematic basis over the term of the research collaboration. Contingent revenue attributable to the achievement of development milestones is recognized only on the achievement of the applicable milestone, consideration to be received is fixed or determinable, and collectability is reasonably assured.

F-89


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

Contract revenue

The Company recognizes revenue from research and development contracts as expenses are incurred. Funding received for services to be rendered in the future is reflected as deferred revenue.

Research and development costs

Research and development costs are charged to income as incurred, net of grants or related tax credits, unless they meet the criteria under Canadian GAAP for deferral and amortization. No development costs have been deferred to date.

The Company records investment tax credits when there is reasonable assurance that the assistance will be realized. Government assistance recognized as a credit to research and development costs for the year ended June 30, 2012 was $1,362,147 [2011 - $1,371,702].

Foreign currency translation

Transactions denominated in foreign currencies have been translated into Canadian dollars at the average rates of exchange prevailing at the time of the respective transactions. Monetary assets and liabilities have been translated into Canadian dollars at the year-end exchange rate. All gains and losses are included in the statement of operations and deficit.

Income taxes

Income taxes are recorded using the asset and liability method whereby future tax assets and liabilities are recorded based on the differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the substantively enacted tax rates and laws expected to be in effect when the differences are expected to reverse. A valuation allowance is recorded for the portion of the future tax assets where the realization of any value is uncertain.

Stock-based compensation

The Company uses the fair value method of accounting for stock options granted to employees and non-employees. The Company incorporates an expected volatility assumption in fair valuing stock options awarded to employees which is expensed over the vesting period and for non-employees is expensed as the services are received.

F-90


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

B. FIRST-TIME ADOPTION OF ACCOUNTING STANDARDS FOR PRIVATE ENTERPRISES

These financial statements are the first financial statements which the Company has prepared in accordance with Part II of the CICA Handbook – Accounting Standards for Private Enterprises, which constitutes generally accepted accounting principles for non-publicly accountable enterprises in Canada. In preparing its opening balance sheet as at July 1, 2010, the Company has applied Section 1500, First-time Adoption, retrospectively using the following four principles such that it has:

  • Recognized all assets and liabilities whose recognition is required by GAAP;
  • Not recognized items as assets or liabilities if GAAP does not permit such recognition;
  • Reclassified items recognized previously as one type of asset, liability or component of equity, but are now recognized as a different type of asset, liability or component of equity; and
  • Applied GAAP in measuring all recognized assets and liabilities.

The accounting policies that the Company has used in the preparation of its opening balance sheet through application of these principles has not resulted in adjustments to balances which were presented in the balance sheet prepared in accordance with Part V of the CICA Handbook - Accounting XFI ["Previous GAAP"].

Section 1500 provides a number of elective exemptions from the retrospective adoption of GAAP. The Company did not elect to use any of the transitional exemptions.

There are no reconciling items for the deficit as at July 1, 2010 and net loss for the year ended June 30, 2011 and the deficit as presented under Previous GAAP with those computed under GAAP.

F-91


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

3. PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

 

                                      July 1,  

 

  June 30, 2012     June 30, 2011     2010  

 

              Net                 Net     Net  

 

        Accumulated     book           Accumulated     book     book  

 

  Cost     amortization     value     Cost     amortization     value     value  

 

$   $   $   $   $   $   $  

 

                                         

Research equipment

  865,203     744,282     120,921     877,633     686,317     191,316     234,550  

Computer hardware and software

  70,555     61,946     8,609     117,848     107,001     10,847     13,546  

Office equipment

  38,574     33,034     5,540     38,574     31,649     6,925     8,656  

Leasehold improvements

  52,452     47,702     4,750     52,452     45,327     7,125     10,687  

 

  1,026,784     886,964     139,820     1,086,507     870,294     216,213     267,439  

During 2012, the Company revised its estimate of the remaining useful life of certain research equipment and computer hardware and recognized $40,977 of additional amortization expense. The Company also wrote off $20,118 of research equipment and $50,754 of computer hardware which was fully amortized and no longer in use. The write-downs have been included in amortization expense on the statements of operations and deficit.

4. TECHNOLOGY RIGHTS

Technology rights consist of the following:

    June 30,     June 30,     July 1,  
    2012     2011     2010  
  $   $   $  
                   
Cost   2,469,062     2,469,062     2,469,062  
Less accumulated amortization   2,469,062     2,381,562     2,219,251  
        87,500     249,811  

F-92


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

[a]

On February 1, 2010, the Company entered into two separate license agreements with the University Health Network and The Hospital For Sick Children to acquire intellectual property relating to the methods and compounds for the modulation of the SIRPα-CD47 interaction for use in human hematopoietic stem cell transplantation and therapeutic cancer applications. The Company paid two up-front license fees of $150,000 and committed to pay annual maintenance fees of $25,000 under each agreement in addition to patent issuance, development and regulatory milestones, and royalties on commercial sales. As at June 30, 2012, no future contingent consideration [note 13[a]] had been paid. These technology rights have been fully amortized.

   
[b]

On March 26, 2008, the Company entered into a license agreement with the University of Maryland, Baltimore ["UMB"] wherein UMB granted the Company an exclusive license and non-exclusive license under the UMB patent rights and a non-exclusive sublicense under the Children's Medical Center Corporation patent rights related to the Company's TTI-1612 technology.

   

The Company has a commitment to pay U.S.$10,000 in annual maintenance fees and there is future contingent consideration in the form of milestone payments and royalties. During the year ended June 30, 2012, the Company paid a $25,000 milestone fee to UMB on the initiation of its Phase I trial for TTI-1612. As at June 30, 2012, no other future contingent consideration [note 13[a]] had been paid. These technology rights have been fully amortized.

   
[c]

In December 2005, the Company acquired an exclusive worldwide license from the Children's Hospital, Inc., Columbus, Ohio to a patent application entitled "Methods of Treating Intestinal Ischemia Using Heparin-Binding Epidermal Growth Factor" [TTI-1612]. The Company has a commitment to pay annual license fees in the range of U.S.$12,500 to U.S.$22,500 during the terms of the agreements and paid U.S.$22,500 in fiscal 2012 and 2011. In addition, there is future contingent consideration in the form of milestone payments and royalties that may be paid by the Company in relation to clinical trial enrollment, regulatory filings and commercial sales. As at June 30, 2012, no future contingent consideration [note 13[a]] had been paid. These technology rights have been fully amortized.

5. LOAN PAYABLE

On February 1, 2012, the Company entered into a contribution agreement with the Federal Economic Development Agency for Southern Ontario where the Company can receive a repayable contribution of up to $965,000 to support the clinical development of its TTI-1612 program. The period of contribution is up to December 31, 2013. As at June 30, 2012, the Company has repayable contributions of $292,363 representing the outstanding principal balance, repayable in monthly installments of $16,083 for 60 months beginning on December 1, 2014. The loan payable bears no interest.

F-93


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

6. CONVERTIBLE DEBENTURES

Continuity of convertible debentures

    Amount  
  $  
       
Balance at July 1, 2010   3,861,425  
Debt portion of convertible debentures issued   1,613,911  
Accreted interest   1,311,257  
Balance at June 30, 2011   6,786,593  
Debt portion of convertible debentures issued   1,293,712  
Accreted interest   1,629,817  
Balance at June 30, 2012   9,710,122  

On September 15, 2011, the Company issued $2,000,000 of 12% convertible debentures with a maturity date of August 31, 2012 and received net proceeds of $1,993,634 after cash issue costs. The debentures plus accrued and unpaid interest are convertible at any time at the option of the holder, and under certain conditions, into Class A preference shares of the Company at the Class A Conversion Price, established by the Company's shareholders' agreement, divided by 1.5. Under the terms of the debentures subscription agreement, the Company issued 451,128 Class A preference share purchase warrants entitling the holders to purchase one Class A preference share at a price of $1.33 per share, subject to adjustment at any time up to September 16, 2016.

In three separate transactions in fiscal 2011, the Company issued an aggregate of $3,000,000 of 12% convertible debentures with a maturity date of August 31, 2012 and received net proceeds of $2,947,832 after cash issue costs. Under the terms of the debentures subscription agreement, the Company issued 676,692 Class A preference share purchase warrants entitling the holders to purchase one Class A preference share at a price of $1.33 per share, subject to adjustment at any time up to September 16, 2016.

Consistent with CICA Handbook Part II Section 3856, the debentures were split into separate debt and equity components on the balance sheet. The fair value of the debt, initially determined to be $1,293,712 [2011 - $1,613,911] and described as "convertible debentures" on the balance sheet, has been estimated as the present value of future payments based on the Company's estimated incremental borrowing rates for similar debt agreements. The fair value of the equity portion of the debentures of $699,922 [2011 - $1,333,921] was included in contributed surplus and was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions: risk-free interest rate of 0.9% [2011 - 1.5%]; dividend yield of 0% [2011 - 0%]; expected volatility of 93% [2011 - 90%]; and an expected life of 1.0 year [2011 - 1.8 years]. The warrants were issued for nominal consideration.

F-94


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

Subsequent to June 30, 2012, the debenture holders unanimously extended the maturity date of all outstanding convertible debentures to August 31, 2013.

7. PREFERENCE SHARE LIABILITY

The Company is authorized to issue an unlimited number of Class A preference shares. Based on the terms of these shares, the consideration received on their issuance was split into debt and equity components.

Continuity of issued preference shares

    Shares     Amount  
    #   $  
             
Balance at July 1, 2010, June 30, 2011 and 2012   10,150,377     13,500,000  

The equity component of the issued preference shares of $7,610,125 is included in contributed surplus.

The Class A preference shares are convertible into common shares at the Class A Conversion Price, initially at $1.33 per share, which is subject to adjustment. Each holder of a Class A preference share is entitled to vote for each common share into which the holder's Class A preference shares are convertible. Dividends on these shares are cumulative at 8% per annum. The cumulative dividends on the Class A preference shares amount to $13,663,608 [2011 - $11,646,743; July 1, 2010 - $9,784,566], none of which has been paid as at June 30, 2012. This amount of cumulative dividends is described as "interest payable" on the balance sheet. Also included in the "interest payable" balance is the Part VI.1 tax liability on these dividends of $5,265,443 [2011 - $4,458,697; July 1, 2010 - $3,713,826] and accrued interest on the debentures of $3,721,147 [2011 - $2,213,869; July 1, 2010 - $1,195,101]. All warrants issued to purchase Class A preference shares were issued for nominal consideration.

The Class A preference shares are redeemable at the option of the holder five years after issue if holders of at least 67% of the then outstanding Class A preference shares request the Company to redeem, at which time all Class A preference shares shall be redeemed at the greater of the original purchase price plus any cumulative dividends and the fair market value of the shares. The Class A preference shareholders do not intend to redeem these shares in the next 12 months.

F-95


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

Upon the closing of a qualified public offering, immediately prior to a qualified acquisition, or upon the approval of holders of 67% of the then outstanding Class A preference shares, all outstanding Class A preference shares shall automatically be converted into common shares.

Warrants

The Company issued Class A preference share purchase warrants in connection with its Class A preference share and convertible debenture financings. Each warrant is exercisable into one Class A preference share at a price of $1.33 per share, subject to adjustment. As at June 30, 2012, there were 5,300,752 [2011 - 4,849,624] warrants issued and outstanding. All warrants expire on September 16, 2016.

8. SHARE CAPITAL Authorized

The Company is authorized to issue an unlimited number of common shares and an unlimited number of Class A preference shares [note 7] .

Continuity of issued common shares

    Shares     Amount  
    #   $  
             
Balance at July 1, 2010, June 30, 2011 and 2012   6,116,667     1,639,868  

9. STOCK-BASED COMPENSATION

[a]

Stock options

   

Under the Company's stock option plan enacted April 10, 2003, options may be granted to directors, officers, employees and consultants of the Company to purchase up to 2,429,129 common shares. Options are granted at the fair market value of the common shares on the date of grant. Options vest at various rates and have a term not exceeding 10 years.

   

The Company issued 20,000 [2011 - 20,000] options with an exercise price of $0.43 [2011 - $0.43] per common share during the year ended June 30, 2012. During the year, 20,000 [2011 - nil] options with an exercise price of $0.62 expired.

F-96


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

The following table summarizes information about stock options outstanding as at June 30, 2012:

      Options outstanding           Options exercisable  
            Weighted     Weighted           Weighted  
            average     average           average  
  Exercise   Options     remaining     exercise     Options     exercise  
  price   outstanding     contractual life     price     exercisable     price  
  $   #     [years]   $     #   $  
                                 
  0.43   165,000     7.51     0.43     101,666     0.43  
  0.77   1,332,673     1.08     0.77     1,332,673     0.77  
  0.83   739,000     4.48     0.83     739,000     0.83  
      2,236,673     2.68     0.76     2,173,339     0.77  

[b]

Stock-based compensation

   

During the year ended June 30, 2012, the Company issued options with a fair value of $7,500 [2011 - $7,440] and recorded stock-based compensation expense of $14,117 [2011 - $27,414]. The fair value of the options granted was estimated using the Black-Scholes option pricing model with the following assumptions:


      2012     2011  
      %     %  
               
  Risk-free interest rate   2.1     3.4  
  Dividend yield   0.0     0.0  
  Expected volatility   93     89  
  Expected life of options   10 years     10 years  

F-97


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

10. CONTRIBUTED SURPLUS

Continuity of contributed surplus

    Amount  
  $  
       
Balance at July 1, 2010   9,851,922  
Equity portion of convertible debentures issued [note 6]   1,333,921  
Balance at June 30, 2011   11,185,843  
Equity portion of convertible debentures issued [note 6]   699,922  
Balance at June 30, 2012   11,885,765  

11. INCOME TAXES

Income tax recoveries attributable to losses from operations differ from the amounts computed by applying the combined Canadian federal and provincial income tax rates to pre-tax losses from operations primarily as a result of the provision of a valuation allowance on net future income tax benefits.

Significant components of future tax assets are as follows:

 

  June 30,     June 30,     July 1,  

 

  2012     2011     2010  

 

$   $   $  

 

                 

Future tax assets

                 

Non-capital losses carried forward

  6,898,398     5,641,887     4,809,126  

Research and development expenditures

  2,752,162     2,330,572     2,012,133  

Investment tax credits

  485,532     364,020     296,811  

Carrying value of property and equipment and technology rights in excess of accounting basis

  1,000,626     861,135     769,062  

Ontario harmonization tax credit

  501,594     501,594     561,786  

Convertible debenture interest not deducted for tax

  986,358     553,591     298,842  

Debt issuance costs

  17,395     25,058     21,937  

License fees deductible for tax purposes [previously taxed]

  1,107     5,538     87,535  

Total future tax assets

  12,643,172     10,283,395     8,857,232  

Valuation allowance

  (12,643,172 )   (10,283,395 )   (8,857,232 )

Net future tax assets

           

F-98


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

The Company has available $10,385,000 of federal research and development expenditures for income tax purposes, which may be carried forward indefinitely to reduce future years' taxable income, and $10,235,000 of federal non-capital losses available to reduce future years' taxable income that expire from 2027 to 2032.

The Company also has accumulated unclaimed scientific research and experimental development investment tax credits which can be used to offset future years' taxable income. The investment tax credits expire as follows:

   
       
2020   32,911  
2021   223  
2022   7,893  
2023   8,819  
2024   43,049  
2025   81,560  
2026   62,285  
2027   107,947  
2028   52,234  
2029   17,460  
2030   5,053  
2031   1,147  
2032   2,248  
    422,829  

F-99


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

12. STATEMENTS OF CASH FLOWS

The net change in non-cash working capital balances related to operations consists of the following:

    2012     2011  
  $   $  
             
Decrease (increase) in current assets            
Accounts receivable   (87,265 )   (610 )
Prepaid expenses   (24,183 )   5,378  
Tax credits receivable   (40,000 )   (305,000 )
Contract research deposits   50,094     (32,735 )
    (101,354 )   (332,967 )
             
Increase (decrease) in current liabilities            
Accounts payable and accrued liabilities   (224,042 )   187,419  
Deferred revenue   (11,359 )   (254,848 )
    (235,401 )   (67,429 )
    (336,755 )   (400,396 )

13. COMMITMENTS AND CONTINGENCIES

[a]

The Company enters into research, development and license agreements with various parties in the ordinary course of business whereby the Company receives research services and rights to proprietary technologies [note 4] . The agreements require compensation to be paid by the Company, typically by a combination of the following methods:


  [i]

Fees comprising amounts due initially upon entering into the agreements as well as additional amounts due either on specified timelines or defined services to be provided.

     
  [ii]

Milestone payments that are dependent on products developed under the agreements proceeding towards specified plans of clinical trials and commercial development.

     
  [iii]

Royalty payments calculated as a percentage of net sales commencing upon commercial sales of any product candidates developed from the technologies.

During the year ended June 30, 2012, the Company made sublicense payments under the above agreements in the amount of $127,512 [2011 - $83,114].

F-100


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

As at June 30, 2012, the Company has commitments under agreements to fund research, pre-clinical studies and manufacturing in the amount of $497,211 over the next year [2011 - $1,105,601]. During the year ended June 30, 2012, the Company incurred $250,000 [2011 - $400,000] in expenses to shareholders for research and scientific advisory services and license fees which were recorded at the agreed-upon exchange amount.

   

Milestone and royalty-related amounts that may become due under various agreements are dependent on, among other factors, pre-clinical safety and efficacy, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which are uncertain. Amounts due per the various agreements for milestone payments will be accrued once the occurrence of a milestone is likely. Amounts due as royalty payments will be accrued as commercial revenues from the product are earned.

   
[b]

The Company's future minimum annual commitments under operating leases for premises and equipment are as follows:


    $  
  2013   69,416  

[c]

The Company enters into license agreements with third parties that include indemnification provisions in the ordinary course of business that are customary in the industry. Those guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of third-party claims or damages arising from these transactions. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions is unlimited. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount that it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the accompanying financial statements with respect to these indemnification obligations.

14. FINANCIAL INSTRUMENTS

Financial instruments of the Company consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued liabilities, and loan payable. As at June 30, 2012, there was no significant difference between the carrying values of the cash and cash equivalents, marketable securities, accounts receivable, and accounts payable and accrued liabilities and their estimated fair values due to their short-term nature. The fair value of the loan payable approximates its carrying value as it is non-interest bearing, consistent with loans of this nature. The Company manages its cash and cash equivalents and marketable securities in

F-101


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

accordance with an investment policy that establishes guidelines for investment eligibility, credit quality, liquidity and foreign currency exposure.

[a]

Credit risk

   

Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company manages its exposure to credit risk by placing its cash with major financial institutions and investing in high-quality government and corporate issuers with low credit risk. Cash and cash equivalents held by the Company are not subject to any external restrictions.

   
[b]

Liquidity risk

   

The Company's exposure to liquidity risk is dependent on purchasing obligations and the raising of funds to meet commitments and sustain operations. The Company is a development stage company and is reliant on external fundraising to support its operations [note 1] . Once funds have been raised, the Company manages its liquidity risk by investing in highly liquid corporate and government bonds with staggered or short-term maturities to provide regular cash flow for current operations. It also manages liquidity risk by monitoring actual and projected cash flows. The Board of Directors reviews and approves the Company's operating and capital budgets, as well as any material transactions not in the ordinary course of business. The majority of the Company's accounts payable and accrued liabilities have maturities of less than three months.

   
[c]

Market risk

   

Interest rate risk arises due to the Company's marketable securities bearing fixed interest rates, and foreign exchange risk arises on its holdings of U.S. dollar denominated cash and cash equivalents. The Company manages its interest rate risk by holding its investments to maturity, where possible. The Company manages its exposure to currency fluctuations by holding cash and cash equivalents denominated in U.S. dollars in amounts not exceeding current U.S. dollar financial liabilities and U.S. dollar planned expenditures. As at June 30, 2012, the Company held U.S. dollar cash and cash equivalents in the amount of $38,303.

15. SUBSEQUENT EVENT

Subsequent to June 30, 2012, the debenture holders unanimously extended the maturity date of all outstanding convertible debentures to August 31, 2013 [note 1] .

F-102


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

16. DIFFERENCES BETWEEN CANADIAN AND UNITED STATES GENERALLY ACCEPTED ACCOUNTING PRINCIPLES

The financial statements have been prepared in accordance with Canadian GAAP, which differ in certain respects from those principles that the Company would have followed if its financial statements had been prepared in accordance with generally accepted accounting principles in the United States (US GAAP).

A reconciliation of net earnings from Canadian GAAP to conform with US GAAP is as follows:

 

        June 30,     June 30,  

 

  Note     2012     2011  

 

      $   $  

 

                 

Net loss for the year based on Canadian GAAP

        (8,464,683 )   (7,320,872 )

Acquired research and development

  B     87,500     162,311  

Preference shares – accrued dividends

  C     2,016,865     1,862,177  
Convertible debentures – accreted interest expense   D     1,629,817     1,311,257  

Convertible debentures – issue costs

  D     (30,494 )   (21,062 )

 

                 

Net loss and comprehensive loss for the year based on US GAAP

    (4,760,995 )   (4,006,189 )

A reconciliation of shareholders’ deficiency from Canadian GAAP to conform with US GAAP is as follows:

 

        June 30,     June 30,     July 1,  

 

  Note     2012     2011     2010  

 

      $   $   $  

 

                       

Shareholders’ deficiency based on Canadian GAAP

    (42,749,984 )   (34,999,340 )   (29,039,803 )

Acquired research and development

  B     -     87,500     249,811  

Preference shares – accreted interest

  C     7,610,125     7,610,125     7,610,125  

Preference shares – equity component

  C     (7,610,125 )   (7,610,125 )   (7,610,125 )

Convertible debentures – accreted interest

  D     4,190,543     2,560,727     1,249,470  
Convertible debentures – equity component   D     (4,275,640 )   (3,575,719 )   (2,241,797 )

Convertible debentures – issue costs

  D     20,178     48,437     46,374  

 

                       

Shareholders’ deficiency based on US GAAP

        (42,814,903 )   (35,878,395 )   (29,735,945 )

F-103


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

16. DIFFERENCES BETWEEN CANADIAN AND UNITED STATES GENERALLY ACCEPTED ACCOUNTING PRINCIPLES (continued)

Reconciling items

A) Government assistance – investment tax credits

Under Canadian GAAP, the Company records its investment tax credits arising from research and development activities on a net basis against costs to which they relate. Under US GAAP, the Company recognizes its investment tax credits as a reduction of tax expense. Accordingly, to reconcile to US GAAP, research and development costs would increase and income tax recovery would increase for the years ended June 30, 2012 and 2011 by $1,362,147 and $1,371,702, respectively. Since both adjustments are on the statement of operations and deficit, there is no impact on net loss.

B) Acquired research and development

Under Canadian GAAP, the technology rights of $0, $87,500 and $249,811 as at June 30, 2012, June 30, 2011 and July 1, 2010, respectively, are acquired research and development assets that have been capitalized on the balance sheet and are being amortized over their estimated useful lives. Under US GAAP, research and development assets acquired without alternative uses are expensed at the time of acquisition, and the amount of technology rights would be nil as at June 30, 2012, June 30, 2011 and July 1, 2010.

As a result of immediately expensing the acquired research and development under US GAAP, the amortization reflected in the statement of operations and deficit for the years ended June 30, 2012 and 2011 would be lower by $87,500 and $162,311, respectively.

F-104


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

16. DIFFERENCES BETWEEN CANADIAN AND UNITED STATES GENERALLY ACCEPTED ACCOUNTING PRINCIPLES (continued)

C) Preference shares

Under Canadian GAAP, the preference shares are initially bifurcated into debt and equity components. Interest is accreted on the debt component up to the original subscription amount of the shares and both accrued cumulative dividends and Part IV.1 tax are recognized as interest expense and included in interest payable. Since the shares have reached their redemption date, they are recorded at their original subscription amount in the financial statements. Under US GAAP, the preference shares are classified as temporary equity and adjusted to their maximum redemption amount each balance sheet date once they become redeemable. Accrued cumulative dividends are recorded as a charge to equity and included in temporary equity. Part VI.1 tax is recognized as income tax expense and included in taxes payable. Accordingly, to reconcile to US GAAP, (a) the $13,500,000 recorded as a non-current liability under Canadian GAAP as at June 30, 2012, June 30, 2011 and July 1, 2010 (which is currently equal to the shares’ maximum redemption amount) is reclassified to temporary equity, (b) $7,610,125 set up in contributed surplus on the original bifurcation under Canadian GAAP as at June 30, 2012, June 30, 2011 and July 1, 2010 is deducted from shareholders’ deficiency and $7,610,125 of cumulative accreted interest included in the deficit as at June 30, 2012, June 30, 2011 and July 1, 2010 is added back to shareholders’ deficiency, (c) the $13,663,608, $11,646,743, and $9,784,566 of accrued cumulative dividends classified as interest payable under Canadian GAAP is reclassified to temporary equity under US GAAP as at June 30, 2012, June 30, 2011 and July 1, 2010, respectively, and the $2,016,865 and $1,862,177 of accrued cumulative dividends recognized as interest expense for the years ended June 30, 2012 and 2011, respectively, is added back to net loss, and (d) the $5,265,443, $4,458,697, and $3,713,826 of Part VI.1 tax liability classified as interest payable under Canadian GAAP as at June 30, 2012, June 30, 2011 and July 1, 2010, respectively, is reclassified to taxes payable and the $806,746 and $744,871 of Part VI.1 tax recognized as interest expense for the years ended June 30, 2012 and 2011, respectively, is reclassified to income tax expense.

Preference share subscribers also received warrants exercisable into preference shares. Under Canadian GAAP, the Company did not account for the warrants in the financial statements as it was determined that the fair value of the warrants at the time of issuance is nominal. Under US GAAP, the warrants are classified as a liability and carried at the fair value both initially and on an on-going basis. Consistent with Canadian GAAP, the Company determined the initial fair value of the warrants to be nominal. The Company also determined the fair value of the warrants has remained nominal since the time of issuance resulting in no measurement difference between Canadian and US GAAP.

F-105


Trillium Therapeutics Inc.
[A development stage company]

NOTES TO FINANCIAL STATEMENTS

June 30, 2012

16. DIFFERENCES BETWEEN CANADIAN AND UNITED STATES GENERALLY ACCEPTED ACCOUNTING PRINCIPLES (continued)

D) Convertible debentures

Under Canadian GAAP, the convertible debentures are initially bifurcated into debt and equity components and interest is accreted on the debt component up to its face amount of the shares. Under US GAAP, the convertible debenture is classified as debt and carried at amortized cost. Accordingly, to reconcile to US GAAP, accreted interest expense recorded of $4,190,543, $2,560,727 and $1,249,470 as at June 30, 2012, June 30, 2011, and July 1, 2010, respectively, must be added back to shareholders’ deficiency and the amount set up in equity on the original bifurcation of the convertible debt under Canadian GAAP needs to be deducted from shareholders’ deficiency and added to the convertible debt liability in the amounts of $4,275,640, $3,575,719 and $2,241,797 as at June 30, 2012, June 30, 2011, and July 1, 2010, respectively.

Similarly, accreted interest expense recorded under Canadian GAAP would need to be added back to the net loss under US GAAP in the amounts of $1,629,817 and $1,311,257 for the years ended June 30, 2012 and 2011, respectively.

There is also a balance sheet classification difference related to the costs incurred to issue the convertible debt. Under Canadian GAAP the costs were allocated to the debt and equity components on initial bifurcation and only the portion allocated to the debt component was subsequently amortized, whereas US GAAP requires all of the costs to be set up as a separate asset and amortized. Accordingly, the issue costs allocated to equity under Canadian GAAP are amortized under US GAAP, resulting in a decrease in net income of $30,494 and $21,062 for the years ended June 30, 2012 and 2011, respectively. Additionally, the total balance of unamortized issue costs is reclassified to deferred financing costs, including the unamortized portion of the issue costs allocated to equity under Canadian GAAP in the amounts of $20,178, $48,437 and $46,374 as at June 30, 2012, June 30, 2011 and July 1, 2010, respectively.

Convertible debt subscribers also received warrants exercisable into preference shares. Under Canadian GAAP, the Company did not account for the warrants in the financial statements as it was determined that the fair value of the warrants at the time of issuance is nominal. Under US GAAP, the warrants are classified as a liability and carried at fair value, both initially and on an on-going basis. Consistent with Canadian GAAP, the Company determined the initial fair value of the warrants to be nominal. The Company also determined that the fair value of the warrants has remained nominal since the time of issuance, resulting in no measurement difference between Canadian and US GAAP

Cash flow

In addition to the differences between Canadian and US GAAP related to the recognition and measurement of transactions by the Company, there are differences in the manner in which items are classified in the statement of cash flows. These classification differences have no impact on cash used in operating, investing and financing activities.

F-106


20-F Pro Forma Financial Statements Rider

The following table sets forth Trillium Therapeutics Inc.’s (or “ Trillium ”, formerly Stem Cell Therapeutics Corp.) unaudited pro forma consolidated statement of loss and comprehensive loss for the year ended December 31, 2013 after giving effect to the acquisition of the private company Trillium Therapeutics Inc. (“ Trillium Privateco ”) as if it had occurred on January 1, 2013 rather than on April 9, 2013.

The unaudited pro forma consolidated statement of loss and comprehensive loss for the year ended December 31, 2013 is not necessarily indicative of the results of operations that would have occurred in the year ended December 31, 2013, had the acquisition been effective on the assumed date, or of the results of operations expected in 2014 and future years.

The unaudited pro forma consolidated statement of loss and comprehensive loss for the year ended December 31, 2013 has been derived from and should be read in conjunction with:

the description of the acquisition of Trillium Privateco contained under the heading “Item 4.A History and Development of the Company” of this registration statement;

   

Trillium’s audited annual consolidated financial statements for the year ended December 31, 2013 and 2012 (in the name of Stem Cell Therapeutics Corp.), which are included in this registration statement;

   

pro forma adjustments giving effect to the acquisition and the related assumptions as described in the notes to the pro forma consolidated statement of loss and comprehensive loss below.

The unaudited pro forma consolidated statement of loss and comprehensive loss has been prepared in accordance with International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standards Board (“ IASB ”) as described in the audited consolidated financial statements of Trillium for the year ended December 31, 2013 and 2012.

The financial statements of Trillium Privateco were prepared in accordance with Part II of the CICA Handbook - Accounting Standards for Private Enterprises (“ ASPE ”). These accounting policies were reviewed by management for conformity with IFRS. It was determined that there were measurement differences with respect to share-based compensation, however, as the Trillium Privateco stock options were cancelled at the time of the acquisition, there was no impact on conversion to IFRS on a consolidated basis.

The accounting policies used in the preparation of the unaudited pro forma consolidated statement of loss and comprehensive loss are those set out in the Trillium audited consolidated financial statements as at and for the year ended December 31, 2013.

F-107


Unaudited Pro Forma Consolidated Statement of Loss and Comprehensive Loss
For the year ended December 31, 2013
All amounts are expressed in Canadian dollars unless otherwise indicated.

Trillium
Consolidated
Year ended
December 31,
2013
$
Trillium
Privateco
Period from
January 1, 2013
To April 9,
2013
$
Pro forma
Adjustments
$
Note
 
Pro forma
Consolidated
Year ended
December
31, 2013
$
EXPENSES
Research and development
General and administrative

3,336,706
962,200

810,422
212,032

88,907
(68,835)

i,ii,iii
iii,iv

4,236,035
1,105,397
Operating expenses 4,298,906 1,022,454 20,072   5,341,432
Finance income
Finance costs
(54,028)
44,430
(5,895)
972,035
-
(970,442)

v
(59,923)
46,023
Net finance (income) costs (9,598) 966,140 (970,442)   (13,900)
Net loss and comprehensive loss 4,289,308 1,988,594 (950,370) 5,327,532
Basic and diluted loss per common shares (0.11) (0.13)

The unaudited pro forma consolidated statement of loss and comprehensive loss reflects the following adjustments as if the acquisition had occurred on January 1, 2013:

  (i)

On applying the acquisition method of accounting, the purchase consideration of $2,850,836 exceeded the net tangible assets acquired of Trillium Privateco in the amount of $1,018,037 which was attributed to the in-process research and development. Amortization has been recognized on a straight-line basis over the estimated useful lives of the intangible assets estimated at three years. For the pro forma consolidated statement of loss and comprehensive loss an additional 99 days of amortization have been reflected in research and development expenses for the period January 1, 2013 to April 9, 2013 in the amount of $92,042;

     
  (ii)

A reduction in the net book value of Trillium Privateco property and equipment to the estimated fair value of the assets of $91,000 at January 1, 2013 results in lower depreciation expense on Trillium Privateco assets of $2,844 and is reflected in research and development expenses;

     
  (iii)

On acquisition all previously issued stock options of Trillium Privateco were cancelled and accordingly the share-based compensation expenses recorded are deducted in the amount of $291 from research and development expenses and $1,585 from general and administrative expenses;

F-108



  (iv)

Legal costs in the amount of $67,250 related to the acquisition recorded in the Trillium Privateco statement of operations for the period from January 1, 2013 to April 9, 2013 were deducted from general and administrative expenses;

     
  (v)

On the elimination of the equity and debt securities of Trillium Privateco on consolidation, the interest on convertible debt and accrued dividends on the preference shares are eliminated for the period from January 1, 2013 to April 9, 2013 in the aggregate amount of $970,442;

     
  (vi)

Pro forma loss per share has been calculated using the weighted average number of shares that would have been outstanding for the year ended December 31, 2013, after giving effect to the acquisition as if it had occurred on January 1, 2013. The pro forma weighted average number of common shares outstanding is 42,340,086.

F-109


EXHIBIT INDEX

Exhibit    
Number   Description
     
1.1   Articles of Incorporation dated March 31, 2004
     
1.2   Articles of Amendment dated October 19, 2004
     
1.3   Articles of Amendment dated February 6, 2013
     
1.4  

Articles of Continuance dated November 7, 2013

     
1.5  

Articles of Amendment dated December 12, 2013

     
1.6  

Articles of Amalgamation dated June 1, 2014

     
1.7  

By-law No.1 of Trillium Therapeutics Inc. amended and restated as of May 27, 2014

     
2.1  

Rights Agreement between Trillium Therapeutics Inc. and Computershare Investor Services Inc. dated September 16, 2013 and amended on June 3, 2014 including the form of rights certificate

     
4.1  

Amended and restated License Agreement between Trillium Privateco, the University Health Network and The Hospital for Sick Children effective February 1, 2010 and amended June 1, 2012

     
4.2  

Debenture Purchase Agreement and Merger Agreement among Stem Cell Therapeutics Corp., Trillium Privateco, 2364556 Ontario Limited, and the Trillium Privateco debenture holders dated March 25, 2013

     
4.3*  

GPEx ® -Derived Cell Line Sale Agreement between Trillium Therapeutics Inc. and Catalent Pharma Solutions, LLC dated August 12, 2014 for TTI-621

     
4.4*  

GPEx ® -Derived Cell Line Sale Agreement between Trillium Therapeutics Inc. and Catalent Pharma Solutions, LLC dated August 12, 2014 for TTI-622

     
4.5  

2014 Stock Option Plan

     
4.6  

2014 Deferred Share Unit Plan

     
4.7  

Warrant Indenture between Stem Cell Therapeutics Corp. and Computershare Trust Company of Canada dated March 15, 2013

     
4.8  

Warrant Indenture between Stem Cell Therapeutics Corp. and Computershare Trust Company of Canada dated April 8, 2013

     
4.9  

Warrant Indenture between Stem Cell Therapeutics Corp. and Computershare Trust Company of Canada dated December 13, 2013

     
4.10  

Agency Agreement among Stem Cell Therapeutics Corp. and Bloom Burton & Co. Inc. and Roth Capital Partners, LLC dated December 13, 2013

     
15.1  

Consent of Ernst & Young LLP

     
15.2  

Consent of Ernst & Young LLP

* to be filed by amendment

103



Exhibit 1.1

CORPORATE ACCESS NUMBER: 2010999734

Alberta

BUSINESS CORPORATIONS ACT

CERTIFICATE

OF

INCORPORATION

NEUROGENESIS BIOTECH CORP.
WAS INCORPORATED IN ALBERTA ON 2004/03/31.


 


Articles Of Incorporation
Business Corporations Act
Section 6

1.

Name of Corporation

   

NEUROGENESIS BIOTECH CORP.


2.

The classes of shares, and any maximum number of shares that the corporation is authorized to issue:

   

The attached Schedule Re Authorized Shares is incorporated in this form.


3.

Restrictions on share transfers (if any):

   

N/A


4.

Number, or minimum and maximum number, of directors that the corporation may have:

Minimum: 3; Maximum: 10
The attached Schedule Re Number of Directors is incorporated in this form.

5.

If the corporation is restricted FROM carrying on a certain business or restricted TO carrying on a certain business, specify the restriction(s):

N/A

6.

Other provisions (if any):

The attached Schedule Re Other Provisions is incorporated in this form.

7.

Date authorized by Incorporators:

2004        03         30  
    Year / Month / Day  

Incorporators
Name of Person Authorizing (please print)
Andrew D. Grasby
Address: (Including postal code)
3300, 421 7 Avenue SW
Calgary, AB T2P 4K9
Signature    (signed) "Andrew D. Grasby "
of Person Authorizing (please print Address: (including postal code)
Signature

This information is being collected for the purposes of corporate registry records in accordance with the Business Corporations Act. Questions about the collection of this Information can be directed to the Freedom of Information and Protection of Privacy Coordinator for Alberta Registries, Research and Program Support, 3rd Floor, Commerce Place, 10155 — 102 Street, Edmonton, Alberta T5J 4L4, (780) 422-7330

yyy


SCHEDULE RE AUTHORIZED SHARES

The authorized capital of the Corporation shall consist of an unlimited number of Common shares, Class B shares, and First Preferred shares, in each case without nominal or par value. The rights, privileges, restrictions and conditions attaching to the said shares are as set out herein.

1.

The rights, privileges, restrictions and conditions attaching to the Common shares are as follows:

     
(a)

Voting Rights: The holders of the Common shares shall be entitled to receive notice of and to attend all annual and special meetings of the shareholders of the Corporation and to one vote in respect of each Common Share held at all such meetings.

     
(b)

Payment of Dividends: The holders of the Common shares shall be entitled to receive dividends if, as and when declared by the board of directors of the Corporation out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner as the board of directors may from time to time determine. Subject to the rights of the holders of any other class of shares of the Corporation entitled to receive dividends in priority to or concurrently with the holders of the Common shares, the board of directors may in its sole discretion declare dividends on the Common shares to the exclusion of any other class of shares of the Corporation.

     
(c)

Participation upon Liquidation, Dissolution or Winding Up: In the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Common shares shall, subject to the rights of the holders of any other class of shares of the Corporation entitled to receive assets of the Corporation upon such a distribution in priority to or concurrently with the holders of the Common shares, be entitled to participate in the distribution. Such distribution shall be made in equal amounts per share on all the Common shares at the time outstanding without preference or distinction.

     
2.

The rights, privileges, restrictions and conditions attaching to the Class B shares are as follows:

     
(a)

Voting Rights: The holders of the Class B shares shall be entitled to receive notice of and to attend any meeting of the shareholders of the Corporation but shall not be entitled to vote any of their Class B shares at any such meeting.

     
(b)

Participation upon Liquidation, Dissolution or Winding Up: In the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Class B shares shall, subject to the rights of the holders of any other class of shares of the Corporation entitled to receive assets of the Corporation upon such a distribution in priority to the Class B shares, be entitled to participate rateably with the Common shares in any distribution of the assets of the Corporation.



2

  (c)

Conversion At Holders' Option:

       
  (i)

Each issued and fully paid Class B share may at any time be converted, at the option of the holder, into one Common share. The conversion privilege herein provided for may be exercised by notice in writing given to the Corporation accompanied by a certificate or certificates representing the Class B shares in respect of which the holder thereof desires to exercise such right of conversion and such notice shall be signed by the person registered on the books of the Corporation as the holder of the Class B shares in respect of which such right is being exercised or by his duly authorized attorney and shall specify the number of Class B shares which the holder desires to have converted. The holder shall also pay any governmental or other tax imposed in respect of such transaction. Upon receipt of such notice the Corporation shall issue certificates representing fully paid Common shares upon the basis above prescribed and in accordance with the provisions hereof to the registered holder of the Class B shares represented by the certificate or certificates accompanying such notice. If less than all of the Class B shares represented by any certificate are to be converted, the holder shall be entitled to receive a new certificate for the Class B shares representing the shares comprised in the original certificates which are not to be converted.

       
  (ii)

Idem: All Common shares resulting from any conversion of issued and fully paid Class B shares into Common shares pursuant to clause 2(c)(i) hereof shall be deemed to be fully paid and non-assessable.

       
  (iii)

Idem: None of the Class B shares or the Common shares shall be subdivided, consolidated, reclassified or otherwise changed unless contemporaneously therewith the other said class of shares is subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner.


3.

The rights, privileges, restrictions and conditions attaching to the First Preferred Shares are as follows:

     
(a)

Series: The First Preferred Shares may at any time and from time to time be issued in one or more series. Subject to the provisions of clauses 3(b) and (c), the board of directors of the Corporation may from time to time before the issue thereof fix the number of shares in, and determine the designation, rights, privileges, restrictions and conditions attaching to the shares of, each series of First Preferred Shares.



- 3 -

  (b)

Idem: The First Preferred Shares shall be entitled to priority over the Common Shares and Class B Shares and all other shares ranking junior to the First Preferred Shares with respect to the payment of dividends and the distribution of assets of the Corporation in the event of any liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs.

     
  (c)

Idem: The First Preferred Shares of each series shall rank on a parity with the First Preferred Shares of every other series with respect to priority in the payment of dividends and in the distribution of assets of the Corporation in the event of any liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs



SCHEDULE RE NUMBER OF DIRECTORS

The board of directors shall consist of such number of directors, being a minimum of three directors and a maximum of ten directors, as may from time to time be determined by resolution of the board of directors.

 

 

 


SCHEDULE RE OTHER PROVISIONS

(a)

Subject to the foregoing, the directors may, between annual general meetings, appoint one or more additional directors of the Corporation to serve until the next annual general meeting but the number of additional directors shall not at any time exceed one-third (1/3) of the number of directors who held office at expiration of the last annual meeting.

   
(b)

In addition to anywhere in Alberta, the Corporation is permitted to hold shareholders meetings in any city or at any location in any of the other provisions forming part of Canada.

 

 

151895-342058
Alrearthv Titrault UP CAL DOGS #1401230 v. 1



Exhibit 1.2

CORPORATE ACCESS NUMBER: 2010999734

Alberta

BUSINESS CORPORATIONS ACT

CERTIFICATE

OF

AMENDMENT

NEUROGENESIS BIOTECH CORP.
CHANGED ITS NAME TO STEM CELL THERAPEUTICS CORP. ON 2004/10/19.


Articles Of Amendment

Business Corporations
Act Sections 29 or 177

1. Name of Corporation 2. Corporate Access
  Number
     NEUROGENESIS BIOTECH CORP.  
  2010999734

3. Item number 1 of the

Articles of the above named corporation is amended in accordance with
Section 173(1)(a) of the Business Corporations Act (Alberta) by deleting the name
"Neurogenesis Biotech Corp." therein and substituting therefor the name:

"STEM CELL THERAPEUTICS CORP."

FILED

McCarthy   Tetrault LLP

P e r :

President    
Title (please print)   October 7, 2004
    Date
JOSEPH E.L. TUCKER   (signed) "Joseph Tucker"
Name of Person Authorizing (please print)   Signature

 

 

This information is being collected for the purposes of corporate registry records in accordance with the Business Corporations Act. Questions about the collection of this Information can be directed to the Freedom of Information and Protection of Privacy Coordinator for Alberta Registries, Research and Program Support, 3rd Floor, Commerce Place, 10155 — 102 Street, Edmonton, Alberta T5J 4L4, (780) 422-7330

REG 5054 (99.91)


Name Change Alberta Corporation - Registration Statement

Service Request Number: 6573136  
Corporate Access Number: 2010999734
Legal Entity Name:   NEUROGENESIS BIOTECH CORP.
French Equivalent Name:  
Legal Entity Status:   Active

Alberta Corporation Type:   Named Alberta Corporation
New Legal Entity Name:   STEM CELL THERAPEUTICS CORP.
New French Equivalent Name:  
Nuans Number:   81484748
Nuans Date:   2004/10/05
French Nuans Number:  
French Nuans Date:  

Professional Endorsement Provided:
Future Dating Required:

Annual Return
No Records returned
 

Attachment

Attachment Type Microfilm Bar Date Recorded
Director Schedule ELECTRONIC 2004/03/31
Other Rules or Provisions ELECTRONIC 2004/03/31
Share Structure ELECTRONIC 2004/03/31

Registration Authorized By: ANDREW D. GRASSY
                                                    SOLICITOR


Name Change Alberta Corporation - Pre-Registration Confirmation Report

Service Request Number: 6573136  
Corporate Access Number: 2010999734
Legal Entity Name:   NEUROGENESIS BIOTECH CORP.
French Equivalent Name:  
Legal Entity Status:   Active

Alberta Corporation Type:   Named Alberta Corporation
New Legal Entity Name:   STEM CELL THERAPEUTICS CORP.
New French Equivalent Name:  
Nuans Number:   81484748
Nuans Date:   2004/10/05
French Nuans Number:  
French Nuans Date:  

Professional Endorsement Provided:
Future Dating Required:

Annual Return
No Records returned
 

Attachment

Attachment Type Microfilm Bar Code Date Recorded
Director Schedule ELECTRONIC 2004/03/31
Other Rules or Provisions ELECTRONIC 2004/03/31
Share Structure ELECTRONIC 2004/03/31

Registration Authorized By: ANDREW D. GRASBY
                                                   SOLICITOR

                                                                                                



Exhibit 1.3

CORPORATE ACCESS NUMBER: 2010999734

BUSINESS CORPORATIONS ACT

CERTIFICATE

OF

AMENDMENT

STEM CELL THERAPEUTICS CORP.
AMENDED ITS ARTICLES ON 2013/02/06.



Name/Structure Change Alberta Corporation - Registration Statement

Alberta Amendment Date: 2013/02/06

Service Request Number: 19201516
Corporate Access Number: 2010999734
Legal Entity Name: STEM CELL THERAPEUTICS CORP.
French Equivalent Name:  
Legal Entity Status: Active
   
Alberta Corporation Type: Named Alberta Corporation
New Legal Entity Name: STEM CELL THERAPEUTICS CORP.
New French Equivalent  
Name:  
Nuans Number: 81484748
Nuans Date: 2004/10/05
French Nuans Number:  
French Nuans Date:  
   
Share Structure: REFER TO THE ATTACHED SCHEDULE RE: AUTHORIZED
  SHARES FORMING PART OF THESE ARTICLES
Share Transfers NONE
Restrictions:  
Number of Directors:  
Min Number Of Directors: 3
Max Number Of Directors: 10
Business Restricted To: NONE
Business Restricted From: NONE
  REFER TO THE ATTACHED SCHEDULE RE: OTHER
Other Provisions: PROVISIONS FORMING PART OF THESE ARTICLES
BCA Section/Subsection: SECTION 173(1)(F)
   
Professional Endorsement  
Provided:  
Future Dating Required:  
 


Annual Return

File Year Date Filed
2012 2012/08/07
2011 2011/05/31
2010 2010/06/14

Attachment

Attachment Type Microfilm Bar Code Date Recorded
Director Schedule ELECTRONIC 2004/03/31
Other Rules or Provisions ELECTRONIC 2004/03/31
Share Structure ELECTRONIC 2004/03/31
Consolidation, Split, Exchange ELECTRONIC 2013/02/06

Registration Authorized By: JAMES PARSONS
                                                     OFFICER


SCHEDULE OF SHARE STRUCTURE CONSOLIDATION

Pursuant to Section 173(1)(f) of the Business Corporations Act (Alberta) such that the Corporation's issued and outstanding 186,619,359 Common Shares, representing all of the issued and outstanding shares of such class, shall be consolidated on the basis of 1 new share for every 10 old shares held such that the number of issued and outstanding Common Shares after the consolidation will be 18,661,936. No fractional shares will be issued.



Exhibit 1.4

1

Ontario Corporation Number
Numéro de la société en Ontario
1892251

  ARTICLES OF CONTINUANCE
Form 6 STATUTS DE MAINTIEN
Business    
Corporations 1. The name of the corporation is: (Set out in BLOCK CAPITAL LETTERS)
Act   Dénomination sociale de la société : (Écrire en LETTRES MAJUSCULES SEULEMENT):
Formule 6   STEM CELL THERAPEUTICS CORP
Loi sur les    
sociétés par    
actions    
     
     
     
     
  2. The corporation is to be continued under the name (if different from 1):
    Nouvelle dénomination sociale de la société (si elle différente de celle inscrite ci-dessus ):
    N / A
     
     
     
     
  3. Name of jurisdiction the corporation is leaving : I Nom du territoire (province ou territoire, Ét at ou pays) que quitte la société:
     
    Alberta
    Name of jurisdiction / Nom du territoire
     
     
  4. Date of incorporation/amalgamation : / Date de la constitution ou de la fusion:
     
    2004-03-31
    Year, Month, Année / année, mois, jour
     
     
  5. The address of the registered office is:/ Adresse du siège social en:
     
    96 Skyway Avenue,
    Street & Number or R.R. Number & if Multi-Office Building give Room No.
    Rue et numéro ou numéro de la R.R. et, s’il s’agit d’un édifice à bureaux, numéro du bureau
     
     
    Toronto ONTARIO M9W 4Y9
    Name of Municipality or Post Office / Nom de la municipalité ou du bureau de poste Postal Code/ Code postal


2

6. Number of directors is/are: Fixed number    OR minimum and maximum 3 10
  Nombre d’administrateurs: Nombre fixe    OU minimum et maximum    
             
7. The director(s) is/are:/ Administrateur(s) Address for service, giving Street & No. or R.R. No., Resident Canadian
  First name, middle names and surname Municipality, Province, Country and Postal Code State ‘Yes’ or ‘No’
  Prénom, autres prénoms et nom de Domicile élu, y compris la rue et le numéro ou le numéro de la Résident canadien
  famille R.R., le nom de la municipalité, la province, le pays et le code Oui/Non
    postal  
       
  Dr. David Allan 96 Skyway Avenue, Toronto, Ontario M9W 4Y9 Yes
  Dr. James DeMesa 807 S Packwood Ave., Tampa, Florida, 33606 No
  Dr. Henry Friesen 96 Skyway Avenue, Toronto, Ontario M9W 4Y9 Yes
  Dr. R. Dean Peterson 96 Skyway Avenue, Toronto, Ontario M9W 4Y9 Yes
  Dr. Niclas Stiernholm 96 Skyway Avenue, Toronto, Ontario M9W 4Y9 Yes
  Dr. Calvin Stiller 96 Skyway Avenue, Toronto, Ontario M9W 4Y9 Yes
       
8. Restrictions, if any, on business the corporation may carry on or on powers the corporation may exercise.  
  Limites, s’il y a lieu, imposées aux activités commerciales ou aux pourvoirs de la société.  
  none    


2A

      ANNEX / ANNEXE
7. The director(s) of the corporation are: Administrateur(s)  
       
  First name, initials and surname Address for service, giving Street & No. or R.R. No., Resident
  Prénom, initiales et nom de famille Municipality and Postal Code. Canadian
    Domicile élu, y compris la rue et le numéro, le numéro de la State
    R.R., ou le nom de la municipalité et le code postal Yes or No
      Résident
      canadien
      Oui/Non
       
  Dr. Michael Moore The Gate House, 105 Palace Road, East Molesey, Surrey, No
    United Kingdom, KT8 9DU  


3

9.

The classes and any maximum number of shares that the corporation is authorized to issue:

Catégories et nombre maximal, s’il y a lieu, d’actions que la société est autorisée à émettre:

   

an unlimited number of Common shares;
an unlimited number of Class B shares; and
an unlimited number of First Preferred shares.



4

10.

Rights, privileges: restrictions and conditions (if any) attaching to each class of shares and directors authority with respect to any class of shares which may be issued in series:

Droits, privilèges, restrictions et conditions, s’il y a lieu, rattachés à chaque catégorie d’actions et pouvoirs des administrateurs relatifs à chaque catégorie d’actions qui peut être émise en série:

 

 

1. The rights, privileges, restrictions and conditions attaching to the Common shares are as follows:

 

 

(a) Voting Rights: The holders of the Common shares shall be entitled to receive notice of and to attend all annual and special meetings of the shareholders of the Corporation and to one vote in respect of each Common Share held at all such meetings.

 

 

(b) Payment of Dividends: The holders of the Common shares shall be entitled to receive dividends if, as and when declared by the board of directors of the Corporation out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner as the board of directors may from time to time determine. Subject to the rights of the holders of any other class of shares of the Corporation entitled to receive dividends in priority to or concurrently with the holders of the Common shares, the board of directors may in its sole discretion declare dividends on the Common shares to the exclusion of any other class of shares of the Corporation.

 

 

(c) Participation upon Liquidation, Dissolution or Winding Up: in the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Common shares shall, subject to the rights of the holders of any other class of shares of the Corporation entitled to receive assets of the Corporation upon such a distribution in priority to or concurrently with the holders of the Common shares, be entitled to participate in the distribution. Such distribution shall be made in equal amounts per share on all the Common shares at the time outstanding without preference or distinction.

 

 

2. The rights, privileges, restrictions and conditions attaching to the Class B shares are as follows:

 

 

(a) Voting Rights: The holders of the Class B shares shall be entitled to receive notice of and to attend any meeting of the shareholders of the Corporation but shall not be entitled to vote any of their Class B shares at any such meeting.

 

 

(b) Participation upon Liquidation, Dissolution or Winding Up: In the event of the liquidation, dissolution or wilding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Class B shares shall, subject to the rights of the holders of any other class of shares of the Corporation entitled to receive assets of the Corporation upon such a distribution in priority to the Class B shares, be entitled to participate rateably with the Common shares in any distribution of the assets of the Corporation.

 

 

(c) Conversion At Holders' Option:

 

 

(i) Each issued and fully paid Class B share may at any time be converted, at the option of the holder, into one Common share. The conversion privilege herein provided for may be exercised by notice in writing given to the Corporation accompanied by a certificate or certificates representing the Class B shares in respect of which the holder thereof desires to exercise such right of conversion and such notice shall be signed by the person registered on the books of the Corporation as the holder of the Class B shares in respect of which such right is being exercised or by his duly authorized attorney and shall specify the number of Class B shares which the holder desires to have converted, The holder shall also pay any governmental or other tax imposed in respect of such transaction. Upon receipt of such notice the Corporation shall issue certificates representing fully paid Common shares upon the basis above prescribed and in accordance with the provisions hereof to the registered holder of the Class B shares represented by the certificate or certificates accompanying such notice. If less than all of the Class B shares represented by any certificate are to be converted, the holder shall be entitled to receive a new certificate for the Class B shares representing the shares comprised in the original certificates which are not to be converted.

 

 

(ii) Idem: All Common shares resulting from any conversion of issued and fully paid Class B shares into Common shares pursuant to clause 2(c)) hereof shall he deemed to be fully paid and non-assessable.

 

 

(iii) Idem: None of the Class B shares or the Common shares shall be subdivided, consolidated, reclassified or otherwise changed unless contemporaneously therewith the other said class of shares is subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner.

 

 

3. The rights, privileges, restrictions and conditions attaching to the First Preferred Shares are as follows:

 

 

(a) Series: The First Preferred Shares may at any time and from time to time be issued in one or more series. Subject to the provisions of clauses 3(b) and (c), the board of directors of the Corporation may from time to time before the issue thereof fix the number of shares in, and determine the designation, rights, privileges, restrictions and conditions attaching to the shares of, each series of First Preferred Shares.

 

 

(b) Idem: The First Preferred Shares shall be entitled to priority over the Common Shares and Class B Shares and all other shares ranking junior to the First Preferred Shares with respect to the payment of dividends and the distribution of assets of the Corporation in the event of any liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs.

 

 

(c) Idem: The First Preferred Shares of each series shall rank on a parity with the First Preferred Shares of every other series with respect to priority in the payment of dividends and in the distribution of assets of the Corporation in the event of any liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs.



5

11.

The issue, transfer or ownership of shares is/is not restricted and the restrictions (if any) are as follows :

L’émission, le transfert ou la propriété d’actions est/n’est pas restreint. Les restrictions, s’il y a lieu, sont les suivantes :

   

none



6

12.

Other provisions, (if any):

Autres dispositions s’il y a lieu:

   

none



7

13.

The corporation has complied with subsection 180(3) of the Business Corporations Act.
La société s’est conformée au paragraphe 180(3) de la Loi sur les sociétés par actions.

   
14.

The continuation of the corporation under the laws of the Province of Ontario has been properly authorized under the laws of the jurisdiction in which the corporation was incorporated/amalgamated or previously continued on

Le maintien de la société en vertu des lois de la province de l’Ontario a été dûment autorisé en vertu des lois de l’autorité législative sous le régime de laquelle la société a été constituée ou fusionnée ou antérieurement maintenue le


  2013-10-17
  Year, Month, Day
  année, mois, jour

15.

The corporation is to be continued under the Business Corporations Act to the same extent as if it had been incorporated thereunder.

Le maintien de la société en vertu de la Loi sur les sociétés par actions a le même effet que si la société avait été constituée en vertu de cette loi.

   

These articles are signed in duplicate.

Les présents statuts sont signés en double exemplaire.


  STEM CELL THERAPEUTICS CORP.
  Name of Corporation / Dénomination sociale de la société
   
  By/Par
   
   
  (signed) « James Parsons »
  Signature / Signature
   
   
  James Parsons
  Print name of signatory / Nom du signataire en lettres moulées
   
   
   
  Chief Financial Officer
  Description of Office / Fonction

These articles must be signed by a director or officer of the corporation (e.g. president, secretary)
Ces statuts doivent être signés par un administrateur ou un dirigeant de la société (p. ex. : président, secrétaire).



Exhibit 1.5

Ontario Corporation Number
Numéro de la société en Ontario

1892251

  ARTICLES OF AMENDMENT
Form 3 STATUTS DE MODIFICATION
Business    
Corporations 1. The name of the corporation is: (Set out in BLOCK CAPITAL LETTERS)
Act   Dénomination sociale actuelle de la société ( é crire en LETTRES MAJUSCULES SEULEMENT) :
Formule 3   STEM CELL THERAPEUTICS CORP.
Loi sur les    
sociétés par    
actions    
     
     
     
     
  2. The name of the corporation is changed to (if applicable): (Set out in BLOCK CAPITAL LETTERS)
    Nouvelle dénomination sociale de la société (s’il y a lieu) (écrire en LETTRES MAJUSCULES SEULEMENT) :
    N / A
     
     
     
     
  3. Date of incorporation/amalgamation:
    Date de la constitution ou de la fusion :
    2004/03/31
    (Year, Month, Day)
    (année, mois, jour)
     
  4. Complete only if there is a change in the number of directors or the minimum / maximum number of directors.
    Il faut remplir cette partie seulement si le nombre d’administrateurs ou si le nombre minimal ou maximal
    d’administrateurs a changé.
     
    Number of directors is/are: minimum and maximum number of directors is/are:
    Nombre d’administrateurs : nombres minimum et maximum d’administrateurs :
             
    Number       minimum and maximum  
    Nombre       minimum et maximum  
             
         or      
         ou      
             
  5. The articles of the corporation are amended as follows:
    Les statuts de la société sont modifi é s de la façon suivante :
     
    See attached pages 1A through to 1E.

07119 (2008/06) © Queen’s Printer for Ontario, 2008 / © Imprimeur de la Reine pour l’Ontario, 2008 Page 1 of/de 2


1A

STEM CELL THERAPEUTICS CORP. (the “Corporation”)

The articles of the Corporation are amended as follows:

A.

To declare that the authorized capital of the Corporation consists of: a) an unlimited number of Common Shares, b) an unlimited number of Class B shares, and c) an unlimited number of First Preferred shares; and

   
B.

To create a new series of First Preferred shares designated as Series I Non-Voting Convertible First Preferred Shares and the rights, privileges, restrictions and conditions attaching to the Series I Non-Voting Convertible First Preferred Shares are as follows:

1(a)       Voting Rights :

  (i)

The holders of Series I Non-Voting Convertible First Preferred Shares shall be entitled to receive notice of and to attend at any meeting of the shareholders of the Corporation but shall not be entitled to vote at any such meeting, except with respect to such matters and in the manner as to which voting rights are accorded to the holders of specified classes of shares pursuant to the provisions of the Business Corporations Act (Ontario) or applicable law (the “ Exception ”).

     
  (ii)

In the event of an Exception, and to the extent permitted by law, a holder of Series I Non-Voting Convertible First Preferred Shares shall: (A) vote together with the holders of Common Shares as a single class; and (B) be entitled to cast that number of votes equal to the number of whole Common Shares into which the Series I Non-Voting Convertible First Preferred Shares held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matters.

1(b)       Dividends : The holders of the Series I Non-Voting Convertible First Preferred Shares shall be entitled to receive and the Corporation shall pay thereon, dividends if, as and when declared by the board of directors of the Corporation out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner (and whether in money or otherwise) as the board of directors may from time to time determine, equally, on a share-for-share basis, with the holders of other series of First Preferred Shares and, at the discretion of the board of directors, either in priority to, or equally on a share-for-share basis with, the holders of Common Shares and Class B Shares.

1(c)       Liquidation, Dissolution and Winding-up Rights : In the event of liquidation, dissolution or winding-up of the affairs of the Corporation, whether voluntary or involuntary, or in the event of any other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, or in the event of a reduction or redemption of the capital stock of the Corporation, the holders of the Series I Non-Voting Convertible First Preferred Shares shall be entitled to receive an amount per share equal to that amount of money that was received by the Corporation as consideration for such Series I Non-Voting Convertible First Preferred Shares or in the event that Series I Non-Voting Convertible First Preferred Shares were not issued for money, then the amount equal to the fair value of any property received by the Corporation as consideration for the issuance of such Series I Non-Voting Convertible First Preferred Shares (where such fair value is determined at the time of the issuance of the Series I Non-Voting Convertible First Preferred Shares) divided by the number of Series I Non-Voting Convertible First Preferred Shares issued, in lawful money of Canada, the whole before any amount shall be paid by the Corporation or any assets of the Corporation shall be distributed to holders of Common Shares and Class B Shares. After payment to the holders of the Series I Non-Voting Convertible First Preferred Shares of the amount so payable to them in accordance with this Section, they shall not be entitled to share in any further distribution of property or assets of the Corporation.

1(d)       Authority to Issue Series I Non-Voting Convertible First Preferred Shares : The board of directors of the Corporation may from time to time authorize the issuance of the Series I Non-Voting Convertible First Preferred Shares and fix the number of Series I Non-Voting Convertible First Preferred Shares to be allotted and issued and the amount and kind of consideration to be received by the Corporation in respect of each such issuance of Series I Non-Voting Convertible First Preferred Shares.

1(e)       Reservation of Common Shares Issuable Upon Conversion . The Corporation shall at all times reserve and keep available out of its authorized and unissued Common Shares for the sole purpose of issuance upon conversion of the Series I Non-Voting Convertible First Preferred Shares, free from pre-emptive rights or any other actual contingent purchase rights of Persons other than the holders of the Series I Non-Voting Convertible First Preferred Shares, not less than such aggregate number of Common Shares as shall be issuable (taking into account the adjustments of Section 1(f)(5)) upon the conversion of all outstanding Series I Non-Voting Convertible First Preferred Shares. All Common Shares that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.


1B

1(f)       Conversion :

(1)

Interpretation

In this Section 1(f), the following terms shall have the following respective meanings:

Alternate Consideration ” has the meaning given to it in Section 1(f)(5)(c);

CDS ” means the CDS Clearing and Depository Services Inc. and its successors;

CDS Participant ” means a broker, dealer, bank, other financial institution or other person who, directly or indirectly, from time to time, effects book-based transfers with CDS and pledges of securities deposited with CDS;

Conversion Date ” means the date as of which the subject Series I Non-Voting Convertible First Preferred Shares are to be converted;

Conversion Price ” means Cdn.$0.21, subject to adjustment in accordance with Section 1(f)(5);

Conversion Ratio ” means, for each Series I Non-Voting Convertible First Preferred Share, an amount equal to the Reference Price divided by the Conversion Price;

Exchange ” means the TSX Venture Exchange or, if applicable, such other stock exchange on which the Common Shares are principally traded;

Fundamental Transaction ” has the meaning given to it in Section 1(f)(5)(c);

Notice of Conversion ” means a notice of conversion of Series I Non-Voting Convertible First Preferred Shares given by a holder of such shares or by the Corporation;

Person ” means an individual, partnership, corporation, trust, unincorporated association, joint venture or other entity and includes a group of Persons acting jointly or in concert;

Reference Price ” means Cdn.$0.21; and

Underlying Shares ” means, in respect of Series I Non-Voting Convertible First Preferred Shares to be converted, the Common Shares to be issued upon such conversion.

(2)

Conversion Rights of Holders

Each holder of Series I Non-Voting Convertible First Preferred Shares shall have the right to convert all or any of the holder’s Series I Non-Voting Convertible First Preferred Shares into that number of Common Shares equal to the Conversion Ratio in effect at the time of such conversion.

(3)

Notice of Conversion


  (a)

A Notice of Conversion by a holder of Series I Non-Voting Convertible First Preferred Shares to the Corporation must be given not less than seven (7) calendar days prior to the Conversion Date.

     
  (b)

A Notice of Conversion shall be in writing and shall be validly and effectively given on the date on which it is received, if delivered personally, or sent, if sent by fax or email to the Corporation.

     
  (c)

A Notice of Conversion given by a holder of Series I Non-Voting Convertible First Preferred Shares to the Corporation shall set out:


  (i)

the Conversion Date which shall be specified by the holder;

     
  (ii)

unless all the Series I Non-Voting Convertible First Preferred Shares held by the holder who delivered the Notice of Conversion are to be converted (which, if such is the case, shall be stated in the notice), the number of Series I Non-Voting Convertible First Preferred Shares which are to be converted; and

     
  (iii)

the representation that the Underlying Shares will be registered in the name of the registered holder of the Series I Non-Voting Convertible First Preferred Shares to be converted unless, alternatively, subject to applicable securities laws and restrictions on transfer, including, if applicable, United States securities laws, the transfer agent of the Corporation (the Transfer Agent) receives from such holder, on or before the seventh calendar day prior to the Conversion Date, at the principal transfer office of the Transfer Agent in the City of Toronto, written notice in a form and executed in a manner satisfactory to the Transfer Agent directing the Corporation to register the Underlying Shares in some other name or names (the Transferee(s)) and stating the name(s) (with address(es)) accompanied by payment by the holders to the Transfer Agent of any transfer tax that may be payable by reason thereof and a written declaration of such matters as may be required by law in order to determine the entitlement of the Transferees to be transferred or hold the Underlying Shares.



1C

(4)

Delivery of Share Certificates / Recording of Beneficial Interest upon Conversion


  (a)

On the Conversion Date, a holder of Series I Non-Voting Convertible First Preferred Shares shall receive, upon surrender for cancellation of the certificate or certificates representing the Series I Non-Voting Convertible First Preferred Shares, a certificate evidencing the Underlying Shares issuable to such holder in accordance with this Section 1(f), which Underlying Shares so issued shall be listed on the Exchange. Alternatively, subject to applicable securities laws, including, if applicable, United States securities laws, such holder may request, in the Notice of Conversion or by written request delivered to the Corporation not later than ten calendar days prior to the Conversion Date, that the Corporation record or cause to be recorded, in the book-based system administered by CDS in respect of the Common Shares, such holder’s interest in such shares, in which case the Notice of Conversion (or the subsequent written request) shall provide the account particulars of the holder’s CDS Participant and other details necessary to record such interest in the CDS system.

     
  (b)

Any Series I Non-Voting Convertible First Preferred Shares so converted shall be converted effective on the Conversion Date. From and after the Conversion Date, a holder of Series I Non-Voting Convertible First Preferred Shares so converted shall cease to be entitled to exercise any of the rights attributable to such shares (but, for greater certainty, will continue to be entitled to receive dividends on the Series I Non-Voting Convertible First Preferred Shares so converted in respect of which the ex-dividend date occurs prior to the Conversion Date but are paid on or after the Conversion Date), and shall become a holder of the Underlying Shares of record, effective on the Conversion Date.

     
  (c)

If less than all of the Series I Non-Voting Convertible First Preferred Shares of a holder are converted on any Conversion Date, the Corporation shall issue to such holder on the Conversion Date a new share certificate representing the balance of the Series I Non-Voting Convertible First Preferred Shares not converted.


(5)

Certain Adjustments


  (a)

Stock Dividends and Stock Splits . If the Corporation, at any time while any Series I Non-Voting Convertible First Preferred Shares are outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in Common Shares (which, for avoidance of doubt, shall not include any Common Shares issued by the Corporation upon conversion of Series I Non-Voting Convertible First Preferred Shares) with respect to the then outstanding Common Shares; (B) subdivides outstanding Common Shares into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding Common Shares into a smaller number of shares, the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of Common Shares (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of Common Shares outstanding immediately after such event. Any adjustment made pursuant to this Section 1(f)(5)(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.

     
  (b)

Rights Upon Distribution of Assets . If the Corporation shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Common Shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, reorganization, plan of arrangement or other similar transaction) (a “ Distribution ”), a holder of Series I Non-Voting Convertible First Preferred Shares shall be entitled to receive the dividend or distribution of assets that would have been payable to such holder pursuant to the Distribution had such holder converted his, her or its Series I Non-Voting Convertible First Preferred Shares (or, if he, she or it had partially converted such shares prior to the Distribution, any unconverted portion thereof) immediately prior to such record date.



1D

  (c)

Fundamental Transaction .


  (i)

Right to Receive Consideration . If, at any time while any Series I Non-Voting Convertible First Preferred Shares are outstanding:


  (A)

the Corporation effects any amalgamation, merger, business combination or other transaction of the Corporation with another person, other than a wholly-owned subsidiary, or an arrangement pursuant to the Business Corporations Act (Ontario) involving the Corporation or another transaction pursuant to which a Person, or a group of Persons acting jointly or in concert, acquires all of the issued and outstanding Common Shares;

     
  (B)

the Corporation effects any sale, lease or other disposition of all or substantially all of the assets or undertaking of the Corporation;

     
  (C)

the Corporation effects any reclassification of Common Shares or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by Section 1(f)(5)(a) above) to which the Common Shares are effectively converted into or exchanged for other securities, cash or property, or any similar transaction of series of transactions involving the Corporation or any of its subsidiaries, directly or indirectly,


 

(in any such case, a “ Fundamental Transaction ”), then, a holder of Series I Non-Voting Convertible First Preferred Shares shall have the right to receive (in exchange for such Series I Non-Voting Convertible First Preferred Shares in the event that the Common Shares are exchanged for other securities, cash or property in the Fundamental Transaction) the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of Common Shares, assuming conversion of the Series I Non-Voting Convertible First Preferred Shares in accordance with Section 1(f)(2) (the “ Alternate Consideration ”).

     
  (ii)

Alternate Consideration . If holders of Common Shares are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the a holder of Series I Non-Voting Convertible First Preferred Shares shall be given the same choice as to the Alternate Consideration it receives upon any conversion of Series I Non-Voting Convertible First Preferred Shares following such Fundamental Transaction.

     
  (iii)

Takeover Bid . In the event of a “takeover bid” that is a “formal bid” (as such terms are defined in the Securities Laws in the Province of Ontario) for the Common Shares, the offeror of such bid shall make an offer (the “ Preferred Share Offer ”) to acquire the same percentage of outstanding Series I Non-Voting Convertible First Preferred Shares as the percentage of Common Shares for which the formal bid is being made, and such Preferred Share Offer shall be on the same terms and for the same amount and kind of per share consideration that is offered to the holders of Common Shares under the formal bid.

     
  (iv)

Successor in Interest . To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation in such Fundamental Transaction shall include in its constating documents shares having the same terms and conditions and issue to the holders of Series I Non-Voting Convertible First Preferred Shares new preferred shares consistent with the foregoing provisions and evidencing the such holders’ right to convert such preferred shares into Alternate Consideration.

     
  (v)

Ibid . The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor to comply with the provisions of this Section 1(f)(5)(c) and ensuring that the Series I Non-Voting Convertible First Preferred Shares (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.

     
  (vi)

Notice . The Corporation shall cause to be delivered to each holder, at its last address as it shall appear upon the share register of the Corporation, written notice of any Fundamental Transaction at least 61 days prior to the date on which such Fundamental Transaction is expected to become effective or close.



1E

  (d)

Notice to the Holders .


  (i)

Adjustment to Conversion Price . Whenever the Conversion Price is adjusted pursuant to any provision of this Section 1(f), the Corporation shall promptly deliver to each holder of Series I Non-Voting Convertible First Preferred Shares a notice setting forth the Conversion Ratio after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

     
  (ii)

Other Notices . If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Shares, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of Common Shares, (C) the Corporation shall authorize the granting to all holders of Common Shares of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Corporation shall be required in connection with any reclassification of the Common Shares, any business combination, amalgamation or plan of arrangement to which the Corporation is a party, any sale or transfer of all or substantially all of the assets or undertaking of the Corporation, of any compulsory share exchange whereby the Common Shares are converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of Series I Non-Voting Convertible First Preferred Shares, and shall cause to be delivered to each holder of Series I Non- Voting Convertible First Preferred Shares at its last address as it shall appear upon the share register of the Corporation, at least 61 days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, business combination, amalgamation, plan of arrangements, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Shares of record shall be entitled to exchange such shares for securities, cash or other property deliverable upon such reclassification, consolidation, business combination, amalgamation, plan of arrangements, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.


(6)

Fractional Shares

No fractional Common Shares shall be issued upon the conversion of Series I Non-Voting Convertible First Preferred Shares. As to any fraction of a Common Share which a holder would otherwise be entitled to receive upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole Common Share.

(7)

Tax Election

An election in prescribed form and within the prescribed time limit shall be made by the Corporation under subsection 191.2(1) of the Income Tax Act (Canada) with respect to the Series I Non-Voting Convertible First Preferred Shares.



6.

The amendment has been duly authorized as required by sections 168 and 170 (as applicable) of the Business Corporations Act.
La modification a été dûment autorisée conformément aux articles 168 et 170 (selon le cas) de la Loi sur les sociétés par actions.

   
7.

The resolution authorizing the amendment was approved by the shareholders/directors (as applicable) of the corporation on
Les actionnaires ou les administrateurs (selon le cas) de la société ont approuvé la résolution autorisant la modification le

   

2013/12/12

  (Year, Month, Day)  

(année, mois, jour)

   

These articles are signed in duplicate.

Les présents statuts sont signés en double exemplaire.


  Stem Cell Therapeutics Corp.
  (Print name of corporation from Article 1 on page 1)
  (Veuillez écrir le nom de la société de l’article un à la page une).

  By/  
  Par :  
     
   (signed) « James Parsons »                                 Chief Financial Officer                                      
  (Signature) (Description of Office)
  (Signature) (Fonction)
     
                                               James Parsons  

Page 2 of/de 2



Exhibit 1.6

Ontario Corporation Number
Numéro de la société en Ontario
1916667








 

  ARTICLES OF AMALGAMATION
Form 4 STATUTS DE FUSION
Business    
Corporations 1. The name of the corporation is: (Set out in BLOCK CAPITAL LETTERS)
Act   Dénomination sociale de la société: (Écrire en LETTRES MAJUSCULES SEULEMENT):
             
Formule 4   TRILLIUM THERAPEUTICS INC
Loi sur les    
sociétés parés par    
actions    
  2. The address of the registered office is:
    Adresse du siège social en :
     
    96 Skyway Avenue,
    Street & Number or R.R. Number & if Multi-Office Building give Room No. /
    Rue et numéro ou numéro de la R.R. et, s’il s’agit d’un édifice á bureaux, numéro du bureau
         
    Toronto ONTARIO M 9 W 4 Y 9
    Name of Municipality or Post Office /   Postal Code/ Code postal
    Nom de la municipalité ou du bureau de poste    
               
  3. Number of directors is/are:
Nombre d’administrateurs:
Fixed number
Nombre fixe
  OR minimum and maximum
OU minimum et maximum
3 10
         
  4. The director(s) is/are:/ Administrateur(s):    
    First name, middle names and surname
Prénom, autres prénoms et nom de famille
Address for service, giving Street & No. or R.R. No., Municipality, Province, Country and Postal Code
Domicile élu, y compris la rue et le numéro ou le numéro de la
R.R., le nom de la municipalité, la province, le pays et le code postal
Resident Canadian
State ‘Yes’ or ‘No’
Résident canadien

Oui/Non
         
    Luke Beshar 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
No
         
    Henry Friesen 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
Yes
         
    Robert Kirkman 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
No
         

Page 1 of/de 6



        Annex / Annexe
         
  4. The director(s) is/are:   1A
    Administrateur(s)    
First name, middle names and surname
Prénom, autres prénoms et nom de famille
Address for service, giving Street & No. or R.R. No., Municipality, Province, Country and Postal Code
Domicile élu, y compris la rue et le numéro ou le numéro de la R.R., le nom de la municipalité, la province, le pays et le code postal
Resident Canadian
State ‘Yes’ or ‘No’
Résident canadien
Oui/Non
         
Calvin Stiller 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
Yes
         
Michael Moore 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
No
         
Thomas Reynolds 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
No
         
Niclas Stiernholm 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
Yes



  5 Method of amalgamation, check A or B
    Méthode choisie pour la fusion – Cocher A ou B:
      A - Amalgamation Agreement / Convention de fusion :
         
    [   ]   The amalgamation agreement has been duly adopted by the shareholders of each of the amalgamating corporations as required by subsection 176 (4) of the Business Corporations Act on the date set out below.
        Les actionnaires de chaque société qui fusionne ont dûment adopté la convention de fusion conformément au paragraphe 176(4) de la Loi sur les sociétés par actions à la date mentionnée ci-dessous.
    or    
    ou    
      B - Amalgamation of a holding corporation and one or more of its subsidiaries or amalgamation of subsidiaries / Fusion d’une société mère avec une ou plusieurs de ses fillales ou fusion de fillales :
         
    [X]   The amalgamation has been approved by the directors of each amalgamating corporation by a resolution as required by section 177 of the Business Corporations Act on the date set out below.
        Les administrateurs de chaque société qui fusionne ont approuvé la fusion par voie de résolution conformément à l’article 177 de la Loi sur les sociétés par actions à la date mentionnée ci-dessous.
         
        The articles of amalgamation in substance contain the provisions of the articles of incorporation of
        Les statuts de fusion reprennent essentiellement les dispositions des statuts constitutifs de
         
        Stem Cell Therapeutics Corp.
        and are more particularly set out in these articles.
        et sont énoncés textuellement aux présents statuts.
         
    Names of amalgamating corporations Ontario Corporation Number Date of Adoption/Approval
    Dénomination sociale de sociétés qui fusionnent Numéro de société en Ontario Date d’adoption ou d’approbation
        Year Month Day
        Année Mois jour
             
    Stem Cell Therapeutics Corp. 1892251 2014-05-27
             
             
    Trillium Therapeutics Inc. 1893906 2014-05-27


Page 2 of/de 6

  6. Restrictions, if any, on business the corporation may carry on or on powers the corporation may exercise.
    Limites, s’il y a lieu, imposées aux activités commerciales ou aux pouvoirs de la société.
     
    None
     
  7. The classes and any maximum number of shares that the corporation is authorized to issue:
    Catégories et nombre maximal, s’il y a lieu, d’actions que la société est autorisée à émettre :
     
    an unlimited number of Common shares;
    an unlimited number of Class B shares;
    an unlimited number of First Preferred shares; and
    an unlimited number of Series I Non-Voting Convertible First Preferred shares.


 Page 3 of/de 6

8 Rights, privileges: restrictions and conditions (if any) attaching to each class of shares and directors authority with respect to any class of shares which may be issued in series:
Droits, privilèges, restrictions et conditions, s’il y a lieu, rattachés à chaque catégorie d’actions et pouvoirs des administrateurs relatifs à chaque catégorie d’actions qui peut être émise en série:
     
    See pages 4a – 4k


4a

1.             The rights, privileges, restrictions and conditions attaching to the Common shares are as follows:

(a)

Voting Rights:

The holders of the Common shares shall be entitled to receive notice of and to attend all annual and special meetings of the shareholders of the Corporation and to one vote in respect of each Common share held at all such meetings.

(b)

Payment of Dividends:

The holders of the Common shares shall be entitled to receive dividends if, as and when declared by the board of directors of the Corporation out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner as the board of directors may from time to time determine. Subject to the rights of the holders of any other class of shares of the Corporation entitled to receive dividends in priority to or concurrently with the holders of the Common shares, the board of directors may in its sole discretion declare dividends on the Common shares to the exclusion of any other class of shares of the Corporation.

(c)

Participation upon Liquidation, Dissolution or Winding Up:

In the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Common shares shall, subject to the rights of the holders of any other class of shares of the Corporation entitled to receive assets of the Corporation upon such a distribution in priority to or concurrently with the holders of the Common shares, be entitled to participate in the distribution. Such distribution shall be made in equal amounts per share on all the Common shares at the time outstanding without preference or distinction.

2.             The rights, privileges, restrictions and conditions attaching to the Class B shares are as follows:

(a)

Voting Rights:

The holders of the Class B shares shall be entitled to receive notice of and to attend any meeting of the shareholders of the Corporation but shall not be entitled to vote any of their Class B shares at any such meeting.

(b)

Participation upon Liquidation, Dissolution or Winding Up:

In the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Class B shares shall, subject to the rights of the holders of any other class of shares of the Corporation entitled to receive assets of the Corporation upon such a distribution in priority to the Class B shares, be entitled to participate rateably with the Common shares in any distribution of the assets of the Corporation.


 4b

(c)

Conversion At Holders’ Option:

     
(1)

Each issued and fully paid Class B share may at any time be converted, at the option of the holder, into one Common share. The conversion privilege herein provided for may be exercised by notice in writing given to the Corporation accompanied by a certificate or certificates representing the Class B shares in respect of which the holder thereof desires to exercise such right of conversion and such notice shall be signed by the person registered on the books of the Corporation as the holder of the Class B shares in respect of which such right is being exercised or by his duly authorized attorney and shall specify the number of Class B shares which the holder desires to have converted. The holder shall also pay any governmental or other tax imposed in respect of such transaction. Upon receipt of such notice the Corporation shall issue certificates representing fully paid Common shares upon the basis above prescribed and in accordance with the provisions hereof to the registered holder of the Class B shares represented by the certificate or certificates accompanying such notice. If less than all of the Class B shares represented by any certificate are to be converted, the holder shall be entitled to receive a new certificate for the Class B shares representing the shares comprised in the original certificates which are not to be converted.

     
(2)

Idem: All Common shares resulting from any conversion of issued and fully paid Class B shares into Common shares pursuant to clause 2(c)(1) hereof shall be deemed to be fully paid and non-assessable.

     
(3)

Idem: None of the Class B shares or the Common shares shall be subdivided, consolidated, reclassified or otherwise changed unless contemporaneously therewith the other said class of shares is subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner.

3.             The rights, privileges, restrictions and conditions attaching to the First Preferred shares are as follows:

(a)

Series:

The First Preferred shares may at any time and from time to time be issued in one or more series. Subject to the provisions of clauses 3(b) and (c), the board of directors of the Corporation may from time to time before the issue thereof fix the number of shares in, and determine the designation, rights, privileges, restrictions and conditions attaching to the shares of, each series of First Preferred shares.

(b)

Idem:

The First Preferred shares shall be entitled to priority over the Common shares and Class B shares and all other shares ranking junior to the First Preferred shares with respect to the payment of dividends and the distribution of assets of the Corporation in the event of any liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs.


 4c

(c)

Idem:

The First Preferred shares of each series shall rank on a parity with the First Preferred shares of every other series with respect to priority in the payment of dividends and in the distribution of assets of the Corporation in the event of any liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs.

4.             The rights, privileges, restrictions and conditions attaching to the Series I Non-Voting Convertible First Preferred shares are as follows:

(a)

Voting Rights:

     
(1)

The holders of Series I Non-Voting Convertible First Preferred shares shall be entitled to receive notice of and to attend at any meeting of the shareholders of the Corporation but shall not be entitled to vote at any such meeting, except with respect to such matters and in the manner as to which voting rights are accorded to the holders of specified classes of shares pursuant to the provisions of the Business Corporations Act (Ontario) or applicable law (the “Exception”).

     
(2)

In the event of an Exception, and to the extent permitted by law, a holder of Series I Non-Voting Convertible First Preferred shares shall: (A) vote together with the holders of Common shares as a single class; and (B) be entitled to cast that number of votes equal to the number of whole Common shares into which the Series I Non-Voting Convertible First Preferred shares held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matters.

     
(b)

Dividends:

The holders of the Series I Non-Voting Convertible First Preferred shares shall be entitled to receive and the Corporation shall pay thereon, dividends if, as and when declared by the board of directors of the Corporation out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner (and whether in money or otherwise) as the board of directors may from time to time determine, equally, on a share-for-share basis, with the holders of other series of First Preferred shares and, at the discretion of the board of directors, either in priority to, or equally on a share-for-share basis with, the holders of Common shares and Class B shares.

(c)

Liquidation, Dissolution and Winding-up Rights:

In the event of liquidation, dissolution or winding-up of the affairs of the Corporation, whether voluntary or involuntary, or in the event of any other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, or in the event of a reduction or redemption of the capital stock of the Corporation, the holders of the Series I Non-Voting Convertible First Preferred shares shall be entitled to receive an amount per share equal to that amount of money that was received by the Corporation as consideration for such Series I Non-Voting Convertible First Preferred shares or in the event that Series I Non-Voting Convertible First Preferred shares were not issued for money, then the amount equal to the fair value of any property received by the Corporation as consideration for the issuance of such Series I Non-Voting Convertible First Preferred shares (where such fair value is determined at the time of the issuance of the Series I Non-Voting Convertible First Preferred shares) divided by the number of Series I Non-Voting Convertible First Preferred shares issued, in lawful money of Canada, the whole before any amount shall be paid by the Corporation or any assets of the Corporation shall be distributed to holders of Common shares and Class B shares. After payment to the holders of the Series I Non-Voting Convertible First Preferred shares of the amount so payable to them in accordance with this Section, they shall not be entitled to share in any further distribution of property or assets of the Corporation.


 4d

(d)

Authority to Issue Series I Non-Voting Convertible First Preferred shares:

The board of directors of the Corporation may from time to time authorize the issuance of the Series I Non-Voting Convertible First Preferred shares and fix the number of Series I Non-Voting Convertible First Preferred shares to be allotted and issued and the amount and kind of consideration to be received by the Corporation in respect of each such issuance of Series I Non-Voting Convertible First Preferred shares.

(e)

Reservation of Common shares Issuable Upon Conversion:

The Corporation shall at all times reserve and keep available out of its authorized and unissued Common shares for the sole purpose of issuance upon conversion of the Series I Non-Voting Convertible First Preferred shares, free from pre-emptive rights or any other actual contingent purchase rights of Persons other than the holders of the Series I Non-Voting Convertible First Preferred shares, not less than such aggregate number of Common shares as shall be issuable (taking into account the adjustments of Section 4(f)(5)) upon the conversion of all outstanding Series I Non-Voting Convertible First Preferred shares. All Common shares that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.

(f)

Conversion:

     
(1)

Interpretation:

In this Section 4(f), the following terms shall have the following respective meanings:

“Alternate Consideration” has the meaning given to it in Section 4(f)(5)(c);

“CDS” means the CDS Clearing and Depository Services Inc. and its successors;

“CDS Participant” means a broker, dealer, bank, other financial institution or other person who, directly or indirectly, from time to time, effects book-based transfers with CDS and pledges of securities deposited with CDS;

“Conversion Date” means the date as of which the subject Series I Non-Voting Convertible First Preferred shares are to be converted;


4e

“Conversion Price” means Cdn.$0.21, subject to adjustment in accordance with Section 4(f)(5);

“Conversion Ratio” means, for each Series I Non-Voting Convertible First Preferred share, an amount equal to the Reference Price divided by the Conversion Price;

“Exchange” means the TSX Venture Exchange or, if applicable, such other stock exchange on which the Common shares are principally traded;

“Fundamental Transaction” has the meaning given to it in Section 4(f)(5)(c);

“Notice of Conversion” means a notice of conversion of Series I Non-Voting Convertible First Preferred shares given by a holder of such shares or by the Corporation;

“Person” means an individual, partnership, corporation, trust, unincorporated association, joint venture or other entity and includes a group of Persons acting jointly or in concert;

“Reference Price” means Cdn.$0.21; and

“Underlying shares” means, in respect of Series I Non-Voting Convertible First Preferred shares to be converted, the Common shares to be issued upon such conversion.

  (2)

Conversion Rights of Holders: Each holder of Series I Non-Voting Convertible First Preferred shares shall have the right to convert all or any of the holder’s Series I Non-Voting Convertible First Preferred shares into that number of Common shares equal to the Conversion Ratio in effect at the time of such conversion.

         
  (3)

Notice of Conversion:

         
a.

A Notice of Conversion by a holder of Series I Non-Voting Convertible First Preferred shares to the Corporation must be given not less than seven (7) calendar days prior to the Conversion Date.

         
  b.

A Notice of Conversion shall be in writing and shall be validly and effectively given on the date on which it is received, if delivered personally, or sent, if sent by fax or email to the Corporation.

         
  c.

A Notice of Conversion given by a holder of Series I Non-Voting Convertible First Preferred shares to the Corporation shall set out:

         

i.
the Conversion Date which shall be specified by the holder;
         
ii. unless all the Series I Non-Voting Convertible First Preferred shares held by the holder who delivered the Notice of Conversion are to be converted (which, if such is the case, shall be stated in the notice), the number of Series I Non-Voting Convertible First Preferred shares which are to be converted; and


 4f

 

iii.

the representation that the Underlying shares will be registered in the name of the registered holder of the Series I Non-Voting Convertible First Preferred shares to be converted unless, alternatively, subject to applicable securities laws and restrictions on transfer, including, if applicable, United States securities laws, the transfer agent of the Corporation (the Transfer Agent) receives from such holder, on or before the seventh calendar day prior to the Conversion Date, at the principal transfer office of the Transfer Agent in the City of Toronto, written notice in a form and executed in a manner satisfactory to the Transfer Agent directing the Corporation to register the Underlying shares in some other name or names (the Transferee(s)) and stating the name(s) (with address(es)) accompanied by payment by the holders to the Transfer Agent of any transfer tax that may be payable by reason thereof and a written declaration of such matters as may be required by law in order to determine the entitlement of the Transferees to be transferred or hold the Underlying shares.

         
  (4)

Delivery of Share Certificates / Recording of Beneficial Interest upon Conversion:

         
  a.

On the Conversion Date, a holder of Series I Non-Voting Convertible First Preferred shares shall receive, upon surrender for cancellation of the certificate or certificates representing the Series I Non-Voting Convertible First Preferred shares, a certificate evidencing the Underlying shares issuable to such holder in accordance with this Section 4(f), which Underlying shares so issued shall be listed on the Exchange. Alternatively, subject to applicable securities laws, including, if applicable, United States securities laws, such holder may request, in the Notice of Conversion or by written request delivered to the Corporation not later than ten calendar days prior to the Conversion Date, that the Corporation record or cause to be recorded, in the book-based system administered by CDS in respect of the Common shares, such holder’s interest in such shares, in which case the Notice of Conversion (or the subsequent written request) shall provide the account particulars of the holder’s CDS Participant and other details necessary to record such interest in the CDS system.

         
  b.

Any Series I Non-Voting Convertible First Preferred shares so converted shall be converted effective on the Conversion Date. From and after the Conversion Date, a holder of Series I Non-Voting Convertible First Preferred shares so converted shall cease to be entitled to exercise any of the rights attributable to such shares (but, for greater certainty, will continue to be entitled to receive dividends on the Series I Non-Voting Convertible First Preferred shares so converted in respect of which the ex-dividend date occurs prior to the Conversion Date but are paid on or after the Conversion Date), and shall become a holder of the Underlying shares of record, effective on the Conversion Date.



  4g

  c.

If less than all of the Series I Non-Voting Convertible First Preferred shares of a holder are converted on any Conversion Date, the Corporation shall issue to such holder on the Conversion Date a new share certificate representing the balance of the Series I Non-Voting Convertible First Preferred shares not converted.

         
  (5)

Certain Adjustments

         
a.

Stock Dividends and Stock Splits. If the Corporation, at any time while any Series I Non-Voting Convertible First Preferred shares are outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in Common shares (which, for avoidance of doubt, shall not include any Common shares issued by the Corporation upon conversion of Series I Non-Voting Convertible First Preferred shares) with respect to the then outstanding Common shares; (B) subdivides outstanding Common shares into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding Common shares into a smaller number of shares, the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of Common shares (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of Common shares outstanding immediately after such event. Any adjustment made pursuant to this Section 4(f)(5)(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.

         
  b.

Rights Upon Distribution of Assets. If the Corporation shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Common shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, reorganization, plan of arrangement or other similar transaction) (a “Distribution”), a holder of Series I Non-Voting Convertible First Preferred shares shall be entitled to receive the dividend or distribution of assets that would have been payable to such holder pursuant to the Distribution had such holder converted his, her or its Series I Non-Voting Convertible First Preferred shares (or, if he, she or it had partially converted such shares prior to the Distribution, any unconverted portion thereof) immediately prior to such record date.

         
  c.

Fundamental Transaction.

 

 
 

i.

Right to Receive Consideration. If, at any time while any Series I Non-Voting Convertible First Preferred shares are outstanding:



 4h

  (A)

the Corporation effects any amalgamation, merger, business combination or other transaction of the Corporation with another person, other than a wholly-owned subsidiary, or an arrangement pursuant to the Business Corporations Act (Ontario) involving the Corporation or another transaction pursuant to which a Person, or a group of Persons acting jointly or in concert, acquires all of the issued and outstanding Common shares;

     
  (B)

the Corporation effects any sale, lease or other disposition of all or substantially all of the assets or undertaking of the Corporation;

     
  (C)

the Corporation effects any reclassification of Common shares or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by Section 4(f)(5)(a) above) to which the Common shares are effectively converted into or exchanged for other securities, cash or property, or any similar transaction of series of transactions involving the Corporation or any of its subsidiaries, directly or indirectly,

     
 

(in any such case, a “Fundamental Transaction”), then, a holder of Series I Non-Voting Convertible First Preferred shares shall have the right to receive (in exchange for such Series I Non-Voting Convertible First Preferred shares in the event that the Common shares are exchanged for other securities, cash or property in the Fundamental Transaction) the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of Common shares, assuming conversion of the Series I Non-Voting Convertible First Preferred shares in accordance with Section 4(f)(2) (the “Alternate Consideration”).


  ii.

Alternate Consideration. If holders of Common shares are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the a holder of Series I Non-Voting Convertible First Preferred shares shall be given the same choice as to the Alternate Consideration it receives upon any conversion of Series I Non-Voting Convertible First Preferred shares following such Fundamental Transaction.

     
  iii.

Takeover Bid. In the event of a “takeover bid” that is a “formal bid” (as such terms are defined in the Securities Laws in the Province of Ontario) for the Common shares, the offeror of such bid shall make an offer (the “Preferred Share Offer”) to acquire the same percentage of outstanding Series I Non-Voting Convertible First Preferred shares as the percentage of Common shares for which the formal bid is being made, and such Preferred Share Offer shall be on the same terms and for the same amount and kind of per share consideration that is offered to the holders of Common shares under the formal bid.



4i

  iv.

Successor in Interest. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation in such Fundamental Transaction shall include in its constating documents shares having the same terms and conditions and issue to the holders of Series I Non-Voting Convertible First Preferred shares new preferred shares consistent with the foregoing provisions and evidencing the such holders’ right to convert such preferred shares into Alternate Consideration.

       
  v.

Ibid. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor to comply with the provisions of this Section 4(f)(5)(c) and ensuring that the Series I Non-Voting Convertible First Preferred shares (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.

       
  vi.

Notice. The Corporation shall cause to be delivered to each holder, at its last address as it shall appear upon the share register of the Corporation, written notice of any Fundamental Transaction at least 61 days prior to the date on which such Fundamental Transaction is expected to become effective or close.

       
  d.

Notice to the Holders:

       
  i.

Adjustment to Conversion Price. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 4(f), the Corporation shall promptly deliver to each holder of Series I Non-Voting Convertible First Preferred shares a notice setting forth the Conversion Ratio after such adjustment and setting forth a brief statement of the facts requiring such adjustment.



       
  ii.

Other Notices. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common shares, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of Common shares, (C) the Corporation shall authorize the granting to all holders of Common shares of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Corporation shall be required in connection with any reclassification of the Common shares, any business combination, amalgamation or plan of arrangement to which the Corporation is a party, any sale or transfer of all or substantially all of the assets or undertaking of the Corporation, of any compulsory share exchange whereby the Common shares are converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of Series I Non-Voting Convertible First Preferred shares, and shall cause to be delivered to each holder of Series I Non-Voting Convertible First Preferred shares at its last address as it shall appear upon the share register of the Corporation, at least 61 days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, business combination, amalgamation, plan of arrangements, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common shares of record shall be entitled to exchange such shares for securities, cash or other property deliverable upon such reclassification, consolidation, business combination, amalgamation, plan of arrangements, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.


  (6)

Fractional shares:

     
 

No fractional Common shares shall be issued upon the conversion of Series I Non-Voting Convertible First Preferred shares. As to any fraction of a Common share which a holder would otherwise be entitled to receive upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole Common share.



 4k

  (7)

Tax Election:

     
 

An election in prescribed form and within the prescribed time limit shall be made by the Corporation under subsection 191.2(1) of the Income Tax Act (Canada) with respect to the Series I Non-Voting Convertible First Preferred shares.




9.

The issue, transfer or ownership of shares is/is not restricted and the restrictions (if any) are as follows:

 

L’émission, le transfert ou la propriété d’actions est/n’est pas restreint. Les restrictions, s’il y a lieu, sont les suivantes :

     
 

None

     
  10.

Other provisions, (if any):
Autres dispositions s’il y a lieu :

     
 

None

     
11.

The statements required by subsection 178(2) of the Business Corporations Act are attached as Schedule ”A”.

 

Les déclarations exigées aux termes du paragraphe 178(2) de la Loi sur les sociétés par actions constituent l’annexe A.

     
  12.

A copy of the amalgamation agreement or directors’ resolutions (as the case may be) is/are attached as Schedule “B”.
Une copie de la convention de fusion ou les résolutions des administrateurs (selon le cas) constitue(nt) l’annexe B.

Page 5 of/de 6


These articles are signed in duplicate.
Les présents status sont signés en double exemplaire.

Name and original signature of a director or authorized signing officer of each of the amalgamating corporations. Include the name of each corporation, the signatories name and description of office (e.g. president, secretary). Only a director or authorized signing officer can sign on behalf of the corporation. / Nom et signature originale d’un administrateur ou d’un signataire autorisé de chaque société qui fusionne. Indiquer la dénomination sociale de chaque société, le nom du signataire et sa fonction (p. ex. : président, secrétaire). Seul un administrateur ou un dirigeant habilité peut signer au nom de la société.


  S tem Cell Therapeutics Corp.        
           
  Name of Corporations / Dénomination sociale des sociétés  
           
  By / Par   James Parsons   Chief Financial Officer
           
  (signed) « James Parsons »        
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
      Nom du signataire en lettres moulées    
           
  Trillium Therapeutics Inc.        
           
  Name of Corporations / Dénomination sociale des sociétés        
           
  By / Par   James Parsons   Chief Financial Officer
           
  (signed) « James Parsons »        
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
      Nom du signataire en lettres moulées    
             
             
  Name of Corporations / Dénomination sociale des sociétés  
           
  By / Par        
            
           
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
       Nom du signataire en lettres moulées    
            
            
  Name of Corporations / Dénomination sociale des sociétés  
           
  By / Par        
            
           
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
      Nom du signataire en lettres moulées    
           
           
  Name of Corporations / Dénomination sociale des sociétés  
           
  By / Par        
           
           
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
      Nom du signataire en lettres moulées    

Page 6 of/de 6


SCHEDULE “A”

STATEMENT OF DIRECTOR OR OFFICER

1.

I am the Chief Financial Officer of Stem Cell Therapeutics Corp. (“Amalgamating Corporation 1”) and as such have knowledge of its affairs.

     
2.

I am the Chief Financial Officer of Trillium Therapeutics Inc. (“Amalgamating Corporation 2”) and as such have knowledge of its affairs.

     
3.

I have conducted such examinations of the books and records of Amalgamating Corporation 1 and of Amalgamating Corporation 2 and have made such enquiries and investigations as are necessary to enable me to make this statement.

     
4.

There are reasonable grounds for believing that:

     
(a)

each of the Amalgamating Corporations is and the corporation to be formed by their amalgamation (the “Amalgamated Corporation”) will be able to pay its liabilities as they become due;

     
(b)

the realizable value of the assets of the Amalgamated Corporation will not be less than the aggregate of its liabilities and stated capital of all classes; and

     
(c)

no creditor of the Amalgamating Corporation will be prejudiced by such amalgamation.

Dated as of the 27 th day of May, 2014.

  (signed) “ James Parsons
  James Parsons, Chief Financial Officer


SCHEDULE “B”

STEM CELL THERAPEUTICS CORP.
(the “Corporation”)

RESOLUTION OF THE DIRECTORS

Dated as of the 27th day of May, 2014.

RECITAL:

The Corporation wishes to amalgamate with its wholly-owned subsidiary, Trillium Therapeutics Inc. (the “Subsidiary”), under the Business Corporations Act (Ontario) (the “Act”).

RESOLVED that:

1.

the Corporation amalgamate with the Subsidiary and continue as one corporation (the “Amalgamated Corporation”) under subsection 177(1) of the Act effective June 1, 2014 or such other date as may be determined by any director or officer of the Corporation;

     
2.

except as may be prescribed, the articles of amalgamation of the Amalgamated Corporation be the same as the articles of the Corporation;

     
3.

the by-laws of the Amalgamated Corporation be the same as the by-laws of the Corporation;

     
4.

on the issuance of a Certificate of Amalgamation under subsection 178(4) of the Act:

     
(a)

all shares of the Subsidiary be cancelled without any repayment of capital;

     
(b)

no securities be issued and no assets be distributed by the Amalgamated Corporation in connection with the amalgamation; and

     
(c)

the stated capital of the Amalgamated Corporation be the same as the stated capital of the Corporation; and

     
5.

any director or officer of the Corporation is authorized and directed to do on behalf of the Corporation any and all acts and things and execute all documents as such director or officer considers necessary, desirable or useful to carry out and give effect to the amalgamation of the Corporation and the Subsidiary and to this resolution.

The undersigned certifies that the foregoing is a true and complete copy of a resolution of Stem Cell Therapeutics Corp. which was consented to by all the directors of the Corporation on the 27 th day of May, 2014, and that the said resolution is in force and effect, unamended, at the date hereof.

Dated as of the 27th day of May, 2014. (signed) “ James Parsons
  James Parsons, Chief Financial Officer


SCHEDULE “B”

TRILLIUM THERAPEUTICS INC.
(the “Corporation”)

RESOLUTION OF THE DIRECTORS

Dated as of the 27 th day of May, 2014.

RECITAL:

The Corporation is a wholly-owned subsidiary of, and wishes to amalgamate with, Stem Cell Therapeutics Corp. (“Holdco”), under the Business Corporations Act (Ontario) (the “Act”).

RESOLVED that:

1.

the Corporation amalgamate with Holdco and continue as one corporation (the “Amalgamated Corporation”) under subsection 177(1) of the Act effective June 1, 2014 or such other date as may be determined by any director or officer of the Corporation;

     
2.

except as may be prescribed, the articles of amalgamation of the Amalgamated Corporation be the same as the articles of Holdco;

     
3.

the by-laws of the Amalgamated Corporation be the same as the by-laws of Holdco;

     
4.

on the issuance of a Certificate of Amalgamation under subsection 178(4) of the Act:

     
(a)

all shares of the Corporation be cancelled without any repayment of capital;

     
(b)

no securities be issued and no assets be distributed by the Amalgamated Corporation in connection with the amalgamation; and

     
(c)

the stated capital of the Amalgamated Corporation he the same as the stated capital of Holdco; and

     
5.

any director or officer of the Corporation is authorized and directed to do on behalf of the Corporation any and all acts and things and execute all documents as such director or officer considers necessary, desirable or useful to carry out and give effect to the amalgamation of the Corporation and Holdco and to this resolution.

The undersigned certifies that the foregoing is a true and complete copy of a resolution of Trillium Therapeutics Inc. which was consented to by all the directors of the Corporation on the 27th day of May, 2014, and that the said resolution is in force and effect, unamended, at the date hereof.

Dated as of the 27 th day of May, 2014. (signed) “ James Parsons
  James Parsons, Chief Financial Officer



Exhibit 1.7

BY-LAW NO. 1

A by-law relating generally to the transaction of the business and affairs
of

Trillium Therapeutics Inc.

amended and restated on May 27, 2014

CONTENTS

  Section 1 - Interpretation  
  Section 2 - Business of the Corporation  
  Section 3 - Borrowing and Securities  
  Section 4 - Directors  
  Section 5 - Delegation  
  Section 6 - Officers  
  Section 7 - Protection of Directors, Officers and Others  
  Section 8 - Shares  
  Section 9 - Dividends and Rights  
  Section 10 - Meetings of Shareholders  
  Section 11 - Notices  
  Section 12 - Repeal  
  Section 13   Effective Date  

BE IT ENACTED as a by-law of the Corporation as follows:

SECTION 1
INTERPRETATION

1.1 Definitions - In the by-laws of the Corporation, unless the context otherwise requires, capitalized terms used but not defined in this By-Law shall have the meanings attributed to them in the Act, except that:

" Act " means the Business Corporations Act (Ontario), and any statute that may be substituted therefor, as amended, restated or in effect from time to time;

" appoint " includes " elect " and vice-versa;

" articles " means the original or restated articles of incorporation, articles of amendment, articles of amalgamation, articles of continuance, articles of reorganization, articles of arrangement, articles of dissolution or articles of revival and includes any amendments thereto;

" Board " means the board of directors of the Corporation;

" by-laws " means this by-law and all other by-laws of the Corporation from time to time in force and effect;


" Corporation " means Trillium Therapeutics Inc.;

" meeting of shareholders " includes an annual meeting of shareholders or a special meeting of shareholders; " special meeting of shareholders " includes a meeting of any class or classes of shareholders and a special meeting of all shareholders entitled to vote at an annual meeting of shareholders;

" non-business day " means Saturday, Sunday and any other day that is a holiday as defined in the Interpretation Act (Canada) and any statute that may be substituted therefor, as amended, restated or in effect from time to time;

" recorded address " means:

  (a)

in the case of a shareholder, that person's address as recorded in the securities register;

     
  (b)

in the case of joint shareholders, the address appearing in the securities register in respect of such joint holding or the first address so appearing if there are more than one; and

     
  (c)

in the case of a director, officer, auditor or member of a committee of the Board, that individual's latest address as recorded in the records of the Corporation;

" Regulations " means the regulations made under the Act, as amended, restated or in effect from time to time;

" signing officer " means, in relation to any instrument, any person authorized to sign the instrument on behalf of the Corporation by Section 2.2 or by a resolution passed pursuant thereto; and

" unanimous shareholder agreement " means:

  (a)

an otherwise lawful written agreement among all the shareholders of the Corporation, or among all the shareholders and one or more persons who are not shareholders, that restricts, in whole or in part, the powers of the directors to manage, or supervise the management of, the business and affairs of the Corporation, as amended, supplemented, restated and replaced from time to time in accordance with its provisions; or

     
  (b)

a written declaration made by a person who is the beneficial owner of all of the issued shares of the Corporation that restricts in whole or in part, the powers of the directors to manage, or supervise the management of, the business and affairs of the Corporation, as amended, supplemented, restated and replaced from time to time in accordance with its provisions.

1.2 Interpretation – Words in the singular include the plural and vice-versa, words in one gender include all genders, and words importing persons include individuals, bodies corporate, partnerships, trusts and unincorporated organizations.

- 2 -


SECTION 2
BUSINESS OF THE CORPORATION

2.1 Corporate Seal - The Corporation may have one or more different corporate seals which may be adopted or changed from time to time by the Board, on which the name of the Corporation appears in the language or one or more of the languages set out in the articles.

2.2 Execution of Instruments - Deeds, transfers, assignments, contracts, obligations, certificates and other instruments may be signed on behalf of the Corporation by any one of the directors or officers. In addition, the Board may from time to time direct the manner in which and the person or persons by whom any particular instrument or class of instruments may or shall be signed. Any signing officer may affix the corporate seal (if any) to any instrument. Any signing officer may certify a copy of any instrument, resolution, by-law or other document of the Corporation to be a true copy thereof.

2.3 Execution in Counterpart - Any articles, notice, resolution, requisition, statement or other document required or permitted to be executed in several documents of like form each of which is executed by all persons required or permitted, as the case may be, to do so, shall be deemed to constitute one document and to bear date as of the date of execution thereof by the last person.

2.4 Banking Arrangements - The banking business of the Corporation including, without limitation, the borrowing of money and the giving of security therefor, shall be transacted with such banks, trust companies or other bodies corporate or organizations as may from time to time be designated by or under the authority of the Board. Such banking business or any part thereof shall be transacted under such agreements, instructions and delegations of powers as the Board may from time to time prescribe or authorize.

2.5 Voting Rights in Other Bodies Corporate - The signing officers of the Corporation may execute and deliver proxies and arrange for the issuance of voting certificates or other evidence of the right to exercise the voting rights attaching to any securities held by the Corporation. Such instruments, certificates or other evidence shall be in favour of such person or persons as may be determined by the officers executing such proxies or arranging for the issuance of voting certificates or such other evidence of the right to exercise such voting rights. In addition, the Board may from time to time direct the manner in which and the person or persons by whom any particular voting rights or class of voting rights may or shall be exercised.

2.6 Withholding Information from Shareholders - Subject to the Act, no shareholder shall be entitled to discovery of any information respecting any details or conduct of the Corporation's business which, in the opinion of the Board, it would be inexpedient in the interests of the shareholders or the Corporation to communicate to the public. The Board may from time to time determine whether and to what extent and at what time and place and under what conditions or regulations the accounts, records and documents of the Corporation or any of them shall be open to the inspection of shareholders and no shareholder shall have any right of inspecting any account, record or document of the Corporation except as conferred by the Act or authorized by the Board or by resolution passed at a meeting of shareholders.

SECTION 3
BORROWING AND SECURITIES

3.1 Borrowing Power - Without limiting the borrowing powers of the Corporation as provided by the Act, but subject to the articles and any unanimous shareholder agreement, the Board may from time to time on behalf of the Corporation, without authorization of the shareholders:

- 3 -



(a)

borrow money on the credit of the Corporation;

   
(b)

issue, reissue, sell, pledge or hypothecate bonds, debentures, notes or other evidences of indebtedness of the Corporation, whether secured or unsecured;

   
(c)

give a guarantee on behalf of the Corporation to secure performance of any present or future indebtedness, liability or obligation of any person; and

   
(d)

mortgage, hypothecate, pledge or otherwise create a security interest in all or any currently owned or subsequently acquired real or personal, movable or immovable, property of the Corporation including book debts, rights, powers, franchises and undertakings, to secure any such bonds, debentures, notes or other evidences of indebtedness or guarantee or any other present or future indebtedness, liability or obligation of the Corporation.

The Board may from time to time delegate to one or more of the directors and officers of the Corporation as may be designated by the Board all or any of the powers conferred on the Board in this Section 3.1 to the extent and in the manner as the Board shall determine at the time of such delegation.

Nothing in this Section limits or restricts the borrowing of money by the Corporation on bills of exchange or promissory notes made, drawn, accepted or endorsed by or on behalf of the Corporation.

 3.2 Delegation - Subject to any unanimous shareholder agreement, the Board may from time to time delegate to a committee of the Board, a director or an officer of the Corporation or any other person as may be designated by the Board all or any of the powers conferred on the Board by Section 3.1 or by the Act to such extent and in such manner as the Board shall determine at the time of each such delegation.

SECTION 4
DIRECTORS

4.1 Number of Directors and Quorum – Subject to the articles, the Board shall consist of the number of directors specified in the articles, except that if the articles provide for a minimum and maximum number of directors, the board shall consist of the number of directors determined from time to time by a special resolution of the shareholders (or, if the directors are empowered by a special resolution to determine the number, by a resolution of the Board) within such minimum and maximum. Subject to Section 4.18, a majority of the number of directors so specified or determined shall constitute a quorum at any meeting of the Board.

4.2 Qualification - No person shall be qualified for election as a director:

(a)

if the person is less than 18 years of age;

   
(b)

if the person has been found under the Substitute Decisions Act , 1992 (Ontario) or under the Mental Health Act (Ontario) to be incapable of managing property or who has been found to be incapable by a court in Canada or elsewhere;

   
(c)

if the person is not an individual; or

   
(d)

if the person has the status of a bankrupt.

- 4 -


Subject to the articles, a director need not be a shareholder. Subject to the Act, at least 25% of the directors must be resident Canadians. If the Corporation has less than four directors, at least one director must be a resident Canadian.

4.3 Election and Term - The election of directors shall take place at the first meeting of shareholders and at each annual meeting of shareholders and all the directors then in office shall retire but, if qualified, shall be eligible for re-election. The election shall be by resolution. If an election of directors is not held at the proper time, the incumbent directors shall continue in office until their successors are elected.

4.4 Removal of Directors - Subject to the Act, the shareholders may by ordinary resolution passed at an annual or special meeting remove any director from office and the vacancy created by such removal may be filled at the same meeting failing which it may be filled by the Board.

4.5 Vacation of Office - A director ceases to hold office when such director: (a) dies or, subject to the Act, resigns; (b) is removed from office by the shareholders in accordance with the Act; or (c) ceases to be qualified for election as a director in accordance with the Act. A resignation of a director becomes effective at the time a written resignation is sent or delivered to the Corporation or the time specified in such resignation, whichever is later.

4.6 Vacancies - Subject to the Act and the articles, a quorum of the Board may fill a vacancy in the Board, except a vacancy resulting from:

(a)

an increase in the number of directors, unless the directors are authorized to determine the number of directors and the appointment of an additional director would not result in a total number of directors greater than one and one-third times the number of directors required to have been elected at the last annual meeting of shareholders;

   
(b)

an increase in the maximum number of directors; or

   
(c)

a failure of the shareholders to elect the number of directors required to be elected at any meeting of shareholders.

In the absence of a quorum of the Board, or if the vacancy has arisen from a failure of the shareholders to elect the number of directors required to be elected at any meeting of shareholders, the Board shall forthwith call a special meeting of shareholders to fill the vacancy. If the Board fails to call such meeting or if there are no directors then in office, any shareholder may call the meeting.

4.7 Action by the Board - Subject to any unanimous shareholder agreement, the Board shall manage, or supervise the management of, the business and affairs of the Corporation. Subject to Section 4.8, the powers of the Board may be exercised by resolution passed at a meeting at which a quorum is present or by resolution in writing signed by all the directors entitled to vote on that resolution at a meeting of the Board. Where there is a vacancy in the Board, the remaining directors may exercise all the powers of the Board so long as a quorum remains in office. Where the Corporation has only one director, that director may constitute a meeting.

4.8 Meeting by Communications Facilities - If all the directors of the Corporation consent, a meeting of the Board or of a committee of the Board may be held by means of such telephone, electronic or other communications facilities as permit all persons participating in the meeting to communicate with each other simultaneously and instantaneously, and a director participating in such a meeting by such means is deemed to be present at the meeting. Any such consent shall be effective whether given before or after the meeting to which it relates and may be given with respect to all meetings of the Board and committees of the Board. If a majority of directors participating in a meeting held under this Section are then in Canada, the meeting shall be deemed to be held in Canada.

- 5 -


4.9 Place of Meetings - Meetings of the Board may be held at any place within or outside Ontario. In any financial year of the Corporation, a majority of the meetings of the Board need not be held in Canada.

4.10 Calling of Meetings - Meetings of the Board shall be held from time to time at such time and at such place as the Board, the chair of the Board, the chief executive officer, the president, a vice-president or any two directors may determine.

4.11 Notice of Meeting - Notice of the time and place of each meeting of the Board shall be given in the manner provided in Section 11.1 to each director not less than 48 hours before the time when the meeting is to be held. A notice of a meeting of directors need not specify the purpose of or the business to be transacted at the meeting except where the Act requires such purpose or business to be specified. A director may in any manner waive notice of a meeting of the Board, and attendance of a director at a meeting constitutes a waiver of notice, except where the director attends a meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called.

4.12 First Meeting of New Board - Provided a quorum of directors is present, each newly elected Board may without notice hold its first meeting immediately following the meeting of shareholders at which such Board is elected.

4.13 Adjourned Meeting - Notice of an adjourned meeting of the Board is not required if the time and place of the adjourned meeting is announced at the original meeting.

4.14 Regular Meetings - The Board may appoint a day or days in any month or months for regular meetings of the Board at a place and hour to be named. A copy of any resolution of the Board fixing the place and time of such regular meetings shall be sent to each director forthwith after being passed, but no other notice shall be required for any such regular meeting except where the Act requires the purpose thereof or the business to be transacted thereat to be specified.

4.15 Meetings Without Notice . A meeting of the Board may be held at any time and place permitted by the Act or the articles or the by-laws without notice or on shorter notice than that provided for in this by-law, and proceedings at such meeting shall not be invalidated if all or if all the directors are present in person (except where a director attends the meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called) or if not so present have received notice, or before or after the meeting or the time prescribed for the notice of such meeting, in writing waive notice of or accept short notice of such meeting.

4.16 Chair - The chair of any meeting of the Board shall be the first mentioned of such of the following officers as have been appointed and who is a director and is present at the meeting: chair of the Board, chief executive officer, president, or a vice-president. If no such officer is present, the directors present shall choose one of their number to be chair.

4.17 Votes to Govern - At all meetings of the Board every question shall be decided by a majority of the votes cast on the question of those directors entitled to vote. In case of an equality of votes the chair of the meeting shall not be entitled to a second or casting vote.

- 6 -


4.18 Conflict of Interest - A director or officer who:

(a)

is a party to; or

   
(b)

is a director or an officer of, or has a material interest in, any person who is a party to;

a material contract or transaction or proposed material contract or transaction with the Corporation shall disclose the nature and extent of such director's or officer's interest at the time and in the manner provided by the Act. Any such contract or transaction or proposed material contract or transaction shall be referred to the Board or shareholders for approval in accordance with the Act even if such contract or proposed material contract or transaction is one that in the ordinary course of the Corporation's business would not require approval by the Board or shareholders, and a director interested in a contract or transaction so referred to the Board shall not attend any part of a meeting of the Board during which the contract or transaction is discussed and shall not vote on any resolution to approve such contract or transaction except as provided by the Act.

4.19 Remuneration and Expenses - Subject to the articles and any unanimous shareholder agreement, the directors shall be paid such remuneration for their services as the Board may from time to time determine. The directors shall also be entitled to be reimbursed for travelling and other expenses properly incurred by them in attending meetings of the Board or any committee thereof. Nothing herein contained shall preclude any director from serving the Corporation in any other capacity and receiving remuneration therefor in that capacity.

SECTION 5
DELEGATION

5.1 Committee of Directors - The Board may appoint a committee of directors and delegate to such committee any of the powers of the Board except those which, under the Act, a committee of directors has no authority to exercise.

5.2 Transaction of Business - The powers of a committee of directors may be exercised by a meeting at which a quorum is present or by resolution in writing signed by all the members of such committee who would have been entitled to vote on that resolution at a meeting of the committee. Meetings of such committee may be held at any place within or outside Ontario.

5.3 Procedure - Unless otherwise determined by the Board, each committee shall have the power to fix its quorum at not less than a majority of its members, to elect its chair and to regulate its procedure.

- 7 -


SECTION 6
OFFICERS

6.1 Appointment - Subject to the articles and any unanimous shareholder agreement, the Board may from time to time appoint a chief executive officer, president, chief financial officer, one or more vice-presidents (to which title may be added words indicating seniority or function), a secretary, a treasurer and such other officers as the Board may determine, including one or more assistants to any of the officers so appointed. The Board may specify the duties of and, in accordance with this by-law and subject to the Act, the articles and any unanimous shareholder agreement, delegate to such officers powers to manage the business and affairs of the Corporation. Subject to Section 6.2, an officer may but need not be a director and one person may hold more than one office.

6.2 Chair of the Board - The Board may from time to time also appoint a chair of the Board who shall be a director. If appointed, the Board may assign to the chair any of the powers and duties that are by any provision of this by-law assigned to the chief executive officer; and the chair shall, subject to the Act, have such other powers and duties as the Board may specify. During the absence or disability of the chair of the Board, the chair's duties shall be performed and the chair's powers exercised by the chief executive officer if the chief executive officer is a director, failing which, such other director as the majority of the directors shall determine.

6.3 Chief Executive Officer – If appointed, the chief executive officer, subject to the authority of the Board, shall be responsible for implementing the strategic plans and policies of the Corporation as established by the Board; and the chief executive officer shall have such other powers and duties as the Board may specify. During the absence or disability of the chair, or if no chair has been appointed, the chief executive officer shall have the powers and duties of that office as contemplated in Section 6.2.

6.4 President - If appointed, the president shall have general supervision of the business of the Corporation and shall have such other powers and duties as the Board may specify. During the absence or disability of the chief executive officer, or if no chief executive officer has been appointed, the president shall also have the powers and duties of that office.

6.5 Chief Financial Officer – If appointed, the chief financial officer shall keep proper accounting records in compliance with the Act and shall be responsible for the deposit of money, the safekeeping of securities and the disbursement of the funds of the Corporation; the chief financial officer shall render to the Board whenever required an account of all transactions as chief financial officer and of the financial position of the Corporation; and shall have such other powers and duties as the Board or the chief executive officer may specify.

6.6 Vice-President - If appointed, a vice-president shall have such powers and duties as the Board or the chief executive officer may specify.

6.7 Secretary - If appointed, the secretary shall attend and be the secretary of all meetings of the Board, shareholders and committees of the Board and shall enter or cause to be entered in records kept for that purpose minutes of all proceedings thereat; the secretary shall give or cause to be given, as and when instructed, all notices to shareholders, directors, officers, auditors and members of committees of the Board; the secretary shall be the custodian of the stamp or mechanical device generally used for affixing the corporate seal of the Corporation and of all books, papers, records, documents and instruments belonging to the Corporation, except when some other officer or agent has been appointed for that purpose; and the secretary shall have such other powers and duties as the Board or the chief executive officer may specify.

- 8 -


6.8 Treasurer - If appointed, the treasurer shall have such powers and duties as the Board or the chief financial officer may specify. During the absence or disability of the chief financial officer, or if no chief financial officer has been appointed, the treasurer shall have the powers and duties of that office.

6.9 Powers and Duties of Other Officers - The powers and duties of all other officers shall be such as the terms of their engagement call for or as the Board or the chief executive officer may specify. Any of the powers and duties of an officer to whom an assistant has been appointed may be exercised and performed by such assistant, unless the Board or the chief executive officer otherwise directs. 6.10 Variation of Powers and Duties - The Board may from time to time and subject to the Act, vary, add to or limit the powers and duties of any officer.

6.11 Term of Office - The Board, in its discretion, may remove any officer of the Corporation, without prejudice to such officer's rights under any employment contract. Otherwise each officer appointed by the Board shall hold office until such officer's successor is appointed, or until such officer's earlier resignation.

6.12 Terms of Employment and Remuneration - The terms of employment and the remuneration of officers appointed by the Board shall be settled by it from time to time.

6.13 Conflict of Interest - An officer who:

(a)

is a party to; or

   
(b)

is a director or an officer of, or has a material interest in, any person who is a party to;

a material contract or transaction or proposed material contract or transaction with the Corporation shall disclose the nature and extent of such officer's interest at the time and in the manner provided by the Act.

6.14 Agents and Attorneys - The Board shall have power from time to time to appoint agents or attorneys for the Corporation in or outside Canada with such powers of management or otherwise (including the power to sub-delegate) as may be thought fit.

6.15 Fidelity Bonds - The Board may require such officers, employees and agents of the Corporation as the Board deems advisable to furnish bonds for the faithful discharge of their powers and duties, in such form and with such surety as the Board may from time to time determine.

SECTION 7
PROTECTION OF DIRECTORS, OFFICERS AND OTHERS

7.1 Limitation of Liability - No director or officer shall be liable for the acts, receipts, neglects or defaults of any other director or officer or employee, or for joining in any receipt or other act for conformity, or for any loss, damage or expense happening to the Corporation through the insufficiency or deficiency of title to any property acquired for or on behalf of the Corporation, or for the insufficiency or deficiency of any security in or on which any of the moneys of the Corporation shall be invested, or for any loss or damage arising from the bankruptcy, insolvency or tortious acts of any person with whom any of the moneys, securities or effects of the Corporation shall be deposited, or for any loss occasioned by any error of judgment or oversight on such individual's part, or for any other loss, damage or misfortune whatever which shall happen in the execution of the duties of such individual's office or in relation thereto; provided that nothing herein shall relieve any director or officer from the duty to act in accordance with the Act and the Regulations or from liability for any breach thereof.

- 9 -


7.2 Indemnity - Subject to the Act, the Corporation shall indemnify a director or officer of the Corporation, a former director or officer of the Corporation or another individual who acts or acted at the Corporation's request as a director or officer, or an individual acting in a similar capacity, of another entity, and such person's heirs and legal representatives, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the Corporation or other entity, if:

(a)

the individual acted honestly and in good faith with a view to the best interests of the Corporation or, as the case may be, to the best interest of the other entity for which the individual acted as a director or officer or in a similar capacity at the Corporation's request; and

   
(b)

in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the person had reasonable grounds for believing that the individual's conduct was lawful.

7.3 Insurance - Subject to the Act, the Corporation may purchase and maintain such insurance for the benefit of its directors and officers as such, as the Board may from time to time determine.

SECTION 8
SHARES

8.1 Allotment - Subject to the Act, the articles and any unanimous shareholder agreement, the Board may from time to time allot or grant options to purchase the whole or any part of the authorized and unissued shares of the Corporation at such times and to such persons and for such consideration as the Board shall determine, provided that no share shall be issued until it is fully paid as provided by the Act.

8.2 Commissions - The Board may from time to time authorize the Corporation to pay a reasonable commission to any person in consideration of such person purchasing or agreeing to purchase shares of the Corporation, whether from the Corporation or from any other person, or procuring or agreeing to procure purchasers for any such shares.

8.3 Registration of Transfer - Subject to the Act, no transfer of shares shall be registered in a securities register except on presentation of the certificate or acknowledgment of the right to receive a certificate representing such shares with an endorsement which complies with the Act, together with such reasonable assurance or evidence of signature, identification and authority to transfer as the Board may from time to time prescribe, on payment of all applicable taxes and any fees prescribed by the Board, on compliance with such restrictions on transfer as are authorized by the articles and on satisfaction of any lien referred to in Section 8.5.

8.4 Transfer Agents and Registrars - The Board may from time to time appoint a registrar to maintain the securities register and a transfer agent to maintain the register of transfers and may also appoint one or more branch registrars to maintain branch securities registers and one or more branch transfer agents to maintain branch registers of transfers, but one person may be appointed both registrar and transfer agent. The Board may at any time terminate any such appointment.

- 10 -


8.5 Lien for Indebtedness - If the articles provide that the Corporation shall have a lien on shares registered in the name of a shareholder indebted to the Corporation, such lien may be enforced, subject to any other provision of the articles and to any unanimous shareholder agreement, by the sale of the shares thereby affected or by any other action, suit, remedy or proceeding authorized or permitted by law or by equity and, pending such enforcement, the Corporation may refuse to register a transfer of the whole or any part of such shares.

8.6 Non-recognition of Trusts - Subject to the Act, the Corporation may treat the person in whose name a share is registered in the securities register as the person exclusively entitled to vote, to receive notices, to receive any dividend or other payments in respect of the share and otherwise to exercise all the rights and powers of an owner.

8.7 Security Certificates - Every holder of one or more securities of the Corporation shall be entitled, at the Corporation’s option, to a security certificate, or to a non-transferable written acknowledgement of such security holder's right to obtain a security certificate, stating the number and class or series of securities held by such security holder as shown on the securities register. Security certificates and acknowledgements of a security holder's right to a security certificate, respectively, shall be in such form as the Board shall from time to time approve. Any security certificate shall be signed in accordance with Section 2.2 and need not be under the corporate seal; provided that, unless the Board otherwise determines, certificates representing securities in respect of which a transfer agent and/or registrar has been appointed shall not be valid unless countersigned by or on behalf of such transfer agent and/or registrar. The signature of one of the signing officers or, in the case of security certificates which are not valid unless countersigned by or on behalf of a transfer agent and/or registrar, the signatures of both signing officers, may be printed or mechanically reproduced in facsimile on security certificates and every such facsimile signature shall for all purposes be deemed to be the signature of the officer whose signature it reproduces and shall be binding on the Corporation. A security certificate executed as aforesaid shall be valid notwithstanding that one or both of the officers whose facsimile signature appears thereon no longer holds office at the date of issue of the certificate.

8.8 Replacement of Security Certificates - The Board or any officer or agent designated by the Board may in its or such person's discretion direct the issue of a new security certificate in lieu of and on cancellation of a security certificate that has been mutilated or in substitution for a security certificate claimed to have been lost, destroyed or wrongfully taken on payment of such fee, not exceeding the amount prescribed by the Regulations, and on such terms as to indemnity, reimbursement of expenses and evidence of loss and of title as the Board may from time to time prescribe, whether generally or in any particular case.

8.9 Joint Security Holders - If two or more persons are registered as joint holders of any security, the Corporation shall not be bound to issue more than one certificate in respect thereof, and delivery of such certificate to one of such persons shall be sufficient delivery to all of them. Any one of such persons may give effectual receipts for the certificate issued in respect thereof or for any dividend, bonus, return of capital or other money payable or warrant issuable in respect of such security.

8.10 Deceased Security Holders - In the event of the death of a holder, or of one of the joint holders, of any security, the Corporation shall not be required to make any entry in the securities register in respect thereof or to make payment of any dividends thereon except on production of all such documents as may be required by law and on compliance with the reasonable requirements of the Corporation and its transfer agents.

- 11 -


SECTION 9
DIVIDENDS AND RIGHTS

9.1 Dividends - Subject to the Act, the Board may from time to time declare dividends payable to the shareholders according to their respective rights and interests in the Corporation. Dividends may be paid in money or property or by issuing fully paid shares of the Corporation.

9.2 Dividend Cheques - A dividend payable in money shall be paid by cheque drawn on the Corporation's bankers or one of them to the order of each registered holder of shares of the class or series in respect of which it has been declared and mailed by prepaid ordinary mail to such registered holder at such registered holder's recorded address, unless such holder otherwise directs. In the case of joint holders the cheque shall, unless such joint holders otherwise direct, be made payable to the order of all of such joint holders and mailed to them at their recorded address. The mailing of such cheque as aforesaid, unless the same is not paid on due presentation, shall satisfy and discharge the liability for the dividend to the extent of the sum represented thereby plus the amount of any tax which the Corporation is required to and does withhold.

9.3 Non-receipt of Cheques - In the event of non-receipt of any dividend cheque by the person to whom it is sent as aforesaid, the Corporation shall issue to such person a replacement cheque for a like amount on such terms as to indemnity, reimbursement of expenses and evidence of non-receipt and of title as the Board may from time to time prescribe, whether generally or in any particular case. 9.4 Record Date for Dividends and Rights - The Board may fix in advance a date, preceding by not more than 50 days, the date for the payment of any dividend or the date for the issue of any warrant or other evidence of the right to subscribe for securities of the Corporation, as a record date for the determination of the persons entitled to receive payment of such dividend or to exercise the right to subscribe for such securities, provided that notice of any such record date shall be given, not less than 7 days before such record date. Where no record date is fixed so, the record date for the determination of the persons entitled to receive payment of any dividend or to exercise the right to subscribe for securities of the Corporation shall be at the close of business on the day on which the resolution relating to such dividend or right to subscribe is passed by the Board.

9.5 Unclaimed Dividends - Any dividend unclaimed after the expiry of the applicable limitation period shall be forfeited and shall revert to the Corporation.

SECTION 10
MEETINGS OF SHAREHOLDERS

10.1 Annual Meetings - The annual meeting of shareholders shall be held at such time in each year and, subject to Section 10.3, at such place as the Board, may from time to time determine, for the purpose of considering the financial statements and reports required by the Act to be placed before the annual meeting, electing directors, appointing auditors and for the transaction of such other business as may properly be brought before the meeting.

10.2 Special Meetings - The Board, the chair of the Board, the chief executive officer, or the president shall have power to call a special meeting of shareholders at any time.

10.3 Place of Meetings – Subject to the articles and any unanimous shareholder agreement, meetings of shareholders shall be held at the registered office of the Corporation or, if the Board shall so determine, at some other place in Ontario or, at some place outside Ontario if all the shareholders entitled to vote at the meeting so agree. A meeting of shareholders held under Section 10.4 is deemed to be held at the place where the registered office is located.

- 12 -


10.4 Participation by Electronic Means - If the Corporation chooses to make available a telephonic or electronic facility that permits all participants to communicate adequately with each other during a meeting of shareholders, any shareholder entitled to attend such meeting may participate in the meeting by means of such telephonic or electronic communication facility. A shareholder, who through such means votes at the meeting or establishes a communications link to the meeting is deemed to be present at the meeting. Notwithstanding any other provision of this bylaw, any person participating in a meeting of shareholders pursuant to this Section who is entitled to vote at that meeting may vote, in accordance with the Act and the Regulations, by means of any telephonic, electronic or other communication facility that the Corporation has made available for that purpose.

10.5 Notice of Meetings - Notice of the time and place of each meeting of shareholders shall be given in the manner provided in Section 11.1 not less than 10 nor more than 50 days before the date of the meeting, or within such other period as may be provided by the Act or prescribed by the Regulations to each director, to the auditor and to each shareholder who at the close of business on the record date for notice, is entered in the securities register as the holder of one or more shares carrying the right to vote at the meeting. Notice of a meeting of shareholders called for any purpose other than consideration of the financial statements and auditors report, election of directors and reappointment of the incumbent auditors shall state the nature of such business in sufficient detail to permit the shareholder to form a reasoned judgment thereon and shall state the text of any special resolution to be submitted to the meeting.

10.6 List of Shareholders Entitled to Notice - For every meeting of shareholders, the Corporation shall prepare within the time specified by the Act a list of shareholders entitled to receive notice of the meeting, arranged in alphabetical order and showing the number of shares held by each shareholder. If a record date for notice is fixed pursuant to Section 10.7, the shareholders listed shall be those registered at the close of business on such record date. If no record date for notice is so fixed, the shareholders listed shall be those registered (a) at the close of business on the day immediately preceding the day on which notice of the meeting is given, or (b) on the day on which the meeting is held where no such notice is given. The list shall be available for examination by any shareholder during usual business hours at the registered office of the Corporation or at the place where the central securities register is maintained and at the meeting for which the list was prepared. 10.7 Record Date for Notice The Board may fix in advance a date, preceding the date of any meeting of shareholders by not less than 21 days and not more than 50 days, as a record date for the determination of the shareholders entitled to notice of the meeting, and notice of any such record date shall be given not less than 7 days before such record date by newspaper advertisement and written notice in the manner provided by the Act. If no record date for notice is so fixed, the record date for the determination of the shareholders entitled to notice of the meeting shall be (a) at the close of business on the day immediately preceding the day on which notice of the meeting is given, or (b) on the day on which the meeting is held where no such notice is given.

10.8 Meetings without Notice - A meeting of shareholders may be held at any time and place permitted by the Act without notice or on shorter notice than that provided for herein, and proceedings thereat shall not be invalidated (a) if all the shareholders entitled to vote thereat are present in person or represented by proxy (other than as expressly to object that the meeting is not lawfully called) or if those not present in person or represented by proxy waive notice before or after the meeting or the time prescribed for the notice thereof, in writing of such meeting being held, and (b) if the auditors and the directors are present or if those not present, waive notice of or otherwise consent to such meeting being held. At such a meeting any business may be transacted which the Corporation at a meeting of shareholders may transact. If the meeting is held at a place outside Ontario, shareholders not present in person or represented by proxy, but who have waived notice of such meeting, shall also be deemed to have consented to the meeting being held at such place.

- 13 -


10.9 Chair, Secretary and Scrutineers - The chair of any meeting of shareholders shall be the first mentioned of such of the following officers as have been appointed and who is present at the meeting: chief executive officer, president, chair of the Board, or a vice-president who is a director. If no such officer is present within 15 minutes from the time fixed for holding the meeting, the persons present and entitled to vote shall choose one of their number to be chair. If the secretary of the Corporation is absent, the chair shall appoint some person, who need not be a shareholder, to act as secretary of the meeting. If desired, one or more scrutineers, who need not be shareholders, may be appointed by a resolution or by the chair with the consent of the meeting.

10.10 Persons Entitled to be Present - The only persons entitled to attend a meeting of shareholders shall be those entitled to vote thereat, the directors and auditor of the Corporation and others who, although not entitled to vote, are entitled or required under the Act or the articles or bylaws to be present at the meeting. Any other person may be admitted only on the invitation of the chair of the meeting or with the consent of the meeting.

10.11 Quorum - Subject to the Act, a quorum for the transaction of business at any meeting of shareholders shall be two or more persons present in person, each being a shareholder entitled to vote thereat, or a duly appointed proxy or proxy holder for an absent shareholder so entitled, holding or representing in the aggregate not less than 33 1/3 % of the issued and outstanding shares of the Corporation. If a quorum is present at the opening of any meeting of shareholders, the shareholders present in person or represented by proxy may proceed with the business of the meeting notwithstanding that a quorum is not present throughout the meeting. If a quorum is not present at the opening of any meeting of shareholders, the shareholders present in person or represented by proxy may adjourn the meeting to a fixed time and place, but may not transact any other business.

10.12 Right to Vote - Subject to the Act as to authorized representatives of any other body corporate or association, at any meeting of shareholders for which the Corporation must prepare a list referred to in Section 10.6, every person who is named in such list shall be entitled to vote the shares shown opposite such person's name.

10.13 Proxies - Every shareholder entitled to vote at a meeting of shareholders may appoint a proxyholder, or one or more alternate proxyholders, who need not be shareholders, to attend and act at the meeting in the manner and to the extent authorized and with the authority conferred by the proxy. A proxy shall be in writing executed by the shareholder or such shareholder's attorney and shall conform with the Act. Every such shareholder which is a body corporate or association may by resolution of its directors or governing body authorize an individual who need not be a shareholder to represent it at a meeting of shareholders and such individual may exercise on the shareholder's behalf all the powers it could exercise if it were an individual shareholder. The authority of such an individual shall be established by depositing with the Corporation a certified copy of such resolution, or in such other manner as may be satisfactory to the secretary of the Corporation or the chair of the meeting.

10.14 Time for Deposit of Proxies - The Board may specify in a notice calling a meeting of shareholders a time, preceding the time of such meeting by not more than 48 hours exclusive of non-business days, before which time proxies to be used at such meeting must be deposited. A proxy shall be acted on only if, prior to the time so specified, it shall have been deposited with the Corporation or an agent thereof specified in such notice or, if no such time is specified in such notice, unless it has been received by the secretary of the Corporation or by the chair of the meeting or any adjournment thereof prior to the time of voting.

- 14 -


10.15 Joint Shareholders - If two or more persons hold shares jointly, one of them present in person or represented by proxy at a meeting of shareholders may, in the absence of the other or others, vote the shares; but if two or more of those persons are present in person or represented by proxy and vote, they shall vote as one on the shares jointly held by them.

10.16 Votes to Govern - At any meeting of shareholders every question shall, unless otherwise required by the articles or by-laws or by law, be determined by a majority of the votes cast on the question. In case of an equality of votes either on a show of hands or on a ballot or on results of electronic voting, the chair of the meeting shall not be entitled to a second or casting vote.

10.17 Show of Hands - Subject to the Act, any question at a meeting of shareholders shall be decided by a show of hands unless a ballot thereon is required or demanded as hereinafter provided. On a show of hands every person who is present and entitled to vote shall have one vote. Whenever a vote by show of hands shall have been taken on a question, unless a ballot thereon is so required or demanded, a declaration by the chair of the meeting that the vote on the question has been carried or carried by a particular majority or not carried and an entry to that effect in the minutes of the meeting shall be prima facie evidence of the fact without proof of the number or proportion of the votes recorded in favour of or against any resolution or other proceeding in respect of the question, and the result of the vote so taken shall be the decision of the shareholders on the question.

10.18 Ballots - On any question proposed for consideration at a meeting of shareholders, and whether or not a show of hands has been taken thereon, the chair may require a ballot of any person present or any shareholder or proxyholder entitled to vote on such question at the meeting may demand a ballot. A ballot so demanded shall be taken in such manner as the chair shall direct. A demand for a ballot may be withdrawn at any time prior to the taking of the ballot. If a ballot is taken each person present shall be entitled, in respect of the shares which such person is entitled to vote at the meeting on the question, to that number of votes provided by the Act or the articles, and the result of the ballot so taken shall be the decision of the shareholders on the question.

10.19 Adjournment - If a meeting of shareholders is adjourned by one or more adjournments for an aggregate of less than 30 days it is not necessary to give notice of the adjourned meeting other than by announcement at the time of an adjournment. If a meeting of shareholders is adjourned by one or more adjournments for an aggregate of 30 days or more but not more than 90 days, notice of the adjourned meeting shall be given as for an original meeting but the management of the Corporation shall not be required to send a form of proxy in the form provided by the Act to each shareholder who is entitled to receive notice of the meeting.

10.20 Resolution in Writing - A resolution in writing signed by all the shareholders entitled to vote on that resolution at a meeting of shareholders is as valid as if it had been passed at a meeting of the shareholders unless a written statement with respect to the subject matter of the resolution is submitted by a director or the auditors in accordance with the Act.

10.21 Only One Shareholder - Where the Corporation has only one shareholder or only one holder of any class or series of shares, the shareholder present in person or by proxy constitutes a meeting.

- 15 -


SECTION 11
NOTICES

11.1 Method of Giving Notices - Any notice (which term includes any communication or document) to be given (which term includes sent, delivered or served) pursuant to the Act, the Regulations, the articles, the by-laws or otherwise to a shareholder, director, officer or member of a committee of the Board or to the auditors shall be sufficiently given if delivered personally to the person to whom it is to be given or if delivered to such person's recorded address or if mailed to such person at such person's recorded address by prepaid ordinary or air mail or if sent to such person at such person's recorded address by facsimile or if provided to such person by electronic means in accordance with the Electronic Commerce Act, 2000 (Ontario). A notice so delivered shall be deemed to have been given when it is delivered personally or to the recorded address as aforesaid; a notice so mailed shall be deemed to have been received by the addressee on the fifth day after mailing; and a notice so provided by electronic means (including by facsimile) shall be deemed to have been sent and received in the manner and at the time specified in the Electronic Commerce Act, 2000 (Ontario). The secretary may change or cause to be changed the recorded address of any shareholder, director, officer, auditor or member of a committee of the Board in accordance with any information believed by the secretary to be reliable.

11.2 Notice to Joint Shareholders - If two or more persons are registered as joint holders of any share, any notice shall be addressed to all of such joint holders but notice to one of such persons shall be sufficient notice to all of them.

11.3 Computation of Time - In computing the date when notice must be given under any provision requiring a specified number of days notice of any meeting or other event, the date of giving the notice shall be excluded and the date of the meeting or other event shall be included.

11.4 Undelivered Notices - If any notice given to a shareholder pursuant to Section 11.1 is returned on two consecutive occasions because such shareholder cannot be found, the Corporation shall not be required to give any further notices to such shareholder until such shareholder informs the Corporation in writing of such shareholder's new address.

11.5 Omissions and Errors - The accidental omission to give any notice to any shareholder, director, officer, auditor or member of a committee of the Board or the non-receipt of any notice by any such person or any error in any notice not affecting the substance thereof shall not invalidate any action taken at any meeting held pursuant to such notice or otherwise founded thereon.

11.6 Persons Entitled by Death or Operation of Law - Every person who, by operation of law, transfer, death of a shareholder or any other means whatsoever, shall become entitled to any share, shall be bound by every notice in respect of such share which shall have been duly given to the shareholder from whom such person derives title to such share prior to such person's name and address being entered on the securities register (whether such notice was given before or after the happening of the event on which such person became so entitled) and prior to such person furnishing to the Corporation the proof of authority or evidence of entitlement provided by the Act.

11.7 Waiver of Notice - Any shareholder, (or such shareholder's duly appointed proxyholder), director, officer, auditors or member of a committee of the Board may at any time waive any notice, or waive or abridge the time for any notice, required to be given to such person under the Act, the Regulations, the articles, the by-laws or otherwise and such waiver or abridgement, whether given before or after the meeting or other event of which notice is required to be given, shall cure any default in the giving or in the time of such notice, as the case may be. Any such waiver or abridgement shall be in writing or by electronic means in accordance with the Electronic Commerce Act, 2002 (Ontario) except a waiver of notice of a meeting of shareholders or of the Board or of a committee of the Board which may be given in any manner.

- 16 -


SECTION 12
REPEAL

12.1 Repeal - By-law No. 2, entitled “A by-law relating generally to the transaction of the business and affairs of Stem Cell Therapeutics Corp.” and made as of August 23, 2005, is repealed as of the coming into force of this by-law provided that such repeal shall not affect the previous operation of any by-law so repealed or affect the validity of any act done or right, privilege, obligation or liability acquired or incurred under or the validity of any contract or agreement made pursuant to any such by-law prior to its repeal. All officers and persons acting under any by-law so repealed shall continue to act as if appointed by the directors under the provisions of this by-law or the Act until their successors are appointed.

SECTION 13
EFFECTIVE DATE

13.1 Effective Date - This by-law shall be effective when made by the Board.

Dated as of the 27 th day of May, 2014.

Signed “Calvin Stiller”                                     
Calvin Stiller
Chairman

- 17 -



Exhibit 2.1

 

RIGHTS AGREEMENT

DATED AS OF September 16, 2013

as amended on June 3, 2014

 

between

 

TRILLIUM THERAPEUTICS INC.
(formerly, Stem Cell Therapeutics Corp.)

and

COMPUTERSHARE INVESTOR SERVICES INC.

as Rights Agent


TABLE OF CONTENTS

ARTICLE 1 INTERPRETATION   1
      1.1 Certain Definitions 1
      1.2 Holder 12
      1.3 Acting Jointly or in Concert 12
      1.4 Application of Statutes, Regulations and Rules   12
      1.5 Currency 12
      1.6 Headings and References 12
      1.7 Singular, Plural, etc. 12
ARTICLE 2 THE RIGHTS   12
      2.1 Legend on Common Share Certificates 12
      2.2 Initial Exercise Price: Exercise of Rights: Detachment of Rights 13
      2.3 Adjustments to Exercise Price, Number of Rights 15
      2.4 Date on Which Exercise is Effective 19
      2.5 Execution, Authentication, Delivery and Dating of Rights Certificates 19
      2.6 Registration, Registration of Transfer and Exchange 19
      2.7 Mutilated, Destroyed, Lost and Stolen Rights Certificates 20
      2.8 Persons Deemed Owners 20
      2.9 Delivery and Cancellation of Certificates 20
      2.10 Agreement of Rights Holders 21
      2.11 Rights Certificate Holder Not Deemed a Shareholder 21
ARTICLE 3 ADJUSTMENTS TO THE RIGHTS IN THE EVENT OF CERTAIN TRANSACTIONS 21
      3.1 Flip-in Event 21
ARTICLE 4 THE RIGHTS AGENT   23
      4.1 General 23
      4.2 Merger or Amalgamation or Change of Name of Rights Agent 23
      4.3 Duties of Rights Agent 24
      4.4 Change of Rights Agent 25
ARTICLE 5 MISCELLANEOUS   26
      5.1 Redemption and Waiver 26
      5.2 Expiration 27
      5.3 Issuance of New Rights Certificates 27
      5.4 Supplements and Amendments 27
      5.5 Fractional Rights and Fractional Common Shares 29
      5.6 Rights of Action 29
      5.7 Non-Canadian or United States Holders 29
      5.8 Notices 29
      5.9 Compliance with Anti-Money Laundering Legislation 30
      5.10 Fiduciary Duties of the Directors 30
      5.11 Privacy Legislation 30
      5.12 Costs of Enforcement 31
      5.13 Successors 31
      5.14 Benefits of this Agreement 31
      5.15 Governing Law 31
      5.16 Counterparts 31
      5.17 Severability 31
      5.18 Determinations and Actions by the Board 31
      5.19 Regulatory Approvals 32
      5.20 Effective Date 32


RIGHTS AGREEMENT

RIGHTS AGREEMENT dated as of September 16, 2013, as amended on June 3, 2014 between TRILLIUM THERAPEUTICS INC. (formerly, Stem Cell Therapeutics Corp.) (the “ Corporation ”) and COMPUTERSHARE INVESTOR SERVICES INC. , as rights agent (the “ Rights Agent ”, which term shall include any successor Rights Agent hereunder).

WHEREAS:

A.

The board of directors of the Corporation (the “ Board ”) has determined it advisable and in the best interests of the Corporation to adopt a shareholder rights plan (the “ Rights Plan ”) to ensure, to the extent possible, that all shareholders of the Corporation are treated fairly in connection with any take-over offer for the Corporation; and

     
B.

In order to implement the Rights Plan, the Board:

     
(a)

authorized and declared a distribution of one right (“ Right ”) effective 5:00 p.m. (Toronto time on September 16, 2013 in respect of each Common Share (as hereinafter defined) outstanding at the Record Time (as hereinafter defined);

     
(b)

authorized the issuance of one Right in respect of each Common Share issued after the Record Time and prior to the earlier of the Separation Time (as hereinafter defined) and the Expiration Time (as hereinafter defined); and

     
(c)

the Corporation appointed the Rights Agent to act on behalf of the Corporation and the holders of Rights, and the Rights Agent was willing to so act, in connection with the issuance, transfer, exchange and replacement of Rights Certificates (as hereinafter defined), the exercise of Rights and other matters referred to herein;

     
C.

Each Right entitles the holder thereof, after the Separation Time, to purchase securities of the Corporation pursuant to the terms and subject to the conditions set forth herein; and

     
D.

The Rights Agent has agreed to act on behalf of the Corporation in connection with the issuance, transfer, exchange and replacement of Rights Certificates (as hereinafter defined), the exercise of Rights and other matters referred to herein.

NOW THEREFORE , in consideration of the premises and the respective agreements set forth herein, the Corporation and the Rights Agent hereby agree as follows:

ARTICLE 1
INTERPRETATION

1.1

Certain Definitions

       

In this Agreement, unless the context otherwise requires:

       
(a)

Acquiring Person ” means any Person who is the Beneficial Owner of 20% or more of the outstanding Voting Shares; provided however , that the term “ Acquiring Person ” does not include:

       
(i)

the Corporation or any Subsidiary of the Corporation,

       
(ii)

an underwriter or member of a banking or selling group that acquires Voting Shares from the Corporation in connection with a distribution of securities, or




  (iii)

any Person who becomes the Beneficial Owner of 20% or more of the outstanding Voting Shares as a result of one or any combination of:

       
  (A)

a Voting Share Reduction which, by reducing the number of Voting Shares outstanding, increases the percentage of Voting Shares Beneficially Owned by such Person to 20% or more of the Voting Shares then outstanding,

       
  (B)

a Permitted Bid Acquisition,

       
  (C)

an Exempt Acquisition,

       
  (D)

a Pro-Rata Acquisition, or

       
  (E)

a Convertible Security Acquisition,

       
 

in each such case, until such time thereafter as such Person becomes the Beneficial Owner (otherwise than pursuant to any one or more of a Voting Share Reduction, a Permitted Bid Acquisition, an Exempt Acquisition, a Pro-Rata Acquisition, or a Convertible Security Acquisition) of additional Voting Shares constituting more than 1% of the Voting Shares then outstanding, in which event such Person shall become an Acquiring Person as of the date and time of acquisition of such additional Voting Shares;

       
  (iv)

for a period of 10 days after the Disqualification Date (as hereinafter defined), any Person who becomes the Beneficial Owner of 20% or more of the outstanding Voting Shares as a result of such Person becoming disqualified from relying on clauses (vi) or (viii) of the definition of Beneficial Owner. In this definition, “ Disqualification Date ” means the first date of public announcement of facts indicating that such Person has or is making or has announced an intention to make a Take-over Bid alone or by acting jointly or in concert with any other Person; or

       
  (v)

a Grandfathered Person; provided however, that this exemption does not apply to any Grandfathered Person in the event that such Grandfathered Person becomes, after the Record Time, the Beneficial Owner of additional Voting Shares such that its Beneficial Ownership of Voting Shares is increased by more than 1% of the number of Voting Shares then outstanding (other than pursuant to any one or more of a Voting Share Reduction, a Permitted Bid Acquisition, an Exempt Acquisition, a Pro-Rata Acquisition, or a Convertible Security Acquisition).


  (b)

Affiliate ”, when used to indicate a relationship with a specified corporation, means a Person that directly, or indirectly through one or more controlled intermediaries, controls, or is controlled by, or is under common control with, such specified corporation.

       
  (c)

Agreement ” means this Rights Agreement as amended and supplemented from time to time.

       
  (d)

Associate ”, when used to indicate a relationship with a specified Person, means (i) a spouse of such specified Person, (ii) any Person of either sex with whom such specified Person is living in a conjugal relationship outside marriage or (iii) any relative of such specified Person or of a Person mentioned in clauses (i) or (ii) of this definition if that relative has the same residence as the specified Person.

       
  (e)

A Person is deemed the “ Beneficial Owner ” and to have “Beneficial Ownership ” of and to “ Beneficially Own ”, any securities:

       
  (i)

of which such Person or any of such Person’s Affiliates or Associates is the owner at law or in equity;

2



  (ii)

as to which such Person or any of such Person’s Affiliates or Associates has the right to become owner at law or in equity (where such right is exercisable within a period of 60 days, whether or not on condition or the happening of any contingency or the making of any payment) pursuant to any agreement, arrangement, pledge or understanding, whether or not in writing (other than (x) customary agreements with and between underwriters and/or banking group members and/or selling group members with respect to a public offering or private placement of securities, and (y) pledges of securities in the ordinary course of business), or upon the exercise of any Convertible Securities; and

     
  (iii)

which are Beneficially Owned within the meaning of clauses (i) or (ii) of this definition by any other Person with which such Person or any of such Person’s Affiliates is acting jointly or in concert,

provided however , that a Person is not deemed the “ Beneficial Owner ”, or to have “ Beneficial Ownership ” of, or to “ Beneficially Own ”, any security:

  (iv)

by reason of such security having been deposited or tendered pursuant to a tender or exchange offer or Take-over Bid made by such Person or any of such Person’s Affiliates or Associates or any other Person referred to in clause (iii) of this definition until the earlier of such deposited or tendered security (A) being accepted unconditionally for payment or exchange or (B) being taken up and paid for;

       
  (v)

by reason of the holder of such security having agreed to deposit or tender such security to a Take-over Bid made by such Person or any of such Person’s Affiliates or Associates or any other Person referred to in clause (iii) of this definition pursuant to a Permitted Lock-up Agreement;

       
  (vi)

by reason of such Person, any of such Person’s Affiliates or Associates or any other Person referred to in clause (iii) of this definition holding such security, provided that:

       
  (A)

the ordinary business of the Person (in this definition, the “ Manager ”) includes the management of mutual funds or investment funds for others (which others may include or be limited to one or more employee benefit plans or pension plans) and such security is held by the Manager in the ordinary course of such business in the performance of such Manager’s duties for the account of any other Person (in this definition, a “ Client ”), including non-discretionary accounts held on behalf of a Client by a dealer or broker registered under applicable laws;

       
  (B)

the Person (in this definition, a “ Trust Company ”) is licenced to carry on the business of a trust company under applicable law and, as such, acts as a trustee or administrator or in a similar capacity in relation to the estates of deceased or incompetent Persons (each, in this definition, an “ Estate Account ”) or in relation to other accounts (each, in this definition, an “ Other Account ”) and holds such security, and is acting, in the ordinary course of such duties for the Estate Account or for such Other Accounts;

       
  (C)

the ordinary business of such Person includes acting as an agent of the Crown in the management of public assets (in this definition, the “ Crown Agent ”);

       
  (D)

the Person is an independent Person established by statute for purposes that include, and the ordinary business or activity of such Person (in this definition, the “ Statutory Body ”) includes, the management of investment funds for employee benefit plans, pension plans, insurance plans of various public bodies and the Statutory Body holds such security for the purposes of its activities as such; or

3



  (E)

the Person (in this definition, the “ Administrator ”) is the administrator or trustee of one or more pension funds or plans (each, in this definition, a “ Plan ”) or is a Plan registered under the laws of Canada or any province thereof or the corresponding laws of the jurisdiction by which such Plan is governed and the Administrator or Plan holds such security for the purposes of its activities as such,


 

but only if the Manager, the Trust Company, the Crown Agent, the Statutory Body, the Administrator or the Plan, as the case may be, is not then making and has not announced a current intention to make a Take-over Bid, other than an Offer to Acquire Common Shares or other securities pursuant to a distribution by the Corporation or by means of ordinary market transactions (including prearranged trades entered into in the ordinary course of business of such Person) executed through the facilities of a stock exchange or an organized over-the-counter market, alone or by acting jointly or in concert with any other Person;

       
  (vii)

because such Person, or any other Person acting jointly or in concert with such Person is:

       
  (A)

a Client of the same Manager as another Person on whose account the Manager holds such security;

       
  (B)

an Estate Account or an Other Account of the same Trust Company as another Person on whose account the Trust Company holds such security; or

       
  (C)

a Plan with the same Administrator as another Plan on whose account the Administrator holds such securities;

       
  (viii)

because such Person, or any other Person acting jointly or in concert with such Person, is:

       
  (A)

a Client of a Manager and such security is owned at law or in equity by the Manager;

       
  (B)

an Estate Account or an Other Account of a Trust Company and such security is owned at law or in equity by the Trust Company; or

       
  (C)

a Plan and such security is owned at law or in equity by the Administrator of the Plan; or

       
  (ix)

because such Person is the registered holder of securities as a result of carrying on the business of, or acting as nominee for, a securities depository.

For purposes of this Agreement, the percentage of Voting Shares Beneficially Owned by any Person at any time shall be and be deemed to be the product determined by the formula:

100 x A
           B

where: A =

the number of votes for the election of all directors generally attached to the Voting Shares Beneficially Owned by such Person at such time; and

       
B =

the number of votes for the election of all directors generally attaching to all Voting Shares actually outstanding.

Where any Person is deemed to Beneficially Own unissued Voting Shares, such Voting Shares shall be deemed to be outstanding for the purpose of calculating the percentage of Voting Shares Beneficially Owned by such Person, but unissued Voting Shares which another Person may be deemed to Beneficially Own shall not be included in the denominator of the above formula.

4



  (f)

Business Corporations Act ” means the corporate statute under which the Corporation subsists at the relevant time.

         
  (g)

Business Day ” means any day other than (i) Saturday, (ii) Sunday or, (iii) unless otherwise specified, a day on which Canadian chartered banks in the City of Toronto, Ontario are generally authorized or obligated by law to close.

         
  (h)

Canadian-U.S. Exchange Rate ” means, on any date, the inverse of the U.S.-Canadian Exchange Rate.

         
  (i)

Canadian Dollar Equivalent ” of any amount which is expressed in United States dollars means, on any date, the Canadian dollar equivalent of such amount determined by reference to the Canadian-U.S. Exchange Rate on such date.

         
  (j)

Close of Business ” on any given date means 5:00 p.m. (Toronto time, unless otherwise specified), on such date; provided however , that if such date is not a Business Day, “ Close of Business ” on such date shall mean 5:00 p.m., (Toronto time, unless otherwise specified), on the next succeeding Business Day.

         
  (k)

Common Shares ” means the common shares in the capital of the Corporation.

         
  (l)

Competing Permitted Bid ” means a Take-over Bid that:

         
  (i)

is made after a Permitted Bid or Competing Permitted Bid has been made and prior to the expiry of that Permitted Bid or Competing Permitted Bid (in this definition, the “ Prior Bid ”);

         
  (ii)

satisfies all components of the definition of a Permitted Bid other than the requirements set out in clause (ii) of that definition; and

         
  (iii)

contains, and the take up and payment for securities tendered or deposited thereunder are subject to, irrevocable and unqualified conditions that no Voting Shares shall be taken up or paid for pursuant to the Competing Permitted Bid:

         
  (A)

prior to the Close of Business (Toronto time) on a date that is not earlier than the later of 35 days after the date of such Competing Permitted Bid and the earliest date on which Voting Shares may be taken up or paid for under any Prior Bid in existence at the date of such Competing Permitted Bid; and

         
  (B)

then only if, at the time that such Voting Shares are first taken up or paid for, more than 50% of the then outstanding Voting Shares held by Independent Shareholders have been deposited or tendered pursuant to the Competing Permitted Bid and not withdrawn.

         
  (m)

a Person is “ controlled ” by another Person if:

         
  (i)

securities entitled to vote in the election of directors, trustees or others occupying a corresponding office carrying more than 50% of the votes for the election of directors, trustees or others occupying a corresponding office are held, directly or indirectly, by or on behalf of the other Person; and

         
  (ii)

the votes carried by such securities are entitled, if exercised, to elect a majority of the directors, trustees or others occupying a corresponding office of such Person, and “ controls ”, “ controlling ” and “ under common control with ” shall be interpreted accordingly.

5



  (n)

Convertible Securities ” means at any time:

       
  (i)

any right (contractual or otherwise and regardless of whether such right constitutes a security) to acquire Voting Shares from the Corporation; and

       
  (ii)

any securities issued by the Corporation from time to time (other than the Rights) carrying any exercise, conversion or exchange right,

       
 

which is then exercisable or exercisable within a period of 60 days from that time pursuant to which the holder thereof may acquire Voting Shares or other securities convertible into or exercisable or exchangeable for Voting Shares (in each case, whether such right is then exercisable or exercisable within a period of 60 days from that time and whether or not on condition or the happening of any contingency).

       
  (o)

Convertible Security Acquisition ” means the acquisition of Voting Shares upon the exercise of Convertible Securities received by a Person pursuant to a Permitted Bid Acquisition, an Exempt Acquisition or a Pro-Rata Acquisition.

       
  (p)

Effective Date ” means September 16, 2013.

       
  (q)

Exchange Act of 1934 ” means the Securities Exchange Act of 1934, as amended, of the United States of America and the rules and regulations thereunder, unless otherwise specified, as the same exist on the date hereof.

       
  (r)

Exempt Acquisition ” means a Share acquisition:

       
  (i)

in respect of which the Board has waived the application of Section 3.1 pursuant to the provisions of Section 5.1 hereof;

       
  (ii)

pursuant to a regular dividend reinvestment or other plan of the Corporation made available by it to all holders of Voting Shares of a class or series of Voting Shares where such plan permits the holder to direct that dividends paid in respect of such Voting Shares be applied to the purchase from the Corporation of further securities of the Corporation;

       
  (iii)

pursuant to a distribution of Shares or Convertible Securities made by the Corporation pursuant to a prospectus or private placement, provided that such prospectus or private placement was approved by the Board and any applicable regulatory authorities; or

       
  (iv)

pursuant to a distribution of Shares or Convertible Securities made by the Corporation pursuant to a statutory procedure requiring Shareholder approval, including an amalgamation, merger or plan of arrangement.

       
  (s)

Exercise Price ” means, as of any date, the price at which a holder may purchase the securities issuable upon exercise of one whole Right. Until adjustment thereof in accordance with the terms hereof, the Exercise Price equals $100.

       
  (t)

Expiration Time ” means the earliest of: (i) the Termination Time and (ii) the termination of the annual meeting of the Corporation in the year 2016 unless at such meeting the duration of this Agreement is extended.

       
  (u)

Flip-in Event ” means a transaction or event that results in a Person becoming an Acquiring Person.

6



  (v)

Fiduciary ” means a trust company registered under the laws of Canada or any province thereof or a portfolio manager registered under the securities legislation of one or more provinces of Canada.

       
  (w)

Grandfathered Person ” means a person who is the Beneficial Owner of more than 20% of the outstanding Voting Shares as of the Record Time.

       
  (x)

Independent Shareholders ” means all holders of Common Shares other than:

       
  (i)

any Acquiring Person;

       
  (ii)

any Offeror;

       
  (iii)

any Affiliate or Associate of any Acquiring Person or Offeror;

       
  (iv)

any Person acting jointly or in concert with any Person referred to in clauses (i) or (ii); and

       
  (v)

any employee benefit plan, deferred profit sharing plan, stock participation plan or trust for the benefit of employees of the Corporation or a wholly-owned Subsidiary of the Corporation, unless the beneficiaries of such plan or trust direct the manner in which such Common Shares are to be voted or direct whether the Common Shares are to be tendered to a Take-over Bid.

       
  (y)

Market Price ” per security of any securities on any date means the average of the daily closing prices per security of such securities (determined as described below) on each of the 20 consecutive Trading Days through and including the Trading Day immediately preceding such date; provided however , that if an event of a type analogous to any of the events described in Section 2.3 hereof has caused the closing prices used to determine the Market Price on any Trading Days not to be fully comparable with the closing price on such date (or, if such date is not a Trading Day, on the immediately preceding Trading Day), each such closing price so used is to be appropriately adjusted in a manner analogous to the applicable adjustment provided for in Section 2.3 hereof in order to make it fully comparable with the closing price on such date (or, if such date is not a Trading Day, on the immediately preceding Trading Day). The closing price per security of any securities on any date shall be:

       
  (i)

the closing board lot sale price or, in the case no such sale takes place on such date, the average of the closing bid and asked prices for each share of such securities as reported by the principal stock exchange in Canada on which such shares are listed or posted for trading;

       
  (ii)

if such shares are not listed or posted for trading on any stock exchange in Canada, the last sale price, regular way, or, in case no such sale takes place on such date, the average of the closing bid and asked prices, regular way, for each share of such securities as reported in the principal consolidated transaction reporting system with respect to securities listed or admitted to trading on the principal national securities exchange in the United States on which such shares are listed or admitted to trading;

       
  (iii)

if for any reason none of such prices is available on such day or the securities are not listed or admitted to trading on a stock exchange in Canada or a national securities exchange in the United States, the last quoted price, or if not so quoted, the average of the high bid and low asked prices for each share of such securities in the over-the-counter market, as reported by the National Association of Securities Dealers, Inc. Automated Quotation System (“ NASDAQ ”) or such other system then in use; or

7



  (iv)

if on any such date such shares are not quoted by any such organization, the average of the closing bid and asked prices as furnished by a professional market maker making a market in such shares selected in good faith by the Board; provided however, that if on any such date such shares are not traded in the over-the-counter market, the closing price per share of such securities on such date shall mean the fair value per share of such securities on such date as determined by a nationally or internationally recognized investment dealer or investment banker. The Market Price shall be expressed in Canadian dollars and if initially determined in respect of any day forming part of the 20 consecutive Trading Day period in question in United States dollars, such amount shall be translated into Canadian dollars at the Canadian Dollar Equivalent thereof on the relevant Trading Day.


  (z)

Offer to Acquire ” includes:

       
  (i)

an offer to purchase, or a solicitation of an offer to sell, (including an offer commenced by public announcement or advertisement);

       
  (ii)

an acceptance of an offer to sell, whether or not such offer to sell has been solicited,

       
 

or any combination thereof, and the Person accepting an offer to sell shall be deemed to be making an Offer to Acquire to the Person that made the offer to sell.

       
  (aa)

Offeror ” means a Person who is making or has announced a current intention to make a Take- over Bid (including a Permitted Bid or Competing Permitted Bid but excluding an ordinary market transaction (including a prearranged trade in the ordinary course of business) contemplated in paragraph (vi) of the definition of Beneficial Owner) but only so long as the Take-over Bid so announced or made has not been withdrawn or terminated or has not expired.

       
  (bb)

Permitted Bid ” means a Take-over Bid which is made by means of a Take-over Bid circular and which also complies with the following additional provisions:

       
  (i)

the Take-over Bid is made to all holders of Voting Shares as registered on the books of the Corporation, other than the Offeror;

       
  (ii)

the Take-over Bid contains, and the take-up and payment for securities tendered or deposited thereunder are subject to, an irrevocable and unqualified condition that no Voting Shares shall be taken up or paid for pursuant to the Take-over Bid prior to the Close of Business (Toronto time) on a date which is not less than 60 days after the date of the Take-over Bid and only if at such date more than 50% of the Voting Shares held by Independent Shareholders have been deposited or tendered pursuant to the Take-over Bid and not withdrawn;

       
  (iii)

the Take-over Bid contains an irrevocable and unqualified provision that, unless the Take-over Bid is withdrawn, Voting Shares may be deposited pursuant to such Take-over Bid at any time during the period of time between the date of the Take-over Bid and the date on which Voting Shares may be taken up and paid for and that any Voting Shares deposited pursuant to the Take-over Bid may be withdrawn until taken up and paid for; and

       
  (iv)

the Take-over Bid contains an irrevocable and unqualified provision that if, on the date on which Voting Shares may be taken up and paid for, more than 50% of the Voting Shares held by Independent Shareholders have been deposited or tendered pursuant to the Take-over Bid and not withdrawn, the Offeror will make a public announcement of that fact and the Take-over Bid will remain open for deposits and tenders of Voting Shares for not less than 10 Business Days from the date of such public announcement, provided that a Permitted Bid will cease to be a Permitted Bid at any time when such bid ceases to meet any of the provisions of this definition.

8



  (cc)

Permitted Bid Acquisition ” means a Share acquisition made pursuant to a Permitted Bid or Competing Permitted Bid.

     
  (dd)

Permitted Lock-Up Agreement ” means an agreement (the “ Lock-up Agreement ”) between a Person and one or more holders of Voting Shares (each holder referred to herein as a “ Locked-up Person ”), the terms of which are publicly disclosed and a copy of which is made available to the public, including the Corporation, pursuant to which such holders agree to deposit or tender Voting Shares to a Take-over Bid (the “ Lock-up Bid ”) made by the Person or any of such Person’s Affiliates or Associates or any other Person referred to in clause (iii) of the definition of Beneficial Owner, whether such Lock-up Bid is made before or after the Lock-up Agreement is signed, provided that:


  (i)

the Lock-up Agreement permits the Locked-up Person to terminate its agreement to deposit or tender to or to not withdraw Voting Shares from the Lock-up Bid in the event a “ Superior Offer ” is made to the Locked-up Person. For purposes of this Subsection, a “Superior Offer” is any Take-over Bid, amalgamation, arrangement or similar transaction pursuant to which the cash equivalent value of the consideration per share to be received by holders of the Voting Shares under such transaction (the “ Superior Offer Consideration ”) is greater than the cash equivalent value per share to be received by holders of Voting Shares under the Lock-up Bid (the “ Lock-up Bid Consideration ”). Notwithstanding the foregoing, the Lock-up Agreement may require that the Superior Offer Consideration must exceed the Lock-up Bid Consideration by a specified percentage before such termination rights take effect, provided such specified percentage is not greater than 7%.

For greater clarity, the Lock-up Agreement may contain a right of first refusal or require a period of delay to give the Person who made the Lock-up Bid an opportunity to match a higher price in another Take-over Bid or transaction or similar limitation on the Locked-up Person’s right to withdraw Voting Shares from the agreement, so long as the limitation does not preclude the exercise by the Locked-up Person of the right to withdraw Voting Shares during the period of the other Take-over Bid or transaction; and

  (ii)

no “ break-up ” fees, “ top-up ” fees, penalties, expenses, or other amounts that exceed, in the aggregate, the greater of:

       
  (A)

2.5% of the Lock-up Bid Consideration payable under the Lock-up Agreement to the Locked-up Person; and

       
  (B)

one-half of the difference between the Superior Offer Consideration payable to the Locked-up Person and the Lock-up Bid Consideration the Locked-up Person would have received under the Lock-up Bid,

shall be payable pursuant to the Lock-up Agreement in the event that the Locked-up Person fails to tender Voting Shares pursuant to the Lock-up Bid or withdraws Voting Shares from the Lock-Up Bid in order to accept the other Take-over Bid or transaction.

  (ee)

Person ” includes any individual, firm, partnership, association, trust, body corporate, joint venture, syndicate or other form of unincorporated organization, government and its agencies and instrumentalities or other entity or group (whether or not having legal personality) and any successor (by merger, statutory amalgamation or arrangement, or otherwise) thereof.

     
  (ff)

Pro-Rata Acquisition ” means the acquisition of Voting Shares or securities convertible into or exchangeable for Voting Shares (i) as a result of a stock dividend, stock split or other event pursuant to which a Person receives or acquires Voting Shares or securities convertible into or exchangeable for Voting Shares on the same pro-rata basis as all other holders of Voting Shares of the same class or series, or (ii) pursuant to the receipt and/or exercise of rights issued by the Corporation on a pro-rata basis to all holders of a class or series of Voting Shares to subscribe for or purchase Voting Shares or securities convertible into or exchangeable for Voting Shares provided that such rights are acquired directly from the Corporation and not from any other Person, provided that the Person acquiring such Voting Shares does not thereby acquire a greater percentage of such Voting Shares, or securities convertible into or exchangeable for such Voting Shares, than the Person’s percentage of Voting Shares Beneficially Owned immediately prior to such acquisition.

9



  (gg)

Record Time ” means the Close of Business (Toronto time) on September 16, 2013.

       
  (hh)

Redemption Price ” has the meaning ascribed to that term in Subsection 5.1(a) hereof.

       
  (ii)

Regular Periodic Cash Dividends ” means cash dividends paid at regular intervals in any fiscal year of the Corporation to the extent that such cash dividends do not exceed, in the aggregate, the greatest of:

       
  (i)

200% of the aggregate amount of cash dividends declared payable by the Corporation on its Common Shares in its immediately preceding fiscal year;

       
  (ii)

300% of the arithmetic mean of the aggregate amount of cash dividends declared payable by the Corporation on its Common Shares in its three immediately preceding fiscal years; and

       
  (iii)

100% of the aggregate consolidated net income of the Corporation, before extraordinary items, for its immediately preceding fiscal year.

       
  (jj)

Rights Certificate ” has the meaning ascribed to that term in Subsection 2.2(c) hereof.

       
  (kk)

Rights Holders’ Special Meeting ” means a meeting of the holders of Rights called by the Board and conducted in accordance with the terms hereof.

       
  (ll)

Securities Act of 1933 ” means the Securities Act of 1933, as amended, of the United States of America and the rules and regulations thereunder, unless otherwise specified, as the same exist on the date hereof.

       
  (mm)

Securities Act ” means the Securities Act, R.S.O. 1990, c. S-5, as amended, and the regulations and rules thereunder, unless otherwise specified, as the same exist on the date hereof.

       
  (nn)

Separation Time ” means the Close of Business (Toronto time) on the tenth Trading Day after the earliest of:

       
  (i)

the Stock Acquisition Date;

       
  (ii)

the date of the commencement of, or first public announcement of the intent of any Person (other than the Corporation or any Subsidiary of the Corporation) to commence, a Take-over Bid (other than a Permitted Bid or a Competing Permitted Bid, as the case may be); and

       
  (iii)

the date upon which a Permitted Bid or Competing Permitted Bid ceases to be such,

or such later date as may be determined by the Board provided however, that if any such Take-over Bid expires, is cancelled, terminated or otherwise withdrawn prior to the Separation Time, such Take-over Bid shall be deemed, for purposes of this definition, never to have been made.

10



  (oo)

Shares ” means the shares in the capital of the Corporation.

     
  (pp)

Stock Acquisition Date ” means the first date of public announcement (which, for purposes of this definition, shall include, without limitation, a report filed pursuant to Section 5.2 of Multilateral Instrument 62-104 Take-Over Bids and Issuer Bids or Section 13(d) under the Exchange Act of 1934, as amended from time to time and any provision substituted therefor) by the Corporation or an Acquiring Person of facts indicating that an Acquiring Person has become such.

     
  (qq)

Subsidiary ”:

     
 

A body corporate is a Subsidiary of another body corporate if:


  (i)

it is controlled by (A) that other, or (B) that other and one or more bodies corporate, each of which is controlled by that other, or (C) two or more bodies corporate, each of which is controlled by that other; or

     
  (ii)

it is a Subsidiary of a body corporate that is that other’s Subsidiary.


  (rr)

Take-over Bid ” means an Offer to Acquire Voting Shares or securities convertible into Voting Shares, where the Voting Shares subject to the Offer to Acquire, together with the Voting Shares, if any, into which the securities subject to the Offer to Acquire are convertible and the Voting Shares Beneficially Owned by the Offeror at the date of the Offer to Acquire constitute, in the aggregate, 20% or more of the then outstanding Voting Shares.

     
  (ss)

Termination Time ” means the time at which the right to exercise Rights shall terminate pursuant to Section 5.1 hereof.

     
  (tt)

Trading Day ”, when used with respect to any securities, means a day on which the principal securities exchange in Canada on which such securities are listed or admitted to trading is open for the transaction of business or, if the securities are not listed or admitted to trading on any securities exchange in Canada, a day on which the principal securities exchange in the United States of America on which such securities are listed or admitted to trading is open for the transaction of business, or if the securities are not listed or admitted to trading on any securities exchange in Canada or the United States of America, a Business Day.

     
  (uu)

U.S.-Canadian Exchange Rate ” means, on any date:


  (i)

if on such date the Bank of Canada sets an average noon spot rate of exchange for the conversion of one United States dollar into Canadian dollars, such rate; and

     
  (ii)

in any other case, the rate for such date for the conversion of one United States dollar into Canadian dollars calculated in the manner which shall be determined by the Board from time to time.


  (vv)

U.S. Dollar Equivalent ” of any amount which is expressed in Canadian dollars means, on any date, the United States dollar equivalent of such amount determined by reference to the U.S.- Canadian Exchange Rate on such date.

     
  (ww)

Voting Share Reduction ” means an acquisition or a redemption by the Corporation of Voting Shares.

     
  (xx)

Voting Shares ” means, collectively, the Common Shares and any other Shares entitled to vote generally for the election of directors.

11



1.2

Holder

   

As used in this Agreement, unless the context otherwise requires, the “ holder ” when used with reference to Rights, means the registered holder of such Rights or, prior to the Separation Time, the associated Common Shares.

   
1.3

Acting Jointly or in Concert

   

For purposes of this Agreement, a Person is acting jointly or in concert with every other Person who is a party to any agreement, commitment or understanding (whether formal or informal and whether or not in writing), to acquire or offer to acquire Voting Shares (other than customary agreements with and between underwriters and banking group or selling group members with respect to the distribution of securities pursuant to a prospectus or by way of private placement and other than pursuant to pledges of securities in the ordinary course of business).

   
1.4

Application of Statutes, Regulations and Rules

   

Where a statute, regulation or rule is referred to in a definition or other provision of this Agreement, it shall be conclusively deemed to have application in the contemplated circumstances notwithstanding that such statute, regulation or rule might not, but for the provisions of this Section 1.4, have application for want of jurisdiction or otherwise.

   
1.5

Currency

   

All sums of money which are referred to in this Agreement are expressed in lawful money of Canada, unless otherwise specified.

   
1.6

Headings and References

   

The headings of the Articles and Sections of this Agreement and the Table of Contents are inserted for convenience and reference only and shall not affect the construction or interpretation of this Agreement. All references to Articles, Sections, Subsections and Exhibits are to articles and sections and subsections of and exhibits to, and forming part of, this Agreement. The words “ hereto ”, “ herein ”, “ hereof ”, “ hereunder ”, “ this Agreement ”, “ the Rights Agreement ” and similar expressions refer to this Agreement including the Exhibits, as the same may be amended, modified or supplemented at any time or from time to time.

   
1.7

Singular, Plural, etc.

   

In this Agreement, where the context so admits, words importing the singular number include the plural and vice versa and words importing gender include the masculine, feminine and neuter genders.

ARTICLE 2
THE RIGHTS

2.1

Legend on Common Share Certificates

   

Certificates for Common Shares issued after the Record Time hereof and prior to the earlier of the Separation Time and the Expiration Time shall evidence one Right for each Common Share represented thereby and shall have impressed, printed, or written thereon or otherwise affixed thereto a legend in substantially the following form:

“Until the earlier of the Separation Time or the Expiration Time (as such terms are defined in the Rights Agreement referred to below), this certificate also evidences and entitles the holder hereof to certain Rights as set forth in a Rights Agreement dated as of September 16, 2013 (the “Rights Agreement”), as amended on June 3, 2014 between Trillium Therapeutics Inc. (the “Corporation”) and Computershare Investor Services Inc., as Rights Agent, the terms of which are hereby incorporated herein by reference and a copy of which is on file and may be inspected during normal business hours at the principal executive offices of the Corporation. Under certain circumstances, as set forth in the Rights Agreement, such Rights may be amended or redeemed, may expire, may become void, or may be evidenced by separate certificates and may no longer be evidenced by this certificate. The Corporation will mail or arrange for the mailing of a copy of the Rights Agreement to the holder of this certificate without charge within five days after the receipt of a written request therefor.”

12



Certificates representing Common Shares that are issued and outstanding at the Record Time shall evidence one Right for each Common Share evidenced thereby notwithstanding the absence of a legend in substantially the foregoing form until the earlier of the Separation Time and the Expiration Time.

       
2.2

Initial Exercise Price: Exercise of Rights: Detachment of Rights

       
(a)

Subject to adjustment as herein set forth, each Right will entitle the holder thereof, after the Separation Time and prior to the Expiration Time, to purchase, for the Exercise Price, one Common Share. Notwithstanding any other provision of this Agreement, any Rights held by the Corporation or any of its Subsidiaries are void.

       
(b)

Until the Separation Time,

       
(i)

the Rights are not exercisable and no Right may be exercised; and

       
(ii)

for administrative purposes, each Right shall be evidenced by the certificate for the associated Common Share registered in the name of the holder thereof (which certificate is deemed to represent a Rights Certificate) and is transferable only together with, and shall be transferred by a transfer of, such associated Common Share.

       
(c)

After the Separation Time and prior to the Expiration Time, the Rights (i) may be exercised and

       
(ii)

shall be registered and transferable independent of Common Shares. Promptly following the Separation Time, the Corporation shall prepare and the Rights Agent shall mail to each holder of record of Common Shares as of the Separation Time (other than an Acquiring Person, any other Person whose Rights are or become void pursuant to the provisions of Subsection 3.1(b) hereof and, in respect of any Rights Beneficially Owned by such Acquiring Person which are not held of record by such Acquiring Person, the holder of record of such Rights), at such holder’s address as shown in the records of the Corporation (the Corporation hereby agreeing to furnish copies of such records to the Rights Agent for this purpose),

       
(i)

a certificate (a “ Rights Certificate ”) in substantially the form of Exhibit A hereto appropriately completed and registered in such holder’s name, representing the number of Rights held by such holder at the Separation Time and having such marks of identification or designation and such legends, summaries or endorsements printed thereon as the Corporation may deem appropriate and as are not inconsistent with the provisions of this Agreement, or as may be required to comply with any applicable law or with any rule or regulation made pursuant thereto or with any rule or regulation of any stock exchange or quotation system on which the Rights may from time to time be listed or traded, or to conform to usage; and

       
(ii)

a disclosure statement describing the Rights.

       
(d)

Rights may be exercised in whole at any time or in part from time to time on any Business Day (or other day that is not a bank holiday at the place of exercise) after the Separation Time and prior to the Expiration Time by submitting to the Rights Agent at its office in the City of Toronto, Canada or at any other office of the Rights Agent or any Co-Rights Agent in the city(ies) specified in the Rights Certificate or designated from time to time for that purpose by the Corporation after consultation with the Rights Agent:

13



  (i)

the Rights Certificate evidencing such Rights with an Election to Exercise (an “ Election to Exercise ”) substantially in the form attached to the Rights Certificate, appropriately completed and duly executed by the holder or his executors or administrators or other personal representatives or his legal attorney duly appointed by instrument in writing in form and executed in a manner satisfactory to the Rights Agent; and

     
  (ii)

payment by certified cheque or money order payable to the order of the Corporation, of a sum equal to the Exercise Price multiplied by the number of Rights being exercised and a sum sufficient to cover any transfer tax or charge which may be payable in respect of any transfer involved in the issuance, transfer or delivery of Rights Certificates or the issuance, transfer or delivery of certificates for Common Shares in a name other than that of the holder of the Rights being exercised.


  (e)

Upon receipt of a Rights Certificate accompanied by a duly completed and executed Election to Exercise which does not indicate that Rights evidenced by such Rights Certificate have become void pursuant to Subsection 3.1(b) hereof and payment as set forth in Subsection 2.2(d) above, the Rights Agent (unless otherwise instructed by the Corporation) shall thereupon promptly:

       
  (i)

requisition from a transfer agent of the Common Shares certificates for the number of Common Shares to be purchased (the Corporation hereby irrevocably authorizing its transfer agents to comply with all such requisitions);

       
  (ii)

when appropriate, requisition from the Corporation the amount of cash to be paid in lieu of issuing fractional Common Shares;

       
  (iii)

after receipt of such certificates, deliver the same to or upon the order of the registered holder of such Rights Certificate, registered in such name or names as may be designated by such holder together with, where applicable, any cash payment in lieu of a fractional interest; and

       
  (iv)

tender to the Corporation all payments received on exercise of the Rights.

       
  (f)

In case the holder of any Rights shall exercise less than all the Rights evidenced by such holder’s Rights Certificate, a new Rights Certificate evidencing (subject to the provisions of Subsection 5.5(a) hereof) the Rights remaining unexercised will be issued by the Rights Agent to such holder or to such holder’s duly authorized assigns.

       
  (g)

The Corporation covenants and agrees to:

       
  (i)

take all such action as may be necessary on its part and within its powers to ensure that all Shares delivered upon exercise of Rights shall, at the time of delivery of the certificates evidencing such Shares (subject to payment of the Exercise Price), be duly and validly authorized, executed, issued and delivered and be fully paid and non- assessable;

       
  (ii)

take all reasonable action as may be necessary on its part and within its power to comply with any applicable requirements of the Business Corporations Act, the securities acts or comparable legislation of each of the provinces and territories of Canada and the Securities Act of 1933 , and the rules and regulations thereunder, and any other applicable law, rule or regulation, in connection with the issuance and delivery of Rights Certificates and of any securities of the Corporation upon exercise of Rights;

14



  (iii)

use its reasonable efforts to cause all Common Shares issued upon exercise of Rights to be listed on the stock exchanges on which the Common Shares were traded immediately before the Stock Acquisition Date; and

     
  (iv)

pay when due and payable any and all Canadian and United States federal, provincial and state transfer taxes (not including any taxes referable to the income or profit of the holder or exercising Person or any liability of the Corporation to withhold tax) and charges which may be payable in respect of the original issuance or delivery of the Rights Certificates or of any Shares of the Corporation issued upon the exercise of Rights, provided that the Corporation shall not be required to pay any transfer tax or charge - which may be payable in respect of any transfer involved in the transfer or delivery of Rights Certificates or the issuance or delivery of certificates for securities in a name other than that of the holder of the Rights being transferred or exercised.


2.3

Adjustments to Exercise Price, Number of Rights

       

The Exercise Price, the number and kind of securities subject to purchase upon exercise of each Right and the number of Rights outstanding are subject to adjustment from time to time as provided in this Section 2.3.

       
(a)

If the Corporation shall at any time after the Record Time and prior to the Expiration Time:

       
(i)

declare or pay a dividend on Common Shares payable in Common Shares (or other Shares of capital or securities exchangeable for or convertible into or giving a right to acquire Common Shares or other Shares of capital) otherwise than pursuant to any optional share dividend program;

       
(ii)

subdivide or change the outstanding Common Shares into a greater number of Common Shares;

       
(iii)

consolidate or change the outstanding Common Shares into a smaller number of Common Shares; or

       
(iv)

issue any Common Shares (or other shares of capital or securities exchangeable for or convertible into or giving a right to acquire Common Shares or other Shares of capital) in respect of, in lieu of, or in exchange for, existing Common Shares in a reclassification or redesignation of Common Shares, an amalgamation or statutory arrangement,

the Exercise Price and the number of Rights outstanding, or, if the payment or effective date therefore shall occur after the Separation Time, the securities purchasable upon exercise of Rights shall be adjusted in the manner set forth below. If an event occurs which would require an adjustment under both this Section 2.3 and Subsection 3.1(a), the adjustment provided for in this Section 2.3 shall be in addition to, and shall be made prior to, any adjustment required under Subsection 3.1(a) . If the Exercise Price and number of Rights are to be adjusted,

  (v)

the Exercise Price in effect after such adjustment shall be equal to the Exercise Price in effect immediately prior to such adjustment divided by the number of Common Shares (or other Shares of capital) (the “ Expansion Factor ”) that a holder of one Common Share immediately prior to such dividend, subdivision, change, consolidation or issuance would hold immediately thereafter as a result thereof (assuming the exercise of all such exchange or conversion rights, if any); and

     
  (vi)

each Right held prior to such adjustment shall become that number of Rights equal to the Expansion Factor, and the adjusted number of Rights shall be deemed to be distributed among the Common Shares with respect to which the original Rights were associated (if they remain outstanding) and the Shares issued in respect of such dividend, subdivision, change, consolidation or issuance, so that each such Common Share (or other whole Share or security exchangeable for or convertible into a whole Share of capital) shall have exactly one Right associated with it.

15



 

If the securities purchasable upon exercise of Rights are to be adjusted, the securities purchasable upon exercise of each Right after such adjustment shall be the securities that a holder of the securities purchasable upon exercise of one Right immediately prior to such dividend, subdivision, change, consolidation or issuance would hold immediately thereafter as a result thereof. To the extent that any such rights of exchange, conversion or acquisition are not exercised prior to the expiration thereof, the Exercise Price shall be readjusted to the Exercise Price which would then be in effect based upon the number of Common Shares (or securities convertible into or exchangeable for Common Shares) actually issued upon the exercise of such rights. If, after the Record Time and prior to the Expiration Time, the Corporation issues any shares of its authorized capital other than Common Shares in a transaction of a type described in the first sentence of this Subsection 2.3(a), such shares shall be treated herein as nearly equivalent to Common Shares as may be practicable and appropriate under the circumstances and the Corporation and the Rights Agent agree to amend this Agreement in order to effect such treatment.

     
 

If the Corporation, at any time after the Record Time and prior to the Separation Time, issues any Common Shares otherwise than in a transaction referred to in the preceding paragraph, each such Common Share so issued shall automatically have one new Right associated with it, which Right shall be evidenced by the certificate representing such Share.

     
  (b)

If the Corporation, at any time after the Record Time and prior to the Separation Time, fixes a record date for the making of a distribution to all holders of Common Shares of rights or warrants entitling them (for a period expiring within 45 days after such record date) to subscribe for or purchase Common Shares (or securities convertible into or exchangeable for or carrying a right to purchase or subscribe for Common Shares) at a price per Common Share (or, in the case of a security convertible into or exchangeable for or carrying a right to purchase or subscribe for Common Shares, having a conversion, exchange or exercise price (including the price required to be paid to purchase such convertible or exchangeable security or right) per share) that is less than 90% of the Market Price per Common Share on such record date, the Exercise Price shall be adjusted. The Exercise Price in effect after such record date shall equal the Exercise Price in effect immediately prior to such record date multiplied by a fraction, of which the numerator shall be the number of Common Shares outstanding on such record date plus the number of Common Shares which the aggregate offering price of the total number of Common Shares so to be offered (and/or the aggregate initial conversion, exchange or exercise price of the convertible or exchangeable securities or rights so to be offered (including the price required to be paid to purchase such convertible or exchangeable securities or rights)) would purchase at such Market Price and of which the denominator shall be the number of shares of Common Shares outstanding on such record date plus the number of additional Common Shares to be offered for subscription or purchase (or into which the convertible or exchangeable securities or rights so to be offered are initially convertible, exchangeable or exercisable). In case such subscription price may be paid in a consideration part or all of which is in a form other than cash, the value of such consideration shall be as determined by the Board. To the extent that any such rights or warrants are not so issued or, if issued, are not exercised prior to the expiration thereof, the Exercise Price shall be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or to the Exercise Price which would then be in effect based upon the number of Common Shares (or securities convertible into or exchangeable for Common Shares) actually issued upon the exercise of such rights or warrants, as the case may be. For purposes of this Agreement, the granting of the right to purchase Common Shares (whether previously unissued, treasury shares or otherwise) pursuant to any optional dividend reinvestment plan and/or any Common Share purchase plan providing for the reinvestment of dividends payable on securities of the Corporation and/or employee stock option, stock purchase or other employee benefit plan (so long as such right to purchase is in no case evidenced by the delivery of rights or warrants) shall not be deemed to constitute an issue of rights or warrants by the Corporation; provided however , that, in the case of any dividend reinvestment plan, the right to purchase Common Shares is at a price per share of not less than 90% of the then current market price per share (determined as provided in such plan) of the Common Shares.

16



  (c)

If the Corporation, at any time after the Record Time and prior to the Separation Time, fixes a record date for the making of a distribution to all holders of Common Shares of evidences of indebtedness or assets (other than a Regular Periodic Cash Dividend or a dividend paid in Common Shares) or rights or warrants (excluding those referred to in Subsection 2.3(a) or 2.3(b)), the Exercise Price shall be adjusted. The Exercise Price in effect after such record date shall, subject to adjustment as provided in the penultimate sentence of Subsection 2.3(b), equal the Exercise Price in effect immediately prior to such record date less the fair market value of the portion of the assets, evidences of indebtedness, rights or warrants so to be distributed applicable to the securities purchasable upon exercise of one Right.

       
  (d)

Each adjustment made pursuant to this Section 2.3 shall be made as of:

       
  (i)

the payment or effective date for the applicable dividend, subdivision, change, consolidation or issuance in the case of an adjustment made pursuant to Subsection 2.3(a) above; and

       
  (ii)

the record date for the applicable dividend or distribution, in the case of an adjustment made pursuant to subsections 2.3(b) or (c) above.

       
  (e)

Notwithstanding anything herein to the contrary, no adjustment to the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least 1% in such Exercise Price; provided however , that any adjustments which by reason of this Subsection 2.3(e) are not required to be made shall be carried forward and taken into account in any subsequent adjustment. Each adjustment made pursuant to this Section 2.3 shall be calculated to the nearest cent or to the nearest one ten-thousandth of a Common Share or Right, as the case may be.

       
  (f)

All Rights originally issued by the Corporation subsequent to any adjustment made to an Exercise Price hereunder shall evidence the right to purchase, at the adjusted Exercise Price, the number of Common Shares purchasable from time to time hereunder upon exercise of the Rights, all subject to further adjustment as provided herein.

       
  (g)

Unless the Corporation has exercised its election as provided in Subsection 2.3(h), upon each adjustment of an Exercise Price as a result of the calculations made in subsections 2.3(b) or (c), each Right outstanding immediately prior to the making of such adjustment shall thereafter evidence the right to purchase, at the adjusted Exercise Price, that number of Common Shares (calculated to the nearest one ten-thousandth) obtained by:

       
  (i)

multiplying (A) the number of Common Shares covered by a Right immediately prior to this adjustment, by (B) the Exercise Price in effect immediately prior to such adjustment of the Exercise Price; and

       
  (ii)

dividing the product so obtained by the Exercise Price in effect immediately after such adjustment of the Exercise Price.

       
  (h)

The Corporation may elect on or after the date of any adjustment of an Exercise Price to adjust the number of Rights, in lieu of any adjustment in the number of Common Shares purchasable upon the exercise of a Right. Each of the Rights outstanding after the adjustment in the number of Rights shall be exercisable for the number of Common Shares for which a Right was exercisable immediately prior to such adjustment. Each Right held of record immediately prior to such adjustment of the number of Rights shall become the number of Rights (calculated to the nearest one ten-thousandth) obtained by dividing the Exercise Price in effect immediately prior to the adjustment of the Exercise Price by the Exercise Price in effect immediately after adjustment of the Exercise Price. The Corporation shall make a public announcement of its election to adjust the number of Rights, indicating the record date for the adjustment and, if known at the time, the amount of the adjustment to be made. This record date may be the date on which the Exercise Price is adjusted or any date thereafter, but, if the Rights Certificates have been issued, shall be at least 10 calendar days after the date of the public announcement. If Rights Certificates have been issued, upon each adjustment of the number of Rights pursuant to this Subsection 2.3(h), the Corporation shall, as promptly as practicable, cause to be distributed to holders of record of Rights Certificates on such record date, Rights Certificates evidencing the additional Rights to which such holder shall be entitled as a result of such adjustment, or, at the option of the Corporation, shall cause to be distributed to such holders of record in substitution or replacement for the Rights Certificates held by such holders prior to the date of adjustment, and upon surrender thereof, if required by the Corporation, new Rights Certificates evidencing all the Rights to which such holders shall be entitled after such adjustment. Rights Certificates so to be distributed shall be issued, executed and countersigned in the manner provided for herein and may bear, at the option of the Corporation, the adjusted Exercise Price and shall be registered in the names of the holders of record of Rights Certificates on the record date specified in the public announcement.

17



  (i)

Irrespective of any adjustment or change in the securities purchasable upon exercise of the Rights, the Rights Certificates theretofore and thereafter issued may continue to express the securities so purchasable which were expressed in the initial Rights Certificates issued hereunder.

       
  (j)

If, as a result of an adjustment made pursuant to Section 3.1, the holder of any Right thereafter Exercised shall become entitled to receive any securities other than Common Shares, thereafter the number of such other securities so receivable upon exercise of any Right and the applicable Exercise Price thereof shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as may be practicable to the provisions with respect to the Common Shares contained in the foregoing subsections of this Section 2.3 and the provisions of this Agreement with respect to the Common Shares shall apply on like terms to any such other securities.

       
  (k)

In any case in which this Section 2.3 requires that any adjustment in the Exercise Price be made effective as of a record date for a specified event, the Corporation may elect to defer until the occurrence of such event the issuance to the holder of any Right exercised after such record date of the number of Common Shares and other securities of the Corporation, if any, issuable upon such exercise over and above the number of Common Shares and other securities of the Corporation, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment; provided however , that the Corporation shall deliver to such holder a due bill or other appropriate instrument evidencing such holder’s right to receive such additional Common Shares or other securities upon the occurrence of the event requiring such adjustment.

       
  (l)

Whenever an adjustment to the Exercise Price or a change in the securities purchasable upon the exercise of Rights is made pursuant to this Section 2.3, the Corporation shall promptly:

       
  (i)

prepare a certificate setting forth such adjustment and a brief statement of the facts accounting for such adjustment;

       
  (ii)

file with the Rights Agent and with each transfer agent for the Common Shares, a copy of such certificate; and

       
  (iii)

cause notice of the particulars of such adjustment or change to be given to the holders of the Rights.

Failure to file such certificate or to cause such notice to be given as aforesaid, or any defect therein, shall not affect the validity of any such adjustment or change.

18



2.4

Date on Which Exercise is Effective

     

Each Person in whose name any certificate for Shares is issued upon the exercise of Rights shall for all purposes be deemed to have become the holder of record of the Shares represented thereby on, and such certificate shall be dated, the date upon which the Rights Certificate evidencing such Rights was duly submitted (together with a duly completed Election to Exercise) and payment of the Exercise Price for such Rights (and any applicable transfer taxes and other charges payable by the exercising holder hereunder) was made; provided however, that if the date of such exercise is a date upon which the relevant Share transfer books of the Corporation are closed, such Person shall be deemed to have become the recorded holder of such Shares on, and such certificate shall be dated, the next succeeding Business Day on which the said Share transfer books of the Corporation are open.

     
2.5

Execution, Authentication, Delivery and Dating of Rights Certificates

     
(a)

The Rights Certificates shall be executed on behalf of the Corporation by its Chairman, President and Chief Executive Officer or one of its Vice-Presidents, under its corporate seal reproduced thereon attested by its Secretary or one of its Assistant Secretaries. The signature of any of these officers on the Rights Certificates may be manual or facsimile.

     
(b)

Rights Certificates bearing the manual or facsimile signatures of individuals who were at any time the proper officers of the Corporation shall bind the Corporation, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the countersignature and delivery of such Rights Certificates.

     
(c)

Promptly after the Corporation learns of the Separation Time, the Corporation shall notify the Rights Agent of such Separation Time and shall deliver Rights Certificates executed by the Corporation to the Rights Agent for countersignature, and the Rights Agent shall countersign (manually or by facsimile signature in a manner satisfactory to the Corporation) and deliver such Rights Certificates to the holders of the Rights pursuant to Subsection 2.2(c) hereof. No Rights Certificate shall be valid for any purpose until countersigned by the Rights Agent in the manner described above.

     
(d)

Each Rights Certificate shall be dated the date of countersignature thereof.

     
2.6

Registration, Registration of Transfer and Exchange

     
(a)

The Corporation shall cause to be kept a register (the “ Rights Register ”) in which, subject to such reasonable regulations as it may prescribe, the Corporation shall provide for the registration and transfer of Rights. The Rights Agent is hereby appointed “ Rights Registrar ” for the purpose of maintaining the Rights Register for the Corporation and registering Rights and transfers of Rights as herein provided. If the Rights Agent shall cease to be the Rights Registrar, the Rights Agent shall have the right to examine the Rights Register at all reasonable times.

     

After the Separation Time and prior to the Expiration Time, upon surrender for registration of transfer or exchange of any Rights Certificate, and subject to the provisions of Subsection 2.6(c) below, the Corporation shall execute, and the Rights Agent shall countersign and deliver, in the name of the holder or the designated transferee or transferees, as required pursuant to the holder’s instructions, one or more new Rights Certificates evidencing the same aggregate number of Rights as did the Rights Certificate so surrendered.

     
(b)

All Rights issued upon any registration of transfer or exchange of Rights Certificates shall be the valid obligations of the Corporation, and such Rights shall be entitled to the same benefits under this Agreement as the Rights surrendered upon such registration of transfer or exchange.

     
(c)

Every Rights Certificate surrendered for registration of transfer or exchange shall have the form of assignment thereon duly completed and endorsed, or be accompanied by a written instrument of transfer in form satisfactory to the Corporation or the Rights Agent, as the case may be, duly executed by the holder thereof or such holder’s attorney duly authorized in writing. As a condition to the issuance of any new Rights Certificate under this Section 2.6, the Corporation may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and other expenses (including the reasonable fees and expenses of its Rights Agent) connected therewith.

19



  (d)

The Corporation is not required to register the transfer or exchange of any Rights after the Rights have been terminated pursuant to the provisions of this Agreement.


2.7

Mutilated, Destroyed, Lost and Stolen Rights Certificates

     
(a)

If any mutilated Rights Certificate is surrendered to the Rights Agent prior to the Expiration Time, the Corporation shall execute and the Rights Agent shall countersign and deliver a new Rights Certificate evidencing the same number of Rights as did the Rights Certificate so surrendered.

     
(b)

If the Corporation and the Rights Agent receive prior to the Expiration Time (i) evidence to their satisfaction of the destruction, loss or theft of any Rights Certificate and (ii) such security or indemnity as may be required by them to save each of them and their respective agents harmless, then, in the absence of notice to the Corporation or the Rights Agent that such Rights Certificate has been acquired by a bona fide purchaser, the Corporation shall execute and upon the Corporation’s request, the Rights Agent shall countersign and deliver, in lieu of any such destroyed, lost or stolen Rights Certificate, a new Rights Certificate evidencing the same number of Rights as did the Rights Certificate so destroyed, lost or stolen.

     
(c)

As a condition to the issuance of any new Rights Certificate under this Section 2.7, the Corporation may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the reasonable fees and expenses of the Rights Agent) connected therewith.

     
(d)

Every new Rights Certificate issued pursuant to this Section 2.7 in lieu of any destroyed, lost or stolen Rights Certificate shall evidence an original additional contractual obligation of the Corporation, whether or not the destroyed, lost or stolen Rights Certificate shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Agreement equally and proportionately with any and all other Rights duly issued hereunder.

     
2.8

Persons Deemed Owners

     

Prior to due presentment of a Rights Certificate (or, prior to the Separation Time, the associated Share certificate) for registration of transfer, the Corporation, the Rights Agent and any agent of the Corporation or the Rights Agent may deem and treat the Person in whose name such Rights Certificate (or, prior to the Separation Time, such Share certificate) is registered as the absolute owner thereof and of the Rights evidenced thereby for all purposes whatsoever. As used in this Agreement, unless the context otherwise requires, the term “ holder ” of any Rights means the registered holder of such Rights (or, prior to the Separation Time, the associated Shares).

     
2.9

Delivery and Cancellation of Certificates

     

All Rights Certificates surrendered upon exercise or for redemption, registration of transfer or exchange shall, if surrendered to any Person other than the Rights Agent, be delivered to the Rights Agent and, in any case, shall be promptly cancelled by the Rights Agent. The Corporation may at any time deliver to the Rights Agent for cancellation any Rights Certificates previously countersigned and delivered hereunder which the Corporation may have acquired in any manner whatsoever, and all Rights Certificates so delivered shall be promptly cancelled by the Rights Agent. No Rights Certificates shall be countersigned in lieu of or in exchange for any Rights Certificates cancelled as provided in this Section 2.9, except as expressly permitted by this Agreement. The Rights Agent shall destroy all cancelled Rights Certificates and deliver a certificate of destruction to the Corporation.

20



2.10

Agreement of Rights Holders

     

Every holder of Rights by accepting the same consents and agrees with the Corporation and the Rights Agent and with every other holder of Rights that:

     
(a)

such holder shall be bound by and subject to the provisions of this Agreement, as amended from time to time in accordance with the terms hereof, in respect of all Rights held;

     
(b)

prior to the Separation Time, each Right is transferable only together with, and shall be transferred by a transfer of, the associated Share;

     
(c)

after the Separation Time, the Rights Certificates are transferable only on the Rights Register as provided herein;

     
(d)

prior to due presentment of a Rights Certificate (or, prior to the Separation Time, the associated Share certificate) for registration of transfer, the Corporation, the Rights Agent and any agent of the Corporation or the Rights Agent may deem and treat the Person in whose name the Rights Certificate (or, prior to the Separation Time, the associated Share certificate) is registered as the absolute owner thereof and of the Rights evidenced thereby (notwithstanding any notations of ownership or writing on such Rights Certificate or the associated Share certificate made by anyone other than the Corporation or the Rights Agent) for all purposes whatsoever, and neither the Corporation nor the Rights Agent shall be affected by any notice to the contrary;

     
(e)

such holder has waived all rights to receive any fractional Right or fractional Share upon exercise of a Right;

     
(f)

this Agreement may be supplemented or amended from time to time pursuant to Subsection 5.4(a) or the last sentence of the penultimate paragraph of Subsection 2.3(a) hereof upon the sole authority of the Board without the approval of any holder of Rights.

     
2.11

Rights Certificate Holder Not Deemed a Shareholder

     

No holder of any Rights or Rights Certificate is entitled, as such holder, to vote, receive dividends or be considered for any purpose the holder of any Common Share or any other share or security of the Corporation which may at any time be issuable on the exercise of the Rights represented thereby, and nothing contained herein or in any Rights Certificate is to be construed as conferring upon the holder of any Right or Rights Certificate, as such, any right of a holder of Common Shares or any other shares or securities of the Corporation or any right to vote at any meeting of shareholders of the Corporation whether for the election of directors or otherwise or upon any matter submitted to holders of Common Shares or any other shares of the Corporation at any meeting thereof, or to give or withhold consent to any action of the Corporation or to receive notice of any meeting or other action affecting any holder of Common Shares or any other shares of the Corporation except as expressly provided herein, or to receive dividends, distributions or subscription rights, or otherwise, until the Rights evidenced by Rights Certificates have been duly exercised in accordance with the terms and provisions hereof.

ARTICLE 3
ADJUSTMENTS TO THE RIGHTS
IN THE EVENT OF CERTAIN TRANSACTIONS

3.1

Flip-in Event

     
(a)

Subject to the provisions of Subsection 3.1(b) and Section 5.1 hereof, if prior to the Expiration Time a Flip-in Event occurs, each Right shall thereafter constitute, effective at the Close of Business on the tenth Business Day after the relevant Stock Acquisition Date, the right to purchase from the Corporation, upon exercise thereof in accordance with the terms hereof, that number of Common Shares of the Corporation having an aggregate Market Price on the date of consummation or occurrence of such Flip-in Event equal to twice the Exercise Price for an amount in cash equal to the Exercise Price (such right to be appropriately adjusted in a manner analogous to the applicable adjustment provided for in Section 2.3 hereof in the event that, after such date of consummation or occurrence, an event of a type analogous to any of the events described in Section 2.3 hereof shall have occurred with respect to such Common Shares).

21



  (b)

Notwithstanding anything in this Agreement to the contrary, upon the occurrence of a Flip-In Event, any Rights that are or were Beneficially Owned on or after the earlier of the Separation Time and the Stock Acquisition Date by:

       
  (i)

an Acquiring Person (or any Person acting jointly or in concert with an Acquiring Person or with an Affiliate or Associate of an Acquiring Person); or

       
  (ii)

a direct or indirect transferee of, or other successor in title to, such Rights (a “ Transferee ”), who becomes a Transferee concurrently with or subsequent to the Acquiring Person becoming an Acquiring Person, in a transfer, whether or not for consideration, that the Board has determined is part of a plan, understanding or scheme of an Acquiring Person (or an Affiliate or Associate of an Acquiring Person or any Person acting jointly or in concert with an Acquiring Person or an Affiliate or Associate of an Acquiring Person) that has the purpose or effect of avoiding the provisions of this Subsection 3.1(b) applicable in the circumstances contemplated in clause (i) hereof,

       
 

shall thereupon be void and any holder of such Rights (including any Transferee) shall thereafter have no rights whatsoever with respect to such Rights, whether under any provision of this Agreement or otherwise. The holder of any Rights represented by a Rights Certificate which is submitted to the Rights Agent, or any Co-Rights Agent, upon exercise or for registration of transfer or exchange which does not contain the necessary certifications set forth in the Rights Certificate establishing that such Rights are not void under this Subsection 3.1(b) shall be deemed to be an Acquiring Person for the purposes of this Subsection 3.1(b) and such rights shall be null and void.

       
  (c)

From and after the Separation Time the Corporation shall do all such acts and things as shall be necessary and within its power to ensure compliance with the provisions of this Section 3.1, including without limitation, all such acts and things as may be required to satisfy the requirements of the Business Corporations Act , the Securities Act and the securities laws or comparable legislation in each of the provinces of Canada in respect of the issue of Common Shares upon the exercise of Rights in accordance with this Agreement.

       
  (d)

Any Rights Certificate that represents Rights Beneficially Owned by a Person described in either clauses (i) or (ii) of Subsection 3.1(b) hereof or transferred to any nominee of any such Person, and any Rights Certificate issued upon the transfer, exchange or replacement of any other Rights Certificate referred to in this sentence shall contain the following legend:

“The Rights represented by this Rights Certificate were issued to a Person who was an Acquiring Person or an Affiliate or an Associate of an Acquiring Person (as such terms are defined in the Rights Agreement) or was acting jointly or in concert with any of them. This Rights Certificate and the Rights represented hereby shall become void in the circumstances specified in Subsection 3.1(b) of the Rights Agreement.”

provided however , that the Rights Agent shall not be under any responsibility to ascertain the existence of facts that would require the imposition of such legend but shall be required to impose such legend only if instructed to do so by the Corporation or if a holder fails to certify upon transfer or exchange in the space provided on the Rights Certificate that such holder is not an Acquiring Person or an Affiliate or Associate thereof or acting jointly or in concert with any of them.

22


ARTICLE 4
THE RIGHTS AGENT

4.1

General

     
(a)

The Corporation hereby appoints the Rights Agent to act as agent for the Corporation and the holders of Rights in accordance with the terms and conditions hereof, and the Rights Agent hereby accepts such appointment. The Corporation may from time to time appoint one or more co-rights agents (each, a “ Co-Rights Agent ”) as it may deem necessary or desirable after consultation with and subject to the approval of the Rights Agent. In such event, the respective duties of the Rights Agent and any Co-Rights Agent shall be as the Corporation may determine after consultation with the Rights Agent and Co-Rights Agent. The Corporation agrees to pay to the Rights Agent reasonable compensation for all services rendered by it hereunder and, from time to time on demand of the Rights Agent, its reasonable expenses and counsel fees and other disbursements incurred in the administration and execution of this Agreement and the exercise and performance of its duties hereunder. The Corporation also agrees to indemnify the Rights Agent, its officers, directors, employees and agents for, and to hold them harmless against, any loss, liability, or expense, incurred without gross negligence, bad faith or wilful misconduct on the part of the Rights Agent, its officers, directors, employees or agents, for anything done or omitted by them in connection with the acceptance and performance of this Agreement, including legal costs and expenses, which right to indemnification shall survive the termination of this Agreement or the resignation or removal of the Rights Agent.

     
(b)

The Rights Agent shall be protected from, and shall incur no liability for or in respect of, any action taken, suffered or omitted by it in connection with its performance of this Agreement in reliance upon any certificate for Shares, Rights Certificate, certificate for other securities of the Corporation, instrument of assignment or transfer, power of attorney, endorsement, affidavit, letter, notice, direction, consent, certificate, opinion, statement, or other paper or document believed by it to be genuine and to be signed, executed and, where necessary, verified or acknowledged, by the proper Person or Persons.

     
(c)

The Corporation shall inform the Rights Agent in a reasonably timely manner of events which may materially affect the administration of this Agreement by the Rights Agent and, at any time upon written request, shall provide to the Rights Agent an incumbency certificate certifying the then current officers of the Corporation.

     
(d)

It is understood that instructions to the Rights Agent will, except where circumstances make it impracticable or the Rights Agent otherwise agrees, be given in writing and, where not in writing, such instructions will be confirmed in writing as soon as reasonably possible after the giving of such instructions.

     
(e)

The Corporation shall give notice in writing to the Rights Agent of any supplement, amendment, deletion, variation, or recession to this Agreement pursuant to Section 5.4 within 5 Business Days of the date of such supplement, amendment, deletion, variation, or recession, provided that failure to give such notice, or any defect therein, shall not affect the validity of any such supplement, amendment, deletion, variation, or recession.

     
4.2

Merger or Amalgamation or Change of Name of Rights Agent

     
(a)

Any body corporate into which the Rights Agent or any successor Rights Agent may be merged or amalgamated with or into, or any body corporate succeeding to the securityholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such body corporate would be eligible for appointment as a successor Rights Agent under the provisions of Section 4.4 hereof. In case at the time such successor Rights Agent succeeds to the agency created by this Agreement any of the Rights Certificates have been countersigned but not delivered, any such successor Rights Agent may adopt the countersignature of the predecessor Rights Agent and deliver such Rights Certificates so countersigned; and in case at that time any of the Rights Certificates have not been countersigned, any successor Rights Agent may countersign such Rights Certificates either in the name of the predecessor Rights Agent or in the name of the successor Rights Agent; and in all such cases such Rights Certificates shall have the full force provided in the Rights Certificates and in this Agreement.

23



  (b)

In case at any time the name of the Rights Agent is changed and at such time any of the Rights Certificates shall have been countersigned but not delivered, the Rights Agent may adopt the countersignature under its prior name and deliver Rights Certificates so countersigned; and in case at that time any of the Rights Certificates shall not have been countersigned, the Rights Agent may countersign such Rights Certificates either in its prior name or in its changed name; and in all such cases such Rights Certificates shall have the full force provided in the Rights Certificates and in this Agreement.


4.3

Duties of Rights Agent

     

The Rights Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and conditions, by all of which the Corporation and the holders of Rights Certificates, by their acceptance thereof, shall be bound:

     
(a)

The Rights Agent, at the expense of the Corporation, may retain and consult with legal counsel (who may be legal counsel for the Corporation), and the opinion of such counsel will be full and complete authorization and protection to the Rights Agent as to any action taken or omitted by it in good faith and in accordance with such opinion.

     
(b)

Whenever in the performance of its duties under this Agreement the Rights Agent deems it necessary or desirable that any fact or matter be proved or established by the Corporation prior to taking or suffering any action or refraining from taking any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by an individual believed by the Rights Agent to be the Chairman, the President and Chief Executive Officer or any Vice-President and by the Treasurer or any Assistant Treasurer or the Secretary or any Assistant Secretary of the Corporation and delivered to the Rights Agent; and such certificate shall be full authorization to the Rights Agent for any action taken, omitted or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.

     
(c)

The Rights Agent shall be liable hereunder only for its own gross negligence, bad faith or wilful misconduct.

     
(d)

The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the certificates for Shares or the Rights Certificates (except its countersignature thereof) or be required to verify the same, but all such statements and recitals are and will be deemed to have been made by the Corporation only.

     
(e)

The Rights Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the due authorization, execution and delivery hereof by the Rights Agent) or in respect of the validity or execution of any Share certificate or Rights Certificate (except its countersignature thereof); nor will it be responsible for any breach by the Corporation of any covenant or condition contained in this Agreement or in any Rights Certificate; nor will it be responsible for any change in the exercisability of the Rights (including the Rights becoming void pursuant to Subsection 3.1(b) hereof) or any adjustment required under the provisions of Section 2.3 hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment (except with respect to the exercise of Rights after receipt of the certificate contemplated by Section 2.3 hereof describing any such adjustment); nor will it by any act hereunder be deemed to make any representation or warranty is to the authorization or reservation of any Shares to be issued pursuant to this Agreement or any Rights or as to whether any Shares shall, when issued, be duly and validly authorized, executed, issued and delivered and be fully paid and non-assessable.

24



  (f)

The Corporation agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement.

     
  (g)

The Rights Agent is hereby authorized to rely upon and directed to accept written instructions with respect to the performance of its duties hereunder from any individual believed by the Rights Agent to be the Chairman, the President and Chief Executive Officer or any Vice-President or the Secretary or any Assistant Secretary or the Treasurer or any Assistant Treasurer of the Corporation, and to apply to such individuals for advice or instructions in connection with its duties, and it shall not be liable for any action taken, omitted or suffered by it in good faith in accordance with instructions of any such individual.

     
  (h)

The Rights Agent and any shareholder, director, officer or employee of the Rights Agent may buy, sell or deal in Shares, Rights or other securities of the Corporation or become pecuniarily interested in any transaction in which the Corporation may be interested, or contract with or lend money to the Corporation or otherwise act as fully and freely as though it were not Rights Agent under this Agreement. Nothing herein shall preclude the Rights Agent from acting in any other capacity for the Corporation or for any other legal entity.

     
  (i)

The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorneys or agents or for any loss to the Corporation resulting from any such act, omission, default, neglect or misconduct, provided reasonable care was exercised in the selection and continued employment thereof.


4.4

Change of Rights Agent

   

The Rights Agent may resign and be discharged from its duties under this Agreement upon 60 days’ notice (or such lesser notice as is acceptable to the Corporation) in writing delivered or mailed to the Corporation and to each transfer agent of Shares by first class mall, and mailed or delivered to the holders of the Rights in accordance with Section 5.8 hereof. The Corporation may remove the Rights Agent upon 30 days’ notice in writing, mailed or delivered to the Rights Agent and to each transfer agent of the Shares by first class mail, and mailed to the holders of the Rights in accordance with Section 5.8 hereof. If the Rights Agent should resign or be removed or otherwise become incapable of acting, the Corporation shall appoint a successor to the Rights Agent. If the Corporation fails to make such appointment within a period of 30 days after such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent or by the holder of any Rights (which holder shall, with such notice, submit such holder’s Rights Certificate for inspection by the Corporation), then the holder of any Rights may apply, at the Corporation’s expense, to any court of competent jurisdiction for the appointment of a new Rights Agent. Any successor Rights Agent, whether appointed by the Corporation or by such a court, shall be a corporation incorporated under the laws of Canada or a province thereof and authorized to carry on the business of acting as a rights agent in the Province of Ontario. After appointment, the successor Rights Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Rights Agent without further act or deed; but the predecessor Rights Agent shall deliver and transfer to the successor Rights Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any such appointment, the Corporation shall file notice thereof in writing with the predecessor Rights Agent and each transfer agent of the Shares, and mail a notice thereof in writing to the holders of the Rights in accordance with Section 5.8. Failure to give any notice provided for in this Section 4.4, however, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be. For greater certainty, any notice required to be sent pursuant to this Agreement to holders of the Rights by the Rights Agent after its resignation or removal shall be at the expense of the Corporation.

25


ARTICLE 5
MISCELLANEOUS

5.1

Redemption and Waiver

       
(a)

With the prior consent of the holders of Voting Shares (obtained as described in Section 5.4(b)), the Board may, at any time prior to the occurrence of a Flip-in Event, elect to redeem all but not less than all of the then outstanding Rights at a redemption price of $0.000001 per Right appropriately adjusted in a manner analogous to the applicable adjustment provided for in Section 2.3 if an event of the type analogous to any of the events described in Section 2.3 shall have occurred (such redemption price being herein referred to as the “ Redemption Price ”).

       
(b)

The Board may waive the application of Section 3.1 in respect of the occurrence of any Flip-in Event if the Board has determined within 10 Trading Days following a Stock Acquisition Date that a Person became an Acquiring Person by inadvertence and without any intention to become, or knowledge that it would become, an Acquiring Person under this Agreement and if such a waiver is granted by the Board, such Stock Acquisition Date is deemed not to have occurred. Any such waiver pursuant to this Subsection 5.1(b) must be on the condition that such Person has, within 14 days after the foregoing determination by the Board or such earlier or later date as the Board may determine (the “ Disposition Date ”), reduced its Beneficial Ownership of Voting Shares such that the Person is no longer an Acquiring Person. If the Person remains an Acquiring Person at the close of business on the Disposition Date, the Disposition Date is deemed to be the date of occurrence of a further Stock Acquisition Date and Section 3.1 applies thereto.

       
(c)

If before the occurrence of a Flip-in Event a Person acquires, pursuant to:

       
(i)

a Permitted Bid;

       
(ii)

a Competing Permitted Bid; or

       
(iii)

a Take-over Bid in respect of which the Board has waived the application of Section 3.1 pursuant to Subsection 5.1(d),


 

any outstanding Common Shares, the Corporation shall, immediately upon such acquisition and without further formality, redeem the Rights at the Redemption Price.

     
  (d)

The Board acting in good faith may, prior to the occurrence of a Flip-in Event, upon prior written notice to the Rights Agent, waive the application of Section 3.1 to that particular Flip-in Event, provided that the Flip-in Event would occur by reason of a Take-over Bid made by means of a Take-over Bid circular sent to all holders of record of Voting Shares, further provided that if the Board waives the application of Section 3.1 to that particular Flip-in Event, the Board shall be deemed to have waived the application of Section 3.1 to any other Flip-in Event occurring by reason of a Take-over Bid made by means of a Take-over Bid circular sent to all holders of record of Voting Shares prior to the expiry of any Take-over Bid (as the same may be extended from time to time), in respect of which a waiver is, or is deemed to have been, granted under this Subsection 5.1(d).

26



  (e)

If the Rights are redeemed pursuant to this Agreement, the right to exercise the Rights will thereupon, without further action and without notice, terminate and the only right thereafter of the holders of Rights is to receive the Redemption Price.

     
  (f)

Within 10 days after the Rights are redeemed pursuant to this Agreement, the Corporation shall give notice of redemption to the holders of the then outstanding Rights by mailing such notice to all such holders at their last address as they appear upon the registry books of the Rights Agent or, prior to the Separation Time, on the registry books of the transfer agent for the Voting Shares. Any notice which is mailed in the manner herein provided shall be deemed given, whether or not the holder receives the notice. Each such notice of redemption must state how the Redemption Price will be paid.

     
  (g)

Where a Take-over Bid that is not a Permitted Bid or a Competing Permitted Bid expires, is withdrawn or otherwise terminates after the Separation Time has occurred and prior to the occurrence of a Flip-in Event, the Board may elect to redeem all the outstanding Rights at the Redemption Price.

     
  (h)

Upon the Rights being redeemed pursuant to Subsection 5.1(g), the Board shall be deemed to have distributed new Rights to the holders of Common Shares as of such date and in respect of each additional Common Share issued thereafter, on the same basis as Rights were first distributed hereunder and thereafter, all the provisions of this Agreement shall continue to apply to such redistributed Rights as if the Separation Time referred to in Section 5.1(g) had not occurred and which for all purposes of this Agreement shall be deemed to not have occurred and the new Rights shall be outstanding and attached to the outstanding Common Shares as of and after such date, subject to and in accordance with the provisions of this Agreement.

     
  (i)

Until the occurrence of a Flip-in Event as to which the application of Section 3.1 has not been waived pursuant to this Section, upon written notice to the Rights Agent, the Board, with the prior consent of the holders of Voting Shares given in accordance with Subsection 5.4(b), may determine, if such Flip-in Event would occur by reason of an acquisition of Voting Shares other than pursuant to a Take-over Bid made by means of a Take-over Bid circular to all holders of Voting Shares and other than in the circumstances set forth in Subsection 5.1(b), to waive the application of Section 3.1 to such Flip-in Event. If the Board proposes such a waiver, the Board shall extend the Separation Time to a date subsequent to and not more than 10 Business Days following the meeting of shareholders called to approve such waiver.


5.2

Expiration

     

No Person shall have any rights pursuant to this Agreement or any Right after the Expiration Time, except as provided in Section 4.1 hereof.

     
5.3

Issuance of New Rights Certificates

     

Notwithstanding any of the provisions of this Agreement or of the Rights to the contrary, the Corporation may, at its option, issue new Rights Certificates evidencing Rights in such form as may be approved by the Board to reflect any adjustment or change in the number or kind or class of Shares purchasable upon exercise of Rights made in accordance with the provisions of this Agreement.

     
5.4

Supplements and Amendments

     
(a)

At any time, the Corporation may, by resolution of the Board, amend this Agreement to correct any clerical or typographical errors or to maintain the validity of this Agreement as a result of any changes in applicable legislation or applicable rules or policies of securities regulatory authorities or stock exchanges, and such amendments shall be in force immediately after such a resolution is passed by the Board.

27



  (b)

Prior to the Separation Time, the Corporation may, by resolution of the Board, and with the prior consent of the holders of Voting Shares obtained as set forth below, supplement or amend this Agreement and the Rights (whether or not such action would materially adversely affect the interests of the holders of Rights generally). Such consent is deemed to have been given if the supplement or amendment is approved by the affirmative vote of a majority of the votes cast by Independent Shareholders represented in person or by proxy and entitled to be voted at a meeting of the holders of Voting Shares duly called and held in compliance with applicable laws and the Articles and bylaws of the Corporation.

       
  (c)

After the Separation Time, the Corporation may, by resolution of the Board, and with the prior consent of the holders of Rights obtained as set forth below, supplement or amend this Agreement and the Rights (whether or not such action would materially adversely affect the interests of the holders of Rights generally). Such consent is deemed to have been given if provided by the holders of Rights at a Rights Holders’ Special Meeting, which Rights Holders’ Special Meeting is called and held in compliance with applicable laws and regulatory requirements and, to the extent possible, with the requirements in the Articles and by-laws of the Corporation applicable to meetings of holders of Voting Shares varied as the Corporation thinks appropriate. Subject to compliance with any requirements imposed by the foregoing, consent is given if the proposed supplement or amendment, is approved by the affirmative vote of a majority of the votes cast by holders of Rights (other than holders of Rights whose Rights have become void pursuant to Subsection 3.1(b)), represented in person or by proxy at the Rights Holders’ Special Meeting.

       
  (d)

Notwithstanding anything in this Section 5.4 to the contrary, no such supplement or amendment shall be made to the provisions of Article 4 except with the written concurrence of the Rights Agent to such supplement or amendment.

       
  (e)

Any supplement to or amendment to this Agreement is subject to the approval of the TSX or such other stock exchange on which the Corporation’s shares may be listed at the time of the supplement or amendment.

       
  (f)

Any amendments to this Agreement made pursuant to Subsection 5.4(a) which are required to maintain the validity of this Agreement as a result of any changes in applicable legislation or applicable rules or policies of securities regulatory authorities or stock exchanges shall:

       
  (i)

if made before the Separation Time, be submitted to the shareholders of the Corporation at the next meeting of shareholders and the shareholders may, by a vote of the majority referred to in Subsection 5.4(b), confirm or reject such amendment; and

       
  (ii)

if made after the Separation Time, be submitted to holders of Rights at a meeting to be called for on a date not later than immediately following the next meeting of shareholders of the Corporation and the holders of Rights may, by a vote of the majority referred to in Subsection 5.4(c), confirm or reject such amendment.

Any such amendment shall be effective from the date of the resolution of the Board adopting such amendment, until it is confirmed or rejected in accordance with this Subsection 5.4(f) or until it ceases to be effective (as described below) and, where such amendment is confirmed, it continues in effect in the form so confirmed. If such amendment is rejected by shareholders or holders of Rights or is not submitted to shareholders or holders of Rights as required, then such amendment shall cease to be effective from and after the termination of the meeting at which it was rejected or to which it should have been but was not submitted or from and after the date of the meeting of holders of Rights that should have been but was not held, and no subsequent resolution of the Board to amend this Agreement to substantially the same effect shall be effective until confirmed by shareholders or holders of Rights, as the case may be.

28



5.5

Fractional Rights and Fractional Common Shares

     
(a)

The Corporation shall not be required to issue fractions of Rights or to distribute Right Certificates which evidence fractional Rights or to pay any amount to a holder of record of Rights Certificates in lieu of such fractional Rights.

     
(b)

The Corporation shall not be required to issue fractions of Common Shares upon exercise of the Rights or to distribute certificates which evidence fractional Common Shares. In lieu of issuing fractional Common Shares, the Corporation shall pay to the registered holders of Right Certificates at the time such Rights are exercised as herein provided, an amount in cash equal to the same fraction of the Market Price of one Common Share that the fraction of a Common Share that would otherwise be issuable upon the exercise of such Right is of a whole Common Share.

     
5.6

Rights of Action

     

Subject to the terms of this Agreement, rights of action in respect of this Agreement, other than rights of action vested solely in the Rights Agent, are vested in the respective holders of the Rights, and any holder of any Rights, without the consent of the Rights Agent or of the holder of any other Rights may, on such holder’s own behalf and for such holder’s own benefit and the benefit of other holders of Rights, enforce, and may institute and maintain any suit, action or proceeding against the Corporation to enforce, or otherwise act in respect of, such holder’s right to exercise such holder’s Rights in the manner provided in such holder’s Rights Certificate and in this Agreement. Without limiting the foregoing or any remedies available to the holders of Rights, it is specifically acknowledged that the holders of Rights would not have an adequate remedy at law for any breach of this Agreement and will be entitled to specific performance of the obligations under, and injunctive relief against actual or threatened violations of the obligations of any Person subject to, this Agreement.

     
5.7

Non-Canadian or United States Holders

     

If in the opinion of the Board (who may rely upon the advice of counsel) any action or event contemplated by this Agreement would require compliance by the Corporation with the securities laws or comparable legislation of a jurisdiction outside Canada or the United States, the Board acting in good faith may take such actions as it may deem appropriate to ensure that such compliance is not required, including without limitation establishing procedures for the issuance to a Canadian resident Fiduciary of Rights or securities issuable on exercise of Rights, the holding thereof in trust for the Persons entitled thereto (but reserving to the Fiduciary or to the Fiduciary and the Corporation, as the Corporation may determine, absolute investment discretion with respect thereto) and the sale thereof and remittance of the proceeds of such sale, if any, to the Persons entitled thereto. In no event has the Corporation or the Rights Agent an obligation to issue or deliver Rights or securities issuable on exercise of Rights to Persons who are citizens, residents or nationals of any jurisdiction other than Canada and the United States, in which jurisdiction such issue or delivery would be unlawful without registration of the relevant Persons, securities or issue or delivery for such purposes.

     
5.8

Notices

     

Any notice, demand or other communication required or permitted to be given or made by the Rights Agent or by the holder of any Rights to or on the Corporation or by the Corporation or by the holder of any Rights to or on the Rights Agent shall be in writing and shall be well and sufficiently given or made if:

     
(a)

delivered in person during normal business hours on a Business Day and left with the receptionist or other responsible employee at the relevant address set forth below; or

     
(b)

except during any general interruption of postal services due to strike, lockout or other cause, sent by first-class mail; or

     
(c)

sent by telegraph, facsimile or other form of recorded electronic communication, charges prepaid and confirmed in writing as aforesaid;

29


if to the Corporation, addressed to it at:

95 Skyway Avenue
Toronto, Ontario M9W 4Y9

Attention: President
Fax. No.: (416) 595-0627

and if to the Rights Agent, addressed to it at:

Computershare Investor Services Inc.
100 University Avenue, 8 th Floor
Toronto, Ontario M5J 2Y1

Attention: Stock Transfer Services
Fax No.: (416) 981-9800

Notices, demands or other communications required or permitted to be given or made by the Corporation or the Rights Agent to or on the holder of any Rights shall be in writing and shall be well and sufficiently given or made if delivered personally to such holder or delivered or mailed by first class mail to the address of such holder as it appears on the Rights Register maintained by the Rights Registrar, or, prior to the Separation Time, in the register of Shareholders maintained by the transfer agent for the Common Shares.

   

Any notice so given or made shall be deemed to have been given and to have been received on the day of delivery, if so delivered; on the third Business Day (excluding each day during which there exists any general interruption of postal service due to strike, lockout, or other cause) following the mailing thereof, if so mailed; and on the day of telegraphing, telecopying or sending of the same by other means of recorded electronic communication (provided such sending is during the normal business hours of the addressee on a Business Day and if not, on the first Business Day thereafter). Each of the Corporation and the Rights Agent may from time to time change its address for notice by notice to the other given in the manner aforesaid.

   
5.9

Compliance with Anti-Money Laundering Legislation

   

The Rights Agent shall retain the right not to act and shall not be liable for refusing to act if, due to a lack of information or for any other reason whatsoever, the Rights Agent reasonably determines that such an act might cause it to be in non-compliance with any applicable anti-money laundering or anti-terrorist legislation, regulation or guideline. Further, should the Rights Agent reasonably determine at any time that its acting under this Agreement has resulted in it being in non-compliance with any applicable anti-money laundering or anti-terrorist legislation, regulation or guideline, then it shall have the right to resign on 10 days’ prior written notice to the Corporation, provided: (i) that the Rights Agent’s written notice shall describe the circumstances of such non-compliance; and (ii) that if such circumstances are rectified to the Rights Agent’s satisfaction within such 10 day period, then such resignation shall not be effective.

   
5.10

Fiduciary Duties of the Directors

   

Nothing contained herein shall be construed to suggest or imply that the Board shall not be entitled to recommend that holders of the Voting Shares and/or Convertible Securities reject or accept any Take-over Bid or take any other action including the commencement, prosecution, defence or settlement of any litigation and the solicitation of additional or alternative Take-over Bids or other proposals to shareholders that the directors believe are necessary or appropriate in the exercise of their fiduciary duties.

   
5.11

Privacy Legislation

   

The parties acknowledge that federal and/or provincial legislation that addresses the protection of individual’s personal information (collectively, " Privacy Laws ") applies to obligations and activities under this Agreement. Despite any other provision of this Agreement, neither party will take or direct any action that would contravene, or cause the other to contravene, applicable Privacy Laws. The Corporation will, prior to transferring or causing to be transferred personal information to the Rights Agent, obtain and retain required consents of the relevant individuals to the collection, use and disclosure of their personal information, or will have determined that such consents either have previously been given upon which the parties can rely or are not required under the Privacy Laws. The Rights Agent will use commercially reasonable efforts to ensure that its services hereunder comply with Privacy Laws.

30



5.12

Costs of Enforcement

   

The Corporation agrees that if the Corporation fails to fulfil any of its obligations pursuant to this Agreement, then the Corporation shall reimburse the holder of any Rights for the costs and expenses (including reasonable legal fees) incurred by such holder and actions to enforce his rights pursuant to any Rights or this Agreement.

   
5.13

Successors

   

All the covenants and provisions of this Agreement by or for the benefit of the Corporation or the Rights Agent shall bind and inure to the benefit of their respective successors and permitted assigns hereunder.

   
5.14

Benefits of this Agreement

   

Nothing in this Agreement shall be construed to give to any Person other than the Corporation, the Rights Agent and the holders of the Rights any legal or equitable right, remedy or claim under this Agreement; but this Agreement shall be for the sole and exclusive benefit of the Corporation, the Rights Agent and the holders of the Rights.

   
5.15

Governing Law

   

This Agreement and each Right issued hereunder shall be deemed to be a contract made under the laws of the Province of Ontario and for all purposes shall be governed by and construed in accordance with the laws of such Province applicable to contracts to be made and performed entirely within such Province.

   
5.16

Counterparts

   

This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

   
5.17

Severability

   

If any term or provision hereof or the application thereof to any circumstance shall, in any jurisdiction and to any extent, be invalid or unenforceable, such term or provision shall be ineffective as to such Jurisdiction to the extent of such invalidity or unenforceability without invalidating or rendering unenforceable the remaining terms and provisions hereof or the application of such term or provision to circumstances other than those as to which it is held invalid or unenforceable.

   
5.18

Determinations and Actions by the Board

   

All actions, calculations and determinations (including all omissions with respect to the foregoing) in connection with the administration of this Agreement which are done or made by the Board, in good faith, shall not subject the Board to any liability to the holders of the Rights.

31



5.19

Regulatory Approvals

     

Any obligation of the Corporation or action or event contemplated by this Agreement, or any amendment or supplement to this Agreement, shall be subject to receipt of any requisite approval or consent from any governmental or regulatory authority or stock exchange having jurisdiction.

     

IN WITNESS WHEREOF , the parties hereto have caused this Agreement to be duly executed as of the date first above written.

     
5.20

Effective Date

     

Subject to Section 5.20(b), this Agreement:

     
(a)

Shall be effective and in full force and effect in accordance with its terms from and after the Effective Date and shall constitute the entire agreement between the parties pertaining to the subject matter hereof as of the Effective Date; and shall expire and be of no further force of effect from and after the Expiration Time.

     
(b)

Notwithstanding Section 5.20(a), if the Agreement is not ratified and confirmed by a resolution passed by a majority of the votes cast by Independent Shareholders who vote in respect of ratification and confirmation of this Agreement at a meeting of the holders of Voting Shares called for such purpose and held within six months of the Effective Date, then all outstanding Rights and this Agreement shall terminate and be null and void and of no further force and effect from and after the earlier of the date of such meeting or any adjournment thereof and the date that is six months from the Effective Date.

TRILLIUM THERAPEUTICS INC.

 

  By: /s/ Niclas Stiernholm
    Niclas Stiernholm
    President and Chief Executive Officer
     
     
  By: /s/ James Parsons
    James Parsons
    Chief Financial Officer

 

COMPUTERSHARE INVESTOR SERVICES INC.

 

  By:  /s/ Josette Koffyberg
    Josette Koffyberg , Relationship Manager
     
  By: /s/ Bryce Dochert
    Bryce Docherty , Relationship Manager

32


EXHIBIT A

[Form of Rights Certificate]

Certificate No.   __________________Rights

THE RIGHTS ARE SUBJECT TO REDEMPTION ON THE TERMS SET FORTH IN THE RIGHTS AGREEMENT. UNDER CERTAIN CIRCUMSTANCES (SPECIFIED IN THE RIGHTS AGREEMENT), RIGHTS BENEFICIALLY OWNED BY AN ACQUIRING PERSON OR ANY PERSON ACTING JOINTLY OR IN CONCERT WITH AN ACQUIRING PERSON OR WITH AN ASSOCIATE OR AFFILIATE OF AN ACQUIRING PERSON (AS SUCH TERMS ARE DEFINED IN THE RIGHTS AGREEMENT) OR TRANSFEREES OF ANY OF THE FOREGOING WILL BECOME VOID WITHOUT FURTHER ACTION.

RIGHTS CERTIFICATE

This certifies that ______________________ , or registered assigns, is the registered holder of the number of Rights set forth above, each of which entitles the registered holder thereof, subject to the terms, provisions and conditions of a Rights Agreement, dated as of September 16, 2013, as amended on June 3, 2014 (the “ Rights Agreement ”) between Trillium Therapeutics Inc. (the “ Corporation ”) and Computershare Investor Services Inc. , as Rights Agent, to purchase from the Corporation at any time after the Separation Time and prior to the Expiration Time (as such terms are defined in the Rights Agreement), one fully paid common share in the capital of the Corporation (a “ Common Share ”) (subject to adjustment as provided in the Rights Agreement) at the Exercise Price referred to below, upon presentation and surrender of this Rights Certificate with a duly completed and executed Form of Election to Exercise at the principal office of the Rights Agent in the City of Toronto, Canada. The Exercise Price shall initially be $100 per Right and shall be subject to adjustment in certain events as provided in the Rights Agreement.

This Rights Certificate is subject to all the terms, provisions and conditions of the Rights Agreement which terms, provisions and conditions are hereby incorporated herein by this reference and made a part hereof and to which Rights Agreement reference is hereby made for a full description of the rights, limitations of rights, obligations, duties and immunities thereunder of the Rights Agent, the Corporation and the holders of the Rights Certificates. Copies of the Rights Agreement are on file at the registered office of the Corporation and are available upon written request.

This Rights Certificate, with or without other Rights Certificates, upon surrender at any office of the Rights Agent or any Co-Rights Agent designated for such purpose, may be exchanged for another Rights Certificate or Rights Certificates of like tenor and date evidencing an aggregate number of Rights equal to the aggregate number of Rights evidenced by the Rights Certificate or Rights Certificates so surrendered. If this Rights Certificate shall be exercised in part, the registered holder shall be entitled to receive, upon surrender hereof, another Rights Certificate or Rights Certificates for the number of whole Rights not exercised.

Subject to the provision of the Rights Agreement, the Rights evidenced by this Certificate may be redeemed by the Corporation at a redemption price of $0.000001 per Right.

No fractional Common Shares will be issued upon the exercise of any Right or Rights evidenced hereby nor will Rights Certificates be issued for less than one whole Right. In lieu thereof, a cash payment will be made as provided in the Rights Agreement.

No holder of this Rights Certificate, as such, shall be entitled to vote or receive dividends or be deemed for any purpose the Holder of Common Shares or of any other securities which may at any time be issuable on the exercise hereof, nor shall anything contained in the Rights Agreement or herein be construed to confer upon the holder hereof, as such, any of the rights of a shareholder of the Corporation or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to give or withhold consent to any corporate action, or to receive notice of meetings or other actions affecting shareholders (except as provided in the Rights


ii

Agreement), or to receive dividends or subscription rights, or otherwise, until the Rights evidenced by this Rights Certificate shall have been exercised as provided in the Rights Agreement.

This Rights Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by the Rights Agent.

WITNESS the facsimile signature of the proper officers of the Corporation and its corporate seal.

Date:_________________________________________

ATTEST: TRILLIUM THERAPEUTICS INC.
     
     
  By:  
     
     
  By:  

 

Countersigned:

COMPUTERSHARE INVESTOR SERVICES INC.

 

By:     
                     Authorized Signatory  


iii

[Form of Reverse Side of Rights Certificate]

FORM OF ASSIGNMENT

(To be executed by the registered holder if such holder desires to transfer the Rights Certificates.)

FOR VALUE RECEIVED ____________________________________________________________________________________

hereby sells, assigns and transfers

unto ___________________________________________________________________________________________________________________________


(Please print name and address of transferee)

this Rights Certificate, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint _____________________________ Attorney, to transfer the within Rights Certificate on the books of the within-named Corporation, with full power of substitution.

Dated:_________________________________________

Signature Guaranteed:

   
  Signature
  (Signature must correspond to name as written upon the
  face of this Rights Certificate in every particular,
  without alteration or enlargement or any change
  whatsoever)

Signatures must be guaranteed by a Schedule 1 Canadian Chartered Bank or a financial institution that is a member of a recognized STAMP, MSP or SEMP Program.

(To be completed if true)

CERTIFICATION

The undersigned hereby represents and certifies, for the benefit of all holders of Rights and Common Shares, that the Rights evidenced by this Rights Certificate are not, and, to the knowledge of the undersigned, have not been, Beneficially Owned by an Acquiring Person or any Person acting jointly or in concert with any Acquiring Person or with any Affiliate or Associate thereof (all as defined in the Rights Agreement).

   
  Signature

NOTICE

In the event the certification set forth above is not completed in connection with a purported assignment, the Beneficial Owner of the Rights evidenced by this Rights Certificate will be deemed to be an Acquiring Person or a Person acting jointly or in concert with such Acquiring Person or an Affiliate or Associate of such Acquiring Person (all as defined in the Rights Agreement) and accordingly the Rights evidenced by this Rights Certificate will be null and void.


iv

[To be attached to each Rights Certificate]

FORM OF ELECTION TO EXERCISE

(To be executed if holder desires to exercise the Rights Certificate.)

TO:

The undersigned hereby irrevocably elects to exercise ________________ whole Rights represented by the attached Rights Certificate to purchase the Shares issuable upon the exercise of such Rights and requests that certificates for such Shares be issued in the name of:


Address:


 


Social Insurance, Social Security or

Other Taxpayer Identification Number: __________________________________________________________________________

If such number of Rights shall not be all the whole Rights evidenced by this Rights Certificate, a new Rights Certificate for the balance of such whole Rights shall be registered in the name of and delivered to:


Address:


 


Social Insurance, Social Security or

Other Taxpayer Identification Number: __________________________________________________________________________

Dated:_________________________________________

 Signature Guaranteed:

   
  Signature
  (Signature must correspond to name as written upon the
  face of this Rights Certificate in every particular,
  without alteration or enlargement or any change
  whatsoever)

Signatures must be medallion guaranteed by a Schedule 1 Canadian Chartered Bank or a financial institution that is a member of a recognized STAMP, MSP or SEMP Program.


(To be completed if true)

CERTIFICATION

The undersigned hereby represents, for the benefit of all holders of Rights and Shares, that the Rights evidenced by this Rights Certificate are not, and, to the knowledge of the undersigned, have never been, Beneficially Owned by an Acquiring Person or any Person acting jointly or in concert with any Acquiring Person or with any Affiliate or Associate thereof (all as defined in the Rights Agreement).

 

   
  Signature

NOTICE

 

In the event the certification set forth above is not completed in connection with a purported exercise, the Beneficial Owner of the Rights evidenced by this Rights Certificate will be deemed to be an Acquiring Person or a Person acting jointly or in concert with an Acquiring Person or an Affiliate or Associate of an Acquiring Person (all as defined in the Rights Agreement) and accordingly will deem the Rights evidenced by this Rights Certificate will be null and void.



Exhibit 4.1

Execution Copy

AMENDED & RESTATED LICENSE AGREEMENT

This amended and restated second license agreement (“ Agreement ”, as further defined herein) is made effective as of February 1 st , 2010 (the " Effective Date "), and is amended as of June 1, 2012 (the “ Amendment Date ”), and is between:

UNIVERSITY HEALTH NETWORK an Ontario corporation incorporated by special statute under the University Health Network Act , 1997 , having a principal office at 190 Elizabeth Street, R. Fraser Elliott Building – Room 1S-417, Toronto, Ontario M5G 2C4 (“ UHN ”)

-AND-

THE HOSPITAL FOR SICK CHILDREN , an Ontario not-for profit corporation having an address at 555 University Avenue, Toronto, Ontario, M5G 1X8 (“ HSC ”)

-AND-

TRILLIUM THERAPEUTICS INC ., an Ontario corporation, having a principal office at 96 Skyway Avenue, Toronto, ON, M9W 4Y9 (“ TTI ”)

(Herein this Agreement, (i) UHN, HSC and TTI may be referred to individually as a “ Party ”, or collectively as the “ Parties ”, and (ii) UHN, and HSC may be referred to collectively as the “ Institutions ”.)

BACKGROUND:

Whereas:

A.

UHN and HSC own and/or control certain intellectual property developed by UHN or HSC researchers Drs. John E. Dick and Jean Wang (of UHN) and Dr. Jayne S. Danska (of HSC; collectively the “ Principal Investigators ”) relating to methods and compounds for the modulation of the SIRPα-CD47 interaction for therapeutic cancer applications (the “ Licensed Patents ”, as further defined herein).

   
B.

Pursuant to a second sponsored research agreement (the “ SRA #2 ”, as further defined herein) UHN and HSC previously conducted, under the direction of the Principal Investigators and with financial and other support from TTI, a Research Program relating to the further research and development of the aforementioned methods and compounds (the “ Research Program(s) ”, as further defined herein).




C.

Pursuant to a third sponsored research agreement (the “ SRA #3 ”, as further defined herein) UHN and HSC desire to further undertake under the direction of the Principal Investigators and with financial and other support from TTI, an additional Research Program relating to the continued research and development of the aforementioned methods and compounds .

   
D.

HSC Research & Development Limited Partnership (“ RDLP ”) is the commercialization office of HSC and as such shall act as the agent for HSC in respect of the receipt of funds derived from the commercialization of the Licensed Patents.

   
E.

UHN and HSC have entered into an inter-institutional agreement dated April 22, 2009 whereby UHN shall manage the commercialization of the Licensed Patents on behalf of HSC.

   
F.

Institutions desire to license certain rights in the Licensed Patents and the intellectual property arising from the aforementioned SRA #2 and SRA #3 Research Programs to TTI, and TTI desires to obtain said rights from Institutions.

            NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration for the mutual promises, representations, covenants and agreements of the Parties contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows.

ARTICLE 1 - INTERPRETATION

1.1

Defined Terms . For the purposes of this Agreement, unless the context otherwise requires, the following terms shall have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:

     
(a)

"Agreement" means this amended and restated second license agreement and all Schedules attached hereto, and the terms "herein", "hereunder", "hereto" and such similar expressions shall refer to this Agreement;

     
(b)

“BLA” means a Biologic License Application further to the U.S. FDA Regulations (as amended), and its foreign equivalents;

     
(c)

“Confidential Information” of a Party means any and all information of and disclosed by, said Party and/or any of its affiliates (a “Disclosing Party” ) which has or will come into the possession or knowledge of an other Party and/or any of its affiliates (a “Receiving Party” ) in connection with or as a result of entering into this Agreement and which is marked as confidential or is identified as confidential at the time of disclosure, including information concerning the Disclosing Party's past, present and future business, research and development, technology, customers and suppliers. Information shall not be considered “Confidential Information” to the extent that, when considered as a whole and in the context disclosed, the information:

2


  (i)

is part of the public domain at the time of disclosure,

     
  (ii)

subsequently becomes part of the public domain through no act or fault of the Receiving Party or its agents or employees,

     
  (iii)

can be demonstrated by the Receiving Party’s written records to have been known or otherwise available to the receiving party prior to the disclosure by the Disclosing Party,

     
  (iv)

can be demonstrated by the Receiving Party’s written records to have been subsequently provided to the receiving Party, without restriction, by a third party who is not under a duty of confidentiality respecting the information disclosed and who has a legal right to disclose it,

     
  (v)

can be demonstrated by the Receiving Party’s written records was subsequently and independently developed by employees or consultants of the Receiving Party who had no knowledge of or access to the information disclosed,

     
  (vi)

is required to be disclosed by law or an order of a court, tribunal, or government agency, provided that the Receiving Party gives to the Disclosing Party prompt notice of the required disclosure in order to allow the Disclosing Party reasonable opportunity to seek a confidentiality order or the like, or

     
  (vii)

is identified in writing by the Disclosing Party as no longer constituting Confidential Information;


  (d)

"Contract Year" means each successive twelve calendar month period during the term of this Agreement. The first Contract Year shall begin on the Effective Date of this Agreement; the last Contract Year shall end on the day that this Agreement expires or is otherwise earlier terminated;

     
  (e)

“FDA” means the United States Food and Drug Administration, or any successor agency thereof;

     
  (f)

“Field” means use in, and applications for, therapeutic cancer applications;

     
  (g)

“First License Agreement” means the first license agreement (dated February 1, 2010) executed by the Parties;

     
  (h)

“Gross Revenue” means the gross amount invoiced by TTI or others on its behalf in respect of all Products and Services. Any Products and Services used by TTI or sold or otherwise transferred by TTI in other than an arms-length transaction shall be deemed to be invoiced for the fair market value of the Product or Service;

3



  (i)

"Including" means including without limitation;

     
  (j)

"Improvements by Institutions" means any improvement to the Licensed Technology developed at UHN or HSC by or under the direction of the Principal Investigators during the two (2) year period immediately following the expiration (but not earlier termination) of the SRA #3 (the “Post Research Term” ), the commercialization of which, but for the License, would constitute an infringement of the Licensed Patents, and for purposes of certainty and clarity does not include (i) any improvement to the Licensed Technology developed at Institutions not by or under the direction of Principal Investigators after the Effective Date, and (ii) any improvement to the Licensed Technology developed at Institutions by or under the direction of Principal Investigators after the Post Research Term;

     
  (k)

"Improvements by TTI" means any improvement to the Licensed Technology made by TTI, its employees, agents and consultants during the Post Research Term, the commercialization of which, but for the License, would constitute an infringement of the Licensed Patents;

     
  (l)

“Institutions Research Program IP” means any and all Intellectual Property conceived or developed solely by either or both of UHN and HSC (which includes its personnel, staff members, employees, students, agents and consultants) pursuant to activities conducted specifically in respect of the Research Program under the SRA #2 and SRA #3, as further described and listed in Section 2 of Schedule A (as amended from time-to- time);

     
  (m)

"Intellectual Property" or “IP” mean inventions (whether patentable or unpatentable), discoveries, written material, compounds, information, know-how, trade secrets, copyright, designs, plant breeders’ rights, integrated circuit topographies, ideas (including but not limited to any computer software), formulae, algorithms, concepts, proprietary data, techniques, instructions, processes, expert opinions, information, materials, program listings, flow charts, logic diagrams, manuals, specifications, instructions, or any copies of the foregoing in any medium, or the expression thereof;

     
  (n)

"Intellectual Property Rights" or “IP Rights” means any rights in Intellectual Property which a Party owns or is seeking to own, including any regular or provisional patent applications filed in the U.S., Canada or any other jurisdiction, and any divisions, continuations, patents issuing thereon or renewals, or reissues, or extensions and any and all patents and patent applications in other countries corresponding thereto, for the Licensed Technology;

4



  (o)

“Joint Research Program IP” means any and all Intellectual Property conceived or developed with contributions by (i) at least one of either UHN and HSC, and (ii) TTI (which includes their respective personnel, staff members, employees, students, agents and consultants) pursuant to activities conducted in respect of the Research Program under the SRA #2 and SRA #3, as further described and listed in Section 3 of Schedule A (as amended from time-to-time);

     
  (p)

"License" shall have the meaning provided in Section 2.1;

     
  (q)

"Licensed Patents" means the patents and patent applications further described and listed in Section 1 of Schedule A;

     
  (r)

“Licensed Technology” means: (i) the Licensed Patents, (ii) the Institutions Research Program IP, and (iii) Institution’s interest in the Joint Research Program IP, all as further described and listed in Schedule A (as amended);

     
  (s)

"Net Revenues" means the Gross Revenue received by TTI excluding standard industry discounts, refunds and taxes, all as determined from the books and records of the TTI, or its parent and subsidiaries, maintained in accordance with Canadian generally accepted accounting principles consistently applied;

     
  (t)

"Notice" shall have the meaning provided in Section 13.1;

     
  (u)

"Product" means any product the manufacture, sale or use of which either (a) exploits Licensed Technology, or (b) would, but for the License, infringe a Valid Claim;

     
  (v)

"Publication" means any means of making available to the public information by way of speech, talk, paper, drawing, photograph, printed work, tape, video recording or other electronic means, or any other disclosure given or distributed;

     
  (w)

"Quarter Yearly Period" means each successive three calendar month period during the term of this Agreement ending March 31 st , June 30 tht , September 30 th and December 31 st of each Contract Year. The first and last Quarter Yearly Periods may be less than three calendar months and will commence on the Effective Date of this Agreement and terminate on the date this Agreement expires or is earlier terminated respectively;

     
  (x)

“Research Program(s)” means the sponsored research relating to the research and development of methods and compounds for the modulation of the SIRPα-CD47 interaction for therapeutic cancer applications undertaken by the Institutions under the SRA #2 and SRA #3;

5



  (y)

"Service" means any service provided using, or otherwise encompasses or is premised on, in whole or in part, the Licensed Technology;

     
  (z)

“SRA #2” means the second sponsored research agreement pertaining to the conduct of the Research Program, between the Institutions and TTI dated February 1, 2010;

     
  (aa)

“SRA #3” means the third sponsored research agreement pertaining to the conduct of the Research Program, between the Institutions and TTI dated June 1, 2012;

     
  (bb)

“Term” shall have the meaning provided in Section 9.1;

     
  (cc)

“Territory" means the World; and

     
  (dd)

“TTI Research Program IP” means any and all Intellectual Property conceived or developed by TTI (which includes its personnel, staff members, employees, students, agents and consultants) without any contribution from Institutions (which includes its personnel, staff members, employees, students, agents and consultants), pursuant to activities conducted specifically in respect of the Research Program under the SRA #2 and SRA #3.

     
  (ee)

Valid Claim means a claim in an issued, unexpired patent or in a pending patent application within or in respect of the Licensed Technology that (a) has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, and (d) is not lost through an interference proceeding. Notwithstanding the foregoing, if a claim of a pending patent application within or in respect of the Licensed Technology has not issued as a claim of a patent within seven (7) years after the Patent Cooperation Treaty (“PCT”) filing date (or the first national filing date if no PCT was filed), such claim shall not be a Valid Claim for the purposes of this Agreement unless and until such claim issues as a claim of an issued patent (from and after which time the same shall be deemed a Valid Claim subject to subsections (a) and (b) above).

All other defined terms in this Agreement shall have the meanings as otherwise specifically set out within the body of this Agreement.

6



1.2

Sections and Headings . The division of this Agreement into articles, sections and subsections and the insertion of headings are for reference purposes only and shall not affect the interpretation of this Agreement. Unless otherwise indicated, any reference herein to a particular article, section, subsection or Schedule refers to the specified article, section or subsection of or Schedule to this Agreement.

   
1.3

Number, Gender and Persons . In this Agreement, words importing the singular number shall include the plural and vice versa, words importing gender shall include all genders and words importing persons shall include individuals, corporations, partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or business entities.

   
1.4

Currency . All monetary amounts in this Agreement are in Canadian funds.

   
1.5

Schedules . The following Schedules are annexed to and form part of this Agreement:

   

Schedule A – Licensed Technology

   
1.6

Accounting Principles . Any reference in this Agreement to “generally accepted accounting principles” refers to generally accepted accounting principles as approved from time to time by the Canadian Institute of Chartered Accountants or any successor institute.

   
1.7

Best of Knowledge . "To the best of the knowledge" or "to the knowledge", unless otherwise qualified hereunder means a statement of the declaring Party’s knowledge of the actual facts or circumstances to which such phrase relates without having made any inquiries or investigations in connection with such facts and circumstances.

ARTICLE 2 - GRANT OF RIGHTS

2.1

License. Subject to the terms and conditions of this Agreement, Institutions grant to TTI an exclusive, royalty-bearing license, with the further right to grant sublicenses subject to Section 2.5, in any and all of their rights in and to the Licensed Technology to commercialize said Licensed Technology for the Field in the Territory, which includes the right to research, develop, manufacture, have manufactured, use, have used, sell or have sold, offer for sale, import and export Product(s) and Service(s) (the “ License ”).

   
2.2

Restriction . The License granted to TTI under Section 2.1 is subject to Institutions’ retention of their rights to use the Licensed Technology without charge for research, scholarly publication, educational or other non-commercial use, with a further retention of its right to grant licenses to third parties for similar such purposes, subject to the Confidential Information and Publication provisions of this Agreement.

7



2.3

Improvements by Institutions . TTI is granted a right of first refusal to negotiate an exclusive, royalty bearing license to any Improvements by Institutions. TTI will have thirty (30) days after receiving written notice of an Improvement by Institutions to indicate its intent in writing (to UHN on behalf of Institutions) to license said Improvement by Institutions (" Notice of Intent "). If UHN (on behalf of Institutions) does not receive a Notice of Intent within this thirty (30) day period, TTI’s right of first refusal will lapse and Institutions will be free to dispose of the Improvement by Institutions as they see fit. Upon UHN’s receipt of a Notice of Intent, the Parties shall engage in good faith negotiations in respect of any such prospective license. Any such license shall be on terms and conditions that are consistent with other such licenses within the industry and satisfactory to Institutions. If a license agreement has not been signed within one- hundred-and- twenty (120) days of said receipt of a Notice of Intent (or such other period of time as the Parties may agree to), Institutions will be free to exploit and/or dispose of the Improvement by Institutions as they see fit.

   
2.4

TTI Research Program IP / Improvements by TTI . TTI may provide Institutions with access and/or a non-exclusive license to TTI Research Program IP and any Improvements by TTI solely for research, scholarly publication, educational or other non-commercial use, subject to the Confidential Information, Publication and licensing option provisions of this Agreement and subject to the execution of appropriate legal documentation (e.g. material transfer agreement).

   
2.5

Sublicenses . TTI shall have a right to grant sublicenses to the Licensed Technology with the prior consent of UHN and HSC, which consent shall not be unreasonably withheld and shall (a) be limited to the identity of a third party sublicensee, and (b) only be withheld for ethical reasons. Notwithstanding, TTI shall ensure that any such sublicenses contain terms and conditions that are consistent with this Agreement.

ARTICLE 3 - CONSIDERATION

3.1

Payment of Funds . UHN shall be responsible for the receipt of payments on behalf of Institutions, and for the transferring to RDLP (on behalf of HSC) of HSC’s share of revenues received under this Agreement. Payment to be made by TTI to Institutions hereunder shall be made by cheque payable to the order of “University Health Network” and sent to the following address:

University Health Network

Technology Development & Commercialization
College Street - Suite 150
Heritage Building - MaRS Centre
Toronto, Ontario, Canada, M5G 1L7

Attention: Cheryl Adamo - Compliance Specialist

8



3.2

Up-Front License Fee . TTI shall pay to Institutions an up-front, non-refundable and non-creditable license fee of $150,000 on execution of this Agreement (the “ Up-Front License Payment ”).

   
3.3

R&D Maintenance Fee . TTI shall pay to Institutions a yearly non-refundable and non-creditable maintenance fee of $25,000 (the “ R&D Maintenance Fee ”). The R&D Maintenance Fee shall be due on the yearly anniversary of the Effective Date; yearly payments of the R&D Maintenance Fee shall end on the sale of a first Product for which royalties are owed to Institutions further to this Agreement.

   
3.4

Milestone Payments. In partial consideration of the License, TTI shall pay to Institutions the following milestone payments:


  (a)

Patent Issuance Milestones :

       
  (i)

$25,000 for a first patent issued in the U.S.,

       
  (ii)

$25,000 for a first patent issued in Europe, and

       
  (iii)

$10,000 for a first patent issued in Asia (which includes without limitation, China, Japan and India);

       
  (b)

Product Development Milestones ( payable for a first indication only ):

       
  (i)

$100,000 for the dosing of a first patient in a first FDA-approved (or alternatively, foreign equivalent) Phase-I clinical trial,

       
  (ii)

$200,000 for the dosing of a first patient in a first FDA-approved (or alternatively, foreign equivalent) Phase-II clinical trial, and

       
  (iii)

$300,000 for the dosing of a first patient in a first FDA-approved (or alternatively, foreign equivalent) Phase-III clinical trial;

       
  (c)

Regulatory Milestones :

       
  (i)

$1,000,000 for the submission of a first BLA in the U.S.,

       
  (ii)

$1,000,000 for the submission of a first BLA in the European Union,

       
  (iii)

$500,000 for the submission of a first BLA in Asia (which includes without limitation, China, Japan and India),

       
  (iv)

$1,000,000 for receipt of a first regulatory approval in the U.S.,

       
  (v)

$1,000,000 for receipt of a first regulatory approval in the European Union,

       
  (vi)

$500,000 for receipt of a first regulatory approval in Asia (which includes without limitation, China, Japan and India), and

9



  (vii)

fifty percent (50%) of the milestone payments noted in Subsections 3.4(c)(i) - (vi) for each subsequent additional BLA submission(s) and regulatory approval(s) in any particular jurisdiction.


3.5

Basic Royalty. TTI shall pay a royalty of


  (a)

three percent (3%) of Net Revenues from Product covered by a Valid Claim; or

     
  (b)

one percent (1%) of Net Revenues from Product that is not covered by a Valid Claim but uses Licensed Technology.


Royalty payments shall be made on Net Revenues received by TTI in each Quarter Yearly Period. Payment(s) shall be made within thirty (30) days of the end of each Quarter Yearly Period. In the event that TTI obtains a license from a third party in respect of intellectual property rights of said third party which are reasonably useful for the development of a Product or Service or further essentially required for the sale of a Product or Services, TTI’s’ royalty payments under this Section 3.3 shall be reduced by the amount payable by TTI to such third party that is allocable to the sale of Product or Service (whether such payments take the form of royalties, milestone payments or otherwise); provided however , that in no event will a deduction, or deductions, under this Section 3.5 reduce any royalty payment to Institutions in respect of Net Revenues of Product or Service by more than fifty percent (50%). If, but for the proviso in the preceding sentence, the deduction under this Section 3.5 would have reduced a royalty payment to Institutions by more than fifty percent (50%), the amount of such deduction that exceeds fifty percent (50%) shall not be carried over to subsequent or future royalty payments owed by TTI to Institutions.

   
3.6

Date of Sale . Products and Services will be deemed sold and revenue received when Product is shipped, or Service provided by, the TTI.

   
3.7

Sublicensing Royalty. In further consideration of the License, TTI shall pay to Institutions a royalty of twenty percent (20%) on the first $50,000,000CAD of sublicensing revenues (including without limitation, upfront payments, milestones and royalties) collected or received by TTI from non-related, arms length third party sublicensees of Licensed Technology, and fifteen percent (15%) on any sublicensing amounts collected or received by TTI thereafter (the “Sublicensing Royalty” ). Notwithstanding the foregoing, the Sublicensing Royalty shall exclude any and all R&D payments, reimbursements, loans and equity investments in TTI (except as contemplated below), but only to the extent such remuneration is a bona fide payment in respect of such matters (and not being made in order to reallocate what is otherwise intended to be upfront payments, milestones and royalties). The value of any equity investments in TTI by a sublicensee in excess of the valuation based upon TTI’s last share transaction with a Third Party (other than an officer, employee or shareholder of TTI), where such Third Party share transaction has a value of more than $100,000 shall, provided that such increase in not otherwise arising from a bona fide increase in the fair market value of such equity investments from the last share transaction, be treated as a Sublicensing Royalty.

10


3.8

Credits .

     
(a)

Any amounts paid to Institutions further to Section 3.3 and 3.4 shall be creditable by TTI against amounts subsequently due to Institutions further to Section 3.7.

     
(b)

For purposes of certainty and clarity, the payment of the Sublicensing Royalty further to Section 3.7 shall preclude any further subsequent “R&D Maintenance Fee” and “milestone” payments which may become owing to Institutions under Sections 3.3 and 3.4.


3.9

Interest . All monies payable to Institutions by TTI hereunder and not paid when due bear interest at the prime rate of interest quoted by the Bank of Canada, plus 5% (five percent) per annum until the date paid to Institutions. Institutions will be entitled to that interest in addition to any other rights or remedies available to it in respect of TTI’s payment default.

   
3.10

Withholdings . In the event that TTI is required by any law to withhold and/or make payments to tax authorities in respect of any payments payable by TTI to Institutions under this Agreement, the liability of TTI under this Agreement shall be to that extent satisfied, and such amounts shall be deemed to have been paid to Institutions on their due dates, provided that TTI shall furnish to Institutions acceptable evidence of such payments.

   
3.11

Royalty Report . TTI shall prepare a report (the " Royalty Report "), setting out the Gross Revenue, the number of Products manufactured and Services rendered, an itemized statement of all costs and disbursements and the Net Revenues, if any, for the relevant period. For so long as the Gross Revenue of TTI is less than $10,000 in any consecutive 12 month period, TTI shall prepare one Royalty Report for every 12 month period. If no payments are due for any reporting period, then the Royalty Report shall so state. Once the Gross Revenue of TTI is at least $10,000 in any consecutive 12-month period, TTI shall prepare a Royalty Report for each Quarter Yearly Period. Royalty Reports shall be due within thirty (30) days of the end of the relevant reporting period.


3.12

Complete Records . TTI shall keep true and accurate records and books of account containing all data reasonably required for the computing and verification of all payments owed by TTI to Institutions, including records for Gross Revenue, the number of Products manufactured and Services rendered, costs/disbursements, and Net Revenues in accordance with generally accepted accounting principles. Such records shall be maintained by the TTI for at least six (6) years from the date of the payment to which such records are relevant.

11



3.13

Inspection of Records . The records specified in this Agreement shall be available for inspection by Institutions or their duly appointed auditor, upon reasonable notice and during normal business hours at the principal place of business of TTI, for the sole purpose of verifying payments owed under this Agreement. The costs of any such inspection shall be borne by Institutions unless the report of an auditor shows that the Royalty Report was understated by more than five percent (5%), in which case the costs of the examination shall be paid by TTI.

   
3.14

Discrepancy in Records . In the event that the records inspection conducted under Section 3.13 reveals any underpayment of royalties due to Institutions, TTI will promptly pay Institutions the full amount of that underpayment together with interest thereon at the rate of interest referred to in Section 3.9 herein.

ARTICLE 4 – REPRESENTATIONS, WARRANTIES AND LIABILITY

4.1

UHN/HSC Warranties . UHN and HSC each represent and warrant to TTI that:

     
(a)

each is duly incorporated and organized and validly existing under the laws of Ontario and have all requisite corporate power and authority to enter into and perform their obligations under this Agreement;

     
(b)

each has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and effectively, the execution and delivery of this Agreement; and

     
(c)

UHN and HSC are co-owners of the Licensed Patents.

     
4.2

TTI Warranties . TTI represents and warrants to Institutions that:

     
(a)

TTI is duly incorporated and organized and validly existing under the laws of Ontario and has all the requisite corporate power and authority to enter into and perform its obligations under this Agreement;

     
(b)

TTI has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and effectively, the execution and delivery of this Agreement and the performance of its obligations hereunder and to cause all necessary meetings of directors and shareholders of TTI to be held for such purposes;

     
(c)

the execution and delivery of this Agreement by TTI and the performance of its obligations hereunder shall not result in either a breach or violation of any of the provisions of, or constitute a default under, or conflict with or cause the acceleration of any obligation of TTI under:


  (i)

any agreement to which TTI is a party or is otherwise bound by;

12



  (ii)

any of the terms and provisions of the constating documents or by- laws, or resolutions of the board of directors (or any committee thereof), of TTI;

     
  (iii)

any judgement, decree, order or award of any court, governmental body or arbitrator having jurisdiction over TTI;

     
  (iv)

any license, permit, approval, consent or authorization held by TTI; or

     
  (v)

any applicable law, statute, ordinance, regulation or rule.


4.3

EXCEPT AS OTHERWISE EXPRESSLY SET OUT IN THIS AGREEMENT:


  (A)

INSTITUTIONS EXPRESSLY DISCLAIM ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND MAKE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, SAFETY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE LICENSED TECHNOLOGY;

     
  (B)

INSTITUTIONS DO NOT WARRANT OR REPRESENT THAT ISSUED PATENTS ARE VALID, OR PENDING PATENT APPLICATIONS WILL ISSUE, OR WHEN ISSUED WILL BE VALID, OR THAT THE PRACTICE OR EXPLOITATION OF ANY LICENSED TECHNOLOGY, TECHNICAL INFORMATION OR KNOW-HOW DISCLOSED TO TTI PURSUANT TO THIS AGREEMENT DOES NOT, OR WILL NOT, CONSTITUTE INFRINGEMENT OF RIGHTS OF PERSONS NOT PARTIES HERETO. NOTWITHSTANDING THE FOREGOING, INSTITUTIONS WARRANT THAT THEY HAVE NOT KNOWINGLY GRANTED RIGHTS ESSENTIALLY SIMILAR TO THOSE OF THIS AGREEMENT TO THIRD PARTIES;

     
  (C)

INSTITUTIONS SHALL NOT BE LIABLE TO TTI FOR ANY DAMAGE, INCLUDING ANY DIRECT, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGE SUFFERED BY TTI RESULTING FROM THE USE OR OTHER EXPLOITATION OF THE LICENSED TECHNOLOGY, INCLUDING WITHOUT LIMITATION THE SALE OF ANY PRODUCT AND SERVICE. FURTHER, INSTITUTIONS MAKE NO REPRESENTATION THAT THE LICENSED TECHNOLOGY IS FREE FROM DEFECT OR LIABILITY OF INTELLECTUAL PROPERTY INFRINGEMENT.


4.4

LIMITED LIABILITY. SUBJECT TO SECTION 4.3, INSTITUTIONS’ ENTIRE LIABILITY TO TTI FOR DAMAGES OR ALLEGED DAMAGES HEREUNDER, WHETHER IN CONTRACT, TORT OR ANY OTHER LEGAL THEORY, IS LIMITED TO, AND WILL NOT EXCEED AN AMOUNT EQUAL TO THE SUM OF TOTAL ROYALTIES PAID BY TTI TO INSTITUTIONS UNDER SECTION 3.5 IN THE MOST RECENT FOUR (4) CONSECUTIVE QUARTER YEARLY PERIODS.

13


ARTICLE 5 – FURTHER TTI COVENANTS .

5.1

The TTI covenants and agrees for the benefit of Institutions that it shall:

     
(a)

exercise the License granted herein in accordance with all applicable laws, statutes, ordinances, regulations, guidelines and rules, including, all applicable statutes and regulations and applicable guidelines set forth by the Canadian Institutes of Health Research (CIHR), National Institutes of Health (NIH) or other governmental agencies where applicable;

     
(b)

ensure that all employees, consultants, sublicensees, and any other persons having access to the subject matter of this Agreement are aware of any and all obligations under this Agreement, including any and all confidentiality obligations, and have agreed to be legally bound by them;

     
(c)

cause to be applied to pertinent papers denoting any Products or Services that same are produced or rendered under license from Institutions;

     
(d)

cause to be applied to Products and Services where appropriate any markings required by applicable government statutes and laws to maintain continued validity and enforcement of Intellectual Property Rights and will confirm to Institutions that such markings are required and if so, will confirm that same are being adhered to;

     
(e)

include terms and conditions in any agreement with its customers in connection with the Products and/or Services relating to the Licensed Technology limitations of representations, warranties and conditions, limits of liability and indemnities from its customers and users which extend the benefit of such provisions to Institutions;

     
(f)

notify Institutions of the development of any TTI Research IP and Improvements by TTI;

     
(g)

per Section 2.5, ensure that the terms and conditions of any sublicenses are consistent with this Agreement; and

     
(h)

use commercially reasonable efforts to develop and commercialize Product(s) and Service(s). As such (in part) TTI or its delegate or sublicensee shall undertake and fund the required IND-enabling experiments (e.g. PK/PD/toxicology) with the lead candidate Products and utilize commercial best efforts to move these into an appropriate clinical trial program alone or in partnership within five (5) years of the Effective Date.

ARTICLE 6 - MANAGEMENT OF INTELLECTUAL PROPERTY RIGHTS

14



6.1

Institutions Ownership. UHN and HSC shall own all applications and registrations for Intellectual Property Rights in the Licensed Technology (subject to Section 6.4, and with the caveat that UHN and/or HSC are co-owners with TTI of any Joint Research Program IP) and Improvements by Institutions.

   
6.2

TTI Ownership. TTI shall own and have carriage of applications and registrations for Intellectual Property Rights for Improvements by TTI, including with respect to the preparation, filing, prosecution and maintenance of patent applications.

   
6.3

Information to Institutions. TTI will keep Institutions promptly informed of all patent applications and registrations by TTI filed in accordance with Section 6.2 hereof.

   
6.4

Patent Prosecution. With appropriate reasonable input from Institutions, TTI shall have the right to control preparing, filing, prosecuting, obtaining and maintaining, at its sole cost and expense, and using patent counsel reasonably acceptable to Institutions, all Intellectual Property Rights to Licensed Technology for the Field throughout the Territory. TTI (a) will provide Institutions with a copy of any proposed patent application in respect of the Licensed Technology for review and comment reasonably in advance of filing, and (b) will keep Institutions reasonably informed of the status of such filing, prosecution and maintenance, including (i) by providing Institutions with copies of all material communications received from or filed in patent office(s) with respect to such filing, and (ii) by providing Institutions a reasonable time prior to taking or failing to take any action that would materially affect the scope or validity of any such filing, with prior written notice of such proposed action or inaction so that Institutions have a reasonable opportunity to review and comment. In the event that TTI decides to (x) forego or cease prosecution, or (y) cease maintenance, of any Intellectual Property Rights in the Licensed Technology (in whole or in part) in any jurisdiction, Institutions may (in their sole discretion and expense) continue such prosecution or maintenance and TTI shall have no further obligations and rights in respect of Institutions rights in such Intellectual Property.

   
6.5

Cooperation and Notice . As provided for in this Article 6, a Party shall cooperate with the other Parties in the preparation, filing, prosecution and maintenance of any applications and registrations for Intellectual Property Rights, including executing all papers and instruments required in order to enable the Party to apply for, to prosecute and to maintain applications and registrations in any country. Each Party shall provide to the others prompt notice as to all matters which come to its attention and which may affect the preparation, filing, prosecution or maintenance of any such applications or registrations, and shall at all times keep the other fully and promptly informed of all developments in the preparation, filing, prosecution and maintenance of any such applications or registrations.

15



6.6

Infringement . If any infringement or threatened infringement of the Licensed Technology is perceived by Institutions or TTI, said Party will immediately notify the other Parties. The Parties shall co-operate fully in the enforcement of any Intellectual Property Rights in the Licensed Technology. TTI and its sublicensee(s) shall have initial carriage of any such action(s), but Institutions shall retain ultimate authority over, the commencement, conduct and settlement of any infringement action against a third party. TTI or its sublicensee(s) shall be responsible for all reasonable costs, including legal fees, disbursements and awards by the Court against Institutions or TTI pertaining to the enforcement of any Intellectual Property Rights in the Licensed Technology. Any monies awarded to the Parties as a result of any action or settlement shall first go to reimburse TTI or its sublicensee(s) for reasonable costs incurred in the action. Any remainder monies shall be divided as arranged by the Parties before the commencement of any such action.


6.7

No Actions. TTI agrees to not knowingly take any action which would jeopardize the obtaining or maintaining of Institutions’ Intellectual Property Rights in the Licensed Technology.

   
6.8

No Challenges . TTI shall not challenge the validity of any of Institutions’ Intellectual Property Rights in the Licensed Technology or otherwise under this Agreement.

   
6.9

Communications with Institutions. UHN shall be responsible on behalf of Institutions for the receipt of any notices and communications, and shall enage in any required discussions with TTI, in respect of IP-related matters further to this Article 6.

ARTICLE 7 - CONFIDENTIAL INFORMATION

7.1

Confidentiality . The Parties shall take all proper measures, and at least the same measures as it takes in respect of its own Confidential Information, to keep confidential the Confidential Information of the other Parties. A Receiving Party will ensure that everyone having access to the Confidential Information of another Party is under a legal obligation to maintain such Confidential Information in confidence and is duly informed of this obligation. A Receiving Party will neither use nor disclose to any other party any of the Confidential Information of the other Parties except as expressly permitted hereunder.

   
7.2

Disclosure to Advisors . Notwithstanding the confidentiality obligations of this Agreement, each Party shall be permitted to disclose the terms of this Agreement without the prior written consent of the other Party (i) to those of its advisors, shareholders, investors, potential investors, underwriters and others who are on a need to know basis, under circumstances that reasonably ensure the confidentiality thereof, or (ii) to the extent as otherwise required by law.

16


ARTICLE 8 - PUBLICATION

8.1

Publications . At the request of UHN, HSC or TTI (as appropriate), TTI, HSC or UHN (as appropriate) shall acknowledge the contribution and ownership of the other Parties to the Licensed Technology, Improvements by Institutions or Improvements by TTI, as the case may be. No Publication by a Party shall disclose the Confidential Information of another Party without the prior written consent of that other Party.

ARTICLE 9 - TERM & TERMINATION

9.1

Term . Unless earlier terminated pursuant to Sections 9.2 or 9.3, the Term of the License Agreement shall expire,

     
(a)

on a country-by-country basis, in countries wherein a Valid Claim exists,

     

when the last Valid Claim expires in any such country, and

     
(b)

in countries wherein a Valid Claim does not exist, when the last Valid Claim in

     

the United States expires.

     
9.2

Earlier Termination . This Agreement shall earlier terminate:


  (a)

at the discretion of TTI upon forty five (45) days notice to Institutions;

       
  (b)

at least one (1) day prior to the occurrence of any of the following events:

       
  (i)

TTI files a voluntary petition in bankruptcy or insolvency or shall petition for reorganization under any bankruptcy law, or makes a general assignment for the benefit of creditors, or otherwise acknowledges insolvency or is adjudged bankrupt;

       
  (ii)

TTI shall consent to an involuntary petition in bankruptcy or if a receiving order is given against it under the Bankruptcy and Insolvency Act (or such other equivalent Act in the respective jurisdiction); or

       
  (iii)

the appointment of a receiver or other similar representative for TTI by a court of competent jurisdiction;

       
  (c)

at the discretion of Institutions and upon notice to TTI, if TTI materially breaches any of its obligations under this Agreement (including the payment of any monies as required under Sections 3.2, 3.3, 3.4, 3.5, and 3.7) and fails to, refuses to, or cannot remedy the breach within thirty (30) days after being given written notice thereof by Institutions;

17



  (d)

at the discretion of Institutions, immediately upon notice to TTI (and/or sublicensee, as appropriate) for a failure to have or maintain adequate insurance per Article 11; or

     
  (e)

by mutual consent of the Parties pursuant to Section 9.3.


9.3

Termination by Mutual Consent . The Parties may terminate this Agreement at any time by mutual consent, which consent shall be evidenced by a written agreement duly executed by the Parties.

   
9.4

Obligations on Insolvency . In the event that this Agreement is terminated for insolvency further to Section 9.2, the License and any sublicenses granted in accordance with this Agreement will be automatically terminated, and as such all rights to the Licensed Technology granted by Institutions to TTI, or granted by TTI to sublicensees, shall revert to Institutions. Licensed Technology shall not in any manner form part of the assets of TTI or the assets of any sublicensee of TTI.

   
9.5

Post-Termination . In the event of the earlier termination of this Agreement:


  (a)

TTI shall cease and desist any further use or exploitation of, and otherwise cease to derive any benefit from, the Licensed Technology, and within thirty (30) days either destroy or return to Institutions (at the request of Institutions in their sole discretion) all of Institutions’ property, including all Licensed Technology and UHN and HSC Confidential Information;

     
  (b)

TTI shall within thirty (30) days of the date of such earlier termination, pay Institutions all current amounts then owed to Institutions pursuant to Article 3; for purposes of certainty and clarity , no term or provision of this Agreement shall be construed to waive the payment of any monies to Institutions accrued at the date of said earlier termination, or arising thereafter;

     
  (c)

no termination of this Agreement shall be construed as a termination of any valid sublicense of any sublicensee hereunder, and thereafter each such sublicensee shall be considered a direct licensee of Institutions, provided that (i) such sublicensee is then in full compliance with all terms and conditions of its sublicense, and (ii) such sublicensee agrees in writing to assume all material obligations (including, without limitation, those of a financial nature), hereunder this Agreement;

     
  (d)

the Parties shall take all necessary steps in a prudent business manner to effect the orderly termination of this Agreement; and

     
  (e)

TTI may continue to sell any existing stock of any Products manufactured at fair market value and TTI shall pay Institutions all royalties owed pursuant to Article 3.

18


ARTICLE 10 - INDEMNIFICATION

10.1

Indemnification . TTI, for and in consideration of and as a condition to the granting of the License, agrees to indemnify, save harmless, and defend Institutions, their directors, officers, research staff, employees, research trainees, students, and agents, against any and all claims, suits, losses, damages, costs, fees, and expenses (including reasonable legal expenses), resulting from and arising out of this Agreement including but not limited to any product liability and any third party Intellectual Property infringement or alleged infringement claims and any damages, losses, or liabilities, whatsoever with respect to death or injury to any person and damage to any property arising from this Agreement and the License granted herein, including, without limitation, the manufacture, design, distribution, and offer for sale of Products and Services or otherwise arising from any exploitation of the Licensed Technology, except to the extent caused by the negligence or willful misconduct of Institutions or any of the indemnified parties thereof.

ARTICLE 11 – INSURANCE

11.1

TTI Insurance . No later than thirty (30) days prior to the first use of Licensed Technology in humans, TTI, at TTI’s expense, shall obtain and maintain appropriate general liability and product liability insurance (the “ TTI Insurance ”) at an overall level, incident level, and deductible amount as are standard in the industry at such time, naming TTI and Institutions as co-insured. TTI shall provide to Institutions a Certificate of Insurance evidencing compliance with this provision within thirty (30) days prior to such first use and, in no event, shall TTI use the Licensed Technology in humans prior to the delivery to Institutions of the Certificate of Insurance. TTI shall, at its own expense, obtain and maintain the TTI Insurance from the date required by this Section 11.1 until the end of the Term of this Agreement (as described in Article 9 hereof) and for a period of six (6) years thereafter.

   
11.2

Sublicensee Insurance . TTI shall ensure that all approved sublicensee(s), at the sublicense(s)’ or TTI’s expense, obtain and maintain appropriate liability insurance at a level commensurate with the TTI Insurance, naming TTI and Institutions as co-insured. TTI shall provide to Institutions a Certificate of Insurance evidencing compliance with this provision, within thirty (30) days prior to the first use of the Licensed Technology in humans under any sublicense agreement. TTI shall ensure that in no event shall the sublicense(s) use the Licensed Technology in humans under this or any sublicense agreement prior to the delivery to Institutions of the Certificate of Insurance. TTI shall ensure that sublicensee(s) (at no expense to Institutions) obtain and maintain from the date required by this Section 11.2 until the end of the Term of this Agreement and for a period of six (6) years thereafter, a policy of appropriate liability insurance at a level commensurate with the TTI Insurance.

19



11.3

Qualified Insurance . All insurance policies required in accordance with this Article 11 shall be obtained from a qualified insurance company licensed to do business in the jurisdictions governed by this Agreement.

   
11.4

Notice . All insurance policies required in accordance with this Article 11 shall provide for fifteen (15) business days written notice by the insurer to TTI and Institutions by registered or certified mail in the event of any modification, cancellation or termination of such insurance policy.

   
11.5

Copy of Policy . TTI shall, on written request, provide Institutions with a copy of the insurance policy in force at the time of the request and this provision shall survive the termination or expiration of this Agreement.

   
11.6

Incomplete Insurance . In the event TTI (or sublicensee, as appropriate) is unable to obtain the insurance coverage required by this Article 11, or if any portion of the TTI Insurance / sublicensee insurance or other required coverage is cancelled and not immediately replaced, TTI shall promptly inform Institutions and Institutions shall be free to terminate this Agreement upon notice to TTI/sublicensee in accordance with Section 9.2(d).

ARTICLE 12 - DISPUTE RESOLUTION

12.1

Best Efforts. The Parties agree to use reasonable best efforts to resolve amicably among themselves any dispute arising out of this Agreement.

   
12.2

Referral for Resolution. If the Parties are unable to resolve the dispute under Section 12.1, the dispute shall be referred to the Vice President, Research of UHN (or designate), Chief of Research of HSC (or designate) and the CEO (or designate) of TTI for their discussion and resolution. The Parties may agree to mediation of the dispute.

   
12.3

Arbitration . Any dispute which cannot be settled amicably between the Parties as provided in Sections 12.1 and 12.2 shall be submitted to arbitration, by an arbitrator to be mutually agreed upon by the Parties, in accordance with the provisions of the Arbitration Act, 1991 , S.O. 1991, c.17, as amended from time to time. The arbitration will take place in the City of Toronto.

   
12.4

Termination under Section 9.2 and/or for inadequate or lack of insurance under Article 11, shall not be subject to this Article 12.

ARTICLE 13 – NOTICE

13.1

Notice . All notices which are required or permitted to be given hereunder (“ Notices ”) including judicial payment notices must be in writing. All such Notices must be sent as follows:

20


to UHN:

  Attention: Brian H. Barber, PhD
    Director, Technology Development & Commercialization
    University Health Network
    101 College Street – Suite 150
    Heritage Building – MaRS Centre
    Toronto, Ontario, Canada M5G 1L7
     
    Telephone No.: (416) 581-7410
    Facsimile No.: (416) 977-4765
     
  to HSC:  
     
  Attention: Arlene Yee
    Director, Technology Partnerships
    The Hospital for Sick Children
    555 University Avenue
    Toronto, Ontario, Canada M5G 1X8
     
    Telephone No.: (416) 813-8858
    Facsimile No.: (416) 813-5968
    E-mail: arlene.yee@sickkids.ca
     
  to RDLP:  
     
  Attention: Dr. Stuart Howe
    President
    HSC Research & Development Limited Partnership
    525 University Avenue – Suite 1030
    Toronto, Ontario M5G 2L3
    Canada
     
    Telephone: (416) 813-8138
    Facsimile No.: (416) 813-5085
    E-mail: stuart.howe@sickkids.ca
     
     
  to TTI:  
     
  Attention: Dr. Niclas Stiernholm
    Chief Executive Officer
     
    Trillium Therapeutics Inc.
    96 Skyway Avenue
    Toronto, Ontario, M9W 4Y9
    Canada

21


Direct: (416) 595-9491
Phone: (416) 595-0627 x222
Fax: (416) 595-5835
E-mail: niclas@trilliumtherapeutics.com

or to such other address as a Party may designate by Notice given in accordance with this Article 13. Any such Notice may be delivered by hand, by registered mail, or sent by facsimile and will be deemed to have been delivered on the date of delivery if delivered by hand, five (5) days after mailing if sent by registered mail, or on the first business day following the date of sending, if sent by telecopy.

ARTICLE 14 – GENERAL

14.1

Entire Agreement . The Parties hereto acknowledge that this Agreement and its Schedule set forth the entire agreement and understanding of the Parties hereto as to the subject matter hereof, and supersedes all prior discussions, agreements and writings in respect hereto.

     
14.2

General Assurances . The Parties agree to do all such things and to execute such instruments and documents as may be necessary or desirable in order to carry out the provisions and intent of this Agreement.

     
14.3

Enure to Benefit . This Agreement shall enure to the benefit of and be binding upon the respective Parties and, where the context admits or requires, their respective permitted successors or assigns.

     
14.4

Assignment .

     
(a)

This Agreement cannot be assigned, sold, transferred or encumbered in any manner by TTI without the expressed written consent of Institutions, which consent will not be unreasonably withheld.

     
(b)

Notwithstanding Subsection 14.4(a), in the event TTI sells all or substantially all of its assets to another entity, TRILLIUM may assign its rights and obligations hereunder to the surviving or acquiring entity if: (i) TRILLIUM is not then in breach of this Agreement; (ii) the proposed assignee has or will have sufficient available resources, including liquid financial resources, management experience, and sufficient scientific, business and other expertise comparable or superior to TTI, that will be committed in order to satisfy its obligations hereunder; (iii) TRILLIUM provides written notice of the assignment to Institutions, together with documentation satisfactory to Institutions sufficient to demonstrate the requirements set forth in subparagraphs (i) through (ii) above, at least thirty (30) days prior to the effective date of the assignment; and (iv) Institutions receive from the assignee, in writing, at least thirty (30) days prior to the effective date of the assignment: (w) reaffirmation of the terms of this Agreement; (x) an agreement to be bound by the terms of this Agreement; (y) an agreement to perform the obligations of Licensee under this Agreement, and (z) details satisfactory to Institutions concerning subparagraphs (iii) of this Subsection 14.4(b).

22



  (c)

In the event of the sale, transfer or other disposition of the whole of TTI’s business to a third party, or that part encompassing or otherwise associated with the development and commercialization of the Licensed Technology, TTI shall pay to Institutions a “ License Transfer Fee ” equal to two percent (2%) of the (monetized) amount received by TTI in respect of said sale/transfer/disposition, to a maximum of $3,000,000, such payment to be made by TTI to UHN (on behalf of Institutions) within thirty (30) days of the closing of such sale/transfer/disposition. For purposes of certainty and clarity, only a single License Transfer Fee shall be owed and payable in the event of the aforementioned sale, transfer or other disposition of TTI’s business encompassing the Licensed Technology and/or the analogous sale, transfer or other disposition of TTI’s business encompassing the licensed technology of the First License Agreement.

     
  (d)

Notwithstanding any other term or provision of this Agreement, no assignment of the Agreement (and any License thereunder) shall be finalized and executed absent the receipt by Institutions of the License Transfer Fee.


14.5

No Use of Names . TTI shall not use the name, logo, trade-mark or trade-name of Institutions in connection with any products, publicity, promotion news release, advertising or similar public statements or otherwise without the prior written consent of Institutions.

   
14.6

No Joint Venture . Each Party is and will remain at all times independent of each other. The Parties are not and shall not be considered to be joint venturers, partners or agents of each other and neither of them shall have the power to bind or obligate the other except as set forth in this Agreement. The Parties mutually covenant and agree that neither shall they, in any way, incur any contractual or other obligation in the name of the other, nor shall they have liability for any debts incurred by the other. No representation will be made or acts taken by any of the Parties which could establish any apparent relationship of agency, joint venture, partnership or employment.

   
14.7

Waiver . No amendment, supplement or waiver of any provision of this Agreement shall be binding on any Party unless consented to in writing by such Party. No waiver of any provision of this Agreement shall constitute a waiver of any other provision, nor shall any waiver constitute a continuing waiver unless otherwise expressly provided. Further, no failure or delay by any Party in exercising any right or remedy shall operate as a waiver thereof, nor shall any single or partial exercise or waiver of any right or remedy preclude its further exercise or the exercise of any other right or remedy.

23



14.8

Time of the Essence . Time is of the essence in this Agreement and of each and every term and condition hereof.

   
14.9

Joint Preparation . This Agreement shall be deemed to be jointly prepared by the Parties, and any ambiguity herein shall not be construed for or against any single Party.

   
14.10

Governing Law . This Agreement shall be governed by the laws of the Province of Ontario and the laws of Canada and shall be treated as an Ontario contract. Subject to Article 12, the Parties irrevocably and unconditionally submits to the non-exclusive jurisdiction the courts of such Province and all courts competent to hear appeals therefrom in connection with any matters arising under this Agreement.

   
14.11

Severability of Provisions . In the event that any provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction in any jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision in said jurisdiction and such determination shall not affect the validity or enforceability of such provision or the Agreement in any other jurisdiction. The Parties shall in good faith negotiate a substitute clause for any provision declared invalid or unenforceable, which shall most nearly approximate the intent of the Parties in entering this Agreement.

   
14.12

Force Majeure . In the event that any one of the Parties is prevented from fulfilling any of its obligations herein by acts of God, war, terrorism, strikes, riots, storms, fires, governmental orders or restrictions or any other cause beyond its control, the payment of royalties, or the applicable pro rata portion thereof, shall be suspended during the full period of any such prevention, but payment of royalties which has accrued for payment prior to, or after such cause shall not be excused. Institutions will have the right to terminate this Agreement in the event that the TTI is unable to fulfill its obligations herein for a period of at least three (3) months.

   
14.13

Survival . Articles 1, 3, 7, 8, 10, 11, 12, 13, 14 in their entirety and Sections 2.4, 4.3, 4.4, 5.1(b) through (e), 6.1, 6.2, 6.7, 6.8, 9.4 and 9.5 shall remain in force and effect after the expiration or earlier termination of this Agreement until such time as specifically noted in a particular Article or Section, or the Parties mutually agree to the release (singly or collectively) of the obligations contained therein.

   
14.14

Counterparts . This Agreement may be executed in counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement to be effective as of the Effective Date.

24



UNIVERSITY HEALTH NETWORK


Per: (signed) “ Dr. Christopher Paige ”                                     
Name: Dr. Christopher J. Paige
Title: Vice President Research
HOSPITAL FOR SICK CHILDREN


Per: (signed) “ Dr. Stuart Howe ”                                                
Name: Dr. Stuart Howe
Title: Executive Director, Business
Services and Development
TRILLIUM THERAPEUTICS INC.


Per: (signed) “ Dr. Niclas Stiernholm ”                                    
Name: Dr. Niclas Stiernholm
Title: Chief Executive Officer





25


Execution Copy

SCHEDULE A
Licensed Technology

1.

Licensed Patents


  A.

Filed Patent Applications:

       
  (i)

Patent family entitled: “Modulation of SIRPalpha - CD47 interaction for

       
 

increasing human hematopoietic stem cell engraftment and compounds thereof.” (J. E. Dick, K. Takenaka, T. Prasolova & J.S. Danska (inventors)) including: US Prov. Appln. No. 60/960,724 (filed Oct. 11, 2007); and PCT Appl. No. PCT/CA2008/001814 (filed Oct. 10, 2008).

       
  (ii)

Patent family entitled: “Compositions and methods for treating

       
 

hematologic cancers targeting the SIRPalpha - CD47 interaction.” (J.C.Y. Wang, J. E. Dick, T. Prasolova, L. Jing, A. Theocharides & J.S. Danska (inventors)) including: US Prov. Appln. No. 61/178,553 (filed May 15, 2009).

       
  (iii)

Patent family entitled: “Compositions and methods for treating

       
 

leukemia targeting the SIRPalpha - CD47 interaction.” (J.C.Y. Wang, J. E. Dick, T. Prasolova, L. Jing, A. Theocharides & J.S. Danska (inventors)) including: US Prov. Appln. No. 61/178,559 (filed May 15, 2009).


  B.

Foreign Dependent Applications:

Any patent application(s) claiming priority to the applications listed in Part 1 of this Schedule A.

  C.

Continuations, Divisionals, Renewals, Extensions:

     
 

For greater certainty, the Licensed Patents shall further include:


  (a)

any issued patent(s) or patent application(s) described or listed in this Schedule A;

     
  (b)

all continuations and continuations-in-part applications to the issued patent or patent application described in Part 1 of this Schedule A (solely to the extent such continuations-in-part applications contain subject matter on which claims issuing obtain the benefit of a priority date of any patent or patent application described in Part 1 of this Schedule A);

     
  (c)

all divisions, patents of addition, reissues, renewals and extensions of any of the patent, patent application, continuations and continuations-in-part applications set out in the foregoing paragraphs (a) and (b) of Part 1(C) of this Schedule A; and




  (d)

all foreign counterparts of any of the foregoing (including, without limitation, European Supplementary Protection Certificates or its equivalent).


2.

Institutions Research Program IP

To be amended from time-to-time, as required.

3.

Joint Research Program IP:

To be amended from time-to-time, as required.

27



Exhibit 4.2

DEBENTURE PURCHASE AGREEMENT

AND

MERGER AGREEMENT

AMONG

STEM CELL THERAPEUTICS CORP.

 - and -

2364556 ONTARIO INC.

- and -

TRILLIUM THERAPEUTICS INC.

 - and -

COVINGTON FUND II INC.

- and -

GROWTHWORKS CANADIAN FUND LTD.

 - and -

 BDC CAPITAL INC.

- and -

MaRS INVESTMENT ACCELERATOR FUND INC.

 

March 25, 2013


Table of Contents

      Page
       
1. INTERPRETATION 2
  1.1 Definitions 2
  1.2 Currency 7
  1.3 Interpretation 7
  1.4 Knowledge and Disclosure 8
  1.5 Number and Gender 8
  1.6 Date of any Action 9
  1.7 Accounting Matters 9
  1.8 Statutory References 9
  1.9 Legal, Valid and Binding 9
  1.10 Appendices and Schedules 9
       
2. THE TRANSACTION 10
  2.1 The Transaction 10
  2.2 Trillium Meeting 11
  2.3 Purchase and Sale of Debentures 11
  2.4 Withholding 12
       
3. REPRESENTATIONS AND WARRANTIES 13
  3.1 Mutual Representations and Warranties 13
  3.2 Representations and Warranties of Stem Cell 16
  3.3 Representations and Warranties of Trillium 24
       
4. PURCHASE OF DEBENTURES AND CANCELATION OF WARRANTS 32
  4.1 Representations and Warranties of the Debentureholders 32
       
5. COVENANTS 33
  5.1 Mutual Covenants of Stem Cell, Trillium and Acquisitionco 33
  5.2 Access to Information 39
  5.3 Covenants of Debentureholders 40
  5.4 Additional Mutual Covenants 40
  5.5 Confidentiality 41
  5.6 Privacy Matters 42
  5.7 Directors and Officers 43
  5.8 Employee Benefits and Related Matters 43
  5.9 Non-Solicit 44
  5.10 Right to Accept a Superior Proposal 45
       
6. CONDITIONS PRECEDENT 45
  6.1 Mutual Conditions Precedent 45
  6.2 Additional Conditions Precedent to the Obligations of Trillium and Debentureholders
  6.3 Additional Conditions Precedent to the Obligations of Stem Cell and Acquisitionco


- 2 -

7. TERMINATION OF AGREEMENT 48
  7.1 Termination by Certain Parties 48
  7.2 Void upon Termination 49
  7.3 Non-Completion Fee Payable by Trillium 49
  7.4 Notice of Unfulfilled Conditions 50
       
8. GENERAL 50
  8.1 Notices 50
  8.2 Fees and Expenses 52
  8.3 No Assignment 52
  8.4 Binding Effect 52
  8.5 Time of Essence 53
  8.6 Public Announcements 53
  8.7 Governing Law 53
  8.8 Entire Agreement 53
  8.9 Third Party Rights 53
  8.10 Amendment 54
  8.11 Waiver, Modifications and Remedies 54
  8.12 Severability 55
  8.13 Mutual Interest 56
  8.14 Further Assurances 56
  8.15 Injunctive Relief 56
  8.16 No Personal Liability 56
  8.17 Counterparts and Execution 56

APPENDIX A A-1
APPENDIX B B-1
APPENDIX C C-1


DEBENTURE PURCHASE AGREEMENT

AND

MERGER AGREEMENT

THIS AGREEMENT made the 25th day of March, 2013,

AMONG: STEM CELL THERAPEUTICS CORP. , a body corporate incorporated under the Business Corporations Act (Alberta)
   
  (“ Stem Cell ”)
   
AND: 2364556 ONTARIO INC. , a corporation incorporated under the Business Corporations Act (Ontario)
   
 (“ Acquisitionco ”)
   
AND: TRILLIUM THERAPEUTICS INC. , a corporation incorporated under the Business Corporations Act (Ontario)
   
  (“ Trillium ”)
   
AND: COVINGTON FUND II INC.
   
  (“ Covington ”)
   
AND: GROWTHWORKS CANADIAN FUND LTD.
   
  (“ GrowthWorks ”)
   
AND: BDC CAPITAL INC.
   
  (“ BDC ”)
   
AND: MaRS INVESTMENT ACCELERATOR FUND INC.
   
  (“ IAF ”)
   
(Covington, GrowthWorks, BDC and IAF collectively, the “ Debentureholders ”)

WHEREAS:

A.

The Board of Directors of each of Stem Cell and Trillium has determined that it is in the best interests of Stem Cell and Trillium, respectively, to combine the businesses carried on by each of them;

   
B.

Stem Cell has taken the initiative in incorporating and organizing Acquisitionco and is the legal and beneficial owner of all of the issued and outstanding shares of Acquisitionco;



- 2 -

C.

The parties have agreed to effect the proposed business combination by way of an amalgamation involving Trillium and its shareholders, Acquisitionco and Stem Cell;

   
D.

Trillium has previously issued convertible secured debentures (the “ Debentures ”) in the aggregate principal amount of $10,000,000 which are currently held by the Debentureholders and which are convertible into the Class A preference shares of Trillium (the “ Trillium Class A Pref Shares ”);

   
E.

Certain of the Debentureholders are also the registered holders of 3 Trillium Class A Pref Shares and the Debentureholders are also the holders of 5,300,752 Trillium Class A Pref Warrants (as hereinafter defined);

   
F.

Trillium has issued and outstanding stock options to acquire 1,418,250 Trillium Common Shares pursuant to the ESOP (as hereinafter defined);

   
G.

In furtherance of the foregoing Transaction (as defined herein), the Debentureholders wish to sell, and Stem Cell wishes to purchase the Debentures at the Debenture Purchase Price (as defined herein) pursuant to the terms and conditions of this Agreement. Concurrently with such purchase of Debentures, the Debentureholders shall also tender all of their Trillium Class A Pref Warrants for consideration of $1.00.

   
H.

The parties have agreed to enter into this Agreement setting out the terms and conditions on which the Transaction will be carried out;

NOW THEREFORE in consideration of the mutual covenants and agreements herein contained and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each of the parties hereto, the parties hereto hereby agree as follows:

1.

INTERPRETATION

   
1.1

Definitions

In this Agreement, unless otherwise defined or expressly stated herein or unless the context otherwise requires:

Acquisition Proposal ” means any of the following (other than the transactions contemplated by this Agreement or the Arrangement): (a) any merger, amalgamation, arrangement, share exchange, take-over bid, tender offer, recapitalization, consolidation or business combination directly or indirectly involving Trillium or any of its subsidiaries, (b) any acquisition of assets representing 20% or more of the book value (on a consolidated basis) of the assets of Trillium and its subsidiaries, taken as a whole (or any lease, long-term supply agreement, exchange, mortgage, pledge or other arrangement having a similar economic effect) in a single transaction or a series of related transactions, (c) any acquisition of beneficial ownership of 20% or more of the Trillium Shares in a single transaction or a series of related transactions, or (d) any bona fide proposal to, or public announcement of an intention to, do any of the foregoing;

Agreement ” means this Agreement (including the Schedules attached hereto) as the same may be amended, supplemented, restated or otherwise modified from time to time in accordance with the terms hereof;

Amalco ” means the corporation resulting from the amalgamation of Trillium and Acquisitionco;


- 3 -

Amalco Class A Pref Shares ” means the redeemable, retractable Class A preferred share of Amalco, with a redemption price of $0.00000000000001 per share;

Amalco Class B Pref Shares ” means the redeemable, retractable Class B preferred shares of Amalco with a redemption price of $0.00000000000001 per share;

Amalgamation ” means the amalgamation of Trillium and Acquisitionco arising as a result of the filing of the Articles of Amalgamation pursuant to the Amalgamation Agreement;

Amalgamation Agreement ” means the amalgamation agreement to be entered into between Acquisitionco and Trillium in respect of the Articles of Amalgamation substantially in the form attached hereto as Appendix A;

Applicable Privacy Laws ” means any and all applicable Laws relating to privacy and the collection, use and disclosure of Personal Information in all applicable jurisdictions, including the Personal Information Protection and Electronic Documents Act (Canada) and any comparable provincial law;

Applicable Securities Laws ” at any time means the applicable securities legislation of each province and territory of Canada and the respective rules and regulations made or promulgated under that legislation and the published forms and blanket rulings and orders issued by the regulatory authorities administering that legislation in effect at such time, in each case as amended and in force from time to time;

Articles of Amalgamation ” means the articles of amalgamation and related amalgamation agreement giving effect to the amalgamation of Acquisitionco and Trillium, substantially in the form attached hereto as Appendix B;

Business Day ” means any day other than a Saturday or Sunday or a day observed as a holiday in Toronto, Ontario;

Commercially reasonable efforts ” with respect to any party hereto means the agreement of such party to use and cause the affiliates of such party controlled by it to use their respective reasonable efforts consistent with reasonable commercial practice without payment or incurrence of any liability or obligation, other than reasonable expenses, or the requirement to engage in litigation;

Confidential Information ” has the meaning defined in section 5.5;

Constating documents ” means, with respect to any Person, the certificate and articles of incorporation, amalgamation or continuation, by-laws, articles of organization, limited liability company agreement, operating agreement, partnership agreement, certificate of formation, formation agreement, joint venture agreement, unanimous shareholders agreement or declaration or similar charter or governing documents of such Person;

Debentureholders ” means collectively, Covington, GrowthWorks, BDC and IAF;

Debentures ” means the 12% convertible secured debentures of Trillium presently held by the Debentureholders in the aggregate principal amount of $10,000,000 with a maturity date of October 31, 2013;


- 4 -

Debenture Purchase Price ” has the meaning ascribed there to in Section 2.3.2;

Depositary ” means Computershare Trust Company of Canada;

Effective Date ” unless otherwise agreed to by the parties hereto means the date on which all conditions to the completion of the Transaction as set out in Article 6 have been satisfied or waived in accordance with the provisions of this Agreement and all documents agreed to be delivered hereunder have been delivered to the satisfaction of the parties hereto, acting reasonably;

Effective Time ” means the first moment in time on the Effective Date upon the issue of the certificate of amalgamation issued by the Director appointed under the Business Corporations Act (Ontario) in respect of the amalgamation;

Encumbrance ” means any mortgage, lien, hypothec, security interest, pledge, or other encumbrance, charge or adverse right or claim;

ESOP ” means the 2003 Employee Stock Option Plan dated April 10, 2003 established by Trillium;

Exchange ” means the TSX Venture Exchange;

Governmental Authority ” means (i) any federal, provincial, state, regional, municipal, local or other government or governmental body and any ministry, department, division, bureau, agent, agency, commission, board or authority of any government or governmental body, domestic or foreign, (ii) any domestic, foreign or international judicial, quasi-judicial or administrative court, tribunal, commission, board, panel, arbitrator or arbitral body acting under the authority of any of the foregoing or (iii) any quasi-governmental or private body exercising any statutory, regulatory, expropriation or taxing authority under the authority of any of the foregoing;

Laws ” means all laws, statutes, codes, ordinances, decrees, rules, regulations, by-laws, judicial or arbitral or administrative or ministerial or departmental or regulatory judgments, orders, decisions, rulings, determinations or awards of any Governmental Authority having the force of law and any legal requirements or bases of liability under the common law and the term “ applicable ” with respect to such Laws and, in the context that refers to any Person, means such Laws as are applicable to such Person or its business, undertaking, property or securities and that emanate from a Governmental Authority having jurisdiction over the Person or its business, undertaking, property or securities;

Material Adverse Effect ”, with respect to Stem Cell or Trillium, means any change, event, occurrence, development or effect which has or would reasonably be expected to have a durational material adverse effect on the business, affairs, operations, results of operations, assets, properties, capital, capitalization, condition (financial or otherwise), rights, liabilities, obligations (whether absolute, accrued, conditional or otherwise), prospects or privileges, whether contractual or otherwise, of the party and its Subsidiaries, taken as a whole;

Material Contract ” with respect to Stem Cell or Trillium, means a contract, agreement, licence, indenture, other instrument, commitment or right or obligation, whether or not in writing, (in this definition, a “ contract ”) pursuant to which such party or any of its Subsidiaries has material continuing contractual rights or obligations relating to or affecting the conduct of its business or any of its property or assets;


- 5 -

Misrepresentation ” means an untrue statement of a material fact or an omission to state a material fact required to be stated or necessary in order to make the statements made, in light of the circumstances under which they were made, not false or misleading;

Parties ” means, collectively, the parties to this Agreement, and “ party ” means any one of them;

Person ” includes an individual, sole proprietorship, partnership, limited partnership, unincorporated association, unincorporated syndicate, unincorporated organization, trust, body corporate, a natural person in his or her capacity as trustee, executor, administrator, or other legal representative, government or Governmental Authority;

Personal Information ” means information about an identifiable individual collected, used or disclosed by Intrawest or any of its subsidiaries, such as an individuals’ name, address, age, gender, identification number, income, family status, citizenship, employment, assets, liabilities, source of funds, payment records, credit information, personal references and health records;

Securities Act ” means the Securities Act (Ontario);

Securities Authorities ” means the applicable securities commissions and other securities regulatory authorities in Canada;

Stem Cell Common Shares ” means the common shares in the capital of Stem Cell;

Stem Cell Disclosure Record ” means all documents and information publicly filed by Stem Cell under Applicable Securities Laws since December 31, 2011;

Stem Cell Financial Statements ” means the audited consolidated annual financial statements of Stem Cell as at and for the financial year ended December 31, 2011 and the unaudited consolidated interim financial statements of Stem Cell as at and for the nine-month period ending September 30, 2012, including the notes thereto;

Stem Cell Intellectual Property Rights ” has the meaning defined in section 3.2.13;

Stem Cell Offering ” means the public offering by way of prospectus supplement, to the short form base shelf prospectus of Stem Cell, qualifying the distribution of up to 14,000,000 Stem Cell Units at a price of $0.25 per unit, resulting in gross proceeds of not less than $2,500,000 to Stem Cell;

Stem Cell Reports ” has the meaning defined in section 3.2.8(e);

Stem Cell Share Consolidation ” means the consolidation by Stem Cell of its 186,619,359 issued and outstanding Stem Cell Shares on February 6, 2013 on the basis of one post-consolidation Stem Cell Share for every 10 pre-consolidation Stem Cell Shares;

“Stem Cell Supplement” means the prospectus supplement of Stem Cell dated March 11, 2013 pursuant to the Stem Offering;

Stem Cell Technology ” has the meaning defined in section 3.2.13;


- 6 -

Stem Cell Unit ” means the units issued pursuant to the Stem Cell Offering comprised of one Stem Cell Common Share and one Stem Cell Common Share purchase warrant;

Subsidiary ” means, with respect to a specified entity, any:

(a)

corporation of which issued and outstanding voting securities of each corporation to which are attached more than 50% of the votes that may be cast to elect directors of the corporation (whether or not shares of any other class or classes will or might be entitled to vote upon the happening of any event or contingency) are at the time owned by such specified entity and the votes attached to those voting securities are sufficient, if exercised, to elect a majority of the directors of such corporation;

   
(b)

partnership, limited liability company, joint venture or other similar entity in which such specified entity has more than 50% of the equity interests and the power to direct the policies, management and affairs thereof; and

   
(c)

a subsidiary (as defined in clauses (a) and (b) hereof) of any subsidiary (as so defined) of such specified entity;

Superior Proposal ” means any unsolicited bona fide written proposal by a third party, directly or indirectly, to acquire assets representing more than 50% of the book value (on a consolidated basis) of Trillium’s total assets or more than 50% of the Trillium Shares, whether by way of merger, amalgamation, arrangement, share exchange, take-over bid, recapitalization, sale of assets or otherwise, and that in the good faith determination of the Board of Directors of Trillium (a) is reasonably capable of being completed without undue delay, taking into account all legal, financial, regulatory and other aspects of such proposal and the party making such proposal, and (b) would, if consummated in accordance with its terms, result in a transaction more favourable to Trillium’s Securityholders from a financial point of view than the transactions contemplated by this Agreement;

Tax Act ” means the Income Tax Act , R.S.C. 1985 (5th Supp.) c. 1;

Taxes ” means all Canadian federal, provincial, municipal, local and foreign taxes, assessments and other governmental charges, levies, duties, impositions and liabilities lawfully imposed by any Governmental Authority, including taxes based or measured on gross receipts, income, profits, sales, capital, use, occupation, net worth, goods and services, value added, ad valorem , withholding, payroll or employment, franchise, premium, land transfer, excise or property taxes, Canada or Quebec pension plan premiums, social security premiums, workers’ compensation premiums, employment or unemployment insurance premiums, stamp taxes and custom duties together with all interest, penalties, fines and additions imposed with respect to such amounts;

Transaction ” means the proposed transaction pursuant to the terms of this Agreement whereby Acquisitionco and Trillium will file the Articles of Amalgamation and complete the Amalgamation pursuant to the Amalgamation Agreement; (i) the holders of Trillium Class A Shares will receive Amalco Class A Pref Shares on the basis of one (1) Amalco Class A Pref Shares for every one (1) Trillium Class A Pref Share held; (ii) the holders of Trillium Common Shares will receive Amalco Class B Pref Shares on the basis of one (1) Amalco Class B Pref Shares for every one (1) Trillium Common Share held; and (iii) concurrently with the amalgamation of Acquisitionco and Trillium, Stem Cell will purchase all of the Debentures and Trillium Class A Pref Warrants; and (iv) immediately following the amalgamation of Trillium and Acquisitionco into Amalco, Amalco shall redeem all of the issued and outstanding Amalco Class A Pref Shares and Amalco Class B Pref Shares;


- 7 -

Transaction Resolutions ” means the resolutions to be considered and, if thought fit, passed by the Trillium Shareholders at the Trillium Meeting to approve the Transaction;

Trillium Class A Pref Shares ” means the Class A preferred shares in the capital of Trillium;

Trillium Class A Pref Warrants ” means the 5,300,752 share purchase warrants entitling the holders thereof to purchase Trillium Class A Pref Shares;

Trillium Common Shares ” means the common shares in the capital of Trillium;

Trillium Financial Statements ” means the audited annual financial statements of Trillium as at and for the year ended June 30, 2012 and the unaudited interim financial statements of Trillium as at and for the three-month period ended September 30, 2012 including the notes thereto;

Trillium Intellectual Property Rights ” has the meaning defined in section 3.3.15;

Trillium Meeting ” means the special meeting of Trillium Shareholders, including any adjournment, adjournments, postponement or postponements thereof, to be called to consider and, if thought fit, approve the Transaction Resolutions;

Trillium Notice ” means the notice of the Trillium Meeting, including all schedules, appendices and exhibits thereto, to be sent to the Trillium Shareholders in connection with the Trillium Meeting, as the same may be amended, supplemented or otherwise modified from time to time;

Trillium Options ” means the 1,418,250 issued and outstanding options to purchase Trillium Common Shares;

Trillium Optionholders ” means the holders of Trillium Options as of the date hereof;

Trillium Securityholders ” at any time mean the holders of Trillium Class A Pref Shares, Trillium Common Shares, Trillium Class A Pref Warrants and Debentures;

Trillium Shareholders ” at any time mean the holders at that time of Trillium Class A Shares and Trillium Common Shares; and

Trillium Technology ” has the meaning defined in section 3.3.15.

1.2

Currency

Except where otherwise specified, all sums of money which are referred to in this Agreement are expressed in lawful money of Canada.

1.3

Interpretation


  1.3.1

Divisions and Headings . The division of this Agreement into Articles, sections, paragraphs and subparagraphs and the insertion of a table of contents and headings are for convenience of reference only and shall not affect the construction or interpretation of this Agreement.



- 8 -

  1.3.2

Agreement . The terms “ this Agreement ”, “ hereof ”, “ herein ”, “ hereunder ” and similar expressions refer to this Agreement, including the Schedules hereto, as a whole, and not to any particular Article, section or other portion or subdivision hereof.

     
  1.3.3

Division References . Unless a contrary intention appears, references in this Agreement to an Article, section, subsection, paragraph, clause, subclause or schedule by number or letter or both refer to that Article, section, subsection, paragraph, clause, subclause or schedule, respectively, bearing that designation in this Agreement.

     
  1.3.4

Date of Agreement . Any references to the date of this Agreement, “ the date hereof ” or similar expressions or references shall mean the date first written above, except as expressly provided herein. Unless otherwise defined or expressly stated or unless the context otherwise requires, all terms defined in this Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant hereto.


1.4

Knowledge and Disclosure


  1.4.1

Knowledge . Any reference in this Agreement to the “ knowledge ” or the “ awareness ” of the senior officers or consultants of Stem Cell or Trillium, as the case may be, or of such party, shall (unless otherwise specified or the context otherwise requires) mean, in the case of Stem Cell the actual knowledge, after all due inquiry, of David Allan, Executive Chairman or James Parsons, Chief Financial Officer and, in the case of Trillium, the actual knowledge, after due inquiry, of Niclas Stiernholm, Chief Executive Officer, as applicable, as of the date of this Agreement, and does not include any knowledge or awareness of any other individual or any constructive, implied or imputed knowledge or awareness.

     
  1.4.2

No Admission . Disclosure of any item or other matter herein is disclosed solely for the purposes of this Agreement and no information set forth therein shall be construed as an admission or indication by any party hereto or to any third party of any matter whatsoever, including of any violation of law or breach of any contract or agreement.


1.5

Number and Gender


  1.5.1

Number and Gender . Unless the context otherwise requires, words in this Agreement should be construed to refer to such gender or number as the circumstances require and words importing the singular number include the plural and vice versa; words importing any gender shall include all genders and neuter; and words importing persons shall include firms and corporations and vice versa.

     
  1.5.2

Includes . Whenever used in this Agreement, the words “including”, “includes” or “include” and similar terms of inclusion shall not, unless expressly modified by the words “only” or “solely”, be construed as terms of limitation, but rather be construed as though they were followed by the words “but not limited to” or “without limiting the generality of the foregoing”, so that references to included matters shall be regarded as illustrative without being either characterizing or exhaustive.



- 9 -

1.6

Date of any Action

In the event that any date on which any action is required to be taken hereunder by any of the parties hereto is not a Business Day, such action shall be required to be taken on the next succeeding day which is a Business Day.

1.7

Accounting Matters


  1.7.1

Generally Accepted Accounting Principles . Whenever in this Agreement reference is made to generally accepted accounting principles, such reference will be deemed to refer to applicable IFRS (International Financial Reporting Standards) or Canadian generally accepted accounting principles applicable as at the date on which any applicable calculation is made or required to be made in accordance with generally accepted accounting principles.

     
  1.7.2

Accounting Terms and Determinations . Unless otherwise stated, or the context otherwise requires, all accounting terms used in this Agreement in respect of Stem Cell or Trillium, as the case may be, will have the meanings attributable thereto under generally accepted accounting principles and all determinations of an accounting nature in respect of Stem Cell or Trillium, as the case may be, required to be made will be made in a manner consistent with generally accepted accounting principles consistently applied.


1.8

Statutory References

In this Agreement, unless something in the subject matter or context is inconsistent therewith or unless otherwise herein provided, a reference to any statute, enactment or legislation or to any section or provision thereof include a reference to any order, ordinance, regulation, rule or by-law or proclamation made under or pursuant to that statute, enactment or legislation and all amendments, modifications, consolidations, re-enactments or replacements thereof or substitutions therefore from time to time.

1.9

Legal, Valid and Binding

All representations, warranties and covenants in this Agreement as to any covenant, agreement or document being legal, valid and binding are subject to the qualification that enforceability of such covenant, agreement or document is subject to bankruptcy, insolvency, reorganization, fraudulent transfer, moratorium and other Laws relating to or affecting the availability of equitable remedies and the enforcement of creditors’ rights generally and general principles of equity and public policy and to the qualification that equitable remedies such as specific performance and injunction may be granted only in the discretion of a court of competent jurisdiction and that enforcement may otherwise be limited under applicable Laws.

1.10

Appendices and Schedules

The following are the Appendices and Schedules to this Agreement:


- 10 -

Appendix A Amalgamation Agreement
Appendix B Articles of Amalgamation
Appendix C Schedules
Schedule 3.3.1 Trillium Issued and Outstanding Trillium Securities
Schedule 3.3.15 Trillium Intellectual Property Rights

2.

THE TRANSACTION

   
2.1

The Transaction


  2.1.1

Implementation of Transaction . Stem Cell, Acquisitionco and Trillium agree that the Transaction shall be implemented in accordance with and subject to the terms and conditions contained in this Agreement.

     
  2.1.2

Trillium Meeting . Subject to the terms of this Agreement and in accordance with applicable Laws, Trillium will convene and hold the Trillium Meeting on or about April 5, 2013 and not later than April 15, 2013, or such other date as may be agreed to by Stem Cell and Trillium, or as soon as reasonably practicable thereafter and will not, without the prior written consent of Stem Cell, which consent shall not be unreasonably withheld, cancel, postpone or adjourn the Trillium Meeting.

     
  2.1.3

Completion of Transaction . Subject to the satisfaction or waiver (subject to applicable Laws) of the conditions (excluding conditions that by their terms cannot be satisfied until the Effective Date, but subject to the satisfaction or, where permitted, waiver of those conditions as of the Effective Date) set forth in Article 6 (as confirmed by each party hereto to the other in writing), as soon as reasonably practicable thereafter, the parties will complete the Transaction on the next Business Day following such satisfaction or waiver.

     
  2.1.4

Filing of Articles of Amalgamation . On the Effective Date the Amalgamation Agreement will be executed and Articles of Amalgamation will be filed.

     
  2.1.5

Purchase of the Debentures and Trillium Class A Pref Warrants . Concurrently with implementation of the Amalgamation, Stem Cell will purchase all of the Debentures and all of Trillium Class A Pref Warrants pursuant to the terms in Sections 2.3.3 and 2.3.4

     
  2.1.6

Redemption of Amalco Shares . Immediately following the Amalgamation, Amalco shall redeem all of the issued and outstanding Amalco Class A Pref Shares and Amalco Class B Pref Shares issued in connection with the Amalgamation.

     
  2.1.7

Closing . The closing of the Transaction will take place in the offices of McCarthy Tétrault LLP at Suite 3300, 421 - 7th Avenue SW, Calgary AB, T2P 4K9 (or such other time as may be agreed by Stem Cell, Trillium and the Debentureholders) on the Effective Date.



- 11 -

2.2

Trillium Meeting


  2.2.1

Trillium Notice

       
  (a)

Preparation of Trillium Notice . Subject to Stem Cell and Acquisitionco complying with sections 2.2.2, on or before March 26, 2013, or such other date as may be agreed to by Stem Cell and Trillium, or as soon as reasonably practicable thereafter, Trillium will prepare the Trillium Notice.

       
  (b)

Mailing of Trillium Notice . As promptly as practicable after the completion of the Trillium Notice, Trillium will cause the Trillium Notice to be sent to the Trillium Shareholders as required by applicable Laws.

       
  (c)

Trillium Board Recommendation . Subject to a determination by the Board of Directors of a Superior Proposal, the Trillium Notice will set forth, among other things, the recommendation of the Board of Directors of Trillium that the Trillium Shareholders vote in favour of the Transaction Resolutions.


  2.2.2

Stem Cell Opportunity to Review Trillium Notice . Trillium will provide Stem Cell and its representatives with a reasonable opportunity to review and comment on the Trillium Notice, and Stem Cell and Acquisitionco shall review in a timely and expeditious manner any information to be supplied by Stem Cell and Acquisitionco for inclusion in the Trillium Notice, prior to its being filed and sent to Trillium Shareholders in accordance with applicable laws.

     
  2.2.3

Trillium Notice. Trillium will ensure that the Trillium Notice complies with all requirements under the applicable laws.

     
  2.2.4

Dissents . Trillium will promptly advise Stem Cell of any written notice of dissent or purported exercise by any Trillium Shareholder of dissent rights received by the Trillium in relation to the Trillium Meeting and the Transaction Resolutions and any withdrawal of dissent rights received by Trillium.


2.3

Purchase and Sale of Debentures

     
2.3.1

Subject to the terms and provisions hereof, each of the Debentureholders hereby severally, and not jointly and severally, agrees to, sell, transfer, assign and convey to Stem Cell and Stem Cell agrees to purchase from such Debentureholder that all of the Debentures held by such Debentureholder at the Effective Time. Schedule 3.3.1 sets out the holdings of the Debentures by Debentureholders at the date hereof. Each Debentureholder agrees not to transfer any of the Debentures except to a Person who agrees to be bound by the Debentureholder’s rights and obligations hereunder insofar as relate to the transferred Debenture(s). The sale of the Debentures shall be at the Debenture Purchase Price (as contemplated below).

     
2.3.2

The aggregate purchase price of $2,850,000 (the “ Debenture Purchase Price ”) payable for the Debentures (which shall be allocated to each Debentureholder based upon their pro rata share of the principal amount of issued and outstanding Debentures plus accrued interest accumulated thereon, which for the sake of clarity is as follows: (i) 51.36% to Covington, (ii) 21.0% to GrowthWorks, (iii) 19.26% to BDC and (iv) 8.38% to IAF;



- 12 -

  2.3.3

The Debenture Purchase Price will be paid by Stem Cell to the Debentureholders at the time of closing on the Closing Date as follows (all of which shall be in the proportions set out in Section 2.3.2);

       
  (a)

$1,200,000 will be paid in cash by certified cheque, bank draft or wire transfer as each Debentureholders so directs in writing;

       
  (b)

$825,000 shall be paid by the issuance and delivery of 2,779,181 Stem Cell Common Shares, based upon the 5-day volume weighted average price ending the trading day immediately prior to the announcement of the letter agreement between Stem Cell, Trillium and the Debentureholders, which issuance shall be evidenced by share certificates registered in the name of the respective Debentureholder or as a Debentureholder otherwise directs Stem Cell in writing prior to the Closing Date;

       
  (c)

$825,000 shall be paid by the issuance and delivery of 3,300,000 Stem Cell Units based upon the price per Stem Cell Unit under the Stem Cell Offering, which issuance shall be evidenced by definitive certificates registered in the name of the respective Debentureholder or as a Debentureholder otherwise directs Stem Cell in writing prior to the Closing Date; For the sake of clarity, the common share purchase warrants comprising the foregoing Stem Cell Units shall be exercisable at $0.40 per share until 5:00 pm EST on March 11, 2018; and

       
  (d)

The percentages set forth in Section 2.3.2 are inclusive all accrued interest and there shall be no further adjustment to the Debenture Purchase Price for any accrued interest between the date hereof and the Closing Date.

       
  2.3.4

Concurrently with such purchase of Debentures, the Debentureholders shall also tender all of their Trillium Class A Pref Warrants for consideration of $1.00 per Debentureholder.


2.4

Withholding

Trillium, Stem Cell, Acquisitionco or Amalco, as the case may be, shall be entitled to deduct and withhold or cause to be deducted and withheld, as appropriate, from any amount otherwise payable or deliverable pursuant to this Agreement to any Trillium Securityholder (including any consideration payable to holders of Trillium Class A Pref Shares, Trillium Common Shares, Debentures or any payments to Trillium Shareholders that exercise dissent rights with respect to the exercise of such rights) such amounts as are required to be deducted and withheld with respect to any such payment by the Tax Act and will be entitled to deduct and withhold such amounts as may be required by any other Law relating to Taxes as counsel may advise is required to be made by Trillium, Stem Cell, Acquisitionco or Amalco, as the case may be. To the extent any amounts are so deducted and withheld and remitted or caused to be deducted, withheld or remitted to the appropriate Governmental Authority by Trillium, Stem Cell, Acquisitionco or Amalco, as the case may be, such amount will be treated for all purposes of this Agreement as having been paid to the particular Trillium Securityholder on account of the obligation to make any payments to such Trillium Securityholder hereunder.


- 13 -

3.

REPRESENTATIONS AND WARRANTIES

   
3.1

Mutual Representations and Warranties

Except as disclosed in writing by it to the other party, each of Trillium, Stem Cell and Acquisitionco represents and warrants to the other party and to the Debentureholders (as several, and not joint and several representations) as follows and acknowledges that the other party and to the Debentureholders is relying upon such representations and warranties in entering into this Agreement:

  3.1.1

Organization and Capacity . It and each Subsidiary (if applicable):

       
  (a)

is a corporation duly incorporated, amalgamated or continued, or an entity duly formed, and is validly existing under the Laws of its respective jurisdiction of incorporation, amalgamation, continuation or formation;

       
  (b)

has the requisite corporate (or in the case of a non-corporate entity, other legal) power and capacity to own its assets as now owned and to carry on its business as it is now being carried on; and

       
  (c)

is duly registered or otherwise qualified or authorized to do business and, to the extent such concept is legally recognized, is in good standing in each jurisdiction in which the nature of its assets, or the nature of its activities, makes such registration, authorization or qualification necessary.

       
  (a)

Power and Authority . It has all requisite corporate power and authority to enter into this Agreement and (in the case of Trillium, subject to obtaining the approval of the Trillium Shareholders of the Transaction Resolutions) and to perform its obligations hereunder.

       
  (b)

Authorization and Binding Agreement . The execution and delivery of this Agreement has been duly authorized by all necessary corporate approvals (except, in the case of Trillium, subject to obtaining the approval of the Trillium Shareholders of the Transaction Resolutions), and no other corporate proceedings on its part are necessary to authorize the execution by it of this Agreement or the consummation by it of the Transaction (except, in the case of Trillium, subject to obtaining the approval of the Trillium Shareholders of the Transaction Resolutions), and this Agreement has been duly executed and delivered by it and constitutes a legal, valid and binding obligation of it enforceable against it in accordance with its terms.

       
  3.1.3

Approval by Directors . As at the date hereof, its Board of Directors has approved this Agreement and the Transaction and has determined that the Transaction is in its best interests (except that, in the case of Trillium and Stem Cell, certain directors have declared a conflict of interest and have refrained from voting) and those Trillium directors voting on the approval of this Agreement and the Transaction have resolved to unanimously recommend approval of the Transaction by the Trillium Shareholders.



- 14 -

  3.1.4

No Violations . Subject to obtaining the authorizations, consents and approvals referred to in sections 3.1.6, 3.1.8, and 3.3.12 and complying with applicable corporate, securities, competition and anti-trust Laws, to the knowledge of such party, the execution and delivery by it of this Agreement and the performance by it of its obligations hereunder do not and will not (nor will they with the giving of notice or the lapse of time or both):

       
  (a)

result in a material contravention, breach or violation or default under any Laws applicable to it or any Subsidiaries (subject to compliance with any Laws contemplated by this Agreement);

       
  (b)

result in a material contravention, violation, breach or default under the constating documents of it or any Subsidiaries;

       
  (c)

result in a material contravention, breach or default under or termination of, or accelerate or permit the acceleration of the performance required by, any Material Contract;

       
  (d)

result in the cancellation, suspension or material alteration in the terms of any material license, permit, approval or authorization from any Governmental Authority held by it or any of its Subsidiaries except for such licenses, permits, approvals or authorizations where the consent or approval or authorization of one or more Governmental Authorities is required in order to avoid such cancellation, suspension or alteration, which consent, approval or authorization is such that is required in the normal course or is of a purely administrative nature or which will either be obtained prior to the Effective Date or which can reasonably be expected to be obtained after the Effective Time without adverse effect on the conduct of the operations of such party or its Subsidiaries; or

       
  (e)

result in the creation or imposition of any Encumbrance upon any of the properties or assets of such party or any of its Subsidiaries,

       
  3.1.5

Compliance with Laws .

       
  (a)

Compliance with Laws . To the knowledge of such party, it and each Subsidiary is conducting its businesses in compliance, in all material respects, with all applicable Laws of each jurisdiction in which its business is carried on and is not in breach of any applicable Laws to which it is subject or which apply to it.

       
  (b)

Investigation or Review . To the knowledge of such party, no investigation or review by any Governmental Authority with respect to such party or any of its Subsidiaries is pending or to the knowledge of such party threatened, nor has any Governmental Authority indicated in writing an intention to conduct the same.



- 15 -

  3.1.6

Consents, Approvals and Authorizations .

       
  (a)

Consents, Approvals and Authorizations . Such party and its Subsidiaries has obtained and is in compliance with licenses, permits, certificates, orders, grants, classifications, registrations and other consents, approvals and authorizations of any Governmental Authority required by applicable Laws necessary for such party or its Subsidiaries to own its respective assets and to lawfully carry on their respective businesses as they are now being carried on (for greater certainty, excluding any consent, approval or authorization by any Governmental Authority of any product or product candidate which is currently under development).

       
  (b)

No Violation . None of such party nor any of its Subsidiaries is in conflict with, or in default or violation of any of the consents, approvals or authorizations.

       
  3.1.7

Absence of Proceedings .

       
  (a)

Legal Proceedings . To the knowledge of such party, there is no court, administrative, regulatory or similar proceeding (whether civil, quasi-criminal or criminal), arbitration or other dispute settlement procedure, or any claim, action, suit, demand, arbitration, charge, indictment, hearing or other similar civil, quasi-criminal or criminal, administrative or investigative material matter or proceeding, or any investigation or inquiry by or complaint before any Governmental Authority (collectively, “ proceedings ”), against or involving it or any of its Subsidiaries, or any of the businesses, properties or assets of it or any of its Subsidiaries (whether in progress or, to the knowledge of such party, threatened) that could, if adversely determined, result in any claims against, or obligations or liabilities of, such party or any of its Subsidiaries.

       
  (b)

Judgments . To the knowledge of such party, no event has occurred which might reasonably be expected to give rise to any proceeding and there is no judgment, decree, injunction, rule, award or order of any Governmental Authority outstanding against it or any of its Subsidiaries in respect of their businesses, properties or assets.

       
  3.1.8

Governmental Approvals . No authorization, license, permit, certificate, registration, consent, order or approval of, or filing with, or notification to, any Governmental Authority is required to be obtained or made by or with respect to it or any of its Subsidiaries for the execution and delivery of this Agreement, the performance by it of its obligations hereunder or the consummation by it of the Transaction, other than:

       
  (a)

filing of the Articles of Amalgamation;

       
  (b)

filings required pursuant to Applicable Securities Laws; and

       
  (c)

conditional approval of the Exchange for the Transaction.



- 16 -

  3.1.9

Restrictions on Business Activities . To the knowledge of such party, there is no agreement, judgment, injunction, order or decree binding upon such party or any of its Subsidiaries that has or could reasonably expected to have the effect of prohibiting or materially restricting or impairing any business practice material to such party and its Subsidiaries, taken as a whole any acquisition of property material to such party and its Subsidiaries, taken as a whole or the conduct of business by such party and its Subsidiaries as currently conducted.


3.2

Representations and Warranties of Stem Cell

Stem Cell and Acquisitionco represent and warrant to Trillium and to the Debentureholders as follows and acknowledge that Trillium and the Debentureholders are relying upon these representations and warranties in entering into this Agreement:

  3.2.1

Capital Structure . The authorized capital of Stem Cell consists of an unlimited number of Stem Cell Common Shares, Class B shares and first preferred shares. As at the date of this Agreement, 30,976,936 Stem Cell Common Shares are outstanding and no Class B shares or first preferred shares are outstanding. All outstanding shares of capital of Stem Cell have been duly authorized and validly issued and are fully paid and non-assessable.

       
  3.2.2

Stem Cell Common Shares .

       
  (a)

Stem Cell Common Shares Issuable in Connection with the Transaction . The Stem Cell Common Shares to be issued under the Transaction, will be validly issued in compliance with the constating documents of Stem Cell and all applicable Laws, including the requirements of Applicable Securities Laws, and will be fully paid and non-assessable.

       
  (b)

Securities Exemptions . The Stem Cell Shares, Amalco Class A Pref Shares and Amalco Class B Pref Shares issued under the Transaction will be exempt from the dealer registration and prospectus requirements under Applicable Securities Laws in Canada. Subject to applicable law and the rules of the Exchange, the Stem Cell Shares and Stem Cell Units issued pursuant to the Transaction shall be freely tradeable.

       
  3.2.3

Subsidiaries .

       
  (a)

Ownership of Subsidiary . Stem Cell beneficially owns, directly or indirectly, all of the outstanding shares or other ownership interests of each of Acquisitionco and Stem Cell Therapeutics Inc. free and clear of any material Encumbrances.

       
  (b)

Rights to Acquire Securities . There is no outstanding option, warrant, put, call or other right, entitlement, agreement, understanding or commitment (pre-emptive, contingent or otherwise) giving any other Person the right to acquire any such share or ownership interest in any Subsidiary of Stem Cell and no option, warrant, subscription, put, call, conversion privilege, or other right, agreement, arrangement, entitlement, commitment or understanding (pre-emptive, contingent or otherwise) of any nature whatsoever obligating or which may obligate any such Subsidiary to issue or sell any share or ownership interest of such Subsidiary or security or obligation of any kind convertible into or exchangeable for, or otherwise evidencing a right to acquire, any shares or ownership interest of any such Subsidiary.



- 17 -

  (c)

Acquisitionco . Without limiting the generality of the foregoing or of any other provision hereof, all of the outstanding shares of Acquisitionco are held and beneficially owned, directly by Stem Cell. Acquisitionco is a wholly-owed subsidiary of Stem Cell which has not carried on any business or operations of any kind and does not have any liabilities or obligations of any kind whatsoever and does not have any material assets.

       
  3.2.4

No Dissolution . No proceeding has been instituted or is pending for the dissolution, winding-up or liquidation of Stem Cell, Stem Cell Therapeutics Inc. or Acquisitionco.

       
  3.2.5

Rights to Acquire Securities .

       
  (a)

Outstanding Options and Warrants . As at the close of business on the date preceding the date of this Agreement there are outstanding employee stock options, warrants, securities or other rights to acquire Stem Cell Common Shares or any other securities in Stem Cell other than (i) employee stock options to purchase an aggregate of 700,000 Stem Cell Common Shares with an average weighted exercise price of $1.03 per share; (ii) an aggregate of 13,224,090 purchase warrants to purchase Stem Cell Common Shares with a weighted average exercise price of $0.48 per share; and (iii) an aggregate of 941,323 compensation purchase warrants to purchase Stem Cell Common Shares with an exercise price of $0.36 per share.

       
  (b)

No Rights to Acquire Securities . Except for such securities in Section 3.2.5(b) and for the grant of employee stock options to employees as may be permitted pursuant to the terms of its existing stock compensation plan in the normal course, Stem Cell has no outstanding option, warrant, subscription, put, call or other right, entitlement, agreement, understanding or commitment (pre-emptive, contingent or otherwise) of any nature obligating or which may obligate it to issue or sell any shares or other securities, including any security or obligation of any kind convertible into or exchangeable for, or otherwise evidencing a right to acquire, any shares or other securities of Stem Cell.

       
  (c)

Securities Law Compliance . All shares and other securities of Stem Cell, including securities of Stem Cell that are convertible into, or exchangeable or exercisable for, or otherwise evidencing a right to acquire, any shares of Stem Cell, have been issued in compliance, in all material respects, with all applicable securities Laws.

       
  (d)

Voting Rights . Other than the securities in Section 3.2.5(b), there are no bonds, debentures or other evidence of indebtedness, or other securities, of Stem Cell or any of its Subsidiaries outstanding which have the right to vote generally (or are convertible into or exchangeable for or otherwise evidence a right to acquire, securities which have the right to vote generally) with the Stem Cell Common Shares on the election of directors of Stem Cell or other matters in respect of which holders of Stem Cell Shares are entitled to vote at general meetings of Stem Cell.



- 18 -

  (e)

Agreements . There is no outstanding shareholder agreement, voting trust or right to require registration or qualification for sale to the public under any applicable securities laws (including the Applicable Securities Laws) or any other arrangement or commitment to which Stem Cell or any of its Subsidiaries is a party or bound, with respect to the voting, disposition or transfer of any outstanding securities of Stem Cell or any of its Subsidiaries or registration or qualification for sale to the public of any outstanding securities of Stem Cell or any of its Subsidiaries under any securities laws (including the Applicable Securities Laws).

       
  3.2.6

Financial Statements .

       
  (a)

Compliance with IFRS. The Stem Cell Financial Statements have been prepared in accordance with IFRS (International Financial Reporting Standards) applied on a basis consistent with those of previous years except as otherwise stated in the notes to such statements (provided that unaudited interim financial statements are subject to adjustment and the notes to such interim statements may not include all notes or footnotes required under IFRS).

       
  (b)

Contents . To the knowledge of Stem Cell, the Stem Cell Financial Statements, together with the related management’s discussion and analysis, present fairly, in all material respects, the financial position of Stem Cell and its Subsidiaries as at the respective dates thereof and the results of operations of Stem Cell and its Subsidiaries on a consolidated basis for the periods covered thereby (subject, in the case of unaudited statements, to the fact that such statements may not contain all notes or footnotes required under generally accepted accounting principles and subject to normal year-end adjustments that are not expected, individually or in the aggregate, to be material) and the notes to such financial statements and the related management’s discussion and analysis filed under the Applicable Securities Laws do not contain any misstatement of a material fact nor do they omit to state a material fact required to make any statement contained therein not misleading in light of the circumstances in which it was made.

       
  3.2.7

No Undisclosed Liability; Absence of Certain Changes or Events . Except as contemplated in the Stem Cell Disclosure Record and in this Agreement:

       
  (a)

No Undisclosed Liability . Stem Cell and its Subsidiaries have no material liability or material obligation of any nature (whether accrued, absolute, contingent or otherwise), which individually or in the aggregate has not been reflected in the Stem Cell Financial Statements and the related management’s discussion and analysis filed under the Applicable Securities Laws, other than liabilities, indebtedness or obligations incurred by Stem Cell and its Subsidiaries in the ordinary course of business and attributable to the period since December 31, 2011 or incurred in connection with this Agreement or the transactions contemplated herein; and



- 19 -

  (b)

Absence of Certain Changes or Events . Since December 31, 2011:


  (i)

Conduct of Business . Stem Cell and its Subsidiaries, taken as a whole, have conducted their business only in the ordinary course;

     
  (ii)

Liabilities and Obligations . To the knowledge of Stem Cell, no liability, indebtedness, obligation, expense, claim, deficiency, guarantee or endorsement of any kind or nature (whether accrued, absolute, contingent, matured, unmatured or otherwise and whether or not required to be reflected in financial statements and related management’s discussion and analysis in accordance with generally accepted accounting principles) material to Stem Cell and any Subsidiary, taken as a whole, has been incurred or assumed by Stem Cell or any Subsidiary other than liabilities or obligations incurred in the ordinary course of business or incurred in connection with this Agreement and the transactions contemplated herein;

     
  (iii)

No Material Adverse Effect . To the knowledge of Stem Cell, there has not occurred (or been threatened) any change, or any condition or event, which individually or in the aggregate, has had, or would reasonably be expected to have, a Material Adverse Effect with respect to Stem Cell;

     
  (iv)

Employment Matters . No collective bargaining agreement or Stem Cell employee plan has been adopted, entered into, terminated, or amended or modified by Stem Cell or any of its Subsidiaries and there has been except for certain salary increases made in the ordinary course of business, no increase in any manner in any salary or other compensation or benefits payable to or to become payable by Stem Cell or its Subsidiaries to any current or former director, officer, employee or consultant of Stem Cell or any Subsidiary, in any form;

     
  (v)

Constating Documents . There has been no amendment to the articles or by-laws or other constating documents of Stem Cell;

     
  (vi)

Share Capital . Other than the Stem Cell Share Consolidation, there has been (i) no split, combination or reclassification of share capital of Stem Cell or (ii) no issuance or authorization of the issuance of any other securities in respect of, in lieu of or in substitution for shares in its share capital, or (iii) no purchase, redemption or other acquisition of any shares of share capital of Stem Cell or any of its Subsidiaries or any other securities thereof or any rights, warrants or options to acquire any such shares or other securities; and (iv) no amendment of any material term of any outstanding security of Stem Cell or any of its Subsidiaries;



- 20 -

  3.2.8

Securities Law Compliance .

       
  (a)

Reporting Issuer . Stem Cell is a “reporting issuer” within the meaning of that expression under the Applicable Securities Laws in each of the provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia and not on the list of reporting issuers in default under the Applicable Securities Laws of such provinces.

       
  (b)

Cease Trade Orders . To the knowledge of Stem Cell, no securities commission or similar regulatory authority has issued any order preventing or suspending trading of any securities of Stem Cell and Stem Cell is in compliance in all material respects with the Applicable Securities Laws and not materially in default of any material provision of Applicable Securities Laws.

       
  (c)

Inquiry or Investigation . To the knowledge of Stem Cell, no inquiry or investigation (formal or informal) of any Securities Authority is in effect or ongoing or, to its knowledge, expected to be implemented or undertaken which would reasonably be expected to have a Material Adverse Effect on Stem Cell.

       
  (d)

Exchange Listing . The Stem Cell Shares are listed on the Exchange and trading in the Stem Cell Common Shares is not currently halted or suspended.

       
  (e)

Public Filings . Since December 31, 2011, Stem Cell has filed each report, proxy statement and other document (including financial statements, material change reports and management proxy circulars) required to be filed by Stem Cell under Applicable Securities Laws and the rules and regulations of the Exchange (collectively, including any reports filed with any Securities Authority after the date of this Agreement, the “ Stem Cell Reports ”).

       
  (f)

Stem Cell Reports . The Stem Cell Reports filed prior to the date of this Agreement are publicly available in full without redaction on SEDAR’s website (and have been so available for not less than two days prior to the date of this Agreement), or copies thereof have otherwise been, and for Stem Cell Reports filed after the date of this Agreement, will otherwise be, provided or made available to Trillium.

       
  (g)

Contents of Filings . The documents and information comprising the Stem Cell Disclosure Record, as at the respective date they were filed, or, as applicable, the time of becoming effective, (or, if amended or superseded by a subsequent filing made prior to the date of this Agreement, as of the date of such filing) were in compliance in all material respects with Applicable Securities Laws and, where applicable, the rules and policies of the Exchange and did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.



- 21 -

  (h)

Currency of Filing . Stem Cell is current in the filing of all forms, reports, statements and documents required to be filed by it under the Applicable Securities Laws and, where applicable, the rules and policies of the Exchange.

     
  (i)

No Confidential Filings . Stem Cell has not filed any confidential material change report or other Trillium Report on a confidential basis with any Securities Authority in Canada or with the Exchange that at the date of this Agreement remains confidential in whole or in part.

     
  (j)

Subsequent Reports . Each Stem Cell Report filed subsequent to the date of this Agreement will comply, in all material respects, with the requirements of Applicable Securities Laws and the rules and policies of the Exchange and will not, at the time filed, contain any untrue statement of material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading.

     
  (k)

Subsidiaries . No Subsidiary of Stem Cell are, or have at any time been a reporting issuer under any Applicable Securities Laws in Canada and such Subsidiary is not or has not been required to file any form, report, registration statement or other document with any Canadian Securities authority. As used in this section, the term “ filed ” shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to any Securities Authority.


  3.2.9

Financial Advisors . None of Stem Cell or any of its Subsidiaries has incurred any obligation or liability, contingent or otherwise, or agreed to pay or reimburse any broker, finder, financial adviser or investment banker for any brokerage, finder’s, advisory or other fee or commission, or for the reimbursement of expenses, in connection with this Agreement or the transactions contemplated herein except Stem Cell has retained Euro Pacific Canada Inc. as their financial advisors in connection with the completion of the Stem Cell Offering.

       
  3.2.10

Taxes .

       
  (a)

Tax Returns . Stem Cell and each of its Subsidiaries has filed all necessary returns in respect of Taxes and other material reports and information under the Tax Act , the income tax or corporation capital tax legislation of any province of Canada or any foreign country or political subdivision thereof in which it carries on business or to a jurisdiction of which it is otherwise subject, any sales or excise tax legislation of a province of Canada or any foreign country, or political subdivision thereof or legislation affecting any other Taxes, applicable to Stem Cell or its Subsidiaries pursuant to which any of them are liable or required to pay or remit Taxes required to be filed by or in respect of Stem Cell or its Subsidiaries, respectively, for all periods in respect of which such filings are required and under the applicable Laws required to be filed with any Governmental Authority in respect of which such filings are required and due under applicable Laws.



- 22 -

  (b)

Tax Remittances . To the knowledge of Stem Cell, Stem Cell and its Subsidiaries have fully and timely paid all material Taxes owed by them (whether or not shown on any return, declaration or report) and have made adequate provision for any Taxes that are not yet due and payable for all taxation years ending on or before the date of this Agreement. Stem Cell and each of its Subsidiaries has withheld and remitted in the manner and within the time required under applicable Laws to tax collection or other authorities such Taxes and other deductions as are required by applicable Laws to be withheld and remitted in respect of any payment made by it.

       
  (c)

Assessments . To the knowledge of Stem Cell, there are no pending or threatened audits, actions, suits, investigations or proceedings and no assessment or reassessment pending or threatened by any Governmental Authority in respect of Taxes owing by Stem Cell or any of its Subsidiaries, and to the knowledge of Stem Cell there are no matters of dispute or matters under discussion with any Governmental Authority relating to Taxes assessed by any Governmental Authority against Stem Cell or any of its Subsidiaries or relating to any matters which could result in claims for Taxes or additional Taxes.

       
  (d)

Taxes Accruing . The Stem Cell Financial Statements accurately reflect, as at the dates thereof, Stem Cell’s liability for Taxes due and accruing, including Taxes for which a tax return was not yet filed or required to be filed.

       
  (e)

Waivers or Extensions . There are no agreements, waivers or other arrangements made by Stem Cell or any of its Subsidiaries material to Stem Cell extending the statutory period of limitations applicable to, or providing for an extension of time with respect to, any assessment or reassessment of Taxes, the filing of any tax return or the payment of any Taxes by Stem Cell or any of its Subsidiaries.

       
  3.2.11

Books and Records . The accounting and financial books and records of Stem Cell fairly set out and disclose in all material respects all material financial transactions of Stem Cell and its Subsidiaries, taken as a whole, and such transactions have been accurately recorded in such books and records.

       
  3.2.12

Corporate Records . To the knowledge of Stem Cell, the minute books and corporate records of Stem Cell containing minutes of meetings and proceedings of, and resolutions passed by (including resolutions consented to in writing), the shareholders and directors (including any committee thereof) of Stem Cell are complete and up-to-date in all material respects and the minutes and resolutions contained therein are complete and accurate.



- 23 -

  3.2.13

Intellectual Property .

       
  (a)

Intellectual Property Rights . Stem Cell and its Subsidiaries own or have validly licensed (and are not in material breach of such licenses), all patents, trade-marks, trade names, service marks, domain names, copyrights, know-how, trade secrets, software, technology and other intellectual property and proprietary rights that are material to the conduct of the business, as presently conducted, of Stem Cell and its Subsidiaries, taken as a whole, and sufficient and necessary to enable Stem Cell and its Subsidiaries to conduct such business substantially in the manner in which it is currently being conducted (all such rights as are owned are herein collectively referred to as the “ Stem Cell Owned IP Rights ” and the Stem Cell Owned IP Rights together with such rights as are licensed are herein collectively referred to as “ Stem Cell Intellectual Property Rights ”).

       
  (b)

No Infringement of Other Rights . To its knowledge, the Stem Cell Owned IP Rights are valid and enforceable and the conduct of the business of Stem Cell and its Subsidiaries (including the Stem Cell Owned IP Rights and the products and services of Stem Cell and its Subsidiaries) does not infringe upon, misappropriate or otherwise violate any other Person’s intellectual property and proprietary rights, and the entering into of this Agreement and completion of the transactions contemplated herein will not render invalid or unenforceable, or result in the loss or require additional payment with respect to, any Stem Cell Intellectual Property Rights.

       
  (c)

No Infringement of Stem Cell Owned IP Rights . To the knowledge of Stem Cell, there is no material unauthorized use, infringement or misappropriation of any of the Stem Cell Owned IP Rights by any Person, including any employee or former employee of Stem Cell or any of its Subsidiaries.

       
  (d)

Technology . Stem Cell and its Subsidiaries own, or have validly licensed (and are not in material breach of such licenses), all tangible embodiments of the Stem Cell Intellectual Property Rights, whether in electronic, written or other media, including hardware, software and firmware, processed data, technical documentation, technology infrastructure, computer systems, specifications, designs, test reports, routines, formulae, lab notebooks, processes, prototypes, samples, studies and other know-how and works of authorship that are material to the conduct of the business, as presently conducted, of Stem Cell and its Subsidiaries, taken as a whole (collectively, the “ Stem Cell Technology ”), all of which are up-to-date and sufficient for conducting such business, as presently conducted and Stem Cell and its Subsidiaries have taken commercially reasonable steps to implement and maintain appropriate virus protection and security measures in relation to the Stem Cell Technology and have reasonable back-up systems and a disaster recovery plan adequate to ensure the continuing availability of the functionality of the Stem Cell Technology, and have ownership of or a valid license to the Stem Cell Intellectual Property Rights necessary to allow them to continue to provide the functionality provided by the Stem Cell Technology in the event of any malfunction of the Stem Cell Technology or other form of disaster affecting the Stem Cell Technology.



- 24 -

  3.2.14

Compliance with Laws . To the knowledge of Stem Cell, Stem Cell and each of its Subsidiaries has conducted its activities on the lands and properties held or beneficially owned by it or in which it has an interest in material compliance with all applicable Laws and Stem Cell does not have any knowledge of, and none of Stem Cell or any of its Subsidiaries have received any notice of, any claim, regulatory order, investigation or proceeding, pending or threatened against, or which may affect, any of such lands or properties, relating to, or alleging any violation of, any applicable Laws or whether any remedial action is required to be undertaken.


3.3 Representations and Warranties of Trillium
   

Trillium represents and warrants to Stem Cell, Acquisitionco and the Debentureholders as follows and acknowledges that Stem Cell, Acquisitionco and the Debentureholders are relying upon these representations and warranties in entering into this Agreement:

       
3.3.1 Capital Structure . The authorized capital of Trillium consists of an unlimited number of common shares and an unlimited number of Class A preferred shares without par value. As of the date of this Agreement: (i) 16,267,041 Trillium Common Shares and (ii) 3 Trillium Class A Pref Shares are issued and outstanding. All outstanding Trillium Common Shares and Trillium Class A Pref Shares have been duly authorized and validly issued and are fully paid and non-assessable. Schedule 3.3.1 sets out all of the issued and outstanding securities of Trillium.
       
3.3.2 Subsidiary . Trillium does not beneficially own, directly or indirectly, any securities or other ownership interests of any Subsidiary, and Trillium does not hold or beneficially own, directly or indirectly, any shares or other ownership interests in the capital of any corporation, body corporate, partnership, joint venture, association or other entity or hold any securities or obligations of any kind which are convertible into or exchangeable for shares or other ownership interests in the capital of any corporation, body corporate, partnership, joint venture, association or other entity and Trillium is not a party to nor bound by any agreement to acquire any share or other security of any other corporation, body corporate, partnership, joint venture, association or other entity.
       
3.3.3 No Dissolution . No proceeding has been instituted or is pending for the dissolution, winding up or liquidation of Trillium.
       
  3.3.4 Rights to Acquire Securities .
       
(a)

Outstanding Options . As at the date of this Agreement there are outstanding Trillium Options to purchase an aggregate of 1,418,250 Trillium Common Shares.

     

(b)

Outstanding Class A Pref Warrants. As at the date of this Agreement there are outstanding an aggregate of 5,300,752 Trillium Class A Pref Warrants to purchase an aggregate of 5,300,752 Trillium Class A Shares, all of which are held by the Debentureholders.



- 25 -

  (c)

Securities Law Compliance . All shares and other securities of Trillium, including securities of Trillium that are convertible into, or exchangeable or exercisable for, or otherwise evidencing a right to acquire, any shares of Trillium, have been issued in compliance, in all material respects, with all applicable securities Laws.

     
  (d)

Voting Rights . Other than the Trillium Class A Shares, Trillium Common Shares, Trillium Options, Trillium Class A Pref Warrants and the Debentures referred to herein, there are no bonds, debentures or other evidences of indebtedness, or other securities of Trillium outstanding which have the right to vote generally (or are convertible into or exchangeable for or otherwise evidence a right to acquire, securities which have the right to vote generally) with the Trillium Class A Shares or Trillium Common Shares on the election of directors of Trillium or other matters in respect of which holders are entitled to vote at meetings of Trillium.

     
  (e)

Other Rights . There is no outstanding share or stock appreciation right, phantom equity, restricted share unit, deferred share unit or similar right, agreement, arrangement or commitment based on the book value, share price, income or any other attribute of Trillium.

     
  (f)

Agreements . Except for the Fifth Amended and Restated Shareholders’ Agreement and the Fourth Amended and Restated Registration Rights Agreement, each dated as of March 8, 2011 and to which Trillium is a party, there is no outstanding shareholder agreement, voting trust or right to require registration or qualification for sale to the public under any applicable securities laws (including the Applicable Securities Laws) or any other arrangement or commitment to which Trillium is a party or bound, with respect to the voting, disposition or transfer of any outstanding securities of Trillium or registration or qualification for sale to the public of any outstanding securities of Trillium under any securities laws (including the Applicable Securities Laws).

     
  (g)

Shareholder Rights Plan . Trillium has not entered into, and the Board of Directors of Trillium has not adopted or authorized the adoption of, any shareholder rights plan or similar agreement.


  3.3.5

Financial Statements .

       
  (a)

Compliance with GAAP . The Trillium Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a basis consistent with those of previous years except as otherwise stated in the notes to such statements (provided that unaudited interim financial statements are subject to adjustment and the notes to such interim statements may not include all notes or footnotes required under generally accepted accounting principles).



- 26 -

  (b)

Contents . The Trillium Financial Statements, present fairly, in all material respects, the financial position of Trillium on a consolidated basis as at the respective dates thereof and the results of operations of Trillium for the respective periods covered thereby (subject, in the case of unaudited statements, to the fact that such statements may not contain all notes or footnotes required under generally accepted accounting principles and subject to normal year-end adjustments that are not expected to be material) and the notes to such financial statements and do not contain any misstatement of a material fact nor do they omit to state a material fact required to make any statement contained therein not misleading in light of the circumstances in which it was made.

         
  3.3.6

No Undisclosed Liability; Absence of Certain Changes of Events . Except as contemplated this Agreement and the Trillium Financial Statements:

         
  (a)

No Undisclosed Liability . Trillium has no material liability or material obligation of any nature (whether accrued, absolute, contingent or otherwise), which individually or in the aggregate has not been reflected in the Trillium Financial Statements, other than liabilities, indebtedness or obligations incurred by Trillium in the ordinary course of business and attributable to the period since June 30, 2012 or incurred in connection with this Agreement or the transactions contemplated herein; and

         
  (b)

Absence of Certain Changes or Events . Since June 30, 2012:

         
  (i)

Conduct of Business . Trillium has conducted its business only in the ordinary course;

         
  (ii)

Liabilities and Obligations . To the knowledge of Trillium, no liability, indebtedness, obligation, expense, claim, deficiency, guarantee or endorsement of any kind or nature (whether accrued, absolute, contingent, matured, unmatured or otherwise and whether or not required to be reflected in the Trillium Financial Statements in accordance with generally accepted accounting principles) material to Trillium has been incurred or assumed by Trillium other than liabilities or obligations incurred in the ordinary course of business or incurred in connection with this Agreement and the transactions contemplated herein;

         
  (iii)

No Material Adverse Effect . To the knowledge of Trillium, there has not occurred (or been threatened) any change, or any condition or event, which individually or in the aggregate, has had, or would reasonably be expected to have, a Material Adverse Effect with respect to Trillium;

         
  (iv)

Dividends or Distributions . Trillium has not declared or paid, or set aside for payment, any dividends on or made any other distribution (in either case, in stock or cash or property) on or in respect of any outstanding securities of Trillium and Trillium has not made or authorized any payment to or for the benefit of any former or current director, officer or employee of Trillium (except in the ordinary course of business on a basis consistent with prior years or reimbursement of expenses) and the aggregate amount of compensation and benefits, and reimbursement of expenses incurred on behalf of Trillium, or other payments to any former or current director, officer or employee of Trillium has been paid at greater rates than those in corresponding periods in prior years;



- 27 -

  (v)

Loans or Investments . Trillium has not made any loan, advance or capital contribution to or investment in any Person other than loans in the ordinary course of business;

     
  (vi)

Material Contracts . Trillium has not entered into any Material Contract or amended, modified, relinquished, terminated or failed to renew any Material Contract;

     
  (vii)

Constating Documents . There has been no amendment to the articles or bylaws of Trillium;

     
  (viii)

Share Capital . There has been: (i) no split, combination or reclassification of share capital of Trillium or (ii) no issuance or authorization of the issuance of any other securities in respect of, in lieu of or in substitution for shares in its share capital, or (iii) no purchase, redemption or other acquisition of any shares of share capital of Trillium or any rights, warrants or options to acquire any such shares or other securities; and (iv) no amendment of any material term of any outstanding security of Trillium;

     
  (ix)

Encumbrances . There has been no creation or incurrence by Trillium of any material Encumbrance on any of its material properties or assets, or any agreement to do so (except for any lien for unpaid taxes not yet due), other than in the ordinary course of business; and


  3.3.7

Securities Law Compliance .

       
  (a)

Non-Reporting Issuer . Trillium is not a “reporting issuer” within the meaning of that expression under the Applicable Securities Laws in any province of Canada; and Trillium has not, at any time been, a reporting issuer under any Applicable Securities Laws in Canada and has not been required to file any form, report, registration statement or other document with any Canadian Securities authority. As used in this section, the term “ filed ” shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to any Securities Authority

       
  (b)

Inquiry or Investigation . To the knowledge of Trillium, no inquiry or investigation (formal or informal) of any Securities Authority is in effect or ongoing, or to its knowledge, expected to be implemented or undertaken which would reasonably be expected to have a Material Adverse Effect on Trillium.



- 28 -

  3.3.8

Employment Agreements and Other Arrangements .

       
  (a)

Termination or Change of Control Agreements . Trillium is not a party to or bound by any employment, retention or change of control agreement or other contract, commitment, arrangement, obligation or understanding (including any contract of employment or contract for service, contract of personal service, whether as a dependent or independent contractor, agent, secondee, temporary or leased employee or consultant or otherwise) relating to any retention, bonus, severance, termination, unemployment compensation, golden parachute, change of control payment, or termination payment or notice of termination to any former or current director, officer or employee in connection with termination of their office or employment or following a change of control, other than as required by applicable Laws for employees without agreements as to notice or severance.

       
  (b)

Loans or Indebtedness . Trillium does not have any loans or indebtedness outstanding or owing (other than obligations incurred in the ordinary course of business with respect to employee benefits and salaries and wages, management or other fees or reimbursement of expenses) to any former or current director, officer or employee of Trillium.

       
  (c)

Royalty or Other Interests . No former or current director, officer or employee of Trillium owns, has or is entitled to any royalty, net profits interest, carried interest or other Encumbrance of any kind or nature whatsoever which is based on revenues from any of the properties or assets of Trillium or any revenue or rights attributed thereto, or has any cause of action or other claim whatsoever against, or owes any amount to, Trillium, except for any claims in the ordinary course of business, such as for accrued vacation pay, accrued employee benefits or reimbursement of expenses.

       
  3.3.9

Financial Advisors . Trillium has not incurred any obligation or liability, contingent or otherwise, or agreed to pay or reimburse any broker, finder, financial adviser or investment banker for any brokerage, finder’s, advisory or similar fee or commission, or for the reimbursement of expenses, in connection with this Agreement or the transactions contemplated herein except for the $50,000 (plus 13% HST) payable to Cameron Groome in connection with the Transaction.

       
  3.3.10

Taxes .

       
  (a)

Tax Returns . Trillium has filed all necessary returns in respect of Taxes and other material reports and information under the Tax Act , the income tax or corporation capital tax legislation of any province of Canada or any foreign country or political subdivision thereof in which it carries on business or to a jurisdiction of which it is otherwise subject, any sales or excise tax legislation of a province of Canada or any foreign country, or political subdivision thereof or legislation affecting any other Taxes, applicable to Trillium pursuant to which any of them are liable or required to pay or remit Taxes required to be filed by or in respect of Trillium for all periods in respect of which such filings are required and under the applicable Laws required to be filed with any Governmental Authority in respect of which such filings are required and due under applicable Laws.



- 29 -

  (b)

Tax Remittances . To the knowledge of Trillium, Trillium has fully and timely paid all material Taxes owed by them (whether or not shown on any return, declaration or report) and have made adequate provision for any Taxes that are not yet due and payable for all taxation years ending on or before the date of this Agreement. Each of Trillium and any Subsidiary has withheld and remitted in the manner and within the time required under applicable Laws to tax collection or other authorities such Taxes and other deductions as are required by applicable Laws to be withheld and remitted in respect of any payment made by it.

     
  (c)

Assessments . To the knowledge of Trillium, there are no pending or threatened audits, actions, suits, investigations or proceedings and no assessment or reassessment pending or threatened by any Governmental Authority in respect of Taxes owing by Trillium and to the knowledge of Trillium there are no matters of dispute or matters under discussion with any Governmental Authority relating to Taxes assessed by any Governmental Authority against Trillium or relating to any matters which could result in claims for Taxes or additional Taxes.

     
  (d)

Taxes Accruing. The Trillium Financial Statements accurately reflect as of the dates thereof, Trillium’s liability for Taxes due and accruing, including Taxes for which a tax return was not yet filed or required to be filed.

     
  (e)

Waiver or Extensions . There are no agreements, waivers or other arrangements made by Trillium extending the statutory period of limitations applicable to, or providing for an extension of time with respect to, any assessment or reassessment of Taxes, the filing of any tax return or the payment of any Taxes by Trillium.


  3.3.11

Material Contracts .

       
  (a)

Material Contracts . Other than as disclosed in writing to Stem Cell prior to the signing of this Agreement, Trillium is not a party to or bound by any outstanding Material Contact other than this Agreement. All such Material Contracts are in full force and effect, in all material respects unamended.

       
  (b)

Performance of Obligations . Trillium has performed in all material respects all of the obligations to be performed by them, and are entitled to all material rights and benefits under all of such Material Contracts.

       
  (c)

No Breaches . To the knowledge of Trillium, there exists no material breach or default or event of default or event, occurrence, condition or act with respect to Trillium or to the knowledge of Trillium, the other contracting party or otherwise that, with or without the giving of notice, the lapse of time or the happening of any other event or condition, would (A) constitute a breach or become a default or event of default or (B) result in the loss or expiration of any right or option by Trillium (or the gain thereof by any third party), under any Material Contract to which Trillium is a party or by which Trillium is bound.



- 30 -

  3.3.12

Required Consents . Except for the consent required under the Contribution Agreement dated as of February 1, 2012 (as amended March 14, 2012) between Trillium and Her Majesty the Queen in Right of Canada, to the knowledge of Trillium, there are no Material Contracts to which Trillium is a party where any waiver, consent or approval by the other party thereto is required to be obtained by Trillium in order for Trillium to consummate the Transaction.

       
  3.3.13

Books and Records . The accounting and financial books and records of Trillium fairly set out and disclose in all material respects all material financial transactions of Trillium and such transactions have been accurately recorded in such books and records.

       
  3.3.14

Corporate Records . To the knowledge of Trillium, the minute books and corporate records of Trillium containing minutes of meetings and proceedings of, and resolutions passed by (including resolutions consented to in writing), the shareholders and directors (including any committee thereof) of Trillium are complete and up-to-date in all material respects and the minutes and resolutions contained therein are complete and accurate.

       
  3.3.15

Intellectual Property .

       
  (a)

Intellectual Property Rights . Trillium owns, or has validly licensed (and are not in material breach of such licenses), all patents, trade-marks, trade names, service marks, domain names, copyrights, know-how, trade secrets, software, technology and other intellectual property and proprietary rights that are material to the conduct of the business, as presently conducted, of Trillium and necessary to enable Trillium to conduct such business substantially in the manner in which it is currently being conducted (all such rights as are owned are herein collectively referred to as the “ Trillium Owned IP Rights ” and the Trillium Owned IP Rights together with such rights as are licensed are herein collectively referred to as “ Trillium Intellectual Property Rights ”). The Trillium Intellectual Property Rights are as described in Schedule 3.3.15 hereto.

       
  (b)

No Infringement of Other Rights . To its knowledge, the Trillium Owned IP Rights are valid and enforceable and the conduct of the business of Trillium (including the Trillium Owned IP Rights and the products and services of Trillium) does not infringe upon, misappropriate or otherwise violate any other Person’s intellectual property and proprietary rights, and the entering into of this Agreement and completion of the transactions contemplated herein will not render invalid or unenforceable, or result in the loss or require additional payment with respect to, any Trillium Intellectual Property Rights.

       
  (c)

No Infringement of Trillium Owned IP Rights . To the knowledge of Trillium, there is no material unauthorized use, infringement or misappropriation of any of the Trillium Owned IP Rights by any Person, including any employee or former employee of such party.



- 31 -

  (d)

Technology . Trillium owns, or has validly licensed (and are not in material breach of such licenses), all tangible embodiments of the Trillium Intellectual Property Rights, whether in electronic, written or other media, including hardware, software and firmware, processed data, technical documentation, technology infrastructure, computer systems, specifications, designs, test reports, routines, formulae, lab notebooks, processes, prototypes, samples, studies and other know-how and works of authorship that are material to the conduct of the business, as presently conducted, of Trillium (collectively, the “ Trillium Technology ”), all of which are up-to-date and sufficient for conducting such business, as presently conducted, and Trillium has taken commercially reasonable steps to implement and maintain appropriate virus protection and security measures in relation to the Trillium Technology and have reasonable back-up systems and a disaster recovery plan adequate to ensure the continuing availability of the functionality of the Trillium Technology, and have ownership of or a valid license to the Trillium Intellectual Property Rights necessary, to allow them to continue to provide the functionality provided by the Trillium Technology in the event of any malfunction of the Trillium Technology or other form of disaster affecting the Trillium Technology.

     
  (e)

No Obligation to Compensate Others . To the knowledge of Trillium, Trillium is not compensating or has any obligation to compensate or account to any Person for the use of any of the Trillium Intellectual Property Rights or Trillium Technology.

     
  (f)

No Restrictions . To the knowledge of Trillium, no Trillium Intellectual Property Rights are subject to any outstanding judgment, decree, order, writ, award, injunction or determination of any court or Governmental Authority (other than office actions and correspondence regarding pending patent applications and trademark applications) or arbitration restricting in any manner the rights of Trillium with respect thereto, except to the extent any such restriction would not have a Material Adverse Effect on Trillium.

     
  (g)

No Misappropriation . To the knowledge of Trillium, no employee, independent contractor or agent of Trillium has misappropriated any trade secrets of any other Person in the course of performance as an employee, independent contractor or agent of its business and, to the knowledge of Trillium, no employee, independent contractor or agent of Trillium is in default or breach of any term of any employment agreement, nondisclosure agreement, assignment of invention agreement or similar agreement or contract relating in any way to the protection, ownership, development, use or transfer of any Trillium Intellectual Property Rights or Trillium Technology.

     
  (h)

No Governmental Funding . Except as contemplated under the Contribution Agreement dated as of February 1, 2012 (as amended March 14, 2012) between Trillium and Her Majesty the Queen in Right of Canada, no funding facilities or personnel of any Government Authority or educational institution were used, directly or indirectly, to develop or create, in whole or in part, any of the Trillium Intellectual Property Rights or Trillium Technology.



- 32 -

  (i)

No Required Licenses or Impairment . To the knowledge of Trillium, Trillium has not made any written submission to, and is not subject to any agreement with, any standard bodies or other entities that would obligate Trillium to a grant license to any Person, or otherwise impair its control of the Trillium Intellectual Property Rights.

       
  3.3.16

Compliance with Laws . To the knowledge of Trillium, Trillium has conducted its activities on the lands and properties held or beneficially owned by it or in which it has an interest in material compliance with all applicable Laws and Trillium does not have any knowledge of, and Trillium has not received any notice of, any claim, regulatory order, investigation or proceeding, pending or threatened against, or which may affect, any of such lands or properties, relating to, or alleging any violation of, any applicable Laws or whether any remedial action is required to be undertaken.

       
  3.3.17

Trillium Notice . The Trillium Notice will comply as to form in all material respects with the requirements of the Applicable Securities Laws. On the date filed with Securities Authorities and on the date first published, sent or given to the Trillium Shareholderholders, the Trillium Notice will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstance under which they were made, not misleading.


4.

PURCHASE OF DEBENTURES AND CANCELATION OF WARRANTS

   
4.1

Representations and Warranties of the Debentureholders

Each of the Debentureholders represents and warrants (as several, and not joint and several representations) to Trillium, Stem Cell and Acquisitionco as follows and acknowledges that each of Trillium, Stem Cell and Acquisitionco is relying upon such representations and warranties in entering into this Agreement:

  (a)

Such Debentureholder has all necessary authority to enter into this Agreement, sell its Debentures and Trillium Class A Pref Warrants, and otherwise perform its obligations hereunder and complete the transactions contemplated hereby;

     
  (b)

The execution and delivery by such Debentureholder, and the performance of its obligations under this Agreement and the completion of the transactions contemplated hereby will not result in the violation of any of the terms and provisions of the constating documents of the such Debentureholder;

     
  (c)

This Agreement has been duly authorized, executed and delivered by such Debentureholder and is a valid and binding obligation of such Debentureholder enforceable against such Debentureholder in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency or other laws of general application affecting the rights of creditors and the availability of equitable remedies such as specific performance and injunction which are only available in the discretion of the court from which they are sought;



- 33 -

  (d)

Such Debentureholder is a resident of Canada for the purposes of the Tax Act;

     
  (e)

The Debentures and the Trillium Class A Pref Warrants are beneficially owned by such Debentureholder with good title thereto, free and clear of all charges, liens, pledges or other encumbrances and rights of others and are transferable in accordance with the terms and conditions thereof;

     
  (f)

Upon payment to such Debentureholder of the portion of the Debenture Purchase Price payable to such Debentureholder, as directed by such Debentureholder, Trillium shall cease to have any obligations and liabilities to such Debentureholder under the transferred Debentures or the Trillium Class A Pref Warrants; and

     
  (g)

Such Debentureholder will execute and deliver all documentation as may be required to permit the sale, transfer, assignment and conveyance of the Debentures and the Trillium Class A Pref Warrants held by it on the terms set forth herein and such Debentureholder will execute, deliver, file and otherwise assist Stem Cell in filing such reports, undertakings and other documents with respect to the sale of the Debentures and the Trillium Class A Pref Warrants as may be required by applicable securities laws or by any securities regulatory authority or stock exchange or other regulatory authority as may be requested by Stem Cell.

For greater certainty, nothing contained in this Agreement shall result in any liability upon any Debentureholder other than as a result of the breach by such Debentureholder of the representations and warranties contained in this Section 4.1 or breaches by such Debentureholder of the covenants given by such Debentureholder pursuant to Section 5.3. Without limiting the generality of the foregoing, no Debentureholder shall have any liability or responsibility in respect of any breach of a representation, warranty or covenant by either another Debentureholder or by Trillium hereunder.

5.

COVENANTS

   
5.1

Mutual Covenants of Stem Cell, Trillium and Acquisitionco

Except as is otherwise expressly permitted or specifically contemplated in this Agreement or as may be required by applicable Laws and except with the consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed, each of Stem Cell, Trillium and Acquisitionco hereto covenants and agrees to the other and to the Debentureholders, subject to the terms of this Agreement, that, until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms:


- 34 -

  5.1.1

Conduct of Business .


    (a)

Conduct of Business . The business of such party and its Subsidiaries will be conducted only in the ordinary course in a manner that is consistent with the manner in which the business generally has been operated up to the date of this Agreement;

       
    (b)

Preserve Organization and Assets . It will, in the ordinary course of business, use commercially reasonable efforts to preserve the business organization of such party and its subsidiaries intact and to maintain and preserve the assets, properties, material rights, licenses and franchises and goodwill of such party and its subsidiaries, to keep available the services of the current officers and employees of such party and its subsidiaries, and to maintain the relationships and goodwill of such party and its subsidiaries with customers, suppliers, distributors, creditors, licensors, licensees, lessors, employees, business associates and other persons having significant business dealings or relations with such party or any of its subsidiaries;

       
    (c)

Maintain Assets . It will, in the ordinary course of business maintain and keep its material properties and assets in as good repair and condition as at the date of this Agreement, subject to ordinary wear and tear, all for the purpose of endeavouring to maintain its goodwill and ongoing business; and

       
    (d)

Keep Other Party Informed . It will keep the other party fully informed as to the material decisions or actions made or required to be made with respect to, and material developments relating to, the operation of its business and consult with the other party in respect of the operation of its ongoing business.


  5.1.2

Restrictions . It will not, and, where applicable, it will not permit any of its Subsidiaries to, directly or indirectly:


    (a)

Constating Documents . Alter or amend, or adopt any change to, or authorize any alteration or amendment or change to, the constating documents of such party or alter or amend, or adopt any change, or authorize any alteration or amendment or change to, the constating documents of any of its Subsidiaries;

       
    (b)

Dividends or Distributions . Declare, set aside or pay any dividend on, or make any other distribution or payment or return of capital (whether in cash, stock, securities or property or any combination thereof) in respect of the Trillium Shares, in the case of Trillium, or the Stem Cell Shares, in the case of Stem Cell, or any shares of its share capital or other voting security or other equity security of any Subsidiary of such party that is not directly or indirectly a wholly-owned subsidiary of such party that is owned by a Person other than such party or a wholly-owned subsidiary of such party, other than;



- 35 -

    (c)

Capital Reorganization . Split, divide, subdivide, consolidate, combine, exchange or reclassify any of the shares of its capital stock or other equity securities or voting shares or issue or authorize the issuance of any other securities in respect of, in lieu of, or in substitution for, any of such shares or other equity securities or voting securities;

       
    (d)

Issuance of Securities . Other than the Stem Cell Offering, allot, reserve, set aside, issue, sell, deliver, grant or pledge, or agree to reserve, set aside, allot, issue, sell, deliver, grant or pledge, any shares of its share capital, or any shares or equity securities or voting securities of any Subsidiary of such party, or any securities or obligations convertible into or exchangeable or exercisable for, or otherwise evidencing a right to acquire, shares of its capital stock or shares of capital stock or equity securities or voting securities of any of the Subsidiaries of such party;

       
    (e)

Redemptions or Purchases . Redeem, purchase or otherwise acquire or retire any of the outstanding shares of its capital stock or other equity securities or voting securities issued by it, or securities convertible into or exchangeable or exercisable for, or otherwise evidencing a right to acquire, any such shares, equity securities or voting securities, or enter into or announce any agreement or arrangement with respect to the sale or repurchase of any such securities, or registration of any of its securities under any applicable securities laws (including the Applicable Securities Laws), except for transactions required under the terms of such securities or any plans, arrangements, commitments or understandings existing as at the date of this Agreement;

       
    (f)

Amendment of Share Rights . Amend or modify any of the shares in its capital stock or amend or modify in any material respect any of the shares in the capital stock or other equity securities or voting securities of any subsidiary of such party or any securities convertible into or exchangeable or exercisable for, or otherwise evidencing a right to acquire, any such shares or equity or voting securities, or any of the instruments or agreements governing such shares, equity securities or voting securities;

       
    (g)

Dissolution . Resolve or propose that it be wound up, dissolved or liquidated or consolidated or amalgamated or merged into any other Person, appoint or agree to the appointment of a liquidator, receiver or trustee in bankruptcy for it or consent to an order by a court for its winding up, dissolution or liquidation or adopt any plan or agreement of, or resolutions authorizing, approving or providing for, complete or partial liquidation, dissolution, winding-up, merger, consolidation, amalgamation, reorganization, arrangement, restructuring, recapitalization or other reorganization of such party of any of its subsidiaries;

       
    (h)

Accounting Policies or Principles . Make any changes to its existing accounting policies and principles (including by adopting any new accounting policies or principles) or make any material changes to any of its accounting methods, practices or procedures (including by adopting any material new accounting methods, practices or procedures), except as required by applicable Laws or under generally accepted accounting principles;



- 36 -

    (i)

Tax Elections . Make, change, revoke or rescind any election relating to Taxes, materially amend any Tax return, surrender any right to claim a Tax refund, offset or other reduction in Tax liability, consent to any extension or waiver of the limitation period applicable to any Tax claim or assessment, or settle or compromise any material claim, action, suit, litigation, proceeding, arbitration, investigation or controversy relating to Taxes; or

       
    (j)

Contracts . Enter into, modify or terminate any Material Contract to do any of the foregoing.


  5.1.3

Notice of Material Adverse Events . It will notify the other party in writing:


    (a)

Material Adverse Effects . Of any circumstances or development occurring after the date of this Agreement that had, or would reasonably be expected to have, a Material Adverse Effect on it;

       
    (b)

Damage . Of the occurrence of any loss, breakage or damage to properties or assets owned by such party or any of its subsidiaries in excess of $10,000 (irrespective of insurance or third party proceeds which have been or may be received in connection with such loss, breakage or damage);

       
    (c)

Representations and Warranties . Of any circumstances or development that, to its knowledge, would reasonably be expected to cause any of its representations and warranties contained in sections 3.1 or 3.2, in the case of Stem Cell and Acquisitionco, or sections 3.1 and 3.3, in the case of Trillium, not to be true and correct in all material respects at the Effective Date (or in the case of any representation or warranty that refers to a specified date, as of such specified date), such that the condition in section 6.2.1 or 6.3.1 would not be satisfied; and

       
    (d)

Breach or Default . Of any material breach or default by it of any obligation, covenant or agreement in this Agreement to be performed and complied with by it on or before the Effective Date provided, however, that no such notification shall affect the representations or warranties of the parties or the conditions to the obligations of the parties herein.


  5.1.4

Other Restrictions . It will not, and, where applicable, will not permit any of its Subsidiaries to, directly or indirectly, except in the ordinary course of business or pursuant to any contract existing as at the date of this Agreement:

       
  (a)

Disposition of Assets . Sell, assign, lease, license, transfer, dispose of or pledge or encumber any of its assets or properties (including the shares or other equity securities or voting securities of any Subsidiary) of such party or of any Subsidiary (other than transactions between two or more Subsidiaries of such party that each directly or indirectly is a wholly-owned Subsidiary of such party or between such party and one or more such wholly-owned Subsidiaries of such party);



- 37 -

    (b)

Acquisitions . Except for transactions between two or more Subsidiaries of such party that each directly or indirectly is a wholly-owned Subsidiary of such party or between such party and one or more such wholly-owned Subsidiary of such party, acquire (by merger, amalgamation, plan of arrangement, consolidation or business combination or acquisition of shares or other voting or equity securities or interests or acquisition or lease of assets or otherwise) any business or assets of any corporation, partnership, association or other business organization or division thereof, or any property or asset, or make any investment (either by the purchase of securities, contributions of capital, property transfer, or purchase of any property or assets of any other Person), or enter into or extend any option to acquire, or exercise an option to acquire, any property or assets, if any of the foregoing would reasonably be expected to be material to such party and its subsidiaries, taken as a whole;

       
    (c)

Indebtedness . Incur any indebtedness for borrowed money or purchase money indebtedness or issue or sell any debt securities or warrants or rights to acquire debt securities or assume, guarantee, endorse or otherwise as an accommodation become responsible for the obligations of any other Person, in each case, in excess of $25,000, except pursuant to existing credit facilities or debt instruments (or the agreements, indentures or guarantees governing or relating to such facilities or instruments);

       
    (d)

Loans, Advances or Expenditures . Make any loans, advances or capital contributions to, or investments in, any other Person, other than direct or indirect wholly-owned Subsidiaries of such party, in excess of $10,000;

       
    (e)

Satisfaction of Obligations . Pay, discharge or satisfy any claim, liability or obligation which is material to such party and its Subsidiaries, taken as a whole, other than the payment, discharge or satisfaction of liabilities reflected or reserved against in the Stem Cell Financial Statements, in the case of Stem Cell, or in the Trillium Financial Statements, in the case of Trillium;

       
    (f)

Releases . Except pursuant to transactions between two or more Subsidiaries of such party that each directly or indirectly is a wholly-owned Subsidiary of such party or between such party and one or more such wholly-owned Subsidiaries of such party, waive, release, grant or transfer any rights which have a value which is material to such party and its Subsidiaries, taken as a whole;

       
    (g)

New Business Activities . Except as disclosed in the Stem Cell Supplement, engage in any new business, enterprise or other activity that is material to such party and its Subsidiaries, taken as a whole, and that is inconsistent with the existing businesses of such party and its Subsidiaries in the manner such existing businesses generally have been carried on prior to the date of this Agreement; or



- 38 -

  5.1.5

Material Contracts . Except as disclosed in the Stem Cell Supplement, not permit any of its Subsidiaries to, directly or indirectly, except in the ordinary course of business and except for transactions between two or more Subsidiaries of such party that each directly or indirectly is a wholly-owned Subsidiary of such party or between such party and one or more such wholly-owned Subsidiaries:


    (a)

Restriction on Activities . Enter into any Material Contract that would limit or otherwise restrict such party or any of its Subsidiaries or any of their successors, or that would, after the Effective Time, limit or otherwise restrict Stem Cell or any of its Subsidiaries or any of their successors, in each case from engaging or competing in any line of business or in any geographic area; or

       
    (b)

Termination or Amendment of Material Contracts . Terminate, cancel or amend in any material respect any Material Contract, where such termination, cancellation or amendment has had a Materially Adverse Effect on such party.


  5.1.6

Actions and Proceedings . Such party will not, and will not permit any of its Subsidiaries to, except in the ordinary course of business, voluntarily waive, release, assign, settle or compromise (i) any proceeding that is material to such party and its subsidiaries taken as a whole; (ii) any proceeding that is brought by any current, former or purported holder of any securities of such party in its capacity as such; where, in each case, such waiver, release, assignment, settlement or compromise (A) requires any payment to any Person by such party or any subsidiary or (B) adversely affects in any material respect the ability of such party and its subsidiaries taken as a whole to conduct their business in a manner consistent with past practice.

     
  5.1.7

Insurance .


    (a)

Such party will use its commercially reasonable efforts to cause the current insurance (or re-insurance) policies maintained by such party or any of its subsidiaries, including directors’ and officers’ liability insurance, not to be cancelled or terminated or any of the coverage thereunder permitted to lapse, unless at the time of such termination, cancellation or lapse, replacement policies underwritten by insurance or re-insurance companies of nationally recognized standing having comparable deductions and providing coverage comparable to or greater than the coverage under the cancelled, terminated or lapsed policies for substantially similar premiums are in full force and effect; provided that neither such party nor any of its Subsidiaries will obtain or renew any insurance (or re-insurance) policy for a term exceeding 12 months.

       
    (b)

Additionally, upon the occurrence of the Effective Date, Stem Cell agrees that Trillium shall be entitled to directors’ and officer’s liability insurance for Trillium’s present and former directors and officers, covering claims made prior to and within six years after the Effective Date and on a “trailing” or “run-off” basis, which has scope and coverage substantially equivalent in scope and coverage consistent with standard industry practice. Stem Cell agrees to maintain such insurance in place and agrees not to take any action, or to cause Stem Cell to take any action, to terminate such directors’ and officers’ liability insurance or any indemnity agreements in favour of current directors and officers of Trillium in place prior to the date hereof and in the form disclosed to Stem Cell prior to the date hereof. Alternatively, Stem Cell may notify Trillium prior to the Effective Date that such coverage is to be provided under Stem Cell’s officer’s and directors’ liability insurance, in which case the foregoing shall apply mutatis mutandis to Stem Cell’s coverage in respect thereof. The provisions of this Section 5.1.7 are intended for the benefit of present and former directors and officers of Trillium, as and to the extent applicable in accordance with its terms, and shall be enforceable by each of such persons and his heirs, executors, administrators and other legal representatives (collectively, the “ Third Party Beneficiaries ”) and Trillium and any successor to Trillium shall hold the rights and benefits under this section in trust for and on behalf of the Third Party Beneficiaries and Trillium hereby accepts such trust and agrees to hold the benefit of and enforce performance of such covenants on behalf of the Third Party Beneficiaries and which rights are in addition to and not in substitution for any other rights the Third Party Beneficiaries may have by contract or otherwise.



- 39 -

5.2

Access to Information


  5.2.1

Access . Until the earlier of the Effective Date and the termination of this Agreement, each of Stem Cell and Trillium (in this section 5.2 referred to as the “ first party ”) will at all reasonable times permit representatives of the other party reasonable access (in a manner that minimizes disruption to the conduct of the first party’s business) during normal business hours to its properties and its books and records including material contracts, agreements, indentures and instruments, minute books and share registers, and senior officers and other management personnel and give such other party and its representatives such copies and information with respect thereto as may be reasonably required, subject, however, to such access not interfering with the conduct of the business of the first party and provided that:

         
  (a)

no party will contact employees of the other party except after prior consultation with the Chief Financial Officer or Corporate Secretary of the other party;

         
  (b)

no first party will be required to permit any inspection or to disclose any information, if in the reasonably judgment of such first party such inspection or disclosure could:

         
  (i)

result in the disclosure of any trade secrets of third parties or customer specific or competitively sensitive information;

         
  (ii)

violate any obligation of the first party with respect to confidentiality, including information subject to a written confidentiality agreement, covenant or obligation or undertaking with a third party (provided that, at the request of the other party, the party will use commercially reasonable efforts to obtain the consent of the entity in whose favour the obligation exists to the disclosure of any information reasonably requested by the other party which is material to the first party and its Subsidiaries, taken as a whole);



- 40 -

  (iii)

jeopardize protections afforded the first party under any attorney-client privilege or attorney work product doctrine or otherwise undermine or void any applicable legal privilege; or

     
  (iv)

violate any Laws.


  5.2.2

Nothing contained in this Agreement shall be interpreted to extend to the acts or omissions of any person acting in his or her capacity as a director or officer of Stem Cell or Trillium or otherwise to fetter the proper exercise of discretion of such person.

     
  5.2.3

Nothing in this Agreement will prohibit, prevent or restrict either Stem Cell or Trillium or their Board of Directors thereof from:


    (a)

responding, within the time and manner required by the Applicable Securities Laws, to any take-over bid or tender or exchange offer made for its shares or other securities, including making appropriate disclosure with respect thereto to the securityholders of such party; or

       
    (b)

calling and holding a meeting of its shareholders requisitioned by shareholders or ordered to be held by a court in accordance with applicable Laws;


5.3

Covenants of Debentureholders

Except as is otherwise expressly permitted or specifically contemplated in this Agreement or as may be required by applicable Laws and except with the consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed, each of the Debentureholders covenants and agrees to Stem Cell, Trillium and to the other Debentureholders, severally and not jointly and severally, subject to the terms of this Agreement, that, until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms as follows:

  (a)

Such Debentureholder agrees to vote, either in person or by proxy, all of their Trillium Common Shares and Tillium Class A Pref Shares in favour of the Transaction Resolution at the Trillium Meeting;


5.4

Additional Mutual Covenants

Each of Stem Cell, Acquisitionco and Trillium, as applicable, will perform all obligations required to be performed by it under this Agreement and, in connection therewith, use commercially reasonable efforts to do such acts or things as may be necessary in order to consummate and make effective the Transaction on the terms and subject to the conditions set out herein. Each of such parties covenants and agrees that, subject to the terms and conditions set out herein:


- 41 -

  5.4.1

Consents . It will use commercially reasonable efforts to obtain all waivers, consents and approvals from other parties required to be obtained by it or its Subsidiaries to consummate the Transaction.

     
  5.4.2

Satisfaction of Conditions . It will use its commercially reasonable efforts to satisfy, or cause to be satisfied, each of the conditions precedent set forth in Article 6 hereof on or before the Effective Date.

     
  5.4.3

Exchange Approval . Stem Cell and Trillium will use its reasonable commercial efforts to obtain any necessary approval of the Exchange to the transactions contemplated in this Agreement, including, upon completion of the Transaction.

     
  5.4.4

Trillium Options . Following the date hereof and prior to the Effective Date, the board of directors of Trillium shall resolve, in accordance with the provisions of the Trillium ESOP that, upon the occurrence of Effective Date, all issued and outstanding Trillium Options shall no longer have the right to acquire Trillium Common Shares but shall only have the right, upon being duly exercised in accordance with their terms, to acquire Amalco Class B Shares.


5.5

Confidentiality

     
5.5.1

Confidential Information . All information provided by any party to the other, in any form, whether written, electronic or verbal, as to financial condition, business, properties, title, assets and affairs (including any material contracts) as may reasonably be requested by the other party (the “ Confidential Information ”), will be kept confidential by the other party, notwithstanding the termination of this Agreement, other than information that:


  (a)

has become generally available to the public;

     
  (b)

was available to a party hereto or its representatives on a non-confidential basis before the date of this Agreement; or

     
  (c)

has become available to a party hereto or its representatives on a non-confidential basis from a person who is not, to the knowledge of such party or its representatives, otherwise bound by confidentiality obligations to the provider of such information or otherwise prohibited from transmitting the information to the party or its representatives.


  5.5.2

No Disclosure . No Confidential Information may be released to third parties other than legal counsel and other advisors to the parties hereto without the consent of the provider thereof, except that the parties hereto agree that they will not unreasonably withhold such consent to the extent that such Confidential Information is compelled to be released by legal process or must be released to regulatory bodies or included in public documents. In the event that this Agreement is terminated, all documents, if any, of a confidential nature delivered by either Stem Cell or Trillium to the other or to their respective representatives, and all copies thereof, shall be immediately returned to the party supplying same.



- 42 -

5.6

Privacy Matters

       
5.6.1

Disclosure of Personal Information . Stem Cell, Acquisitionco and Trillium acknowledge and agree that:

       
(a)

certain information provided by Trillium to Stem Cell or Acquisitionco in connection with the transactions contemplated hereunder constitutes Personal Information (the “ Disclosed Personal Information ”) which is necessary in connection with completion of the Transaction;

       
(b)

that the disclosure of the Disclosed Personal Information relates solely to the carrying on of the business of Trillium or Stem Cell or the completion of the Transaction; and

       
(c)

that such Disclosed Personal Information:


  (i)

may not be used for any purpose other than those related to the performance of this Agreement;

     
  (ii)

must be kept strictly confidential and Trillium, Stem Cell and Acquisitionco will ensure that access to such Personal Information will be restricted to those officers, employees and other authorized representatives and advisors of Trillium, Stem Cell and Acquisitionco who have a bona fide need for access to such information and will instruct those representatives to protect the confidentiality of such information in a manner consistent with the obligations of Trillium, Stem Cell and Acquisitionco hereunder; and

     
  (iii)

upon the termination of this Agreement, or otherwise upon the request of Trillium, Stem Cell and Acquisitionco will forthwith cease all use of the Disclosed Personal Information acquired by Trillium, Stem Cell and Acquisitionco in connection with this Agreement and will return to Trillium or, at Trillium’s request, destroy in a secure manner the Disclosed Personal Information (and any copies).


  5.6.2

Use of Personal Information . In addition to the foregoing obligations:

       
  (a)

Trillium, Stem Cell and Acquisitionco agree to employ appropriate technology and procedures to prevent accidental loss or corruption of the Disclosed Personal Information, unauthorized input or access to the Disclosed Personal Information, or unauthorized or unlawful collection, storage, disclosure, recording, copying, alteration, removal, deletion, use or other processing of the Disclosed Personal Information; and

       
  (b)

each of Trillium, Stem Cell and Acquisitionco agree to promptly notify the other of all inquiries, complaints, requests for access and claims of which the party is made aware in connection with the Disclosed Personal Information, and the parties will fully cooperate with one another, with the persons to whom the Disclosed Personal Information relates, and any Governmental Authority charged with enforcement of Applicable Privacy Laws, in responding to such inquiries, complaints, requests for access, and claims.



- 43 -

5.7

Directors and Officers

     
5.7.1

Directors . Upon completion of the Transaction, the Board of Directors of Stem Cell shall consist of 7 directors, with the proposed directors upon completion of the Transaction, being Mr. David AIIan, Dr. James DeMesa, Dr. Henry Friesen, Mr. Dean Peterson, Dr. Niclas Stiernholm, Dr. Calvin Stiller and Dr. Michael Moore and each member of such Board of Directors, will serve until the earlier of their resignation or renewal or until their respective successors are duly elected or appointed, as the case may be.

     
5.7.2

Officers . Upon completion of the Transaction, the following individuals shall be the officers of Stem Cell: David AIIan, Chairman, Dr. Niclas Stiernholm, Chief Executive Officer, Dr. Bob Uger, Chief Scientific Officer, Dr. Penka Petrova, Vice President Drug Development and Mr. James Parsons, Chief Financial Officer, subject to such individuals concluding employment arrangements with Stem Cell on terms acceptable to the Board of Directors of Stem Cell until the earlier of their resignation or removal or until their respective successors are duly elected or appointed, as the case may be.

     
5.7.3

Waiver of Severance. Prior to the Effective Date, Dr. Niclas Stiernholm and any other continuing officer of Trillium if applicable, shall have entered into an new employment agreement with Stem Cell on substantially the same terms as his existing Trillium employment contract. Any change of control, severance, termination or unemployment compensation, payable by Trillium pursuant to the existing Trillium employment, including Dr. Stiernholm’s Trillium employment contract, shall have been waived prior to the Effective Date in respect of the Transaction, other than as required by applicable Laws for employees without agreements as to notice or severance

     
5.7.4

Indemnification . All rights to indemnification existing in favour of those persons who are directors and officers of Trillium as of the date of this Agreement (the “ Indemnified Managers ”) for their acts and omissions occurring prior to the Effective Time shall remain in full force and effect notwithstanding the transaction contemplated herein until the expiration of the applicable limitations period with respect to any claims against the Indemnified Managers arising out of such acts or omissions, and Stem Cell hereby assumes and agrees to be responsible for any such indemnification.


5.8

Employee Benefits and Related Matters

     
5.8.1

Stem Cell agrees, and after the Effective Date will cause Trillium or any of its Subsidiaries, as the case may be, to: (i) continue to employ the current employees of Trillium; and (ii) maintain, until their replacement following the closing of the Transaction contemplated herein, employee benefits pursuant to employee benefit plans, programs, policies or arrangements currently maintained by Trillium.



- 44 -

  5.8.2

Nothing herein shall be construed as limiting Stem Cell’s ability to amend, modify or terminate any individual employee benefit plan or arrangement of Trillium, Stem Cell or any of their respective subsidiaries, or (iii) requiring Stem Cell to maintain any particular level of employee benefits for any individual employee following the Effective Date subject to compliance with Section 5.8.1.


5.9

Non-Solicit

       
5.9.1

Trillium shall immediately cease and cause to be terminated any existing solicitation, encouragement, activity, discussion or negotiation with any parties by Trillium, any of its subsidiaries or any of its or its subsidiaries’ officers, directors, employees, representatives and agents with respect to an Acquisition Proposal whether or not initiated by Trillium and in connection therewith, Trillium shall request (and exercise all rights it has to require) the return of information regarding Trillium and its subsidiaries previously provided to such parties and shall request (and exercise all rights it has to require) the destruction of all materials including or incorporating any information regarding Trillium and its subsidiaries.

       
5.9.2

Subject to Section 5.10, Trillium agrees that it shall not, and shall not authorize or permit any of its subsidiaries or any of its or its subsidiaries’ officers, directors, employees, representatives or agents, directly or indirectly, to (i) solicit, initiate, encourage or knowingly facilitate, including by way of furnishing information or entering into any form of agreement, arrangement or understanding, any inquiries or the making of any proposals regarding an Acquisition Proposal, (ii) participate in any discussions or negotiations regarding any Acquisition Proposal, (iii) withdraw or modify in a manner adverse to Stem Cell the approval or recommendation of the Board of Directors of Trillium of the Transactions contemplated hereby, (iv) approve or recommend any Acquisition Proposal or (v) enter into any agreement, arrangement or understanding related to any Acquisition Proposal or requiring Trillium to abandon, terminate or fail to consummate the Transaction or providing for the payment of any break, termination or other fees or expenses to any person in the event that Trillium or any of its subsidiaries completes the Transaction or any other transaction with Stem Cell or any of its affiliates agreed to prior to any termination of this Agreement. Notwithstanding the preceding sentence and any other provisions of this Agreement, the Board of Directors of Trillium may, prior to the approval of the Transaction by the Trillium Shareholders, consider, participate in any discussions or negotiations with, or provide information in accordance with the last sentence of this paragraph to, any person who has delivered a bona fide written Acquisition Proposal which was not solicited or encouraged after the date of this Agreement and did not otherwise result from a breach of this Section 5.9 and that the Board of Directors of Trillium determines in good faith constitutes or is reasonably likely to lead to a Superior Proposal; provided, however, that prior to taking any such action, Trillium must obtain a confidentiality agreement from the person making such Acquisition Proposal; provided further that Trillium shall not commence discussions or negotiations with, or provide information to any person who has delivered an unsolicited bona fide written Acquisition Proposal until 48 hours after Trillium shall have advised Stem Cell of its determination that such Acquisition Proposal constitutes or is reasonably likely to lead to a Superior Proposal and of its intention to take such actions. Trillium shall not consider, negotiate, accept, approve or recommend an Acquisition Proposal or provide information to any person proposing an Acquisition Proposal, in each case after the date of the approval of the Transaction by the Trillium Shareholders. If Trillium receives a request for material non-public information from a person who has made an unsolicited bona fide written Acquisition Proposal and Trillium is permitted, as contemplated under the second sentence of this Section 5.9.2, to negotiate the terms of such Acquisition Proposal, then, and only in such case, the Board of Directors of Trillium may, subject to the execution by such person of the confidentiality agreement as described above, provide such person with access to information regarding Trillium.



- 45 -

  5.9.3

From and after the date of this Agreement, Trillium shall promptly notify Stem Cell, at first orally and then in writing, of any inquiries, proposals or offers relating to or constituting an Acquisition Proposal, or any request for non-public information relating to Trillium or any of its subsidiaries. Such notice shall include a description of the material terms and conditions of any proposal, inquiry or offer, the identity of the person making such proposal, inquiry or offer and provide such other details of the proposal, inquiry or offer as Stem Cell may reasonably request.

     
  5.9.4

Trillium shall ensure that its officers, directors and employees and its subsidiaries and their officers, directors and employees and any financial advisors or other advisors or representatives retained by it are aware of the provisions of this Section 5.9, and it shall be responsible for any breach of this Section 5.9 by such officers, directors, employees, financial advisors or other advisors or representatives.


5.10

Right to Accept a Superior Proposal

If Trillium has complied with Section 5.9 with respect thereto, Trillium may accept, approve, recommend or enter into any agreement, understanding or arrangement in respect of a Superior Proposal prior to the approval of the Transaction by Trillium Shareholders if, and only if (with the exception of a confidentiality agreement the execution of which shall not be subject to the conditions of this Section 5.10), (i) five business days shall have elapsed from the later of (1) the date Stem Cell received written notice advising Stem Cell that Trillium’s Board of Directors has resolved, subject only to compliance with this Section 5.10, to accept, approve, recommend or enter into an agreement in respect of such Superior Proposal, specifying the material terms and conditions of such Superior Proposal and identifying the person making such Superior Proposal, and (2) the date Stem Cell received a copy of such Superior Proposal, (ii) Trillium’s Board of Directors has determined in good faith that failure to take such action would be inconsistent with its fiduciary duties under applicable law, and (iii) Trillium will have paid to Stem Cell the termination fee payable under Section 7.2.

6.

CONDITIONS PRECEDENT

   
6.1

Mutual Conditions Precedent

The respective obligations of the parties hereto to complete the transactions contemplated by this Agreement are subject to the satisfaction of, or mutual waiver (subject to applicable Laws) by Stem Cell and Trillium and the Debentureholders on or before the Effective Date (and, in the case of the condition in section 6.3.3, the satisfaction or mutual waiver of that condition on or before the date of the Trillium Meeting) of each of the following conditions, which are for the mutual benefit of Stem Cell and Acquisitionco, on the one hand, and Trillium and the Debentureholders, on the other hand, and which may be waived (subject to applicable Laws), in whole or in part, by Stem Cell (on its own behalf, and on behalf of Acquisitionco) and Trillium and the Debentureholders at any time:


- 46 -

  6.1.1

Transaction Resolutions . The Transaction Resolutions to approve the Transaction, in form and substance acceptable to Stem Cell and Trillium, acting reasonably, shall have been approved by the Trillium Shareholders at the Trillium Meeting in accordance with applicable Laws;

     
  6.1.2

Securities Exemptions . The issuance and delivery of the Stem Cell Shares, when issued pursuant to the Transaction, will be exempt from the dealer registration and prospectus requirements of Applicable Securities Laws in Canada;

     
  6.1.3

Offering . The Stem Cell Offering shall have been completed, for minimum aggregate gross proceeds of $2,500,000; and

     
  6.1.4

Amalgamation Agreement . The Amalgamation Agreement shall have been executed by the parties thereto.

     
  6.1.5

Exchange Listing . The Exchange shall have conditionally approved the listing of the Stem Cell Shares issuable pursuant to the Transaction.


6.2

Additional Conditions Precedent to the Obligations of Trillium and Debentureholders

The obligation of Trillium and the Debentureholders to complete the transactions contemplated by this Agreement shall be subject to the satisfaction of, or waiver by Trillium and the Debentureholders, on or before the Effective Date or such earlier date stipulated in the following conditions, each of which is for the exclusive benefit of Trillium and the Debentureholders and which may be waived by Trillium and the Debentureholders at any time, in whole or in part, in its sole discretion and without prejudice to any other rights that Trillium and the Debentureholders may have:

  6.2.1

Covenants and Representations and Warranties . Stem Cell and Acquisitionco shall have complied in all material respects with their respective obligations, covenants and agreements in this Agreement to be performed and complied with on or before the Effective Time except if the failure to comply with such obligation, covenant or agreement would not significantly delay or impede completion of the Transaction or the ability of Stem Cell or Acquisitionco to complete the Transaction and shall not be in material default of any covenant contained herein and the representations and warranties of Stem Cell in sections 3.1 and 3.2 shall be true and correct as of the Effective Date as if made on and as of such date (except for such representations and warranties that represent and warrants facts or information as at a specific or particular date, which representations and warranties shall truly and correctly represent such facts or information as of that date), except:



- 47 -

  (a)

as affected by transactions, changes, conditions, events or circumstances contemplated or permitted by this Agreement, or

     
  (b)

for breaches of representations and warranties which in the aggregate do not have a Material Adverse Effect on Stem Cell or prevent or materially delay or impede the consummation of the Transaction or the ability of Stem Cell of Acquisitionco to complete the Transaction, and Trillium shall have received a certificate of Stem Cell and Acquisitionco addressed to Trillium and dated the Effective Date, signed by the Executive Chairman of Stem Cell (on behalf of Stem Cell and Acquisitionco and without personal liability) certifying the foregoing;


  6.2.2

Legal Opinion . Stem Cell shall have furnished the Debentureholders with an opinion of legal counsel to Stem Cell, dated the Effective Date to the effect that the issuance of the Stem Cell Shares and Stem Cell Units to be issued pursuant to the Transaction will be exempt from the prospectus and dealer registration requirements under the Alberta securities laws and the first trade of such securities shall be exempt from restrictions on resale of securities except in the case of a control distribution and assuming certain conditions are met;

     
  6.2.3

No Material Adverse Effects . There shall not exist or have occurred (or been threatened) any change (or any condition, event or development involving a prospective change) which, individually or in the aggregate, has had, or is reasonably likely to have a Material Adverse Effect on Stem Cell; and

     
  6.2.4

Exchange Listing . The Exchange shall have conditionally approved the listing of all the Stem Cell Shares (including the Stem Cell Shares issuable pursuant to the exercise of common share purchase warrant comprising a Stem Cell Unit) issuable pursuant to the Transaction.


6.3

Additional Conditions Precedent to the Obligations of Stem Cell and Acquisitionco

The obligation of Stem Cell and Acquisitionco to complete the transactions contemplated by this Agreement shall be subject to the satisfaction of, or waiver by Stem Cell (on its own behalf and on behalf of Acquisitionco), on or before the Effective Date or such earlier date stipulated in the following conditions, each of which is for the exclusive benefit of Stem Cell and Acquisitionco and which may be waived by Stem Cell (on its own behalf and on behalf of Acquisitionco) at any time, in whole or in part, in its sole discretion and without prejudice to any other rights that Stem Cell and Acquisitionco may have:

  6.3.1

Covenants and Representations and Warranties . Trillium shall have complied in all material respects with its obligations, covenants and agreements in this Agreement to be performed and complied with on or before the Effective Date except if the failure to comply with such obligation, covenant or agreement would not significantly delay or impeded completion of the Transaction or the ability of Trillium to complete the Transaction and shall not be in material default of any covenant contained herein and the representations and warranties of Trillium in sections 3.1 and 3.3 shall be true and correct as of the Effective Date as if made on and as of such date (except for such representations and warranties that represent and warrant facts or information as at a specific or particular date, which representations and warranties shall truly and correctly represent such facts or information as at such date), except (i) as affected by transactions, changes, conditions, events or circumstances contemplated or permitted by this Agreement, or (ii) for breaches of representations and warranties which in the aggregate do not have a Material Adverse Effect on Trillium or prevent or materially delay or impede the consummation of the Transaction or the ability of Trillium to complete the Transaction and Stem Cell and Acquisitionco shall have received a certificate of Trillium addressed to Stem Cell and Acquisitionco and dated the Effective Date, signed by the Chief Executive Officer of Trillium (on behalf of Trillium and without personal liability) certifying the foregoing;



- 48 -

  6.3.2

No Material Adverse Effect . There shall not exist or have occurred (or been threatened) any change (or any condition, event or development involving a prospective change) which, individually or in the aggregate, has had or is reasonably likely to have a Material Adverse Effect on Trillium;

     
  6.3.3

Dissent Rights . The time period for the exercise of any right to dissent conferred upon the Trillium Shareholders in respect of the Transaction shall have expired and the Trillium Shareholders shall not have exercised (and not lost, abandoned or withdrawn) such right of dissent with respect to greater than 5% of the number of outstanding Trillium Shares; and

     
  6.3.4

Directors and Officers . Each of the members of the Board of Directors of Trillium and each of the officers of Trillium (other than such directors and officers as are, as set out in section 5.7, to continue as directors or officers following completion of the Transaction) shall have provided their written resignation and releases as directors and officers of Trillium effective on or before the Effective Date.


7.

TERMINATION OF AGREEMENT

   
7.1

Termination by Certain Parties

This Agreement may be terminated:

  7.1.1

Mutual Agreement . By agreement in writing executed by Stem Cell and Trillium;

     
  7.1.2

Superior Proposal . By Stem Cell, if the Board of Directors of Trillium fails to recommend or withdraws, modifies or changes its approval or recommendation of this Agreement, the Transaction, or the Transaction Resolution in a manner adverse to Stem Cell as a result of a Superior Proposal or recommends or approves a Superior Proposal;

     
  7.1.3

Non-Complete . By Stem Cell, if prior to the Effective Time if any event which may give rise to payment of the Trillium Non-Completion Fee set forth in Section 7.3 hereof occurs;



- 49 -

  7.1.4

Other Termination . By either Stem Cell, Trillium or any of the Debentureholders, upon written notice by either one to the other:

       
  (a)

Completion Deadline . If the Effective Date does not occur on or before April 19, 2013, or such later date as may be agreed between Stem Cell and Trillium and the Debentureholders;

       
  (b)

Trillium Securityholder Approval . If the Trillium Meeting is held and the Transaction Resolutions are not passed by the Trillium Shareholders in accordance with applicable Laws; or

       
  (c)

Prohibited Transaction . If a court of competent jurisdiction or other Governmental Body shall have issued a final and non-appealable order, decree or ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Transaction.


7.2

Void upon Termination

If this Agreement is terminated, it shall, except as provided in this section 7.2 and except for obligations of Trillium in Section 7.3 and the mutual obligations of confidentiality in sections 5.2.1 and 5.5, become void and of no force and effect and no party (inclusive of the Debentureholders), nor its directors, officers or securityholders shall have any liability or further obligation to the other party hereunder, provided that neither the termination of this Agreement nor anything contained in this section 7.2 shall relieve any party from any liability for any wilful breach by it of this Agreement occurring prior to such termination.

7.3

Non-Completion Fee Payable by Trillium

If at any time after the date hereof and prior to termination hereof, any of the following occur:

  7.3.1

Trillium accepts, recommends, approves or enters into an agreement with respect to a Superior Proposal prior to completion of the Transaction;

     
  7.3.2

Trillium is in breach of any of its representations, warranties or covenants made in this Agreement which breach individually or in the aggregate causes or would be reasonably expected to cause a Material Adverse Effect in respect of Trillium or materially impedes the completion of the Transaction, and Trillium fails to cure such breach within five (5) Business Days after receipt of written notice thereof from Stem Cell (except that no cure period shall be provided for a breach which by its nature cannot be cured and, in no event, shall any cure period extend beyond the Effective Date);

then, in the event of termination of this Agreement, Trillium shall pay an amount equal to $100,000 plus G.S.T. (the “ Trillium Non-Completion Fee ”), in immediately available funds to or to an account designated by Stem Cell within two (2) Business Days after the Agreement is terminated.


- 50 -

7.4

Notice of Unfulfilled Conditions

     
7.4.1

Notice . If any party hereto shall determine at any time prior to the Effective Date that it intends to refuse to complete the transactions contemplated herein because of any unfulfilled or unperformed condition contained in this Agreement, such party shall so notify the other party forthwith upon making such determination in order that the other party shall have the right and opportunity to take such steps, at its own expense, as may be necessary for the purpose of fulfilling or performing such condition within a reasonable period of time, but in no event later than April 12, 2013.

     
7.4.2

No Termination . No party may exercise any termination right arising therefrom unless forthwith and in any event prior to the Effective Time, the party intending to rely thereon has given a written notice to the other party specifying in reasonable detail all breaches of covenants, representations and warranties or other matters which the party giving such notice is asserting as the basis for the non-fulfillment of the applicable condition precedent or the exercise of the termination right, as the case may be.

     
7.4.3

Cure Period . If any such notice is given, provided that the other party is proceeding diligently to cure such matter, if such matter is capable of being cured, the party giving such notice may not terminate this Agreement as a result thereof until the earlier of April 16, 2013 and the expiration of a period of 30 days from such notice.

     
7.4.4

Adjournment of Trillium Meeting . If such notice has been given prior to the date of the Trillium Meeting, unless the parties agree otherwise, such meeting shall be adjourned and shall not be held until such time as is reasonably practicable after the earlier of (i) the matter to which the notice relates being cured and (ii) the expiry of such period.

     
7.4.5

Cure . For greater certainty, in the event that such matter is cured within the time period referred to herein, the Agreement may not be terminated as a result thereof.


8.

GENERAL

     
8.1

Notices

     
8.1.1

Notices . All notices and other communications given or made pursuant to this Agreement hereunder will be in writing and will be delivered to the particular party at the following address or sent by telecopy or facsimile transmission (provided that receipt of such telecopy or transmission is confirmed or such telecopy or transmission is recorded as having been transmitted successfully) at the following number or sent or delivered by electronic mail transmission at the following e-mail address or at such other address, telecopier number or e-mail address which any party may, from time to time, notify the other by notice given in accordance with this section:



- 51 -

  (a) if to Stem Cell or Acquisitionco, to them at:
       
    MaRS Centre, Heritage Building
    101 College Street, Suite 200
    Toronto, Ontario
    M5G 1L7  
       
    Attention: David Allan, Executive Chairman
    E-mail: dallan@stemcellthera.com
       
  with a copy (which shall not constitute notice) to:
       
    McCarthy Tétrault LLP
    1150, Claire-Fontaine, 7th Floor
    Québec, Québec
    G1R 5G4  
       
    Attention: Philippe Leclerc
    E-mail: pleclerc@mccarthy.ca
       
  (b) and if to Trillium:
       
    96 Skyway Avenue
    Toronto, Ontario
    M9W 4Y9  
       
    Attention: Niclas Stiernholm, Chief Executive Officer
    E-mail: niclas@trilliumtherapeutics.com
       
  with a copy (which shall not constitute notice) to:
       
    Borden Ladner Gervais LLP
    Suite 4400, Scotia Plaza, 40 King Street West
    Toronto, Ontario
    M5H 3Y4  
       
    Attention: Jay A. Lefton
    E-mail: jlefton@blg.com
       
  (c) if to the Debentureholders:
       
    GrowthWorks Canadian Fund Ltd.
    130 King Street West, Suite 2200
    Toronto, Ontario
    M5X 1E3  
       
    Attention: Joseph Regan
    E-mail: joseph.regan@growthworks.ca
       
    Business Development Bank of Canada


- 52 -

  380, St-Antoine O., bureau 2000
  Montréal, Québec
  H2Y 3X7  
     
  Attention: Charles Cazabon
  E-mail: charles.cazabon@bdc.ca
     
  Covington Capital Corporation
  87 Front Street East, Suite 400
  Toronto, Ontario
  M5E 1B8  
     
  Attention: Lily Lam
  E-mail: lily@covingtoncap.com
     
  MaRS Investment Accelerator Fund
  MaRS Centre, South Tower, Suite 100
  101 College Street
  Toronto, Ontario
  M5G 1L7  
     
  Attention: Michelle McBane
  E-mail: mmcbane@marsdd.com

  8.1.2

Notice Deemed Given . Notice or other communication will be deemed to have been given when it is delivered (either in person, by courier service or other personal method of delivery) by courier or, in the case of notice or communication by electronic mail transmission during regular business hours on a Business Day in the recipient’s city, upon the successful transmission thereof, or otherwise, in the case of electronic mail transmission, at 9:00 a.m. on the next Business Day in the place of receipt if successful transmission is received outside regular business hours in the recipient’s city.


8.2

Fees and Expenses

Except as expressly set out herein, each party hereto will be responsible for and bear all of its own costs and expenses incurred at any time in connection with entering into this Agreement and completing the Transaction and the other transactions contemplated herein, including legal fees, accounting fees, financial advisory fees and all disbursements by advisors.

8.3

No Assignment

Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by any party hereto, in whole or in part (whether by operation of law or otherwise).

8.4

Binding Effect

This Agreement shall be binding upon the parties hereto and shall enure to the benefit of and be binding upon their respective successors (including any successor by reason of amalgamation or statutory arrangement).


- 53 -

8.5

Time of Essence

Except as otherwise expressly provided in this Agreement, time shall be of the essence of this Agreement, both in respect of the dates and periods mentioned and in respect of any dates or periods which may be substituted for them in accordance with the provisions of this Agreement or by agreement in writing between the parties.

8.6

Public Announcements

Stem Cell and Trillium will consult with each other as to the general nature of any press release, public announcement or public statement with respect to this Agreement or the Transaction and, subject to applicable Laws, will use its commercially reasonable efforts to enable the other to review and comment upon any news release, public announcement or public statement regarding this Agreement and the transactions contemplated hereby except (i) filing of a copy of this Agreement as required pursuant to applicable Laws, (ii) as such party may reasonably conclude is required under applicable Laws, or the rules, regulations, policies or other requirements of, or listing agreement with the Exchange and (iii) that, notwithstanding anything to the contrary contained in this section 8.6 or elsewhere in this Agreement.

8.7

Governing Law

This Agreement shall be governed by and construed in accordance with the laws of Ontario and the federal laws of Canada applicable therein. Each party hereto irrevocably submits to and attorns to the non-exclusive jurisdiction of the courts of Ontario with respect to any matter arising under or in relation to this Agreement.

8.8

Entire Agreement

     
8.8.1

Entire Agreement . This Agreement constitutes the entire agreement and understanding between the parties hereto pertaining to the subject matter hereof and supersedes all other prior agreements, arrangements, understandings, undertakings, negotiations and discussions of any nature, whether oral or written, between the parties hereto, or any of them, with respect to the subject matter of this Agreement and shall survive any termination of this Agreement.

     
8.8.2

No Other Representations or Warranties . There are no representations, warranties, covenants, terms, conditions, undertakings or collateral agreements, expressed, implied or statutory, between the parties hereto with respect to the subject matter hereof except as expressly set forth in this Agreement.

     
8.9

Third Party Rights

Except for the rights of the Trillium Shareholders to receive the consideration for their Trillium Shares following the Effective Time pursuant to the Transaction, this Agreement is not intended to confer any rights or remedies upon any other Person other than the parties to the Agreement.

  8.9.1

Trillium Beneficiaries . Section 8.16 is intended for the benefit of the directors, officers and employees of Trillium and such sections shall be enforceable by each of such persons and their heirs, executors, administrators and other legal representatives (collectively, the “ Trillium Beneficiaries ”) and Trillium and any successors to Trillium shall hold the rights and benefits of such sections and this section 8.9 in trust for and on behalf of the Trillium Beneficiaries and Trillium hereby accepts such trust and agrees to hold the benefit of and enforce performances of such covenants on behalf of the Trillium Beneficiaries,



- 54 -

  8.9.2

Stem Cell Beneficiaries . Section 8.16 is intended for the benefit of the directors, officers and employees of Stem Cell and Acquisitionco and shall be enforceable by each of such persons and their heirs, executors, administrators and other legal representatives (collectively, the “ Stem Cell Beneficiaries ”) and Stem Cell and Acquisitionco and any successor to Stem Cell shall hold the rights and benefits of section 8.16 and this section 8.9 in trust for and on behalf of the Stem Cell Beneficiaries and Stem Cell and Acquisitionco hereby accept such trust and agree to hold the benefit of and enforce performance of such covenants on behalf of the Stem Cell Beneficiaries,

and such rights are in addition to, and not in substitution for, any other rights that any Trillium Beneficiary or Stem Cell Beneficiary may have by contract or otherwise.

8.10

Amendment

       
8.10.1

Amendment . Subject to any requirements imposed by applicable Laws, this Agreement may, at any time and from time to time before or after the holding of the Trillium Meeting but not later than the Effective Time, be amended by written agreement of the parties hereto, and any such amendment may, without limitation:

       
(a)

change the time for performance of any of the obligations or acts of the parties;

       
(b)

waive any inaccuracies or modify any representation, warranty, term or provision contained herein or in any document delivered pursuant hereto; or

       
(c)

waive compliance with or modify any of the conditions precedent referred to in Article 6 or any of the covenants herein contained or waive or modify performance of any of the obligations of the parties hereto;

provided, however, that no such amendment may reduce or materially affect the consideration to be received by the Trillium Securityholders under the Transaction without their approval at the Trillium Meeting or, following the Trillium Meeting, without their approval.

8.11

Waiver, Modifications and Remedies

       
8.11.1

Waiver and Modification . Any party hereto may:

       
(a)

waive, whole or in part, any inaccuracy of, or consent to the modification of, any representation or warranty made to them hereunder or in any document to be delivered pursuant hereto;

       
(b)

extend the time for performance of any of the obligations or acts of the other party;



- 55 -

  (c)

waive or consent to the modification of any of the covenants herein contained for their respective benefit or waive or consent to the modification of any of the obligations of the other party hereto; or

       
  (d)

waive the fulfillment of any condition to its obligations contained herein (subject to applicable Laws).

       
  8.11.2

Waiver in Writing . Any waiver or consent to the modifications of any of the provisions of this Agreement, to be effective, must be in writing executed by the party granting such waiver or consent and, unless otherwise provided in such written waiver, will be limited to the specific breach or condition waived.

       
  8.11.3

Rights Not Affected . No failure on the part of any party to exercise any right, power or remedy under this Agreement, and no delay on the part of any party in exercising any right, power or remedy provided by Law or under this Agreement, or failure of any party to assert any of the rights provided by Law or under this Agreement shall affect that right, power or remedy or constitute or operate as a waiver thereof.

       
  8.11.4

Rights Cumulative . All rights and remedies of any party hereto are cumulative of each other and of every other right or remedy such party may otherwise have in law or in equity, and the exercise of one or more rights or remedies shall not prejudice or impair the concurrent or subsequent exercise of other rights or remedies.

       
  8.11.5

Partial Exercise . The single or partial exercise of any right, power or remedy provided by Law or under this Agreement shall not preclude any other or further exercise of such right, power or remedy or the exercise or any further exercise of any other right, power or remedy.

       
  8.11.6

No Continuing Waiver . No waiver or partial waiver of any nature, in any one or more instances, will be deemed or construed a continued waiver of any condition or breach of any other term, representation or warranty in this Agreement or be deemed or construed to constitute a waiver of any other provision (whether or not similar) or a future waiver of the same provisions.


8.12

Severability

If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated herein is not affected in any manner which has a Material Adverse Effect on either Trillium or Stem Cell. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the extent permitted by applicable Law in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the fullest and greatest extent possible.


- 56 -

8.13

Mutual Interest

Notwithstanding the fact that any part of this Agreement may have been drafted or prepared by or on behalf of one of the parties hereto, all parties confirm that this Agreement is the product of negotiation by the parties having the assistance of counsel and other advisors and that they and their respective counsel have reviewed and negotiated this Agreement. The parties hereto have adopted this Agreement as the joint agreement and understanding of the parties, and the language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent. No rule of construction providing that a provision is to be interpreted in favour of the person who contracted the obligation and against the person who stipulated it will be applied against any party hereto.

8.14

Further Assurances

Subject to the conditions and other express provisions of this Agreement, the parties hereto will, from time to time and at all times hereafter, at the request of the other party, do all such further acts and things, including executing and delivering all such further deeds, agreements, transfers, documents, assurances and instruments, as will be reasonably necessary in order to fully perform and carry out the terms and intent of this Agreement.

8.15

Injunctive Relief

The parties agree that irreparable harm and damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached for which money damages would not be an adequate remedy at law. It is accordingly agreed that the parties will be entitled to seek an injunction or injunctions and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof. Any requirement for the securing or posting of any bond in connection with the obtaining of any such injunctive or other equitable relief are hereby waived.

8.16

No Personal Liability

No director, officer or employee of any party shall have any personal liability to any other party under this Agreement or any other document delivered in connection with this Agreement or the transactions contemplated by this Agreement on behalf of such party or any of its subsidiaries.

8.17

Counterparts and Execution


  8.17.1

Execution in Counterpart . This Agreement may be executed and delivered (including by facsimile or electronic transmission) by the different parties hereto in any number of separate counterparts, all of which together shall be considered to constitute one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties.

     
  8.17.2

Facsimile Execution Pages . The exchange of copies of this Agreement and of signature pages by facsimile or electronic transmission will constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of exchange of an executed original Agreement for all purposes and be as effective as delivery of a manually executed copy of the Agreement by each party.



- 57 -

  8.17.3

Facsimile Transmission . Signatures of the authorized signatories of the parties transmitted by facsimile or electronic transmission will be deemed to be their original signatures for all purposes.

     
  8.17.4

Delivery . The parties shall be entitled to rely upon delivery of an executed facsimile or similar electronic copy or electronically transmitted copy of an executed copy or counterpart of this Agreement, and such facsimile, similar electronic or electronically transmitted copy shall be legally effective to create a valid and binding agreement between the parties when one or more manual or facsimile or similar electronic copy or electronically transmitted copies have been so executed by each of the parties and delivered to the other parties.

(Signatures on following page)


- 58 -

IN WITNESS WHEREOF this Agreement has been executed by the parties hereto on March 25, 2013.

STEM CELL THERAPEUTICS CORP.   2364556 ONTARIO INC.
         
Per: (Signed) “ David Allan   Per: (Signed) “ David Allan
  Authorized Signatory     Authorized Signatory
         
TRILLIUM THERAPEUTICS INC.   COVINGTON FUND II INC. by its manager
      COVINGTON CAPITAL CORPORATION
       
Per: (Signed) “ Dr. Niclas Stiernholm   Per: (Signed)
  Authorized Signatory     Authorized Signatory
         
GROWTHWORKS CANADIAN FUND LTD.   BDC CAPITAL INC.
     
Per:  (Signed)   Per: (Signed)
  Authorized Signatory     Authorized Signatory

MaRS INVESTMENT ACCELERATOR FUND INC.  
   
Per: (Signed)  
  Authorized Signatory  


A-1

APPENDIX A

AMALGAMATION AGREEMENT

See document attached


A-2

AMALGAMATION AGREEMENT

THIS AGREEMENT made the _____day of April 2013

AMONG: 2364556 Ontario Inc. , a corporation incorporated under the Business Corporations Act (Ontario)
   
  (“ Acquisitionco ”)
   
AND: Trillium Therapeutics Inc. , a corporation incorporated under the Business Corporations Act (Ontario)
   
  (“ Trillium ”)
   
AND: Stem Cell Therapeutics Corp. , a body corporate incorporated under the Business Corporations Act (Alberta)
   
  (“ Stem Cell ”)

WHEREAS:

A.

Acquisitionco was incorporated under the laws of Ontario by Articles of Incorporation effective March 12, 2013;

   
B.

Acquisitionco is a wholly-owned subsidiary of Stem Cell;

   
C.

Acquisitionco, Trillium, Stem Cell and certain senior securityholders of Trillium have entered into a debenture purchase and merger agreement dated March 25, 2013 (the “Debenture Purchase and Merger Agreement”) with respect to the transactions contemplated herein;

   
D.

As contemplated in the Debenture Purchase and Merger Agreement, Acquisitionco and Trillium wish to amalgamate on the terms and conditions set forth herein and in the Debenture Purchase and Merger Agreement; and

   
E.

Capitalized terms used here but not otherwise defined shall have the meaning ascribed thereto in the Debenture Purchase and Merger Agreement.

NOW THEREFORE , in consideration of the covenants and agreements herein contained, the parties agree as follows:

1.

AMALGAMATION

   
1.1

Acquisitionco and Trillium will amalgamate, pursuant to the provisions of the Business Corporations Act (Ontario), and continue as one corporation (“ Amalco ”) effective immediately upon the issue of the certificate of amalgamation issued by the Director appointed under the Business Corporations Act (Ontario) in respect of the amalgamation (the “ Effective Time ”) upon and subject to the terms and conditions and in the manner set out in this Agreement.



A-3

2.

EFFECT

     
2.1

Upon the amalgamation of Acquisitionco and Trillium becoming effective:

     
2.1.1

their property shall continue to be the property of Amalco;

     
2.1.2

Amalco shall continue to be liable for their obligations;

     
2.1.3

an existing cause of action, claim or liability to prosecution relating to one or more of them shall be unaffected;

     
2.1.4

a civil, criminal or administrative action or proceeding pending by or against one or more of them may be continued to be prosecuted by or against Amalco;

     
2.1.5

a conviction against, or ruling, order or judgment in favour of or against, one or more of them may be enforced by or against Amalco; and

     
2.1.6

Amalco’s Articles of Amalgamation shall be deemed to be its articles of incorporation and Amalco’s Certificate of Amalgamation shall be deemed to be its certificate of incorporation.


3.

AMALGAMATION EVENTS

     
3.1

At the Effective Time:

     
3.1.1

the holders of Acquisitionco common shares will receive Amalco common shares on the basis of one (1) Amalco common share for every one (1) Acquisitionco common shares held;

     
3.1.2

the holders of Trillium Class A Pref Shares will receive Amalco Class A Pref Shares on the basis of one (1) Amalco Class A Pref Share for every one (1) Trillium Class A Pref Share held;

     
3.1.3

the holders of Trillium Common Shares will receive Amalco Class B Pref Shares on the basis of one (1) Amalco Class B Pref Shares for every one (1) Trillium Common Share held;

     
3.1.4

concurrently with the Effective Time, Stem Cell will purchase all of the Debentures and all of the Trillium Class A Pref Warrants from the Debentureholders on the terms set forth in the Debenture Purchase and Merger Agreement; and

     
3.1.5

immediately following the Effective Time, Amalco shall then redeem all of the issued and outstanding Amalco Class A Pref Shares and Amalco Class B Pref Shares at the Redemption Amount of $0.00000000000001 per share.


4.

NAME

   
4.1

The name of Amalco will be Trillium Therapeutics Inc.



A-4

5.

REGISTERED OFFICE

   
5.1

The registered office of Amalco will be situated in the Province of Ontario at Suite 5300, TD Bank Tower, Toronto, Ontario, Canada, M5K 1E6.

   
6.

DIRECTORS

   
6.1

The number of directors of Amalco will be a minimum of 1 and a maximum of 10.

   
6.2

The following persons will be the first directors:


  Name Residence Address
  David Allan  

7.

OFFICERS

   
7.1

The following persons will be the officers of Amalco and will occupy the offices indicated beside their names:


  Name Residence Address Office
  David Allan redacted President and Corporate Secretary

8.

AUTHORIZED CAPITAL

   
8.1

Amalco will be authorized to issue an unlimited number of common shares, an unlimited number of Class A Pref Shares and an unlimited number Class B Pref Shares.

   
8.2

The rights, privileges, restrictions and conditions attaching to the common shares, Class A Pref Shares and Class B Pref Shares of Amalco are set forth in the Articles of Amalgamation attached as Schedule A to this Agreement.

   
9.

STATED CAPITAL

   
9.1

The amounts to be added at the Effective Time to the stated capital accounts to be maintained by Amalco are: (1) an amount equal to the sum of the amount in the stated capital account maintained by Acquisitionco for its common shares will be added to the stated capital account for Amalco common shares and (2) the amount in the stated capital account maintained by Trillium for its common shares and Class A Pref Shares will be added to the stated capital account for Amalco Class B Pref Shares and Amalco Class A Pref Shares, respectively.

   
10.

DISSENTING SHAREHOLDERS


10.1

A holder of Trillium Common Shares and/or Trillium Class A Preference Shares (the “ Trillium Shares ”) who, in connection with the resolutions of the shareholders of Trillium approving the amalgamation (the “ Amalgamation Resolution ”), has validly exercised the right to dissent pursuant to applicable law (the “ Dissenting Shareholder ”) in strict compliance with the provisions thereof and thereby becomes entitled to receive the fair value of his or her Trillium Shares in cash determined as of the close of business on the day before the adoption of the Amalgamation Resolution and has not withdrawn or been deemed to have withdrawn such exercise of dissent rights, but only in respect of Trillium Shares in respect of which dissent rights are validly exercised by such holder.



A-5

10.2

Each Dissenting Shareholder shall cease to have any rights as a shareholder of Trillium (the “ Trillium Shareholder ”) other than the right to paid by Amalco the fair value of the Trillium Shares held by the Dissenting Shareholder in accordance with applicable law.

     
10.3

Trillium Shares which are held by a Dissenting Shareholder shall not be exchanged for Stem Cell Shares at the Effective Time. However, if a Trillium Shareholder fails to perfect or effectively withdraws its claim under applicable law or forfeits its right to make such a claim, or if such Trillium Shareholder’s rights as a shareholder of Trillium are otherwise reinstated, each Trillium Shares held by such Trillium Shareholder shall thereupon be deemed to have been exchanged for a Stem Cell Share as of the Effective Time as if such Trillium Shareholder had participated in, and on the terms provided for, the exchange referred to in Section 3 above.

     
11.

NO RESTRICTIONS ON BUSINESS

     
11.1

There will be no restrictions on the business Amalco may carry on or on the powers Amalco may exercise.

     
12.

RESTRICTIONS ON SECURITY TRANSFERS

     
12.1

The right to transfer securities of Amalco will be restricted in that no security of Amalco, other than a non-convertible debt security, may be transferred without the consent of:

     
12.1.1

the board of directors of Amalco, expressed by a resolution duly passed at a meeting of the directors;

     
12.1.2

a majority of the directors of Amalco, expressed by an instrument or instruments in writing signed by such directors;

     
12.1.3

the holders of the voting shares of Amalco, expressed by a resolution duly passed at a meeting of the holders of voting shares; or

     
12.1.4

the holders of the voting shares of Amalco representing a majority of the votes attached to all the voting shares, expressed by an instrument or instruments in writing signed by such holders.


13.

NUMBER OF DIRECTORS

   
13.1

The actual number of directors within the minimum and maximum number set out in Section 6.1 hereof may be determined from time to time by resolution of the directors. Any vacancy among the directors resulting from an increase in the number of directors as so determined may be filled by resolution of the directors.

   
14.

BY-LAWS

   
14.1

The by-laws of Acquisitionco will, with necessary changes, be the by-laws of Amalco, such by-laws after the Effective Time to be supplemented, amended or repealed in accordance with the provisions of the Business Corporations Act (Ontario) relating to the making, amending and repealing of by-laws. The by-laws of Amalco are set forth in the Schedule B to this Agreement.



A-6

15.

FISCAL YEAR

   
15.1

The fiscal year end of Amalco shall be December 31st.

   
16.

AMENDMENT

   
16.1

Each of the parties may, by resolution of their respective directors, assent to any amendment or variation of this Agreement that the shareholders of the parties may approve and the term “Agreement” as used herein includes this Agreement as so amended or varied.

   
17.

TERMINATION

   
17.1

Notwithstanding the approval of this Agreement by the shareholders of either party, (i) the directors of such party may by resolution terminate this Agreement at any time prior to the Effective Time; and (ii) this Agreement shall terminate automatically upon the termination of the Debenture Purchase and Merger Agreement in accordance with its terms at any time prior to the Effective Time.

   
18.

GOVERNING LAW

   
18.1

This Agreement is governed by and will be construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein.

(Signatures on the following pages)


A-7

IN WITNESS WHEREOF this Agreement has been executed by the parties hereto on the date first written above.

  2364556 ONTARIO INC.
     
  Per:            _____________________________________________________
                     Name:
   
  TRILLIUM THERAPEUTICS INC.
     
  Per:            _____________________________________________________
                     Name:
     
  STEM CELL THERAPEUTICS CORP.
  Per:            _____________________________________________________
                     Name:


A-8

SCHEDULE A
ARTICLES OF AMALGAMATION


A-9

SCHEDULE B
BY-LAWS


B-1

APPENDIX B

ARTICLES OF AMALGAMATION

See document attached


C-1

APPENDIX C


C-2

SCHEDULE 3.3.1

TABLE OF TRILLIUM ISSUED AND OUTSTANDING SECURITIES

Trillium Therapeutics Inc.
Share Ownership
As at March 25, 2013

        Number
        Class A
        Shares
        Issuable
        upon
        Conversion
    Class A Class A of
  Common Pref Pref Debenture
       Name Shares Shares Warrants  
         
         
Founders and individuals        
       David Grant 400,000      
       Robert Zhong 400,000      
       Joaquim Madrenas 400,000      
       Philip Marsden 400,000      
       Willem Wassenaar 266,667      
       David Clark 100,000      
       Reginald Gorczynski 400,000      
Total Founders 2,366,667 - - -

Institutions        
       University Health Network 550,000      
       Robarts Research Institute 225,000      
       London Health Sciences Centre 225,000      
       University of Toronto 200,000      
       University of Western Ontario 50,000      
       St. Michael’s Hospital 50,000      
Total Institutions 1,300,000 - - -

Commercial investors        
       Arthron Pty Ltd. 1,200,000      
       Medarex, Inc. 250,000      
Total Commercial 1,450,000  - -  -


C-3

        Number
        Class A
        Shares
        Issuable
        upon
        Conversion
    Class A Class A of
  Common Pref Pref Debenture
       Name Shares Shares Warrants  
         
         
Venture Capital        
       Covington Fund II Inc. 6,015,037 1 2,942,605 5,690,470
       Growthworks Canadian Fund Ltd. 2,879,699 1 1,029,106 2,325,980
       BDC Capital Inc. 2,255,638 1 1,103,477 2,133,926
       MaRS Investment Accelerator - - 225,564 1,127,820
       Fund Inc.        
Total Venture Capital 11,150,374 3 5,300,752 11,278,196
         
         
Total 16,267,041 3 5,300,752 11,278,196
         
         
Stock Options        
       Issued and outstanding 1,418,250      


C-4


C-5

SCHEDULE 3.3.15

TRILLIUM INTELLECTUAL PROPERTY RIGHTS

Trillium



Title


File


Owner/s


Inventor/s


Application #

Filing
Date d/m/y


Publication #
Publn
Date
d/m/y

Patent
Number


Issue Date
USE OF OX-2 INHIBITORS FOR THE TREATMENT OF CANCER TTI-03-PCT Trillium Therapeutics Gorczynski CA01/01111 07/30/01 WO02/11762 02/14/02 nationalized
USE OF OX-2 INHIBITORS FOR THE TREATMENT OF CANCER TTI-03-PCT-CA Trillium Therapeutics Gorczynski, Clark 2417874 07/30/01 2417874 02/14/02 2417874 10/02/12
USE OF OX-2 INHIBITORS FOR THE TREATMENT OF CANCER TTI-03-US Trillium Therapeutics Gorczynski, Clark 09/917278 07/30/01 20020168364 11/14/02 6955811 10/18/05
USE OF OX-2 INHIBITORS FOR THE TREATMENT OF CANCER TTI-03-US-CON Trillium Therapeutics Gorczynski, Clark 11/192,123 07/29/05 20060029607 02/09/06 7238352 07/03/07
USE OF OX-2 INHIBITORS FOR THE TREATMENT OF CANCER TTI-03-US-CON-2 Trillium Therapeutics Gorczynski, Clark 11/753,908 05/25/07 20070258977 11/08/07 7452536 11/18/08
METHODS OF TREATING CANCER BY ADMINISTERING ANTIBODIES TO CD200 TTI-03-US-CON-3 Trillium Therapeutics Gorczynski, Clark 12/246621 10/07/08 20090053222 02/26/09 7887798 02/15/11
METHODS OF TREATING CANCER BY ADMINISTERING ANTIBODIES TO CD200 TTI-03-US-CON-4 Trillium Therapeutics Gorczynski, Clark 13/025377 02/11/11 20110129466 06/02/11 8187598 05/29/12
                   
ASSAY FOR SOLUBLE CD200 TTI-08-PCT Trillium Therapeutics Gorczynski, Wong PCT/CA2008/001385 07/29/08 WO09121162 10/08/09   nationalized
ASSAY FOR SOLUBLE CD200 TTI-08-PCT-US Trillium Therapeutics Gorczynski, Wong 12/936094 07/29/08 20110052605 03/03/11 8206897 06/26/12
ASSAY FOR SOLUBLE CD200 TTI-08-PCT-US CON Trillium Therapeutics Gorczynski, Wong 13/474855 05/18/12 20120264145 10/18/12    
ASSAY FOR SOLUBLE CD200 TTI-08-PCT-CA Trillium Therapeutics Gorczynski, Wong 2720294 07/29/08 2720294 10/08/09    
ASSAY FOR SOLUBLE CD200 TTI-08-US PROV Trillium Therapeutics Gorczynski, Wong 61/042,342 04/04/08       converted
                   
HEPARIN BINDING MITOGEN WITH HOMOLOGY TO EPIDERMAL GROWTH FACTOR (EGF) TTI-14-US Children's Medical Center Corp./Scios Nova Klagsrun, Abraham, Higashiyama, Besner 08/039364 10/16/91 5811393 09/22/98
                   
HEPARIN BINDING -EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR IN THE DIAGNOSIS OF INTERSTITIAL TTI-16-US University of Maryland, Baltimore Keay, Warren, Hise 09/109548 07/02/98 6156522 12/05/00


C-6



Title


File


Owner/s


Inventor/s


Application #

Filing
Date d/m/y


Publication #
Publn
Date
d/m/y

Patent
Number


Issue Date
CYSTITIS                  
METHOD OF TREATING INTERSTITIAL CYSTITIS WITH RECOMBINANT HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR (HB-EGF) TTI-16-US2 University of Maryland, Baltimore Keay, Warren, Hise 09/293037 04/16/99 6232289 05/15/01
                   
HB-EGF COMPOSITION AND USE THEREOF TO TREAT A CONDITION ASSOCIATED WITH ENHANCED UROTHELIUM PERMEABILITY TTI-18-US PROV Trillium Therapeutics Uger, Petrova 61/326291 04/21/10 converted
HB-EGF COMPOSITION AND USE THEREOF TO TREAT A CONDITION ASSOCIATED WITH ENHANCED UROTHELIUM PERMEABILITY TTI-18-PCT Trillium Therapeutics Uger, Petrova CA2011/000377 04/12/11 WO2011/130824 10/27/11 nationalized
HB-EGF COMPOSITION AND USE THEREOF TO TREAT A CONDITION ASSOCIATED WITH ENHANCED UROTHELIUM PERMEABILITY TTI-18-PCT-US Trillium Therapeutics Uger, Petrova 13/641478 04/12/11
HB-EGF COMPOSITION AND USE THEREOF TO TREAT A CONDITION ASSOCIATED WITH ENHANCED UROTHELIUM PERMEABILITY TTI-18-PCT-CA Trillium Therapeutics Uger, Petrova 2796469 04/12/11 2796469 10/27/11
HB-EGF COMPOSITION AND USE THEREOF TO TREAT A CONDITION ASSOCIATED WITH ENHANCED UROTHELIUM PERMEABILITY TTI-18-PCT-EP Trillium Therapeutics Uger, Petrova 11771429 04/12/11 2560673 02/27/13
HB-EGF COMPOSITION AND USE THEREOF TO TREAT A CONDITION ASSOCIATED WITH ENHANCED UROTHELIUM PERMEABILITY TTI-18-PCT-JP Trillium Therapeutics Uger, Petrova 04/12/11
HB-EGF COMPOSITION AND USE THEREOF TO TREAT A CONDITION ASSOCIATED WITH ENHANCED UROTHELIUM PERMEABILITY TTI-18-PCT-AU Trillium Therapeutics Uger, Petrova 2011242354 04/12/11 11242354
HB-EGF COMPOSITION AND USE THEREOF TO TREAT A CONDITION ASSOCIATED WITH ENHANCED UROTHELIUM PERMEABILITY TTI-18-PCT-CN Trillium Therapeutics Uger, Petrova 2.0118E+11 04/12/11 102858363 02/02/13
                   
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP- ALPHA-CD47 INTERACTION TTI-21-US PROV University Health Network/TheHospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, Rajakumar       61/178553 05/15/09 converted
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP0ALPHA-CD47 INTERACTION TTI-21-PCT University Health Network/TheHospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, 2010/000743 05/14/10 WO2010/130053 11/18/10 nationalized


C-7



Title


File


Owner/s


Inventor/s


Application #

Filing
Date d/m/y


Publication #
Publn
Date
d/m/y

Patent
Number


Issue Date
       Rajakumar                  
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP0ALPHA-CD47 INTERACTION TTI-21-PCT AU University Health Network/TheHospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, Rajakumar 2010246872 05/14/10 10246872 12/01/11
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP0ALPHA-CD47 INTERACTION TTI-21-PCT CA University Health Network/TheHospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, Rajakumar 2761438 05/14/10 2761438 11/18/10
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP- ALPHA-CD47 INTERACTION TTI-21-PCT CN University Health Network/TheHospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, Rajakumar 201080021398.7 05/14/10 102596233 07/18/12
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP- ALPHA-CD47 INTERACTION TTI-21-PCT EP University Health Network/TheHospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, Rajakumar 10774475.7 05/14/10 2429574 10/03/12
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP-ALPHA-CD47 INTERACTION TTI-21-PCT IN University Health Network/The Hospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, Rajakumar   05/14/10        
COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP- ALPHA-CD47 INTERACTION TTI-21-PCT JP University Health Network/TheHospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, Rajakumar 2012-510083 05/14/10 2012526729 05/14/10
COMPOSITONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING … TTI-21-PCT-US University Health Network/TheHospital for Sick Children Wang, Dick, Danska, Jin, Theocharides, Rajakumar 13/320629 05/14/10 2012-0189625 07/26/12
                   
HUMAN ANTIBODIES THAT BIND CD200 AND USES THEREOF TTI-32 US PROV Trillium Therapeutics/ Bristol Chakraborty, Korman, LeBlan 61/661618 19/06/12        
                   
TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS TTI-35 US PROV Trillium Therapeutics Uger, Slavova-Petrova, Pang 61/738008 17/12/12        
TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS TTI-35 US PROV Trillium Therapeutics Uger, Slavova-Petrova, Pang 61/738012 17/12/12        



Exhibit 4.5

TRILLIUM THERAPEUTICS INC.
( formerly, Stem Cell Therapeutics Corp. )

STOCK OPTION PLAN

Amended and Restated
on May 27, 2014

1.        Definitions

              Unless otherwise defined herein or the context otherwise requires, capitalized terms used have the meaning ascribed to them in the Toronto Stock Exchange (“ TSX ”) Company Manual.

2.        Purpose of Plan

            The purpose of the Trillium Therapeutics Inc. (the “ Corporation ”) Stock Option Plan (the “ Plan ”) is to assist the Corporation in attracting, retaining and motivating directors, officers, service providers (the term “service provider” having the definition ascribed thereto in the TSX Company Manual) and employees of the Corporation and its subsidiaries and to closely align the personal interests of such directors, officers, employees and service providers with those of the shareholders of the Corporation by providing them with the opportunity, through options (“ Options ”), to acquire common shares (“ Common Shares ”) in the capital of the Corporation.

3.        Administration

            The Plan shall be administered by the Board of Directors of the Corporation which shall have full and final authority and discretion, subject to the express provisions of the Plan, to interpret the Plan, to prescribe, amend and rescind rules and regulations relating to it and to make all other determinations deemed necessary or advisable for the administration of the Plan, subject to the rules and policies of any exchange or quotation system upon which the Corporation’s Common Shares are listed or quoted including the TSX. The Board of Directors may delegate any or all of its authority and discretion with respect to the administration of the Plan to a compensation committee of directors. When used hereafter in the Plan, “ Board of Directors ” shall be deemed to include the compensation committee acting on behalf of the Board of Directors.

4.          Number of Shares Under Plan

            The number of authorized but unissued Common Shares that may be issued upon the exercise of Options granted under the Plan at any time, plus the number of Common Shares reserved for issuance under outstanding Options otherwise granted by the Corporation (collectively, the “ Optioned Shares ”) shall not exceed ten percent of the combined total of the issued and outstanding Common Shares and the number of Common Shares issuable upon due exercise of the issued and outstanding Preferred Shares, and the number of Optioned Shares reserved for issuance under the Plan shall increase or decrease as the number of issued and outstanding Common Shares and Preferred Shares changes. Any exercise of Options will make new grants available under the Plan. However, the following additional restrictions apply:


- 2 -

  (a)

in no event shall Options be granted to an individual to purchase in excess of five percent of the total of the number of then issued and outstanding Common Shares and the number of Common Shares issuable upon due conversion of the issued and outstanding Preferred Shares of the Corporation in any 12 month period;

     
  (b)

the aggregate number of Common Shares issuable (or reserved for issuance) to Insider Participants under the Plan (such that “ Insider Participant ” shall mean any Participant (as defined in Section 5 below) that is an Insider as defined in Section 613 of the TSX Company Manual) or any other security-based compensation arrangement of the Corporation and its affiliates (including, without limitation, the Corporation’s Deferred Share Unit Plan, which together with this Plan shall be referred to as “ Security-Based Compensation Arrangements ”), may not at any time exceed 10% of the total combined issued and outstanding Common Shares and the number of Common Shares issuable upon due conversion of the issued and outstanding Preferred Shares;

     
  (c)

the aggregate number of Common Shares issued to Insider Participants under the Plan or any other Security-Based Compensation Arrangement of the Company within a one-year period, may not exceed 10% of the total combined number of issued and outstanding Common Shares and the number of Common Shares issuable upon due conversion of the issued and outstanding Preferred Shares; and

     
  (d)

if Options granted to an individual under the Plan in respect of certain Optioned Shares expire or terminate for any reason with or without having been exercised, such Optioned Shares may be made available for other Options to be granted under the Plan.

5.           Eligibility

            Options may be granted under the Plan to such directors, officers, employees of, or service providers to, the Corporation or its subsidiaries as the Board of Directors may from time to time designate as participants (the “ Participants ”) under the Plan. Subject to the provisions of the Plan, the total number of Optioned Shares to be made available under the Plan and to each Participant, the time or times and price or prices at which Options shall be granted, the time or times at which such Options are exercisable and any conditions or restrictions on the exercise of Options shall be in the full and final discretion of the Board of Directors.

            Notwithstanding the expiration date applicable to any Option, if an Option would otherwise expire during or immediately after a Black-out Period, then the expiration date of such Option shall be the tenth business day following the expiration of the Black-out Period, provided that in no event shall the period during which said Option is exercisable be extended beyond 10 years from the date such Option is granted to the Participant. Where used herein, “ Black-out Period ” means the period during which the Corporation has imposed trading restrictions on its Insiders and certain other persons pursuant to its insider trading and disclosure policies.


- 3 -

6.          Terms and Conditions

            All Options under the Plan shall be granted upon and subject to the terms and conditions hereinafter set forth.

  (a)

Exercise Price

     
 

The exercise price payable in respect of each Optioned Share may not be lower than the volume weighted average trading price of the Common Shares on the TSX over a period of five days preceding the date of grant.

     
  (b)

Option Agreement

     
 

All Options granted under the Plan shall be evidenced by means of an agreement (the “ Option Agreement ”) between the Corporation and each Participant in a form as may be approved by the Board of Directors, such approval to be conclusively evidenced by the execution of the Option Agreement by any senior officer or director of the Corporation other than the Participant. The Corporation shall represent in each Option Agreement that the Participant is a bona fide director, officer, or employee of, or service provider to, the Corporation.

     
  (c)

Length of Grant and Vesting

     
 

Each Option granted under the Plan shall expire not later than the 10th anniversary of the date such Option was granted and may be exercised by the Participant subject to such vesting (if any), during the term thereof as the Board of Directors shall determine (“ Option Period ”).

     
  (d)

Non-Assignability of Options

     
 

An Option granted under the Plan shall not be transferable or assignable (whether absolutely or by way of mortgage, pledge or other charge) by a Participant other than to a Participant’s Registered Retirement Savings Plan or wholly-owned corporation or by will or other testamentary instrument or the laws of succession and may be exercisable during the lifetime of the Participant only by such Participant.

     
  (e)

Right to Postpone Exercise

     
 

Each Participant, upon becoming entitled to exercise an Option in respect of any Optioned Shares in accordance with an Option Agreement, shall thereafter be entitled to exercise the Option to purchase such Optioned Shares at any time prior to the expiration or other termination of the Option Agreement or the Option rights granted thereunder in accordance with such agreement.



- 4 -

  (f)

Exercise and Payment

       
 

Any Option granted under the Plan may be exercised by a Participant or the legal representative of a Participant by giving notice to the Corporation specifying the number of Common Shares in respect of which such Option is being exercised, accompanied by payment (by cash or certified cheque payable to the Corporation) of the entire exercise price (determined in accordance with the Option Agreement) for the number of Common Shares specified in the notice. Upon any such exercise of an Option by a Participant, the Corporation shall promptly deliver to such Participant or the legal representative of such Participant, as the case may be, a share certificate in the name of such Participant or the legal representative of such Participant, as the case may be, representing the number of Common Shares specified in the notice.

       
 

If the Corporation is required under the Income Tax Act (Canada) or any other applicable law to remit to any governmental authority an amount on account of tax on the value of any taxable benefit associated with the exercise or disposition of Options by a Participant, then the Participant shall, concurrently with the exercise or disposition:

       
  (i)

pay to the Corporation, in addition to the exercise price for the Options, if applicable, sufficient cash as is determined by the Corporation to be the amount necessary to fund the required tax remittance;

       
  (ii)

where the Corporation so agrees, authorize the Corporation, on behalf of the Participant, to sell in the market on such terms and at such time or times as the Corporation determines such portion of the Common Shares being issued upon exercise of the Options as is required to realize cash proceeds in the amount necessary to fund the required tax remittance; or

       
  (iii)

make other arrangements acceptable to the Corporation to fund the required tax remittance.

       
  (g)

Rights of Participants

       
 

The Participants shall have no rights whatsoever as shareholders in respect of any of the Optioned Shares (including, without limitation, any right to receive dividends or other distributions therefrom, voting rights, warrants or rights under any rights offering) other than in respect of Optioned Shares for which Participants have exercised their Option to purchase and which have been issued by the Corporation.

       
  (h)

Change of Control

       
 

Any Options outstanding immediately prior to the occurrence of a Change in Control, but which are not then exercisable, shall immediately vest and become fully exercisable upon the occurrence of a Change in Control. The term “ Change of Control ” shall mean any one or a combination of:



- 5 -

  (i)

any transaction at any time and by whatever means pursuant to which (A) the Corporation goes out of existence by any means, except for any corporate transaction or reorganization in which the proportionate voting power among holders of securities of the entity resulting from such corporate transaction or reorganization is substantially the same as the proportionate voting power of such holders of Corporation voting securities immediately prior to such corporate transaction or reorganization or (B) any Person or any group of two or more Persons acting jointly or in concert (other than the Corporation, a wholly-owned Subsidiary (as defined in the Securities Act (Ontario)) of the Corporation, an employee benefit plan of the Corporation or of any of its wholly-owned Subsidiaries, including the trustee of any such plan acting as trustee) hereafter acquires the direct or indirect “beneficial ownership” (as defined by the Business Corporations Act (Ontario)) of, or acquires the right to exercise control or direction over, securities of the Corporation representing 50% or more of the Corporation’s then issued and outstanding securities in any manner whatsoever, including, without limitation, as a result of a take-over bid, an exchange of securities, an amalgamation of the Corporation with any other entity, an arrangement, a capital reorganization or any other business combination or reorganization;

     
  (ii)

the sale, assignment or other transfer of all or substantially all of the assets of the Corporation to a Person other than a wholly-owned Subsidiary of the Corporation;

     
  (iii)

the dissolution or liquidation of the Corporation except in connection with the distribution of assets of the Corporation to one or more Persons which were wholly-owned Subsidiaries of the Corporation immediately prior to such event;

     
  (iv)

the occurrence of a transaction requiring approval of the Corporation’s shareholders whereby the Corporation is acquired through consolidation, merger, exchange of securities, purchase of assets, amalgamation, arrangement or otherwise by any other Person (other than a short form amalgamation or exchange of securities with a wholly-owned Subsidiary of the Corporation); or

     
  (v)

the Board passes a resolution to the effect that, for the purposes of some or all of the Option Agreements, an event set forth in (i), (ii), (iii) or (iv) above has occurred.


  (i)

Alterations in Shares

     
 

In the event of a share dividend, share split, issuance of Common Shares or instruments convertible into Common Shares (other than pursuant to the Plan) for less than market value, share consolidation, share reclassification, exchange of Common Shares, recapitalization, amalgamation, merger, consolidation, corporate continuance, reorganization, liquidation or the like of or by the Corporation, the Board of Directors may make such adjustment, if any, of the number of Optioned Shares, or of the exercise price, or both, as it shall deem appropriate to give proper effect to such event, including to prevent, to the extent possible, substantial dilution or enlargement of rights granted to Participants under the Plan. In any such event, the maximum number of Common Shares available under the Plan may be appropriately adjusted by the Board of Directors. If because of a proposed merger, amalgamation or other corporate continuance or reorganization, the exchange or replacement of Common Shares in the Corporation for those in another corporation is imminent, the Board of Directors may, in a fair and equitable manner, determine the manner in which all unexercised Option rights granted under the Plan shall be treated including, for example, requiring the acceleration of the time for the exercise of such rights by the Participants and of the time for the fulfilment of any conditions or restrictions on such exercise. All determinations of the Board of Directors under this paragraph (j) shall be full and final,



- 6 -

  (j)

Termination for Cause

       
 

If a Participant is dismissed as a director, officer or employee of, or service provider to, the Corporation or one of its subsidiaries for cause, all unexercised Option rights of that Participant under the Plan shall immediately become terminated and shall lapse notwithstanding the original term of the Option granted to such Participant under the Plan.

       
  (k)

Retirement, Resignation or Termination

       
 

Subject to earlier termination pursuant to Section 6(k) above, if a Participant ceases to be a director, officer or employee of, or service provider to, the Corporation or of one of its subsidiaries as a result of:

       
  (i)

retirement at the normal retirement age prescribed by the Corporation pension plan, if any;

       
  (ii)

resignation; or

       
  (iii)

termination;

such Participant shall have the right for a period of 120 days from the date of ceasing to be a director, officer, employee or service provider to exercise the Option under the Plan with respect to all Optioned Shares of such Participant to the extent they were exercisable on the date of ceasing to hold any such position with the Corporation, or until the normal expiry date of the Option rights of such Participant, whichever is earlier. Upon the expiration of such period, all unexercised Option rights of that Participant shall immediately become terminated and shall lapse notwithstanding the original term of the Option granted to such Participant under the Plan.


- 7 -

  (l)

Disabled Participant

     
 

If a Participant ceases to be a director, officer or employee of, or service provider to, the Corporation or of one of its subsidiaries as a result of disability or illness preventing the Participant from performing the duties routinely performed by such Participant, such Participant shall have the right for a period of 180 days (or until the normal expiry date of the Option rights of such Participant if earlier) from the date of ceasing to be a director, officer, employee or Service provider to exercise the Option under the Plan with respect to all Optioned Shares of such Participant to the extent they were exercisable on the date of ceasing to hold any such position. Upon the expiration of such 180 day period all unexercised Option rights of that Participant shall immediately become terminated and shall lapse notwithstanding the original term of the Option granted to such Participant under the Plan.

     
  (m)

Deceased Participant

     
 

In the event of the death of any Participant, the legal representatives of the deceased Participant shall have the right for a period of one year (or until the normal expiry date of the Option rights of such Participant if earlier) from the date of death of the Participant to exercise the deceased Participant’s Option with respect to all of the Optioned Shares of the deceased Participant to the extent they were exercisable on the date of death. Upon the expiration of such period all unexercised Option rights of the deceased Participant shall immediately become terminated and shall lapse notwithstanding the original term of the Option granted to the deceased Participant under the Plan.

7.          Amendment and Discontinuance of Plan

            The Board has the discretion to make amendments to this Plan and any Options granted hereunder which it may deem necessary, without having to obtain shareholder approval. Such changes include, without limitation:

  (i)

minor changes of a “housekeeping” nature;

     
  (ii)

amending Options under the Plan, including with respect to the Option Period (provided that the period during which an Option is exercisable does not exceed ten years from the date the Option is granted and that such Option is not held by an Insider Participant), vesting period, exercise method and frequency, exercise price of an Option (provided that such Option is not held by an Insider Participant) and method of determining the exercise price, assignability and effect of termination of a Participant’s employment or cessation of the Participant’s directorship;

     
  (iii)

changing the class of Participants eligible to participate under the Plan;



- 8 -

  (iv)

changing the terms and conditions of any financial assistance which may be provided by the Company to Participants to facilitate the purchase of Common Shares under the Plan; and

     
  (v)

adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Common Shares from the Plan reserve.

            Shareholder approval will be required in the case of: (i) any amendment to the amendment provisions of the Plan; (ii) any increase in the maximum number of Common Shares issuable under the Plan; and (iii) any reduction in the exercise price or extension of the Option Period benefiting an Insider Participant, in addition to such other matters that may require shareholder approval under the rules and policies of the TSX.

8.           No Further Right

            Nothing contained in the Plan nor in any Option granted hereunder shall give any Participant or any other person any interest or title in or to any Common Shares of the Corporation or any rights as a shareholder of the Corporation or any other legal or equitable right against the Corporation whatsoever other than as set forth in the Plan and pursuant to the exercise of any Option, nor shall it confer upon the Participants any right to continue as an officer or employee of the Corporation or of its subsidiaries.

9.           Compliance with Laws

            The obligations of the Corporation to sell Common Shares and deliver share certificates under the Plan are subject to such compliance by the Corporation and the Participants with all applicable corporate and securities laws as the Corporation deems necessary or advisable.



Exhibit 4.6

TRILLIUM THERAPEUTICS INC.
(formerly, Stem Cell Therapeutics Corp.)

DEFERRED SHARE UNIT PLAN
FOR DIRECTORS AND EXECUTIVE OFFICERS
Amended and Restated on May 27, 2014

 

PART l - GENERAL PROVISIONS

Purpose

1.1        The purpose of this Plan is to provide an alternative form of compensation to satisfy annual and special bonuses payable to Directors and Executive Officers and to satisfy fees that may be payable to Directors for acting as directors of the Company. This form of compensation promotes a greater alignment of interests amongst Directors and Executive Officers and the Company's shareholders.

Definitions

1.2        In this Plan,

Annual Board Retainer means the annual retainer paid by the Company to a Director, but does not include Chair Fees, Committee Fees and Meeting Fees.

Applicable Withholding Tax has the meaning set forth in Section 3.4;

Awarded Amount has the meaning set forth in Section 2.1;

Board means the Board of Directors of the Company;

Chair means the chair of the Board;

Chair Fees means the fees or retainers, other than Meeting Fees, the Annual Board Retainer and Committee Fees, paid by the Company to a Director for service as the Chair and as chairperson of a committee of the Board;

Committee means the Compensation Committee of the Board, or any other persons designated by the Board to perform the duties contemplated herein;

Committee Fees means the fees or retainers, other than Meeting Fees, the Annual Board Retainer and Chair Fees, paid by the Company to a Director for service on a committee of the Board;

Company means Trillium Therapeutics Inc.;

Deferred Share Unit means a right granted by the Company to an Eligible Person to receive, on a deferred payment basis, a Share on the terms contained in this Plan;

Director means any Director of the Company, or a subsidiary of the Company, appointed and approved by the Board or the shareholders;


2

Eligible Person means any person who is a Director or Executive Officer;

Executive Officer means the Chief Executive Officer, President, Chief Financial Officer and any senior officer of the Company, or any subsidiary of the Company or any persons acting in any such capacity on behalf of the Company or subsidiary of the Company;

Fair Market Value means the five-day volume weighted average trading price, being the VWAP (as the term VWAP is defined in the TSX Company Manual), as at, and including, the relevant determination date or such other applicable date referenced herein provided that such date is a business day and if it is not then calculated as at and including the last business day which preceded such applicable date referenced herein, except that if the Shares are not listed on the TSX, the Fair Market Value will be the value established by the Board based on the five-day average closing price per Share on any other public exchange on which the Shares are listed calculated as at, and including, the relevant determination date or such other applicable date referenced herein provided that such date is a business day and if it is not then calculated as at and including the last business day which proceeded such applicable date referenced herein, or if the Shares are not listed on any public exchange, by the Board based on its determination of the fair value of a Share;

Director Fees means the aggregate total of the Annual Board Retainer, Chair Fees, Committee Fees, Meeting Fees and any other fees payable to a Director;

Insider means an “insider” as defined in Section 613 of the TSX Company Manual;

Meeting Fees means the fees or retainers, other than the Annual Board Retainer, Chair Fees, and Committee Fees, paid by the Company to a Director for attending meetings of the Board or any committee of the Board;

Option means the right to purchase Shares granted pursuant to the Company's stock option plan approved by the Board, as may be amended from time to time in accordance with its terms, or any successor plan accepted for filing by the TSX;

Outstanding Issue means the combined total number of Shares outstanding and the number of Shares issuable upon conversion of the issued and outstanding First Preferred Shares of the Company in accordance with their terms;

Plan means this Deferred Share Unit Plan, as amended from time to time;

Reserved for Issuance refers to Shares that may be issued in the future upon the exercise of Options granted under the Company’s stock option plan, Deferred Share Units which have been or are granted pursuant to this Plan or pursuant to any other Share Compensation Arrangements;

Section 409A means Section 409A of the United States Internal Revenue Code of 1986, as amended, and any applicable United States Treasury Regulations and other binding regulatory guidance thereunder;

Separation from Service of a US Taxpayer means the date the US Taxpayer incurs a separation from service with the Company within the meaning of U.S. Treas. Regs. § 1.409A -1(h);


3

Service Provider means a person who is a bona fide director, officer, employee or consultant of the Company or its affiliates, and also includes a company, of which 100% of the share capital is beneficially owned by one or more such persons;

Share means a common share in the capital of the Company;

Share Compensation Arrangement means the Plan described herein and any other stock option, stock option plan, employee stock purchase plan or any other compensation or incentive mechanism involving the issuance or potential issuance of shares to one or more Eligible Persons, including a share purchase from treasury which is financially assisted by the Company by way of a loan, guaranty or otherwise;

Specified Employee means a US Taxpayer who meets the definition of “specified employee,” as defined in Section 409A(a)(2)(B)(i) of the Code;

Terminated Service means that the Eligible Person has ceased to be a Director or Executive Officer, other than as a result of death;

Total Compensation for a particular Eligible Person means the aggregate of:

  (a)

the discretionary annual bonus determined by the Board for which Directors or Executive Officers are eligible, and

     
  (b)

a bonus, that is not an annual bonus, that may be awarded to a Director or Executive Officer at the discretion of the Board; and

     
  (c)

Director Fees.

TSX means the Toronto Stock Exchange;

US Taxpayer means an Eligible Person whose compensation from the Company is subject to Section 409A.

Effective Date

1.3        Subject to the acceptance by the TSX, this Plan will be effective immediately upon the approval of the shareholders of the Company at the Company’s Annual and Special Meeting to be held May 27, 2014.

Administration

1.4        The Board will, in its sole and absolute discretion, but taking into account relevant corporate, securities and tax laws,

  (a)

interpret and administer this Plan,

     
  (b)

establish, amend and rescind any rules and regulations relating to this Plan, and

     
  (c)

make any other determinations that the Board deems necessary or desirable for the administration of this Plan.

The Board may correct any defect or any omission or reconcile any inconsistency in this Plan in the manner and to the extent the Board deems, in its sole and absolute discretion, necessary or desirable. Any decision of the Board in the interpretation and administration of this Plan will be final, conclusive and binding on all parties concerned. All expenses of administration of this Plan will be borne by the Company.


4

Delegation

1.5        The Board may, to the extent permitted by law, delegate any of its responsibilities under this Plan and powers related thereto (including, without limiting the generality of the foregoing, those referred to under Section 1.4) to the Committee or to one or more officers of the Company and all actions taken and decisions made by the Committee or by such officers in this regard will be final, conclusive and binding on all parties concerned, including, but not limited to, the Company, the Eligible Person, and their legal representatives.

PART 2 - AWARDS UNDER THIS PLAN

Determination of Deferred Share Units

2.1        The Board will, in its sole and absolute discretion, decide at the time of declaring or awarding any Total Compensation to any Eligible Person the amount (the " Awarded Amount ") of the Total Compensation that will be satisfied in the form of Deferred Share Units.

Issue of Deferred Share Units

2.2        The number of Deferred Share Units (including fractional Deferred Share Units, computed to three digits) to be credited to an Eligible Person for services will be determined by dividing the Awarded Amount by the Fair Market Value as at the last trading day before the date the Awarded Amount is declared by the Board.

Maximum Shares Reserved

2.3        Subject to adjustment as provided for herein, the maximum aggregate number of Shares that may be Reserved for Issuance pursuant to this Plan is 2,000,000 Shares (subject to adjustment as provided for herein).

2.4        In no event may the number of Shares that are Reserved for Issuance to any one person pursuant to Deferred Share Units and Options exceed 5% of the Outstanding Issue.

2.5        The maximum aggregate number of Shares that, under all Share Compensation Arrangements,

  (a)

may be Reserved for Issuance to Insiders of the Company, may not exceed 10% of the Outstanding Issue at any time, and

     
  (b)

may be issued to Insiders within a one-year period, may not exceed 10% of the Outstanding Issue.

2.6        For the purposes of Section 2.5, Shares issuable to an Insider pursuant to a Deferred Share Unit or other entitlement that was granted before the person became an Insider will be excluded in determining the number of Shares issuable to Insiders.


5

Shares Not Acquired

2.7        Any Shares not acquired under a Deferred Share Unit granted under the Plan which has expired or been cancelled or terminated may be made the subject of a further Deferred Share Unit pursuant to the provisions of the Plan.

Dividend Equivalents

2.8        On any date on which a cash dividend is paid on Shares, an Eligible Person's account will be credited with the number of Deferred Share Units (including fractional Deferred Share Units, computed to three digits) calculated by,

  (a)

multiplying the amount of the dividend per Share by the aggregate number of Deferred Share Units that were credited to the Eligible Person's account as of the record date for payment of the dividend, and

     
  (b)

dividing the amount obtained in Section 2.8(a) by the Fair Market Value on the date on which the dividend is paid.

Eligible Person's Account

2.9        A written confirmation of the balance in each Eligible Person's account will be sent by the Company to the Eligible Person upon request of the Eligible Person.

Adjustments and Reorganizations

2.10      In the event of any dividend paid in shares, share subdivision, combination or exchange of shares, merger, consolidation, spin-off or other distribution of Company assets to shareholders, or any other change in the capital of the Company affecting Shares, the Board, in its sole and absolute discretion, will make, with respect to the number of Deferred Share Units outstanding under this Plan, any proportionate adjustments as it considers appropriate to reflect that change.

PART 3 - TERMINATION OF SERVICE

Termination of Service

3.1        An Eligible Person who has Terminated Service may elect to receive one Share in respect of each whole Deferred Share Unit credited to the Eligible Person's account (determined in accordance with Section 3.2), by filing with the President of the Company a notice of redemption in the form prescribed from time to time by the Company on or before December 15 of the first calendar year commencing after the date on which the Eligible Person has Terminated Service. If the Eligible Person fails to file such notice on or before that December 15, the Eligible Person will be deemed to have filed with the President of the Company a notice of redemption on that December 15 and will be deemed to have elected to redeem all of his or her Deferred Share Units. The date on which a notice is filed or deemed to be filed with the Secretary of the Company is the "Filing Date". The Company may defer the Filing Date to any other date if such deferral is, in the sole opinion of the Company, desirable to ensure compliance with Section 4.3.


6

Issuance of Shares

3.2        The issuance of the Shares will be made by the Company as soon as reasonably possible following the Filing Date. In no event will the issuance be made later than December 31 of the first calendar year commencing after the Eligible Person has Terminated Service. Fractional Shares may not be issued, and where an Eligible Person would be entitled to receive a fractional Share in respect of any fractional Deferred Share Unit, the Company will pay to such Eligible Person, in lieu of such fractional Share, cash equal to its Fair Market Value, calculated as at the Filing Date.

3.3        Notwithstanding the foregoing provisions of Section 3.1 and Section 3.2, if an Eligible Person is a US Taxpayer, then the following rules shall apply relating to the redemption of Deferred Share Units and issuance of Shares:

  (a)

Deferred Share Units which become redeemable under Section 3.1 shall be redeemed only if the event giving rise to Terminated Service is a Separation from Service; and

     
  (b)

the redemption date shall be any date determined by the Company (and not the US Taxpayer) to occur as soon as reasonably possible (but not later than two months) after the Separation from Service, without a notice of filing required by the Eligible Person, except that if the US Taxpayer is determined to be a Specified Employee, the redemption date shall be the first day of the seventh month after the Separation from Service of the US Taxpayer.

Death

3.4        In the event of the death of an Eligible Person, the Company will, within two months of the Eligible Person's death, pay cash equal to the Fair Market Value of the Shares which would be deliverable to the Eligible Person if the Eligible Person had Terminated Service in respect of the Deferred Share Units credited to the deceased Eligible Person's account (net of any Applicable Withholding Tax) to or for the benefit of the legal representative of the Eligible Person. The Fair Market Value will be calculated on the date of death of the Eligible Person.

Applicable Withholding Tax

3.5        The Company is authorized to deduct such taxes and other amounts as it may be required by law to withhold (" Applicable Withholding Tax "), in such manner as it determines, including, without limiting the generality of the foregoing, by delivering fewer Shares than an Eligible Person otherwise would have received. In addition to, or as an alternative to the foregoing, the Company may require Eligible Persons, as a condition precedent to the issuance and delivery of Shares otherwise to be delivered to them under this Plan, to deliver payment in full of the Applicable Withholding Tax to the Company or undertakings to, or indemnities in favour of, the Company respecting the payment by such Eligible Persons of applicable income or other taxes.


7

PART 4 - GENERAL

Non-Transferability

4.1        Deferred Share Units and all other rights, benefits or interests in this Plan are non-transferable and may not be pledged or assigned or encumbered in any way and are not subject to attachment or garnishment, except that if the Eligible Person dies, the legal representatives of the Eligible Person will be entitled to receive the amount of any payment otherwise payable to the Eligible Person hereunder in accordance with the provisions hereof.

No Right to Service

4.2        Neither participation in this Plan nor any action under this Plan will be construed to give any Eligible Person a right to be retained in the service of the Company.

Applicable Trading Policies

4.3        The Board and each Eligible Person will ensure that all actions taken and decisions made by the Board or the Eligible Person, as the case may be, pursuant to this Plan comply with any applicable securities laws and policies of the Company relating to insider trading or "blackout" periods.

Successors and Assigns

4.4        This Plan will enure to the benefit of and be binding upon the respective legal representatives of the Eligible Person.

Plan Amendment

4.5        The Board has the discretion to make amendments to this Plan and any Deferred Share Units granted hereunder which it may deem necessary, without having to obtain shareholder approval. Such changes may include, without limitation:

  (a)

minor changes of a “housekeeping” nature;

     
  (b)

amending the terms of Deferred Share Units under the Plan and method of determining the Awarded Amount and the number of Deferred Share Units that may be issued to an Eligible Person, and the assignability and effect of Terminated Service of an Eligible Person;

     
  (c)

changing the class of Eligible Persons; and

     
  (d)

changing the method and procedures to be followed with regard to the issuance of Deferred Share Units under the Plan.

4.6        Shareholder approval will be required in the case of: (i) any amendment to the amendment provisions of the Plan; (ii) any increase in the maximum number of Common Shares issuable under the Plan; and (iii) such other matters that may require shareholder approval under the rules and policies of the TSX.


8

Plan Termination

4.7        The Board may terminate this Plan at any time, but no termination will, without the consent of the Eligible Person or unless required by law, adversely affect the rights of an Eligible Person with respect to Deferred Share Units to which the Eligible Person is then entitled under this Plan. In no event will a termination of this Plan accelerate the time at which the Eligible Person would otherwise be entitled to receive any Shares or cash in respect of Deferred Share Units hereunder.

Governing Law

4.8        This Plan and all matters to which reference is made in this Plan will be governed by and construed in accordance with the laws of Ontario and the laws of Canada applicable therein.

Reorganization of the Company

4.9        The existence of this Plan or Deferred Share Units will not affect in any way the right or power of the Company or its shareholders to make or authorize any adjustment, recapitalization, reorganization or other change in the Company's capital structure or its business, or to create or issue any bonds, debentures, shares or other securities of the Company or to amend or modify the rights and conditions attaching thereto or to effect the dissolution or liquidation of the Company, or any amalgamation, combination, merger or consolidation involving the Company or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar nature or otherwise.

No Shareholder Rights

4.10      Deferred Share Units are not considered to be Shares or securities of the Company, and an Eligible Person whose account is credited with Deferred Share Units will not, as such, be entitled to exercise voting rights or any other rights attaching to the ownership of Shares of other securities of the Company, or be considered the owner of Shares by virtue of such crediting of Deferred Share Units.

No Other Benefit

4.11      No amount will be paid to, or in respect of, an Eligible Person under this Plan to compensate for a downward fluctuation in the price of a Share, nor will any other form of benefit be conferred upon, or in respect of, an Eligible Person for such purpose.

Unfunded Plan

4.12      For greater certainty, this Plan will be an unfunded plan, including for tax purposes. Any Eligible Person holding Deferred Share Units or related accruals under this Plan will have the status of a general unsecured creditor of the Company with respect to any relevant rights hereunder.



Exhibit 4.7

WARRANT INDENTURE

Providing for the Issue of Warrants

 

 

BETWEEN

 

 

STEM CELL THERAPEUTICS CORP.

 

 

AND

 

 

COMPUTERSHARE TRUST COMPANY OF CANADA

 

 

 

Dated as of March 15, 2013


Table of Contents

    Page
     
ARTICLE 1 - INTERPRETATION 2
     
      1.1 Definitions 2
      1.2 Gender and Number 6
      1.3 Interpretation not Affected by Headings, etc. 6
      1.4 Day not a Business Day 7
      1.5 Time of the Essence 7
      1.6 Currency 7
      1.7 Assignment 7
      1.8 Applicable Law and Jurisdiction 7
     
ARTICLE 2 - ISSUE OF WARRANTS 7
     
      2.1 Creation and Issue of Warrants 7
      2.2 Terms of the Warrants 7
      2.3 Warrantholder not a Shareholder 8
      2.4 Warrants to Rank Pari Passu 8
      2.5 Form of Warrants 8
      2.6 Execution of Warrant Certificates 8
      2.7 Certification by the Warrant Agent 9
      2.8 Issue in Substitution for Warrant Certificates Lost, etc. 9
      2.9 Exchange of Warrant Certificates 10
      2.10 Transfer and Ownership of Warrants 10
      2.11 Charges for Exchange or Transfer 12
      2.12 Cancellation of Surrendered Warrants 12
      2.13 Registration of Warrants 12
      2.14 CDS and Depository 13
      2.15 NCI Letter of Instruction 15
      2.16 Legends 15
     
ARTICLE 3 - EXERCISE OF WARRANTS 17
     
      3.1 Method of Exercise of Warrants 17
      3.2 Effect of Exercise of Warrants 20
      3.3 Partial Exercise of Warrants; Fractions 21
      3.4 Expiration of Warrants 21
      3.5 Accounting and Recording 21
      3.6 Securities Restrictions 22
      3.7 Prohibition on Exercise in the United States or by U.S. Persons; Exception 22
     
ARTICLE 4 - ADJUSTMENT OF NUMBER OF COMMON SHARES AND EXERCISE PRICE 23
     
      4.1 Adjustment of Number of Common Shares and Exercise Price 23


- ii -

      4.2 Entitlement to Shares on Exercise of Warrant 28
      4.3 No Adjustment for Certain Transactions 28
      4.4 Determination by Corporation’s Auditors 28
      4.5 Proceedings Prior to any Action Requiring Adjustment 28
      4.6 Certificate of Adjustment 28
      4.7 Notice of Special Matters 29
      4.8 No Action After Notice 29
      4.9 Other Action 29
      4.10 Protection of Warrant Agent 29
     
ARTICLE 5 - RIGHTS OF THE CORPORATION AND COVENANTS 30
     
      5.1 Optional Purchases by the Corporation 30
      5.2 General Covenants 30
      5.3 Warrant Agent’s Remuneration and Expenses 31
      5.4 Securities Qualification Requirements 32
      5.5 Performance of Covenants by Warrant Agent 32
      5.6 Enforceability of Warrants 32
     
ARTICLE 6 - ENFORCEMENT 32
     
      6.1 Suits by Warrantholders 32
      6.2 Immunity of Shareholders, etc. 33
      6.3 Limitation of Liability 33
      6.4 Waiver of Default 33
     
ARTICLE 7 – MEETINGS OF WARRANTHOLDERS 33
     
      7.1 Right to Convene Meetings 33
      7.2 Notice 34
      7.3 Chairman 34
      7.4 Quorum 34
      7.5 Power to Adjourn 35
      7.6 Show of Hands 35
      7.7 Poll and Voting 35
      7.8 Regulations 35
      7.9 Corporation and Warrant Agent May be Represented 36
      7.10 Powers Exercisable by Extraordinary Resolution 36
      7.11 Meaning of Extraordinary Resolution 37
      7.12 Powers Cumulative 38
      7.13 Minutes 38
      7.14 Instruments in Writing 39
      7.15 Binding Effect of Resolutions 39
      7.16 Holdings by Corporation Disregarded 39
     
ARTICLE 8 - SUPPLEMENTAL INDENTURES 39
     
      8.1 Provision for Supplemental Indentures for Certain Purposes 39


- iii -

      8.2 Successor Corporations 40
     
ARTICLE 9 - CONCERNING THE WARRANT AGENT 41
     
      9.1 Rights and Duties of Warrant Agent 41
      9.2 Evidence, Experts and Advisers 41
      9.3 Documents, Monies, etc. Held by Warrant Agent 42
      9.4 Actions by Warrant Agent to Protect Interest 43
      9.5 Warrant Agent Not Required to Give Security 43
      9.6 Protection of Warrant Agent 43
      9.7 Replacement of Warrant Agent; Successor by Merger 44
      9.8 Conflict of Interest 45
      9.9 Acceptance of Trust 45
      9.10 Warrant Agent Not to be Appointed Receiver 45
      9.11 Warrant Agent Not Required to Give Notice of Default 45
      9.12 Force Majeure 46
      9.13 Third Parties 46
      9.14 Anti-Money Laundering 46
      9.15 Privacy 46
     
ARTICLE 10 - GENERAL 47
     
      10.1 Notice to the Corporation and the Warrant Agent 47
      10.2 Notice to Warrantholders 48
      10.3 Ownership of Warrants 49
      10.4 Evidence of Ownership 49
      10.5 Counterparts 49
      10.6 Satisfaction and Discharge of Indenture 50
      10.7 Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders 50
      10.8 Common Shares or Warrants Owned by the Corporation or its Subsidiaries - Certificate to be Provided 50

SCHEDULE A FORM OF WARRANT CERTIFICATE A-1
APPENDIX 1 NOTICE OF EXERCISE 1-1
APPENDIX 2 FORM OF TRANSFER 2-1
SCHEDULE B FORM OF DECLARATION FOR REMOVAL OF LEGEND B-1


THIS WARRANT INDENTURE is made as of March 15, 2013

BETWEEN:

STEM CELL THERAPEUTICS CORP. , a corporation incorporated under the laws of the Province of Alberta, having its head office currently in the City of Toronto, in the Province of Ontario;

   
 

(the “ Corporation ”);

   
AND:

COMPUTERSHARE TRUST COMPANY OF CANADA , a trust company incorporated under the laws of Canada and authorized to carry on business in all provinces of Canada;

   
 

(the “ Warrant Agent ”).

WHEREAS:

A.

Under a prospectus supplement, dated as of March 11, 2013, qualifying their distribution, the Corporation may issue a maximum of 14,000,000 Units (as defined below);

   
B.

Additionally the Corporation also intends to complete a non-brokered private placement (“ Concurrent Private Placemen t”) to issue up to 2,000,000 Units for an aggregate of 16,000,000 Units;

   
C.

Each Unit under each of the prospectus supplement or under the Concurrent Private Placement will entitle its holder to receive one (1) Common Share (as defined below) and one (1) common share purchase warrant (each common share purchase warrant referred to herein as a “ Warrant ”);

   
D.

Each whole Warrant will, subject to adjustment, entitle the holder thereof to acquire one (1) Common Share upon payment of the Exercise Price (as defined below) and subject to the terms and conditions set forth herein;

   
E.

In order to satisfy the exercise of the rights attached to each Warrant, the Corporation has agreed to reserve for issuance one (1) Common Share for each whole Warrant outstanding;

   
F.

All acts and deeds necessary have been done and performed to make the Warrants, when created and issued as provided in this Indenture, legal, valid and binding upon the Corporation with the benefits and subject to the terms of this Indenture; and

NOW THEREFORE , in consideration of the premises and mutual covenants hereinafter contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Corporation hereby appoints the Warrant Agent to hold the rights, interests and benefits contained herein for and on behalf of those persons who from time to time become the holders of Warrants issued pursuant to this Indenture and the parties hereto agree as set forth below:


- 2 -

ARTICLE 1 - INTERPRETATION

1.1        Definitions

In this Indenture, including the recitals and schedules hereto, and in all indentures supplemental hereto, unless there is something in the subject matter or context inconsistent therewith:

  1.1.1

Accredited Investor ” means an “accredited investor” as defined in Rule 501(a) of Regulation D, that satisfies the requirements of Rule 501(a);

     
  1.1.2

Adjustment Period ” means the period from and including the Effective Date up to and including the Expiry Time;

     
  1.1.3

Agent ” means Euro Pacific Canada Inc.

     
  1.1.4

Applicable Legislation ” means the provisions of the Business Corporations Act (Alberta), as from time to time amended, and any statute of Canada or a province thereof, and the regulations under any such named or other statute, relating to trust indentures or to the rights, duties and obligations of trustees and of corporations under trust indentures, to the extent that such provisions are at the time in force and applicable to this Indenture;

     
  1.1.5

Beneficial Owner ” means a person that has a beneficial interest in a Warrant that is represented by a Global Certificate;

     
  1.1.6

Book Based System ” means the book based securities transfer system administered by CDS in accordance with its operating procedure from time to time;

     
  1.1.7

Book Entry Only Participant ” means an institution that participates directly or indirectly in the Depository’s book entry registration system for the Warrants;

     
  1.1.8

Business Day ” means a day which is not Saturday or Sunday or a legal holiday in the city of Calgary, Alberta or Toronto, Ontario;

     
  1.1.9

CDS ” means CDS Clearing and Depository Services Inc. and its successors in interest;

     
  1.1.10

CDS Participant ” means a participant in the Book Based System or its nominees;

     
  1.1.11

Closing Date ” means the closing date of the Offering;

     
  1.1.12

Common Shares ” means, subject to Article 4, fully paid and non-assessable common shares of the share capital of the Corporation as presently constituted;



- 3 -

  1.1.13

Corporation ” means Stem Cell Therapeutics Corp., a corporation incorporated under the Business Corporations Act (Alberta) and its lawful successors from time to time;

     
  1.1.14

Corporation’s Auditors ” means Ernst & Young LLP or any other firm of chartered accountants duly appointed as auditors of the Corporation;

     
  1.1.15

Counsel ” means a barrister or solicitor or a firm of barristers and solicitors retained by the Warrant Agent or retained by the Corporation and acceptable to the Warrant Agent;

     
  1.1.16

Concurrent Private Placemen t” means the non-brokered private placement for aggregate gross proceeds of up to $500,000 of Units comprising up to 2,000,000 Warrants at the same price and terms as the Units;

     
  1.1.17

Current Market Price ” of the Common Shares at any date means the volume weighted average of the trading price of the Common Shares for the twenty (20) consecutive Trading Days immediately preceding such date on the principal stock exchange on which the Common Shares are listed and as selected by the directors, or, if such Common Shares are not listed on any stock exchange, then on such over the counter market as may be selected for such purpose by the directors;

     
  1.1.18

Depository ” means CDS or a successor depository or any other depository offering a similar Book Based System for recording beneficial interest in the Warrants which the Corporation, acting reasonably, may designate;

     
  1.1.19

Director ” means a director of the Corporation for the time being and, unless otherwise specified herein, reference to action “ by the directors ” means action by the directors of the Corporation as a board or, whenever duly empowered, action by any committee of such board;

     
  1.1.20

Dividends Paid in the Ordinary Course ” means cash dividends declared payable on the Common Shares in any fiscal year of the Corporation to the extent that such cash dividends do not exceed, in the aggregate, greater than: (i) twenty percent (20%) of the retained earnings of the Corporation as at the end of its immediately preceding fiscal year; and (ii) forty percent (40%) of the aggregate consolidated net income of the Corporation, determined before computation of extraordinary items, for its immediately preceding fiscal year;

     
  1.1.21

Effective Date ” means the date of this Indenture;

     
  1.1.22

Exercise Date ” means, with respect to any Warrant, the date on which the Warrant Certificate representing such Warrant is surrendered for exercise together with full payment of the Exercise Price in accordance with Section 3.1;

     
  1.1.23

Exercise Price ” at any time means, the price at which one (1) Common Share may be purchased by the exercise of one Warrant and which is $0.40, subject to adjustment in accordance with the provisions of Article 4, in which case it shall mean the adjusted price in effect at such time;



- 4 -

  1.1.24

Expiry Date ” means March 15, 2018;

     
  1.1.25

Expiry Time ” means 5:00 p.m. (Toronto time) on the Expiry Date;

     
  1.1.26

Extraordinary Resolution ” has the meaning set forth in Section 7.11;

     
  1.1.27

Global Certificate ” means a certificate that is issued to and registered in the name of CDS;

     
  1.1.28

Internal Procedures ” means in respect of the making of any one or more entries to, changes in or deletions of any one or more entries in the register of Warrantholders at any time (including without limitation, original issuance or registration of transfer of ownership), the minimum number of the Warrant Agent’s internal procedures customary at such time for the entry, change or deletion effected under the operating procedures of the Warrant Agent;

     
  1.1.29

Issue Date ” means the date(s) upon which the Warrants are issued;

     
  1.1.30

NCI Letter of Instruction ” means the Non Certificated Inventory system letter of instruction provided by CDS to the Warrant Agent in connection with the conversion of Warrants;

     
  1.1.31

Offering ” means the offering by the Corporation of up to 14,000,000 Units pursuant to the agency agreement dated March 11, 2013 between the Corporation and the Agent and the Concurrent Private Placement to issue up to 2,000,000 Units for an aggregate of 16,000,000 Units;

     
  1.1.32

Person ” means an individual, body corporate, partnership, trust, trustee, executor, administrator, legal representative or any unincorporated organization;

     
  1.1.33

Qualifying Provinces ” means the provinces of Ontario, Nova Scotia, Manitoba, Alberta and British Columbia;

     
  1.1.34

Regulation D ” means Regulation D adopted by the SEC under the U.S. Securities Act;

     
  1.1.35

Regulation S ” means Regulation S adopted by the SEC under the U.S. Securities Act;

     
  1.1.36

SEC ” means the United States Securities and Exchange Commission;

     
  1.1.37

Shareholder ” means a holder of record of one or more Common Shares;

     
  1.1.38

Subsidiary of the Corporation ” or “ Subsidiary ” means any corporation of which more than fifty percent (50%) of the outstanding Voting Shares are owned, directly or indirectly, by or for the Corporation, provided that the ownership of such shares confers the right to elect at least a majority of the board of directors of such corporation and includes any corporation in like relation to a subsidiary;



- 5 -

  1.1.39

successor corporation ” has the meaning set forth in Section 8.2;

     
  1.1.40

this Warrant Indenture ”, “ this Indenture ”, “ herein ”, “ hereby ”, “ hereof ” and similar expressions mean and refer to this Indenture and any indenture, deed or instrument supplemental hereto; and the expressions “Article”, “Section”, “subsection” and “paragraph” followed by a number, letter or both mean and refer to the specified Article, Section, subsection or paragraph of this Indenture;

     
  1.1.41

Trading Day ” means, with respect to a stock exchange, a day on which such exchange is open for the transaction of business;

     
  1.1.42

Uncertificated Warrant ” means any Warrant which is not represented by a Warrant Certificate;

     
  1.1.43

Unit ” means each unit to be issued under the prospectus supplement dated March 11, 2013 and pursuant to the Concurrent Private Placement consisting of one (1) Common Share and one (1) Warrant;

     
  1.1.44

United States ” means the United States of America, its territories and possessions, any state of the United States, and the District of Columbia collectively;

     
  1.1.45

U.S. Person ” means “U.S. person” as that term is defined in Rule 902 of Regulation S under the U.S. Securities Act;

     
  1.1.46

U.S. Purchaser ” means any holder of Warrants originally purchased from the Corporation by a person who is a U.S. Person, a person in the United States or a person that purchased the Warrants for the account or benefit of a U.S. Person or a person in the United States;

     
  1.1.47

U.S. Securities Act ” means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder;

     
  1.1.48

U.S. Securities Exchange Act ” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder;

     
  1.1.49

Voting Shares ” means shares of the capital stock of any class of any corporation carrying voting rights under all circumstances, provided that, for the purposes of such definition, shares which only carry the right to vote conditionally on the happening of an event shall not be considered Voting Shares, whether or not such event shall have occurred, nor shall any shares be deemed to cease to be Voting Shares solely by reason of a right to vote accruing to shares of another class or classes by reason of the happening of any such event;



- 6 -

  1.1.50

Warrant Agency ” means one of the principal offices of the Warrant Agent in the city of Calgary and in the city of Toronto or such other place(s) as may be designated in accordance with subsection 3.1.3;

     
  1.1.51

Warrant Agent ” means Computershare Trust Company of Canada in its capacity as Warrant agent, or its successors from time to time in the trust hereby created;

     
  1.1.52

Warrant Certificate ” means a certificate, substantially in the form set forth in Schedule “ A ” hereto, issued on or after the Issue Date to evidence the Warrants;

     
  1.1.53

Warrant Exercise Form ” means an exercise form, substantially in the form set forth in Schedule “ A ” hereto, delivered by a Warrantholder to the Warrant Agency at any time after the Issue Date and prior to the Expiry Time;

     
  1.1.54

Warrantholders ”, or “ holders ” without reference to Common Shares, means the persons who are registered owners of Warrants;

     
  1.1.55

Warrantholders’ Request ” means an instrument signed in one or more counterparts by Warrantholders entitled to acquire in the aggregate not less than ten percent (10%) of the aggregate number of Common Shares which could be acquired pursuant to all Warrants then unexercised and outstanding, requesting the Warrant Agent to take some action or proceeding specified therein;

     
  1.1.56

Warrants ” means the Warrants created by and authorized by and issuable under this Indenture to be issued and countersigned hereunder in certificated form and/or held through the book entry registration on a no certificate issued basis, whether by way of Warrant Certificate or Uncertificated Warrant; and

     
  1.1.57

written order of the Corporation ”, “ written request of the Corporation ”, “ written consent of the Corporation ” and “ certificate of the Corporation ” mean, respectively, a written order, request, consent and certificate signed in the name of the Corporation by its Chairman, Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, President, Secretary or any Vice President, or a liaison acting in any such capacity for the Corporation and may consist of one or more instruments so executed.

1.2       Gender and Number

Unless herein otherwise expressly provided or unless the context otherwise requires, words importing the singular include the plural and vice versa and words importing gender include all genders.

1.3        Interpretation not Affected by Headings, etc.

The division of this Indenture into Articles, Sections and subsections, the provision of a table of contents and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation of this Indenture,


- 7 -

1.4       Day not a Business Day

In the event that any day on or before which any action is required to be taken hereunder is not a Business Day, then such action shall be required to be taken at or before the requisite time on the next succeeding day that is a Business Day.

1.5        Time of the Essence

Time shall be of the essence of this Indenture.

1.6       Currency

Except as otherwise expressly provided, all dollar amounts herein are expressed in Canadian dollars.

1.7        Assignment

This Indenture may not be assigned by either party hereto without the consent in writing of the other party. This Indenture shall enure to and bind the parties and their lawful successors and permitted assigns.

1.8       Applicable Law and Jurisdiction

This Indenture and the Warrant Certificates and all documents relating thereto, which by common accord have been and will be drafted in English, shall be construed in accordance with the laws of the Province of Alberta and the federal laws applicable therein and shall be treated in all respects as Alberta contracts.

Each party to this Indenture, by its execution hereof, hereby irrevocably submits to the exclusive jurisdiction of the Courts of the Province of Alberta for the purpose of any action, claim, cause of action or suit (in contract, delict or otherwise), inquiry, proceeding or investigation arising out of or based upon this Indenture, Warrant Certificates or all documents relating thereto.

ARTICLE 2 - ISSUE OF WARRANTS

2.1       Creation and Issue of Warrants

Up to 16,000,000 Warrants in one or more closings, are hereby authorized, all in accordance with the terms and conditions hereof. The Warrant Certificates shall be certified and delivered by the Warrant Agent to such persons as the Corporation may direct by written order of the Corporation.

2.2        Terms of the Warrants

  2.2.1

Each whole Warrant shall entitle the holder thereof, upon exercise, together with the payment of the Exercise Price, to acquire one (1) Common Share, subject to adjustment in accordance with Article 4, at any time after the Issue Date until the Expiry Time.



- 8 -

  2.2.2

No fractional Warrants shall be issued or otherwise provided for hereunder. Any fractional entitlements shall be rounded down to the nearest whole number and a purchaser or holder of any Warrant shall not be entitled to any cash or other consideration in lieu of any fractional interest in a Warrant or claim thereto.

     
  2.2.3

Each Warrant shall entitle the holder thereof to such other rights and privileges as are set forth in this Indenture.

     
  2.2.4

The number of Common Shares which may be purchased pursuant to the Warrants and the Exercise Price therefor shall be adjusted in the events and in the manner specified in Article 4.

     
  2.2.5

Upon the exercise of the Warrants, the Corporation shall issue Common Shares required to fulfill its obligation to sell Common Shares upon the exercise of the Warrants.

2.3        Warrantholder not a Shareholder

Except as may be specifically provided herein, nothing in this Indenture or in the holding of a Warrant or Warrant Certificate or otherwise, shall, in itself, confer or be construed as conferring upon a Warrantholder any right or interest whatsoever as a Shareholder or as any other shareholder of the Corporation, including, but not limited to, the right to vote at, to receive notice of, or to attend, meetings of shareholders or any other proceedings of the Corporation, or the right to receive dividends and other distributions.

2.4       Warrants to Rank Pari Passu

All Warrants shall rank equally and without preference over each other, whatever may be the actual date of issue thereof.

2.5       Form of Warrants

The Warrants may be issued in both certificated and uncertificated form at the discretion of the Corporation and pursuant to the procedures in this Indenture. For the avoidance of doubt, each Warrant originally issued to a U.S. Purchaser shall be evidenced in certificated form. The Warrant Certificates in definitive form evidencing the Warrants authorized in Section 2.1 shall be issuable as fully registered (including all replacements issued in accordance with this Indenture) shall be substantially in the form set out in Schedule “A” hereto, shall be dated as of the Issue Date, shall bear such distinguishing letters and numbers as the Corporation may, with the approval of the Warrant Agent, prescribe, and shall be issuable in any denomination excluding fractions. All Warrants issued to CDS shall be evidenced by a book position on the register of Warrantholders to be maintained by the Warrant Agent in accordance with Section 2.13.

2.6        Execution of Warrant Certificates

The Warrant Certificates shall be signed by any one of the directors and officers of the Corporation and may, but need not be, under seal of the Corporation or a reproduction thereof.


- 9 -

The signatures of any such director or officer may be mechanically reproduced in facsimile and Warrant Certificates bearing such facsimile signatures shall be binding upon the Corporation as if they had been manually signed by such director or officer. Notwithstanding that any person whose manual or facsimile signature appears on any Warrant Certificate as a director or an officer may no longer hold office at the date of such Warrant Certificate or at the date of certification or delivery thereof, any Warrant Certificate signed as aforesaid shall, subject to Section 2.7, be valid and binding upon the Corporation and the holder thereof shall be entitled to the benefits of this Indenture.

2.7        Certification by the Warrant Agent

  2.7.1

No Warrant Certificate shall be issued or, if issued, shall be valid for any purpose or entitle the holder to the benefit hereof until it has been certified by manual signature by or on behalf of the Warrant Agent by its authorized signing officers substantially in the form of the Warrant Certificate, and such certification by the Warrant Agent upon any Warrant Certificate shall be conclusive evidence as against the Corporation that the Warrant Certificate so certified has been duly issued hereunder and that the holder is entitled to the benefits hereof.

     
  2.7.2

No Uncertificated Warrant shall be issued or, if issued, shall be valid for any purpose or entitle the holder to the benefit hereof until it has been certified by the Warrant Agent, once its Internal Procedures have been completed (whether upon original issuance, exchange, registration of transfer, partial payment, or otherwise) and the Corporation shall, and hereby acknowledges that it shall, thereupon be deemed to have duly and validly issued such Uncertificated Warrants under this Indenture. Such certification shall be conclusive evidence that such Uncertificated Warrant has been duly issued hereunder and that the holder or holders are entitled to the benefits of this Indenture. The register shall be final and conclusive evidence as to all matters relating to Uncertificated Warrants with respect to which this Indenture requires the Warrant Agent to maintain records or accounts. In case of differences between the register at any time and any other time, the register at the later time shall be controlling, absent manifest error, and such Uncertificated Warrants are binding on the Corporation.

     
  2.7.3

The certification of the Warrant Agent on Warrant Certificates and/or Uncertificated Warrants issued hereunder shall not be construed as a representation or warranty by the Warrant Agent as to the validity of this Indenture or the Warrant Certificates (except the due certification thereof) or as to the performance by the Corporation of its obligations under this Indenture, and the Warrant Agent shall in no respect be liable or answerable for the use made of the Warrant Certificates or any of them or of the consideration therefor except as otherwise specified herein.


2.8

Issue in Substitution for Warrant Certificates Lost, etc.

     
2.8.1

If any Warrant Certificate becomes mutilated or is lost, destroyed or stolen, the Corporation, subject to applicable law, shall issue and thereupon the Warrant



- 10 -

 

Agent shall certify and deliver, a new Warrant Certificate of like tenor as the one mutilated, lost, destroyed or stolen in exchange for and in place of and upon cancellation of such mutilated Warrant Certificate, or in lieu of and in substitution for such lost, destroyed or stolen Warrant Certificate, and the substituted Warrant Certificate shall be in a form approved by the Warrant Agent and the Warrants evidenced thereby shall be entitled to the benefits hereof and shall rank equally in accordance with its terms with all other Warrants issued or to be issued hereunder.

     
  2.8.2

The applicant for the issue of a new Warrant Certificate pursuant to this Section 2.8 shall bear the cost of the issue thereof and in case of loss, destruction or theft shall, as a condition precedent to the issuance thereof, furnish to the Corporation and to the Warrant Agent such evidence of ownership and of the loss, destruction or theft of the Warrant Certificate so lost, destroyed or stolen as shall be satisfactory to the Corporation and to the Warrant Agent, in their sole discretion, and such applicant may also be required to furnish an indemnity and surety bond in amount and form satisfactory to the Corporation and the Warrant Agent, in their sole discretion, and shall pay the reasonable charges of the Corporation and the Warrant Agent in connection therewith.

     
  2.8.3

Warrant Certificates may be replaced only at the Warrant Agency or at any other place that is designated by the Corporation with the approval of the Warrant Agent.


2.9

Exchange of Warrant Certificates

     
2.9.1

Any one or more Warrant Certificates representing any number of Warrants may, upon compliance with the reasonable requirements of the Warrant Agent (including compliance with applicable securities legislation), be exchanged for one or more other Warrant Certificates representing the same aggregate number of Warrants as represented by the Warrant Certificate or Warrant Certificates so exchanged.

     
2.9.2

Warrant Certificates may be exchanged only at the Warrant Agency or at any other place that is designated by the Corporation with the approval of the Warrant Agent. Any Warrant Certificate tendered for exchange shall be cancelled and surrendered by the Warrant Agency to the Warrant Agent.


2.10

Transfer and Ownership of Warrants

     
2.10.1

Subject to Section 2.14, the Warrants may only be transferred on the register kept by the Warrant Agent at the Warrant Agency by the holder or its legal representatives or its attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent upon surrendering to the Warrant Agent at the Warrant Agency the Warrant Certificates representing the Warrants to be transferred and upon compliance with: (i) the conditions herein; (ii) such reasonable requirements as the Warrant Agent may prescribe; and (iii) all applicable securities legislation and requirements of regulatory authorities; and such transfer shall be duly noted in such register by the Warrant Agent. Upon compliance with such requirements, the Warrant Agent shall issue to the transferee a Warrant Certificate representing the Warrants transferred.



- 11 -

  2.10.2

Subject to the provisions of this Indenture and applicable law, the Warrantholder shall be entitled to the rights and privileges attaching to the Warrants and the issue of Common Shares by the Corporation upon the exercise of Warrants in accordance with the terms and conditions herein contained shall discharge all responsibilities of the Corporation and the Warrant Agent with respect to such Warrants and neither the Corporation nor the Warrant Agent shall be bound to inquire into the title of any such holder.

     
  2.10.3

A Warrant shall be transferable by surrender of the Warrant Certificate relating thereto, accompanied by proper instruments of transfer in suitable form satisfactory to the Warrant Agent for transfer by delivery with the same effect as in the case of a negotiable instrument executed by the Warrantholder or his executors, administrators or other legal representatives or his or their attorney duly appointed by an instrument in form and execution satisfactory to the Warrant Agent; provided that no transfer of any Warrant will be valid unless duly entered on the transfer register referred to in subsection 2.10.1.

     
  2.10.4

A transferee of any Warrant will, after surrender to the Warrant Agent of the Warrant Certificate evidencing such Warrant as required by subsection 2.10.3 and upon compliance with all other conditions in respect thereof required by this Indenture or by law, be entitled to be entered on the transfer register and on the Warrant register as the owner of such Warrant, and the Warrant Agent shall issue to the transferee a Warrant Certificate evidencing the Warrants transferred.

     
  2.10.5

The Warrant Agent was informed by the Corporation that the Warrants and the Common Shares issuable upon exercise thereof have not been registered under the U.S. Securities Act, or the securities laws of any state of the United States, and may not be offered, sold or transferred in the United States, or to or for the account or benefit of, a U.S. Person, unless the Warrants and the Common Shares issuable upon exercise thereof have been registered under the U.S. Securities Act and the securities laws of all applicable states of the United States or an exemption from registration under the U.S. Securities Act and applicable state securities law is available and the holder of the Warrant has presented to the Corporation evidence of the availability of the exemption satisfactory to the Corporation.

     
  2.10.6

The Warrant Agent shall retain until the sixth anniversary of the termination of this Indenture all instruments of transfer of Warrants which are lodged for registration, including the details shown thereon of the persons by or through whom they were lodged, all cancelled Warrants and all other related documents.

     
  2.10.7

Notwithstanding any provision to the contrary contained in this Indenture, the Corporation is entitled to require, add or adopt certain conditions precedent to the transfer of Warrants to ensure compliance with all applicable securities legislation and requirements of regulatory authorities, and may direct the Warrant Agent to refuse to recognize any transfer, or enter the name of any transferee, of a Warrant on the transfer register if such transfer would constitute a violation of any applicable securities legislation or requirements of regulatory authorities or require the Corporation to qualify the Common Shares for distribution in any jurisdiction other than the Qualifying Provinces.



- 12 -

  2.10.8

To the extent not inconsistent with the terms of this Indenture, the provisions of the Business Corporations Act (Alberta) in respect of the transfer of securities, as amended from time to time, shall apply mutatis mutandis to the transfer of Warrants.

     
  2.10.9

Warrants bearing the legend set forth in Section 2.16 may not be transferred except pursuant to registration or compliance with exemptions therefrom under the U.S. Securities Act and all applicable state securities laws, and the Warrant Agent agrees not to register any transfer of the Warrants so legended unless, in addition to the other requirements set forth herein, the Warrantholder has executed and delivered to the Warrant Agent a declaration in the form attached as Schedule "B" hereto (or as the Corporation may otherwise prescribe) to the effect that the transfer is being made pursuant to Rule 904 of Regulation S under the U.S. Securities Act, and in such case the Warrant Certificate issued to the transferee shall not include the legend set forth in Section 2.16.

2.11      Charges for Exchange or Transfer

The transfer or the exchange of any Warrant Certificate or the issue of a new Warrant Certificate pursuant hereto shall be subject to the payment of a reasonable fee levied by the Warrant Agent in addition to the reimbursement of the Warrant Agent or the Corporation for any and all transfer, stamp or similar taxes or other governmental charges required to be paid, and such payment shall be made by the holder requesting a transfer or exchange as a condition precedent to such transfer or exchange.

2.12      Cancellation of Surrendered Warrants

All Warrant Certificates surrendered pursuant to Sections 2.8, 2.9, 2.10, 3.1, 3.3, 3.4or 5.1 shall be returned to the Warrant Agent for cancellation and, after the expiry of any period of retention prescribed by law, destroyed by the Warrant Agent.

2.13      Registration of Warrants

The Corporation hereby appoints the Warrant Agent as registrar and transfer agent of the Warrant. The Warrant Agent shall, at all times while any Warrants are outstanding, keep at the Warrant Agency: (i) a register of Warrantholders in which shall be entered in alphabetical order the names and addresses of the holders of Warrants and particulars of the Warrants held by them, and (ii) a register of transfers in which all transfers of Warrants and the date and other particulars of each transfer shall be entered. Branch registers shall also be kept at such other place or places, if any, as the Corporation, with the approval of the Warrant Agent, may designate. Such registers will at all reasonable times be open for inspection by the Corporation and/or any Warrantholder. The Warrant Agent will from time to time when requested in writing to do so by the Corporation or any Warrantholder, upon payment of the Warrant Agent’s reasonable charges, furnish a list of the names and addresses of Warrantholders showing the number of Warrants held by each such Warrantholder.


- 13 -

2.14      CDS and Depository

  2.14.1

The Corporation may elect to issue all or a portion of the Warrants in “ book entry form ”, such Warrants to be represented by a registered permanent Global Certificate. The Global Certificate shall be held by, or on behalf of, the Depository as custodian of the CDS Participants and shall be registered in the name of “CDS & CO.” or such other name as the Depository may use from time to time as its nominee for the purposes of the Book Based System. For the avoidance of doubt, any Warrants sold in the United States must be in the form of a definitive Certificate and will not be included in the Global Certificate unless ownership is transferred or exchanged to a holder that is outside of the United States.

     
  2.14.2

Any Global Certificate shall bear a legend in substantially the following form, subject to modification as required by the Depository:

     
 

“UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF CDS CLEARING AND DEPOSITORY SERVICES INC. (“CDS”) TO STEM CELL THERAPEUTICS CORP. (THE “ ISSUER ”) OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IN RESPECT THEREOF IS REGISTERED IN THE NAME OF CDS & CO., OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF CDS (AND ANY PAYMENT IS MADE TO CDS & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF CDS), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED HOLDER HEREOF, CDS & CO., HAS A PROPERTY INTEREST IN THE SECURITIES REPRESENTED BY THIS CERTIFICATE HEREIN AND IT IS A VIOLATION OF ITS RIGHTS FOR ANOTHER PERSON TO HOLD, TRANSFER OR DEAL WITH THIS CERTIFICATE.”

     
  2.14.3

Subject to Section 2.10, transfers and registrations to ownership in Warrants represented by the Global Certificate will only be made to another nominee of the Depository, and neither the Corporation nor the Warrant Agent shall be under any obligation to deliver to participants of the Depository, nor shall such participants have any right to require the delivery of a Warrant Certificate.

     
  2.14.4

Subject to Sections 2.9 and 2.10, in the event of a transfer or exchange of ownership, in compliance with applicable laws, of any Warrants, that are represented by a definitive Warrant Certificate, the definitive Warrant Certificate may be surrendered at the Depository for cancellation by the Warrant Agent and the registration of new beneficial interest in such Warrants may be represented by the Global Certificate, which shall be increased by the number of Warrants represented by the Warrant Certificate so surrendered.



- 14 -

  2.14.5

Unless the Book Based System is terminated or unless required to do so by applicable law, or unless otherwise requested and agreed to by the Corporation, owners of the beneficial interests in the Warrants represented by the Global Certificate, shall not receive Warrants registered in their names, shall not receive or Warrant Certificates in definitive form and shall not be considered registered owners or registered holders thereof under this Indenture or any supplemental agreement except in circumstances where CDS resigns or is removed from its responsibility and the Warrant Agent is unable or does not wish to locate a qualified successor. Beneficial interests in the Global Certificate will be represented only through the Book Based System. The Corporation and the Warrant Agent shall not have any responsibility or liability for any aspects of the records relating to or payments made by CDS, or its nominee, on account of the beneficial interests in the Warrants. Nothing herein shall prevent the Beneficial Owners from voting such Warrants.

     
  2.14.6

Notwithstanding anything herein to the contrary, neither the Corporation nor the Warrant Agent nor any agent thereof shall have any responsibility or liability for:


  (a)

the electronic records maintained by the Depository relating to any ownership interests or any other interests in the Warrants or the depository system maintained by the Depository, or payments made on account of any ownership interest or any other interest of any person in any Warrant represented by an electronic position in the book entry registration system (other than the Depository or its nominee);

     
  (b)

maintaining, supervising or reviewing any records of the Depository or any Book Entry Only Participant relating to any such interest; or

     
  (c)

any advice or representation made or given by the Depository or those contained herein that relate to the rules and regulations of the Depository or any action to be taken by the Depository on its own direction or at the direction of any Book Entry Only Participant.


  2.14.7

All references herein to actions by, notices given or payments made to Warrantholders shall, where Warrants are held through CDS, refer to actions taken by, or notices given or payments made to, CDS upon instruction from the CDS Participants in accordance with its rules and procedures. For the purposes of any provision hereof requiring or permitting actions with the consent of or at the direction of Warrantholders evidencing a specified percentage of the aggregate Warrants outstanding, such direction or consent may be given by holders of Warrants acting through CDS and the CDS Participants owning Warrants evidencing the requisite percentage of the Warrants. The rights of a Warrantholder whose Warrants are held through CDS shall be exercised only through CDS and the CDS Participants and shall be limited to those established by law and agreements between such holders and CDS and the CDS Participants upon instructions from the CDS Participants. Each of the Warrant Agent and the Corporation may deal with CDS for all purposes (including the making of payments) as the authorized representative of the respective Warrantholder and such dealing with CDS shall constitute satisfaction or performance, as applicable, of their respective obligations hereunder.



- 15 -

  2.14.8

For so long as Warrants are held through CDS, if any notice or other communication is required to be given to Warrantholders, the Warrant Agent and or the Corporation will give such notices and communications to CDS.

     
  2.14.9

If CDS resigns or is removed from its responsibility as depository and the Warrant Agent is unable or does not wish to locate a qualified successor, CDS shall surrender the Global Certificate to the Warrant Agent with instructions for registration of Warrants in the name and in the amount specified by CDS and the Corporation shall issue, and the Warrant Agent shall certify and deliver, the aggregate number of Warrants then outstanding in the form of definitive Warrant Certificates representing such Warrants.

2.15      NCI Letter of Instruction

Notwithstanding anything to the contrary set out in this Indenture, all physical Warrant Certificates issued to CDS may be surrendered to the Warrant Agent for an electronic position on the register of Warrantholders to be maintained by the Warrant Agent in accordance with this Indenture. All Warrants maintained in such electronic position will entitle the registered holders thereof to the same benefits as those registered holders who hold Warrants in physical certificated form and this Indenture and the provisions contained herein will apply, mutatis mutandis , to such Warrants held in such electronic position. It is understood and agreed by the parties that, unless the Warrant Agent is otherwise in a position to perform electronic exercises, in every instance where Warrants held in an electronic position through CDS are to be exercised in whole or in part, it shall be sufficient for the Warrant Agent to exercise such Warrants upon receiving either the attached exercise form executed by CDS or a NCI Letter of Instruction in a form agreed upon by the Warrant Agent and CDS, or such other form that they may be agreed to by the Warrant Agent and CDS from time to time.

2.16      Legends

  2.16.1

The Warrant Agent acknowledges and understands that the Private Placement Warrants issued hereunder and the Common Shares issuable upon exercise of a Private Placement Warrant have been issued in Canada pursuant to applicable exemptions from securities laws. The Warrant Agent further understands and acknowledges that upon the original issuance thereof, and until such time as the same is no longer required under applicable requirements of Canadian securities laws, certificates representing the Private Placement Warrants issued hereunder  and all certificates issued in exchange therefor or in substitution thereof, shall be overprinted with the following legend:



- 16 -

“UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE JULY [16] , 2013.”

  2.16.2

The Warrant Agent acknowledges and understands that the Warrants issued hereunder and the Common Shares issuable upon exercise of a Warrant have not been and will not be registered under the U.S. Securities Act or any applicable U.S. state securities laws. The Warrant Agent further understands and acknowledges that upon the original issuance thereof, and until such time as the same is no longer required under applicable requirements of the U.S. Securities Act or applicable U.S. state securities laws, certificates representing the Warrants issued hereunder originally issued to a U.S. Purchaser, and all certificates issued in exchange therefor or in substitution thereof, shall be overprinted with the following legend:

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ U.S. SECURITIES ACT ”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THE HOLDER HEREOF, BY PURCHASING THE SECURITIES REPRESENTED HEREBY, AGREES FOR THE BENEFIT OF STEM CELL THERAPEUTICS CORP. AND ITS SUCCESSORS (THE “ CORPORATION ”) THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH LOCAL LAWS AND REGULATIONS, (C) WITHIN THE UNITED STATES PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY (I) RULE 144A OR (II) RULE 144 THEREUNDER, IF APPLICABLE, AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) WITHIN THE UNITED STATES, IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS GOVERNING THE OFFER AND SALE OF SECURITIES, AND IN THE CASE OF TRANSFERS PURSUANT TO (C)(II) OR (D) ABOVE, THE HOLDER HEREOF HAS, PRIOR TO SUCH TRANSFER, FURNISHED TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE CORPORATION TO SUCH EFFECT.

DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE ‘GOOD DELIVERY’ IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.”

provided , that if the Warrants are being sold in compliance with the requirements of Rule 904 of Regulation S and in compliance with local laws and regulations, the legend may be removed by providing to the Warrant Agent: (i) a declaration in the form attached hereto as Schedule “B” (or as the Corporation may prescribe from time to time) and (ii) if required by the Warrant Agent, an opinion of counsel, of recognized standing reasonably satisfactory to the Corporation, or other evidence reasonably satisfactory to the Corporation, that the proposed transfer may be effected without registration under the U.S. Securities Act.


- 17 -

The Warrant Certificates, and all certificates issued in exchange therefore or in substitution thereof, shall bear, in addition to the legends above, the following legend:

THIS WARRANT AND THE SECURITIES DELIVERABLE UPON EXERCISE HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ U.S. SECURITIES ACT ”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THIS WARRANT MAY NOT BE EXERCISED IN THE UNITED STATES OR BY OR ON BEHALF OF, OR FOR THE ACCOUNT OR BENEFIT OF, A U.S. PERSON UNLESS THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH STATE OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS IS AVAILABLE. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE U.S. SECURITIES ACT.

ARTICLE 3 - EXERCISE OF WARRANTS

3.1

Method of Exercise of Warrants

     
3.1.1

The holder of any Warrant may exercise the right conferred on such holder to acquire Common Shares by surrendering, after the Issue Date and prior to the Expiry Time, to the Warrant Agency, (i) the Warrant Certificate representing such Warrant, with a duly completed and executed Warrant Exercise Form, (ii) together with a certified cheque, money order or bank draft, in lawful money of Canada payable to or to the order of the Corporation at par in the city where the Warrant Agency is located in an amount equal to the Exercise Price multiplied by the number of Common Shares subscribed for. In accordance with Section 2.14, if Warrants are exercised through CDS, the payment of such exercise will be done electronically by CDS to the Warrant Agent. The Warrant Agent will, within five (5) days, send such payment to the Corporation.

     

A Warrant Certificate with the duly completed and executed Warrant Exercise Form referred to in this subsection 3.1.1 shall be deemed to be surrendered only upon personal delivery thereof or, if sent by mail or other means of transmission, upon actual receipt thereof at, in each case, the Warrant Agency, provided that such Warrant Certificate is accompanied by the requisite certified cheque, bank draft or money order in the amount of the aggregate Exercise Price for the Warrants represented thereby that are being exercised.

     
3.1.2

Any Warrant Exercise Form referred to in subsection 3.1.1 shall be signed by the Warrantholder and shall specify:



- 18 -

  (a)

the number of Common Shares which the holder wishes to acquire (being not more than those which the holder is entitled to acquire pursuant to the Warrant Certificate(s) surrendered);

     
  (b)

the person or persons in whose name or names such Common Shares are to be issued;

     
  (c)

the address or addresses of such person or persons;

     
  (d)

if an individual, the social insurance number of such person or persons; and

     
  (e)

the number of Common Shares to be issued to each such person if more than one is so specified.


 

If any of the Common Shares subscribed for are to be issued and registered in the name or names of a person or persons other than the Warrantholder, the Warrantholder shall pay to the Corporation or the Warrant Agency on behalf of the Corporation, all applicable transfer or similar taxes and the Corporation shall not be required to issue or deliver certificates evidencing Common Shares unless or until such Warrantholder shall have paid to the Corporation, or the Warrant Agency on behalf of the Corporation, the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid or that no tax is due.

     
  3.1.3

In connection with the exchange of Warrant Certificates and exercise of Warrants and compliance with such other terms and conditions hereof as may be required, the Corporation has appointed the principal offices of the Warrant Agent in Toronto as the Warrant Agency at which Warrant Certificates may be surrendered for exchange, transfer or repurchase or at which Warrants may be exercised and the Warrant Agent has accepted such appointment. The Corporation may from time to time designate alternate or additional places as a Warrant Agency upon notice to and consent of the Warrant Agent of any change of any Warrant Agency. The Corporation shall give notice to Warrantholders of any change of a Warrant Agency.

     
  3.1.4

Subject to and upon compliance with the terms of Article 3, a beneficial holder of Uncertificated Warrants evidenced by a security entitlement in respect of Warrants in the book entry registration system may exercise the right of purchase by causing a Book Entry Only Participant to deliver to the Depository on behalf of the entitlement holder, notice of the owner’s intention to exercise the Warrants in a manner acceptable to the Depository. Forthwith upon receipt by the Depository of such notice, as well as payment for the Exercise Price, the Depository shall deliver to the Warrant Agent an Letter of Instruction confirming its intention to exercise Warrants in a manner acceptable to the Warrant Agent, including by electronic means through the book entry registration system.



- 19 -

  3.1.5

Payment representing the aggregate Exercise Price must be provided to the appropriate office of the Book Entry Only Participant in a manner acceptable to it. A notice in form acceptable to the Book Entry Only Participant and payment from such beneficial holder should be provided to the Book Entry Only Participant sufficiently in advance so as to permit the Book Entry Only Participant to deliver notice and payment to the Depository and for the Depository in turn to deliver notice and payment to the Warrant Agent prior to the Expiry Time. The Depository will initiate the exercise by way of the Letter of Instruction and will forward the aggregate Exercise Price electronically to the Warrant Agent and the Warrant Agent will execute the exercise by issuing to the Depository through the book entry registration system the Common Shares to which the exercising Warrantholder is entitled pursuant to the exercise. Any expense associated with the exercise process will be for the account of the entitlement holder exercising the Warrants and/or the Book Entry Only Participant exercising the Warrants on its behalf.

     
  3.1.6

By causing a Book Entry Only Participant to deliver notice to the Depository, a Warrantholder shall be deemed to have irrevocably surrendered his or her Warrants so exercised and appointed such Book Entry Only Participant to act as his or her exclusive settlement agent with respect to the exercise and the receipt of Shares in connection with the obligations arising from such exercise.

     
  3.1.7

Any notice which the Depository determines to be incomplete, not in proper form, or not duly executed shall for all purposes be void and of no effect and the exercise to which it relates shall be considered for all purposes not to have been exercised thereby. A failure by a Book Entry Only Participant to exercise or to give effect to the settlement thereof in accordance with the Warrant holder’s instructions will not give rise to any obligations or liability on the part of the Corporation or Warrant Agent to the Book Entry Only Participant or the Warrantholder.

     
  3.1.8

Any exercise form or other Letter of Instruction referred to in Article 3 shall be signed by the registered Warrantholder, or its executors or administrators or other legal representatives or an attorney of the registered Warrantholder, duly appointed by an instrument in writing satisfactory to the Warrant Agent but such exercise form need not be executed by the Depository.

     
  3.1.9

Any exercise referred to in Section 3.1 shall require that the entire Exercise Price for Common Shares subscribed must be paid at the time of subscription and such Exercise Price and original exercise form or other Letter of Instruction executed by the registered Warrantholder or the Depository must be received by the Warrant Agent prior to the Warrant Expiry Time.

     
  3.1.10

A beneficial owner of Warrants issued in non-certificated form who desires to exercise his or her Warrants must do so by causing a CDS participant to deliver to the Depository on behalf of the entitlement holder, notice of the owner's intention to exercise Warrants in a manner acceptable to the Depository. Forthwith upon receipt by the Depository of such notice, as well as payment for the Exercise Price, the Depository shall deliver to the Warrant Agent confirmation of its intention to exercise Warrants in a manner acceptable to the Warrant Agent, including by electronic means through the book based registration system. An electronic exercise of the Warrants initiated by the CDS participant through the book based registration system shall constitute a representation to both the Company and the Warrant Agent that the beneficial owner at the time of exercise of such Warrants (i) is not in the United States; (ii) is not a U.S. Person and is not exercising such Warrants on behalf of a U.S. Person or a Person in the United States; and (iii) did not execute or deliver the notice of the owner's intention to exercise such Warrants in the United States. If the Participant is not able to make or deliver the foregoing representation by initiating the electronic exercise of the Warrants, then such Warrants shall be removed from the book based registration system and an individually registered Warrant Certificate shall be issued to such beneficial owner or CDS participant and the exercise procedures set forth in Section 3.1 shall be followed. Any expense associated with the preparation and delivery of Warrant Certificates and/or Warrant subscription forms will be for the account of the beneficial owner exercising such Warrants.



- 20 -

  3.1.11

It is understood and agreed by the parties hereto that, unless the Warrant Agent is otherwise in a position to perform electronic conversions, in every instance where Warrants held in an electronic position through the Depository are to be converted, in whole or in part, such Warrants being converted shalt not be certificated, and it shall be sufficient for the Warrant Agent to convert such Warrants upon receiving either the attached exercise form executed by the Depository or an NCI Letter of Instruction in a form agreed upon by the Warrant Agent and the Depository, or such other form that they may require from time to time along with a certified cheque, bank draft or money order in lawful money of Canada payable to or to the order of the Company at par in Calgary, Alberta in an amount equal to the Exercise Price multiplied by the number of Shares being purchased.


3.2

Effect of Exercise of Warrants

     
3.2.1

Upon the exercise of Warrants pursuant to Section 3.1 and subject to Section 3.3, the Common Shares to be issued pursuant to the Warrants exercised shall be deemed to have been issued and the person or persons to whom such Common Shares are to be issued and registered shall be deemed to have become the holder or holders of record of such Common Shares on the Exercise Date unless the transfer registers of the Corporation shall be closed on such date, in which case the Common Shares subscribed for shall be deemed to have been issued and such person or persons deemed to have become the holder or holders of record of such Common Shares, on the date on which such transfer registers are reopened. It is hereby understood that in order for persons to whom Common Shares are issued to become holders of Common Shares on record on the Exercise Date, beneficial holders must commence the exercise process sufficiently in advance so that the Warrant Agent is in receipt of all items of exercise at least one (1) Business Day prior to such Exercise Date.



- 21 -

  3.2.2

Within five (5) Business Days after the Exercise Date with respect to a Warrant, the Corporation shall (i) cause to be mailed to the person or persons in whose name or names such Warrant is registered or, (ii) if so specified in writing by the holder, cause to be delivered to such person or persons at the Warrant Agency where the Warrant Certificate was surrendered, a certificate or certificates for the appropriate number of Common Shares subscribed for or any other appropriate evidence of the issuance of Common Shares to such person or persons in respect of Common Shares issued under the book entry registration system.


3.3

Partial Exercise of Warrants; Fractions

     
3.3.1

The holder of any Warrants may exercise his right to acquire a number of Common Shares less than the aggregate number which the holder is entitled to acquire pursuant to the surrendered Warrant Certificate(s). In the event of any exercise of a number of Warrants less than the number which the holder is entitled to exercise, the holder of the Warrants upon such exercise shall, in addition, be entitled to receive, without charge therefor, a new Warrant Certificate(s) in respect of the balance of the Warrants represented by the surrendered Warrant Certificate(s) and which were not then exercised.

     
3.3.2

Notwithstanding anything herein contained, including any adjustment provided for in Article 4, neither the Corporation nor the Warrant Agent shall be required, upon the exercise of any Warrants, to issue fractions of Common Shares or to distribute certificates which evidence fractional Common Shares. Any fractional entitlements will be rounded down to the nearest whole number.

3.4        Expiration of Warrants

Immediately after the Expiry Time, all rights under any Warrant in respect of which the right of acquisition provided for herein shall not have been exercised shall cease and terminate and each Warrant shall be void and of no further force or effect except to the extent that the Warrantholder has not received in full all monies to which it is entitled pursuant to Article 4 or Article 5 or has not received certificates representing the Common Shares issued upon exercise of Warrants held by it, in which instances the Warrantholders’ rights hereunder shall continue until it has received that to which it is entitled hereunder.

3.5

Accounting and Recording

     
3.5.1

The Warrant Agent shall promptly account to the Corporation with respect to Warrants exercised and forward to the Corporation (or into an account or accounts of the Corporation with the bank or trust Corporation designated by the Corporation for that purpose), all monies received by the Warrant Agent on the subscription for Common Shares through the exercise of Warrants. All such monies and any securities or other instruments, from time to time received by the Warrant Agent shall be received in trust for, and shall be segregated and kept apart by the Warrant Agent, the Warrantholders and the Corporation as their interests may appear.



- 22 -

  3.5.2

The Warrant Agent shall record the particulars of Warrants exercised, which particulars shall include the names and addresses of the persons who become holders of Common Shares on exercise and the Exercise Date, in respect thereof. The Warrant Agent shall provide such particulars in writing to the Corporation within five Business Days of any request by the Corporation therefor.

3.6       Securities Restrictions

Notwithstanding anything herein contained, Common Shares will only be issued pursuant to any Warrant in compliance with the securities laws of any applicable jurisdiction. The certificates representing the Common Shares issued will bear such legend as may, in the opinion of Counsel to the Corporation be necessary in order to avoid a violation of any securities laws of any province or territory in Canada or of the United States or any state thereof and to comply with the requirements of any stock exchange or over the counter market on which the Common Shares are listed or quoted, as the case may be. Certificates representing Common Shares issued upon the exercise of Warrants may bear the legend set forth in Section 2.16. If, at any time, in the opinion of Counsel to the Corporation, such legends are no longer necessary in order to avoid a violation of any such laws, or the holder of any such legended certificate, at the holder’s expense, provides the Corporation with evidence satisfactory in form and substance to the Corporation (which may include an opinion of counsel satisfactory to the Corporation) to the effect that such holder is entitled to sell or otherwise transfer such Common Shares in a transaction in which such legends are not required, such legended certificate may thereafter be surrendered to the Warrant Agent in exchange for a certificate which does not bear such legend.

3.7

Prohibition on Exercise in the United States or by U.S. Persons; Exception

     
3.7.1

Warrants may not be exercised in the United States or by or on behalf of a U.S. Person unless an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available and such exercise is made in accordance with Section 3.7.2;

     
3.7.2

Any holder that seeks to exercise a Warrant shall provide to the Corporation and the Warrant Agent, and the Corporation and the Warrant Agent shall be entitled to act and rely on any one of the following:


  (a)

a written certification that such holder (i) at the time of exercise of the Warrant is not in the United States; (ii) is not a U.S. Person and is not exercising the Warrant for the account or benefit of a U.S. Person; (iii) was not offered to exercise the Warrant and did not execute or deliver the exercise form for the Warrant in the United States; (iv) did not acquire the Warrant while it was in the United States or acting for the account or benefit of a U.S. Person and (v) has in all other respects complied with Regulation S; or



- 23 -

  (b)

a written certification that such holder (i) originally purchased the Warrant on its own behalf or on behalf of a beneficial purchaser (a “ Beneficial Purchaser ”) directly from the Corporation pursuant to the Corporation's offering of Units at a time when the holder was and any Beneficial Purchaser was (A) an Accredited Investor and (B) in the United States or a U.S. Person, or was offered Units in the United States; (ii) is exercising the Warrant solely for its own account or for the account of the Beneficial Purchaser, if any, and not on behalf of any other person, (iii) is, and the Beneficial Purchaser, if any, is, an Accredited Investor on the date of exercise of the Warrant and (iv) as of the date of exercise of the Warrant, it reaffirms the representations, warranties, and agreements made by it in that U.S. Purchaser Letter; or

     
  (c)

a written opinion of counsel of recognized standing in form and substance satisfactory to the Corporation to the effect that an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available for the issuance of the Common Shares upon exercise of the Warrants.


  3.7.3

No certificates representing Common Shares will be registered or delivered to an address in the United States unless the holder of Warrants complies with the requirements set forth in subsection 3.7.2(b) or 3.7.2(c), and, in the case of subsection 3.7.2(c), the Corporation has confirmed in writing to the Warrant Agent that the written opinion of counsel is satisfactory to the Corporation and the holder of Warrants provides an executed letter substantially in the form attached hereto as Schedule “C”); and

     
  3.7.4

Certificates representing Common Shares issued upon exercise of the Warrants pursuant to subsection 3.7.2(b) or 3.7.2(c) above shall be “restricted securities” within the meaning of Rule 144(a)(3) under the U.S. Securities Act, may not be offered, sold, pledged or otherwise transferred except pursuant to an exemption or exclusion from the registration requirements of the U.S. Securities Act and applicable state securities laws and shall bear a legend to that effect as designated in Section 2.16.

ARTICLE 4 - ADJUSTMENT OF NUMBER OF COMMON SHARES AND EXERCISE PRICE

4.1       Adjustment of Number of Common Shares and Exercise Price

The acquisition rights as they relate to Common Shares, in effect at any date attaching to the Warrants, and the Exercise Price in respect thereof, shall be subject to adjustment from time to time as follows:

  4.1.1

If and whenever at any time during the Adjustment Period, the Corporation shall: (i) subdivide, redivide or change its outstanding Common Shares into a greater number of shares; (ii) reduce, combine or consolidate its outstanding Common Shares into a smaller number of shares; or (iii) issue Common Shares or securities exchangeable for or convertible into Common Shares to the holders of all or substantially all of the outstanding Common Shares by way of a stock dividend (other than the issue of Common Shares to such holders as a Dividend Paid in the Ordinary Course);



- 24 -

 

the Exercise Price in effect on the effective date of such subdivision, redivision, change, reduction, combination, consolidation or on the record date of such stock dividend, as the case may be, shall in the case of the events referred to in (i) or (iii) above be decreased in proportion to the number of outstanding Common Shares resulting from such subdivision, redivision or stock dividend, or shall, in the case of the events referred to in (ii) above, be increased in proportion to the number of outstanding Common Shares resulting from such reduction, combination or consolidation. Such adjustment shall be made successively whenever any event referred to in this subsection 4.1.1 shall occur. Upon any adjustment of the Exercise Price pursuant to subsection 4.1.1, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;

  4.1.2

If and whenever at any time during the Adjustment Period, the Corporation shall fix a record date for the issuance of rights, options or warrants to all or substantially all the holders of its outstanding Common Shares entitling them, for a period expiring not more than forty-five (45) days after such record date, to subscribe for or purchase Common Shares (or securities convertible or exchangeable into Common Shares) at a price per share (or having a conversion or exchange price per share) less than ninety-five percent (95%) of the Current Market Price on such record date, the Exercise Price shall be adjusted immediately after such record date so that it shall equal the amount determined by multiplying the Exercise Price in effect on such record date by a fraction, of which the numerator shall be the total number of Common Shares outstanding on such record date plus a number of Common Shares equal to the number arrived at by dividing the aggregate price of the total number of additional Common Shares offered for subscription or purchase (or the aggregate conversion or exchange price of the convertible or exchangeable securities so offered) by such Current Market Price, and of which the denominator shall be the total number of Common Shares outstanding on such record date plus the total number of additional Common Shares offered for subscription or purchase or into which the convertible or exchangeable securities so offered are convertible or exchangeable; any Common Shares owned by or held for the account of the Corporation or any Subsidiary shall be deemed not to be outstanding for the purpose of any such computation; such adjustment shall be made successively whenever such a record date is fixed; to the extent that any such rights or warrants are not exercised prior to the expiration thereof the Exercise Price shall be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or to the Exercise Price which would then be in effect based upon the number of Common Shares (or securities convertible or exchangeable into Common Shares) actually issued upon the exercise of such rights or warrants, as the case may be. Upon any adjustment of the Exercise Price pursuant to this subsection 4.1.2, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;



- 25 -

   
     
  4.1.3

If and whenever at any time during the Adjustment Period the Corporation shall fix a record date for the payment, issue or distribution to all or substantially all the holders of its outstanding Common Shares of (i) shares of any class, whether of the Corporation or any other corporation (other than Common Shares and other than shares distributed to holders of Common Shares pursuant to their exercise of options to receive dividends in the form of such shares in lieu of Dividends Paid in the Ordinary Course on the Common Shares), (ii) rights, options or warrants to subscribe for or purchase Common Shares (or other securities convertible into or exchangeable for Common Shares) for a period expiring not more than forty-five (45) days after such record date at a price per share (or having a conversion or exercise price per share) not less than ninety five percent (95%) of the Current Market Price on such record date), (iii) evidences of its indebtedness or (iv) any property or other assets (excluding Dividends Paid in the Ordinary Course) then, in each such case, the Exercise Price shall be adjusted immediately after such record date so that it shall equal the price determined by multiplying the Exercise Price in effect on such record date by a fraction, of which the numerator shall be the total number of Common Shares outstanding on such record date multiplied by such Current Market Price less the aggregate fair market value (as determined by the directors, acting reasonably and in good faith, which determination shall be conclusive) of such shares or rights, options or warrants or evidences of indebtedness or assets actually distributed, as the case may be, and of which the denominator shall be the total number of Common Shares outstanding on such record date multiplied by such Current Market Price; and Common Shares owned by or held for the account of the Corporation or any Subsidiary shall be deemed not be outstanding for the purpose of any such computation; such adjustment shall be made successively whenever such a record date is fixed; to the extent that such distribution is not so made, the Exercise Price shall be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or to the Exercise Price which would then be in effect based upon such shares or rights, options or warrants or evidences of indebtedness or assets actually distributed, as the case may be; in clause (7) of this subsection 4.1.3 the term “ Dividends Paid in the Ordinary Course ” shall include the value of any securities or other property or assets distributed in lieu of cash Dividends Paid in the Ordinary Course at the option of shareholders. Upon any adjustment of the Exercise Price pursuant to this subsection 4.1.3, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;



- 26 -

  4.1.4

If and whenever at any time during the Adjustment Period, there is a reclassification of the Common Shares or a capital reorganization of the Corporation other than as described in subsection 4.1.1 or a consolidation, amalgamation, arrangement or merger of the Corporation with or into any other body corporate, trust, partnership or other entity, or a sale or conveyance of the property and assets of the Corporation as an entirety or substantially as an entirety to any other body corporate, trust, partnership or other entity in which the holders of Common Shares are entitled to receive shares, other securities or property, including cash, any Warrantholder who has not exercised its right of acquisition prior to the effective date of such reclassification, capital reorganization, consolidation, amalgamation, arrangement or merger, sale or conveyance, upon the exercise of such right thereafter, shall be entitled to receive and shall accept for the same aggregate consideration, in lieu of the number of Common Shares then sought to be acquired by it, the number of shares or other securities or property of the Corporation or of the body corporate, trust, partnership or other entity resulting from such merger, amalgamation or consolidation, or to which such sale or conveyance may be made, as the case may be, that such Warrantholder would have been entitled to receive on such reclassification, capital reorganization, consolidation, amalgamation, arrangement or merger, sale or conveyance, if, on the record date or the effective date thereof, as the case may be, the Warrantholder had been the registered holder of the number of Common Shares sought to be acquired by it and to which it was entitled to acquire upon the exercise of the Warrants. If determined appropriate by the Warrant Agent to give effect to or to evidence the provisions of this subsection 4.1.4, the Corporation, its successor, or such purchasing body corporate, partnership, trust or other entity, as the case may be, shall, prior to or contemporaneously with any such reclassification, capital reorganization, consolidation, amalgamation, arrangement, merger, sale or conveyance, enter into an indenture which shall provide, to the extent possible, for the application of the provisions set forth in this Indenture with respect to the rights and interests thereafter of the Warrantholders to the end that the provisions set forth in this Indenture shall thereafter correspondingly be made applicable, as nearly as may reasonably be, with respect to any shares, other securities or property to which a Warrantholder is entitled on the exercise of its acquisition rights thereafter. Any indenture entered into between the Corporation and the Warrant Agent pursuant to the provisions of this subsection 4.1.4 shall be a supplemental indenture entered into pursuant to the provisions of Article 8. Any indenture entered into between the Corporation; any successor to the Corporation or such purchasing body corporate, partnership, trust or other entity and the Warrant Agent shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided in this Section 4.1 and which shall apply to successive reclassifications, capital reorganizations, amalgamations, consolidations, mergers, sales or conveyances;



- 27 -

  4.1.5

In any case in which this Section 4.1 shall require that an adjustment shall become effective immediately after a record date for an event referred to herein, the Corporation may defer, until the occurrence of such event, issuing to the holder of any Warrant exercised after such event the additional Common Shares issuable upon such conversion by reason of the adjustment required by such event before giving effect to such adjustment; provided, however, that the Corporation shall deliver to such holder an appropriate instrument evidencing such holder’s right to receive such additional Common Shares upon the occurrence of the event requiring such adjustment and the right to receive any distributions made on such additional Common Shares declared in favour of holders of record of Common Shares on and after the relevant date of exercise or such later date as such holder would, but for the provisions of this subsection 4.1.5, have become the holder of record of such additional Common Shares pursuant to subsection 4.1.4;

     
  4.1.6

In any case in which subsections 4.1.2 or 4.1.3 require that an adjustment be made to the Exercise Price, no such adjustment shall be made if the holders of the outstanding Warrants receive the rights, options or warrants referred to in subsection 4.1.2 or the shares, rights, options, warrants, evidences of indebtedness, property or assets referred to in subsection 4.1.3, as the case may be, in such kind and number as they would have received if they had been holders of Common Shares on the applicable record date or effective date, as the case may be, by virtue of their outstanding Warrants having then been exercised into Common Shares at the Exercise Price in effect on the applicable record date or effective date, as the case may be. Any such issuance of shares, rights, options, or warrants will be subject to regulatory approval;

     
  4.1.7

The adjustments provided for in this Section 4.1 are cumulative, and shall, in the case of adjustments to the Exercise Price be computed to the nearest whole cent and shall apply to successive subdivisions, redivisions, reductions, combinations, consolidations, distributions, issues or other events resulting in any adjustment under the provisions of this Section 4.1, provided that, notwithstanding any other provision of this Section, no adjustment of the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least one (1%) percent in the Exercise Price then in effect; provided, however, that any adjustments which by reason of this subsection 4.1.7 are not required to be made shall be carried forward and taken into account in any subsequent adjustment; and

     
  4.1.8

After any adjustment pursuant to this Section 4.1, the term “ Common Shares ” where used in this Indenture shall be interpreted to mean securities of any class or classes which, as a result of such adjustment and all prior adjustments pursuant to this Section 4.1, the Warrantholder is entitled to receive upon the exercise of his Warrant, and the number of Common Shares indicated by any exercise made pursuant to a Warrant shall be interpreted to mean the number of Common Shares or other property or securities a Warrantholder is entitled to receive, as a result of such adjustment and all prior adjustments pursuant to this Section 4.1, upon the full exercise of a Warrant.



- 28 -

4.2       Entitlement to Shares on Exercise of Warrant

All shares of any class or other securities which a Warrantholder is at the time in question entitled to receive on the exercise of its Warrant, whether or not as a result of adjustments made pursuant to this Article 4, shall, for the purposes of the interpretation of this Indenture, be deemed to be shares which such Warrantholder is entitled to acquire pursuant to such Warrant.

4.3       No Adjustment for Certain Transactions

Notwithstanding anything in this Article 4, no adjustment shall be made in the acquisition rights attached to the Warrants if the issue of Common Shares is being made pursuant to or in connection with:

  4.3.1

any stock option or stock purchase plan in force from time to time for directors, officers, employees, consultants or other service providers of the Corporation; or

     
  4.3.2

the satisfaction of existing instruments issued at or prior to the date hereof.

4.4        Determination by Corporation’s Auditors

In the event of any question arising with respect to the adjustments provided for in this Article 4 such question shall be conclusively determined by the Corporation’s Auditors who shall have access to all necessary records of the Corporation, and such determination shall be binding upon the Corporation, the Warrant Agent, all Warrantholders and all other persons interested therein.

4.5       Proceedings Prior to any Action Requiring Adjustment

As a condition precedent to the taking of any action which would require an adjustment in any of the acquisition rights pursuant to any of the Warrants, including the number of Common Shares which are to be received upon the exercise thereof, the Corporation shall take any corporate action which may, in the opinion of Counsel, be necessary in order that the Corporation has unissued and reserved in its authorized capital and may validly and legally issue as fully paid and non-assessable all the shares (or other securities or property) which the holders of such Warrants are entitled to receive on the full exercise thereof in accordance with the provisions hereof.

4.6        Certificate of Adjustment

The Corporation shall from time to time immediately after the occurrence of any event which requires an adjustment or readjustment as provided in Article 4, deliver a certificate of the Corporation to the Warrant Agent specifying the nature of the event requiring the same and the amount of the adjustment or readjustment necessitated thereby and setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based, which certificate shall be supported by a certificate of the Corporation’s Auditors verifying such calculation.


- 29 -

4.7        Notice of Special Matters

The Corporation covenants with the Warrant Agent that, so long as any Warrant remains outstanding, it will give notice to the Warrant Agent and to the Warrantholders of its intention to fix a record date that is prior to the Expiry Date for the purpose of an event that requires or that may require an adjustment in any of the exercise rights pursuant to any Warrants as provided in this Article 4. Such notice shall specify the particulars of such event and the record date for such event, provided that the Corporation shall only be required to specify in the notice such particulars of the event as shall have been fixed and determined on the date on which the notice is given. The notice shall be given in each case not less than fourteen (14) days prior to such applicable record date.

4.8        No Action After Notice

The Corporation covenants with the Warrant Agent that it will not close its transfer books or take any other corporate action which might deprive the holder of a Warrant of the opportunity to exercise its right of acquisition pursuant thereto during the period of fourteen (14) days after the giving of the certificate or notices set forth in Sections 4.6 and 4.7.

4.9        Other Action

In case the Corporation, after the date hereof, shall take any action affecting the Common Shares other than action described in Section 4.1, which in the reasonable opinion of the directors of the Corporation would materially affect the rights of Warrantholders, the number of Common Shares which may be acquired upon exercise of the Warrants shall be adjusted in such manner and at such time, by action of the directors, acting reasonably, as they may determine to be equitable in the circumstances, provided that no such adjustment will be made unless prior approval of any stock exchange on which the Common Shares are listed for trading has been obtained, if required by any such stock exchange.

4.10      Protection of Warrant Agent

Except as provided in Section 9.1, the Warrant Agent shall not:

  4.10.1

At any time be under any duty or responsibility to any Warrantholder to determine whether any facts exist which may require any adjustment contemplated by Section 4.1, or with respect to the nature or extent of any such adjustment when made, or with respect to the method employed in making the same;

     
  4.10.2

Be accountable with respect to the validity or value (or the kind or amount) of any Common Shares or of any shares or other securities or property which may at any time be issued or delivered upon the exercise of the rights attaching to any Warrant;

     
  4.10.3

Be responsible for any failure of the Corporation to issue, transfer or deliver Common Shares or certificates for the same upon the surrender of any Warrants for the purpose of the exercise of such rights or to comply with any of the covenants contained in this Article; and



- 30 -

  4.10.4

Incur any liability or responsibility whatsoever or be in any way responsible for the consequences of any breach on the part of the Corporation of any of the representations, warranties or covenants herein contained or of any acts of the directors, officers, employees, agents or servants of the Corporation.

ARTICLE 5 - RIGHTS OF THE CORPORATION AND COVENANTS

5.1       Optional Purchases by the Corporation

Subject to compliance with applicable securities legislation and approval of applicable regulatory authorities, the Corporation may from time to time purchase on any stock exchange, in the open market, by private contract or otherwise, any of the Warrants. Any such purchase shall be made at the lowest price or prices at which, in the opinion of the directors, such Warrants are then obtainable, plus reasonable costs of purchase, and may be made in such manner, from such persons and on such other terms as the Corporation, in its sole discretion, may determine, Any Warrant Certificates representing the Warrants purchased pursuant to this Section 5.1 shall forthwith be delivered to and cancelled by the Warrant Agent. No Warrants shall be issued in replacement thereof.

5.2       General Covenants

The Corporation covenants with the Warrant Agent that so long as any Warrants remain outstanding and may be exercised:

  5.2.1

it will reserve and keep available a sufficient number of Common Shares for the purpose of enabling it to satisfy its obligations to issue Common Shares upon the exercise of the Warrants;

     
  5.2.2

it will cause the Common Shares and the certificates representing the Common Shares from time to time acquired pursuant to the exercise of the Warrants to be duly issued and delivered in accordance with the Warrant Certificates and the terms hereof;

     
  5.2.3

all Common Shares which shall be issued upon exercise of the right to acquire provided for herein and in the Warrant Certificates, upon payment of the prevailing Exercise Price herein provided for and in the Warrant Certificates shall be fully paid and non-assessable;

     
  5.2.4

if any of its Common Shares are listed on a stock exchange, it will use all reasonable efforts to ensure that the Common Shares comprising the Units, and all Common Shares outstanding or issuable from time to time (including, without limitation, the Common Shares issuable on the exercise of the Warrants) are listed and posted for trading on such stock exchange;



- 31 -

  5.2.5

it will make all requisite filings under applicable Canadian securities legislation and stock exchange rules, including (on a reasonable efforts basis) those necessary to remain a reporting issuer not in default in each of the provinces of Canada in which it is a reporting issuer as of the date hereof and those necessary to report the exercise of the right to acquire Common Shares pursuant to Warrants;

     
  5.2.6

it will provide to Warrantholders copies of all financial statements and other documentation required to be provided by applicable laws to registered holders of Common Shares as if such Warrantholders were registered shareholders of the Corporation. The Warrant Agent shall be entitled to rely on notice-and-access delivery of theses applicable materials to Warrantholders set out in National Instrument 51-102 - Continuous Disclosure Obligations and National Instrument 54-101 - Communication with Beneficial Owners of a Reporting Issuer ;

     
  5.2.7

it shall not close its transfer books or take any other action which might deprive the Warrantholders of the opportunity of exercising their right of purchase pursuant to the Warrants held by such persons after the giving of the notice required by Section 4.7;

     
  5.2.8

generally, it will well and truly perform and carry out all of the acts or things to be done by it as provided in this Indenture;

     
  5.2.9

the Corporation confirms that as at the date of execution of this Indenture it does not have a class of securities registered pursuant to Section 12 of the U.S. Securities Exchange Act or have a reporting obligation pursuant to Section 15(d) of the U.S. Securities Exchange Act; the Corporation covenants that in the event that (i) any class of its securities shall become registered pursuant to Section 12 of the U.S. Securities Exchange Act or the Corporation shall incur a reporting obligation pursuant to Section 15(d) of the U.S. Securities Exchange Act, or (ii) any such registration or reporting obligation shall be terminated by the Corporation in accordance with the U.S. Securities Exchange Act, the Corporation shall promptly deliver to the Warrant Agent an Officers’ Certificate (in a form provided by the Warrant Agent) notifying the Warrant Agent of such registration or termination and such other information as the Warrant Agent may require at the time. The Corporation acknowledges that the Warrant Agent is relying upon the foregoing representation and covenants in order to meet certain SEC obligations with respect to those clients who are filing with the SEC.

5.3       Warrant Agent’s Remuneration and Expenses

The Corporation covenants that it will pay to the Warrant Agent from time to time reasonable remuneration for its services hereunder and will pay or reimburse the Warrant Agent upon its request for all reasonable expenses, disbursements and advances incurred or made by the Warrant Agent in the administration or execution of the trusts hereby created (including the reasonable compensation and the disbursements of its Counsel and all other advisers and assistants not regularly in its employ) both before any default hereunder and thereafter until all duties of the Warrant Agent hereunder shall be finally and fully performed, except any such expense, disbursement or advance as may arise out of or result from the Warrant Agent’s gross negligence, willful misconduct or bad faith.


- 32 -

5.4       Securities Qualification Requirements

If, in the opinion of Counsel, any instrument is required to be filed with, or any permission is required to be obtained from, any governmental authority in Canada or any other step is required under any federal, provincial or territorial law of Canada before any Common Shares which a Warrantholder is entitled to acquire pursuant to the exercise of any Warrant may properly and legally be issued and subscribed for upon due exercise thereof and thereafter traded, without further formality or restriction, the Corporation covenants that it will take such required action.

5.5       Performance of Covenants by Warrant Agent

If the Corporation shall fail to perform any of its covenants contained in this Indenture and shall have not rectified such failure within ten (10) Business Days after receiving notice from the Warrant Agent of such failure, the Warrant Agent may notify the Warrantholders of such failure on the part of the Corporation or may itself perform any of the covenants capable of being performed by it but, subject to Section 9.1, shall be under no obligation to perform said covenants or to notify the Warrantholders of such performance by it. All sums expended or advanced by the Warrant Agent in so doing shall be repayable as provided in Section 5.3. No such performance, expenditure or advance by the Warrant Agent shall relieve the Corporation of any default hereunder or of its continuing obligations under the covenants herein contained.

5.6        Enforceability of Warrants

The Corporation covenants and agrees that it is duly authorized to create and issue the Warrants to be issued hereunder and that the Warrants, when issued as herein provided, will be valid and enforceable against the Corporation in accordance with the provisions hereof and the terms hereof and that, subject to the provisions of this Indenture, the Corporation will cause the Common Shares from time to time acquired pursuant to the Warrants under this Indenture and the certificates representing such Common Shares to be duly issued and delivered in accordance with the terms of this Indenture.

ARTICLE 6 - ENFORCEMENT

6.1        Suits by Warrantholders

All or any of the rights conferred upon any Warrantholder by any of the terms of the Warrant Certificates or of this Indenture, or of both, may be enforced by the Warrantholder by appropriate proceedings but without prejudice to the right which is hereby conferred upon the Warrant Agent to proceed in its own name to enforce each and all of the provisions herein contained for the benefit of the Warrantholders.


- 33 -

6.2       Immunity of Shareholders, etc.

The Warrant Agent and, by the acceptance of the Warrant Certificates and as part of the consideration for the issue of the Warrants, the Warrantholders hereby waive and release any right, cause of action or remedy now or hereafter existing in any jurisdiction against any incorporator or any past, present or future shareholder or agent of the Corporation on any covenant, agreement, representation or warranty by the Corporation herein or contained in the Warrant Certificates.

6.3       Limitation of Liability

The obligations hereunder are not personally binding upon, nor shall resort hereunder be had to, the private property of any of the past, present or future directors or shareholders of the Corporation or any of the past, present or future officers, employees or agents of the Corporation. Only the property of the Corporation or any successor corporation shall be bound in respect hereof.

6.4       Waiver of Default

Upon the happening of any default hereunder:

  6.4.1

the holders of not less than fifty one percent (51%) of the Warrants then outstanding shall have power (in addition to the powers exercisable by Extraordinary Resolution) by requisition in writing to instruct the Warrant Agent to waive any default hereunder and the Warrant Agent shall thereupon waive the default upon such terms and conditions as shall be prescribed in such requisition; or

     
  6.4.2

the Warrant Agent shall have power to waive any default hereunder upon such terms and conditions as the Warrant Agent may deem advisable, if, in the Warrant Agent’s reasonable opinion or, in the opinion of counsel acceptable to the Warrant Agent, the same shall have been cured or adequate provision made therefor;

     
 

provided that no delay or omission of the Warrant Agent or of the Warrantholders to exercise any right or power accruing upon any default shall impair any such right or power or shall be construed to be a waiver of any such default or acquiescence therein and provided further that no act or omission either of the Warrant Agent or of the Warrantholders in the premises shall extend to or be taken in any manner whatsoever to affect any subsequent default hereunder of the rights resulting therefrom.

ARTICLE 7 – MEETINGS OF WARRANTHOLDERS

7.1       Right to Convene Meetings

The Warrant Agent may at any time and from time to time, and shall on receipt of a written request of the Corporation or of a Warrantholders’ Request and upon being indemnified to its reasonable satisfaction by the Corporation or by the Warrantholders signing such Warrantholders’ Request against the costs which may be incurred in connection with the calling and holding of such meeting, convene a meeting of the Warrantholders. In the event of the Warrant Agent failing to so convene a meeting within fifteen (15) days after receipt of such written request of the Corporation or such Warrantholders’ Request and indemnity given as aforesaid, the Corporation or such Warrantholders, as the case may be, may convene such meeting. Every such meeting shall be held in Toronto or at such other place as may be approved or determined by the Warrant Agent and approved by the Corporation.


- 34 -

7.2        Notice

At least twenty one (21) days’ prior written notice of any meeting of Warrantholders shall be given to the Warrantholders in the manner provided for in Article 10 and a copy of such notice shall be sent by mail to the Warrant Agent (unless the meeting has been called by the Warrant Agent) and to the Corporation (unless the meeting has been called by the Corporation). Such notice shall state the time when and the place where the meeting is to be held, shall state briefly the general nature of the business to be transacted thereat and shall contain such information as is reasonably necessary to enable the Warrantholders to make a reasoned decision on the matter, but it shall not be necessary for any such notice to set out the terms of any resolution to be proposed or any of the provisions of this Article 7. The notice convening any such meeting may be signed by an appropriate officer of the Warrant Agent or of the Corporation or the person or persons designated by such Warrantholders, as the case may be.

7.3        Chairman

An individual (who need not be a Warrantholder) designated in writing by the Warrant Agent shall be chairman of the meeting and if no individual is so designated, or if the individual so designated is not present within fifteen (15) minutes from the time fixed for the holding of the meeting, the Warrantholders present in person or by proxy shall choose some individual present to be chairman.

7.4       Quorum

Subject to the provisions of Section 7.11, at any meeting of the Warrantholders a quorum shall consist of Warrantholders present in person or by proxy and entitled to purchase at least ten percent (10%) of the aggregate number of Common Shares which could be acquired pursuant to all the then outstanding Warrants, provided that at least two persons entitled to vote thereat, in person or by proxy, are personally present. If a quorum of the Warrantholders shall not be present within thirty (30) minutes from the time fixed for holding any meeting, the meeting shall be adjourned to the same day in the next week (unless such day is not a Business Day, in which case it shall be adjourned to the next following Business day) at the same time and place and no notice of the adjournment need be given. Any business may be brought before or dealt with at an adjourned meeting which might have been dealt with at the original meeting in accordance with the notice calling the same. No business shall be transacted at any meeting unless a quorum be present at the commencement of business; provided that at the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum and may transact the business for which the meeting was originally convened, notwithstanding that they may not be entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all then outstanding Warrants.


- 35 -

7.5       Power to Adjourn

The chairman of any meeting at which a quorum of the Warrantholders is present may, with the consent of the meeting, adjourn any such meeting, and no notice of such adjournment need be given except such notice, if any, as the meeting may prescribe.

7.6        Show of Hands

Every question submitted to a meeting shall be decided in the first place by a majority of the votes given on a show of hands except that votes on an Extraordinary Resolution shall be given in the manner hereinafter provided. At any such meeting, unless a poll is duly demanded as herein provided, a declaration by the chairman that a resolution has been carried or carried unanimously or by a particular majority or lost or not carried by a particular majority shall be conclusive evidence of the fact.

7.7       Poll and Voting

On every Extraordinary Resolution, and on any other question submitted to a meeting and after a vote by show of hands when demanded by the chairman or by one or more of the Warrantholders acting in person or by proxy, a poll shall be taken in such manner as the chairman shall direct. Questions other than those required to be determined by Extraordinary Resolution shall be decided by a majority of the votes cast on the poll.

On a show of hands, every person who is present and entitled to vote, whether as a Warrantholder or as proxy for one or more absent Warrantholders, or both, shall have one vote. On a poll, each Warrantholder present in person or represented by a proxy duly appointed by instrument in writing shall be entitled to one vote in respect of each whole Common Share which it is entitled to acquire pursuant to the Warrant or Warrants then held or represented by it. A proxy need not be a Warrantholder. In the case of joint holders, any one of them present in person or by proxy at the meeting may vote in the absence of the other or others, but in case more than one of them shall be present in person or by proxy, they shall vote together in respect of Warrants of which they are joint registered holders. The chairman of any meeting shall be entitled, both on a show of hands and on a poll, to vote in respect of the Warrants, if any, held or represented by him.

7.8       Regulations

The Warrant Agent, or the Corporation with the approval of the Warrant Agent, may from time to time make and from time to time vary such regulations as it shall think fit for:

  7.8.1

the setting of the record date for a meeting for the purpose of determining Warrantholders entitled to receive notice of and to vote at the meeting;

     
  7.8.2

the issue of voting certificates by any bank, trust company or other depositary satisfactory to the Warrant Agent stating that the Warrant Certificates specified therein have been deposited with it by a named person and will remain on deposit until after the meeting, which voting certificate shall entitle the persons named therein to be present and vote at any such meeting and at any adjournment thereof or to appoint a proxy or proxies to represent them and vote for them at any such meeting and at any adjournment thereof in the same manner and with the same effect as though the persons so named in such voting certificates were the actual bearers of the Warrant Certificates specified therein;



- 36 -

  7.8.3

the deposit of voting certificates and instruments appointing proxies at such place and time as the Warrant Agent, the Corporation or the Warrantholders convening the meeting, as the case may be, may in the notice convening the meeting direct;

     
  7.8.4

the deposit of voting certificates and instruments appointing proxies at some approved place or places other than the place at which the meeting is to be held and enabling particulars of such instruments appointing proxies to be mailed or telecopied before the meeting to the Corporation or to the Warrant Agent at the place where the same is to be held and for the voting of proxies so deposited as though the instruments themselves were produced at the meeting;

     
  7.8.5

the form of the instrument of proxy and the manner in which the instrument of proxy must be executed; and

     
  7.8.6

generally for the calling of meetings of Warrantholders and the conduct of business thereat.

Any regulations so made shall be binding and effective and the votes given in accordance therewith shall be valid and shall be counted. Save as such regulations may provide, the only persons who shall be recognized at any meeting as a Warrantholder, or be entitled to vote or be present at the meeting in respect thereof (subject to Section 7.9), shall be Warrantholders or their counsel, or proxies of Warrantholders.

7.9        Corporation and Warrant Agent May be Represented

The Corporation and the Warrant Agent, by their respective directors and officers, and the Counsel for the Corporation and for the Warrant Agent may attend any meeting of the Warrantholders, but shall not be entitled to vote thereat, whether in respect of any Warrants held by them or otherwise.

7.10      Powers Exercisable by Extraordinary Resolution

In addition to all other powers conferred upon them by any other provisions of this Indenture or by law, the Warrantholders at a meeting shall, subject to the provisions of Section 7.11, have the power, exercisable from time to time by Extraordinary Resolution:

  7.10.1

to agree to any modification, abrogation, alteration, compromise or arrangement of the rights of Warrantholders or the Warrant Agent in its capacity as Warrant Agent hereunder (subject to the Warrant Agent’s prior consent) or on behalf of the Warrantholders against the Corporation whether such rights arise under this Indenture or the Warrant Certificates or otherwise;



- 37 -

  7.10.2

to amend, alter or repeal any Extraordinary Resolution previously passed or sanctioned by the Warrantholders;

     
  7.10.3

to direct or to authorize the Warrant Agent, subject to subsection 9.1.2, to enforce any of the covenants on the part of the Corporation contained in this Indenture or the Warrant Certificates or to enforce any of the rights of the Warrantholders in any manner specified in such Extraordinary Resolution or to refrain from enforcing any such covenant or right;

     
  7.10.4

to waive, and to direct the Warrant Agent to waive, any default on the part of the Corporation in complying with any provisions of this Indenture or the Warrant Certificates either unconditionally or upon any conditions specified in such Extraordinary Resolution;

     
  7.10.5

to restrain any Warrantholder from taking or instituting any suit, action or proceeding against the Corporation for the enforcement of any of the covenants on the part of the Corporation in this Indenture or the Warrant Certificates or to enforce any of the rights of the Warrantholders;

     
  7.10.6

to direct any Warrantholder who, as such, has brought any suit, action or proceeding to stay or to discontinue or otherwise to deal with the same upon payment of the costs, charges and expenses reasonably and properly incurred by such Warrantholder in connection therewith;

     
  7.10.7

to consent to any change in or omission from the provisions contained in the Warrant Certificates and this Indenture or any ancillary or supplemental instrument which may be agreed to by the Corporation, and to authorize the Warrant Agent to concur in and execute any ancillary or supplemental indenture embodying the change or omission;

     
  7.10.8

with the consent of the Corporation, such consent not to be unreasonably withheld, to remove the Warrant Agent or its successor in office and to appoint a new trustee or trustees to take the place of the Warrant Agent so removed; and

     
  7.10.9

to consent to any compromise or arrangement with any creditor or creditors or any class or classes of creditors, whether secured or otherwise, and with holders of any shares or other securities of the Corporation.


7.11

Meaning of Extraordinary Resolution

     
7.11.1

The expression “ Extraordinary Resolution ” when used in this Indenture means, subject as hereinafter provided in this Section 7.11 and in Section 7.14, a resolution proposed at a meeting of Warrantholders duly convened for that purpose and held in accordance with the provisions of this Article 7 at which there are present in person or by proxy at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants and passed by the affirmative votes of Warrantholders entitled to acquire not less than sixty six and two third percent (662/3%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants present or represented at the meeting and voted on the poll upon such resolution.



- 38 -

  7.11.2

If, at the meeting at which an Extraordinary Resolution is to be considered, at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants are not present in person or by proxy within thirty (30) minutes after the time appointed for the meeting, then the meeting shall stand adjourned to such day, being not less than fifteen (15) or more than sixty (60) days later, and to such place and time as may be appointed by the chairman. Not less than ten (10) days’ prior notice shall be given of the time and place of such adjourned meeting in the manner provided for in Sections 10.1 and 10.2. Such notice shall state that at the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum but it shall not be necessary to set forth the purposes for which the meeting was originally called or any other particulars. At the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum and may transact the business for which the meeting was originally convened and a resolution proposed at such adjourned meeting and passed by the requisite vote as provided in subsection 7.11.1 shall be an Extraordinary Resolution within the meaning of this Indenture notwithstanding that at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants are not present in person or represented by proxy at such adjourned meeting.

     
  7.11.3

Votes on an Extraordinary Resolution shall always be given on a poll and no demand for a poll on an Extraordinary Resolution shall be necessary.

7.12      Powers Cumulative

Any one or more of the powers or any combination of the powers in this Indenture stated to be exercisable by the Warrantholders by Extraordinary Resolution or otherwise may be exercised from time to time and the exercise of any one or more of such powers or any combination of powers from time to time shall not be deemed to exhaust the right of the Warrantholders to exercise such power or powers or combination of powers then or thereafter from time to time.

7.13      Minutes

Minutes of all resolutions and proceedings at every meeting of Warrantholders shall be made and duly entered in books to be provided from time to time for that purpose by the Warrant Agent at the expense of the Corporation, and any such minutes as aforesaid, if signed by the chairman or the secretary of the meeting at which such resolutions were passed or proceedings had shall be prima facie evidence of the matters therein stated and, until the contrary is proved, every such meeting in respect of the proceedings of which minutes shall have been made shall be deemed to have been duly convened and held, and all resolutions passed thereat or proceedings taken shall be deemed to have been duly passed and taken.


- 39 -

7.14      Instruments in Writing

All actions which may be taken and all powers that may be exercised by the Warrantholders at a meeting held as provided in this Article 7 may also be taken and exercised by Warrantholders entitled to acquire at least sixty six and two third percent (662/3%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants by an instrument in writing signed in one or more counterparts by such Warrantholders in person or by attorney duly appointed in writing, and the expression “ Extraordinary Resolution ” when used in this Indenture shall include an instrument so signed.

7.15      Binding Effect of Resolutions

Every resolution and every Extraordinary Resolution passed in accordance with the provisions of this Article 7 at a meeting of Warrantholders shall be binding upon all the Warrantholders, whether present at or absent from such meeting, and every instrument in writing signed by Warrantholders in accordance with Section 7.14 shall be binding upon all the Warrantholders, whether signatories thereto or not, and each and every Warrantholder and the Warrant Agent (subject to the provisions for indemnity herein contained) shall be bound to give effect accordingly to every such resolution and instrument in writing. In the case of an instrument in writing, the Warrant Agent shall give notice in the manner contemplated in Sections 10.1 and 10.2 of the effect of the instrument in writing to all Warrantholders and the Corporation as soon as reasonably practicable.

7.16      Holdings by Corporation Disregarded

In determining whether Warrantholders holding Warrant Certificates evidencing the entitlement to acquire the required number of Common Shares are present at a meeting of Warrantholders for the purpose of determining a quorum or have concurred in any consent, waiver, Extraordinary Resolution, Warrantholders’ Request or other action under this Indenture, Warrants owned legally or beneficially by the Corporation or any Subsidiary of the Corporation shall be disregarded.

ARTICLE 8 - SUPPLEMENTAL INDENTURES

8.1        Provision for Supplemental Indentures for Certain Purposes

From time to time the Corporation (when authorized by action of the directors) and the Warrant Agent may, subject to the provisions hereof, and they shall, when so directed in accordance with the provisions hereof, execute and deliver by their proper officers, indentures or instruments supplemental hereto, which thereafter shall form part hereof, for any one or more or all of the following purposes:

  8.1.1

setting forth any adjustments resulting from the application of the provisions of Article 4;



- 40 -

  8.1.2

adding to the provisions hereof such additional covenants and enforcement provisions as, in the opinion of Counsel to the Corporation, are necessary or advisable in the circumstances, provided that the same are not in the opinion of the Warrant Agent prejudicial to the interests of the Warrantholders;

     
  8.1.3

giving effect to any Extraordinary Resolution passed as provided in Article 7;

     
  8.1.4

making such provisions not inconsistent with this Indenture as may be necessary or desirable with respect to matters or questions arising hereunder or for the purpose of obtaining a listing or quotation of the Warrants on any stock exchange, provided that such provisions are not, in the opinion of the Warrant Agent, prejudicial to the interests of the Warrantholders;

     
  8.1.5

adding to or altering the provisions hereof in respect of the transfer of Warrants, making provision for the exchange of Warrant Certificates, and making any modification in the form of the Warrant Certificates which does not affect the substance thereof, in each case provided that such provisions are not, in the opinion of the Warrant Agent, relying on an opinion of Counsel to the Warrant Agent, prejudicial to the interests of the Warrantholders;

     
  8.1.6

with the prior approval of the TSX Venture Exchange, modifying any of the provisions of this Indenture, including relieving the Corporation from any of the obligations, conditions or restrictions herein contained, provided that such modification or relief shall be or become operative or effective only if, in the opinion of the Warrant Agent, relying on an opinion of Counsel to the Warrant Agent, such modification or relief in no way prejudices any of the rights of the Warrantholders or of the Warrant Agent, and provided further that the Warrant Agent may decline to enter into any such supplemental indenture which in its opinion, relying on an opinion of Counsel to the Warrant Agent, may not afford adequate protection to the Warrant Agent when the same shall become operative; and

     
  8.1.7

for any other purpose not inconsistent with the terms of this Indenture, including the correction or rectification of any ambiguities, defective or inconsistent provisions, errors, mistakes or omissions herein, provided that in the opinion of the Warrant Agent the rights of the Warrant Agent and of the Warrantholders are in no way prejudiced thereby.

8.2        Successor Corporations

In the case of the consolidation, amalgamation, arrangement, merger or transfer of the undertaking or assets of the Corporation as an entirety or substantially as an entirety to another Corporation (the “ successor corporation ”), the successor corporation resulting from such consolidation, amalgamation, arrangement, merger or transfer (if not the Corporation) shall expressly assume, by supplemental indenture satisfactory in form to the Warrant Agent and executed and delivered to the Warrant Agent, the due and punctual performance and observance of each and every covenant and condition of this Indenture to be performed and observed by the Corporation.


- 41 -

ARTICLE 9 - CONCERNING THE WARRANT AGENT

9.1

Rights and Duties of Warrant Agent

     
9.1.1

In the exercise of the rights and duties prescribed or conferred by the terms of this Indenture, the Warrant Agent shall act honestly and in good faith with the view to the best interest of the Warrantholders and shall exercise that degree of care, diligence and skill that a reasonably prudent trustee would exercise in comparable circumstances. No provision of this Indenture shall be construed to relieve the Warrant Agent from, or require any other person to indemnify the Warrant Agent from liability for its own gross negligence, its own willful misconduct, bad faith or any breach by it of its obligations or duties under the Indenture.

     
9.1.2

The obligation of the Warrant Agent to commence or continue any act, action or proceeding for the purpose of enforcing any rights of the Warrant Agent or the Warrantholders hereunder shall be conditional upon the Warrantholders furnishing, when required by notice by the Warrant Agent, sufficient funds to commence or to continue such act, action or proceeding and an indemnity reasonably satisfactory to the Warrant Agent to protect and to hold harmless the Warrant Agent against the costs, charges and expenses and liabilities to be incurred thereby and any loss and damage it may suffer by reason thereof. None of the provisions contained in this Indenture shall require the Warrant Agent to expend or to risk its own funds or otherwise to incur financial liability in the performance of any of its duties or in the exercise of any of its rights or powers unless indemnified as aforesaid.

     
9.1.3

The Warrant Agent may, before commencing or at any time during the continuance of any such act, action or proceeding, require the Warrantholders, at whose instance it is acting to deposit with the Warrant Agent the Warrants held by them, for which Warrants the Warrant Agent shall issue receipts.

     
9.1.4

Every provision of this Indenture that by its terms relieves the Warrant Agent of liability or entitles it to rely upon any evidence submitted to it is subject to the provisions of Applicable Legislation, of this Section 9.1 and of Section 9.2.


9.2

Evidence, Experts and Advisers

     
9.2.1

In addition to the reports, certificates, opinions and other evidence required by this Indenture, the Corporation shall furnish to the Warrant Agent such additional evidence of compliance with any provision hereof, and in such form, as may be prescribed by Applicable Legislation or as the Warrant Agent may reasonably require by written notice to the Corporation.

     
9.2.2

In the exercise of its rights and duties hereunder, the Warrant Agent may, if it is acting in good faith, rely as to the truth of the statements and the accuracy of the opinions expressed in statutory declarations, opinions, reports, written requests, consents, or orders of the Corporation, certificates of the Corporation or other evidence furnished to the Warrant Agent pursuant to a request of the Warrant Agent, provided that such evidence complies with Applicable Legislation and that the Warrant Agent complies with Applicable Legislation and that the Warrant Agent examines the same and determines that such evidence complies with the applicable requirements of this Indenture.



- 42 -

  9.2.3

Whenever it is provided in this Indenture or under Applicable Legislation that the Corporation shall deposit with the Warrant Agent resolutions, certificates, reports, opinions, requests, orders or other documents, it is intended that the truth, accuracy and good faith on the effective date thereof and the facts and opinions stated in all such documents so deposited shall, in each and every such case, be conditions precedent to the right of the Corporation to have the Warrant Agent take the action to be based thereon.

     
  9.2.4

Proof of the execution of an instrument in writing, including a Warrantholders’ Request, by any Warrantholder may be made by the certificate of a notary public, or other officer with similar powers, that the person signing such instrument acknowledged to it the execution thereof, or by an affidavit of a witness to such execution or in any other manner which the Warrant Agent may consider adequate.

     
  9.2.5

The Warrant Agent may employ or retain such counsel, accountants, appraisers or other experts or advisers as it may reasonably require for the purpose of discharging its duties hereunder and may pay reasonable remuneration for all services so performed by any of them, without taxation of costs of any counsel, and shall not be responsible for any misconduct or negligence on the part of any such experts or advisers who have been appointed with due care by the Warrant Agent.

9.3       Documents, Monies, etc. Held by Warrant Agent

Any securities, documents of title or other instruments that may at any time be held by the Warrant Agent subject to the trusts hereof may be placed in the deposit vaults of the Warrant Agent or of any Canadian chartered bank listed in Schedule I to the Bank Act (Canada) or of any trust company registered to do business in Canada or deposited for safekeeping with any such bank or trust company. Unless herein otherwise expressly provided, any monies so held pending the application or withdrawal thereof under any provisions of this Indenture upon the direction of the Corporation shall be or, with the consent of the Corporation may be: (i) deposited in the name of the Warrant Agent in any Canadian chartered bank listed in Schedule I to the Bank Act (Canada) or any trust company registered to do business in Canada at the rate of interest (if any) then current on similar deposits; (ii) deposited in the deposit department of the Warrant Agent; or (iii) invested in treasury bills or short term interest bearing or discounted obligations issued or guaranteed by the Government of Canada or a province thereof, of any Canadian chartered bank listed in Schedule I of the Bank Act (Canada) or of the Warrant Agent, provided that the securities shall not have a maturity date of more than sixty (60) days from the date of such investment. Unless the Corporation shall be in default hereunder or unless otherwise specifically provided herein, all interest or other income received by the Warrant Agent in respect of such deposits and investments shall belong to the Corporation.


- 43 -

9.4       Actions by Warrant Agent to Protect Interest

The Warrant Agent shall have power to institute and to maintain such actions and proceedings as it may consider necessary or expedient to preserve, protect or enforce its interests and the interests of the Warrantholders.

9.5       Warrant Agent Not Required to Give Security

The Warrant Agent shall not be required to give any bond or security in respect of the execution of the trusts and powers of this Indenture or otherwise in respect of the premises.

9.6       Protection of Warrant Agent

By way of supplement to the provisions of any law for the time being relating to trustees it is expressly declared and agreed as follows:

  9.6.1

the Warrant Agent shall not be liable for or by reason of any statements of fact or recitals in this Indenture or in the Warrant Certificates (except the representation contained in Section 9.8 or in the certificate of the Warrant Agent on the Warrant Certificates) or be required to verify the same, but all such statements or recitals are and shall be deemed to be made by the Corporation;

     
  9.6.2

nothing herein contained shall impose any obligation on the Warrant Agent to see to or to require evidence of the registration or filing (or renewal thereof) of this Indenture or any instrument ancillary or supplemental hereto;

     
  9.6.3

the Warrant Agent shall not be bound to give notice to any person or persons of the execution hereof;

     
  9.6.4

subject to subsection 9.1.1, the Warrant Agent shall not incur any liability or responsibility whatever or be in any way responsible for the consequence of any breach on the part of the Corporation of any of the covenants herein contained or of any acts of any directors, officers, employees, agents or servants of the Corporation; and

     
  9.6.5

the Corporation hereby indemnifies and agrees to hold harmless the Warrant Agent from and against any and all liabilities, losses, damages, penalties, claims, actions, suits, costs, expenses and disbursements, including legal fees and disbursements of whatever kind and nature which may at any time be imposed on, incurred by or asserted against the Warrant Agent, whether groundless or otherwise, arising from or out of any act, omission or error of the Warrant Agent made in good faith in the conduct of its duties hereunder, provided that the Warrant Agent has met the standard of care, diligence and skill provided for in subsection 9.1.1 and, provided further that, the Corporation shall not be required to indemnify the Warrant Agent in the event of gross negligence, willful misconduct, bad faith or breach of the obligations of the Warrant Agent as provided in subsection 9.1.1, and this provision shall survive the resignation or removal of the Warrant Agent or the termination or discharge of this Agreement.



- 44 -

9.7

Replacement of Warrant Agent; Successor by Merger

     
9.7.1

The Warrant Agent may resign its agency and be discharged from all further duties and liabilities hereunder, subject to this Section 9.7, by giving to the Corporation not less than ninety (90) days’ prior notice in writing or such shorter prior notice as the Corporation may accept as sufficient. The Warrantholders by Extraordinary Resolution shall have power at any time to remove the existing Warrant Agent and to appoint a new Warrant Agent. In the event of the Warrant Agent resigning or being removed as aforesaid or being dissolved, becoming bankrupt, going into liquidation or otherwise becoming incapable of acting hereunder, the Corporation shall forthwith appoint a warrant agent unless a warrant agent has already been appointed by the Warrantholders; failing such appointment by the Corporation, the retiring Warrant Agent or any Warrantholder may apply to a justice of the Superior Court of the Province of Alberta on such notice as such justice may direct, for the appointment of a new warrant agent; but any new warrant agent so appointed by the Corporation or by the Court shall be subject to removal as aforesaid by the Warrantholders. Any new warrant agent appointed under any provision of this Section 9.7 shall be a corporation authorized to carry on the business of a trust company in each of the provinces of Canada. On any such appointment the new warrant agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named herein as Warrant Agent without any further assurance, conveyance, act or deed; but there shall be immediately executed, at the expense of the Corporation, all such conveyances or other instruments as may, in the opinion of Counsel to the Warrant Agent, be necessary or advisable for the purpose of assuring the same to the new warrant agent, provided that any resignation or removal of the Warrant Agent and appointment of a successor warrant agent shall not become effective until the successor warrant agent shall have executed an appropriate instrument accepting such appointment and, at the request of the Corporation, the predecessor Warrant Agent shall execute and deliver to the successor warrant agent an appropriate instrument transferring to such successor warrant agent all rights and powers of the Warrant Agent hereunder so ceasing to act.

     
9.7.2

Upon the appointment of a successor trustee, the Corporation shall promptly notify the Warrantholders thereof in the manner provided for in Section 10.1.

     
9.7.3

Any corporation into or with which the Warrant Agent may be merged or consolidated, or amalgamated, or any corporation resulting therefrom to which the Warrant Agent shall be a party, or any corporation succeeding to the trust business of the Warrant Agent shall be the successor to the Warrant Agent hereunder without any further act on its part or any of the parties hereto, provided that such corporation would be eligible for appointment as a successor warrant agent under subsection 9.7.1.



- 45 -

  9.7.4

Any Warrant Certificates certified but not delivered by a predecessor trustee may be certified by the successor trustee in the name of the predecessor or successor warrant agent.


9.8

Conflict of Interest

     
9.8.1

The Warrant Agent represents to the Corporation that at the time of execution and delivery hereof no material conflict of interest exists between its role as a trustee hereunder and its role in any other capacity and agrees that in the event of a material conflict of interest arising hereafter it will, within ninety (90) days after ascertaining that it has such material conflict of interest, either eliminate the same or assign its trust hereunder to a successor trustee approved by the Corporation and meeting the requirements set forth in subsection 9.7.1. Notwithstanding the foregoing provisions of this subsection 9.8.1, if any such material conflict of interest exists or hereafter shall exist, the validity and enforceability of this Indenture and the Warrant Certificate shall not be affected in any manner whatsoever by reason thereof.

     
9.8.2

Subject to subsection 9.8.1, the Warrant Agent, in its personal or any other capacity, may buy, lend upon and deal in securities of the Corporation and generally may contract and enter into financial transactions with the Corporation or any Subsidiary of the Corporation without being liable to account for any profit made thereby.

9.9        Acceptance of Trust

The Warrant Agent hereby accepts the trusts in this Indenture declared and provided for and agrees to perform the same upon the terms and conditions herein set forth.

9.10      Warrant Agent Not to be Appointed Receiver

The Warrant Agent and any person related to the Warrant Agent shall not be appointed a receiver, a receiver and manager or liquidator of all or any part of the assets or undertaking of the Corporation.

9.11      Warrant Agent Not Required to Give Notice of Default

The Warrant Agent shall not be bound to give any notice or do or take any act, action or proceeding by virtue of the powers conferred on it hereby unless and until it shall have been required so to do under the terms hereof; nor shall the Warrant Agent be required to take notice of any default hereunder, unless and until notified in writing of such default, which notice shall distinctly specify the default desired to be brought to the attention of the Warrant Agent and in the absence of any such notice the Warrant Agent may for all purposes of this Indenture conclusively assume that no default has been made in the observance or performance of any of the representations, warranties, covenants, agreements or conditions contained herein. Any such notice shall in no way limit any discretion herein given to the Warrant Agent to determine whether or not the Warrant Agent shall take action with respect to any default.


- 46 -

9.12      Force Majeure

Except for the payment obligations of the Corporation contained herein, neither party shall be liable to the other, or held in breach of this Agreement, if prevented, hindered, or delayed in the performance or observance of any provision contained herein by reason of act of God, riots, terrorism, acts of war, epidemics, governmental action or judicial order, earthquakes, or any other similar causes (including, but not limited to, mechanical, electronic or communication interruptions, disruptions or failures). Performance times under this Agreement shall be extended for a period of time equivalent to the time lost because of any delay that is excusable under this Section.

9.13      Third Parties

The Corporation hereby represents to the Warrant Agent that any account to be opened by, or interest to held by, Warrant Agent in connection with this Agreement, for or to the credit of the Corporation, either (i) is not intended to be used by or on behalf of any third party; or (ii) is intended to be used by or on behalf of a third party, in which case the Corporation agrees to complete and execute forthwith a declaration in the Warrant Agent’s prescribed form as to the particulars of such third party.

9.14      Anti-Money Laundering

The Warrant Agent shall retain the right not to act and shall not be liable for refusing to act if, due to a lack of information or for any other reason whatsoever, the Warrant Agent, in its sole judgment, determines that such act might cause it to be in non-compliance with any applicable anti money laundering or anti-terrorist or economic sanctions legislation, regulation or guideline. Further, should the Warrant Agent, in its sole judgment, determine at any time that its acting under this Agreement has resulted in its being in non-compliance with any applicable anti money laundering or antiterrorist legislation, regulation or guideline, then it shall have the right to resign on ten (10) days’ written notice to the Corporation, provided that (i) the Warrant Agent’s written notice shall describe the circumstances of such non-compliance; and (ii) if such circumstances are rectified to the Warrant Agent’s satisfaction within such ten (10) day period, then such resignation shall not be effective.

9.15      Privacy

The parties acknowledge that the Warrant Agent may, in the course of providing services hereunder, collect or receive financial and other personal information about such parties and/or their representatives, as individuals, or about other individuals related to the subject matter hereof, and use such information for the following purposes:

  (a)

to provide the services required under this Indenture and other services that may be requested from time to time;



- 47 -

  (b)

to help the Warrant Agent manage its servicing relationships with such individuals;

     
  (c)

to meet the Warrant Agent’s legal and regulatory requirements; and

     
  (d)

if social insurance numbers are collected by the Warrant Agent, to perform tax reporting and to assist in verification of an individual’s identity for security purposes.

Each party acknowledges and agrees that the Warrant Agent may receive, collect, use and disclose personal information provided to it or acquired by it in the course of this agreement for the purposes described above and, generally, in the manner and on the terms described in its Privacy Code, which the Warrant Agent shall make available on its website or upon request, including revisions thereto. Some of this personal information may be transferred to servicers in the U.S.A. for data processing and/or storage. Further, each party agrees that it shall not provide or cause to be provided to the Warrant Agent any personal information relating to an individual who is not a party to this agreement unless that party has assured itself that such individual understands and has consented to the aforementioned terms, uses and disclosures.

ARTICLE 10 - GENERAL

10.1

Notice to the Corporation and the Warrant Agent

     
10.1.1

Unless herein otherwise expressly provided, any notice to be given hereunder to the Corporation or the Warrant Agent shall be deemed to be validly given if delivered, sent by registered letter, postage prepaid or telecopied:


  (a)

If to the Corporation:

     
 

Stem Cell Therapeutics Corp.
MaRS Centre, Heritage Building
101 College Street, Suite 200
Toronto, Ontario M5G 1L7
Attention:            James Parsons, CFO
Email:                    jparsons@stemcellthera

     
  (b)

If to the Warrant Agent:

     
 

Computershare Trust Company of Canada
600, 530 – 8 Avenue S.W.

Calgary, Alberta T2P 3S8

 

Attention:            Manager, Corporate Trust
Facsimile:             403-267-6598

and any such notice delivered in accordance with the foregoing shall be deemed to have been received on the date of delivery or, if mailed, on the fifth (5th) Business Day following the date of the postmark on such notice or, if telecopied, on the next Business Day following the date of transmission provided that its contents are transmitted and received completely and accurately.


- 48 -

  10.1.2

The Corporation or the Warrant Agent, as the case may be, may from time to time notify the other in the manner provided in subsection 10.1.1 of a change of address which, from the effective date of such notice and until changed by like notice, shall be the address of the Corporation or the Warrant Agent, as the case may be, for all purposes of this Indenture.

     
  10.1.3

If, by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given to the Warrant Agent or to the Corporation hereunder could reasonably be considered unlikely to reach its destination, such notice shall be valid and effective only if it is delivered to the named officer of the party to which it is addressed or, if it is delivered to such party at the appropriate address provided in subsection 10.1.1, by telecopy or other means of prepaid, transmitted and recorded communication.


10.2

Notice to Warrantholders

     
10.2.1

Unless otherwise provided herein, notice to the Warrantholders under the provisions of this Indenture shall be valid and effective if delivered or sent by telecopy or by ordinary post addressed to such holders at their post office addresses appearing on the register hereinbefore mentioned and shall be deemed to have been effectively given on the date of delivery or, if mailed, on the fifth Business Day following the date of the postmark on such notice or, if telecopied, on the next Business Day following the date of transmission, provided that its contents are transmitted and received completely and accurately.

     
10.2.2

If, by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given to the Warrantholders hereunder could reasonably be considered unlikely to reach its destination, such notice shall be valid and effective only if such notice is published once in the National Edition of The Globe and Mail or, if the National Edition of The Globe and Mail is not being generally circulated, in The National Post, and, if the National Edition of The Globe and Mail (or The National Post if the notice is published therein) is not circulated in a city where a Warrant Agency is situated, in an English language daily newspaper of general circulation in such city; provided that in the case of a notice convening a meeting of Warrantholders, the Warrant Agent may require such additional publications of such notice, in the same or another city or both as it may deem necessary for the reasonable protection of the Warrantholders or to comply with any applicable requirements of law or of any stock exchange. Any notice so given shall be deemed to have been given on the day on which it has been published in the National Edition of The Globe and Mail or The National Post, as the case may be, and in all of the cities in which such publication was required (or first published in all such cities if more than one publication in any such city is required). In determining under any provision hereof the date when notice of any meeting or other event must be given, the date of giving notice shall be included and the date of the meeting or other event shall be excluded.



- 49 -

10.3      Ownership of Warrants

The Corporation and the Warrant Agent may deem and treat the registered owner of any Warrants as the absolute owner thereof for all purposes, and the Corporation and the Warrant Agent shall not be affected by any notice or knowledge to the contrary except where the Corporation or the Warrant Agent is required to take notice by statute or by order of a court of competent jurisdiction. A Warrantholder shall be entitled to the rights evidenced by its Warrant Certificate free from all equities or rights of set off or counterclaim between the Corporation and the original or any intermediate holder of the Warrants and all persons may act accordingly. The receipt of any such Warrantholder for the Common Shares which may be acquired pursuant thereto, or the receipt of the amount payable to such Warrantholder upon the exercise of the repurchase right referred to in Section 5.1 shall be a good discharge to the Corporation and the Warrant Agent for the same and neither the Corporation nor the Warrant Agent shall be bound to inquire into the title of any such holder except where the Corporation or the Warrant Agent is required to take notice by statute or by order of a court of competent jurisdiction.

10.4

Evidence of Ownership

     
10.4.1

Upon receipt of a certificate of any bank, trust company or other depositary satisfactory to the Warrant Agent stating that the Warrants specified therein have been deposited by a named person with such bank, trust company or other depositary and will remain so deposited until the expiry of the period specified therein, the Corporation and the Warrant Agent may treat the person so named as the owner, and such certificate as sufficient evidence of the ownership by such person of such Warrant during such period, for the purpose of any requisition, direction, consent, instrument or other document to be made, signed or given by the holder of the Warrant so deposited.

     
10.4.2

The Corporation and the Warrant Agent may accept as sufficient evidence of the fact and date of the signing of any requisition, direction, consent, instrument or other document by any person (i) the signature of any officer of any bank, trust company, or other depositary satisfactory to the Warrant Agent as witness of such execution, (ii) the certificate of any notary public or other officer authorized to take acknowledgements of deeds to be recorded at the place where such certificate is made that the person signing acknowledged to him the execution thereof, (iii) a statutory declaration of a witness of such execution, or (iv) any other documentation satisfactory to the Corporation and the Warrant Agent.

10.5      Counterparts

This Indenture may be executed in several counterparts, each of which when so executed shall be deemed to be an original and such counterparts together shall constitute one and the same instrument and notwithstanding their date of execution they shall be deemed to be dated as of the date hereof:


- 50 -

10.6       Satisfaction and Discharge of Indenture

Upon the earlier of:

  10.6.1

the date by which there shall have been delivered to the Warrant Agent for exercise or destruction all Warrant Certificates contemplated to be certified hereunder; or

     
  10.6.2

the Expiry Time;

and if all certificates representing Common Shares required to be issued in compliance with the provisions hereof have been issued and delivered hereunder or to the Warrant Agent in accordance with such provisions and if all payments required to be made in accordance with such provisions have been made, this Indenture shall cease to be of further effect and the Warrant Agent, on demand of and at the cost and expense of the Corporation and upon delivery to the Warrant Agent of a certificate of the Corporation stating that all conditions precedent to the satisfaction and discharge of this Indenture have been complied with, shall execute proper instruments acknowledging satisfaction of and discharging this Indenture. Notwithstanding the foregoing, the indemnities provided to the Warrant Agent by the Corporation hereunder shall remain in full force and effect and survive the termination of this Indenture.

10.7       Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders

Nothing in this Indenture or in the Warrant Certificates, expressed or implied, shall give or be construed to give to any person other than the parties hereto and the Warrantholders, as the case may be, any legal or equitable right, remedy or claim under this Indenture, or under any covenant or provision herein or therein contained, all such covenants and provisions being for the sole benefit of the parties hereto and the Warrantholders.

10.8      Common Shares or Warrants Owned by the Corporation or its Subsidiaries -Certificate to be Provided

For the purpose of disregarding any Warrants owned legally or beneficially by the Corporation or any Subsidiary of the Corporation in Section 7.16, the Corporation shall provide to the Warrant Agent, from time to time, a certificate of the Corporation setting forth as at the date of such certificate:

  10.8.1

the names (other than the name of the Corporation) of the registered holders of Warrants which, to the knowledge of the Corporation, are owned by or held for the account of the Corporation or any Subsidiary of the Corporation; and

     
  10.8.2

the number of Warrants owned legally or beneficially by the Corporation or any Subsidiary of the Corporation;

and the Warrant Agent, in making the computations in Section 7.16, shall be entitled to rely on such certificate without any additional evidence.


- 51 -

[Signatures on following page]


- 52 -

IN WITNESS WHEREOF the parties hereto have executed this Indenture under their respective corporate seals and the hands of their proper officers in that behalf.

STEM CELL THERAPEUTICS CORP.

  Per: (signed) “ James Parsons
    Name: James Parsons
    Title: Chief Financial Officer

COMPUTERSHARE TRUST COMPANY OF CANADA

  Per: (signed) “ Pui Hong
    Name: Pui Hong
    Title: Corporate Trust Officer
     
  Per: (signed) “ Shannon Grover
    Name: Shannon Grover
    Title: Corporate Trust Officer


A-1

SCHEDULE A
FORM OF WARRANT CERTIFICATE

UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE JULY [16] , 2013.

[CERTIFICATES REPRESENTING WARRANTS ISSUED TO U.S. PURCHASERS MUST BEAR THE FOLLOWING LEGEND.]

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ U.S. SECURITIES ACT ”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THE HOLDER HEREOF, BY PURCHASING THE SECURITIES REPRESENTED HEREBY, AGREES FOR THE BENEFIT OF STEM CELL THERAPEUTICS CORP. AND ITS SUCCESSORS (THE “ CORPORATION ”) THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH LOCAL LAWS AND REGULATIONS, (C) WITHIN THE UNITED STATES PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY (I) RULE 144A OR (II) RULE 144 THEREUNDER, IF APPLICABLE, AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) WITHIN THE UNITED STATES, IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS GOVERNING THE OFFER AND SALE OF SECURITIES, AND IN THE CASE OF TRANSFERS PURSUANT TO (C)(II) OR (D) ABOVE, THE HOLDER HEREOF HAS, PRIOR TO SUCH TRANSFER, FURNISHED TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE CORPORATION TO SUCH EFFECT.

DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE ‘GOOD DELIVERY’ IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.

[CERTIFICATES REPRESENTING WARRANTS ISSUED TO ALL PURCHASERS MUST BEAR THE FOLLOWING LEGEND.]

THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ U.S. SECURITIES ACT ”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THIS WARRANT MAY NOT BE EXERCISED IN THE UNITED STATES OR BY OR ON BEHALF OF, OR FOR THE ACCOUNT OR BENEFIT OF, A U.S. PERSON UNLESS THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH STATE OR EXEMPTIONS FROM SUCH REGISTRATION REQUIREMENTS ARE AVAILABLE. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE U.S. SECURITIES ACT


A-2

Certificate No.: ______________________  No. of Warrants: _________________________   ISN No.: • 
                                                                                                                                                                             CUSIP No.: •

WARRANTS
Exercisable to Acquire
Common Shares
of
STEM CELL THERAPEUTICS CORP.

(Incorporated under the Business Corporations Act (Alberta))

THIS IS TO CERTIFY THAT, for value received, • (the “ holder ”) is the registered holder of the number of Warrants of Stem Cell Therapeutics Corp. (“ SCT ”) specified above and, for each whole Warrant held, is thereby entitle to be issued, subject to adjustment and except as otherwise described herein, one fully paid and non-assessable Common Share and subject to the limitation referred to below by surrendering to Computershare Trust Company of Canada (the “ Warrant Agent ”) at its principal transfer office in Calgary, Alberta or Toronto, Ontario during the exercise period hereinafter referred to (i) a certified cheque, bank draft or money order made payable to SCT in the amount of the Exercise Price as hereinafter determined in respect of each Common Share to be issued, (ii) this Warrant Certificate and (iii) a notice of exercise in the form set forth in Appendix 1 annexed hereto duly completed and executed.

Capitalized terms which are not otherwise defined herein shall have the same meaning as in the Warrant indenture (which indenture, together with all instruments supplemental or ancillary thereto, is herein referred to as the “ Warrant Indenture ”) dated March 15, 2013 between SCT and the Warrant Agent.

Surrender of this Warrant Certificate will be deemed to have been effected only on personal delivery thereof to, or, if sent by mail or other means of transmission, on actual receipt thereof by, the Warrant Agent at the office specified above.

This Warrant Certificate evidences Warrants of SCT issued or issuable under the provisions of the Warrant Indenture. Reference is made to the Warrant Indenture for particulars of the rights of the holders of the Warrants and of SCT and of the Warrant Agent in respect thereof and of the terms and conditions upon which the Warrants are issued and held, all to the same effect as if the provisions of the Warrant Indenture were herein set forth in full, to all of which the holder, by acceptance hereof, assents. To the extent of any inconsistency between the terms of the Warrant Indenture and the terms of this Warrant Certificate, the terms of the Warrant Indenture shall prevail. SCT will furnish to the holder, on request and upon payment of a reasonable charge for photocopying and postage, a copy of the Warrant Indenture.

The Warrants evidenced by this Warrant Certificate may be exercised by the holder (including, if applicable, any agent under any power of attorney granted by such holder) at any time until the Expiry Time.


A-3

Except as otherwise expressly provided, all dollar amounts herein are expressed in Canadian dollars.

On and after the date of any exercise of the Warrants evidenced by this Warrant Certificate, the holder will have no rights hereunder except to receive certificates representing the Common Shares thereby issued to him upon delivery of a certified cheque, bank draft or money order payable to SCT in respect of each Common Share to be issued in the amount of $0.40 (the “ Exercise Price ”), this Warrant Certificate and a duly completed notice of exercise as set out in Appendix 1 hereto to the Warrant Agent at its principal office in Calgary, Alberta or Toronto, Ontario. After the Expiry Time, all rights under any unexercised Warrant evidenced hereby will wholly cease and terminate and this Warrant Certificate will be void.

SCT will not be obligated to issue any fraction of a Common Share on the exercise of any Warrant. To the extent that a holder of Warrants would otherwise have been entitled to receive, on the exercise of Warrants, a fraction of a Common Share, such right may only be exercised in respect of such fraction in connection with another Warrant or Warrants which in the aggregate entitle the holder to receive a whole number of Common Shares. If a Warrantholder is not able to combine Warrants so as to be entitled to acquire a whole number of Common Shares, the number of Common Shares which such Warrantholder is entitled to receive shall be rounded down to the prior whole number, as applicable.

The Warrant Indenture provides for adjustments to the number of Common Shares issuable and to the Exercise Price in certain events set forth therein.

The Warrant Indenture contains provisions making binding on all holders of Warrants outstanding thereunder resolutions passed at meetings of such holders held in accordance with such provisions and instruments in writing signed by holders of a specified majority of all outstanding Warrants.

On presentation at the principal office of the Warrant Agent in Calgary, Alberta or Toronto, Ontario, subject to the provisions of the Warrant Indenture and on compliance with the reasonable requirements of the Warrant Agent, one or more Warrant Certificates may be exchanged at no cost to the holder for one or more Warrant Certificates of different denominations evidencing in the aggregate the same number of Warrants as the Warrant Certificate or Warrant Certificates being exchanged.

The Warrants evidenced by this Warrant Certificate may only be transferred, upon compliance with the conditions prescribed in the Warrant Indenture, on the register of transfers to be kept at the principal office of the Warrant Agent in Calgary, Alberta or Toronto, Ontario by the holder or his executors, administrators or other legal representatives or his or their attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent, and, upon compliance with such requirements and such other reasonable requirements as the Warrant Agent may prescribe, including the completion of a form of transfer as set out in Appendix 2 hereto, such transfer will be duly noted on such register of transfers by the Warrant Agent. Notwithstanding the foregoing, SCT will be entitled, and may direct the Warrant Agent, to refuse to record any transfer of any Warrant on such register if such transfer would constitute a violation of the securities laws of any jurisdiction or require SCT to qualify the Common Shares for distribution in any jurisdiction other than the Qualifying Provinces.


A-4

No Common Shares will be issued pursuant to any exercise of any Warrant if the issue of such security would constitute a violation of the securities laws of any applicable jurisdiction.

The holding of this Warrant Certificate will not constitute the holder a shareholder of SCT or entitle such holder to any right or interest in respect thereof except as otherwise provided in the Warrant Indenture.

This Warrant Certificate will not be valid for any purpose until it has been certified by or on behalf of the Warrant Agent for the time being under the Warrant Indenture. Time will be of the essence hereof.

THE WARRANTS REPRESENTED BY THIS CERTIFICATE WILL BE VOID AND OF NO VALUE UNLESS EXERCISED PRIOR TO 5:00 P.M. (TORONTO TIME) ON OR BEFORE MARCH 15, 2018.

IN WITNESS WHEREOF SCT has caused this Warrant Certificate to be signed by its officer or other individual duly authorized in that behalf as of

STEM CELL THERAPEUTICS CORP.

  Per:   
    Name:
    Title:

 

This Warrant Certificate is one of the Warrant Certificates referred to in the Warrant Indenture within mentioned.

 

COMPUTERSHARE TRUST COMPANY OF CANADA

  Per:   
    Name:
    Title:
     
  Per:   
    Name:
    Title:


1-1

APPENDIX 1
NOTICE OF EXERCISE

To: STEM CELL THERAPEUTICS CORP.
   
And To: COMPUTERSHARE TRUST COMPANY OF CANADA

600, 530 – 8 Avenue S.W. or 100 University Avenue, 9th Floor
Calgary, Alberta T2P 3S8   Toronto, Ontario M5J 2Y1

The undersigned holder of the Warrants evidenced by the within Warrant Certificate hereby exercises its right to be issued Common Shares of Stem Cell Therapeutics Corp. (or such other securities or property to which such exercise entitles such holder in lieu thereof or in addition thereto under the provisions of the Warrant Indenture mentioned in such Warrant Certificate) that are issuable upon the exercise of such Warrants, on the terms specified in such Warrant Certificate and Warrant Indenture.

The undersigned hereby irrevocably directs that the said Common Shares be issued, registered and delivered as follows:

        Number of Common Shares and
Name(s) in Full   Address(es)   Number of Warrants (# and #)
         
         
         
         
         
         

(Please print full name in which certificates for Common Shares are to be issued. If any shares are to be issued to a person or persons other than the holder, the holder must pay to the Warrant Agent all exigible transfer taxes or other government charges and sign the Form of Transfer.)

DATED this ________day of  _________________________, ________.

 

     
Witness   Signature of Registered Holder
     
     
    Signature of Registered Holder

Note: The name of the Registered Holder on this Notice of Exercise must be the same as the name appearing on the face page of the Warrant Certificate to which this Notice of Exercise is attached.


1-2

The undersigned represents, warrants and certifies as follows (one of the following must be checked):

[   ]   A.      The undersigned holder (i) at the time of exercise of the Warrant is not in the United States; (ii) is not a U.S. Person and is not exercising the Warrant for the account or benefit of a U.S. Person; (iii) was not offered to exercise the Warrant and did not execute or deliver the exercise form for the Warrant in the United States; (iv) did not acquire the Warrant in the United States; and (v) has in all other respects complied with Regulation S of the United States Securities Act of 1933, as amended.

[   ]   B.      The undersigned holder (i) originally purchased the Warrant on its own behalf or on behalf of a beneficial purchaser (a “ Beneficial Purchaser ”) directly from the Corporation pursuant to the Corporation’s offering of Units at a time when the holder was and any Beneficial Purchaser was (A) an “accredited investor”, as defined in Rule 501(a) under the U.S. Securities Act (“ Accredited Investor ”) and (B) in the United States or a U.S. Person, or was offered Units in the United States, (ii) is exercising the Warrant solely for its own account or for the account of the Beneficial Purchaser, if any, and not on behalf of any other person, (iii) is, and the Beneficial Purchaser, if any, is, an Accredited Investor on the date of exercise of the Warrant, and (iv) as of the date of exercise of the Warrant, it reaffirms the representations, warranties, and agreements made by it in the U.S. Purchaser Letter.

[   ]   C.       An exemption from registration under the U.S. Securities Act and any applicable state securities law is available, and attached hereto is an opinion of counsel to such effect, it being understood that any opinion of counsel tendered in connection with the exercise of Warrants must be in form and substance satisfactory to Stem Cell Therapeutics Corp.

The undersigned holder understands that (i) unless box A is checked, the certificate representing the Common Shares will bear a legend restricting transfer without registration under the U.S. Securities Act and applicable state securities laws unless an exemption from registration is available, and (ii) Common Shares will not be delivered to an address in the United States unless box B or box C is checked and, if box C is checked, the required opinion of counsel is in form and substance satisfactory to Corporation and an executed letter, substantially in the form of Schedule “D” to the Indenture, is delivered to the Warrant Agent (a copy of which is available upon request from the Warrant Agent or the Corporation).

DATED this ___ day of _____________, 20__.

Signature Guarantee:

The signature on this exercise form must correspond with the name as written upon the face of the certificate(s), in every particular, without alteration or enlargement, or any change whatsoever and must be guaranteed by a Canadian Schedule 1 chartered bank or a member of the Securities Transfer Agents Medallion Program (STAMP), a member of the Stock Exchange Medallion Program (SEMP) or a member of the New York Stock Exchange Inc. Medallion Signature Program (MSP). The guarantor must affix a stamp bearing the actual words “Signature Guaranteed”


1-3

[   ]

Please check if the Common Share certificates are to be delivered at the office where this Warrant Certificate is surrendered, failing which such certificates will be mailed.

Certificates will be delivered or mailed as soon as practicable after the due surrender of the Warrant Certificate to which this Appendix is attached.


2-1

APPENDIX 2
FORM OF TRANSFER

FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers to

Name:          ___________________________________________________________________________________

Address:     ___________________________________________________________________________________

(such person, the “ Transferee ”) ____________________ Warrants of Stem Cell Therapeutics Corp. (the “ Corporation ”) represented by the attached Warrant Certificate and does hereby appoint ____________________ as its attorney with full power of a substitution to transfer the Warrants on the appropriate register of the Warrant Agent.

If the Warrant Certificate contains a legend restricting transfer of the Warrants except in compliance with the United States Securities Act of 1933, as amended (the “ U.S. Securities Act ”), and applicable state securities laws, this Transfer Form must be accompanied by a declaration to the effect that the Warrants are being transferred outside the United States in compliance with Rule 904 of Regulation S under the U.S. Securities Act in the form set forth in the Form of Declaration for Removal of Legend that follows (or as otherwise prescribed by the Corporation).

If the sale evidenced hereby is being made to a U.S. Person (as such term is defined in Regulation S to the United States Securities Act of 1933 (the “ Act ”), the undersigned, by the execution of this form of transfer, certifies that such sale does not require registration of the Warrants being transferred hereby under the Act and tenders herewith evidence satisfactory to the Corporation to such effect.

DATED this ________ day of _________________________, ________.

 

 

     
Witness   Signature of Transferor
     
     
     
    Signature of Registered Holder

Note: The name of the Transferor on this Form of Transfer must be the same as the name appearing on the face page of the Warrant.


B-1

SCHEDULE B
FORM OF DECLARATION FOR REMOVAL OF LEGEND

to the Warrant Indenture made as of , 2013 between Stem Cell Therapeutics Corp. and
Computershare Trust Company of Canada as Warrant Agent

TO:

COMPUTERSHARE TRUST COMPANY OF CANADA as warrant agent for Warrants of Stem Cell Therapeutics Corp.

The undersigned (a) acknowledges that the sale of securities of Stem Cell Therapeutics Corp. (the “ Company ”) to which this declaration relates is being made in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the “ U.S. Securities Act ”) and (b) certifies that (1) the undersigned is not an “affiliate” of the Company as that term is defined in Rule 405 under the U.S. Securities Act, (2) the offer of such securities was not made to a person in the United States and either (A) at the time the buy order was originated, the buyer was outside the United States, or the seller and any person acting on its behalf reasonably believed that the buyer was outside the United States, or (B) the transaction was executed in, on or through the facilities of a “designated offshore securities market” as that term is defined in Regulation S under the U.S. Securities Act and neither the seller nor any person acting on its behalf knows that the transaction has been prearranged with a buyer in the United States, (3) neither the seller nor any affiliate of the seller not any person acting on any of their behalf has engaged or will engage in “directed selling efforts” in the United States in connection with the offer and sale of such securities, (4) the sale is bona fide and not for the purposes of “washing off” the resale restrictions imposed because the securities are “restricted securities” (as such term is defined in Rule 144(a)(3) under the U.S. Securities Act), (5) the seller does not intend to replace the securities sold in reliance on Rule 904 under the U.S. Securities Act with fungible unrestricted securities and (6) the contemplated sale is not a transaction, or part of a series of transactions which, although in technical compliance with Regulation S, is part of a plan or scheme to evade the registration provisions of the U.S. Securities Act. Terms used herein have the meanings given to them by Regulation S under the U.S. Securities Act.

Date:      
      Name of Seller
       
       
      Per:
                 Name
                 Title



Exhibit 4.8

WARRANT INDENTURE

Providing for the Issue of Warrants

 

BETWEEN

 

STEM CELL THERAPEUTICS CORP.

 

AND

 

COMPUTERSHARE TRUST COMPANY OF CANADA

 

Dated as of April 8, 2013


Table of Contents

    Page
     
ARTICLE 1 - INTERPRETATION 2
     
      1.1 Definitions 2
      1.2 Gender and Number 6
      1.3 Interpretation not Affected by Headings, etc. 6
      1.4 Day not a Business Day 6
      1.5 Time of the Essence 6
      1.6 Currency 6
      1.7 Assignment 6
      1.8 Applicable Law and Jurisdiction 7
     
ARTICLE 2 - ISSUE OF WARRANTS 7
     
      2.1 Creation and Issue of Warrants 7
      2.2 Terms of the Warrants 7
      2.3 Warrantholder not a Shareholder 7
      2.4 Warrants to Rank Pari Passu 8
      2.5 Form of Warrants 8
      2.6 Execution of Warrant Certificates 8
      2.7 Certification by the Warrant Agent 8
      2.8 Issue in Substitution for Warrant Certificates Lost, etc. 9
      2.9 Exchange of Warrant Certificates 10
      2.10 Transfer and Ownership of Warrants 10
      2.11 Charges for Exchange or Transfer 12
      2.12 Cancellation of Surrendered Warrants 12
      2.13 Registration of Warrants 12
      2.14 CDS and Depository 12
      2.15 NCI Letter of Instruction 15
      2.16 Legends 15
     
ARTICLE 3 - EXERCISE OF WARRANTS 17
     
      3.1 Method of Exercise of Warrants 17
      3.2 Effect of Exercise of Warrants 20
      3.3 Partial Exercise of Warrants; Fractions 20
      3.4 Expiration of Warrants 21
      3.5 Accounting and Recording 21
      3.6 Securities Restrictions 21
      3.7 Prohibition on Exercise in the United States or by U.S. Persons; Exception 22
     
ARTICLE 4 - ADJUSTMENT OF NUMBER OF COMMON SHARES AND EXERCISE PRICE 23
     
      4.1 Adjustment of Number of Common Shares and Exercise Price 23


- ii -

      4.2 Entitlement to Shares on Exercise of Warrant 27
      4.3 No Adjustment for Certain Transactions 27
      4.4 Determination by Corporation’s Auditors 28
      4.5 Proceedings Prior to any Action Requiring Adjustment 28
      4.6 Certificate of Adjustment 28
      4.7 Notice of Special Matters 28
      4.8 No Action After Notice 28
      4.9 Other Action 29
      4.10 Protection of Warrant Agent 29
     
ARTICLE 5 - RIGHTS OF THE CORPORATION AND COVENANTS 29
     
      5.1 Optional Purchases by the Corporation 29
      5.2 General Covenants 30
      5.3 Warrant Agent’s Remuneration and Expenses 31
      5.4 Securities Qualification Requirements 31
      5.5 Performance of Covenants by Warrant Agent 32
      5.6 Enforceability of Warrants 32
     
ARTICLE 6 - ENFORCEMENT 32
     
      6.1 Suits by Warrantholders 32
      6.2 Immunity of Shareholders, etc. 32
      6.3 Limitation of Liability 32
      6.4 Waiver of Default 33
     
ARTICLE 7 – MEETINGS OF WARRANTHOLDERS 33
     
      7.1 Right to Convene Meetings 33
      7.2 Notice 33
      7.3 Chairman 34
      7.4 Quorum 34
      7.5 Power to Adjourn 34
      7.6 Show of Hands 34
      7.7 Poll and Voting 35
      7.8 Regulations 35
      7.9 Corporation and Warrant Agent May be Represented 36
      7.10 Powers Exercisable by Extraordinary Resolution 36
      7.11 Meaning of Extraordinary Resolution 37
      7.12 Powers Cumulative 38
      7.13 Minutes 38
      7.14 Instruments in Writing 38
      7.15 Binding Effect of Resolutions 38
      7.16 Holdings by Corporation Disregarded 39
     
ARTICLE 8 - SUPPLEMENTAL INDENTURES 39
     
      8.1 Provision for Supplemental Indentures for Certain Purposes 39


- iii -

      8.2 Successor Corporations 40
     
ARTICLE 9 - CONCERNING THE WARRANT AGENT 40
     
      9.1 Rights and Duties of Warrant Agent 40
      9.2 Evidence, Experts and Advisers 41
      9.3 Documents, Monies, etc. Held by Warrant Agent 42
      9.4 Actions by Warrant Agent to Protect Interest 42
      9.5 Warrant Agent Not Required to Give Security 42
      9.6 Protection of Warrant Agent 43
      9.7 Replacement of Warrant Agent; Successor by Merger 43
      9.8 Conflict of Interest 44
      9.9 Acceptance of Trust 45
      9.10 Warrant Agent Not to be Appointed Receiver 45
      9.11 Warrant Agent Not Required to Give Notice of Default 45
      9.12 Force Majeure 45
      9.13 Third Parties 46
      9.14 Anti-Money Laundering 46
      9.15 Privacy 46
     
ARTICLE 10 - GENERAL 47
     
      10.1 Notice to the Corporation and the Warrant Agent 47
      10.2 Notice to Warrantholders 48
      10.3 Ownership of Warrants 48
      10.4 Evidence of Ownership 49
      10.5 Counterparts 49
      10.6 Satisfaction and Discharge of Indenture 49
      10.7 Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders 50
      10.8 Common Shares or Warrants Owned by the Corporation or its Subsidiaries - Certificate to be Provided 50
     
SCHEDULE A FORM OF WARRANT CERTIFICATE A-1
   
      APPENDIX 1 NOTICE OF EXERCISE 1-1
   
      APPENDIX 2 FORM OF TRANSFER 2-1
   
SCHEDULE B FORM OF DECLARATION FOR REMOVAL OF LEGEND B-1


THIS WARRANT INDENTURE is made as of April 8, 2013

BETWEEN:

STEM CELL THERAPEUTICS CORP. , a corporation incorporated under the laws of the Province of Alberta, having its head office currently in the City of Toronto, in the Province of Ontario;

 

 

(the “ Corporation ”);

 

AND:

COMPUTERSHARE TRUST COMPANY OF CANADA , a trust company incorporated under the laws of Canada and authorized to carry on business in all provinces of Canada;

 

 

(the “ Warrant Agent ”).

WHEREAS:

A.

The Corporation desires to issue, from time to time, up to a maximum of 10,000,000 Warrants (as defined below) pursuant to applicable exemptions from prospectus and registration requirements of securities laws;

   
B.

Each Warrant issued under this Indenture shall entitle its holder to receive one (1) Common Share (as defined below) and one (1) common share purchase warrant (each common share purchase warrant referred to herein as a “ Warrant ”);

   
C.

Each whole Warrant will, subject to adjustment, entitle the holder thereof to acquire one (1) Common Share upon payment of the Exercise Price (as defined below) and subject to the terms and conditions set forth herein;

   
D.

In order to satisfy the exercise of the rights attached to each Warrant, the Corporation has agreed to reserve for issuance one (1) Common Share for each whole Warrant outstanding;

   
E.

All acts and deeds necessary have been done and performed to make the Warrants, when created and issued as provided in this Indenture, legal, valid and binding upon the Corporation with the benefits and subject to the terms of this Indenture; and

NOW THEREFORE , in consideration of the premises and mutual covenants hereinafter contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Corporation hereby appoints the Warrant Agent to hold the rights, interests and benefits contained herein for and on behalf of those persons who from time to time become the holders of Warrants issued pursuant to this Indenture and the parties hereto agree as set forth below:


- 2 -

ARTICLE 1 - INTERPRETATION

1.1

Definitions

In this Indenture, including the recitals and schedules hereto, and in all indentures supplemental hereto, unless there is something in the subject matter or context inconsistent therewith:

  1.1.1

Accredited Investor ” means an “accredited investor” as defined in Rule 501(a) of Regulation D, that satisfies the requirements of Rule 501(a);

     
  1.1.2

Adjustment Period ” means the period from and including the Effective Date up to and including the Expiry Time;

     
  1.1.3

Agent ” means Euro Pacific Canada Inc.

     
  1.1.4

Applicable Legislation ” means the provisions of the Business Corporations Act (Alberta), as from time to time amended, and any statute of Canada or a province thereof, and the regulations under any such named or other statute, relating to trust indentures or to the rights, duties and obligations of trustees and of corporations under trust indentures, to the extent that such provisions are at the time in force and applicable to this Indenture;

     
  1.1.5

Beneficial Owner ” means a person that has a beneficial interest in a Warrant that is represented by a Global Certificate;

     
  1.1.6

Book Based System ” means the book based securities transfer system administered by CDS in accordance with its operating procedure from time to time;

     
  1.1.7

Book Entry Only Participant ” means an institution that participates directly or indirectly in the Depository’s book entry registration system for the Warrants;

     
  1.1.8

Business Day ” means a day which is not Saturday or Sunday or a legal holiday in the city of Calgary, Alberta or Toronto, Ontario;

     
  1.1.9

CDS ” means CDS Clearing and Depository Services Inc. and its successors in interest;

     
  1.1.10

CDS Participant ” means a participant in the Book Based System or its nominees;

     
  1.1.11

Common Shares ” means, subject to Article 4, fully paid and non-assessable common shares of the share capital of the Corporation as presently constituted;

     
  1.1.12

Corporation ” means Stem Cell Therapeutics Corp., a corporation incorporated under the Business Corporations Act (Alberta) and its lawful successors from time to time;



- 3 -

  1.1.13

Corporation’s Auditors ” means Ernst & Young LLP or any other firm of chartered accountants duly appointed as auditors of the Corporation;

     
  1.1.14

Counsel ” means a barrister or solicitor or a firm of barristers and solicitors retained by the Warrant Agent or retained by the Corporation and acceptable to the Warrant Agent;

     
  1.1.15

Current Market Price ” of the Common Shares at any date means the volume weighted average of the trading price of the Common Shares for the twenty (20) consecutive Trading Days immediately preceding such date on the principal stock exchange on which the Common Shares are listed and as selected by the directors, or, if such Common Shares are not listed on any stock exchange, then on such over the counter market as may be selected for such purpose by the directors;

     
  1.1.16

Depository ” means CDS or a successor depository or any other depository offering a similar Book Based System for recording beneficial interest in the Warrants which the Corporation, acting reasonably, may designate;

     
  1.1.17

Director ” means a director of the Corporation for the time being and, unless otherwise specified herein, reference to action “ by the directors ” means action by the directors of the Corporation as a board or, whenever duly empowered, action by any committee of such board;

     
  1.1.18

Dividends Paid in the Ordinary Course ” means cash dividends declared payable on the Common Shares in any fiscal year of the Corporation to the extent that such cash dividends do not exceed, in the aggregate, greater than: (i) twenty percent (20%) of the retained earnings of the Corporation as at the end of its immediately preceding fiscal year; and (ii) forty percent (40%) of the aggregate consolidated net income of the Corporation, determined before computation of extraordinary items, for its immediately preceding fiscal year;

     
  1.1.19

Effective Date ” means the date of this Indenture;

     
  1.1.20

Exercise Date ” means, with respect to any Warrant, the date on which the Warrant Certificate representing such Warrant is surrendered for exercise together with full payment of the Exercise Price in accordance with Section 3.1;

     
  1.1.21

Exercise Price ” at any time means, the price at which one (1) Common Share may be purchased by the exercise of one Warrant and which is $0.40, subject to adjustment in accordance with the provisions of Article 4, in which case it shall mean the adjusted price in effect at such time;

     
  1.1.22

Expiry Date ” means March 15, 2018;

     
  1.1.23

Expiry Time ” means 5:00 p.m. (Toronto time) on the Expiry Date;

     
  1.1.24

Extraordinary Resolution ” has the meaning set forth in Section 7.11;



- 4 -

  1.1.25

Global Certificate ” means a certificate that is issued to and registered in the name of CDS;

     
  1.1.26

Internal Procedures ” means in respect of the making of any one or more entries to, changes in or deletions of any one or more entries in the register of Warrantholders at any time (including without limitation, original issuance or registration of transfer of ownership), the minimum number of the Warrant Agent’s internal procedures customary at such time for the entry, change or deletion effected under the operating procedures of the Warrant Agent;

     
  1.1.27

Issue Date ” means the date(s) upon which the Warrants are issued;

     
  1.1.28

NCI Letter of Instruction ” means the Non Certificated Inventory system letter of instruction provided by CDS to the Warrant Agent in connection with the conversion of Warrants;

     
  1.1.29

Person ” means an individual, body corporate, partnership, trust, trustee, executor, administrator, legal representative or any unincorporated organization;

     
  1.1.30

Regulation D ” means Regulation D adopted by the SEC under the U.S. Securities Act;

     
  1.1.31

Regulation S ” means Regulation S adopted by the SEC under the U.S. Securities Act;

     
  1.1.32

SEC ” means the United States Securities and Exchange Commission;

     
  1.1.33

Shareholder ” means a holder of record of one or more Common Shares;

     
  1.1.34

Subsidiary of the Corporation ” or “ Subsidiary ” means any corporation of which more than fifty percent (50%) of the outstanding Voting Shares are owned, directly or indirectly, by or for the Corporation, provided that the ownership of such shares confers the right to elect at least a majority of the board of directors of such corporation and includes any corporation in like relation to a subsidiary;

     
  1.1.35

successor corporation ” has the meaning set forth in Section 8.2;

     
  1.1.36

this Warrant Indenture ”, “ this Indenture ”, “ herein ”, “ hereby ”, “ hereof ” and similar expressions mean and refer to this Indenture and any indenture, deed or instrument supplemental hereto; and the expressions “Article”, “Section”, “subsection” and “paragraph” followed by a number, letter or both mean and refer to the specified Article, Section, subsection or paragraph of this Indenture;

     
  1.1.37

Trading Day ” means, with respect to a stock exchange, a day on which such exchange is open for the transaction of business;

     
  1.1.38

Uncertificated Warrant ” means any Warrant which is not represented by a Warrant Certificate;



- 5 -

  1.1.39

United States ” means the United States of America, its territories and possessions, any state of the United States, and the District of Columbia collectively;

     
  1.1.40

U.S. Person ” means “U.S. person” as that term is defined in Rule 902 of Regulation S under the U.S. Securities Act;

     
  1.1.41

U.S. Purchaser ” means any holder of Warrants originally purchased from the Corporation by a person who is a U.S. Person, a person in the United States or a person that purchased the Warrants for the account or benefit of a U.S. Person or a person in the United States;

     
  1.1.42

U.S. Securities Act ” means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder;

     
  1.1.43

U.S. Securities Exchange Act ” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder;

     
  1.1.44

Voting Shares ” means shares of the capital stock of any class of any corporation carrying voting rights under all circumstances, provided that, for the purposes of such definition, shares which only carry the right to vote conditionally on the happening of an event shall not be considered Voting Shares, whether or not such event shall have occurred, nor shall any shares be deemed to cease to be Voting Shares solely by reason of a right to vote accruing to shares of another class or classes by reason of the happening of any such event;

     
  1.1.45

Warrant Agency ” means one of the principal offices of the Warrant Agent in the city of Calgary and in the city of Toronto or such other place(s) as may be designated in accordance with subsection 3.1.3;

     
  1.1.46

Warrant Agent ” means Computershare Trust Company of Canada in its capacity as Warrant agent, or its successors from time to time in the trust hereby created;

     
  1.1.47

Warrant Certificate ” means a certificate, substantially in the form set forth in Schedule “ A ” hereto, issued on or after the Issue Date to evidence the Warrants;

     
  1.1.48

Warrant Exercise Form ” means an exercise form, substantially in the form set forth in Schedule “ A ” hereto, delivered by a Warrantholder to the Warrant Agency at any time after the Issue Date and prior to the Expiry Time;

     
  1.1.49

Warrantholders ”, or “ holders ” without reference to Common Shares, means the persons who are registered owners of Warrants;

     
  1.1.50

Warrantholders’ Request ” means an instrument signed in one or more counterparts by Warrantholders entitled to acquire in the aggregate not less than ten percent (10%) of the aggregate number of Common Shares which could be acquired pursuant to all Warrants then unexercised and outstanding, requesting the Warrant Agent to take some action or proceeding specified therein;



- 6 -

  1.1.51

Warrants ” means the Warrants created by and authorized by and issuable under this Indenture to be issued and countersigned hereunder in certificated form and/or held through the book entry registration on a no certificate issued basis, whether by way of Warrant Certificate or Uncertificated Warrant; and

     
  1.1.52

written order of the Corporation ”, “ written request of the Corporation ”, “ written consent of the Corporation ” and “ certificate of the Corporation ” mean, respectively, a written order, request, consent and certificate signed in the name of the Corporation by its Chairman, Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, President, Secretary or any Vice President, or a liaison acting in any such capacity for the Corporation and may consist of one or more instruments so executed.


1.2

Gender and Number

Unless herein otherwise expressly provided or unless the context otherwise requires, words importing the singular include the plural and vice versa and words importing gender include all genders.

1.3

Interpretation not Affected by Headings, etc.

The division of this Indenture into Articles, Sections and subsections, the provision of a table of contents and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation of this Indenture,

1.4

Day not a Business Day

In the event that any day on or before which any action is required to be taken hereunder is not a Business Day, then such action shall be required to be taken at or before the requisite time on the next succeeding day that is a Business Day.

1.5

Time of the Essence

Time shall be of the essence of this Indenture.

1.6

Currency

Except as otherwise expressly provided, all dollar amounts herein are expressed in Canadian dollars.

1.7

Assignment

This Indenture may not be assigned by either party hereto without the consent in writing of the other party. This Indenture shall enure to and bind the parties and their lawful successors and permitted assigns.


- 7 -

1.8

Applicable Law and Jurisdiction

This Indenture and the Warrant Certificates and all documents relating thereto, which by common accord have been and will be drafted in English, shall be construed in accordance with the laws of the Province of Alberta and the federal laws applicable therein and shall be treated in all respects as Alberta contracts.

Each party to this Indenture, by its execution hereof, hereby irrevocably submits to the exclusive jurisdiction of the Courts of the Province of Alberta for the purpose of any action, claim, cause of action or suit (in contract, delict or otherwise), inquiry, proceeding or investigation arising out of or based upon this Indenture, Warrant Certificates or all documents relating thereto.

ARTICLE 2 - ISSUE OF WARRANTS

2.1

Creation and Issue of Warrants

Up to 10,000,000 Warrants in one or more closings, are hereby authorized, all in accordance with the terms and conditions hereof. The Warrant Certificates shall be certified and delivered by the Warrant Agent to such persons as the Corporation may direct by written order of the Corporation.

2.2

Terms of the Warrants

     
2.2.1

Each whole Warrant shall entitle the holder thereof, upon exercise, together with the payment of the Exercise Price, to acquire one (1) Common Share, subject to adjustment in accordance with Article 4, at any time after the Issue Date until the Expiry Time.

     
2.2.2

No fractional Warrants shall be issued or otherwise provided for hereunder. Any fractional entitlements shall be rounded down to the nearest whole number and a purchaser or holder of any Warrant shall not be entitled to any cash or other consideration in lieu of any fractional interest in a Warrant or claim thereto.

     
2.2.3

Each Warrant shall entitle the holder thereof to such other rights and privileges as are set forth in this Indenture.

     
2.2.4

The number of Common Shares which may be purchased pursuant to the Warrants and the Exercise Price therefor shall be adjusted in the events and in the manner specified in Article 4.

     
2.2.5

Upon the exercise of the Warrants, the Corporation shall issue Common Shares required to fulfill its obligation to sell Common Shares upon the exercise of the Warrants.

     
2.3

Warrantholder not a Shareholder

Except as may be specifically provided herein, nothing in this Indenture or in the holding of a Warrant or Warrant Certificate or otherwise, shall, in itself, confer or be construed as conferring upon a Warrantholder any right or interest whatsoever as a Shareholder or as any other shareholder of the Corporation, including, but not limited to, the right to vote at, to receive notice of, or to attend, meetings of shareholders or any other proceedings of the Corporation, or the right to receive dividends and other distributions.


- 8 -

2.4

Warrants to Rank Pari Passu

All Warrants shall rank equally and without preference over each other, whatever may be the actual date of issue thereof.

2.5

Form of Warrants

The Warrants may be issued in both certificated and uncertificated form at the discretion of the Corporation and pursuant to the procedures in this Indenture. For the avoidance of doubt, each Warrant originally issued to a U.S. Purchaser shall be evidenced in certificated form. The Warrant Certificates in definitive form evidencing the Warrants authorized in Section 2.1 shall be issuable as fully registered (including all replacements issued in accordance with this Indenture) shall be substantially in the form set out in Schedule “A” hereto, shall be dated as of the Issue Date, shall bear such distinguishing letters and numbers as the Corporation may, with the approval of the Warrant Agent, prescribe, and shall be issuable in any denomination excluding fractions. All Warrants issued to CDS shall be evidenced by a book position on the register of Warrantholders to be maintained by the Warrant Agent in accordance with Section 2.13.

2.6

Execution of Warrant Certificates

The Warrant Certificates shall be signed by any one of the directors and officers of the Corporation and may, but need not be, under seal of the Corporation or a reproduction thereof. The signatures of any such director or officer may be mechanically reproduced in facsimile and Warrant Certificates bearing such facsimile signatures shall be binding upon the Corporation as if they had been manually signed by such director or officer. Notwithstanding that any person whose manual or facsimile signature appears on any Warrant Certificate as a director or an officer may no longer hold office at the date of such Warrant Certificate or at the date of certification or delivery thereof, any Warrant Certificate signed as aforesaid shall, subject to Section 2.7, be valid and binding upon the Corporation and the holder thereof shall be entitled to the benefits of this Indenture.

2.7

Certification by the Warrant Agent

     
2.7.1

No Warrant Certificate shall be issued or, if issued, shall be valid for any purpose or entitle the holder to the benefit hereof until it has been certified by manual signature by or on behalf of the Warrant Agent by its authorized signing officers substantially in the form of the Warrant Certificate, and such certification by the Warrant Agent upon any Warrant Certificate shall be conclusive evidence as against the Corporation that the Warrant Certificate so certified has been duly issued hereunder and that the holder is entitled to the benefits hereof.



- 9 -

2.7.2

No Uncertificated Warrant shall be issued or, if issued, shall be valid for any purpose or entitle the holder to the benefit hereof until it has been certified by the Warrant Agent, once its Internal Procedures have been completed (whether upon original issuance, exchange, registration of transfer, partial payment, or otherwise) and the Corporation shall, and hereby acknowledges that it shall, thereupon be deemed to have duly and validly issued such Uncertificated Warrants under this Indenture. Such certification shall be conclusive evidence that such Uncertificated Warrant has been duly issued hereunder and that the holder or holders are entitled to the benefits of this Indenture. The register shall be final and conclusive evidence as to all matters relating to Uncertificated Warrants with respect to which this Indenture requires the Warrant Agent to maintain records or accounts. In case of differences between the register at any time and any other time, the register at the later time shall be controlling, absent manifest error, and such Uncertificated Warrants are binding on the Corporation.

     
2.7.3

The certification of the Warrant Agent on Warrant Certificates and/or Uncertificated Warrants issued hereunder shall not be construed as a representation or warranty by the Warrant Agent as to the validity of this Indenture or the Warrant Certificates (except the due certification thereof) or as to the performance by the Corporation of its obligations under this Indenture, and the Warrant Agent shall in no respect be liable or answerable for the use made of the Warrant Certificates or any of them or of the consideration therefor except as otherwise specified herein.

     
2.8

Issue in Substitution for Warrant Certificates Lost, etc.

     
2.8.1

If any Warrant Certificate becomes mutilated or is lost, destroyed or stolen, the Corporation, subject to applicable law, shall issue and thereupon the Warrant Agent shall certify and deliver, a new Warrant Certificate of like tenor as the one mutilated, lost, destroyed or stolen in exchange for and in place of and upon cancellation of such mutilated Warrant Certificate, or in lieu of and in substitution for such lost, destroyed or stolen Warrant Certificate, and the substituted Warrant Certificate shall be in a form approved by the Warrant Agent and the Warrants evidenced thereby shall be entitled to the benefits hereof and shall rank equally in accordance with its terms with all other Warrants issued or to be issued hereunder.

     
2.8.2

The applicant for the issue of a new Warrant Certificate pursuant to this Section 2.8 shall bear the cost of the issue thereof and in case of loss, destruction or theft shall, as a condition precedent to the issuance thereof, furnish to the Corporation and to the Warrant Agent such evidence of ownership and of the loss, destruction or theft of the Warrant Certificate so lost, destroyed or stolen as shall be satisfactory to the Corporation and to the Warrant Agent, in their sole discretion, and such applicant may also be required to furnish an indemnity and surety bond in amount and form satisfactory to the Corporation and the Warrant Agent, in their sole discretion, and shall pay the reasonable charges of the Corporation and the Warrant Agent in connection therewith.



- 10 -

2.8.3

Warrant Certificates may be replaced only at the Warrant Agency or at any other place that is designated by the Corporation with the approval of the Warrant Agent.

     
2.9

Exchange of Warrant Certificates

     
2.9.1

Any one or more Warrant Certificates representing any number of Warrants may, upon compliance with the reasonable requirements of the Warrant Agent (including compliance with applicable securities legislation), be exchanged for one or more other Warrant Certificates representing the same aggregate number of Warrants as represented by the Warrant Certificate or Warrant Certificates so exchanged.

     
2.9.2

Warrant Certificates may be exchanged only at the Warrant Agency or at any other place that is designated by the Corporation with the approval of the Warrant Agent. Any Warrant Certificate tendered for exchange shall be cancelled and surrendered by the Warrant Agency to the Warrant Agent.

     
2.10

Transfer and Ownership of Warrants

     
2.10.1

Subject to Section 2.14, the Warrants may only be transferred on the register kept by the Warrant Agent at the Warrant Agency by the holder or its legal representatives or its attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent upon surrendering to the Warrant Agent at the Warrant Agency the Warrant Certificates representing the Warrants to be transferred and upon compliance with: (i) the conditions herein; (ii) such reasonable requirements as the Warrant Agent may prescribe; and (iii) all applicable securities legislation and requirements of regulatory authorities; and such transfer shall be duly noted in such register by the Warrant Agent. Upon compliance with such requirements, the Warrant Agent shall issue to the transferee a Warrant Certificate representing the Warrants transferred.

     
2.10.2

Subject to the provisions of this Indenture and applicable law, the Warrantholder shall be entitled to the rights and privileges attaching to the Warrants and the issue of Common Shares by the Corporation upon the exercise of Warrants in accordance with the terms and conditions herein contained shall discharge all responsibilities of the Corporation and the Warrant Agent with respect to such Warrants and neither the Corporation nor the Warrant Agent shall be bound to inquire into the title of any such holder.

     
2.10.3

A Warrant shall be transferable by surrender of the Warrant Certificate relating thereto, accompanied by proper instruments of transfer in suitable form satisfactory to the Warrant Agent for transfer by delivery with the same effect as in the case of a negotiable instrument executed by the Warrantholder or his executors, administrators or other legal representatives or his or their attorney duly appointed by an instrument in form and execution satisfactory to the Warrant Agent; provided that no transfer of any Warrant will be valid unless duly entered on the transfer register referred to in subsection 2.10.1.



- 11 -

  2.10.4

A transferee of any Warrant will, after surrender to the Warrant Agent of the Warrant Certificate evidencing such Warrant as required by subsection 2.10.3 and upon compliance with all other conditions in respect thereof required by this Indenture or by law, be entitled to be entered on the transfer register and on the Warrant register as the owner of such Warrant, and the Warrant Agent shall issue to the transferee a Warrant Certificate evidencing the Warrants transferred.

     
  2.10.5

The Warrant Agent was informed by the Corporation that the Warrants and the Common Shares issuable upon exercise thereof have not been registered under the U.S. Securities Act, or the securities laws of any state of the United States, and may not be offered, sold or transferred in the United States, or to or for the account or benefit of, a U.S. Person, unless the Warrants and the Common Shares issuable upon exercise thereof have been registered under the U.S. Securities Act and the securities laws of all applicable states of the United States or an exemption from registration under the U.S. Securities Act and applicable state securities law is available and the holder of the Warrant has presented to the Corporation evidence of the availability of the exemption satisfactory to the Corporation.

     
  2.10.6

The Warrant Agent shall retain until the sixth anniversary of the termination of this Indenture all instruments of transfer of Warrants which are lodged for registration, including the details shown thereon of the persons by or through whom they were lodged, all cancelled Warrants and all other related documents.

     
  2.10.7

Notwithstanding any provision to the contrary contained in this Indenture, the Corporation is entitled to require, add or adopt certain conditions precedent to the transfer of Warrants to ensure compliance with all applicable securities legislation and requirements of regulatory authorities, and may direct the Warrant Agent to refuse to recognize any transfer, or enter the name of any transferee, of a Warrant on the transfer register if such transfer would constitute a violation of any applicable securities legislation or requirements of regulatory authorities or require the Corporation to qualify the Common Shares for distribution in any jurisdiction.

     
  2.10.8

To the extent not inconsistent with the terms of this Indenture, the provisions of the Business Corporations Act (Alberta) in respect of the transfer of securities, as amended from time to time, shall apply mutatis mutandis to the transfer of Warrants.

     
  2.10.9

Warrants bearing the legend set forth in Section 2.16 may not be transferred except pursuant to registration or compliance with exemptions therefrom under the U.S. Securities Act and all applicable state securities laws, and the Warrant Agent agrees not to register any transfer of the Warrants so legended unless, in addition to the other requirements set forth herein, the Warrantholder has executed and delivered to the Warrant Agent a declaration in the form attached as Schedule "B" hereto (or as the Corporation may otherwise prescribe) to the effect that the transfer is being made pursuant to Rule 904 of Regulation S under the U.S. Securities Act, and in such case the Warrant Certificate issued to the transferee shall not include the legend set forth in Section 2.16.



- 12 -

2.11

Charges for Exchange or Transfer

The transfer or the exchange of any Warrant Certificate or the issue of a new Warrant Certificate pursuant hereto shall be subject to the payment of a reasonable fee levied by the Warrant Agent in addition to the reimbursement of the Warrant Agent or the Corporation for any and all transfer, stamp or similar taxes or other governmental charges required to be paid, and such payment shall be made by the holder requesting a transfer or exchange as a condition precedent to such transfer or exchange.

2.12

Cancellation of Surrendered Warrants

All Warrant Certificates surrendered pursuant to Sections 2.8, 2.9, 2.10, 3.1, 3.3, 3.4or 5.1 shall be returned to the Warrant Agent for cancellation and, after the expiry of any period of retention prescribed by law, destroyed by the Warrant Agent.

2.13

Registration of Warrants

The Corporation hereby appoints the Warrant Agent as registrar and transfer agent of the Warrant. The Warrant Agent shall, at all times while any Warrants are outstanding, keep at the Warrant Agency: (i) a register of Warrantholders in which shall be entered in alphabetical order the names and addresses of the holders of Warrants and particulars of the Warrants held by them, and (ii) a register of transfers in which all transfers of Warrants and the date and other particulars of each transfer shall be entered. Branch registers shall also be kept at such other place or places, if any, as the Corporation, with the approval of the Warrant Agent, may designate. Such registers will at all reasonable times be open for inspection by the Corporation and/or any Warrantholder. The Warrant Agent will from time to time when requested in writing to do so by the Corporation or any Warrantholder, upon payment of the Warrant Agent’s reasonable charges, furnish a list of the names and addresses of Warrantholders showing the number of Warrants held by each such Warrantholder.

2.14

CDS and Depository

     
2.14.1

The Corporation may elect to issue all or a portion of the Warrants in “ book entry form ”, such Warrants to be represented by a registered permanent Global Certificate. The Global Certificate shall be held by, or on behalf of, the Depository as custodian of the CDS Participants and shall be registered in the name of “CDS & CO.” or such other name as the Depository may use from time to time as its nominee for the purposes of the Book Based System. For the avoidance of doubt, any Warrants sold in the United States must be in the form of a definitive Certificate and will not be included in the Global Certificate unless ownership is transferred or exchanged to a holder that is outside of the United States.



- 13 -

  2.14.2

Any Global Certificate shall bear a legend in substantially the following form, subject to modification as required by the Depository:

“UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF CDS CLEARING AND DEPOSITORY SERVICES INC. (“CDS”) TO STEM CELL THERAPEUTICS CORP. (THE “ ISSUER ”) OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IN RESPECT THEREOF IS REGISTERED IN THE NAME OF CDS & CO., OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF CDS (AND ANY PAYMENT IS MADE TO CDS & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF CDS), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED HOLDER HEREOF, CDS & CO., HAS A PROPERTY INTEREST IN THE SECURITIES REPRESENTED BY THIS CERTIFICATE HEREIN AND IT IS A VIOLATION OF ITS RIGHTS FOR ANOTHER PERSON TO HOLD, TRANSFER OR DEAL WITH THIS CERTIFICATE.”

  2.14.3

Subject to Section 2.10, transfers and registrations to ownership in Warrants represented by the Global Certificate will only be made to another nominee of the Depository, and neither the Corporation nor the Warrant Agent shall be under any obligation to deliver to participants of the Depository, nor shall such participants have any right to require the delivery of a Warrant Certificate.

     
  2.14.4

Subject to Sections 2.9 and 2.10, in the event of a transfer or exchange of ownership, in compliance with applicable laws, of any Warrants, that are represented by a definitive Warrant Certificate, the definitive Warrant Certificate may be surrendered at the Depository for cancellation by the Warrant Agent and the registration of new beneficial interest in such Warrants may be represented by the Global Certificate, which shall be increased by the number of Warrants represented by the Warrant Certificate so surrendered.

     
  2.14.5

Unless the Book Based System is terminated or unless required to do so by applicable law, or unless otherwise requested and agreed to by the Corporation, owners of the beneficial interests in the Warrants represented by the Global Certificate, shall not receive Warrants registered in their names, shall not receive or Warrant Certificates in definitive form and shall not be considered registered owners or registered holders thereof under this Indenture or any supplemental agreement except in circumstances where CDS resigns or is removed from its responsibility and the Warrant Agent is unable or does not wish to locate a qualified successor. Beneficial interests in the Global Certificate will be represented only through the Book Based System. The Corporation and the Warrant Agent shall not have any responsibility or liability for any aspects of the records relating to or payments made by CDS, or its nominee, on account of the beneficial interests in the Warrants. Nothing herein shall prevent the Beneficial Owners from voting such Warrants.



- 14 -

  2.14.6

Notwithstanding anything herein to the contrary, neither the Corporation nor the Warrant Agent nor any agent thereof shall have any responsibility or liability for:

       
  (a)

the electronic records maintained by the Depository relating to any ownership interests or any other interests in the Warrants or the depository system maintained by the Depository, or payments made on account of any ownership interest or any other interest of any person in any Warrant represented by an electronic position in the book entry registration system (other than the Depository or its nominee);

       
  (b)

maintaining, supervising or reviewing any records of the Depository or any Book Entry Only Participant relating to any such interest; or

       
  (c)

any advice or representation made or given by the Depository or those contained herein that relate to the rules and regulations of the Depository or any action to be taken by the Depository on its own direction or at the direction of any Book Entry Only Participant.

       
  2.14.7

All references herein to actions by, notices given or payments made to Warrantholders shall, where Warrants are held through CDS, refer to actions taken by, or notices given or payments made to, CDS upon instruction from the CDS Participants in accordance with its rules and procedures. For the purposes of any provision hereof requiring or permitting actions with the consent of or at the direction of Warrantholders evidencing a specified percentage of the aggregate Warrants outstanding, such direction or consent may be given by holders of Warrants acting through CDS and the CDS Participants owning Warrants evidencing the requisite percentage of the Warrants. The rights of a Warrantholder whose Warrants are held through CDS shall be exercised only through CDS and the CDS Participants and shall be limited to those established by law and agreements between such holders and CDS and the CDS Participants upon instructions from the CDS Participants. Each of the Warrant Agent and the Corporation may deal with CDS for all purposes (including the making of payments) as the authorized representative of the respective Warrantholder and such dealing with CDS shall constitute satisfaction or performance, as applicable, of their respective obligations hereunder.

       
  2.14.8

For so long as Warrants are held through CDS, if any notice or other communication is required to be given to Warrantholders, the Warrant Agent and or the Corporation will give such notices and communications to CDS.

       
  2.14.9

If CDS resigns or is removed from its responsibility as depository and the Warrant Agent is unable or does not wish to locate a qualified successor, CDS shall surrender the Global Certificate to the Warrant Agent with instructions for registration of Warrants in the name and in the amount specified by CDS and the Corporation shall issue, and the Warrant Agent shall certify and deliver, the aggregate number of Warrants then outstanding in the form of definitive Warrant Certificates representing such Warrants.



- 15 -

2.15

NCI Letter of Instruction

Notwithstanding anything to the contrary set out in this Indenture, all physical Warrant Certificates issued to CDS may be surrendered to the Warrant Agent for an electronic position on the register of Warrantholders to be maintained by the Warrant Agent in accordance with this Indenture. All Warrants maintained in such electronic position will entitle the registered holders thereof to the same benefits as those registered holders who hold Warrants in physical certificated form and this Indenture and the provisions contained herein will apply, mutatis mutandis , to such Warrants held in such electronic position. It is understood and agreed by the parties that, unless the Warrant Agent is otherwise in a position to perform electronic exercises, in every instance where Warrants held in an electronic position through CDS are to be exercised in whole or in part, it shall be sufficient for the Warrant Agent to exercise such Warrants upon receiving either the attached exercise form executed by CDS or a NCI Letter of Instruction in a form agreed upon by the Warrant Agent and CDS, or such other form that they may be agreed to by the Warrant Agent and CDS from time to time.

2.16

Legends

     
2.16.1

The Warrant Agent acknowledges and understands that the Warrants issued hereunder and the Common Shares issuable upon exercise of a Warrant have been issued in Canada pursuant to applicable exemptions from securities laws. The Warrant Agent further understands and acknowledges that, if applicable, upon the original issuance thereof, and until such time as the same is no longer required under applicable requirements of Canadian securities laws, certificates representing the Warrants issued hereunder and all certificates issued in exchange therefor or in substitution thereof, shall be overprinted with the following legend:

“UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE ●, 2013.”

  2.16.2

The Warrant Agent acknowledges and understands that the Warrants issued hereunder and the Common Shares issuable upon exercise of a Warrant have not been and will not be registered under the U.S. Securities Act or any applicable U.S. state securities laws. The Warrant Agent further understands and acknowledges that upon the original issuance thereof, and until such time as the same is no longer required under applicable requirements of the U.S. Securities Act or applicable U.S. state securities laws, certificates representing the Warrants issued hereunder originally issued to a U.S. Purchaser, and all certificates issued in exchange therefor or in substitution thereof, shall be overprinted with the following legend:

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ U.S. SECURITIES ACT ”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THE HOLDER HEREOF, BY PURCHASING THE SECURITIES REPRESENTED HEREBY, AGREES FOR THE BENEFIT OF STEM CELL THERAPEUTICS CORP. AND ITS SUCCESSORS (THE “ CORPORATION ”) THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH LOCAL LAWS AND REGULATIONS, (C) WITHIN THE UNITED STATES PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY (I) RULE 144A OR (II) RULE 144 THEREUNDER, IF APPLICABLE, AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) WITHIN THE UNITED STATES, IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS GOVERNING THE OFFER AND SALE OF SECURITIES, AND IN THE CASE OF TRANSFERS PURSUANT TO (C)(II) OR (D) ABOVE, THE HOLDER HEREOF HAS, PRIOR TO SUCH TRANSFER, FURNISHED TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE CORPORATION TO SUCH EFFECT.


- 16 -

DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE ‘GOOD DELIVERY’ IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.

provided , that if the Warrants are being sold in compliance with the requirements of Rule 904 of Regulation S and in compliance with local laws and regulations, the legend may be removed by providing to the Warrant Agent: (i) a declaration in the form attached hereto as Schedule “B” (or as the Corporation may prescribe from time to time) and (ii) if required by the Warrant Agent, an opinion of counsel, of recognized standing reasonably satisfactory to the Corporation, or other evidence reasonably satisfactory to the Corporation, that the proposed transfer may be effected without registration under the U.S. Securities Act.

The Warrant Certificates, and all certificates issued in exchange therefore or in substitution thereof, shall bear, in addition to the legends above, the following legend:

THIS WARRANT AND THE SECURITIES DELIVERABLE UPON EXERCISE HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ U.S. SECURITIES ACT ”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THIS WARRANT MAY NOT BE EXERCISED IN THE UNITED STATES OR BY OR ON BEHALF OF, OR FOR THE ACCOUNT OR BENEFIT OF, A U.S. PERSON UNLESS THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH STATE OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS IS AVAILABLE. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE U.S. SECURITIES ACT.


- 17 -

ARTICLE 3 - EXERCISE OF WARRANTS

3.1

Method of Exercise of Warrants

     
3.1.1

The holder of any Warrant may exercise the right conferred on such holder to acquire Common Shares by surrendering, after the Issue Date and prior to the Expiry Time, to the Warrant Agency, (i) the Warrant Certificate representing such Warrant, with a duly completed and executed Warrant Exercise Form, (ii) together with a certified cheque, money order or bank draft, in lawful money of Canada payable to or to the order of the Corporation at par in the city where the Warrant Agency is located in an amount equal to the Exercise Price multiplied by the number of Common Shares subscribed for. In accordance with Section 2.14, if Warrants are exercised through CDS, the payment of such exercise will be done electronically by CDS to the Warrant Agent. The Warrant Agent will, within five (5) days, send such payment to the Corporation.

A Warrant Certificate with the duly completed and executed Warrant Exercise Form referred to in this subsection 3.1.1 shall be deemed to be surrendered only upon personal delivery thereof or, if sent by mail or other means of transmission, upon actual receipt thereof at, in each case, the Warrant Agency, provided that such Warrant Certificate is accompanied by the requisite certified cheque, bank draft or money order in the amount of the aggregate Exercise Price for the Warrants represented thereby that are being exercised.

  3.1.2

Any Warrant Exercise Form referred to in subsection 3.1.1 shall be signed by the Warrantholder and shall specify:

       
  (a)

the number of Common Shares which the holder wishes to acquire (being not more than those which the holder is entitled to acquire pursuant to the Warrant Certificate(s) surrendered);

       
  (b)

the person or persons in whose name or names such Common Shares are to be issued;

       
  (c)

the address or addresses of such person or persons;

       
  (d)

if an individual, the social insurance number of such person or persons; and

       
  (e)

the number of Common Shares to be issued to each such person if more than one is so specified.

If any of the Common Shares subscribed for are to be issued and registered in the name or names of a person or persons other than the Warrantholder, the Warrantholder shall pay to the Corporation or the Warrant Agency on behalf of the Corporation, all applicable transfer or similar taxes and the Corporation shall not be required to issue or deliver certificates evidencing Common Shares unless or until such Warrantholder shall have paid to the Corporation, or the Warrant Agency on behalf of the Corporation, the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid or that no tax is due.


- 18 -

  3.1.3

In connection with the exchange of Warrant Certificates and exercise of Warrants and compliance with such other terms and conditions hereof as may be required, the Corporation has appointed the principal offices of the Warrant Agent in Toronto as the Warrant Agency at which Warrant Certificates may be surrendered for exchange, transfer or repurchase or at which Warrants may be exercised and the Warrant Agent has accepted such appointment. The Corporation may from time to time designate alternate or additional places as a Warrant Agency upon notice to and consent of the Warrant Agent of any change of any Warrant Agency. The Corporation shall give notice to Warrantholders of any change of a Warrant Agency.

     
  3.1.4

Subject to and upon compliance with the terms of Article 3, a beneficial holder of Uncertificated Warrants evidenced by a security entitlement in respect of Warrants in the book entry registration system may exercise the right of purchase by causing a Book Entry Only Participant to deliver to the Depository on behalf of the entitlement holder, notice of the owner’s intention to exercise the Warrants in a manner acceptable to the Depository. Forthwith upon receipt by the Depository of such notice, as well as payment for the Exercise Price, the Depository shall deliver to the Warrant Agent an Letter of Instruction confirming its intention to exercise Warrants in a manner acceptable to the Warrant Agent, including by electronic means through the book entry registration system.

     
  3.1.5

Payment representing the aggregate Exercise Price must be provided to the appropriate office of the Book Entry Only Participant in a manner acceptable to it. A notice in form acceptable to the Book Entry Only Participant and payment from such beneficial holder should be provided to the Book Entry Only Participant sufficiently in advance so as to permit the Book Entry Only Participant to deliver notice and payment to the Depository and for the Depository in turn to deliver notice and payment to the Warrant Agent prior to the Expiry Time. The Depository will initiate the exercise by way of the Letter of Instruction and will forward the aggregate Exercise Price electronically to the Warrant Agent and the Warrant Agent will execute the exercise by issuing to the Depository through the book entry registration system the Common Shares to which the exercising Warrantholder is entitled pursuant to the exercise. Any expense associated with the exercise process will be for the account of the entitlement holder exercising the Warrants and/or the Book Entry Only Participant exercising the Warrants on its behalf.

     
  3.1.6

By causing a Book Entry Only Participant to deliver notice to the Depository, a Warrantholder shall be deemed to have irrevocably surrendered his or her Warrants so exercised and appointed such Book Entry Only Participant to act as his or her exclusive settlement agent with respect to the exercise and the receipt of Shares in connection with the obligations arising from such exercise.



- 19 -

  3.1.7

Any notice which the Depository determines to be incomplete, not in proper form, or not duly executed shall for all purposes be void and of no effect and the exercise to which it relates shall be considered for all purposes not to have been exercised thereby. A failure by a Book Entry Only Participant to exercise or to give effect to the settlement thereof in accordance with the Warrant holder’s instructions will not give rise to any obligations or liability on the part of the Corporation or Warrant Agent to the Book Entry Only Participant or the Warrantholder.

     
  3.1.8

Any exercise form or other Letter of Instruction referred to in Article 3 shall be signed by the registered Warrantholder, or its executors or administrators or other legal representatives or an attorney of the registered Warrantholder, duly appointed by an instrument in writing satisfactory to the Warrant Agent but such exercise form need not be executed by the Depository.

     
  3.1.9

Any exercise referred to in Section 3.1 shall require that the entire Exercise Price for Common Shares subscribed must be paid at the time of subscription and such Exercise Price and original exercise form or other Letter of Instruction executed by the registered Warrantholder or the Depository must be received by the Warrant Agent prior to the Warrant Expiry Time.

     
  3.1.10

A beneficial owner of Warrants issued in non-certificated form who desires to exercise his or her Warrants must do so by causing a CDS participant to deliver to the Depository on behalf of the entitlement holder, notice of the owner's intention to exercise Warrants in a manner acceptable to the Depository. Forthwith upon receipt by the Depository of such notice, as well as payment for the Exercise Price, the Depository shall deliver to the Warrant Agent confirmation of its intention to exercise Warrants in a manner acceptable to the Warrant Agent, including by electronic means through the book based registration system. An electronic exercise of the Warrants initiated by the CDS participant through the book based registration system shall constitute a representation to both the Company and the Warrant Agent that the beneficial owner at the time of exercise of such Warrants (i) is not in the United States; (ii) is not a U.S. Person and is not exercising such Warrants on behalf of a U.S. Person or a Person in the United States; and (iii) did not execute or deliver the notice of the owner's intention to exercise such Warrants in the United States. If the Participant is not able to make or deliver the foregoing representation by initiating the electronic exercise of the Warrants, then such Warrants shall be removed from the book based registration system and an individually registered Warrant Certificate shall be issued to such beneficial owner or CDS participant and the exercise procedures set forth in Section 3.1 shall be followed. Any expense associated with the preparation and delivery of Warrant Certificates and/or Warrant subscription forms will be for the account of the beneficial owner exercising such Warrants.

     
  3.1.11

It is understood and agreed by the parties hereto that, unless the Warrant Agent is otherwise in a position to perform electronic conversions, in every instance where Warrants held in an electronic position through the Depository are to be converted, in whole or in part, such Warrants being converted shalt not be certificated, and it shall be sufficient for the Warrant Agent to convert such Warrants upon receiving either the attached exercise form executed by the Depository or an NCI Letter of Instruction in a form agreed upon by the Warrant Agent and the Depository, or such other form that they may require from time to time along with a certified cheque, bank draft or money order in lawful money of Canada payable to or to the order of the Company at par in Calgary, Alberta in an amount equal to the Exercise Price multiplied by the number of Shares being purchased.



- 20 -

3.2

Effect of Exercise of Warrants

     
3.2.1

Upon the exercise of Warrants pursuant to Section 3.1 and subject to Section 3.3, the Common Shares to be issued pursuant to the Warrants exercised shall be deemed to have been issued and the person or persons to whom such Common Shares are to be issued and registered shall be deemed to have become the holder or holders of record of such Common Shares on the Exercise Date unless the transfer registers of the Corporation shall be closed on such date, in which case the Common Shares subscribed for shall be deemed to have been issued and such person or persons deemed to have become the holder or holders of record of such Common Shares, on the date on which such transfer registers are reopened. It is hereby understood that in order for persons to whom Common Shares are issued to become holders of Common Shares on record on the Exercise Date, beneficial holders must commence the exercise process sufficiently in advance so that the Warrant Agent is in receipt of all items of exercise at least one (1) Business Day prior to such Exercise Date.

     
3.2.2

Within five (5) Business Days after the Exercise Date with respect to a Warrant, the Corporation shall (i) cause to be mailed to the person or persons in whose name or names such Warrant is registered or, (ii) if so specified in writing by the holder, cause to be delivered to such person or persons at the Warrant Agency where the Warrant Certificate was surrendered, a certificate or certificates for the appropriate number of Common Shares subscribed for or any other appropriate evidence of the issuance of Common Shares to such person or persons in respect of Common Shares issued under the book entry registration system.

     
3.3

Partial Exercise of Warrants; Fractions

     
3.3.1

The holder of any Warrants may exercise his right to acquire a number of Common Shares less than the aggregate number which the holder is entitled to acquire pursuant to the surrendered Warrant Certificate(s). In the event of any exercise of a number of Warrants less than the number which the holder is entitled to exercise, the holder of the Warrants upon such exercise shall, in addition, be entitled to receive, without charge therefor, a new Warrant Certificate(s) in respect of the balance of the Warrants represented by the surrendered Warrant Certificate(s) and which were not then exercised.



- 21 -

3.3.2

Notwithstanding anything herein contained, including any adjustment provided for in Article 4, neither the Corporation nor the Warrant Agent shall be required, upon the exercise of any Warrants, to issue fractions of Common Shares or to distribute certificates which evidence fractional Common Shares. Any fractional entitlements will be rounded down to the nearest whole number.

     
3.4

Expiration of Warrants

Immediately after the Expiry Time, all rights under any Warrant in respect of which the right of acquisition provided for herein shall not have been exercised shall cease and terminate and each Warrant shall be void and of no further force or effect except to the extent that the Warrantholder has not received in full all monies to which it is entitled pursuant to Article 4 or Article 5 or has not received certificates representing the Common Shares issued upon exercise of Warrants held by it, in which instances the Warrantholders’ rights hereunder shall continue until it has received that to which it is entitled hereunder.

3.5

Accounting and Recording

     
3.5.1

The Warrant Agent shall promptly account to the Corporation with respect to Warrants exercised and forward to the Corporation (or into an account or accounts of the Corporation with the bank or trust Corporation designated by the Corporation for that purpose), all monies received by the Warrant Agent on the subscription for Common Shares through the exercise of Warrants. All such monies and any securities or other instruments, from time to time received by the Warrant Agent shall be received in trust for, and shall be segregated and kept apart by the Warrant Agent, the Warrantholders and the Corporation as their interests may appear.

     
3.5.2

The Warrant Agent shall record the particulars of Warrants exercised, which particulars shall include the names and addresses of the persons who become holders of Common Shares on exercise and the Exercise Date, in respect thereof. The Warrant Agent shall provide such particulars in writing to the Corporation within five Business Days of any request by the Corporation therefor.


3.6

Securities Restrictions

Notwithstanding anything herein contained, Common Shares will only be issued pursuant to any Warrant in compliance with the securities laws of any applicable jurisdiction. The certificates representing the Common Shares issued will bear such legend as may, in the opinion of Counsel to the Corporation be necessary in order to avoid a violation of any securities laws of any province or territory in Canada or of the United States or any state thereof and to comply with the requirements of any stock exchange or over the counter market on which the Common Shares are listed or quoted, as the case may be. Certificates representing Common Shares issued upon the exercise of Warrants may bear the legend set forth in Section 2.16. If, at any time, in the opinion of Counsel to the Corporation, such legends are no longer necessary in order to avoid a violation of any such laws, or the holder of any such legended certificate, at the holder’s expense, provides the Corporation with evidence satisfactory in form and substance to the Corporation (which may include an opinion of counsel satisfactory to the Corporation) to the effect that such holder is entitled to sell or otherwise transfer such Common Shares in a transaction in which such legends are not required, such legended certificate may thereafter be surrendered to the Warrant Agent in exchange for a certificate which does not bear such legend.


- 22 -

3.7

Prohibition on Exercise in the United States or by U.S. Persons; Exception

       
3.7.1

Warrants may not be exercised in the United States or by or on behalf of a U.S. Person unless an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available and such exercise is made in accordance with Section 3.7.2;

       
3.7.2

Any holder that seeks to exercise a Warrant shall provide to the Corporation and the Warrant Agent, and the Corporation and the Warrant Agent shall be entitled to act and rely on any one of the following:

       
(a)

a written certification that such holder (i) at the time of exercise of the Warrant is not in the United States; (ii) is not a U.S. Person and is not exercising the Warrant for the account or benefit of a U.S. Person; (iii) was not offered to exercise the Warrant and did not execute or deliver the exercise form for the Warrant in the United States; (iv) did not acquire the Warrant while it was in the United States or acting for the account or benefit of a U.S. Person and (v) has in all other respects complied with Regulation S; or

       
(b)

a written certification that such holder (i) originally purchased the Warrant on its own behalf or on behalf of a beneficial purchaser (a “ Beneficial Purchaser ”) directly from the Corporation pursuant to the Corporation's offering of Units at a time when the holder was and any Beneficial Purchaser was (A) an Accredited Investor and (B) in the United States or a U.S. Person, or was offered Units in the United States; (ii) is exercising the Warrant solely for its own account or for the account of the Beneficial Purchaser, if any, and not on behalf of any other person, (iii) is, and the Beneficial Purchaser, if any, is, an Accredited Investor on the date of exercise of the Warrant and (iv) as of the date of exercise of the Warrant, it reaffirms the representations, warranties, and agreements made by it in that U.S. Purchaser Letter; or

       
(c)

a written opinion of counsel of recognized standing in form and substance satisfactory to the Corporation to the effect that an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available for the issuance of the Common Shares upon exercise of the Warrants.

       
3.7.3

No certificates representing Common Shares will be registered or delivered to an address in the United States unless the holder of Warrants complies with the requirements set forth in subsection 3.7.2(b) or 3.7.2(c), and, in the case of subsection 3.7.2(c), the Corporation has confirmed in writing to the Warrant Agent that the written opinion of counsel is satisfactory to the Corporation and the holder of Warrants provides an executed letter substantially in the form attached hereto as Schedule “C”); and



- 23 -

  3.7.4

Certificates representing Common Shares issued upon exercise of the Warrants pursuant to subsection 3.7.2(b) or 3.7.2(c) above shall be “restricted securities” within the meaning of Rule 144(a)(3) under the U.S. Securities Act, may not be offered, sold, pledged or otherwise transferred except pursuant to an exemption or exclusion from the registration requirements of the U.S. Securities Act and applicable state securities laws and shall bear a legend to that effect as designated in Section 2.16.

ARTICLE 4 - ADJUSTMENT OF NUMBER OF COMMON SHARES AND EXERCISE PRICE

4.1

Adjustment of Number of Common Shares and Exercise Price

The acquisition rights as they relate to Common Shares, in effect at any date attaching to the Warrants, and the Exercise Price in respect thereof, shall be subject to adjustment from time to time as follows:

  4.1.1

If and whenever at any time during the Adjustment Period, the Corporation shall: (i) subdivide, redivide or change its outstanding Common Shares into a greater number of shares; (ii) reduce, combine or consolidate its outstanding Common Shares into a smaller number of shares; or (iii) issue Common Shares or securities exchangeable for or convertible into Common Shares to the holders of all or substantially all of the outstanding Common Shares by way of a stock dividend (other than the issue of Common Shares to such holders as a Dividend Paid in the Ordinary Course); the Exercise Price in effect on the effective date of such subdivision, redivision, change, reduction, combination, consolidation or on the record date of such stock dividend, as the case may be, shall in the case of the events referred to in (i) or (iii) above be decreased in proportion to the number of outstanding Common Shares resulting from such subdivision, redivision or stock dividend, or shall, in the case of the events referred to in (ii) above, be increased in proportion to the number of outstanding Common Shares resulting from such reduction, combination or consolidation. Such adjustment shall be made successively whenever any event referred to in this subsection 4.1.1 shall occur. Upon any adjustment of the Exercise Price pursuant to subsection 4.1.1, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;



- 24 -

  4.1.2

If and whenever at any time during the Adjustment Period, the Corporation shall fix a record date for the issuance of rights, options or warrants to all or substantially all the holders of its outstanding Common Shares entitling them, for a period expiring not more than forty-five (45) days after such record date, to subscribe for or purchase Common Shares (or securities convertible or exchangeable into Common Shares) at a price per share (or having a conversion or exchange price per share) less than ninety-five percent (95%) of the Current Market Price on such record date, the Exercise Price shall be adjusted immediately after such record date so that it shall equal the amount determined by multiplying the Exercise Price in effect on such record date by a fraction, of which the numerator shall be the total number of Common Shares outstanding on such record date plus a number of Common Shares equal to the number arrived at by dividing the aggregate price of the total number of additional Common Shares offered for subscription or purchase (or the aggregate conversion or exchange price of the convertible or exchangeable securities so offered) by such Current Market Price, and of which the denominator shall be the total number of Common Shares outstanding on such record date plus the total number of additional Common Shares offered for subscription or purchase or into which the convertible or exchangeable securities so offered are convertible or exchangeable; any Common Shares owned by or held for the account of the Corporation or any Subsidiary shall be deemed not to be outstanding for the purpose of any such computation; such adjustment shall be made successively whenever such a record date is fixed; to the extent that any such rights or warrants are not exercised prior to the expiration thereof the Exercise Price shall be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or to the Exercise Price which would then be in effect based upon the number of Common Shares (or securities convertible or exchangeable into Common Shares) actually issued upon the exercise of such rights or warrants, as the case may be. Upon any adjustment of the Exercise Price pursuant to this subsection 4.1.2, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;

     
  4.1.3

If and whenever at any time during the Adjustment Period the Corporation shall fix a record date for the payment, issue or distribution to all or substantially all the holders of its outstanding Common Shares of (i) shares of any class, whether of the Corporation or any other corporation (other than Common Shares and other than shares distributed to holders of Common Shares pursuant to their exercise of options to receive dividends in the form of such shares in lieu of Dividends Paid in the Ordinary Course on the Common Shares), (ii) rights, options or warrants to subscribe for or purchase Common Shares (or other securities convertible into or exchangeable for Common Shares) for a period expiring not more than forty-five (45) days after such record date at a price per share (or having a conversion or exercise price per share) not less than ninety five percent (95%) of the Current Market Price on such record date), (iii) evidences of its indebtedness or (iv) any property or other assets (excluding Dividends Paid in the Ordinary Course) then, in each such case, the Exercise Price shall be adjusted immediately after such record date so that it shall equal the price determined by multiplying the Exercise Price in effect on such record date by a fraction, of which the numerator shall be the total number of Common Shares outstanding on such record date multiplied by such Current Market Price less the aggregate fair market value (as determined by the directors, acting reasonably and in good faith, which determination shall be conclusive) of such shares or rights, options or warrants or evidences of indebtedness or assets actually distributed, as the case may be, and of which the denominator shall be the total number of Common Shares outstanding on such record date multiplied by such Current Market Price; and Common Shares owned by or held for the account of the Corporation or any Subsidiary shall be deemed not be outstanding for the purpose of any such computation; such adjustment shall be made successively whenever such a record date is fixed; to the extent that such distribution is not so made, the Exercise Price shall be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or to the Exercise Price which would then be in effect based upon such shares or rights, options or warrants or evidences of indebtedness or assets actually distributed, as the case may be; in clause (7) of this subsection 4.1.3 the term “ Dividends Paid in the Ordinary Course ” shall include the value of any securities or other property or assets distributed in lieu of cash Dividends Paid in the Ordinary Course at the option of shareholders. Upon any adjustment of the Exercise Price pursuant to this subsection 4.1.3, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;



- 25 -

  4.1.4

If and whenever at any time during the Adjustment Period, there is a reclassification of the Common Shares or a capital reorganization of the Corporation other than as described in subsection 4.1.1 or a consolidation, amalgamation, arrangement or merger of the Corporation with or into any other body corporate, trust, partnership or other entity, or a sale or conveyance of the property and assets of the Corporation as an entirety or substantially as an entirety to any other body corporate, trust, partnership or other entity in which the holders of Common Shares are entitled to receive shares, other securities or property, including cash, any Warrantholder who has not exercised its right of acquisition prior to the effective date of such reclassification, capital reorganization, consolidation, amalgamation, arrangement or merger, sale or conveyance, upon the exercise of such right thereafter, shall be entitled to receive and shall accept for the same aggregate consideration, in lieu of the number of Common Shares then sought to be acquired by it, the number of shares or other securities or property of the Corporation or of the body corporate, trust, partnership or other entity resulting from such merger, amalgamation or consolidation, or to which such sale or conveyance may be made, as the case may be, that such Warrantholder would have been entitled to receive on such reclassification, capital reorganization, consolidation, amalgamation, arrangement or merger, sale or conveyance, if, on the record date or the effective date thereof, as the case may be, the Warrantholder had been the registered holder of the number of Common Shares sought to be acquired by it and to which it was entitled to acquire upon the exercise of the Warrants. If determined appropriate by the Warrant Agent to give effect to or to evidence the provisions of this subsection 4.1.4, the Corporation, its successor, or such purchasing body corporate, partnership, trust or other entity, as the case may be, shall, prior to or contemporaneously with any such reclassification, capital reorganization, consolidation, amalgamation, arrangement, merger, sale or conveyance, enter into an indenture which shall provide, to the extent possible, for the application of the provisions set forth in this Indenture with respect to the rights and interests thereafter of the Warrantholders to the end that the provisions set forth in this Indenture shall thereafter correspondingly be made applicable, as nearly as may reasonably be, with respect to any shares, other securities or property to which a Warrantholder is entitled on the exercise of its acquisition rights thereafter. Any indenture entered into between the Corporation and the Warrant Agent pursuant to the provisions of this subsection 4.1.4 shall be a supplemental indenture entered into pursuant to the provisions of Article 8. Any indenture entered into between the Corporation; any successor to the Corporation or such purchasing body corporate, partnership, trust or other entity and the Warrant Agent shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided in this Section 4.1 and which shall apply to successive reclassifications, capital reorganizations, amalgamations, consolidations, mergers, sales or conveyances;



- 26 -

  4.1.5

In any case in which this Section 4.1 shall require that an adjustment shall become effective immediately after a record date for an event referred to herein, the Corporation may defer, until the occurrence of such event, issuing to the holder of any Warrant exercised after such event the additional Common Shares issuable upon such conversion by reason of the adjustment required by such event before giving effect to such adjustment; provided, however, that the Corporation shall deliver to such holder an appropriate instrument evidencing such holder’s right to receive such additional Common Shares upon the occurrence of the event requiring such adjustment and the right to receive any distributions made on such additional Common Shares declared in favour of holders of record of Common Shares on and after the relevant date of exercise or such later date as such holder would, but for the provisions of this subsection 4.1.5, have become the holder of record of such additional Common Shares pursuant to subsection 4.1.4;

     
  4.1.6

In any case in which subsections 4.1.2 or 4.1.3 require that an adjustment be made to the Exercise Price, no such adjustment shall be made if the holders of the outstanding Warrants receive the rights, options or warrants referred to in subsection 4.1.2 or the shares, rights, options, warrants, evidences of indebtedness, property or assets referred to in subsection 4.1.3, as the case may be, in such kind and number as they would have received if they had been holders of Common Shares on the applicable record date or effective date, as the case may be, by virtue of their outstanding Warrants having then been exercised into Common Shares at the Exercise Price in effect on the applicable record date or effective date, as the case may be. Any such issuance of shares, rights, options, or warrants will be subject to regulatory approval;



- 27 -

4.1.7

The adjustments provided for in this Section 4.1 are cumulative, and shall, in the case of adjustments to the Exercise Price be computed to the nearest whole cent and shall apply to successive subdivisions, redivisions, reductions, combinations, consolidations, distributions, issues or other events resulting in any adjustment under the provisions of this Section 4.1, provided that, notwithstanding any other provision of this Section, no adjustment of the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least one (1%) percent in the Exercise Price then in effect; provided, however, that any adjustments which by reason of this subsection 4.1.7 are not required to be made shall be carried forward and taken into account in any subsequent adjustment; and

     
4.1.8

After any adjustment pursuant to this Section 4.1, the term “ Common Shares ” where used in this Indenture shall be interpreted to mean securities of any class or classes which, as a result of such adjustment and all prior adjustments pursuant to this Section 4.1, the Warrantholder is entitled to receive upon the exercise of his Warrant, and the number of Common Shares indicated by any exercise made pursuant to a Warrant shall be interpreted to mean the number of Common Shares or other property or securities a Warrantholder is entitled to receive, as a result of such adjustment and all prior adjustments pursuant to this Section 4.1, upon the full exercise of a Warrant.

     
4.2

Entitlement to Shares on Exercise of Warrant

All shares of any class or other securities which a Warrantholder is at the time in question entitled to receive on the exercise of its Warrant, whether or not as a result of adjustments made pursuant to this Article 4, shall, for the purposes of the interpretation of this Indenture, be deemed to be shares which such Warrantholder is entitled to acquire pursuant to such Warrant.

4.3

No Adjustment for Certain Transactions

Notwithstanding anything in this Article 4, no adjustment shall be made in the acquisition rights attached to the Warrants if the issue of Common Shares is being made pursuant to or in connection with:

  4.3.1

any stock option or stock purchase plan in force from time to time for directors, officers, employees, consultants or other service providers of the Corporation; or

     
  4.3.2

the satisfaction of existing instruments issued at or prior to the date hereof.



- 28 -

4.4

Determination by Corporation’s Auditors

In the event of any question arising with respect to the adjustments provided for in this Article 4 such question shall be conclusively determined by the Corporation’s Auditors who shall have access to all necessary records of the Corporation, and such determination shall be binding upon the Corporation, the Warrant Agent, all Warrantholders and all other persons interested therein.

4.5

Proceedings Prior to any Action Requiring Adjustment

As a condition precedent to the taking of any action which would require an adjustment in any of the acquisition rights pursuant to any of the Warrants, including the number of Common Shares which are to be received upon the exercise thereof, the Corporation shall take any corporate action which may, in the opinion of Counsel, be necessary in order that the Corporation has unissued and reserved in its authorized capital and may validly and legally issue as fully paid and non-assessable all the shares (or other securities or property) which the holders of such Warrants are entitled to receive on the full exercise thereof in accordance with the provisions hereof.

4.6

Certificate of Adjustment

The Corporation shall from time to time immediately after the occurrence of any event which requires an adjustment or readjustment as provided in Article 4, deliver a certificate of the Corporation to the Warrant Agent specifying the nature of the event requiring the same and the amount of the adjustment or readjustment necessitated thereby and setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based, which certificate shall be supported by a certificate of the Corporation’s Auditors verifying such calculation.

4.7

Notice of Special Matters

The Corporation covenants with the Warrant Agent that, so long as any Warrant remains outstanding, it will give notice to the Warrant Agent and to the Warrantholders of its intention to fix a record date that is prior to the Expiry Date for the purpose of an event that requires or that may require an adjustment in any of the exercise rights pursuant to any Warrants as provided in this Article 4. Such notice shall specify the particulars of such event and the record date for such event, provided that the Corporation shall only be required to specify in the notice such particulars of the event as shall have been fixed and determined on the date on which the notice is given. The notice shall be given in each case not less than fourteen (14) days prior to such applicable record date.

4.8

No Action After Notice

The Corporation covenants with the Warrant Agent that it will not close its transfer books or take any other corporate action which might deprive the holder of a Warrant of the opportunity to exercise its right of acquisition pursuant thereto during the period of fourteen (14) days after the giving of the certificate or notices set forth in Sections 4.6 and 4.7.


- 29 -

4.9

Other Action

In case the Corporation, after the date hereof, shall take any action affecting the Common Shares other than action described in Section 4.1, which in the reasonable opinion of the directors of the Corporation would materially affect the rights of Warrantholders, the number of Common Shares which may be acquired upon exercise of the Warrants shall be adjusted in such manner and at such time, by action of the directors, acting reasonably, as they may determine to be equitable in the circumstances, provided that no such adjustment will be made unless prior approval of any stock exchange on which the Common Shares are listed for trading has been obtained, if required by any such stock exchange.

4.10

Protection of Warrant Agent

Except as provided in Section 9.1, the Warrant Agent shall not:

  4.10.1

At any time be under any duty or responsibility to any Warrantholder to determine whether any facts exist which may require any adjustment contemplated by Section 4.1, or with respect to the nature or extent of any such adjustment when made, or with respect to the method employed in making the same;

     
  4.10.2

Be accountable with respect to the validity or value (or the kind or amount) of any Common Shares or of any shares or other securities or property which may at any time be issued or delivered upon the exercise of the rights attaching to any Warrant;

     
  4.10.3

Be responsible for any failure of the Corporation to issue, transfer or deliver Common Shares or certificates for the same upon the surrender of any Warrants for the purpose of the exercise of such rights or to comply with any of the covenants contained in this Article; and

     
  4.10.4

Incur any liability or responsibility whatsoever or be in any way responsible for the consequences of any breach on the part of the Corporation of any of the representations, warranties or covenants herein contained or of any acts of the directors, officers, employees, agents or servants of the Corporation.

ARTICLE 5 - RIGHTS OF THE CORPORATION AND COVENANTS

5.1

Optional Purchases by the Corporation

Subject to compliance with applicable securities legislation and approval of applicable regulatory authorities, the Corporation may from time to time purchase on any stock exchange, in the open market, by private contract or otherwise, any of the Warrants. Any such purchase shall be made at the lowest price or prices at which, in the opinion of the directors, such Warrants are then obtainable, plus reasonable costs of purchase, and may be made in such manner, from such persons and on such other terms as the Corporation, in its sole discretion, may determine, Any Warrant Certificates representing the Warrants purchased pursuant to this Section 5.1 shall forthwith be delivered to and cancelled by the Warrant Agent. No Warrants shall be issued in replacement thereof.


- 30 -

5.2

General Covenants

The Corporation covenants with the Warrant Agent that so long as any Warrants remain outstanding and may be exercised:

  5.2.1

it will reserve and keep available a sufficient number of Common Shares for the purpose of enabling it to satisfy its obligations to issue Common Shares upon the exercise of the Warrants;

     
  5.2.2

it will cause the Common Shares and the certificates representing the Common Shares from time to time acquired pursuant to the exercise of the Warrants to be duly issued and delivered in accordance with the Warrant Certificates and the terms hereof;

     
  5.2.3

all Common Shares which shall be issued upon exercise of the right to acquire provided for herein and in the Warrant Certificates, upon payment of the prevailing Exercise Price herein provided for and in the Warrant Certificates shall be fully paid and non-assessable;

     
  5.2.4

if any of its Common Shares are listed on a stock exchange, it will use all reasonable efforts to ensure that the Common Shares comprising the Units, and all Common Shares outstanding or issuable from time to time (including, without limitation, the Common Shares issuable on the exercise of the Warrants) are listed and posted for trading on such stock exchange;

     
  5.2.5

it will make all requisite filings under applicable Canadian securities legislation and stock exchange rules, including (on a reasonable efforts basis) those necessary to remain a reporting issuer not in default in each of the provinces of Canada in which it is a reporting issuer as of the date hereof and those necessary to report the exercise of the right to acquire Common Shares pursuant to Warrants;

     
  5.2.6

it will provide to Warrantholders copies of all financial statements and other documentation required to be provided by applicable laws to registered holders of Common Shares as if such Warrantholders were registered shareholders of the Corporation. The Warrant Agent shall be entitled to rely on notice-and-access delivery of theses applicable materials to Warrantholders set out in National Instrument 51-102 - Continuous Disclosure Obligations and National Instrument 54-101 - Communication with Beneficial Owners of a Reporting Issuer ;

     
  5.2.7

it shall not close its transfer books or take any other action which might deprive the Warrantholders of the opportunity of exercising their right of purchase pursuant to the Warrants held by such persons after the giving of the notice required by Section 4.7;



- 31 -

  5.2.8

it will not make any amendments to the Corporation’s warrant indenture dated March 15, 2013 unless the Corporation also offers contemporaneously to the Warrantholders the ability to amend this Warrant Indenture on substantially the same terms and conditions, mutatis mutandis ;

     
  5.2.9

generally, it will well and truly perform and carry out all of the acts or things to be done by it as provided in this Indenture;

     
  5.2.10

the Corporation confirms that as at the date of execution of this Indenture it does not have a class of securities registered pursuant to Section 12 of the U.S. Securities Exchange Act or have a reporting obligation pursuant to Section 15(d) of the U.S. Securities Exchange Act; the Corporation covenants that in the event that (i) any class of its securities shall become registered pursuant to Section 12 of the U.S. Securities Exchange Act or the Corporation shall incur a reporting obligation pursuant to Section 15(d) of the U.S. Securities Exchange Act, or (ii) any such registration or reporting obligation shall be terminated by the Corporation in accordance with the U.S. Securities Exchange Act, the Corporation shall promptly deliver to the Warrant Agent an Officers’ Certificate (in a form provided by the Warrant Agent) notifying the Warrant Agent of such registration or termination and such other information as the Warrant Agent may require at the time. The Corporation acknowledges that the Warrant Agent is relying upon the foregoing representation and covenants in order to meet certain SEC obligations with respect to those clients who are filing with the SEC.


5.3

Warrant Agent’s Remuneration and Expenses

The Corporation covenants that it will pay to the Warrant Agent from time to time reasonable remuneration for its services hereunder and will pay or reimburse the Warrant Agent upon its request for all reasonable expenses, disbursements and advances incurred or made by the Warrant Agent in the administration or execution of the trusts hereby created (including the reasonable compensation and the disbursements of its Counsel and all other advisers and assistants not regularly in its employ) both before any default hereunder and thereafter until all duties of the Warrant Agent hereunder shall be finally and fully performed, except any such expense, disbursement or advance as may arise out of or result from the Warrant Agent’s gross negligence, willful misconduct or bad faith.

5.4

Securities Qualification Requirements

If, in the opinion of Counsel, any instrument is required to be filed with, or any permission is required to be obtained from, any governmental authority in Canada or any other step is required under any federal, provincial or territorial law of Canada before any Common Shares which a Warrantholder is entitled to acquire pursuant to the exercise of any Warrant may properly and legally be issued and subscribed for upon due exercise thereof and thereafter traded, without further formality or restriction, the Corporation covenants that it will take such required action.


- 32 -

5.5

Performance of Covenants by Warrant Agent

If the Corporation shall fail to perform any of its covenants contained in this Indenture and shall have not rectified such failure within ten (10) Business Days after receiving notice from the Warrant Agent of such failure, the Warrant Agent may notify the Warrantholders of such failure on the part of the Corporation or may itself perform any of the covenants capable of being performed by it but, subject to Section 9.1, shall be under no obligation to perform said covenants or to notify the Warrantholders of such performance by it. All sums expended or advanced by the Warrant Agent in so doing shall be repayable as provided in Section 5.3. No such performance, expenditure or advance by the Warrant Agent shall relieve the Corporation of any default hereunder or of its continuing obligations under the covenants herein contained.

5.6

Enforceability of Warrants

The Corporation covenants and agrees that it is duly authorized to create and issue the Warrants to be issued hereunder and that the Warrants, when issued as herein provided, will be valid and enforceable against the Corporation in accordance with the provisions hereof and the terms hereof and that, subject to the provisions of this Indenture, the Corporation will cause the Common Shares from time to time acquired pursuant to the Warrants under this Indenture and the certificates representing such Common Shares to be duly issued and delivered in accordance with the terms of this Indenture.

ARTICLE 6 - ENFORCEMENT

6.1

Suits by Warrantholders

All or any of the rights conferred upon any Warrantholder by any of the terms of the Warrant Certificates or of this Indenture, or of both, may be enforced by the Warrantholder by appropriate proceedings but without prejudice to the right which is hereby conferred upon the Warrant Agent to proceed in its own name to enforce each and all of the provisions herein contained for the benefit of the Warrantholders.

6.2

Immunity of Shareholders, etc.

The Warrant Agent and, by the acceptance of the Warrant Certificates and as part of the consideration for the issue of the Warrants, the Warrantholders hereby waive and release any right, cause of action or remedy now or hereafter existing in any jurisdiction against any incorporator or any past, present or future shareholder or agent of the Corporation on any covenant, agreement, representation or warranty by the Corporation herein or contained in the Warrant Certificates.

6.3

Limitation of Liability

The obligations hereunder are not personally binding upon, nor shall resort hereunder be had to, the private property of any of the past, present or future directors or shareholders of the Corporation or any of the past, present or future officers, employees or agents of the Corporation. Only the property of the Corporation or any successor corporation shall be bound in respect hereof.


- 33 -

6.4

Waiver of Default

Upon the happening of any default hereunder:

  6.4.1

the holders of not less than fifty one percent (51%) of the Warrants then outstanding shall have power (in addition to the powers exercisable by Extraordinary Resolution) by requisition in writing to instruct the Warrant Agent to waive any default hereunder and the Warrant Agent shall thereupon waive the default upon such terms and conditions as shall be prescribed in such requisition; or

     
  6.4.2

the Warrant Agent shall have power to waive any default hereunder upon such terms and conditions as the Warrant Agent may deem advisable, if, in the Warrant Agent’s reasonable opinion or, in the opinion of counsel acceptable to the Warrant Agent, the same shall have been cured or adequate provision made therefor;

     
 

provided that no delay or omission of the Warrant Agent or of the Warrantholders to exercise any right or power accruing upon any default shall impair any such right or power or shall be construed to be a waiver of any such default or acquiescence therein and provided further that no act or omission either of the Warrant Agent or of the Warrantholders in the premises shall extend to or be taken in any manner whatsoever to affect any subsequent default hereunder of the rights resulting therefrom.

ARTICLE 7 – MEETINGS OF WARRANTHOLDERS

7.1

Right to Convene Meetings

The Warrant Agent may at any time and from time to time, and shall on receipt of a written request of the Corporation or of a Warrantholders’ Request and upon being indemnified to its reasonable satisfaction by the Corporation or by the Warrantholders signing such Warrantholders’ Request against the costs which may be incurred in connection with the calling and holding of such meeting, convene a meeting of the Warrantholders. In the event of the Warrant Agent failing to so convene a meeting within fifteen (15) days after receipt of such written request of the Corporation or such Warrantholders’ Request and indemnity given as aforesaid, the Corporation or such Warrantholders, as the case may be, may convene such meeting. Every such meeting shall be held in Toronto or at such other place as may be approved or determined by the Warrant Agent and approved by the Corporation.

7.2

Notice

At least twenty one (21) days’ prior written notice of any meeting of Warrantholders shall be given to the Warrantholders in the manner provided for in Article 10 and a copy of such notice shall be sent by mail to the Warrant Agent (unless the meeting has been called by the Warrant Agent) and to the Corporation (unless the meeting has been called by the Corporation). Such notice shall state the time when and the place where the meeting is to be held, shall state briefly the general nature of the business to be transacted thereat and shall contain such information as is reasonably necessary to enable the Warrantholders to make a reasoned decision on the matter, but it shall not be necessary for any such notice to set out the terms of any resolution to be proposed or any of the provisions of this Article 7. The notice convening any such meeting may be signed by an appropriate officer of the Warrant Agent or of the Corporation or the person or persons designated by such Warrantholders, as the case may be.


- 34 -

7.3

Chairman

An individual (who need not be a Warrantholder) designated in writing by the Warrant Agent shall be chairman of the meeting and if no individual is so designated, or if the individual so designated is not present within fifteen (15) minutes from the time fixed for the holding of the meeting, the Warrantholders present in person or by proxy shall choose some individual present to be chairman.

7.4

Quorum

Subject to the provisions of Section 7.11, at any meeting of the Warrantholders a quorum shall consist of Warrantholders present in person or by proxy and entitled to purchase at least ten percent (10%) of the aggregate number of Common Shares which could be acquired pursuant to all the then outstanding Warrants, provided that at least two persons entitled to vote thereat, in person or by proxy, are personally present. If a quorum of the Warrantholders shall not be present within thirty (30) minutes from the time fixed for holding any meeting, the meeting shall be adjourned to the same day in the next week (unless such day is not a Business Day, in which case it shall be adjourned to the next following Business day) at the same time and place and no notice of the adjournment need be given. Any business may be brought before or dealt with at an adjourned meeting which might have been dealt with at the original meeting in accordance with the notice calling the same. No business shall be transacted at any meeting unless a quorum be present at the commencement of business; provided that at the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum and may transact the business for which the meeting was originally convened, notwithstanding that they may not be entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all then outstanding Warrants.

7.5

Power to Adjourn

The chairman of any meeting at which a quorum of the Warrantholders is present may, with the consent of the meeting, adjourn any such meeting, and no notice of such adjournment need be given except such notice, if any, as the meeting may prescribe.

7.6

Show of Hands

Every question submitted to a meeting shall be decided in the first place by a majority of the votes given on a show of hands except that votes on an Extraordinary Resolution shall be given in the manner hereinafter provided. At any such meeting, unless a poll is duly demanded as herein provided, a declaration by the chairman that a resolution has been carried or carried unanimously or by a particular majority or lost or not carried by a particular majority shall be conclusive evidence of the fact.


- 35 -

7.7

Poll and Voting

On every Extraordinary Resolution, and on any other question submitted to a meeting and after a vote by show of hands when demanded by the chairman or by one or more of the Warrantholders acting in person or by proxy, a poll shall be taken in such manner as the chairman shall direct. Questions other than those required to be determined by Extraordinary Resolution shall be decided by a majority of the votes cast on the poll.

On a show of hands, every person who is present and entitled to vote, whether as a Warrantholder or as proxy for one or more absent Warrantholders, or both, shall have one vote. On a poll, each Warrantholder present in person or represented by a proxy duly appointed by instrument in writing shall be entitled to one vote in respect of each whole Common Share which it is entitled to acquire pursuant to the Warrant or Warrants then held or represented by it. A proxy need not be a Warrantholder. In the case of joint holders, any one of them present in person or by proxy at the meeting may vote in the absence of the other or others, but in case more than one of them shall be present in person or by proxy, they shall vote together in respect of Warrants of which they are joint registered holders. The chairman of any meeting shall be entitled, both on a show of hands and on a poll, to vote in respect of the Warrants, if any, held or represented by him.

7.8

Regulations

The Warrant Agent, or the Corporation with the approval of the Warrant Agent, may from time to time make and from time to time vary such regulations as it shall think fit for:

  7.8.1

the setting of the record date for a meeting for the purpose of determining Warrantholders entitled to receive notice of and to vote at the meeting;

     
  7.8.2

the issue of voting certificates by any bank, trust company or other depositary satisfactory to the Warrant Agent stating that the Warrant Certificates specified therein have been deposited with it by a named person and will remain on deposit until after the meeting, which voting certificate shall entitle the persons named therein to be present and vote at any such meeting and at any adjournment thereof or to appoint a proxy or proxies to represent them and vote for them at any such meeting and at any adjournment thereof in the same manner and with the same effect as though the persons so named in such voting certificates were the actual bearers of the Warrant Certificates specified therein;

     
  7.8.3

the deposit of voting certificates and instruments appointing proxies at such place and time as the Warrant Agent, the Corporation or the Warrantholders convening the meeting, as the case may be, may in the notice convening the meeting direct;

     
  7.8.4

the deposit of voting certificates and instruments appointing proxies at some approved place or places other than the place at which the meeting is to be held and enabling particulars of such instruments appointing proxies to be mailed or telecopied before the meeting to the Corporation or to the Warrant Agent at the place where the same is to be held and for the voting of proxies so deposited as though the instruments themselves were produced at the meeting;



- 36 -

  7.8.5

the form of the instrument of proxy and the manner in which the instrument of proxy must be executed; and

     
  7.8.6

generally for the calling of meetings of Warrantholders and the conduct of business thereat.

Any regulations so made shall be binding and effective and the votes given in accordance therewith shall be valid and shall be counted. Save as such regulations may provide, the only persons who shall be recognized at any meeting as a Warrantholder, or be entitled to vote or be present at the meeting in respect thereof (subject to Section 7.9), shall be Warrantholders or their counsel, or proxies of Warrantholders.

7.9

Corporation and Warrant Agent May be Represented

The Corporation and the Warrant Agent, by their respective directors and officers, and the Counsel for the Corporation and for the Warrant Agent may attend any meeting of the Warrantholders, but shall not be entitled to vote thereat, whether in respect of any Warrants held by them or otherwise.

7.10

Powers Exercisable by Extraordinary Resolution

In addition to all other powers conferred upon them by any other provisions of this Indenture or by law, the Warrantholders at a meeting shall, subject to the provisions of Section 7.11, have the power, exercisable from time to time by Extraordinary Resolution:

  7.10.1

to agree to any modification, abrogation, alteration, compromise or arrangement of the rights of Warrantholders or the Warrant Agent in its capacity as Warrant Agent hereunder (subject to the Warrant Agent’s prior consent) or on behalf of the Warrantholders against the Corporation whether such rights arise under this Indenture or the Warrant Certificates or otherwise;

     
  7.10.2

to amend, alter or repeal any Extraordinary Resolution previously passed or sanctioned by the Warrantholders;

     
  7.10.3

to direct or to authorize the Warrant Agent, subject to subsection 9.1.2, to enforce any of the covenants on the part of the Corporation contained in this Indenture or the Warrant Certificates or to enforce any of the rights of the Warrantholders in any manner specified in such Extraordinary Resolution or to refrain from enforcing any such covenant or right;

     
  7.10.4

to waive, and to direct the Warrant Agent to waive, any default on the part of the Corporation in complying with any provisions of this Indenture or the Warrant Certificates either unconditionally or upon any conditions specified in such Extraordinary Resolution;

     
  7.10.5

to restrain any Warrantholder from taking or instituting any suit, action or proceeding against the Corporation for the enforcement of any of the covenants on the part of the Corporation in this Indenture or the Warrant Certificates or to enforce any of the rights of the Warrantholders;



- 37 -

  7.10.6

to direct any Warrantholder who, as such, has brought any suit, action or proceeding to stay or to discontinue or otherwise to deal with the same upon payment of the costs, charges and expenses reasonably and properly incurred by such Warrantholder in connection therewith;

     
  7.10.7

to consent to any change in or omission from the provisions contained in the Warrant Certificates and this Indenture or any ancillary or supplemental instrument which may be agreed to by the Corporation, and to authorize the Warrant Agent to concur in and execute any ancillary or supplemental indenture embodying the change or omission;

     
  7.10.8

with the consent of the Corporation, such consent not to be unreasonably withheld, to remove the Warrant Agent or its successor in office and to appoint a new trustee or trustees to take the place of the Warrant Agent so removed; and

     
  7.10.9

to consent to any compromise or arrangement with any creditor or creditors or any class or classes of creditors, whether secured or otherwise, and with holders of any shares or other securities of the Corporation.


7.11

Meaning of Extraordinary Resolution

     
7.11.1

The expression “ Extraordinary Resolution ” when used in this Indenture means, subject as hereinafter provided in this Section 7.11 and in Section 7.14, a resolution proposed at a meeting of Warrantholders duly convened for that purpose and held in accordance with the provisions of this Article 7 at which there are present in person or by proxy at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants and passed by the affirmative votes of Warrantholders entitled to acquire not less than sixty six and two third percent (66 2/3%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants present or represented at the meeting and voted on the poll upon such resolution.

     
7.11.2

If, at the meeting at which an Extraordinary Resolution is to be considered, at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants are not present in person or by proxy within thirty (30) minutes after the time appointed for the meeting, then the meeting shall stand adjourned to such day, being not less than fifteen (15) or more than sixty (60) days later, and to such place and time as may be appointed by the chairman. Not less than ten (10) days’ prior notice shall be given of the time and place of such adjourned meeting in the manner provided for in Sections 10.1 and 10.2. Such notice shall state that at the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum but it shall not be necessary to set forth the purposes for which the meeting was originally called or any other particulars. At the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum and may transact the business for which the meeting was originally convened and a resolution proposed at such adjourned meeting and passed by the requisite vote as provided in subsection 7.11.1 shall be an Extraordinary Resolution within the meaning of this Indenture notwithstanding that at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants are not present in person or represented by proxy at such adjourned meeting.



- 38 -

  7.11.3

Votes on an Extraordinary Resolution shall always be given on a poll and no demand for a poll on an Extraordinary Resolution shall be necessary.


7.12

Powers Cumulative

Any one or more of the powers or any combination of the powers in this Indenture stated to be exercisable by the Warrantholders by Extraordinary Resolution or otherwise may be exercised from time to time and the exercise of any one or more of such powers or any combination of powers from time to time shall not be deemed to exhaust the right of the Warrantholders to exercise such power or powers or combination of powers then or thereafter from time to time.

7.13

Minutes

Minutes of all resolutions and proceedings at every meeting of Warrantholders shall be made and duly entered in books to be provided from time to time for that purpose by the Warrant Agent at the expense of the Corporation, and any such minutes as aforesaid, if signed by the chairman or the secretary of the meeting at which such resolutions were passed or proceedings had shall be prima facie evidence of the matters therein stated and, until the contrary is proved, every such meeting in respect of the proceedings of which minutes shall have been made shall be deemed to have been duly convened and held, and all resolutions passed thereat or proceedings taken shall be deemed to have been duly passed and taken.

7.14

Instruments in Writing

All actions which may be taken and all powers that may be exercised by the Warrantholders at a meeting held as provided in this Article 7 may also be taken and exercised by Warrantholders entitled to acquire at least sixty six and two third percent (66/%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants by an instrument in writing signed in one or more counterparts by such Warrantholders in person or by attorney duly appointed in writing, and the expression “ Extraordinary Resolution ” when used in this Indenture shall include an instrument so signed.

7.15

Binding Effect of Resolutions

Every resolution and every Extraordinary Resolution passed in accordance with the provisions of this Article 7 at a meeting of Warrantholders shall be binding upon all the Warrantholders, whether present at or absent from such meeting, and every instrument in writing signed by Warrantholders in accordance with Section 7.14 shall be binding upon all the Warrantholders, whether signatories thereto or not, and each and every Warrantholder and the Warrant Agent (subject to the provisions for indemnity herein contained) shall be bound to give effect accordingly to every such resolution and instrument in writing. In the case of an instrument in writing, the Warrant Agent shall give notice in the manner contemplated in Sections 10.1 and 10.2 of the effect of the instrument in writing to all Warrantholders and the Corporation as soon as reasonably practicable.


- 39 -

7.16

Holdings by Corporation Disregarded

In determining whether Warrantholders holding Warrant Certificates evidencing the entitlement to acquire the required number of Common Shares are present at a meeting of Warrantholders for the purpose of determining a quorum or have concurred in any consent, waiver, Extraordinary Resolution, Warrantholders’ Request or other action under this Indenture, Warrants owned legally or beneficially by the Corporation or any Subsidiary of the Corporation shall be disregarded.

ARTICLE 8 - SUPPLEMENTAL INDENTURES

8.1

Provision for Supplemental Indentures for Certain Purposes

From time to time the Corporation (when authorized by action of the directors) and the Warrant Agent may, subject to the provisions hereof, and they shall, when so directed in accordance with the provisions hereof, execute and deliver by their proper officers, indentures or instruments supplemental hereto, which thereafter shall form part hereof, for any one or more or all of the following purposes:

  8.1.1

setting forth any adjustments resulting from the application of the provisions of Article 4;

     
  8.1.2

adding to the provisions hereof such additional covenants and enforcement provisions as, in the opinion of Counsel to the Corporation, are necessary or advisable in the circumstances, provided that the same are not in the opinion of the Warrant Agent prejudicial to the interests of the Warrantholders;

     
  8.1.3

giving effect to any Extraordinary Resolution passed as provided in Article 7;

     
  8.1.4

making such provisions not inconsistent with this Indenture as may be necessary or desirable with respect to matters or questions arising hereunder or for the purpose of obtaining a listing or quotation of the Warrants on any stock exchange, provided that such provisions are not, in the opinion of the Warrant Agent, prejudicial to the interests of the Warrantholders;

     
  8.1.5

adding to or altering the provisions hereof in respect of the transfer of Warrants, making provision for the exchange of Warrant Certificates, and making any modification in the form of the Warrant Certificates which does not affect the substance thereof, in each case provided that such provisions are not, in the opinion of the Warrant Agent, relying on an opinion of Counsel to the Warrant Agent, prejudicial to the interests of the Warrantholders;



- 40 -

  8.1.6

with the prior approval of the TSX Venture Exchange, modifying any of the provisions of this Indenture, including relieving the Corporation from any of the obligations, conditions or restrictions herein contained, provided that such modification or relief shall be or become operative or effective only if, in the opinion of the Warrant Agent, relying on an opinion of Counsel to the Warrant Agent, such modification or relief in no way prejudices any of the rights of the Warrantholders or of the Warrant Agent, and provided further that the Warrant Agent may decline to enter into any such supplemental indenture which in its opinion, relying on an opinion of Counsel to the Warrant Agent, may not afford adequate protection to the Warrant Agent when the same shall become operative; and

     
  8.1.7

for any other purpose not inconsistent with the terms of this Indenture, including the correction or rectification of any ambiguities, defective or inconsistent provisions, errors, mistakes or omissions herein, provided that in the opinion of the Warrant Agent the rights of the Warrant Agent and of the Warrantholders are in no way prejudiced thereby.


8.2

Successor Corporations

In the case of the consolidation, amalgamation, arrangement, merger or transfer of the undertaking or assets of the Corporation as an entirety or substantially as an entirety to another Corporation (the “ successor corporation ”), the successor corporation resulting from such consolidation, amalgamation, arrangement, merger or transfer (if not the Corporation) shall expressly assume, by supplemental indenture satisfactory in form to the Warrant Agent and executed and delivered to the Warrant Agent, the due and punctual performance and observance of each and every covenant and condition of this Indenture to be performed and observed by the Corporation.

ARTICLE 9 - CONCERNING THE WARRANT AGENT

9.1

Rights and Duties of Warrant Agent

     
9.1.1

In the exercise of the rights and duties prescribed or conferred by the terms of this Indenture, the Warrant Agent shall act honestly and in good faith with the view to the best interest of the Warrantholders and shall exercise that degree of care, diligence and skill that a reasonably prudent trustee would exercise in comparable circumstances. No provision of this Indenture shall be construed to relieve the Warrant Agent from, or require any other person to indemnify the Warrant Agent from liability for its own gross negligence, its own willful misconduct, bad faith.

     
9.1.2

The obligation of the Warrant Agent to commence or continue any act, action or proceeding for the purpose of enforcing any rights of the Warrant Agent or the Warrantholders hereunder shall be conditional upon the Warrantholders furnishing, when required by notice by the Warrant Agent, sufficient funds to commence or to continue such act, action or proceeding and an indemnity reasonably satisfactory to the Warrant Agent to protect and to hold harmless the Warrant Agent against the costs, charges and expenses and liabilities to be incurred thereby and any loss and damage it may suffer by reason thereof. None of the provisions contained in this Indenture shall require the Warrant Agent to expend or to risk its own funds or otherwise to incur financial liability in the performance of any of its duties or in the exercise of any of its rights or powers unless indemnified as aforesaid.



- 41 -

9.1.3

The Warrant Agent may, before commencing or at any time during the continuance of any such act, action or proceeding, require the Warrantholders, at whose instance it is acting to deposit with the Warrant Agent the Warrants held by them, for which Warrants the Warrant Agent shall issue receipts.

     
9.1.4

Every provision of this Indenture that by its terms relieves the Warrant Agent of liability or entitles it to rely upon any evidence submitted to it is subject to the provisions of Applicable Legislation, of this Section 9.1 and of Section 9.2.

     
9.2

Evidence, Experts and Advisers

     
9.2.1

In addition to the reports, certificates, opinions and other evidence required by this Indenture, the Corporation shall furnish to the Warrant Agent such additional evidence of compliance with any provision hereof, and in such form, as may be prescribed by Applicable Legislation or as the Warrant Agent may reasonably require by written notice to the Corporation.

     
9.2.2

In the exercise of its rights and duties hereunder, the Warrant Agent may, if it is acting in good faith, rely as to the truth of the statements and the accuracy of the opinions expressed in statutory declarations, opinions, reports, written requests, consents, or orders of the Corporation, certificates of the Corporation or other evidence furnished to the Warrant Agent pursuant to a request of the Warrant Agent, provided that such evidence complies with Applicable Legislation and that the Warrant Agent complies with Applicable Legislation and that the Warrant Agent examines the same and determines that such evidence complies with the applicable requirements of this Indenture.

     
9.2.3

Whenever it is provided in this Indenture or under Applicable Legislation that the Corporation shall deposit with the Warrant Agent resolutions, certificates, reports, opinions, requests, orders or other documents, it is intended that the truth, accuracy and good faith on the effective date thereof and the facts and opinions stated in all such documents so deposited shall, in each and every such case, be conditions precedent to the right of the Corporation to have the Warrant Agent take the action to be based thereon.

     
9.2.4

Proof of the execution of an instrument in writing, including a Warrantholders’ Request, by any Warrantholder may be made by the certificate of a notary public, or other officer with similar powers, that the person signing such instrument acknowledged to it the execution thereof, or by an affidavit of a witness to such execution or in any other manner which the Warrant Agent may consider adequate.



- 42 -

9.2.5

The Warrant Agent may employ or retain such counsel, accountants, appraisers or other experts or advisers as it may reasonably require for the purpose of discharging its duties hereunder and may pay reasonable remuneration for all services so performed by any of them, without taxation of costs of any counsel, and shall not be responsible for any misconduct or negligence on the part of any such experts or advisers who have been appointed with due care by the Warrant Agent.

     
9.3

Documents, Monies, etc. Held by Warrant Agent

Any securities, documents of title or other instruments that may at any time be held by the Warrant Agent subject to the trusts hereof may be placed in the deposit vaults of the Warrant Agent or of any Canadian chartered bank listed in Schedule I to the Bank Act (Canada) or of any trust company registered to do business in Canada or deposited for safekeeping with any such bank or trust company. Unless herein otherwise expressly provided, any monies so held pending the application or withdrawal thereof under any provisions of this Indenture upon the direction of the Corporation shall be or, with the consent of the Corporation may be: (i) deposited in the name of the Warrant Agent in any Canadian chartered bank listed in Schedule I to the Bank Act (Canada) or any trust company registered to do business in Canada at the rate of interest (if any) then current on similar deposits; (ii) deposited in the deposit department of the Warrant Agent; or (iii) invested in treasury bills or short term interest bearing or discounted obligations issued or guaranteed by the Government of Canada or a province thereof, of any Canadian chartered bank listed in Schedule I of the Bank Act (Canada) or of the Warrant Agent, provided that the securities shall not have a maturity date of more than sixty (60) days from the date of such investment. Unless the Corporation shall be in default hereunder or unless otherwise specifically provided herein, all interest or other income received by the Warrant Agent in respect of such deposits and investments shall belong to the Corporation.

9.4

Actions by Warrant Agent to Protect Interest

The Warrant Agent shall have power to institute and to maintain such actions and proceedings as it may consider necessary or expedient to preserve, protect or enforce its interests and the interests of the Warrantholders.

9.5

Warrant Agent Not Required to Give Security

The Warrant Agent shall not be required to give any bond or security in respect of the execution of the trusts and powers of this Indenture or otherwise in respect of the premises.


- 43 -

9.6

Protection of Warrant Agent

By way of supplement to the provisions of any law for the time being relating to trustees it is expressly declared and agreed as follows:

  9.6.1

the Warrant Agent shall not be liable for or by reason of any statements of fact or recitals in this Indenture or in the Warrant Certificates (except the representation contained in Section 9.8 or in the certificate of the Warrant Agent on the Warrant Certificates) or be required to verify the same, but all such statements or recitals are and shall be deemed to be made by the Corporation;

     
  9.6.2

nothing herein contained shall impose any obligation on the Warrant Agent to see to or to require evidence of the registration or filing (or renewal thereof) of this Indenture or any instrument ancillary or supplemental hereto;

     
  9.6.3

the Warrant Agent shall not be bound to give notice to any person or persons of the execution hereof;

     
  9.6.4

subject to subsection 9.1.1, the Warrant Agent shall not incur any liability or responsibility whatever or be in any way responsible for the consequence of any breach on the part of the Corporation of any of the covenants herein contained or of any acts of any directors, officers, employees, agents or servants of the Corporation; and

     
  9.6.5

the Corporation hereby indemnifies and agrees to hold harmless the Warrant Agent from and against any and all liabilities, losses, damages, penalties, claims, actions, suits, costs, expenses and disbursements, including legal fees and disbursements of whatever kind and nature which may at any time be imposed on, incurred by or asserted against the Warrant Agent, whether groundless or otherwise, arising from or out of any act, omission or error of the Warrant Agent made in good faith in the conduct of its duties hereunder, provided that the Warrant Agent has met the standard of care, diligence and skill provided for in subsection 9.1.1 and, provided further that, the Corporation shall not be required to indemnify the Warrant Agent in the event of gross negligence, willful misconduct or bad faith of the Warrant Agent as provided in subsection 9.1.1, and this provision shall survive the resignation or removal of the Warrant Agent or the termination or discharge of this Agreement.


9.7

Replacement of Warrant Agent; Successor by Merger

     
9.7.1

The Warrant Agent may resign its agency and be discharged from all further duties and liabilities hereunder, subject to this Section 9.7, by giving to the Corporation not less than ninety (90) days’ prior notice in writing or such shorter prior notice as the Corporation may accept as sufficient. The Warrantholders by Extraordinary Resolution shall have power at any time to remove the existing Warrant Agent and to appoint a new Warrant Agent. In the event of the Warrant Agent resigning or being removed as aforesaid or being dissolved, becoming bankrupt, going into liquidation or otherwise becoming incapable of acting hereunder, the Corporation shall forthwith appoint a warrant agent unless a warrant agent has already been appointed by the Warrantholders; failing such appointment by the Corporation, the retiring Warrant Agent or any Warrantholder may apply to a justice of the Superior Court of the Province of Alberta on such notice as such justice may direct, for the appointment of a new warrant agent; but any new warrant agent so appointed by the Corporation or by the Court shall be subject to removal as aforesaid by the Warrantholders. Any new warrant agent appointed under any provision of this Section 9.7 shall be a corporation authorized to carry on the business of a trust company in each of the provinces of Canada. On any such appointment the new warrant agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named herein as Warrant Agent without any further assurance, conveyance, act or deed; but there shall be immediately executed, at the expense of the Corporation, all such conveyances or other instruments as may, in the opinion of Counsel to the Warrant Agent, be necessary or advisable for the purpose of assuring the same to the new warrant agent, provided that any resignation or removal of the Warrant Agent and appointment of a successor warrant agent shall not become effective until the successor warrant agent shall have executed an appropriate instrument accepting such appointment and, at the request of the Corporation, the predecessor Warrant Agent shall execute and deliver to the successor warrant agent an appropriate instrument transferring to such successor warrant agent all rights and powers of the Warrant Agent hereunder so ceasing to act.



- 44 -

  9.7.2

Upon the appointment of a successor trustee, the Corporation shall promptly notify the Warrantholders thereof in the manner provided for in Section 10.1.

     
  9.7.3

Any corporation into or with which the Warrant Agent may be merged or consolidated, or amalgamated, or any corporation resulting therefrom to which the Warrant Agent shall be a party, or any corporation succeeding to the trust business of the Warrant Agent shall be the successor to the Warrant Agent hereunder without any further act on its part or any of the parties hereto, provided that such corporation would be eligible for appointment as a successor warrant agent under subsection 9.7.1.

     
  9.7.4

Any Warrant Certificates certified but not delivered by a predecessor trustee may be certified by the successor trustee in the name of the predecessor or successor warrant agent.


9.8

Conflict of Interest

     
9.8.1

The Warrant Agent represents to the Corporation that at the time of execution and delivery hereof no material conflict of interest exists between its role as a trustee hereunder and its role in any other capacity and agrees that in the event of a material conflict of interest arising hereafter it will, within ninety (90) days after ascertaining that it has such material conflict of interest, either eliminate the same or assign its trust hereunder to a successor trustee approved by the Corporation and meeting the requirements set forth in subsection 9.7.1. Notwithstanding the foregoing provisions of this subsection 9.8.1, if any such material conflict of interest exists or hereafter shall exist, the validity and enforceability of this Indenture and the Warrant Certificate shall not be affected in any manner whatsoever by reason thereof.



- 45 -

9.8.2

Subject to subsection 9.8.1, the Warrant Agent, in its personal or any other capacity, may buy, lend upon and deal in securities of the Corporation and generally may contract and enter into financial transactions with the Corporation or any Subsidiary of the Corporation without being liable to account for any profit made thereby.

     
9.9

Acceptance of Trust

The Warrant Agent hereby accepts the trusts in this Indenture declared and provided for and agrees to perform the same upon the terms and conditions herein set forth.

9.10

Warrant Agent Not to be Appointed Receiver

The Warrant Agent and any person related to the Warrant Agent shall not be appointed a receiver, a receiver and manager or liquidator of all or any part of the assets or undertaking of the Corporation.

9.11

Warrant Agent Not Required to Give Notice of Default

The Warrant Agent shall not be bound to give any notice or do or take any act, action or proceeding by virtue of the powers conferred on it hereby unless and until it shall have been required so to do under the terms hereof; nor shall the Warrant Agent be required to take notice of any default hereunder, unless and until notified in writing of such default, which notice shall distinctly specify the default desired to be brought to the attention of the Warrant Agent and in the absence of any such notice the Warrant Agent may for all purposes of this Indenture conclusively assume that no default has been made in the observance or performance of any of the representations, warranties, covenants, agreements or conditions contained herein. Any such notice shall in no way limit any discretion herein given to the Warrant Agent to determine whether or not the Warrant Agent shall take action with respect to any default.

9.12

Force Majeure

Except for the payment obligations of the Corporation contained herein, neither party shall be liable to the other, or held in breach of this Agreement, if prevented, hindered, or delayed in the performance or observance of any provision contained herein by reason of act of God, riots, terrorism, acts of war, epidemics, governmental action or judicial order, earthquakes, or any other similar causes (including, but not limited to, mechanical, electronic or communication interruptions, disruptions or failures). Performance times under this Agreement shall be extended for a period of time equivalent to the time lost because of any delay that is excusable under this Section.


- 46 -

9.13

Third Parties

The Corporation hereby represents to the Warrant Agent that any account to be opened by, or interest to held by, Warrant Agent in connection with this Agreement, for or to the credit of the Corporation, either (i) is not intended to be used by or on behalf of any third party; or (ii) is intended to be used by or on behalf of a third party, in which case the Corporation agrees to complete and execute forthwith a declaration in the Warrant Agent’s prescribed form as to the particulars of such third party.

9.14

Anti-Money Laundering

The Warrant Agent shall retain the right not to act and shall not be liable for refusing to act if, due to a lack of information or for any other reason whatsoever, the Warrant Agent, in its sole judgment, determines that such act might cause it to be in non-compliance with any applicable anti money laundering or anti-terrorist or economic sanctions legislation, regulation or guideline. Further, should the Warrant Agent, in its sole judgment, determine at any time that its acting under this Agreement has resulted in its being in non-compliance with any applicable anti money laundering or antiterrorist legislation, regulation or guideline, then it shall have the right to resign on ten (10) days’ written notice to the Corporation, provided that (i) the Warrant Agent’s written notice shall describe the circumstances of such non-compliance; and (ii) if such circumstances are rectified to the Warrant Agent’s satisfaction within such ten (10) day period, then such resignation shall not be effective.

9.15

Privacy

The parties acknowledge that the Warrant Agent may, in the course of providing services hereunder, collect or receive financial and other personal information about such parties and/or their representatives, as individuals, or about other individuals related to the subject matter hereof, and use such information for the following purposes:

  (a)

to provide the services required under this Indenture and other services that may be requested from time to time;

     
  (b)

to help the Warrant Agent manage its servicing relationships with such individuals;

     
  (c)

to meet the Warrant Agent’s legal and regulatory requirements; and

     
  (d)

if social insurance numbers are collected by the Warrant Agent, to perform tax reporting and to assist in verification of an individual’s identity for security purposes.

Each party acknowledges and agrees that the Warrant Agent may receive, collect, use and disclose personal information provided to it or acquired by it in the course of this agreement for the purposes described above and, generally, in the manner and on the terms described in its Privacy Code, which the Warrant Agent shall make available on its website or upon request, including revisions thereto. Some of this personal information may be transferred to servicers in the U.S.A. for data processing and/or storage. Further, each party agrees that it shall not provide or cause to be provided to the Warrant Agent any personal information relating to an individual who is not a party to this agreement unless that party has assured itself that such individual understands and has consented to the aforementioned terms, uses and disclosures.


- 47 -

ARTICLE 10 - GENERAL

10.1

Notice to the Corporation and the Warrant Agent

     
10.1.1

Unless herein otherwise expressly provided, any notice to be given hereunder to the Corporation or the Warrant Agent shall be deemed to be validly given if delivered, sent by registered letter, postage prepaid or telecopied:


  (a) If to the Corporation:
       
  Stem Cell Therapeutics Corp.
  MaRS Centre, Heritage Building
  101 College Street, Suite 200
    Toronto, Ontario M5G 1L7
    Attention: James Parsons, CFO
    Email: jparsons@stemcellthera

  (b) If to the Warrant Agent:
       
    Computershare Trust Company of Canada
    600, 530 – 8 Avenue S.W.
    Calgary, Alberta T2P 3S8
    Attention: Manager, Corporate Trust
    Facsimile: 403-267-6598

and any such notice delivered in accordance with the foregoing shall be deemed to have been received on the date of delivery or, if mailed, on the fifth (5th) Business Day following the date of the postmark on such notice or, if telecopied, on the next Business Day following the date of transmission provided that its contents are transmitted and received completely and accurately.

  10.1.2

The Corporation or the Warrant Agent, as the case may be, may from time to time notify the other in the manner provided in subsection 10.1.1 of a change of address which, from the effective date of such notice and until changed by like notice, shall be the address of the Corporation or the Warrant Agent, as the case may be, for all purposes of this Indenture.

     
  10.1.3

If, by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given to the Warrant Agent or to the Corporation hereunder could reasonably be considered unlikely to reach its destination, such notice shall be valid and effective only if it is delivered to the named officer of the party to which it is addressed or, if it is delivered to such party at the appropriate address provided in subsection 10.1.1, by telecopy or other means of prepaid, transmitted and recorded communication.



- 48 -

10.2

Notice to Warrantholders

     
10.2.1

Unless otherwise provided herein, notice to the Warrantholders under the provisions of this Indenture shall be valid and effective if delivered or sent by telecopy or by ordinary post addressed to such holders at their post office addresses appearing on the register hereinbefore mentioned and shall be deemed to have been effectively given on the date of delivery or, if mailed, on the fifth Business Day following the date of the postmark on such notice or, if telecopied, on the next Business Day following the date of transmission, provided that its contents are transmitted and received completely and accurately.

     
10.2.2

If, by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given to the Warrantholders hereunder could reasonably be considered unlikely to reach its destination, such notice shall be valid and effective only if such notice is published once in the National Edition of The Globe and Mail or, if the National Edition of The Globe and Mail is not being generally circulated, in The National Post, and, if the National Edition of The Globe and Mail (or The National Post if the notice is published therein) is not circulated in a city where a Warrant Agency is situated, in an English language daily newspaper of general circulation in such city; provided that in the case of a notice convening a meeting of Warrantholders, the Warrant Agent may require such additional publications of such notice, in the same or another city or both as it may deem necessary for the reasonable protection of the Warrantholders or to comply with any applicable requirements of law or of any stock exchange. Any notice so given shall be deemed to have been given on the day on which it has been published in the National Edition of The Globe and Mail or The National Post, as the case may be, and in all of the cities in which such publication was required (or first published in all such cities if more than one publication in any such city is required). In determining under any provision hereof the date when notice of any meeting or other event must be given, the date of giving notice shall be included and the date of the meeting or other event shall be excluded.

     
10.3

Ownership of Warrants

The Corporation and the Warrant Agent may deem and treat the registered owner of any Warrants as the absolute owner thereof for all purposes, and the Corporation and the Warrant Agent shall not be affected by any notice or knowledge to the contrary except where the Corporation or the Warrant Agent is required to take notice by statute or by order of a court of competent jurisdiction. A Warrantholder shall be entitled to the rights evidenced by its Warrant Certificate free from all equities or rights of set off or counterclaim between the Corporation and the original or any intermediate holder of the Warrants and all persons may act accordingly. The receipt of any such Warrantholder for the Common Shares which may be acquired pursuant thereto, or the receipt of the amount payable to such Warrantholder upon the exercise of the repurchase right referred to in Section 5.1 shall be a good discharge to the Corporation and the Warrant Agent for the same and neither the Corporation nor the Warrant Agent shall be bound to inquire into the title of any such holder except where the Corporation or the Warrant Agent is required to take notice by statute or by order of a court of competent jurisdiction.


- 49 -

10.4

Evidence of Ownership

     
10.4.1

Upon receipt of a certificate of any bank, trust company or other depositary satisfactory to the Warrant Agent stating that the Warrants specified therein have been deposited by a named person with such bank, trust company or other depositary and will remain so deposited until the expiry of the period specified therein, the Corporation and the Warrant Agent may treat the person so named as the owner, and such certificate as sufficient evidence of the ownership by such person of such Warrant during such period, for the purpose of any requisition, direction, consent, instrument or other document to be made, signed or given by the holder of the Warrant so deposited.

     
10.4.2

The Corporation and the Warrant Agent may accept as sufficient evidence of the fact and date of the signing of any requisition, direction, consent, instrument or other document by any person (i) the signature of any officer of any bank, trust company, or other depositary satisfactory to the Warrant Agent as witness of such execution, (ii) the certificate of any notary public or other officer authorized to take acknowledgements of deeds to be recorded at the place where such certificate is made that the person signing acknowledged to him the execution thereof, (iii) a statutory declaration of a witness of such execution, or (iv) any other documentation satisfactory to the Corporation and the Warrant Agent.

     
10.5

Counterparts

This Indenture may be executed in several counterparts, each of which when so executed shall be deemed to be an original and such counterparts together shall constitute one and the same instrument and notwithstanding their date of execution they shall be deemed to be dated as of the date hereof:

10.6

Satisfaction and Discharge of Indenture

Upon the earlier of:

  10.6.1

the date by which there shall have been delivered to the Warrant Agent for exercise or destruction all Warrant Certificates contemplated to be certified hereunder; or

     
  10.6.2

the Expiry Time;

and if all certificates representing Common Shares required to be issued in compliance with the provisions hereof have been issued and delivered hereunder or to the Warrant Agent in accordance with such provisions and if all payments required to be made in accordance with such provisions have been made, this Indenture shall cease to be of further effect and the Warrant Agent, on demand of and at the cost and expense of the Corporation and upon delivery to the Warrant Agent of a certificate of the Corporation stating that all conditions precedent to the satisfaction and discharge of this Indenture have been complied with, shall execute proper instruments acknowledging satisfaction of and discharging this Indenture. Notwithstanding the foregoing, the indemnities provided to the Warrant Agent by the Corporation hereunder shall remain in full force and effect and survive the termination of this Indenture.


- 50 -

10.7

Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders

Nothing in this Indenture or in the Warrant Certificates, expressed or implied, shall give or be construed to give to any person other than the parties hereto and the Warrantholders, as the case may be, any legal or equitable right, remedy or claim under this Indenture, or under any covenant or provision herein or therein contained, all such covenants and provisions being for the sole benefit of the parties hereto and the Warrantholders.

10.8

Common Shares or Warrants Owned by the Corporation or its Subsidiaries - Certificate to be Provided

For the purpose of disregarding any Warrants owned legally or beneficially by the Corporation or any Subsidiary of the Corporation in Section 7.16, the Corporation shall provide to the Warrant Agent, from time to time, a certificate of the Corporation setting forth as at the date of such certificate:

  10.8.1

the names (other than the name of the Corporation) of the registered holders of Warrants which, to the knowledge of the Corporation, are owned by or held for the account of the Corporation or any Subsidiary of the Corporation; and

     
  10.8.2

the number of Warrants owned legally or beneficially by the Corporation or any Subsidiary of the Corporation;

and the Warrant Agent, in making the computations in Section 7.16, shall be entitled to rely on such certificate without any additional evidence.

[Signatures on following page]


- 51 -

IN WITNESS WHEREOF the parties hereto have executed this Indenture under their respective corporate seals and the hands of their proper officers in that behalf.

  STEM CELL THERAPEUTICS CORP.
       
  Per: (Signed) “ James Parsons
    Name: James Parsons
    Title: Chief Financial Officer
       
       
COMPUTERSHARE TRUST COMPANY OF CANADA
       
  Per: (Signed) “ Laura Leong
    Name: Laura Leong
    Title: Corporate Trust Officer
  Per: (Signed) “ Shannon Grover
    Name:  Shannon Grover
    Title:  Corporate Trust Officer


A-1

SCHEDULE A

FORM OF WARRANT CERTIFICATE

[IF APPLICABLE, CERTIFICATES REPRESENTING WARRANTS ISSUED PURSUANT TO A CANADIAN MAY BEAR THE FOLLOWING LEGEND.]

UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE ●, 2013.

[CERTIFICATES REPRESENTING WARRANTS ISSUED TO U.S. PURCHASERS MUST BEAR THE FOLLOWING LEGEND.]

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ U.S. SECURITIES ACT ”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THE HOLDER HEREOF, BY PURCHASING THE SECURITIES REPRESENTED HEREBY, AGREES FOR THE BENEFIT OF STEM CELL THERAPEUTICS CORP. AND ITS SUCCESSORS (THE “ CORPORATION ”) THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH LOCAL LAWS AND REGULATIONS, (C) WITHIN THE UNITED STATES PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY (I) RULE 144A OR (II) RULE 144 THEREUNDER, IF APPLICABLE, AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) WITHIN THE UNITED STATES, IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS GOVERNING THE OFFER AND SALE OF SECURITIES, AND IN THE CASE OF TRANSFERS PURSUANT TO (C)(II) OR (D) ABOVE, THE HOLDER HEREOF HAS, PRIOR TO SUCH TRANSFER, FURNISHED TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE CORPORATION TO SUCH EFFECT.

DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE ‘GOOD DELIVERY’ IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.

THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ U.S. SECURITIES ACT ”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THIS WARRANT MAY NOT BE EXERCISED IN THE UNITED STATES OR BY OR ON BEHALF OF, OR FOR THE ACCOUNT OR BENEFIT OF, A U.S. PERSON UNLESS THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH STATE OR EXEMPTIONS FROM SUCH REGISTRATION REQUIREMENTS ARE AVAILABLE. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE U.S. SECURITIES ACT


A-2

Certificate No.: _______________No. of Warrants: _________________________

WARRANTS
Exercisable to Acquire
Common Shares
of 
STEM CELL THERAPEUTICS CORP.

(Incorporated under the Business Corporations Act (Alberta))

THIS IS TO CERTIFY THAT, for value received, ● (the “ holder ”) is the registered holder of the number of Warrants of Stem Cell Therapeutics Corp. (“ SCT ”) specified above and, for each whole Warrant held, is thereby entitle to be issued, subject to adjustment and except as otherwise described herein, one fully paid and non-assessable Common Share and subject to the limitation referred to below by surrendering to Computershare Trust Company of Canada (the “ Warrant Agent ”) at its principal transfer office in Calgary, Alberta or Toronto, Ontario during the exercise period hereinafter referred to (i) a certified cheque, bank draft or money order made payable to SCT in the amount of the Exercise Price as hereinafter determined in respect of each Common Share to be issued, (ii) this Warrant Certificate and (iii) a notice of exercise in the form set forth in Appendix 1 annexed hereto duly completed and executed.

Capitalized terms which are not otherwise defined herein shall have the same meaning as in the Warrant indenture (which indenture, together with all instruments supplemental or ancillary thereto, is herein referred to as the “ Warrant Indenture ”) dated April 8, 2013 between SCT and the Warrant Agent.

Surrender of this Warrant Certificate will be deemed to have been effected only on personal delivery thereof to, or, if sent by mail or other means of transmission, on actual receipt thereof by, the Warrant Agent at the office specified above.

This Warrant Certificate evidences Warrants of SCT issued or issuable under the provisions of the Warrant Indenture. Reference is made to the Warrant Indenture for particulars of the rights of the holders of the Warrants and of SCT and of the Warrant Agent in respect thereof and of the terms and conditions upon which the Warrants are issued and held, all to the same effect as if the provisions of the Warrant Indenture were herein set forth in full, to all of which the holder, by acceptance hereof, assents. To the extent of any inconsistency between the terms of the Warrant Indenture and the terms of this Warrant Certificate, the terms of the Warrant Indenture shall prevail. SCT will furnish to the holder, on request and upon payment of a reasonable charge for photocopying and postage, a copy of the Warrant Indenture.

The Warrants evidenced by this Warrant Certificate may be exercised by the holder (including, if applicable, any agent under any power of attorney granted by such holder) at any time until the Expiry Time.


A-3

Except as otherwise expressly provided, all dollar amounts herein are expressed in Canadian dollars.

On and after the date of any exercise of the Warrants evidenced by this Warrant Certificate, the holder will have no rights hereunder except to receive certificates representing the Common Shares thereby issued to him upon delivery of a certified cheque, bank draft or money order payable to SCT in respect of each Common Share to be issued in the amount of $0.40 (the “ Exercise Price ”), this Warrant Certificate and a duly completed notice of exercise as set out in Appendix 1 hereto to the Warrant Agent at its principal office in Calgary, Alberta or Toronto, Ontario. After the Expiry Time, all rights under any unexercised Warrant evidenced hereby will wholly cease and terminate and this Warrant Certificate will be void.

SCT will not be obligated to issue any fraction of a Common Share on the exercise of any Warrant. To the extent that a holder of Warrants would otherwise have been entitled to receive, on the exercise of Warrants, a fraction of a Common Share, such right may only be exercised in respect of such fraction in connection with another Warrant or Warrants which in the aggregate entitle the holder to receive a whole number of Common Shares. If a Warrantholder is not able to combine Warrants so as to be entitled to acquire a whole number of Common Shares, the number of Common Shares which such Warrantholder is entitled to receive shall be rounded down to the prior whole number, as applicable.

The Warrant Indenture provides for adjustments to the number of Common Shares issuable and to the Exercise Price in certain events set forth therein.

The Warrant Indenture contains provisions making binding on all holders of Warrants outstanding thereunder resolutions passed at meetings of such holders held in accordance with such provisions and instruments in writing signed by holders of a specified majority of all outstanding Warrants.

On presentation at the principal office of the Warrant Agent in Calgary, Alberta or Toronto, Ontario, subject to the provisions of the Warrant Indenture and on compliance with the reasonable requirements of the Warrant Agent, one or more Warrant Certificates may be exchanged at no cost to the holder for one or more Warrant Certificates of different denominations evidencing in the aggregate the same number of Warrants as the Warrant Certificate or Warrant Certificates being exchanged.

The Warrants evidenced by this Warrant Certificate may only be transferred, upon compliance with the conditions prescribed in the Warrant Indenture, on the register of transfers to be kept at the principal office of the Warrant Agent in Calgary, Alberta or Toronto, Ontario by the holder or his executors, administrators or other legal representatives or his or their attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent, and, upon compliance with such requirements and such other reasonable requirements as the Warrant Agent may prescribe, including the completion of a form of transfer as set out in Appendix 2 hereto, such transfer will be duly noted on such register of transfers by the Warrant Agent. Notwithstanding the foregoing, SCT will be entitled, and may direct the Warrant Agent, to refuse to record any transfer of any Warrant on such register if such transfer would constitute a violation of the securities laws of any jurisdiction or require SCT to qualify the Common Shares for distribution in any jurisdiction.


A-4

No Common Shares will be issued pursuant to any exercise of any Warrant if the issue of such security would constitute a violation of the securities laws of any applicable jurisdiction.

The holding of this Warrant Certificate will not constitute the holder a shareholder of SCT or entitle such holder to any right or interest in respect thereof except as otherwise provided in the Warrant Indenture.

This Warrant Certificate will not be valid for any purpose until it has been certified by or on behalf of the Warrant Agent for the time being under the Warrant Indenture. Time will be of the essence hereof.

THE WARRANTS REPRESENTED BY THIS CERTIFICATE WILL BE VOID AND OF NO VALUE UNLESS EXERCISED PRIOR TO 5:00 P.M. (TORONTO TIME) ON OR BEFORE MARCH 15, 2018.

IN WITNESS WHEREOF SCT has caused this Warrant Certificate to be signed by its officer or other individual duly authorized in that behalf as of

  STEM CELL THERAPEUTICS CORP.
   
  Per:            ____________________________________________________________
                     Name:
                     Title:

This Warrant Certificate is one of the Warrant Certificates referred to in the Warrant Indenture within mentioned.

COMPUTERSHARE TRUST COMPANY OF CANADA
   
  Per:            ____________________________________________________________
                     Name:
                     Title:


1-1

APPENDIX 1
NOTICE OF EXERCISE

To: STEM CELL THERAPEUTICS CORP.
And To:    COMPUTERSHARE TRUST COMPANY OF CANADA

600, 530 – 8 Avenue S.W.
Calgary, Alberta T2P 3S8
or 100 University Avenue, 9th Floor
Toronto, Ontario M5J 2Y1

The undersigned holder of the Warrants evidenced by the within Warrant Certificate hereby exercises its right to be issued Common Shares of Stem Cell Therapeutics Corp. (or such other securities or property to which such exercise entitles such holder in lieu thereof or in addition thereto under the provisions of the Warrant Indenture mentioned in such Warrant Certificate) that are issuable upon the exercise of such Warrants, on the terms specified in such Warrant Certificate and Warrant Indenture.

The undersigned hereby irrevocably directs that the said Common Shares be issued, registered and delivered as follows:

        Number of Common Shares and
Name(s) in Full   Address(es)   Number of Warrants (# and #)
         
         
         
         
         

(Please print full name in which certificates for Common Shares are to be issued. If any shares are to be issued to a person or persons other than the holder, the holder must pay to the Warrant Agent all exigible transfer taxes or other government charges and sign the Form of Transfer.)

DATED this_______________ day of _________________________ , ________ .


     
Witness   Signature of Registered Holder
     
     
    Signature of Registered Holder

Note: The name of the Registered Holder on this Notice of Exercise must be the same as the name appearing on the face page of the Warrant Certificate to which this Notice of Exercise is attached.


1-2

The undersigned represents, warrants and certifies as follows (one of the following must be checked):

[   ]     A.      The undersigned holder (i) at the time of exercise of the Warrant is not in the United States; (ii) is not a U.S. Person and is not exercising the Warrant for the account or benefit of a U.S. Person; (iii) was not offered to exercise the Warrant and did not execute or deliver the exercise form for the Warrant in the United States; (iv) did not acquire the Warrant in the United States; and (v) has in all other respects complied with Regulation S of the United States Securities Act of 1933, as amended.

[   ]      B.      The undersigned holder (i) originally purchased the Warrant on its own behalf or on behalf of a beneficial purchaser (a “ Beneficial Purchaser ”) directly from the Corporation pursuant to the Corporation’s offering of Units at a time when the holder was and any Beneficial Purchaser was (A) an “accredited investor”, as defined in Rule 501(a) under the U.S. Securities Act (“ Accredited Investor ”) and (B) in the United States or a U.S. Person, or was offered Units in the United States, (ii) is exercising the Warrant solely for its own account or for the account of the Beneficial Purchaser, if any, and not on behalf of any other person, (iii) is, and the Beneficial Purchaser, if any, is, an Accredited Investor on the date of exercise of the Warrant, and (iv) as of the date of exercise of the Warrant, it reaffirms the representations, warranties, and agreements made by it in the U.S. Purchaser Letter.

[   ]      C.      An exemption from registration under the U.S. Securities Act and any applicable state securities law is available, and attached hereto is an opinion of counsel to such effect, it being understood that any opinion of counsel tendered in connection with the exercise of Warrants must be in form and substance satisfactory to Stem Cell Therapeutics Corp.

The undersigned holder understands that (i) unless box A is checked, the certificate representing the Common Shares will bear a legend restricting transfer without registration under the U.S. Securities Act and applicable state securities laws unless an exemption from registration is available, and (ii) Common Shares will not be delivered to an address in the United States unless box B or box C is checked and, if box C is checked, the required opinion of counsel is in form and substance satisfactory to Corporation and an executed letter, substantially in the form of Schedule “D” to the Indenture, is delivered to the Warrant Agent (a copy of which is available upon request from the Warrant Agent or the Corporation).

DATED this ___ day of _____________, 20__.

Signature Guarantee:

The signature on this exercise form must correspond with the name as written upon the face of the certificate(s), in every particular, without alteration or enlargement, or any change whatsoever and must be guaranteed by a Canadian Schedule 1 chartered bank or a member of the Securities Transfer Agents Medallion Program (STAMP), a member of the Stock Exchange Medallion Program (SEMP) or a member of the New York Stock Exchange Inc. Medallion Signature Program (MSP). The guarantor must affix a stamp bearing the actual words “Signature Guaranteed”


1-3

[   ]     Please check if the Common Share certificates are to be delivered at the office where this Warrant Certificate is surrendered, failing which such certificates will be mailed.

Certificates will be delivered or mailed as soon as practicable after the due surrender of the Warrant Certificate to which this Appendix is attached.


2-1

      APPENDIX 2
FORM OF TRANSFER

FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers to

Name: _______________________________________________

Address: ____________________________________________

(such person, the “ Transferee ”) ____________________Warrants of Stem Cell Therapeutics Corp. (the “ Corporation ”) represented by the attached Warrant Certificate and does hereby appoint ____________________as its attorney with full power of a substitution to transfer the Warrants on the appropriate register of the Warrant Agent.

If the Warrant Certificate contains a legend restricting transfer of the Warrants except in compliance with the United States Securities Act of 1933, as amended (the “ U.S. Securities Act ”), and applicable state securities laws, this Transfer Form must be accompanied by a declaration to the effect that the Warrants are being transferred outside the United States in compliance with Rule 904 of Regulation S under the U.S. Securities Act in the form set forth in the Form of Declaration for Removal of Legend that follows (or as otherwise prescribed by the Corporation).

If the sale evidenced hereby is being made to a U.S. Person (as such term is defined in Regulation S to the United States Securities Act of 1933 (the “ Act ”), the undersigned, by the execution of this form of transfer, certifies that such sale does not require registration of the Warrants being transferred hereby under the Act and tenders herewith evidence satisfactory to the Corporation to such effect.

DATED this ________day of _________________________, ________.

     
Witness   Signature of Registered Holder
     
     
    Signature of Registered Holder

Note: The name of the Transferor on this Form of Transfer must be the same as the name appearing on the face page of the Warrant.


B-1

SCHEDULE B  
FORM OF DECLARATION FOR REMOVAL OF LEGEND

to the Warrant Indenture made as of ●, 2013 between Stem Cell Therapeutics Corp. and
Computershare Trust Company of Canada as Warrant Agent

TO: COMPUTERSHARE TRUST COMPANY OF CANADA as warrant agent for Warrants of Stem Cell Therapeutics Corp.

The undersigned (a) acknowledges that the sale of securities of Stem Cell Therapeutics Corp. (the “ Company ”) to which this declaration relates is being made in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the “ U.S. Securities Act ”) and (b) certifies that (1) the undersigned is not an “affiliate” of the Company as that term is defined in Rule 405 under the U.S. Securities Act, (2) the offer of such securities was not made to a person in the United States and either (A) at the time the buy order was originated, the buyer was outside the United States, or the seller and any person acting on its behalf reasonably believed that the buyer was outside the United States, or (B) the transaction was executed in, on or through the facilities of a “designated offshore securities market” as that term is defined in Regulation S under the U.S. Securities Act and neither the seller nor any person acting on its behalf knows that the transaction has been prearranged with a buyer in the United States, (3) neither the seller nor any affiliate of the seller not any person acting on any of their behalf has engaged or will engage in “directed selling efforts” in the United States in connection with the offer and sale of such securities, (4) the sale is bona fide and not for the purposes of “washing off” the resale restrictions imposed because the securities are “restricted securities” (as such term is defined in Rule 144(a)(3) under the U.S. Securities Act), (5) the seller does not intend to replace the securities sold in reliance on Rule 904 under the U.S. Securities Act with fungible unrestricted securities and (6) the contemplated sale is not a transaction, or part of a series of transactions which, although in technical compliance with Regulation S, is part of a plan or scheme to evade the registration provisions of the U.S. Securities Act. Terms used herein have the meanings given to them by Regulation S under the U.S. Securities Act.

Date:       
      Name of Seller
       
       
      Per:
                 Name
                 Title



Exhibit 4.9

WARRANT INDENTURE
Providing for the Issue of Warrants

BETWEEN

STEM CELL THERAPEUTICS CORP.

AND

COMPUTERSHARE TRUST COMPANY OF CANADA

Dated as of December 13, 2013


Table of Contents

    Page
     
ARTICLE 1 - INTERPRETATION 5
     1.1 Definitions 5
     1.2 Gender and Number 9
     1.3 Interpretation not Affected by Headings, etc. 9
     1.4 Day not a Business Day 10
     1.5 Time of the Essence 10
     1.6 Currency 10
     1.7 Assignment 10
     1.8 Applicable Law and Jurisdiction 10
ARTICLE 2 - ISSUE OF WARRANTS 10
     2.1 Creation and Issue of Warrants 10
     2.2 Terms of the Warrants 10
     2.3 Warrantholder not a Shareholder 11
     2.4 Warrants to Rank Pari Passu 11
     2.5 Form of Warrants 11
     2.6 Execution of Warrant Certificates 12
     2.7 Certification by the Warrant Agent 12
     2.8 Issue in Substitution for Warrant Certificates Lost, etc. 13
     2.9 Exchange of Warrant Certificates 13
     2.10 Transfer and Ownership of Warrants 14
     2.11 Charges for Exchange or Transfer 15
     2.12 Cancellation of Surrendered Warrants 16
     2.13 Registration of Warrants 16
     2.14 CDS and Depository 16
     2.15 NCI Letter of Instruction 18
     2.16 Legends 19
ARTICLE 3 - EXERCISE OF WARRANTS 21
     3.1 Method of Exercise of Warrants 21
     3.2 Effect of Exercise of Warrants 24
     3.3 Partial Exercise of Warrants; Fractions 25
     3.4 Expiration of Warrants 25
     3.5 Accounting and Recording 26
     3.6 Securities Restrictions 26
     3.7 Prohibition on Exercise in the United States or by U.S. Persons; Exception 26
ARTICLE 4 - ADJUSTMENT OF NUMBER OF COMMON SHARES AND EXERCISE PRICE

28

     4.1 Adjustment of Number of Common Shares and Exercise Price 28
     4.2 Entitlement to Shares on Exercise of Warrant 32


- ii -

     4.3 No Adjustment for Certain Transactions 32
     4.4 Determination by Corporation’s Auditors 33
     4.5 Proceedings Prior to any Action Requiring Adjustment 33
     4.6 Certificate of Adjustment 33
     4.7 Notice of Special Matters 33
     4.8 No Action After Notice 33
     4.9 Other Action 34
     4.10 Protection of Warrant Agent 34
ARTICLE 5 - RIGHTS OF THE CORPORATION AND COVENANTS 35
     5.1 Optional Purchases by the Corporation 35
     5.2 General Covenants 35
     5.3 Warrant Agent’s Remuneration and Expenses 36
     5.4 Securities Qualification Requirements 37
     5.5 Performance of Covenants by Warrant Agent 37
     5.6 Enforceability of Warrants 37
ARTICLE 6 - ENFORCEMENT 37
     6.1 Suits by Warrantholders 37
     6.2 Immunity of Shareholders, etc. 37
     6.3 Limitation of Liability 38
     6.4 Waiver of Default 38
ARTICLE 7 – MEETINGS OF WARRANTHOLDERS 38
     7.1 Right to Convene Meetings 38
     7.2 Notice 39
     7.3 Chairman 39
     7.4 Quorum 39
     7.5 Power to Adjourn 40
     7.6 Show of Hands 40
     7.7 Poll and Voting 40
     7.8 Regulations 40
     7.9 Corporation and Warrant Agent May be Represented 41
     7.10 Powers Exercisable by Extraordinary Resolution 41
     7.11 Meaning of Extraordinary Resolution 42
     7.12 Powers Cumulative 43
     7.13 Minutes 43
     7.14 Instruments in Writing 44
     7.15 Binding Effect of Resolutions 44
     7.16 Holdings by Corporation Disregarded 44
ARTICLE 8 - SUPPLEMENTAL INDENTURES 44
     8.1 Provision for Supplemental Indentures for Certain Purposes 44
     8.2 Successor Corporations 45
ARTICLE 9 - CONCERNING THE WARRANT AGENT 46
     9.1 Rights and Duties of Warrant Agent 46


- iii -

     9.2 Evidence, Experts and Advisers 46
     9.3 Documents, Monies, etc. Held by Warrant Agent 47
     9.4 Actions by Warrant Agent to Protect Interest 48
     9.5 Warrant Agent Not Required to Give Security 48
     9.6 Protection of Warrant Agent 48
     9.7 Corporation to Indemnify 48
     9.8 Replacement of Warrant Agent; Successor by Merger 49
     9.9 Conflict of Interest 50
     9.10 Acceptance of Trust 50
     9.11 Warrant Agent Not to be Appointed Receiver 50
     9.12 Warrant Agent Not Required to Give Notice of Default 51
     9.13 Force Majeure 51
     9.14 Third Parties 51
     9.15 Anti-Money Laundering 51
     9.16 Privacy 52
ARTICLE 10 - GENERAL 52
     10.1 Notice to the Corporation and the Warrant Agent 52
     10.2 Notice to Warrantholders 53
     10.3 Ownership of Warrants 54
     10.4 Evidence of Ownership 54
     10.5 Counterparts 55
     10.6 Satisfaction and Discharge of Indenture 55
     10.7 Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders 55
     10.8 Common Shares or Warrants Owned by the Corporation or its Subsidiaries - Certificate to be Provided 55
      
SCHEDULE “A” FORM OF WARRANT CERTIFICATE 1
    
APPENDIX 1 NOTICE OF EXERCISE 1
    
APPENDIX 2 FORM OF TRANSFER 1
    
SCHEDULE “B” FORM OF DECLARATION FOR REMOVAL OF LEGEND 1


- 4 -

THIS WARRANT INDENTURE is made as of December 13 th , 2013

BETWEEN:

STEM CELL THERAPEUTICS CORP. , a corporation continued under the laws of the Province of Ontario, having its head office currently in the City of Toronto, in the Province of Ontario

(the “ Corporation ”)

AND:

COMPUTERSHARE TRUST COMPANY OF CANADA , a trust company incorporated under the laws of Canada and authorized to carry on business in all provinces of Canada

(the “ Warrant Agent ”)

WHEREAS the Corporation proposes to issue up to 117,857,142 common share purchase warrants (“ Warrants ”) each whole Warrant will entitle the registered holder thereof to purchase one Common Share (as defined herein) (subject to adjustment as herein provided) at the price and upon the terms and conditions herein set forth;

AND WHEREAS for such purpose the Corporation deems it necessary to create and issue Warrants constituted and issued in the manner hereinafter appearing;

AND WHEREAS for such purpose, the Corporation is duly authorized to create and issue the Warrants constituted and issued in the manner hereinafter provided;

AND WHEREAS all things necessary have been done and performed to make the Warrants (and if issued, the Warrant Certificates when certified by the Warrant Agent and issued as provided for in this Indenture) legal, valid and binding upon the Corporation with the benefits of and subject to the terms of this Indenture;

AND WHEREAS the Warrant Agent has agreed to enter into this Indenture and to hold all rights, interests and benefits contained herein for and on behalf of those persons who from time to time become holders of Warrants issued pursuant to this Indenture;

AND WHEREAS the foregoing statements of fact and recitals are made by the Corporation and not the Warrant Agent.

NOW THEREFORE THIS INDENTURE WITNESSES that for good and valuable consideration mutually given and received, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed and declared by the parties hereto as follows: become the holders of Warrants issued pursuant to this Indenture and the parties hereto agree as set forth below:


- 5 -

ARTICLE 1 - INTERPRETATION

1.1

Definitions

In this Indenture, including the recitals and schedules hereto, and in all indentures supplemental hereto, unless there is something in the subject matter or context inconsistent therewith:

  1.1.1

Accredited Investor ” means an “accredited investor” as defined in Rule 501(a) of Regulation D, that satisfies the requirements of Rule 501(a);

     
  1.1.2

Adjustment Period ” means the period from and including the Effective Date up to and including the Expiry Time;

     
  1.1.3

Applicable Legislation ” means the provisions of the Business Corporations Act (Ontario), as from time to time amended, and any statute of Canada or a province thereof, and the regulations under any such named or other statute, relating to trust indentures or to the rights, duties and obligations of trustees and of corporations under trust indentures, to the extent that such provisions are at the time in force and applicable to this Indenture;

     
  1.1.4

Beneficial Owner ” means a person that has a beneficial interest in a Warrant that is represented by a Global Certificate;

     
  1.1.5

Book Based System ” means the book based securities transfer system administered by CDS in accordance with its operating procedure from time to time;

     
  1.1.6

Book Entry Only Participant ” means an institution that participates directly or indirectly in the Depository’s Book Based System for the Warrants;

     
  1.1.7

Business Day ” means a day which is not Saturday or Sunday or a legal holiday in the city of Toronto, Ontario;

     
  1.1.8

CDS ” means CDS Clearing and Depository Services Inc. and its successors in interest;

     
  1.1.9

CDS Participant ” means a participant in the Book Based System or its nominees;

     
  1.1.10

Common Shares ” means, subject to Article 4, fully paid and non-assessable common shares of the share capital of the Corporation as presently constituted;

     
  1.1.11

Corporation ” means Stem Cell Therapeutics Corp., a corporation incorporated under the Business Corporations Act (Ontario) and its lawful successors from time to time;



- 6 -

  1.1.12

Corporation’s Auditors ” means Ernst & Young LLP or any other firm of chartered accountants duly appointed as auditors of the Corporation;

     
  1.1.13

Counsel ” means a barrister or solicitor or a firm of barristers and solicitors retained by the Warrant Agent or retained by the Corporation and acceptable to the Warrant Agent;

     
  1.1.14

Current Market Price ” of the Common Shares at any date means the volume weighted average of the trading price of the Common Shares for the twenty (20) consecutive Trading Days immediately preceding such date on the principal stock exchange on which the Common Shares are listed and as selected by the directors, or, if such Common Shares are not listed on any stock exchange, then on such over the counter market as may be selected for such purpose by the directors;

     
  1.1.15

Depository ” means CDS or a successor depository or any other depository offering a similar Book Based System for recording beneficial interest in the Warrants which the Corporation, acting reasonably, may designate;

     
  1.1.16

Director ” means a director of the Corporation for the time being and, unless otherwise specified herein, reference to action “ by the directors ” means action by the directors of the Corporation as a board or, whenever duly empowered, action by any committee of such board;

     
  1.1.17

Dividends Paid in the Ordinary Course ” means cash dividends declared payable on the Common Shares in any fiscal year of the Corporation to the extent that such cash dividends do not exceed, in the aggregate, greater than: (i) twenty percent (20%) of the retained earnings of the Corporation as at the end of its immediately preceding fiscal year; and (ii) forty percent (40%) of the aggregate consolidated net income of the Corporation, determined before computation of extraordinary items, for its immediately preceding fiscal year;

     
  1.1.18

Effective Date ” means the date of this Indenture;

     
  1.1.19

Exercise Date ” means, with respect to any Warrant, the date on which the Warrant Certificate representing such Warrant is surrendered for exercise together with full payment of the Exercise Price in accordance with Section 3.1;

     
  1.1.20

Exercise Price ” at any time means, the price at which one (1) Common Share may be purchased by the exercise of one Warrant and which is $0.28, subject to adjustment in accordance with the provisions of Article 4, in which case it shall mean the adjusted price in effect at such time;

     
  1.1.21

Expiry Date ” means December 13, 2018;

     
  1.1.22

Expiry Time ” means 5:00 p.m. (Toronto time) on the Expiry Date;



- 7 -

  1.1.23

Extraordinary Resolution ” has the meaning set forth in Section 7.11;

       
  1.1.24

Global Certificate ” means a certificate that is issued to and registered in the name of CDS;

       
  1.1.25

Internal Procedures ” means in respect of the making of any one or more entries to, changes in or deletions of any one or more entries in the register of Warrantholders at any time (including without limitation, original issuance or registration of transfer of ownership), the minimum number of the Warrant Agent’s internal procedures customary at such time for the entry, change or deletion effected under the operating procedures of the Warrant Agent;

       
  1.1.26

Issue Date ” means the date(s) upon which the Warrants are issued;

       
  1.1.27

NCI Letter of Instruction ” means the Non-Certificated Inventory system letter of instruction provided by CDS to the Warrant Agent in connection with the conversion of Warrants;

       
  1.1.28

Person ” means an individual, body corporate, partnership, trust, trustee, executor, administrator, legal representative or any unincorporated organization;

       
  1.1.29

Preferred Shares ” means the series 1 non-voting first preferred shares in the capital of the Corporation;

       
  1.1.30

Preferred Unit ” means one preferred unit consisting of one Preferred Share and three-quarters of one Warrant;

       
  1.1.31

Regulation D ” means Regulation D adopted by the SEC under the U.S. Securities Act;

       
  1.1.32

Regulation S ” means Regulation S adopted by the SEC under the U.S. Securities Act;

       
  1.1.33

SEC ” means the United States Securities and Exchange Commission;

       
  1.1.34

Shareholder ” means a holder of record of one or more Common Shares;

       
  1.1.35

Subsidiary of the Corporation ” or “ Subsidiary ” means any corporation of which more than fifty percent (50%) of the outstanding Voting Shares are owned, directly or indirectly, by or for the Corporation, provided that the ownership of such shares confers the right to elect at least a majority of the board of directors of such corporation and includes any corporation in like relation to a subsidiary;

       
  1.1.36

successor corporation ” has the meaning set forth in Section 8.2;



- 8 -

  1.1.37

this Warrant Indenture ”, “ this Indenture ”, “ herein ”, “ hereby ”, “ hereof ” and similar expressions mean and refer to this Indenture and any indenture, deed or instrument supplemental hereto; and the expressions “Article”, “Section”, “subsection” and “paragraph” followed by a number, letter or both mean and refer to the specified Article, Section, subsection or paragraph of this Indenture;

     
  1.1.38

Trading Day ” means, with respect to a stock exchange, a day on which such exchange is open for the transaction of business;

     
  1.1.39

Uncertificated Warrant ” means any Warrant which is not represented by a Warrant Certificate;

     
  1.1.40

Unit ” means one unit consisting of one Common Share and three-quarters of one Warrant;

     
  1.1.41

United States ” means the United States of America, its territories and possessions, any state of the United States, and the District of Columbia collectively;

     
  1.1.42

U.S. Person ” means “U.S. person” as that term is defined in Rule 902 of Regulation S under the U.S. Securities Act;

     
  1.1.43

U.S. Purchaser ” means any holder of Warrants originally purchased from the Corporation by a person who is a U.S. Person, a person in the United States or a person that purchased the Warrants for the account or benefit of a U.S. Person or a person in the United States;

     
  1.1.44

U.S. Securities Act ” means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder;

     
  1.1.45

U.S. Securities Exchange Act ” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder;

     
  1.1.46

Voting Shares ” means shares of the capital stock of any class of any corporation carrying voting rights under all circumstances, provided that, for the purposes of such definition, shares which only carry the right to vote conditionally on the happening of an event shall not be considered Voting Shares, whether or not such event shall have occurred, nor shall any shares be deemed to cease to be Voting Shares solely by reason of a right to vote accruing to shares of another class or classes by reason of the happening of any such event;

     
  1.1.47

Warrant Agency ” means one of the principal offices of the Warrant Agent in the city of Toronto or such other place(s) as may be designated in accordance with subsection 3.1.3;



- 9 -

  1.1.48

Warrant Agent ” means Computershare Trust Company of Canada in its capacity as Warrant Agent, or its successors from time to time in the trust hereby created;

     
  1.1.49

Warrant Certificate ” means a certificate, substantially in the form set forth in Schedule “A” hereto, issued on or after the Issue Date to evidence the Warrants;

     
  1.1.50

Warrant Exercise Form ” means an exercise form, substantially in the form set forth in Schedule “A” hereto, delivered by a Warrantholder to the Warrant Agency at any time after the Issue Date and prior to the Expiry Time;

     
  1.1.51

Warrantholders ”, or “ holders ” without reference to Common Shares, means the persons who are registered owners of Warrants;

     
  1.1.52

Warrantholders’ Request ” means an instrument signed in one or more counterparts by Warrantholders entitled to acquire in the aggregate not less than ten percent (10%) of the aggregate number of Common Shares which could be acquired pursuant to all Warrants then unexercised and outstanding, requesting the Warrant Agent to take some action or proceeding specified therein;

     
  1.1.53

Warrants ” means the Warrants created by and authorized by and issuable under this Indenture to be issued and countersigned hereunder in certificated form and/or held through the book entry registration on a no certificate issued basis, whether by way of Warrant Certificate or Uncertificated Warrant; and

     
  1.1.54

written order of the Corporation ”, “ written request of the Corporation ”, “ written consent of the Corporation ” and “ certificate of the Corporation ” mean, respectively, a written order, request, consent and certificate signed in the name of the Corporation by its Chairman, Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, President, Secretary or any Vice President, or a liaison acting in any such capacity for the Corporation and may consist of one or more instruments so executed.


1.2

Gender and Number

Unless herein otherwise expressly provided or unless the context otherwise requires, words importing the singular include the plural and vice versa and words importing gender include all genders.

1.3

Interpretation not Affected by Headings, etc.

The division of this Indenture into Articles, Sections and subsections, the provision of a table of contents and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation of this Indenture.


- 10 -

1.4

Day not a Business Day

In the event that any day on or before which any action is required to be taken hereunder is not a Business Day, then such action shall be required to be taken at or before the requisite time on the next succeeding day that is a Business Day.

1.5

Time of the Essence

Time shall be of the essence of this Indenture.

1.6

Currency

Except as otherwise expressly provided, all dollar amounts herein are expressed in Canadian dollars.

1.7

Assignment

This Indenture may not be assigned by either party hereto without the consent in writing of the other party. This Indenture shall enure to and bind the parties and their lawful successors and permitted assigns.

1.8

Applicable Law and Jurisdiction

This Indenture and the Warrant Certificates and all documents relating thereto, which by common accord have been and will be drafted in English, shall be construed in accordance with the laws of the Province of Ontario and the federal laws applicable therein and shall be treated in all respects as Ontario contracts.

Each party to this Indenture, by its execution hereof, hereby irrevocably submits to the exclusive jurisdiction of the Courts of the Province of Ontario for the purpose of any action, claim, cause of action or suit (in contract, delict or otherwise), inquiry, proceeding or investigation arising out of or based upon this Indenture, Warrant Certificates or all documents relating thereto.

ARTICLE 2 - ISSUE OF WARRANTS

2.1

Creation and Issue of Warrants

Up to 117,857,142 Warrants are hereby authorized, all in accordance with the terms and conditions hereof. The Warrant Certificates shall be certified and delivered by the Warrant Agent to such persons as the Corporation may direct by written order of the Corporation.

2.2

Terms of the Warrants

     
2.2.1

Each whole Warrant shall entitle the holder thereof, upon exercise, together with the payment of the Exercise Price, to acquire one (1) Common Share, subject to adjustment in accordance with Article 4, at any time after the Issue Date until the Expiry Time.



- 11 -

  2.2.2

No fractional Warrants shall be issued or otherwise provided for hereunder. Any fractional entitlements shall be rounded down to the nearest whole number and a purchaser or holder of any Warrant shall not be entitled to any cash or other consideration in lieu of any fractional interest in a Warrant or claim thereto.

     
  2.2.3

Each Warrant shall entitle the holder thereof to such other rights and privileges as are set forth in this Indenture.

     
  2.2.4

The number of Common Shares which may be purchased pursuant to the Warrants and the Exercise Price therefor shall be adjusted in the events and in the manner specified in Article 4.

     
  2.2.5

Upon the exercise of the Warrants, the Corporation shall issue Common Shares required to fulfill its obligation to sell Common Shares upon the exercise of the Warrants.


2.3

Warrantholder not a Shareholder

Except as may be specifically provided herein, nothing in this Indenture or in the holding of a Warrant or Warrant Certificate or otherwise, shall, in itself, confer or be construed as conferring upon a Warrantholder any right or interest whatsoever as a Shareholder or as any other shareholder of the Corporation, including, but not limited to, the right to vote at, to receive notice of, or to attend, meetings of shareholders or any other proceedings of the Corporation, or the right to receive dividends and other distributions.

2.4

Warrants to Rank Pari Passu

All Warrants shall rank equally and without preference over each other, whatever may be the actual date of issue thereof.

2.5

Form of Warrants

The Warrants may be issued in both certificated and uncertificated form at the discretion of the Corporation and pursuant to the procedures in this Indenture. For the avoidance of doubt, each Warrant originally issued to a U.S. Purchaser shall be evidenced in certificated form. The Warrant Certificates in definitive form evidencing the Warrants authorized in Section 2.1 shall be issuable as fully registered (including all replacements issued in accordance with this Indenture), shall be substantially in the form set out in Schedule “A” hereto, shall be dated as of the Issue Date, shall bear such distinguishing letters and numbers as the Corporation may, with the approval of the Warrant Agent, prescribe, and shall be issuable in any denomination excluding fractions. All Warrants issued to CDS shall be evidenced by a book position on the register of Warrantholders to be maintained by the Warrant Agent in accordance with Section 2.13.


- 12 -

2.6

Execution of Warrant Certificates

The Warrant Certificates shall be signed by any one of the directors and officers of the Corporation and may, but need not be, under seal of the Corporation or a reproduction thereof. The signatures of any such director or officer may be mechanically reproduced in facsimile and Warrant Certificates bearing such facsimile signatures shall be binding upon the Corporation as if they had been manually signed by such director or officer. Notwithstanding that any person whose manual or facsimile signature appears on any Warrant Certificate as a director or an officer may no longer hold office at the date of such Warrant Certificate or at the date of certification or delivery thereof, any Warrant Certificate signed as aforesaid shall, subject to Section 2.7, be valid and binding upon the Corporation and the holder thereof shall be entitled to the benefits of this Indenture.

2.7

Certification by the Warrant Agent

     
2.7.1

No Warrant Certificate shall be issued or, if issued, shall be valid for any purpose or entitle the holder to the benefit hereof until it has been certified by manual signature by or on behalf of the Warrant Agent by its authorized signing officers substantially in the form of the Warrant Certificate, and such certification by the Warrant Agent upon any Warrant Certificate shall be conclusive evidence as against the Corporation that the Warrant Certificate so certified has been duly issued hereunder and that the holder is entitled to the benefits hereof.

     
2.7.2

No Uncertificated Warrant shall be issued or, if issued, shall be valid for any purpose or entitle the holder to the benefit hereof until it has been certified by the Warrant Agent, once its Internal Procedures have been completed (whether upon original issuance, exchange, registration of transfer, partial payment, or otherwise) and the Corporation shall, and hereby acknowledges that it shall, thereupon be deemed to have duly and validly issued such Uncertificated Warrants under this Indenture. Such certification shall be conclusive evidence that such Uncertificated Warrant has been duly issued hereunder and that the holder or holders are entitled to the benefits of this Indenture. The register shall be final and conclusive evidence as to all matters relating to Uncertificated Warrants with respect to which this Indenture requires the Warrant Agent to maintain records or accounts. In case of differences between the register at any time and any other time, the register at the later time shall be controlling, absent manifest error, and such Uncertificated Warrants are binding on the Corporation.

     
2.7.3

The certification of the Warrant Agent on Warrant Certificates and/or Uncertificated Warrants issued hereunder shall not be construed as a representation or warranty by the Warrant Agent as to the validity of this Indenture or the Warrant Certificates (except the due certification thereof) or as to the performance by the Corporation of its obligations under this Indenture, and the Warrant Agent shall in no respect be liable or answerable for the use made of the Warrant Certificates or any of them or of the consideration therefor except as otherwise specified herein.



- 13 -

2.8

Issue in Substitution for Warrant Certificates Lost, etc.

     
2.8.1

If any Warrant Certificate becomes mutilated or is lost, destroyed or stolen, the Corporation, subject to applicable law, shall issue and thereupon the Warrant Agent shall certify and deliver, a new Warrant Certificate of like tenor as the one mutilated, lost, destroyed or stolen in exchange for and in place of and upon cancellation of such mutilated Warrant Certificate, or in lieu of and in substitution for such lost, destroyed or stolen Warrant Certificate, and the substituted Warrant Certificate shall be in a form approved by the Warrant Agent and the Warrants evidenced thereby shall be entitled to the benefits hereof and shall rank equally in accordance with its terms with all other Warrants issued or to be issued hereunder.

     
2.8.2

The applicant for the issue of a new Warrant Certificate pursuant to this Section 2.8 shall bear the cost of the issue thereof and in case of loss, destruction or theft shall, as a condition precedent to the issuance thereof, furnish to the Corporation and to the Warrant Agent such evidence of ownership and of the loss, destruction or theft of the Warrant Certificate so lost, destroyed or stolen as shall be satisfactory to the Corporation and to the Warrant Agent, in their sole discretion, and such applicant may also be required to furnish an indemnity and surety bond in amount and form satisfactory to the Corporation and the Warrant Agent, in their sole discretion, and shall pay the reasonable charges of the Corporation and the Warrant Agent in connection therewith.

     
2.8.3

Warrant Certificates may be replaced only at the Warrant Agency or at any other place that is designated by the Corporation with the approval of the Warrant Agent.

     
2.9

Exchange of Warrant Certificates

     
2.9.1

Any one or more Warrant Certificates representing any number of Warrants may, upon compliance with the reasonable requirements of the Warrant Agent (including compliance with applicable securities legislation), be exchanged for one or more other Warrant Certificates representing the same aggregate number of Warrants as represented by the Warrant Certificate or Warrant Certificates so exchanged.

     
2.9.2

Warrant Certificates may be exchanged only at the Warrant Agency or at any other place that is designated by the Corporation with the approval of the Warrant Agent. Any Warrant Certificate tendered for exchange shall be cancelled and surrendered by the Warrant Agency to the Warrant Agent.



- 14 -

2.10

Transfer and Ownership of Warrants

     
2.10.1

Subject to Section 2.14, the Warrants may only be transferred on the register kept by the Warrant Agent at the Warrant Agency by the holder or its legal representatives or its attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent upon surrendering to the Warrant Agent at the Warrant Agency the Warrant Certificates representing the Warrants to be transferred and upon compliance with: (i) the conditions herein; (ii) such reasonable requirements as the Warrant Agent may prescribe; and (iii) all applicable securities legislation and requirements of regulatory authorities; and such transfer shall be duly noted in such register by the Warrant Agent. Upon compliance with such requirements, the Warrant Agent shall issue to the transferee a Warrant Certificate representing the Warrants transferred.

     
2.10.2

Subject to the provisions of this Indenture and applicable law, the Warrantholder shall be entitled to the rights and privileges attaching to the Warrants and the issue of Common Shares by the Corporation upon the exercise of Warrants in accordance with the terms and conditions herein contained shall discharge all responsibilities of the Corporation and the Warrant Agent with respect to such Warrants and neither the Corporation nor the Warrant Agent shall be bound to inquire into the title of any such holder.

     
2.10.3

A Warrant shall be transferable by surrender of the Warrant Certificate relating thereto, accompanied by proper instruments of transfer in suitable form satisfactory to the Warrant Agent for transfer by delivery with the same effect as in the case of a negotiable instrument executed by the Warrantholder or his executors, administrators or other legal representatives or his or their attorney duly appointed by an instrument in form and execution satisfactory to the Warrant Agent; provided that no transfer of any Warrant will be valid unless duly entered on the transfer register referred to in subsection 2.10.1.

     
2.10.4

A transferee of any Warrant will, after surrender to the Warrant Agent of the Warrant Certificate evidencing such Warrant as required by subsection 2.10.3 and upon compliance with all other conditions in respect thereof required by this Indenture or by law, be entitled to be entered on the transfer register and on the Warrant register as the owner of such Warrant, and the Warrant Agent shall issue to the transferee a Warrant Certificate evidencing the Warrants transferred.

     
2.10.5

The Warrant Agent was informed by the Corporation that the Warrants and the Common Shares issuable upon exercise thereof have not been registered under the U.S. Securities Act, or the securities laws of any state of the United States, and may not be offered, sold or transferred in the United States, or to or for the account or benefit of, a U.S. Person, unless the Warrants and the Common Shares issuable upon exercise thereof have been registered under the U.S. Securities Act and the securities laws of all applicable states of the United States or an exemption from registration under the U.S. Securities Act and applicable state securities law is available and the holder of the Warrant has presented to the Corporation evidence of the availability of the exemption satisfactory to the Corporation.



- 15 -

  2.10.6

The Warrant Agent shall retain until the sixth anniversary of the termination of this Indenture all instruments of transfer of Warrants which are lodged for registration, including the details shown thereon of the persons by or through whom they were lodged, all cancelled Warrants and all other related documents.

     
  2.10.7

Notwithstanding any provision to the contrary contained in this Indenture, the Corporation is entitled to require, add or adopt certain conditions precedent to the transfer of Warrants to ensure compliance with all applicable securities legislation and requirements of regulatory authorities, and may direct the Warrant Agent to refuse to recognize any transfer, or enter the name of any transferee, of a Warrant on the transfer register if such transfer would constitute a violation of any applicable securities legislation or requirements of regulatory authorities or require the Corporation to qualify the Common Shares for distribution in any jurisdiction.

     
  2.10.8

To the extent not inconsistent with the terms of this Indenture, the provisions of the Securities Transfer Act in respect of the transfer of securities, as amended from time to time, shall apply mutatis mutandis to the transfer of Warrants.

     
  2.10.9

Warrants bearing the legend set forth in Section 2.16.2 may not be transferred except pursuant to registration or compliance with exemptions therefrom under the U.S. Securities Act and all applicable state securities laws, and the Warrant Agent agrees not to register any transfer of the Warrants so legended unless, in addition to the other requirements set forth herein, the Warrantholder has executed and delivered to the Warrant Agent a declaration in the form attached as Schedule “B” hereto (or as the Corporation may otherwise prescribe) to the effect that the transfer is being made pursuant to Rule 904 of Regulation S under the U.S. Securities Act, and in such case the Warrant Certificate issued to the transferee shall not include the legend set forth in Section 2.16.


2.11

Charges for Exchange or Transfer

The transfer or the exchange of any Warrant Certificate or the issue of a new Warrant Certificate pursuant hereto shall be subject to the payment of a reasonable fee levied by the Warrant Agent in addition to the reimbursement of the Warrant Agent or the Corporation for any and all transfer, stamp or similar taxes or other governmental charges required to be paid, and such payment shall be made by the holder requesting a transfer or exchange as a condition precedent to such transfer or exchange.


- 16 -

2.12

Cancellation of Surrendered Warrants

All Warrant Certificates surrendered pursuant to Sections 2.8, 2.9, 2.10, 3.1, 3.3, 3.4 or 5.1 shall be returned to the Warrant Agent for cancellation and, after the expiry of any period of retention prescribed by law, destroyed by the Warrant Agent.

2.13

Registration of Warrants

The Corporation hereby appoints the Warrant Agent as registrar and transfer agent of the Warrants. The Warrant Agent shall, at all times while any Warrants are outstanding, keep at the Warrant Agency: (i) a register of Warrantholders in which shall be entered in alphabetical order the names and addresses of the holders of Warrants and particulars of the Warrants held by them, and (ii) a register of transfers in which all transfers of Warrants and the date and other particulars of each transfer shall be entered. Branch registers shall also be kept at such other place or places, if any, as the Corporation, with the approval of the Warrant Agent, may designate. Such registers will at all reasonable times be open for inspection by the Corporation and/or any Warrantholder. The Warrant Agent will from time to time when requested in writing to do so by the Corporation or any Warrantholder, upon payment of the Warrant Agent’s reasonable charges, furnish a list of the names and addresses of Warrantholders showing the number of Warrants held by each such Warrantholder.

2.14

CDS and Depository

     
2.14.1

The Corporation may elect to issue all or a portion of the Warrants in “ book entry form ”, such Warrants to be represented by a registered permanent Global Certificate. The Global Certificate shall be held by, or on behalf of, the Depository as custodian of the CDS Participants and shall be registered in the name of “CDS & CO.” or such other name as the Depository may use from time to time as its nominee for the purposes of the Book Based System. For the avoidance of doubt, any Warrants sold in the United States must be in the form of a definitive Certificate and will not be included in the Global Certificate unless ownership is transferred or exchanged to a holder that is outside of the United States.

     
2.14.2

Any Global Certificate shall bear a legend in substantially the following form, subject to modification as required by the Depository:

     

“UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF CDS CLEARING AND DEPOSITORY SERVICES INC. (“CDS”) TO STEM CELL THERAPEUTICS CORP. (THE “ ISSUER ”) OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IN RESPECT THEREOF IS REGISTERED IN THE NAME OF CDS & CO., OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF CDS (AND ANY PAYMENT IS MADE TO CDS & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF CDS), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED HOLDER HEREOF, CDS & CO., HAS A PROPERTY INTEREST IN THE SECURITIES REPRESENTED BY THIS CERTIFICATE HEREIN AND IT IS A VIOLATION OF ITS RIGHTS FOR ANOTHER PERSON TO HOLD, TRANSFER OR DEAL WITH THIS CERTIFICATE.”



- 17 -

  2.14.3

Subject to Section 2.10, transfers and registrations to ownership in Warrants represented by the Global Certificate will only be made to another nominee of the Depository, and neither the Corporation nor the Warrant Agent shall be under any obligation to deliver to participants of the Depository, nor shall such participants have any right to require the delivery of a Warrant Certificate.

       
  2.14.4

Subject to Sections 2.9 and 2.10, in the event of a transfer or exchange of ownership, in compliance with applicable laws, of any Warrants, that are represented by a definitive Warrant Certificate, the definitive Warrant Certificate may be surrendered at the Depository for cancellation by the Warrant Agent and the registration of new beneficial interest in such Warrants may be represented by the Global Certificate, which shall be increased by the number of Warrants represented by the Warrant Certificate so surrendered.

       
  2.14.5

Unless the Book Based System is terminated or unless required to do so by applicable law, or unless otherwise requested and agreed to by the Corporation, owners of the beneficial interests in the Warrants represented by the Global Certificate, shall not receive Warrants registered in their names, shall not receive or Warrant Certificates in definitive form and shall not be considered registered owners or registered holders thereof under this Indenture or any supplemental agreement except in circumstances where CDS resigns or is removed from its responsibility and the Warrant Agent is unable or does not wish to locate a qualified successor. Beneficial interests in the Global Certificate will be represented only through the Book Based System. The Corporation and the Warrant Agent shall not have any responsibility or liability for any aspects of the records relating to or payments made by CDS, or its nominee, on account of the beneficial interests in the Warrants. Nothing herein shall prevent the Beneficial Owners from voting such Warrants.

       
  2.14.6

Notwithstanding anything herein to the contrary, neither the Corporation nor the Warrant Agent nor any agent thereof shall have any responsibility or liability for:

       
  (a)

the electronic records maintained by the Depository relating to any ownership interests or any other interests in the Warrants or the depository system maintained by the Depository, or payments made on account of any ownership interest or any other interest of any person in any Warrant represented by an electronic position in the Book Based System (other than the Depository or its nominee);



- 18 -

  (b)

maintaining, supervising or reviewing any records of the Depository or any Book Entry Only Participant relating to any such interest; or

       
  (c)

any advice or representation made or given by the Depository or those contained herein that relate to the rules and regulations of the Depository or any action to be taken by the Depository on its own direction or at the direction of any Book Entry Only Participant.

       
  2.14.7

All references herein to actions by, notices given or payments made to Warrantholders shall, where Warrants are held through CDS, refer to actions taken by, or notices given or payments made to, CDS upon instruction from the CDS Participants in accordance with its rules and procedures. For the purposes of any provision hereof requiring or permitting actions with the consent of or at the direction of Warrantholders evidencing a specified percentage of the aggregate Warrants outstanding, such direction or consent may be given by holders of Warrants acting through CDS and the CDS Participants owning Warrants evidencing the requisite percentage of the Warrants. The rights of a Warrantholder whose Warrants are held through CDS shall be exercised only through CDS and the CDS Participants and shall be limited to those established by law and agreements between such holders and CDS and the CDS Participants upon instructions from the CDS Participants. Each of the Warrant Agent and the Corporation may deal with CDS for all purposes (including the making of payments) as the authorized representative of the respective Warrantholder and such dealing with CDS shall constitute satisfaction or performance, as applicable, of their respective obligations hereunder.

       
  2.14.8

For so long as Warrants are held through CDS, if any notice or other communication is required to be given to Warrantholders, the Warrant Agent and or the Corporation will give such notices and communications to CDS.

       
  2.14.9

If CDS resigns or is removed from its responsibility as depository and the Warrant Agent is unable or does not wish to locate a qualified successor, CDS shall surrender the Global Certificate to the Warrant Agent with instructions for registration of Warrants in the name and in the amount specified by CDS and the Corporation shall issue, and the Warrant Agent shall certify and deliver, the aggregate number of Warrants then outstanding in the form of definitive Warrant Certificates representing such Warrants.


2.15

NCI Letter of Instruction

Notwithstanding anything to the contrary set out in this Indenture, all physical Warrant Certificates issued to CDS may be surrendered to the Warrant Agent for an electronic position on the register of Warrantholders to be maintained by the Warrant Agent in accordance with this Indenture. All Warrants maintained in such electronic position will entitle the registered holders thereof to the same benefits as those registered holders who hold Warrants in physical certificated form and this Indenture and the provisions contained herein will apply, mutatis mutandis , to such Warrants held in such electronic position. It is understood and agreed by the parties that, unless the Warrant Agent is otherwise in a position to perform electronic exercises, in every instance where Warrants held in an electronic position through CDS are to be exercised in whole or in part, it shall be sufficient for the Warrant Agent to exercise such Warrants upon receiving either the attached exercise form executed by CDS or a NCI Letter of Instruction in a form agreed upon by the Warrant Agent and CDS, or such other form that they may be agreed to by the Warrant Agent and CDS from time to time.


- 19 -

2.16

Legends

       
2.16.1

The Warrant Agent acknowledges and understands that the Warrants issued hereunder and the Common Shares issuable upon exercise of a Warrant have been issued in Canada pursuant to applicable exemptions from securities laws. The Warrant Agent further understands and acknowledges that, if applicable, upon the original issuance thereof, and until such time as the same is no longer required under applicable requirements of Canadian securities laws, certificates representing the Warrants issued hereunder and all certificates issued in exchange therefor or in substitution thereof, shall be overprinted with the following legend:

       

“UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE APRIL 14, 2013.”

       

“WITHOUT PRIOR WRITTEN APPROVAL OF TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF TSX VENTURE EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL APRIL 14, 2013.”

       
2.16.2

The Warrant Agent acknowledges and understands that the Warrants issued hereunder and the Common Shares issuable upon exercise of a Warrant have not been and will not be registered under the U.S. Securities Act or any applicable U.S. state securities laws. The Warrant Agent further understands and acknowledges that upon the original issuance thereof, and until such time as the same is no longer required under applicable requirements of the U.S. Securities Act or applicable U.S. state securities laws, certificates representing the Warrants issued hereunder originally issued to a U.S. Purchaser, and all certificates issued in exchange therefor or in substitution thereof, shall be overprinted with the following legend:



- 20 -

THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ 1933 ACT ”), OR UNDER ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF STEM CELL THERAPEUTICS CORP. (THE “ CORPORATION ”) THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT AND IN COMPLIANCE WITH LOCAL LAW, (C) WITHIN THE UNITED STATES IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT PROVIDED BY RULE 144 OR RULE 144A THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS, OR (D) PURSUANT TO ANOTHER EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT AND, IN EACH CASE, IN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AFTER, IN THE CASE OF TRANSFERS PURSUANT TO CLAUSES (C) OR (D) THE SELLER FURNISHES TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING, OR OTHER SUCH EVIDENCE, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE CORPORATION TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE GOOD DELIVERY IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. PROVIDED THAT THE CORPORATION IS A “FOREIGN ISSUER” WITHIN THE MEANING OF REGULATION S AT THE TIME OF SALE, A NEW CERTIFICATE BEARING NO LEGEND DELIVERY OF WHICH WILL CONSTITUTE “GOOD DELIVERY” MAY BE OBTAINED FROM COMPUTERSHARE TRUST COMPANY OF CANADA, AS REGISTRAR AND TRANSFER AGENT, UPON DELIVERY OF THIS CERTIFICATE AND A DULY EXECUTED DECLARATION, IN A FORM REASONABLY SATISFACTORY TO THE CORPORATION, TO THE EFFECT THAT SUCH SALE IS BEING MADE IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT OR IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE 1933 ACT OR ANY APPLICABLE STATE SECURITIES LAWS.

provided , that if the Warrants are being sold in compliance with the requirements of Rule 904 of Regulation S and in compliance with local laws and regulations, and provided further that the Corporation is a “foreign issuer” within the meaning of Regulation S at the time of sale, any such legend may be removed by providing a declaration to the Warrant Agent to the effect set forth in Schedule “B” hereto (or as the Corporation may reasonably prescribe from time to time); and


- 21 -

provided , further that, if a holder resells any Warrants under subsection (C) or (D) above, the legend may be removed by delivery to Warrant Agent of an opinion of counsel, of recognized standing in form and substance reasonably satisfactory to the Corporation, that such legend is no longer required under applicable requirements of the 1933 Act and applicable state securities laws, or such other evidence as the Corporation or Warrant Agent may reasonably request.

  2.16.3

The Warrant Certificates, and all certificates issued in exchange therefore or in substitution thereof, shall bear, in addition to the legends above, the following legend:

     
 

THESE WARRANTS AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”) OR UNDER ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY NOT BE EXERCISED IN THE UNITED STATES OR BY OR ON BEHALF OF A PERSON IN THE UNITED STATES OR A U.S. PERSON UNLESS AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND ALL APPLICABLE STATE SECURITIES LAWS IS AVAILABLE. THE TERMS “UNITED STATES” AND “U.S. PERSON ARE AS DEFINED IN REGULATION S UNDER THE 1933 ACT.

ARTICLE 3 - EXERCISE OF WARRANTS

3.1

Method of Exercise of Warrants

     
3.1.1

The holder of any Warrant may exercise the right conferred on such holder to acquire Common Shares by surrendering, after the Issue Date and prior to the Expiry Time, to the Warrant Agency, (i) the Warrant Certificate representing such Warrant, with a duly completed and executed Warrant Exercise Form, (ii) together with a certified cheque, money order or bank draft, in lawful money of Canada payable to or to the order of the Corporation at par in the city where the Warrant Agency is located in an amount equal to the Exercise Price multiplied by the number of Common Shares subscribed for. In accordance with Section 2.14, if Warrants are exercised through CDS, the payment of such exercise will be done electronically by CDS to the Warrant Agent. The Warrant Agent will, within five (5) days, send such payment to the Corporation.

     

A Warrant Certificate with the duly completed and executed Warrant Exercise Form referred to in this subsection 3.1.1 shall be deemed to be surrendered only upon personal delivery thereof or, if sent by mail or other means of transmission, upon actual receipt thereof at, in each case, the Warrant Agency, provided that such Warrant Certificate is accompanied by the requisite certified cheque, bank draft or money order in the amount of the aggregate Exercise Price for the Warrants represented thereby that are being exercised.



- 22 -

  3.1.2

Any Warrant Exercise Form referred to in subsection 3.1.1 shall be signed by the Warrantholder and shall specify:

       
  (a)

the number of Common Shares which the holder wishes to acquire (being not more than those which the holder is entitled to acquire pursuant to the Warrant Certificate(s) surrendered);

       
  (b)

the person or persons in whose name or names such Common Shares are to be issued;

       
  (c)

the address or addresses of such person or persons;

       
  (d)

if an individual, the social insurance number of such person or persons; and

       
  (e)

the number of Common Shares to be issued to each such person if more than one is so specified.

       

If any of the Common Shares subscribed for are to be issued and registered in the name or names of a person or persons other than the Warrantholder, the Warrantholder shall pay to the Corporation or the Warrant Agency on behalf of the Corporation, all applicable transfer or similar taxes and the Corporation shall not be required to issue or deliver certificates evidencing Common Shares unless or until such Warrantholder shall have paid to the Corporation, or the Warrant Agency on behalf of the Corporation, the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid or that no tax is due.

       
  3.1.3

In connection with the exchange of Warrant Certificates and exercise of Warrants and compliance with such other terms and conditions hereof as may be required, the Corporation has appointed the principal offices of the Warrant Agent in Toronto as the Warrant Agency at which Warrant Certificates may be surrendered for exchange, transfer or repurchase or at which Warrants may be exercised and the Warrant Agent has accepted such appointment. The Corporation may from time to time designate alternate or additional places as a Warrant Agency upon notice to and consent of the Warrant Agent of any change of any Warrant Agency. The Corporation shall give notice to Warrantholders of any change of a Warrant Agency.

       
  3.1.4

Subject to and upon compliance with the terms of Article 3, a beneficial holder of Uncertificated Warrants evidenced by a security entitlement in respect of Warrants in the Book Based System may exercise the right of purchase by causing a Book Entry Only Participant to deliver to the Depository on behalf of the entitlement holder, notice of the owner’s intention to exercise the Warrants in a manner acceptable to the Depository. Forthwith upon receipt by the Depository of such notice, as well as payment for the Exercise Price, the Depository shall deliver to the Warrant Agent an NCI Letter of Instruction confirming its intention to exercise Warrants in a manner acceptable to the Warrant Agent, including by electronic means through the Book Based System.



- 23 -

  3.1.5

Payment representing the aggregate Exercise Price must be provided to the appropriate office of the Book Entry Only Participant in a manner acceptable to it. A notice in form acceptable to the Book Entry Only Participant and payment from such beneficial holder should be provided to the Book Entry Only Participant sufficiently in advance so as to permit the Book Entry Only Participant to deliver notice and payment to the Depository and for the Depository in turn to deliver notice and payment to the Warrant Agent prior to the Expiry Time. The Depository will initiate the exercise by way of the NCI Letter of Instruction and will forward the aggregate Exercise Price electronically to the Warrant Agent and the Warrant Agent will execute the exercise by issuing to the Depository through the Book Based System the Common Shares to which the exercising Warrantholder is entitled pursuant to the exercise. Any expense associated with the exercise process will be for the account of the entitlement holder exercising the Warrants and/or the Book Entry Only Participant exercising the Warrants on its behalf.

     
  3.1.6

By causing a Book Entry Only Participant to deliver notice to the Depository, a Warrantholder shall be deemed to have irrevocably surrendered his or her Warrants so exercised and appointed such Book Entry Only Participant to act as his or her exclusive settlement agent with respect to the exercise and the receipt of Common Shares in connection with the obligations arising from such exercise.

     
  3.1.7

Any notice which the Depository determines to be incomplete, not in proper form, or not duly executed shall for all purposes be void and of no effect and the exercise to which it relates shall be considered for all purposes not to have been exercised thereby. A failure by a Book Entry Only Participant to exercise or to give effect to the settlement thereof in accordance with the Warrant holder’s instructions will not give rise to any obligations or liability on the part of the Corporation or Warrant Agent to the Book Entry Only Participant or the Warrantholder.

     
  3.1.8

Any exercise form or other Letter of Instruction referred to in Article 3 shall be signed by the registered Warrantholder, or its executors or administrators or other legal representatives or an attorney of the registered Warrantholder, duly appointed by an instrument in writing satisfactory to the Warrant Agent but such exercise form need not be executed by the Depository.

     
  3.1.9

Any exercise referred to in Section 3.1 shall require that the entire Exercise Price for Common Shares subscribed must be paid at the time of subscription and such Exercise Price and original exercise form or other Letter of Instruction executed by the registered Warrantholder or the Depository must be received by the Warrant Agent prior to the Warrant Expiry Time.



- 24 -

  3.1.10

A beneficial owner of Warrants issued in non-certificated form who desires to exercise his or her Warrants must do so by causing a CDS participant to deliver to the Depository on behalf of the entitlement holder, notice of the owner’s intention to exercise Warrants in a manner acceptable to the Depository. Forthwith upon receipt by the Depository of such notice, as well as payment for the Exercise Price, the Depository shall deliver to the Warrant Agent confirmation of its intention to exercise Warrants in a manner acceptable to the Warrant Agent, including by electronic means through the book based registration system. An electronic exercise of the Warrants initiated by the CDS participant through the book based registration system shall constitute a representation to both the Company and the Warrant Agent that the beneficial owner at the time of exercise of such Warrants (i) is not in the United States; (ii) is not a U.S. Person and is not exercising such Warrants on behalf of a U.S. Person or a Person in the United States; and (iii) did not execute or deliver the notice of the owner’s intention to exercise such Warrants in the United States. If the Participant is not able to make or deliver the foregoing representation by initiating the electronic exercise of the Warrants, then such Warrants shall be removed from the book based registration system and an individually registered Warrant Certificate shall be issued to such beneficial owner or CDS participant and the exercise procedures set forth in Section 3.1 shall be followed. Any expense associated with the preparation and delivery of Warrant Certificates and/or Warrant subscription forms will be for the account of the beneficial owner exercising such Warrants.

     
  3.1.11

It is understood and agreed by the parties hereto that, unless the Warrant Agent is otherwise in a position to perform electronic conversions, in every instance where Warrants held in an electronic position through the Depository are to be converted, in whole or in part, such Warrants being converted shalt not be certificated, and it shall be sufficient for the Warrant Agent to convert such Warrants upon receiving either the attached exercise form executed by the Depository or an NCI Letter of Instruction in a form agreed upon by the Warrant Agent and the Depository, or such other form that they may require from time to time along with a certified cheque, bank draft or money order in lawful money of Canada payable to or to the order of the Company at par in Toronto, Ontario in an amount equal to the Exercise Price multiplied by the number of Shares being purchased.


3.2

Effect of Exercise of Warrants

     
3.2.1

Upon the exercise of Warrants pursuant to Section 3.1 and subject to Section 3.3, the Common Shares to be issued pursuant to the Warrants exercised shall be deemed to have been issued and the person or persons to whom such Common Shares are to be issued and registered shall be deemed to have become the holder or holders of record of such Common Shares on the Exercise Date unless the transfer registers of the Corporation shall be closed on such date, in which case the Common Shares subscribed for shall be deemed to have been issued and such person or persons deemed to have become the holder or holders of record of such Common Shares, on the date on which such transfer registers are reopened. It is hereby understood that in order for persons to whom Common Shares are issued to become holders of Common Shares on record on the Exercise Date, beneficial holders must commence the exercise process sufficiently in advance so that the Warrant Agent is in receipt of all items of exercise at least one (1) Business Day prior to such Exercise Date.



- 25 -

3.2.2

Within five (5) Business Days after the Exercise Date with respect to a Warrant, the Corporation shall (i) cause to be mailed to the person or persons in whose name or names such Warrant is registered or, (ii) if so specified in writing by the holder, cause to be delivered to such person or persons at the Warrant Agency where the Warrant Certificate was surrendered, a certificate or certificates for the appropriate number of Common Shares subscribed for or any other appropriate evidence of the issuance of Common Shares to such person or persons in respect of Common Shares issued under the Book Based System.

     
3.3

Partial Exercise of Warrants; Fractions

     
3.3.1

The holder of any Warrants may exercise his right to acquire a number of Common Shares less than the aggregate number which the holder is entitled to acquire pursuant to the surrendered Warrant Certificate(s). In the event of any exercise of a number of Warrants less than the number which the holder is entitled to exercise, the holder of the Warrants upon such exercise shall, in addition, be entitled to receive, without charge therefor, a new Warrant Certificate(s) in respect of the balance of the Warrants represented by the surrendered Warrant Certificate(s) and which were not then exercised.

     
3.3.2

Notwithstanding anything herein contained, including any adjustment provided for in Article 4, neither the Corporation nor the Warrant Agent shall be required, upon the exercise of any Warrants, to issue fractions of Common Shares or to distribute certificates which evidence fractional Common Shares. Any fractional entitlements will be rounded down to the nearest whole number.

     
3.4

Expiration of Warrants

Immediately after the Expiry Time, all rights under any Warrant in respect of which the right of acquisition provided for herein shall not have been exercised shall cease and terminate and each Warrant shall be void and of no further force or effect except to the extent that the Warrantholder has not received in full all monies to which it is entitled pursuant to Article 4 or Article 5 or has not received certificates representing the Common Shares issued upon exercise of Warrants held by it, in which instances the Warrantholders’ rights hereunder shall continue until it has received that to which it is entitled hereunder.


- 26 -

3.5

Accounting and Recording

     
3.5.1

The Warrant Agent shall promptly account to the Corporation with respect to Warrants exercised and forward to the Corporation (or into an account or accounts of the Corporation with the bank or trust Corporation designated by the Corporation for that purpose), all monies received by the Warrant Agent on the subscription for Common Shares through the exercise of Warrants. All such monies and any securities or other instruments, from time to time received by the Warrant Agent shall be received in trust for, and shall be segregated and kept apart by the Warrant Agent, the Warrantholders and the Corporation as their interests may appear.

     
3.5.2

The Warrant Agent shall record the particulars of Warrants exercised, which particulars shall include the names and addresses of the persons who become holders of Common Shares on exercise and the Exercise Date, in respect thereof. The Warrant Agent shall provide such particulars in writing to the Corporation within five Business Days of any request by the Corporation therefor.

     
3.6

Securities Restrictions

Notwithstanding anything herein contained, Common Shares will only be issued pursuant to any Warrant in compliance with the securities laws of any applicable jurisdiction. The certificates representing the Common Shares issued will bear such legend as may, in the opinion of Counsel to the Corporation be necessary in order to avoid a violation of any securities laws of any province or territory in Canada or of the United States or any state thereof and to comply with the requirements of any stock exchange or over the counter market on which the Common Shares are listed or quoted, as the case may be. Certificates representing Common Shares issued upon the exercise of Warrants may bear the legend set forth in Section 2.16.2. If, at any time, in the opinion of Counsel to the Corporation, such legends are no longer necessary in order to avoid a violation of any such laws, or the holder of any such legended certificate, at the holder’s expense, provides the Corporation with evidence satisfactory in form and substance to the Corporation (which may include an opinion of counsel satisfactory to the Corporation) to the effect that such holder is entitled to sell or otherwise transfer such Common Shares in a transaction in which such legends are not required, such legended certificate may thereafter be surrendered to the Warrant Agent in exchange for a certificate which does not bear such legend.

3.7

Prohibition on Exercise in the United States or by U.S. Persons; Exception

       
3.7.1

Warrants may not be exercised in the United States or by or on behalf of a U.S. Person unless an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available and such exercise is made in accordance with subsection 3.7.2;



- 27 -

  3.7.2

Any holder that seeks to exercise a Warrant shall provide to the Corporation and the Warrant Agent, and the Corporation and the Warrant Agent shall be entitled to act and rely on any one of the following:

       
  (a)

a written certification that such holder (i) at the time of exercise of the Warrant is not in the United States; (ii) is not a U.S. Person and is not exercising the Warrant for the account or benefit of a U.S. Person; (iii) was not offered to exercise the Warrant and did not execute or deliver the exercise form for the Warrant in the United States; (iv) did not acquire the Warrant while it was in the United States or acting for the account or benefit of a U.S. Person and (v) has in all other respects complied with Regulation S; or

       
  (b)

a written certification that such holder (i) originally purchased the Warrant on its own behalf or on behalf of a beneficial purchaser (a “ Beneficial Purchaser ”) directly from the Corporation pursuant to the Corporation’s offering of Units or Preferred Units at a time when the holder was and any Beneficial Purchaser was (A) an Accredited Investor and (B) in the United States or a U.S. Person, or was offered Units or Preferred Units in the United States; (ii) is exercising the Warrant solely for its own account or for the account of the Beneficial Purchaser, if any, and not on behalf of any other person, and (iii) is, and the Beneficial Purchaser, if any, is, an Accredited Investor on the date of exercise of the Warrant; or

       
  (c)

a written opinion of counsel of recognized standing in form and substance satisfactory to the Corporation to the effect that an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available for the issuance of the Common Shares upon exercise of the Warrants.

       
  3.7.3

No certificates representing Common Shares will be registered or delivered to an address in the United States unless the holder of Warrants complies with the requirements set forth in subsection 3.7.2(b) or 3.7.2(c), and, in the case of subsection 3.7.2(c), the Corporation has confirmed in writing to the Warrant Agent that the written opinion of counsel is satisfactory to the Corporation; and

       
  3.7.4

Certificates representing Common Shares issued upon exercise of the Warrants pursuant to subsection 3.7.2(b) or 3.7.2(c) above shall be “restricted securities” within the meaning of Rule 144(a)(3) under the U.S. Securities Act, may not be offered, sold, pledged or otherwise transferred except pursuant to an exemption or exclusion from the registration requirements of the U.S. Securities Act and applicable state securities laws and shall bear a legend to that effect as designated in Section 2.16.



- 28 -

ARTICLE 4 - ADJUSTMENT OF NUMBER OF COMMON SHARES
AND EXERCISE PRICE

4.1

Adjustment of Number of Common Shares and Exercise Price

The acquisition rights as they relate to Common Shares, in effect at any date attaching to the Warrants, and the Exercise Price in respect thereof, shall be subject to adjustment from time to time as follows:

  4.1.1

If and whenever at any time during the Adjustment Period, the Corporation shall: (i) subdivide, redivide or change its outstanding Common Shares into a greater number of shares; (ii) reduce, combine or consolidate its outstanding Common Shares into a smaller number of shares; or (iii) issue Common Shares or securities exchangeable for or convertible into Common Shares to the holders of all or substantially all of the outstanding Common Shares by way of a stock dividend (other than the issue of Common Shares to such holders as a Dividend Paid in the Ordinary Course); the Exercise Price in effect on the effective date of such subdivision, redivision, change, reduction, combination, consolidation or on the record date of such stock dividend, as the case may be, shall in the case of the events referred to in (i) or (iii) above be decreased in proportion to the number of outstanding Common Shares resulting from such subdivision, redivision or stock dividend, or shall, in the case of the events referred to in (ii) above, be increased in proportion to the number of outstanding Common Shares resulting from such reduction, combination or consolidation. Such adjustment shall be made successively whenever any event referred to in this subsection 4.1.1 shall occur. Upon any adjustment of the Exercise Price pursuant to subsection 4.1.1, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;



- 29 -

  4.1.2

If and whenever at any time during the Adjustment Period, the Corporation shall fix a record date for the issuance of rights, options or warrants to all or substantially all the holders of its outstanding Common Shares entitling them, for a period expiring not more than forty-five (45) days after such record date, to subscribe for or purchase Common Shares (or securities convertible or exchangeable into Common Shares) at a price per share (or having a conversion or exchange price per share) less than ninety-five percent (95%) of the Current Market Price on such record date, the Exercise Price shall be adjusted immediately after such record date so that it shall equal the amount determined by multiplying the Exercise Price in effect on such record date by a fraction, of which the numerator shall be the total number of Common Shares outstanding on such record date plus a number of Common Shares equal to the number arrived at by dividing the aggregate price of the total number of additional Common Shares offered for subscription or purchase (or the aggregate conversion or exchange price of the convertible or exchangeable securities so offered) by such Current Market Price, and of which the denominator shall be the total number of Common Shares outstanding on such record date plus the total number of additional Common Shares offered for subscription or purchase or into which the convertible or exchangeable securities so offered are convertible or exchangeable; any Common Shares owned by or held for the account of the Corporation or any Subsidiary shall be deemed not to be outstanding for the purpose of any such computation; such adjustment shall be made successively whenever such a record date is fixed; to the extent that any such rights or warrants are not exercised prior to the expiration thereof the Exercise Price shall be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or to the Exercise Price which would then be in effect based upon the number of Common Shares (or securities convertible or exchangeable into Common Shares) actually issued upon the exercise of such rights or warrants, as the case may be. Upon any adjustment of the Exercise Price pursuant to this subsection 4.1.2, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;

     
  4.1.3

If and whenever at any time during the Adjustment Period the Corporation shall fix a record date for the payment, issue or distribution to all or substantially all the holders of its outstanding Common Shares of (i) shares of any class, whether of the Corporation or any other corporation (other than Common Shares and other than shares distributed to holders of Common Shares pursuant to their exercise of options to receive dividends in the form of such shares in lieu of Dividends Paid in the Ordinary Course on the Common Shares), (ii) rights, options or warrants to subscribe for or purchase Common Shares (or other securities convertible into or exchangeable for Common Shares) for a period expiring not more than forty-five (45) days after such record date at a price per share (or having a conversion or exercise price per share) not less than ninety-five percent (95%) of the Current Market Price on such record date), (iii) evidences of its indebtedness or (iv) any property or other assets (excluding Dividends Paid in the Ordinary Course) then, in each such case, the Exercise Price shall be adjusted immediately after such record date so that it shall equal the price determined by multiplying the Exercise Price in effect on such record date by a fraction, of which the numerator shall be the total number of Common Shares outstanding on such record date multiplied by such Current Market Price less the aggregate fair market value (as determined by the directors, acting reasonably and in good faith, which determination shall be conclusive) of such shares or rights, options or warrants or evidences of indebtedness or assets actually distributed, as the case may be, and of which the denominator shall be the total number of Common Shares outstanding on such record date multiplied by such Current Market Price; and Common Shares owned by or held for the account of the Corporation or any Subsidiary shall be deemed not be outstanding for the purpose of any such computation; such adjustment shall be made successively whenever such a record date is fixed; to the extent that such distribution is not so made, the Exercise Price shall be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or to the Exercise Price which would then be in effect based upon such shares or rights, options or warrants or evidences of indebtedness or assets actually distributed, as the case may be; in clause (7) of this subsection 4.1.3 the term “ Dividends Paid in the Ordinary Course ” shall include the value of any securities or other property or assets distributed in lieu of cash Dividends Paid in the Ordinary Course at the option of shareholders. Upon any adjustment of the Exercise Price pursuant to this subsection 4.1.3, the number of Common Shares subject to the right of purchase under each Warrant shall be contemporaneously adjusted by multiplying the number of Common Shares theretofore obtainable on the exercise thereof by a fraction of which the numerator shall be the respective Exercise Price in effect immediately prior to such adjustment and the denominator shall be the respective Exercise Price resulting from such adjustment;



- 30 -

  4.1.4

If and whenever at any time during the Adjustment Period, there is a reclassification of the Common Shares or a capital reorganization of the Corporation other than as described in subsection 4.1.1 or a consolidation, amalgamation, arrangement or merger of the Corporation with or into any other body corporate, trust, partnership or other entity, or a sale or conveyance of the property and assets of the Corporation as an entirety or substantially as an entirety to any other body corporate, trust, partnership or other entity in which the holders of Common Shares are entitled to receive shares, other securities or property, including cash, any Warrantholder who has not exercised its right of acquisition prior to the effective date of such reclassification, capital reorganization, consolidation, amalgamation, arrangement or merger, sale or conveyance, upon the exercise of such right thereafter, shall be entitled to receive and shall accept for the same aggregate consideration, in lieu of the number of Common Shares then sought to be acquired by it, the number of shares or other securities or property of the Corporation or of the body corporate, trust, partnership or other entity resulting from such merger, amalgamation or consolidation, or to which such sale or conveyance may be made, as the case may be, that such Warrantholder would have been entitled to receive on such reclassification, capital reorganization, consolidation, amalgamation, arrangement or merger, sale or conveyance, if, on the record date or the effective date thereof, as the case may be, the Warrantholder had been the registered holder of the number of Common Shares sought to be acquired by it and to which it was entitled to acquire upon the exercise of the Warrants. If determined appropriate by the Warrant Agent to give effect to or to evidence the provisions of this subsection 4.1.4, the Corporation, its successor, or such purchasing body corporate, partnership, trust or other entity, as the case may be, shall, prior to or contemporaneously with any such reclassification, capital reorganization, consolidation, amalgamation, arrangement, merger, sale or conveyance, enter into an indenture which shall provide, to the extent possible, for the application of the provisions set forth in this Indenture with respect to the rights and interests thereafter of the Warrantholders to the end that the provisions set forth in this Indenture shall thereafter correspondingly be made applicable, as nearly as may reasonably be, with respect to any shares, other securities or property to which a Warrantholder is entitled on the exercise of its acquisition rights thereafter. Any indenture entered into between the Corporation and the Warrant Agent pursuant to the provisions of this subsection 4.1.4 shall be a supplemental indenture entered into pursuant to the provisions of Article 8. Any indenture entered into between the Corporation; any successor to the Corporation or such purchasing body corporate, partnership, trust or other entity and the Warrant Agent shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided in this Section 4.1 and which shall apply to successive reclassifications, capital reorganizations, amalgamations, consolidations, mergers, sales or conveyances;



- 31 -

  4.1.5

In any case in which this Section 4.1 shall require that an adjustment shall become effective immediately after a record date for an event referred to herein, the Corporation may defer, until the occurrence of such event, issuing to the holder of any Warrant exercised after such event the additional Common Shares issuable upon such conversion by reason of the adjustment required by such event before giving effect to such adjustment; provided, however, that the Corporation shall deliver to such holder an appropriate instrument evidencing such holder’s right to receive such additional Common Shares upon the occurrence of the event requiring such adjustment and the right to receive any distributions made on such additional Common Shares declared in favour of holders of record of Common Shares on and after the relevant date of exercise or such later date as such holder would, but for the provisions of this subsection 4.1.5, have become the holder of record of such additional Common Shares pursuant to subsection 4.1.4;

     
  4.1.6

In any case in which subsections 4.1.2 or 4.1.3 require that an adjustment be made to the Exercise Price, no such adjustment shall be made if the holders of the outstanding Warrants receive the rights, options or warrants referred to in subsection 4.1.2 or the shares, rights, options, warrants, evidences of indebtedness, property or assets referred to in subsection 4.1.3, as the case may be, in such kind and number as they would have received if they had been holders of Common Shares on the applicable record date or effective date, as the case may be, by virtue of their outstanding Warrants having then been exercised into Common Shares at the Exercise Price in effect on the applicable record date or effective date, as the case may be. Any such issuance of shares, rights, options, or warrants will be subject to regulatory approval;



- 32 -

  4.1.7

The adjustments provided for in this Section 4.1 are cumulative, and shall, in the case of adjustments to the Exercise Price be computed to the nearest whole cent and shall apply to successive subdivisions, redivisions, reductions, combinations, consolidations, distributions, issues or other events resulting in any adjustment under the provisions of this Section 4.1, provided that, notwithstanding any other provision of this Section, no adjustment of the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least one (1%) percent in the Exercise Price then in effect; provided, however, that any adjustments which by reason of this subsection 4.1.7 are not required to be made shall be carried forward and taken into account in any subsequent adjustment; and

     
  4.1.8

After any adjustment pursuant to this Section 4.1, the term “ Common Shares ” where used in this Indenture shall be interpreted to mean securities of any class or classes which, as a result of such adjustment and all prior adjustments pursuant to this Section 4.1, the Warrantholder is entitled to receive upon the exercise of his Warrant, and the number of Common Shares indicated by any exercise made pursuant to a Warrant shall be interpreted to mean the number of Common Shares or other property or securities a Warrantholder is entitled to receive, as a result of such adjustment and all prior adjustments pursuant to this Section 4.1, upon the full exercise of a Warrant.


4.2

Entitlement to Shares on Exercise of Warrant

All shares of any class or other securities which a Warrantholder is at the time in question entitled to receive on the exercise of its Warrant, whether or not as a result of adjustments made pursuant to this Article 4, shall, for the purposes of the interpretation of this Indenture, be deemed to be shares which such Warrantholder is entitled to acquire pursuant to such Warrant.

4.3

No Adjustment for Certain Transactions

Notwithstanding anything in this Article 4, no adjustment shall be made in the acquisition rights attached to the Warrants if the issue of Common Shares is being made pursuant to or in connection with:

  4.3.1

any stock option or stock purchase plan in force from time to time for directors, officers, employees, consultants or other service providers of the Corporation; or

     
  4.3.2

the satisfaction of existing instruments issued at or prior to the date hereof.



- 33 -

4.4

Determination by Corporation’s Auditors

In the event of any question arising with respect to the adjustments provided for in this Article 4 such question shall be conclusively determined by the Corporation’s Auditors who shall have access to all necessary records of the Corporation, and such determination shall be binding upon the Corporation, the Warrant Agent, all Warrantholders and all other persons interested therein.

4.5

Proceedings Prior to any Action Requiring Adjustment

As a condition precedent to the taking of any action which would require an adjustment in any of the acquisition rights pursuant to any of the Warrants, including the number of Common Shares which are to be received upon the exercise thereof, the Corporation shall take any corporate action which may, in the opinion of Counsel, be necessary in order that the Corporation has unissued and reserved in its authorized capital and may validly and legally issue as fully paid and non-assessable all the shares (or other securities or property) which the holders of such Warrants are entitled to receive on the full exercise thereof in accordance with the provisions hereof.

4.6

Certificate of Adjustment

The Corporation shall from time to time immediately after the occurrence of any event which requires an adjustment or readjustment as provided in Article 4, deliver a certificate of the Corporation to the Warrant Agent specifying the nature of the event requiring the same and the amount of the adjustment or readjustment necessitated thereby and setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based, which certificate shall be supported by a certificate of the Corporation’s Auditors verifying such calculation.

4.7

Notice of Special Matters

The Corporation covenants with the Warrant Agent that, so long as any Warrant remains outstanding, it will give notice to the Warrant Agent and to the Warrantholders of its intention to fix a record date that is prior to the Expiry Date for the purpose of an event that requires or that may require an adjustment in any of the exercise rights pursuant to any Warrants as provided in this Article 4. Such notice shall specify the particulars of such event and the record date for such event, provided that the Corporation shall only be required to specify in the notice such particulars of the event as shall have been fixed and determined on the date on which the notice is given. The notice shall be given in each case not less than fourteen (14) days prior to such applicable record date.

4.8

No Action After Notice

The Corporation covenants with the Warrant Agent that it will not close its transfer books or take any other corporate action which might deprive the holder of a Warrant of the opportunity to exercise its right of acquisition pursuant thereto during the period of fourteen (14) days after the giving of the certificate or notices set forth in Sections 4.6 and 4.7.


- 34 -

4.9

Other Action

In case the Corporation, after the date hereof, shall take any action affecting the Common Shares other than action described in Section 4.1, which in the reasonable opinion of the directors of the Corporation would materially affect the rights of Warrantholders, the number of Common Shares which may be acquired upon exercise of the Warrants shall be adjusted in such manner and at such time, by action of the directors, acting reasonably, as they may determine to be equitable in the circumstances, provided that no such adjustment will be made unless prior approval of any stock exchange on which the Common Shares are listed for trading has been obtained, if required by any such stock exchange.

4.10

Protection of Warrant Agent

Except as provided in Section 9.1, the Warrant Agent shall not:

  4.10.1

at any time be under any duty or responsibility to any Warrantholder to determine whether any facts exist which may require any adjustment contemplated by Section 4.1, or with respect to the nature or extent of any such adjustment when made, or with respect to the method employed in making the same;

     
  4.10.2

be accountable with respect to the validity or value (or the kind or amount) of any Common Shares or of any shares or other securities or property which may at any time be issued or delivered upon the exercise of the rights attaching to any Warrant;

     
  4.10.3

be responsible for any failure of the Corporation to issue, transfer or deliver Common Shares or certificates for the same upon the surrender of any Warrants for the purpose of the exercise of such rights or to comply with any of the covenants contained in this Article; and

     
  4.10.4

incur any liability or responsibility whatsoever or be in any way responsible for the consequences of any breach on the part of the Corporation of any of the representations, warranties or covenants herein contained or of any acts of the directors, officers, employees, agents or servants of the Corporation.



- 35 -

ARTICLE 5 - RIGHTS OF THE CORPORATION AND COVENANTS

5.1

Optional Purchases by the Corporation

Subject to compliance with applicable securities legislation and approval of applicable regulatory authorities, the Corporation may from time to time purchase on any stock exchange, in the open market, by private contract or otherwise, any of the Warrants. Any such purchase shall be made at the lowest price or prices at which, in the opinion of the directors, such Warrants are then obtainable, plus reasonable costs of purchase, and may be made in such manner, from such persons and on such other terms as the Corporation, in its sole discretion, may determine. Any Warrant Certificates representing the Warrants purchased pursuant to this Section 5.1 shall forthwith be delivered to and cancelled by the Warrant Agent. No Warrants shall be issued in replacement thereof.

5.2

General Covenants

The Corporation covenants with the Warrant Agent that so long as any Warrants remain outstanding and may be exercised:

  5.2.1

it will reserve and keep available a sufficient number of Common Shares for the purpose of enabling it to satisfy its obligations to issue Common Shares upon the exercise of the Warrants;

     
  5.2.2

it will cause the Common Shares and the certificates representing the Common Shares from time to time acquired pursuant to the exercise of the Warrants to be duly issued and delivered in accordance with the Warrant Certificates and the terms hereof;

     
  5.2.3

all Common Shares which shall be issued upon exercise of the right to acquire provided for herein and in the Warrant Certificates, upon payment of the prevailing Exercise Price herein provided for and in the Warrant Certificates shall be fully paid and non-assessable;

     
  5.2.4

if any of its Common Shares are listed on a stock exchange, it will use all reasonable efforts to ensure that the Common Shares comprising the Units, and all Common Shares outstanding or issuable from time to time (including, without limitation, the Common Shares issuable on the exercise of the Warrants) are listed and posted for trading on such stock exchange;

     
  5.2.5

it will make all requisite filings under applicable Canadian securities legislation and stock exchange rules, including (on a reasonable efforts basis) those necessary to remain a reporting issuer not in default in each of the provinces of Canada in which it is a reporting issuer as of the date hereof and those necessary to report the exercise of the right to acquire Common Shares pursuant to Warrants;

     
  5.2.6

it will provide to Warrantholders copies of all financial statements and other documentation required to be provided by applicable laws to registered holders of Common Shares as if such Warrantholders were registered shareholders of the Corporation. The Warrant Agent shall be entitled to rely on notice-and-access delivery of theses applicable materials to Warrantholders set out in National Instrument 51-102 - Continuous Disclosure Obligations and National Instrument 54-101 - Communication with Beneficial Owners of a Reporting Issuer ;



- 36 -

  5.2.7

it shall not close its transfer books or take any other action which might deprive the Warrantholders of the opportunity of exercising their right of purchase pursuant to the Warrants held by such persons after the giving of the notice required by Section 4.7;

       
  5.2.8

generally, it will well and truly perform and carry out all of the acts or things to be done by it as provided in this Indenture;

       
  5.2.9

the Corporation confirms that as at the date of execution of this Indenture it does not have a class of securities registered pursuant to Section 12 of the U.S. Securities Exchange Act or have a reporting obligation pursuant to Section 15(d) of the U.S. Securities Exchange Act; the Corporation covenants that in the event that (i) any class of its securities shall become registered pursuant to Section 12 of the U.S. Securities Exchange Act or the Corporation shall incur a reporting obligation pursuant to Section 15(d) of the U.S. Securities Exchange Act, or (ii) any such registration or reporting obligation shall be terminated by the Corporation in accordance with the U.S. Securities Exchange Act, the Corporation shall promptly deliver to the Warrant Agent an Officers’ Certificate (in a form provided by the Warrant Agent) notifying the Warrant Agent of such registration or termination and such other information as the Warrant Agent may require at the time. The Corporation acknowledges that the Warrant Agent is relying upon the foregoing representation and covenants in order to meet certain SEC obligations with respect to those clients who are filing with the SEC.


5.3

Warrant Agent’s Remuneration and Expenses

The Corporation covenants that it will pay to the Warrant Agent from time to time reasonable remuneration for its services hereunder and will pay or reimburse the Warrant Agent upon its request for all reasonable expenses, disbursements and advances incurred or made by the Warrant Agent in the administration or execution of the trusts hereby created (including the reasonable compensation and the disbursements of its Counsel and all other advisers and assistants not regularly in its employ) both before any default hereunder and thereafter until all duties of the Warrant Agent hereunder shall be finally and fully performed, except any such expense, disbursement or advance as may arise out of or result from the Warrant Agent’s gross negligence, willful misconduct or bad faith.


- 37 -

5.4

Securities Qualification Requirements

If, in the opinion of Counsel, any instrument is required to be filed with, or any permission is required to be obtained from, any governmental authority in Canada or any other step is required under any federal, provincial or territorial law of Canada before any Common Shares which a Warrantholder is entitled to acquire pursuant to the exercise of any Warrant may properly and legally be issued and subscribed for upon due exercise thereof and thereafter traded, without further formality or restriction, the Corporation covenants that it will take such required action.

5.5

Performance of Covenants by Warrant Agent

If the Corporation shall fail to perform any of its covenants contained in this Indenture and shall have not rectified such failure within ten (10) Business Days after receiving notice from the Warrant Agent of such failure, the Warrant Agent may notify the Warrantholders of such failure on the part of the Corporation or may itself perform any of the covenants capable of being performed by it but, subject to Section 9.1, shall be under no obligation to perform said covenants or to notify the Warrantholders of such performance by it. All sums expended or advanced by the Warrant Agent in so doing shall be repayable as provided in Section 5.3. No such performance, expenditure or advance by the Warrant Agent shall relieve the Corporation of any default hereunder or of its continuing obligations under the covenants herein contained.

5.6

Enforceability of Warrants

The Corporation covenants and agrees that it is duly authorized to create and issue the Warrants to be issued hereunder and that the Warrants, when issued as herein provided, will be valid and enforceable against the Corporation in accordance with the provisions hereof and the terms hereof and that, subject to the provisions of this Indenture, the Corporation will cause the Common Shares from time to time acquired pursuant to the Warrants under this Indenture and the certificates representing such Common Shares to be duly issued and delivered in accordance with the terms of this Indenture.

ARTICLE 6 - ENFORCEMENT

6.1

Suits by Warrantholders

All or any of the rights conferred upon any Warrantholder by any of the terms of the Warrant Certificates or of this Indenture, or of both, may be enforced by the Warrantholder by appropriate proceedings but without prejudice to the right which is hereby conferred upon the Warrant Agent to proceed in its own name to enforce each and all of the provisions herein contained for the benefit of the Warrantholders.

6.2

Immunity of Shareholders, etc.

The Warrant Agent and, by the acceptance of the Warrant Certificates and as part of the consideration for the issue of the Warrants, the Warrantholders hereby waive and release any right, cause of action or remedy now or hereafter existing in any jurisdiction against any incorporator or any past, present or future shareholder or agent of the Corporation on any covenant, agreement, representation or warranty by the Corporation herein or contained in the Warrant Certificates.


- 38 -

6.3

Limitation of Liability

The obligations hereunder are not personally binding upon, nor shall resort hereunder be had to, the private property of any of the past, present or future directors or shareholders of the Corporation or any of the past, present or future officers, employees or agents of the Corporation. Only the property of the Corporation or any successor corporation shall be bound in respect hereof.

6.4

Waiver of Default

Upon the happening of any default hereunder:

  6.4.1

the holders of not less than fifty-one percent (51%) of the Warrants then outstanding shall have power (in addition to the powers exercisable by Extraordinary Resolution) by requisition in writing to instruct the Warrant Agent to waive any default hereunder and the Warrant Agent shall thereupon waive the default upon such terms and conditions as shall be prescribed in such requisition; or

     
  6.4.2

the Warrant Agent shall have power to waive any default hereunder upon such terms and conditions as the Warrant Agent may deem advisable, if, in the Warrant Agent’s reasonable opinion or, in the opinion of counsel acceptable to the Warrant Agent, the same shall have been cured or adequate provision made therefor;

provided that no delay or omission of the Warrant Agent or of the Warrantholders to exercise any right or power accruing upon any default shall impair any such right or power or shall be construed to be a waiver of any such default or acquiescence therein and provided further that no act or omission either of the Warrant Agent or of the Warrantholders in the premises shall extend to or be taken in any manner whatsoever to affect any subsequent default hereunder of the rights resulting therefrom.

ARTICLE 7 – MEETINGS OF WARRANTHOLDERS

7.1

Right to Convene Meetings

The Warrant Agent may at any time and from time to time, and shall on receipt of a written request of the Corporation or of a Warrantholders’ Request and upon being indemnified to its reasonable satisfaction by the Corporation or by the Warrantholders signing such Warrantholders’ Request against the costs which may be incurred in connection with the calling and holding of such meeting, convene a meeting of the Warrantholders. In the event of the Warrant Agent failing to so convene a meeting within fifteen (15) days after receipt of such written request of the Corporation or such Warrantholders’ Request and indemnity given as aforesaid, the Corporation or such Warrantholders, as the case may be, may convene such meeting. Every such meeting shall be held in Toronto or at such other place as may be approved or determined by the Warrant Agent and approved by the Corporation.


- 39 -

7.2

Notice

At least twenty-one (21) days’ prior written notice of any meeting of Warrantholders shall be given to the Warrantholders in the manner provided for in Article 10 and a copy of such notice shall be sent by mail to the Warrant Agent (unless the meeting has been called by the Warrant Agent) and to the Corporation (unless the meeting has been called by the Corporation). Such notice shall state the time when and the place where the meeting is to be held, shall state briefly the general nature of the business to be transacted thereat and shall contain such information as is reasonably necessary to enable the Warrantholders to make a reasoned decision on the matter, but it shall not be necessary for any such notice to set out the terms of any resolution to be proposed or any of the provisions of this Article 7. The notice convening any such meeting may be signed by an appropriate officer of the Warrant Agent or of the Corporation or the person or persons designated by such Warrantholders, as the case may be.

7.3

Chairman

An individual (who need not be a Warrantholder) designated in writing by the Warrant Agent shall be chairman of the meeting and if no individual is so designated, or if the individual so designated is not present within fifteen (15) minutes from the time fixed for the holding of the meeting, the Warrantholders present in person or by proxy shall choose some individual present to be chairman.

7.4

Quorum

Subject to the provisions of Section 7.11, at any meeting of the Warrantholders a quorum shall consist of Warrantholders present in person or by proxy and entitled to purchase at least ten percent (10%) of the aggregate number of Common Shares which could be acquired pursuant to all the then outstanding Warrants, provided that at least two persons entitled to vote thereat, in person or by proxy, are personally present. If a quorum of the Warrantholders shall not be present within thirty (30) minutes from the time fixed for holding any meeting, the meeting shall be adjourned to the same day in the next week (unless such day is not a Business Day, in which case it shall be adjourned to the next following Business day) at the same time and place and no notice of the adjournment need be given. Any business may be brought before or dealt with at an adjourned meeting which might have been dealt with at the original meeting in accordance with the notice calling the same. No business shall be transacted at any meeting unless a quorum is present at the commencement of business; provided that at the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum and may transact the business for which the meeting was originally convened, notwithstanding that they may not be entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all then outstanding Warrants.


- 40 -

7.5

Power to Adjourn

The chairman of any meeting at which a quorum of the Warrantholders is present may, with the consent of the meeting, adjourn any such meeting, and no notice of such adjournment need be given except such notice, if any, as the meeting may prescribe.

7.6

Show of Hands

Every question submitted to a meeting shall be decided in the first place by a majority of the votes given on a show of hands except that votes on an Extraordinary Resolution shall be given in the manner hereinafter provided. At any such meeting, unless a poll is duly demanded as herein provided, a declaration by the chairman that a resolution has been carried or carried unanimously or by a particular majority or lost or not carried by a particular majority shall be conclusive evidence of the fact.

7.7

Poll and Voting

On every Extraordinary Resolution, and on any other question submitted to a meeting and after a vote by show of hands when demanded by the chairman or by one or more of the Warrantholders acting in person or by proxy, a poll shall be taken in such manner as the chairman shall direct. Questions other than those required to be determined by Extraordinary Resolution shall be decided by a majority of the votes cast on the poll.

On a show of hands, every person who is present and entitled to vote, whether as a Warrantholder or as proxy for one or more absent Warrantholders, or both, shall have one vote. On a poll, each Warrantholder present in person or represented by a proxy duly appointed by instrument in writing shall be entitled to one vote in respect of each whole Common Share which it is entitled to acquire pursuant to the Warrant or Warrants then held or represented by it. A proxy need not be a Warrantholder. In the case of joint holders, any one of them present in person or by proxy at the meeting may vote in the absence of the other or others, but in case more than one of them shall be present in person or by proxy, they shall vote together in respect of Warrants of which they are joint registered holders. The chairman of any meeting shall be entitled, both on a show of hands and on a poll, to vote in respect of the Warrants, if any, held or represented by him.

7.8

Regulations

The Warrant Agent, or the Corporation with the approval of the Warrant Agent, may from time to time make and from time to time vary such regulations as it shall think fit for:

  7.8.1

the setting of the record date for a meeting for the purpose of determining Warrantholders entitled to receive notice of and to vote at the meeting;

     
  7.8.2

the issue of voting certificates by any bank, trust company or other depositary satisfactory to the Warrant Agent stating that the Warrant Certificates specified therein have been deposited with it by a named person and will remain on deposit until after the meeting, which voting certificate shall entitle the persons named therein to be present and vote at any such meeting and at any adjournment thereof or to appoint a proxy or proxies to represent them and vote for them at any such meeting and at any adjournment thereof in the same manner and with the same effect as though the persons so named in such voting certificates were the actual bearers of the Warrant Certificates specified therein;



- 41 -

  7.8.3

the deposit of voting certificates and instruments appointing proxies at such place and time as the Warrant Agent, the Corporation or the Warrantholders convening the meeting, as the case may be, may in the notice convening the meeting direct;

     
  7.8.4

the deposit of voting certificates and instruments appointing proxies at some approved place or places other than the place at which the meeting is to be held and enabling particulars of such instruments appointing proxies to be mailed or telecopied before the meeting to the Corporation or to the Warrant Agent at the place where the same is to be held and for the voting of proxies so deposited as though the instruments themselves were produced at the meeting;

     
  7.8.5

the form of the instrument of proxy and the manner in which the instrument of proxy must be executed; and

     
  7.8.6

generally for the calling of meetings of Warrantholders and the conduct of business thereat.

Any regulations so made shall be binding and effective and the votes given in accordance therewith shall be valid and shall be counted. Save as such regulations may provide, the only persons who shall be recognized at any meeting as a Warrantholder, or be entitled to vote or be present at the meeting in respect thereof (subject to Section 7.9), shall be Warrantholders or their counsel, or proxies of Warrantholders.

7.9

Corporation and Warrant Agent May be Represented

The Corporation and the Warrant Agent, by their respective directors and officers, and the Counsel for the Corporation and for the Warrant Agent may attend any meeting of the Warrantholders, but shall not be entitled to vote thereat, whether in respect of any Warrants held by them or otherwise.

7.10

Powers Exercisable by Extraordinary Resolution

In addition to all other powers conferred upon them by any other provisions of this Indenture or by law, the Warrantholders at a meeting shall, subject to the provisions of Section 7.11, have the power, exercisable from time to time by Extraordinary Resolution:

  7.10.1

to agree to any modification, abrogation, alteration, compromise or arrangement of the rights of Warrantholders or the Warrant Agent in its capacity as Warrant Agent hereunder (subject to the Warrant Agent’s prior consent) or on behalf of the Warrantholders against the Corporation whether such rights arise under this Indenture or the Warrant Certificates or otherwise;



- 42 -

7.10.2

to amend, alter or repeal any Extraordinary Resolution previously passed or sanctioned by the Warrantholders;

       
7.10.3

to direct or to authorize the Warrant Agent, subject to subsection 9.1.2, to enforce any of the covenants on the part of the Corporation contained in this Indenture or the Warrant Certificates or to enforce any of the rights of the Warrantholders in any manner specified in such Extraordinary Resolution or to refrain from enforcing any such covenant or right;

       
7.10.4

to waive, and to direct the Warrant Agent to waive, any default on the part of the Corporation in complying with any provisions of this Indenture or the Warrant Certificates either unconditionally or upon any conditions specified in such Extraordinary Resolution;

       
7.10.5

to restrain any Warrantholder from taking or instituting any suit, action or proceeding against the Corporation for the enforcement of any of the covenants on the part of the Corporation in this Indenture or the Warrant Certificates or to enforce any of the rights of the Warrantholders;

       
7.10.6

to direct any Warrantholder who, as such, has brought any suit, action or proceeding to stay or to discontinue or otherwise to deal with the same upon payment of the costs, charges and expenses reasonably and properly incurred by such Warrantholder in connection therewith;

       
7.10.7

to consent to any change in or omission from the provisions contained in the Warrant Certificates and this Indenture or any ancillary or supplemental instrument which may be agreed to by the Corporation, and to authorize the Warrant Agent to concur in and execute any ancillary or supplemental indenture embodying the change or omission;

       
7.10.8

with the consent of the Corporation, such consent not to be unreasonably withheld, to remove the Warrant Agent or its successor in office and to appoint a new trustee or trustees to take the place of the Warrant Agent so removed; and

       
7.10.9

to consent to any compromise or arrangement with any creditor or creditors or any class or classes of creditors, whether secured or otherwise, and with holders of any shares or other securities of the Corporation.

       
7.11

Meaning of Extraordinary Resolution

       
7.11.1

The expression “ Extraordinary Resolution ” when used in this Indenture means, subject as hereinafter provided in this Section 7.11 and in Section 7.14, a resolution proposed at a meeting of Warrantholders duly convened for that purpose and held in accordance with the provisions of this Article 7 at which there are present in person or by proxy at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants and passed by the affirmative votes of Warrantholders entitled to acquire not less than sixty-six and two third percent (66 2/3 %) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants present or represented at the meeting and voted on the poll upon such resolution.



- 43 -

  7.11.2

If, at the meeting at which an Extraordinary Resolution is to be considered, at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants are not present in person or by proxy within thirty (30) minutes after the time appointed for the meeting, then the meeting shall stand adjourned to such day, being not less than fifteen (15) or more than sixty (60) days later, and to such place and time as may be appointed by the chairman. Not less than ten (10) days’ prior notice shall be given of the time and place of such adjourned meeting in the manner provided for in Sections 10.1 and 10.2. Such notice shall state that at the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum but it shall not be necessary to set forth the purposes for which the meeting was originally called or any other particulars. At the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum and may transact the business for which the meeting was originally convened and a resolution proposed at such adjourned meeting and passed by the requisite vote as provided in subsection 7.11.1 shall be an Extraordinary Resolution within the meaning of this Indenture notwithstanding that at least two (2) Warrantholders entitled to acquire at least ten percent (10%) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants are not present in person or represented by proxy at such adjourned meeting.

     
  7.11.3

Votes on an Extraordinary Resolution shall always be given on a poll and no demand for a poll on an Extraordinary Resolution shall be necessary.


7.12

Powers Cumulative

Any one or more of the powers or any combination of the powers in this Indenture stated to be exercisable by the Warrantholders by Extraordinary Resolution or otherwise may be exercised from time to time and the exercise of any one or more of such powers or any combination of powers from time to time shall not be deemed to exhaust the right of the Warrantholders to exercise such power or powers or combination of powers then or thereafter from time to time.

7.13

Minutes

Minutes of all resolutions and proceedings at every meeting of Warrantholders shall be made and duly entered in books to be provided from time to time for that purpose by the Warrant Agent at the expense of the Corporation, and any such minutes as aforesaid, if signed by the chairman or the secretary of the meeting at which such resolutions were passed or proceedings had shall be prima facie evidence of the matters therein stated and, until the contrary is proved, every such meeting in respect of the proceedings of which minutes shall have been made shall be deemed to have been duly convened and held, and all resolutions passed thereat or proceedings taken shall be deemed to have been duly passed and taken.


- 44 -

7.14

Instruments in Writing

All actions which may be taken and all powers that may be exercised by the Warrantholders at a meeting held as provided in this Article 7 may also be taken and exercised by Warrantholders entitled to acquire at least sixty-six and two third percent (66 2/3 %) of the aggregate number of Common Shares which may be acquired pursuant to all the then outstanding Warrants by an instrument in writing signed in one or more counterparts by such Warrantholders in person or by attorney duly appointed in writing, and the expression “ Extraordinary Resolution ” when used in this Indenture shall include an instrument so signed.

7.15

Binding Effect of Resolutions

Every resolution and every Extraordinary Resolution passed in accordance with the provisions of this Article 7 at a meeting of Warrantholders shall be binding upon all the Warrantholders, whether present at or absent from such meeting, and every instrument in writing signed by Warrantholders in accordance with Section 7.14 shall be binding upon all the Warrantholders, whether signatories thereto or not, and each and every Warrantholder and the Warrant Agent (subject to the provisions for indemnity herein contained) shall be bound to give effect accordingly to every such resolution and instrument in writing. In the case of an instrument in writing, the Warrant Agent shall give notice in the manner contemplated in Sections 10.1 and 10.2 of the effect of the instrument in writing to all Warrantholders and the Corporation as soon as reasonably practicable.

7.16

Holdings by Corporation Disregarded

In determining whether Warrantholders holding Warrant Certificates evidencing the entitlement to acquire the required number of Common Shares are present at a meeting of Warrantholders for the purpose of determining a quorum or have concurred in any consent, waiver, Extraordinary Resolution, Warrantholders’ Request or other action under this Indenture, Warrants owned legally or beneficially by the Corporation or any Subsidiary of the Corporation shall be disregarded.

ARTICLE 8 - SUPPLEMENTAL INDENTURES

8.1

Provision for Supplemental Indentures for Certain Purposes

From time to time the Corporation (when authorized by action of the directors) and the Warrant Agent may, subject to the provisions hereof, and they shall, when so directed in accordance with the provisions hereof, execute and deliver by their proper officers, indentures or instruments supplemental hereto, which thereafter shall form part hereof, for any one or more or all of the following purposes:

  8.1.1

setting forth any adjustments resulting from the application of the provisions of Article 4;



- 45 -

  8.1.2

adding to the provisions hereof such additional covenants and enforcement provisions as, in the opinion of Counsel to the Corporation, are necessary or advisable in the circumstances, provided that the same are not in the opinion of the Warrant Agent prejudicial to the interests of the Warrantholders;

     
  8.1.3

giving effect to any Extraordinary Resolution passed as provided in Article 7;

     
  8.1.4

making such provisions not inconsistent with this Indenture as may be necessary or desirable with respect to matters or questions arising hereunder or for the purpose of obtaining a listing or quotation of the Warrants on any stock exchange, provided that such provisions are not, in the opinion of the Warrant Agent, prejudicial to the interests of the Warrantholders;

     
  8.1.5

adding to or altering the provisions hereof in respect of the transfer of Warrants, making provision for the exchange of Warrant Certificates, and making any modification in the form of the Warrant Certificates which does not affect the substance thereof, in each case provided that such provisions are not, in the opinion of the Warrant Agent, relying on an opinion of Counsel to the Warrant Agent, prejudicial to the interests of the Warrantholders;

     
  8.1.6

with the prior approval of the TSX Venture Exchange, modifying any of the provisions of this Indenture, including relieving the Corporation from any of the obligations, conditions or restrictions herein contained, provided that such modification or relief shall be or become operative or effective only if, in the opinion of the Warrant Agent, relying on an opinion of Counsel to the Warrant Agent, such modification or relief in no way prejudices any of the rights of the Warrantholders or of the Warrant Agent, and provided further that the Warrant Agent may decline to enter into any such supplemental indenture which in its opinion, relying on an opinion of Counsel to the Warrant Agent, may not afford adequate protection to the Warrant Agent when the same shall become operative; and

     
  8.1.7

for any other purpose not inconsistent with the terms of this Indenture, including the correction or rectification of any ambiguities, defective or inconsistent provisions, errors, mistakes or omissions herein, provided that in the opinion of the Warrant Agent the rights of the Warrant Agent and of the Warrantholders are in no way prejudiced thereby.


8.2

Successor Corporations

In the case of the consolidation, amalgamation, arrangement, merger or transfer of the undertaking or assets of the Corporation as an entirety or substantially as an entirety to another Corporation (the “ successor corporation ”), the successor corporation resulting from such consolidation, amalgamation, arrangement, merger or transfer (if not the Corporation) shall expressly assume, by supplemental indenture satisfactory in form to the Warrant Agent and executed and delivered to the Warrant Agent, the due and punctual performance and observance of each and every covenant and condition of this Indenture to be performed and observed by the Corporation.


- 46 -

ARTICLE 9 - CONCERNING THE WARRANT AGENT

9.1

Rights and Duties of Warrant Agent

     
9.1.1

In the exercise of the rights and duties prescribed or conferred by the terms of this Indenture, the Warrant Agent shall act honestly and in good faith with the view to the best interest of the Warrantholders and shall exercise that degree of care, diligence and skill that a reasonably prudent trustee would exercise in comparable circumstances. No provision of this Indenture shall be construed to relieve the Warrant Agent from, or require any other person to indemnify the Warrant Agent from liability for its own gross negligence, its own willful misconduct, bad faith.

     
9.1.2

The obligation of the Warrant Agent to commence or continue any act, action or proceeding for the purpose of enforcing any rights of the Warrant Agent or the Warrantholders hereunder shall be conditional upon the Warrantholders furnishing, when required by notice by the Warrant Agent, sufficient funds to commence or to continue such act, action or proceeding and an indemnity reasonably satisfactory to the Warrant Agent to protect and to hold harmless the Warrant Agent against the costs, charges and expenses and liabilities to be incurred thereby and any loss and damage it may suffer by reason thereof. None of the provisions contained in this Indenture shall require the Warrant Agent to expend or to risk its own funds or otherwise to incur financial liability in the performance of any of its duties or in the exercise of any of its rights or powers unless indemnified as aforesaid.

     
9.1.3

The Warrant Agent may, before commencing or at any time during the continuance of any such act, action or proceeding, require the Warrantholders, at whose instance it is acting to deposit with the Warrant Agent the Warrants held by them, for which Warrants the Warrant Agent shall issue receipts.

     
9.1.4

Every provision of this Indenture that by its terms relieves the Warrant Agent of liability or entitles it to rely upon any evidence submitted to it is subject to the provisions of Applicable Legislation, of this Section 9.1 and of Section 9.2.

     
9.2

Evidence, Experts and Advisers

     
9.2.1

In addition to the reports, certificates, opinions and other evidence required by this Indenture, the Corporation shall furnish to the Warrant Agent such additional evidence of compliance with any provision hereof, and in such form, as may be prescribed by Applicable Legislation or as the Warrant Agent may reasonably require by written notice to the Corporation.

     
9.2.2

In the exercise of its rights and duties hereunder, the Warrant Agent may, if it is acting in good faith, rely as to the truth of the statements and the accuracy of the opinions expressed in statutory declarations, opinions, reports, written requests, consents, or orders of the Corporation, certificates of the Corporation or other evidence furnished to the Warrant Agent pursuant to a request of the Warrant Agent, provided that such evidence complies with Applicable Legislation and that the Warrant Agent complies with Applicable Legislation and that the Warrant Agent examines the same and determines that such evidence complies with the applicable requirements of this Indenture.



- 47 -

  9.2.3

Whenever it is provided in this Indenture or under Applicable Legislation that the Corporation shall deposit with the Warrant Agent resolutions, certificates, reports, opinions, requests, orders or other documents, it is intended that the truth, accuracy and good faith on the effective date thereof and the facts and opinions stated in all such documents so deposited shall, in each and every such case, be conditions precedent to the right of the Corporation to have the Warrant Agent take the action to be based thereon.

     
  9.2.4

Proof of the execution of an instrument in writing, including a Warrantholders’ Request, by any Warrantholder may be made by the certificate of a notary public, or other officer with similar powers, that the person signing such instrument acknowledged to it the execution thereof, or by an affidavit of a witness to such execution or in any other manner which the Warrant Agent may consider adequate.

     
  9.2.5

The Warrant Agent may employ or retain such counsel, accountants, appraisers or other experts or advisers as it may reasonably require for the purpose of discharging its duties hereunder and may pay reasonable remuneration for all services so performed by any of them, without taxation of costs of any counsel, and shall not be responsible for any misconduct or negligence on the part of any such experts or advisers who have been appointed with due care by the Warrant Agent.


9.3

Documents, Monies, etc. Held by Warrant Agent

Any securities, documents of title or other instruments that may at any time be held by the Warrant Agent subject to the trusts hereof may be placed in the deposit vaults of the Warrant Agent or of any Canadian chartered bank listed in Schedule I to the Bank Act (Canada) or of any trust company registered to do business in Canada or deposited for safekeeping with any such bank or trust company. Unless herein otherwise expressly provided, any monies so held pending the application or withdrawal thereof under any provisions of this Indenture upon the direction of the Corporation shall be or, with the consent of the Corporation may be: (i) deposited in the name of the Warrant Agent in any Canadian chartered bank listed in Schedule I to the Bank Act (Canada) or any trust company registered to do business in Canada at the rate of interest (if any) then current on similar deposits; (ii) deposited in the deposit department of the Warrant Agent; or (iii) invested in treasury bills or short term interest bearing or discounted obligations issued or guaranteed by the Government of Canada or a province thereof, of any Canadian chartered bank listed in Schedule I of the Bank Act (Canada) or of the Warrant Agent, provided that the securities shall not have a maturity date of more than sixty (60) days from the date of such investment. Unless the Corporation shall be in default hereunder or unless otherwise specifically provided herein, all interest or other income received by the Warrant Agent in respect of such deposits and investments shall belong to the Corporation.


- 48 -

9.4

Actions by Warrant Agent to Protect Interest

The Warrant Agent shall have power to institute and to maintain such actions and proceedings as it may consider necessary or expedient to preserve, protect or enforce its interests and the interests of the Warrantholders.

9.5

Warrant Agent Not Required to Give Security

The Warrant Agent shall not be required to give any bond or security in respect of the execution of the trusts and powers of this Indenture or otherwise in respect of the premises.

9.6

Protection of Warrant Agent

By way of supplement to the provisions of any law for the time being relating to trustees it is expressly declared and agreed as follows:

9.6.1

the Warrant Agent shall not be liable for or by reason of any statements of fact or recitals in this Indenture or in the Warrant Certificates (except the representation contained in Section 9.9 or in the certificate of the Warrant Agent on the Warrant Certificates) or be required to verify the same, but all such statements or recitals are and shall be deemed to be made by the Corporation;

     
9.6.2

nothing herein contained shall impose any obligation on the Warrant Agent to see to or to require evidence of the registration or filing (or renewal thereof) of this Indenture or any instrument ancillary or supplemental hereto;

     
9.6.3

the Warrant Agent shall not be bound to give notice to any person or persons of the execution hereof;

     
9.6.4

subject to subsection 9.1.1, the Warrant Agent shall not incur any liability or responsibility whatever or be in any way responsible for the consequence of any breach on the part of the Corporation of any of the covenants herein contained or of any acts of any directors, officers, employees, agents or servants of the Corporation; and

     
9.7

Corporation to Indemnify

     
9.7.1

The Corporation hereby indemnifies and saves harmless the Warrant Agent and its directors, officers, employees and agents from and against any and all loss, damages, charges, expenses, costs (including legal costs on a solicitor– and–client basis), claims, demands, actions or liability whatsoever which may be brought against the Warrant Agent as trustee of the Warrants or which the Warrant Agent may suffer or incur as a result of or arising out of either the performance of the Warrant Agent of its duties and obligations, hereunder save only in the event of the gross negligence, wilful misconduct or bad faith of the Warrant Agent, or the performance of the Corporation of its duties, obligations, responsibilities or any actions of the Corporation otherwise associated with the Warrants, whether such duties, obligations, responsibilities or actions are specified as those of the Corporation. This indemnity will survive the termination or discharge of this Indenture and the resignation or removal of the Warrant Agent. The Warrant Agent shall notify the Corporation promptly of any claim for which it may seek indemnity. The Corporation shall defend the claim and the Warrant Agent shall co-operate in the defence. The Warrant Agent may have separate Counsel and the Corporation shall pay the fees and expenses of such Counsel. This indemnity shall survive the resignation or removal of the Warrant Agent or the termination of this Corporation.



- 49 -

9.8

Replacement of Warrant Agent; Successor by Merger

     
9.8.1

The Warrant Agent may resign its agency and be discharged from all further duties and liabilities hereunder, subject to this Section 9.7, by giving to the Corporation not less than ninety (90) days’ prior notice in writing or such shorter prior notice as the Corporation may accept as sufficient. The Warrantholders by Extraordinary Resolution shall have power at any time to remove the existing Warrant Agent and to appoint a new Warrant Agent. In the event of the Warrant Agent resigning or being removed as aforesaid or being dissolved, becoming bankrupt, going into liquidation or otherwise becoming incapable of acting hereunder, the Corporation shall forthwith appoint a warrant agent unless a warrant agent has already been appointed by the Warrantholders; failing such appointment by the Corporation, the retiring Warrant Agent or any Warrantholder may apply to a justice of the Superior Court of the Province of Ontario on such notice as such justice may direct, for the appointment of a new warrant agent; but any new warrant agent so appointed by the Corporation or by the Court shall be subject to removal as aforesaid by the Warrantholders. Any new warrant agent appointed under any provision of this Section 9.7 shall be a corporation authorized to carry on the business of a trust company in each of the provinces of Canada. On any such appointment the new warrant agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named herein as Warrant Agent without any further assurance, conveyance, act or deed; but there shall be immediately executed, at the expense of the Corporation, all such conveyances or other instruments as may, in the opinion of Counsel to the Warrant Agent, be necessary or advisable for the purpose of assuring the same to the new warrant agent, provided that any resignation or removal of the Warrant Agent and appointment of a successor warrant agent shall not become effective until the successor warrant agent shall have executed an appropriate instrument accepting such appointment and, at the request of the Corporation, the predecessor Warrant Agent shall execute and deliver to the successor warrant agent an appropriate instrument transferring to such successor warrant agent all rights and powers of the Warrant Agent hereunder so ceasing to act.



- 50 -

9.8.2

Upon the appointment of a successor trustee, the Corporation shall promptly notify the Warrantholders thereof in the manner provided for in Section 10.1.

     
9.8.3

Any corporation into or with which the Warrant Agent may be merged or consolidated, or amalgamated, or any corporation resulting therefrom to which the Warrant Agent shall be a party, or any corporation succeeding to the trust business of the Warrant Agent shall be the successor to the Warrant Agent hereunder without any further act on its part or any of the parties hereto, provided that such corporation would be eligible for appointment as a successor warrant agent under subsection 9.8.1.

     
9.8.4

Any Warrant Certificates certified but not delivered by a predecessor trustee may be certified by the successor trustee in the name of the predecessor or successor warrant agent.

     
9.9

Conflict of Interest

     
9.9.1

The Warrant Agent represents to the Corporation that at the time of execution and delivery hereof no material conflict of interest exists between its role as a trustee hereunder and its role in any other capacity and agrees that in the event of a material conflict of interest arising hereafter it will, within ninety (90) days after ascertaining that it has such material conflict of interest, either eliminate the same or assign its trust hereunder to a successor trustee approved by the Corporation and meeting the requirements set forth in subsection 9.8.1. Notwithstanding the foregoing provisions of this subsection 9.9.1, if any such material conflict of interest exists or hereafter shall exist, the validity and enforceability of this Indenture and the Warrant Certificate shall not be affected in any manner whatsoever by reason thereof.

     
9.9.2

Subject to subsection 9.9.1, the Warrant Agent, in its personal or any other capacity, may buy, lend upon and deal in securities of the Corporation and generally may contract and enter into financial transactions with the Corporation or any Subsidiary of the Corporation without being liable to account for any profit made thereby.

     
9.10

Acceptance of Trust

The Warrant Agent hereby accepts the trusts in this Indenture declared and provided for and agrees to perform the same upon the terms and conditions herein set forth.

9.11

Warrant Agent Not to be Appointed Receiver

The Warrant Agent and any person related to the Warrant Agent shall not be appointed a receiver, a receiver and manager or liquidator of all or any part of the assets or undertaking of the Corporation.


- 51 -

9.12

Warrant Agent Not Required to Give Notice of Default

The Warrant Agent shall not be bound to give any notice or do or take any act, action or proceeding by virtue of the powers conferred on it hereby unless and until it shall have been required so to do under the terms hereof; nor shall the Warrant Agent be required to take notice of any default hereunder, unless and until notified in writing of such default, which notice shall distinctly specify the default desired to be brought to the attention of the Warrant Agent and in the absence of any such notice the Warrant Agent may for all purposes of this Indenture conclusively assume that no default has been made in the observance or performance of any of the representations, warranties, covenants, agreements or conditions contained herein. Any such notice shall in no way limit any discretion herein given to the Warrant Agent to determine whether or not the Warrant Agent shall take action with respect to any default.

9.13

Force Majeure

Except for the payment obligations of the Corporation contained herein, neither party shall be liable to the other, or held in breach of this Agreement, if prevented, hindered, or delayed in the performance or observance of any provision contained herein by reason of act of God, riots, terrorism, acts of war, epidemics, governmental action or judicial order, earthquakes, or any other similar causes (including, but not limited to, mechanical, electronic or communication interruptions, disruptions or failures). Performance times under this Agreement shall be extended for a period of time equivalent to the time lost because of any delay that is excusable under this Section.

9.14

Third Parties

The Corporation hereby represents to the Warrant Agent that any account to be opened by, or interest to held by, Warrant Agent in connection with this Agreement, for or to the credit of the Corporation, either (i) is not intended to be used by or on behalf of any third party; or (ii) is intended to be used by or on behalf of a third party, in which case the Corporation agrees to complete and execute forthwith a declaration in the Warrant Agent’s prescribed form as to the particulars of such third party.

9.15

Anti-Money Laundering

The Warrant Agent shall retain the right not to act and shall not be liable for refusing to act if, due to a lack of information or for any other reason whatsoever, the Warrant Agent, in its sole judgment, determines that such act might cause it to be in non-compliance with any applicable anti money laundering or anti-terrorist or economic sanctions legislation, regulation or guideline. Further, should the Warrant Agent, in its sole judgment, determine at any time that its acting under this Agreement has resulted in its being in non-compliance with any applicable anti money laundering or antiterrorist legislation, regulation or guideline, then it shall have the right to resign on ten (10) days’ written notice to the Corporation, provided that (i) the Warrant Agent’s written notice shall describe the circumstances of such non-compliance; and (ii) if such circumstances are rectified to the Warrant Agent’s satisfaction within such ten (10) day period, then such resignation shall not be effective.


- 52 -

9.16

Privacy

The parties acknowledge that the Warrant Agent may, in the course of providing services hereunder, collect or receive financial and other personal information about such parties and/or their representatives, as individuals, or about other individuals related to the subject matter hereof, and use such information for the following purposes:

  (a)

to provide the services required under this Indenture and other services that may be requested from time to time;

     
  (b)

to help the Warrant Agent manage its servicing relationships with such individuals;

     
  (c)

to meet the Warrant Agent’s legal and regulatory requirements; and

     
  (d)

if social insurance numbers are collected by the Warrant Agent, to perform tax reporting and to assist in verification of an individual’s identity for security purposes.

Each party acknowledges and agrees that the Warrant Agent may receive, collect, use and disclose personal information provided to it or acquired by it in the course of this Indenture for the purposes described above and, generally, in the manner and on the terms described in its Privacy Code, which the Warrant Agent shall make available on its website or upon request, including revisions thereto. Some of this personal information may be transferred to servicers in the U.S.A. for data processing and/or storage. Further, each party agrees that it shall not provide or cause to be provided to the Warrant Agent any personal information relating to an individual who is not a party to this agreement unless that party has assured itself that such individual understands and has consented to the aforementioned terms, uses and disclosures.

ARTICLE 10 - GENERAL

10.1

Notice to the Corporation and the Warrant Agent

       
10.1.1

Unless herein otherwise expressly provided, any notice to be given hereunder to the Corporation or the Warrant Agent shall be deemed to be validly given if delivered, sent by registered letter, postage prepaid or telecopied:

       
(a)

If to the Corporation:


  96 Skyway Avenue
  Toronto, Ontario M9W 4Y9
  Attention: Dr. Niclas Stiernholm, President & CEO
  Email: niclas@stemcellthera.com

  (b)

If to the Warrant Agent:

     
 

Computershare Trust Company of Canada
600, 530 – 8 Avenue S.W.



- 53 -

  Calgary, Alberta T2P 3S8
  Attention: Manager, Corporate Trust
  Facsimile: 403-267-6598

    and any such notice delivered in accordance with the foregoing shall be deemed to have been received on the date of delivery or, if mailed, on the fifth (5th) Business Day following the date of the postmark on such notice or, if telecopied, on the next Business Day following the date of transmission provided that its contents are transmitted and received completely and accurately.
     
10.1.2

The Corporation or the Warrant Agent, as the case may be, may from time to time notify the other in the manner provided in subsection 10.1.1 of a change of address which, from the effective date of such notice and until changed by like notice, shall be the address of the Corporation or the Warrant Agent, as the case may be, for all purposes of this Indenture.

     
10.1.3

If, by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given to the Warrant Agent or to the Corporation hereunder could reasonably be considered unlikely to reach its destination, such notice shall be valid and effective only if it is delivered to the named officer of the party to which it is addressed or, if it is delivered to such party at the appropriate address provided in subsection 10.1.1, by telecopy or other means of prepaid, transmitted and recorded communication.

     
10.2

Notice to Warrantholders

     
10.2.1

Unless otherwise provided herein, notice to the Warrantholders under the provisions of this Indenture shall be valid and effective if delivered or sent by telecopy or by ordinary post addressed to such holders at their post office addresses appearing on the register hereinbefore mentioned and shall be deemed to have been effectively given on the date of delivery or, if mailed, on the fifth Business Day following the date of the postmark on such notice or, if telecopied, on the next Business Day following the date of transmission, provided that its contents are transmitted and received completely and accurately.

     
10.2.2

If, by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given to the Warrantholders hereunder could reasonably be considered unlikely to reach its destination, such notice shall be valid and effective only if such notice is published once in the National Edition of The Globe and Mail or, if the National Edition of The Globe and Mail is not being generally circulated, in The National Post, and, if the National Edition of The Globe and Mail (or The National Post if the notice is published therein) is not circulated in a city where a Warrant Agency is situated, in an English language daily newspaper of general circulation in such city; provided that in the case of a notice convening a meeting of Warrantholders, the Warrant Agent may require such additional publications of such notice, in the same or another city or both as it may deem necessary for the reasonable protection of the Warrantholders or to comply with any applicable requirements of law or of any stock exchange. Any notice so given shall be deemed to have been given on the day on which it has been published in the National Edition of The Globe and Mail or The National Post, as the case may be, and in all of the cities in which such publication was required (or first published in all such cities if more than one publication in any such city is required). In determining under any provision hereof the date when notice of any meeting or other event must be given, the date of giving notice shall be included and the date of the meeting or other event shall be excluded.



- 54 -

10.3

Ownership of Warrants

The Corporation and the Warrant Agent may deem and treat the registered owner of any Warrants as the absolute owner thereof for all purposes, and the Corporation and the Warrant Agent shall not be affected by any notice or knowledge to the contrary except where the Corporation or the Warrant Agent is required to take notice by statute or by order of a court of competent jurisdiction. A Warrantholder shall be entitled to the rights evidenced by its Warrant Certificate free from all equities or rights of set off or counterclaim between the Corporation and the original or any intermediate holder of the Warrants and all persons may act accordingly. The receipt of any such Warrantholder for the Common Shares which may be acquired pursuant thereto, or the receipt of the amount payable to such Warrantholder upon the exercise of the repurchase right referred to in Section 5.1 shall be a good discharge to the Corporation and the Warrant Agent for the same and neither the Corporation nor the Warrant Agent shall be bound to inquire into the title of any such holder except where the Corporation or the Warrant Agent is required to take notice by statute or by order of a court of competent jurisdiction.

10.4

Evidence of Ownership

     
10.4.1

Upon receipt of a certificate of any bank, trust company or other depositary satisfactory to the Warrant Agent stating that the Warrants specified therein have been deposited by a named person with such bank, trust company or other depositary and will remain so deposited until the expiry of the period specified therein, the Corporation and the Warrant Agent may treat the person so named as the owner, and such certificate as sufficient evidence of the ownership by such person of such Warrant during such period, for the purpose of any requisition, direction, consent, instrument or other document to be made, signed or given by the holder of the Warrant so deposited.

     
10.4.2

The Corporation and the Warrant Agent may accept as sufficient evidence of the fact and date of the signing of any requisition, direction, consent, instrument or other document by any person (i) the signature of any officer of any bank, trust company, or other depositary satisfactory to the Warrant Agent as witness of such execution, (ii) the certificate of any notary public or other officer authorized to take acknowledgements of deeds to be recorded at the place where such certificate is made that the person signing acknowledged to him the execution thereof, (iii) a statutory declaration of a witness of such execution, or (iv) any other documentation satisfactory to the Corporation and the Warrant Agent.



- 55 -

10.5

Counterparts

This Indenture may be executed in several counterparts, each of which when so executed shall be deemed to be an original and such counterparts together shall constitute one and the same instrument and notwithstanding their date of execution they shall be deemed to be dated as of the date hereof:

10.6

Satisfaction and Discharge of Indenture

Upon the earlier of:

  10.6.1

the date by which there shall have been delivered to the Warrant Agent for exercise or destruction all Warrant Certificates contemplated to be certified hereunder; or

     
  10.6.2

the Expiry Time;

and if all certificates representing Common Shares required to be issued in compliance with the provisions hereof have been issued and delivered hereunder or to the Warrant Agent in accordance with such provisions and if all payments required to be made in accordance with such provisions have been made, this Indenture shall cease to be of further effect and the Warrant Agent, on demand of and at the cost and expense of the Corporation and upon delivery to the Warrant Agent of a certificate of the Corporation stating that all conditions precedent to the satisfaction and discharge of this Indenture have been complied with, shall execute proper instruments acknowledging satisfaction of and discharging this Indenture. Notwithstanding the foregoing, the indemnities provided to the Warrant Agent by the Corporation hereunder shall remain in full force and effect and survive the termination of this Indenture.

10.7

Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders

Nothing in this Indenture or in the Warrant Certificates, expressed or implied, shall give or be construed to give to any person other than the parties hereto and the Warrantholders, as the case may be, any legal or equitable right, remedy or claim under this Indenture, or under any covenant or provision herein or therein contained, all such covenants and provisions being for the sole benefit of the parties hereto and the Warrantholders.

10.8

Common Shares or Warrants Owned by the Corporation or its Subsidiaries - Certificate to be Provided

TOR01: 5403722: v10e Corporation or any Subsidiary of the Corporation in Section 7.16, the Corporation shall provide to the Warrant Agent, from time to time, a certificate of the Corporation setting forth as at the date of such certificate:


- 56 -

  10.8.1

the names (other than the name of the Corporation) of the registered holders of Warrants which, to the knowledge of the Corporation, are owned by or held for the account of the Corporation or any Subsidiary of the Corporation; and

     
  10.8.2

the number of Warrants owned legally or beneficially by the Corporation or any Subsidiary of the Corporation;

and the Warrant Agent, in making the computations in Section 7.16, shall be entitled to rely on such certificate without any additional evidence.

[Signatures on following page]


S-1

IN WITNESS WHEREOF the parties hereto have executed this Indenture as of the date first written above.

  STEM CELL THERAPEUTICS CORP.
       
       
  Per: (Signed) “ Niclas Stiernholm
    Name: Niclas Stiernholm
    Title: President & CEO
       
       
COMPUTERSHARE TRUST COMPANY OF CANADA
       
       
  Per: (Signed) “ Shannon Grover
    Name: Shannon Grover
    Title: Corporate Trust Officer
       
  Per: (Signed) “ Pui Hong
    Name: Pui Hong
    Title: Corporate Trust Officer


1

SCHEDULE “A”
FORM OF WARRANT CERTIFICATE

[IF APPLICABLE, CERTIFICATES REPRESENTING WARRANTS ISSUED PURSUANT TO A CANADIAN PURCHASER MAY BEAR THE FOLLOWING LEGEND.]

UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE APRIL 14, 2014.

THESE WARRANTS AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE 1933 ACT OR UNDER ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY NOT BE EXERCISED IN THE UNITED STATES OR BY OR ON BEHALF OF A PERSON IN THE UNITED STATES OR A U.S. PERSON UNLESS AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND ALL APPLICABLE STATE SECURITIES LAWS IS AVAILABLE. THE TERMS “UNITED STATES” AND “U.S. PERSON ARE AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT.

[CERTIFICATES REPRESENTING WARRANTS ISSUED TO U.S. PURCHASERS MUST BEAR THE FOLLOWING LEGEND.]

THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OR CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ 1933 ACT ”), OR UNDER ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF STEM CELL THERAPEUTICS CORP. (THE “ CORPORATION ”) THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT AND IN COMPLIANCE WITH LOCAL LAW, (C) WITHIN THE UNITED STATES IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT PROVIDED BY RULE 144 OR RULE 144A THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS, OR (D) PURSUANT TO ANOTHER EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT AND, IN EACH CASE, IN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AFTER, IN THE CASE OF TRANSFERS PURSUANT TO CLAUSES (C) OR (D) THE SELLER FURNISHES TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING, OR OTHER SUCH EVIDENCE, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE CORPORATION TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE GOOD DELIVERY IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. PROVIDED THAT THE CORPORATION IS A “FOREIGN ISSUER” WITHIN THE MEANING OF REGULATION S AT THE TIME OF SALE, A NEW CERTIFICATE BEARING NO LEGEND DELIVERY OF WHICH WILL CONSTITUTE “GOOD DELIVERY” MAY BE OBTAINED FROM COMPUTERSHARE TRUST COMPANY OF CANADA, AS REGISTRAR AND TRANSFER AGENT, UPON DELIVERY OF THIS CERTIFICATE AND A DULY EXECUTED DECLARATION, IN A FORM REASONABLY SATISFACTORY TO THE CORPORATION, TO THE EFFECT THAT SUCH SALE IS BEING MADE IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT OR IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE 1933 ACT OR ANY APPLICABLE STATE SECURITIES LAWS.


2

[ CUSIP and ISIN for Canadian Purchaser ][ CUSIP: 858572142
ISIN: CA 8585721423 ]

[ CUSIP and ISIN for U.S. Purchaser ] [ CUSIP: 858572886
ISIN: US 8585728863 ]

Certificate No.: ________________________ No. of Warrants: ________________________

WARRANTS
Exercisable to Acquire
Common Shares
of
STEM CELL THERAPEUTICS CORP.

(Continued under the Business Corporations Act (Ontario))

THIS IS TO CERTIFY THAT, for value received, (the “ holder ”) is the registered holder of the number of Warrants of Stem Cell Therapeutics Corp. (“ SCT ”) specified above and, for each whole Warrant held, is thereby entitle to be issued, subject to adjustment and except as otherwise described herein, one fully paid and non-assessable Common Share and subject to the limitation referred to below by surrendering to Computershare Trust Company of Canada (the “ Warrant Agent ”) at its principal transfer office in Toronto, Ontario during the exercise period hereinafter referred to (i) a certified cheque, bank draft or money order made payable to SCT in the amount of the Exercise Price as hereinafter determined in respect of each Common Share to be issued, (ii) this Warrant Certificate and (iii) a notice of exercise in the form set forth in Appendix 1 annexed hereto duly completed and executed.

Capitalized terms which are not otherwise defined herein shall have the same meaning as in the Warrant indenture (which indenture, together with all instruments supplemental or ancillary thereto, is herein referred to as the “ Warrant Indenture ”) dated December 13, 2013 between SCT and the Warrant Agent.


3

Surrender of this Warrant Certificate will be deemed to have been effected only on personal delivery thereof to, or, if sent by mail or other means of transmission, on actual receipt thereof by, the Warrant Agent at the office specified above.

This Warrant Certificate evidences Warrants of SCT issued or issuable under the provisions of the Warrant Indenture. Reference is made to the Warrant Indenture for particulars of the rights of the holders of the Warrants and of SCT and of the Warrant Agent in respect thereof and of the terms and conditions upon which the Warrants are issued and held, all to the same effect as if the provisions of the Warrant Indenture were herein set forth in full, to all of which the holder, by acceptance hereof, assents. To the extent of any inconsistency between the terms of the Warrant Indenture and the terms of this Warrant Certificate, the terms of the Warrant Indenture shall prevail. SCT will furnish to the holder, on request and upon payment of a reasonable charge for photocopying and postage, a copy of the Warrant Indenture.

The Warrants evidenced by this Warrant Certificate may be exercised by the holder (including, if applicable, any agent under any power of attorney granted by such holder) at any time until the Expiry Time.

Except as otherwise expressly provided, all dollar amounts herein are expressed in Canadian dollars.

On and after the date of any exercise of the Warrants evidenced by this Warrant Certificate, the holder will have no rights hereunder except to receive certificates representing the Common Shares thereby issued to him upon delivery of a certified cheque, bank draft or money order payable to SCT in respect of each Common Share to be issued in the amount of $0.28 (the “ Exercise Price ”), this Warrant Certificate and a duly completed notice of exercise as set out in Appendix 1 hereto to the Warrant Agent at its principal office in Toronto, Ontario. After the Expiry Time, all rights under any unexercised Warrant evidenced hereby will wholly cease and terminate and this Warrant Certificate will be void.

SCT will not be obligated to issue any fraction of a Common Share on the exercise of any Warrant. To the extent that a holder of Warrants would otherwise have been entitled to receive, on the exercise of Warrants, a fraction of a Common Share, such right may only be exercised in respect of such fraction in connection with another Warrant or Warrants which in the aggregate entitle the holder to receive a whole number of Common Shares. If a Warrantholder is not able to combine Warrants so as to be entitled to acquire a whole number of Common Shares, the number of Common Shares which such Warrantholder is entitled to receive shall be rounded down to the prior whole number, as applicable.

The Warrant Indenture provides for adjustments to the number of Common Shares issuable and to the Exercise Price in certain events set forth therein.

The Warrant Indenture contains provisions making binding on all holders of Warrants outstanding thereunder resolutions passed at meetings of such holders held in accordance with such provisions and instruments in writing signed by holders of a specified majority of all outstanding Warrants.


4

On presentation at the principal office of the Warrant Agent in Toronto, Ontario, subject to the provisions of the Warrant Indenture and on compliance with the reasonable requirements of the Warrant Agent, one or more Warrant Certificates may be exchanged at no cost to the holder for one or more Warrant Certificates of different denominations evidencing in the aggregate the same number of Warrants as the Warrant Certificate or Warrant Certificates being exchanged. The Warrants evidenced by this Warrant Certificate may only be transferred, upon compliance with the conditions prescribed in the Warrant Indenture, on the register of transfers to be kept at the principal office of the Warrant Agent in Toronto, Ontario by the holder or his executors, administrators or other legal representatives or his or their attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent, and, upon compliance with such requirements and such other reasonable requirements as the Warrant Agent may prescribe, including the completion of a form of transfer as set out in Appendix 2 hereto, such transfer will be duly noted on such register of transfers by the Warrant Agent. Notwithstanding the foregoing, SCT will be entitled, and may direct the Warrant Agent, to refuse to record any transfer of any Warrant on such register if such transfer would constitute a violation of the securities laws of any jurisdiction or require SCT to qualify the Common Shares for distribution in any jurisdiction.

No Common Shares will be issued pursuant to any exercise of any Warrant if the issue of such security would constitute a violation of the securities laws of any applicable jurisdiction.

The holding of this Warrant Certificate will not constitute the holder a shareholder of SCT or entitle such holder to any right or interest in respect thereof except as otherwise provided in the Warrant Indenture.

This Warrant Certificate will not be valid for any purpose until it has been certified by or on behalf of the Warrant Agent for the time being under the Warrant Indenture. Time will be of the essence hereof.

THE WARRANTS REPRESENTED BY THIS CERTIFICATE WILL BE VOID AND OF NO VALUE UNLESS EXERCISED PRIOR TO 5:00 P.M. (TORONTO TIME) ON OR BEFORE DECEMBER 13, 2018.

IN WITNESS WHEREOF SCT has caused this Warrant Certificate to be signed by its officer or other individual duly authorized in that behalf as of

  STEM CELL THERAPEUTICS CORP.
   
   
  Per: ________________________________________________
            Name:
            Title:


5

This Warrant Certificate is one of the Warrant Certificates referred to in the Warrant Indenture within mentioned.

  COMPUTERSHARE TRUST COMPANY OF CANADA
   
   
  Per: ________________________________________________
           Name:
           Title:
   
  Per: ________________________________________________
           Name:
           Title:


1

APPENDIX 1
NOTICE OF EXERCISE

To: STEM CELL THERAPEUTICS CORP.
And To: COMPUTERSHARE TRUST COMPANY OF CANADA

100 University Avenue,
9th Floor
Toronto, Ontario M5J 2Y1

The undersigned holder of the Warrants evidenced by the within Warrant Certificate hereby exercises its right to be issued Common Shares of Stem Cell Therapeutics Corp. (or such other securities or property to which such exercise entitles such holder in lieu thereof or in addition thereto under the provisions of the Warrant Indenture mentioned in such Warrant Certificate) that are issuable upon the exercise of such Warrants, on the terms specified in such Warrant Certificate and Warrant Indenture.

The undersigned hereby irrevocably directs that the said Common Shares be issued, registered and delivered as follows:

        Number of Common Shares and
Name(s) in Full   Address(es)   Number of Warrants (# and #)
         
         
         
         
         
         

(Please print full name in which certificates for Common Shares are to be issued. If any shares are to be issued to a person or persons other than the holder, the holder must pay to the Warrant Agent all exigible transfer taxes or other government charges and sign the Form of Transfer.)

DATED this ________day of ___________________, _______.

     
Witness   Signature of Registered Holder
     
     
    Signature of Registered Holder

Note: The name of the Registered Holder on this Notice of Exercise must be the same as the name appearing on the face page of the Warrant Certificate to which this Notice of Exercise is attached.


2

The undersigned represents, warrants and certifies as follows (one of the following must be checked):

[   ] A. The undersigned holder (i) at the time of exercise of the Warrant is not in the United States; (ii) is not a U.S. Person and is not exercising the Warrant for the account or benefit of a U.S. Person; (iii) was not offered to exercise the Warrant and did not execute or deliver the exercise form for the Warrant in the United States; (iv) did not acquire the Warrant in the United States; and (v) has in all other respects complied with Regulation S of the United States Securities Act of 1933, as amended.

[   ] B. The undersigned holder (i) originally purchased the Warrant on its own behalf or on behalf of a beneficial purchaser (a “ Beneficial Purchaser ”) directly from the Corporation pursuant to the Corporation’s offering of Units and Preferred Units at a time when the holder was and any Beneficial Purchaser was (A) an “accredited investor”, as defined in Rule 501(a) under the U.S. Securities Act (“ Accredited Investor ”) and (B) in the United States or a U.S. Person, or was offered Units in the United States, (ii) is exercising the Warrant solely for its own account or for the account of the Beneficial Purchaser, if any, and not on behalf of any other person, and (iii) is, and the Beneficial Purchaser, if any, is, an Accredited Investor on the date of exercise of the Warrant.

[   ] C. An exemption from registration under the U.S. Securities Act and any applicable state securities law is available, and attached hereto is an opinion of counsel to such effect, it being understood that any opinion of counsel tendered in connection with the exercise of Warrants must be in form and substance satisfactory to Stem Cell Therapeutics Corp.

The undersigned holder understands that (i) unless box A is checked, the certificate representing the Common Shares will bear a legend restricting transfer without registration under the U.S. Securities Act and applicable state securities laws unless an exemption from registration is available, and (ii) Common Shares will not be delivered to an address in the United States unless box B or box C is checked and, if box C is checked, the required opinion of counsel is in form and substance satisfactory to Corporation.

DATED this ______day of_________________, 20__. Signature Guarantee:

The signature on this exercise form must correspond with the name as written upon the face of the certificate(s), in every particular, without alteration or enlargement, or any change whatsoever and must be guaranteed by a Canadian Schedule 1 chartered bank or a member of the Securities Transfer Agents Medallion Program (STAMP), a member of the Stock Exchange Medallion Program (SEMP) or a member of the New York Stock Exchange Inc. Medallion Signature Program (MSP). The guarantor must affix a stamp bearing the actual words “Signature Guaranteed”

[   ] Please check if the Common Share certificates are to be delivered at the office where this Warrant Certificate is surrendered failing which such certificates will be mailed.


3

Certificates will be delivered or mailed as soon as practicable after the due surrender of the Warrant Certificate to which this Appendix is attached.


1

APPENDIX 2
FORM OF TRANSFER

FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers to

Name: ______________________________________________________
  
Address: ____________________________________________________

(such person, the “ Transferee ”) ______________________Warrants of Stem Cell Therapeutics Corp. (the “ Corporation ”) represented by the attached Warrant Certificate and does hereby appoint ___________________________as its attorney with full power of a substitution to transfer the Warrants on the appropriate register of the Warrant Agent.

If the Warrant Certificate contains a legend restricting transfer of the Warrants except in compliance with the United States Securities Act of 1933, as amended (the “ U.S. Securities Act ”), and applicable state securities laws, this Transfer Form must be accompanied by a declaration to the effect that the Warrants are being transferred outside the United States in compliance with Rule 904 of Regulation S under the U.S. Securities Act in the form set forth in the Form of Declaration for Removal of Legend that follows (or as otherwise prescribed by the Corporation).

If the sale evidenced hereby is being made to a U.S. Person (as such term is defined in Regulation S to the U.S. Securities Act, the undersigned, by the execution of this form of transfer, certifies that such sale does not require registration of the Warrants being transferred hereby under the U.S. Securities Act and tenders herewith evidence satisfactory to the Corporation to such effect.

DATED this _________day of ____________________, ________.

      
Witness   Signature of Transferor
     
     
    Signature of Registered Holder

Note: The name of the Transferor on this Form of Transfer must be the same as the name appearing on the face page of the Warrant.


1

SCHEDULE “B”
FORM OF DECLARATION FOR REMOVAL OF LEGEND

to the Warrant Indenture made as of December 13, 2013 between Stem Cell Therapeutics
Corp. and Computershare Trust Company of Canada as Warrant Agent

TO: COMPUTERSHARE TRUST COMPANY OF CANADA as warrant agent for Warrants of Stem Cell Therapeutics Corp. (the “Company”)

The undersigned is the holder of __________________________securities of the Company (the “ Securities ”), evidenced by certificate no(s). ______________________________, which are “restricted securities” (as defined in Rule 144 under the United States Shares Act of 1933 (the “ 1933 Act ”)) and may not be offered or sold by the undersigned unless the Securities are registered under the 1933 Act or the offer and sale is made pursuant to an available registration exemption. The share certificate(s) has (have) a legend (the “ Restrictive Legend ”) referring to the 1933 Act and such resale restrictions.

The undersigned understands that Rule 904 of Regulation S under the 1933 Act contains an exemption for offshore resales of securities notwithstanding that the Securities are “restricted securities”. Accordingly, the undersigned wishes to offer and sell the Securities pursuant to Rule 904 and hereby requests the Company facilitate such offer and sale by removing the Restrictive Legend so that the Securities may be deposited with a registered broker-dealer (the “ Broker ”) in advance of an offer and sale described below.

In order to induce the Company to remove the Restrictive Legend, the undersigned agrees that (i) any sale of the Securities into the public markets while they remain “restricted securities” will be made solely in an “offshore transaction” meeting the requirements of Rule 904, (ii) the Broker will maintain custody of the certificate(s) representing the Securities and (iii) if the undersigned directs the Broker to deliver out such certificate(s) other than pursuant to an “offshore transaction” meeting the requirements of Rule 904, such certificate(s) will first be returned to the Company’s transfer agent for re-imposition of the Restrictive Legend and the undersigned will pay any fee imposed by the transfer agent for performing this service, and the undersigned represents and warrants to the Company, its transfer agent and their agents that:

(1)

the undersigned is not an “affiliate” of the Company (as that term is defined in the 1933 Act);

   
(2)

the offer of the Securities was not made nor will be made to a person in the United States and either (a) at the time the buy order was originated, the buyer was outside the United States, or the undersigned and any person acting on its behalf reasonably believes that the buyer is outside the United States; or (b) the sale of the Securities will be executed in, on or through the facilities of the TSX Venture Exchange or Toronto Stock Exchange or another “designated offshore securities market” (as defined in Rule 902(b) of Regulation S) and neither the undersigned nor any person acting on its behalf will know that the transaction has been pre-arranged with a buyer in the United States;

   
(3)

neither the undersigned nor any affiliate of the undersigned nor any person acting on any of their behalf has engaged or will engage in any “directed selling efforts” (as defined in Rule 902(c) of Regulation S) in connection with the offer and sale of the Securities;

   
(4)

the sale will be bona fide and not for the purpose of “washing off” the Restrictive Legend;

   
(5)

the undersigned does not intend to replace the Securities with fungible unrestricted securities of the Company; and

   
(6)

the contemplated sale is not a transaction, or part of a series of transactions which, although in technical compliance with Regulation S, is part of a plan or scheme to evade the registration provisions of the 1933 Act.



2

The undersigned understands that the Company, its transfer agent and others are relying upon the representations contained in this declaration and agrees their counsel will be entitled to rely upon the representations, warranties and covenants contained in this Certification to the same extent as if it had been addressed to them .

By: ______________________________________________________ Date: ______________________________________________________
                   Signature  
   
   
Name (please print) __________________________________________



Exhibit 4.10

AGENCY AGREEMENT

December 13, 2013

Stem Cell Therapeutics Corp.
96 Skyway Avenue
Toronto, Ontario M9W4Y9

Attention: Dr. Niclas Stiernholm, President & CEO

Dear Sirs:

Re: Private Placement of Units and Preferred Units

Bloom Burton & Co. Inc. (the “ Lead Agent ”) and ROTH Capital Partners, LLC (together with the Lead Agent, the “ Agents ”) understand that Stem Cell Therapeutics Corp. (the “ Corporation ”) proposes to issue at the Closing Time (as hereinafter defined) units of the Corporation (“ Units ”) and series I non-voting convertible first preferred units of the Corporation (“ Preferred Units ”, and together with the Units, the “ Offered Units ”) at a subscription price of Cdn.$0.21 per Offered Unit (the “ Purchase Price ”) for aggregate gross proceeds of between Cdn.$30 million (the “ Minimum Offering ”) and Cdn.$33 million (the “ Maximum Offering ”).

Each Unit is comprised of one common share of the Corporation (a “ Unit Share ”) and three-quarters of one common share purchase warrant (each whole warrant, a “ Warrant ”). Each Warrant will entitle the holder thereof to subscribe for one common share of the Corporation (a “ Warrant Common Share ”) at an exercise price of Cdn.$0.28 per Warrant Common Share (the “ Exercise Price ”) during the period ending five years after the Closing Date (as hereinafter defined).

Each Preferred Unit is comprised of one series I non-voting convertible first preferred share of the Corporation (a “ Preferred Unit Share ”) and three-quarters of one Warrant. Each Preferred Unit Share will be convertible at the option of the holder into one common share of the Corporation (a “ Preferred Unit Common Share ”).

The Warrants shall be created and issued pursuant to a warrant indenture (the “ Warrant Indenture ”) to be dated as of the Closing Date between Computershare Trust Company of Canada (the “ Warrant Agent ”) and the Corporation.

The Offered Units, together with the underlying Unit Shares and Preferred Unit Shares, the underlying Warrants, the Warrant Common Shares and the Preferred Unit Common Shares are collectively referred to as the “ Offered Securities ”.

Subject to the terms and conditions described herein, the Corporation hereby appoints the Agents as the sole and exclusive agents of the Corporation to solicit, on a commercially reasonable best-efforts basis, orders for the Offered Units from Purchasers (as hereinafter defined) resident in the Offering Jurisdictions (as hereinafter defined) in compliance with all applicable securities laws. The Agents shall effect the offering of the Offered Units in a manner which does not require the Corporation to deliver an offering memorandum to Purchasers and in a manner exempt from the prospectus requirements of the Securities Laws (as hereinafter defined) of the Offering Jurisdictions. The Agents may, but shall not be under any obligation to, purchase any of the Offered Units.


- 2 -

The terms and conditions of this Agreement are as follows:

Section 1. Definitions, Interpretation, Appendices and Schedules

1.1

Definitions : Where used in this Agreement, the following terms will have the following meanings, respectively:

     
1.1.1

1933 Act ” means the U.S. Securities Act of 1933, as amended;

     
1.1.2

1934 Act ” means the U.S. Securities Exchange Act of 1934, as amended;

     
1.1.3

Accredited Investor ” means an “accredited investor” that satisfies one or more of the criteria set forth in Rule 501(a) of Regulation D under the 1933 Act, as amended by the Dodd-Frank Wall Street Reform and Consumer Protection Act;

     
1.1.4

affiliate ” or “ associate ” when used to indicate a relationship with a person or company, has the same meaning ascribed thereto in the Ontario Act as if the word “company” was therein changed to “person”;

     
1.1.5

Agents ” has the meaning given to it above;

     
1.1.6

Agents’ Fee ” has the meaning given to it in Section 8.1 ;

     
1.1.7

Agreement ” means the agreement resulting from the acceptance by the Corporation of the offer made by the Agents by this letter, including all appendices and schedules to this letter and all amendments to and restatements of this letter;

     
1.1.8

Ancillary Documents ” means the Subscription Agreements, the Warrant Indenture and the certificates representing the Compensation Options and where applicable, the Offered Securities;

     
1.1.9

Auditor ” means Ernst & Young LLP, Chartered Accountants, the auditor of the Corporation;

     
1.1.10

Bad Actor Disqualification ” means any disqualification set forth in Rule 506(d) of Regulation D;

     
1.1.11

Business ” means the business of stem cell-based therapeutics through partnerships with research institutions and technology transfer organizations. The Corporation’s objectives include the sourcing and acquisition of stem cell-related development opportunities, and securing capital for the advancement of its licensed or acquired products to be carried on by the Corporation and its Subsidiaries after the Closing Date;



- 3 -

  1.1.12

Business Day ” means a day other than a Saturday, a Sunday or a day on which chartered banks are not open for business in Toronto, Ontario;

     
  1.1.13

CDS ” means CDS Clearing and Depository Services Inc.;

     
  1.1.14

Closing ” means the completion of the issue and sale by the Corporation of the Offered Units on the Closing Date pursuant to this Agreement;

     
  1.1.15

Closing Date ” means December 13, 2013 or such other date as the Corporation and the Agents may mutually agree upon;

     
  1.1.16

Closing Time ” means 9:00 a.m. (Toronto time) on the Closing Date or such other time on the Closing Date as the Corporation and the Agents may mutually agree upon;

     
  1.1.17

Code ” is defined in Section 4.4.5 ;

     
  1.1.18

Common Shares ” means the common shares in the capital of the Corporation;

     
  1.1.19

Compensation Option ” and “ Compensation Option Share ” have the respective meanings given to them in Section 8.2 ;

     
  1.1.20

Compensation Option Securities ” means Compensation Options and Compensation Option Shares, collectively;

     
  1.1.21

Corporation ” has the meaning given to it above, and includes any successor corporation thereto;

     
  1.1.22

Directed Selling Efforts ” means directed selling efforts as that term is defined in Rule 902(c) of Regulation S. Without limiting the foregoing, but for greater clarity in this Agreement, it means, subject to the exclusions from the definition of directed selling efforts contained in Regulation S, any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for the Offered Securities and includes the placement of any advertisement in a publication “with a general circulation in the United States” (as defined in Rule 902(c)(2) of Regulation S) that refers to the offering of the Offered Securities;

     
  1.1.23

Engagement Letter ” means the engagement letter dated October 16, 2013 relating to the Offering between the Corporation and the Lead Agent;

     
  1.1.24

Environmental Laws ” is defined in Section 9.1.51 ;

     
  1.1.25

Exempt List ” means the list of Purchasers described in Schedule C to the Engagement Letter;



- 4 -

  1.1.26

Exercise Price ” has the meaning given to it above;

     
  1.1.27

Financial Statements ” means, collectively: (a) the audited comparative financial statements of the Corporation as at and for the years ended December 31, 2012 and 2011, together with the notes thereto, the auditor’s report thereon and management’s discussion and analysis in relation thereto; (b) the unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2013 and 2012, together with the notes thereto and management’s discussion and analysis in relation thereto; and (c) the financial statements of Trillium Therapeutics Inc. included or referenced in the business acquisition report of the Corporation dated June 21, 2013.

     
  1.1.28

Foreign Issuer ” means a foreign issuer as that term is defined in Rule 902(e) of Regulation S. Without limiting the foregoing, but for greater clarity it means any issuer which is (a) the government of any foreign country or of any political subdivision of a foreign country; or (b) a corporation or other organization incorporated under the laws of any foreign country, except an issuer meeting the following conditions as of the last business day of its most recently completed second fiscal quarter: (1) more than 50 percent of the outstanding voting securities of such issuer are directly or indirectly owned of record by residents of the United States; and (2) any of the following; (i) the majority of the executive officers or directors are United States citizens or residents, (ii) more than 50 percent of the assets of the issuer are located in the United States, or (iii) the business of the issuer is administered principally in the United States;

     
  1.1.29

General Solicitation ” and “ General Advertising ” means “general solicitation” and “general advertising”, respectively, as used in Rule 502(c) of Regulation D, including, without limitation, advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or broadcast over television, radio or the Internet, or any seminar or meeting whose attendees had been invited by general solicitation or general advertising;

     
  1.1.30

Information Record ” means all information filed by the Corporation on the System for Electronic Document Analysis and Retrieval, commonly known as SEDAR, during the period commencing January 1, 2012 to the date of Closing, together with all written information, if any, prepared by the Corporation and provided to the Lead Agent in connection with the Offering;

     
  1.1.31

Intellectual Property ” means, collectively, all intellectual property rights of whatsoever nature, kind or description, including all: (i) trademarks, service marks, trade-mark and service mark registrations, trade-mark and service mark applications, rights under registered user agreements, trade names and other trade- mark and service mark rights, including associated good will; (ii) copyrights and applications therefor, including all computer software and rights related thereto and any associated waivers of moral rights; (iii) all foreign and domestic patents and patent applications (including all provisional, divisional, substitution, continuation and continuation in-part applications, and all foreign counterparts thereof) and all foreign and domestic patents (including extensions, reissues, reexaminations, renewals, inventors certificates and foreign counterparts thereof); (iv) preclinical and clinical data and results, (v) trade secrets and proprietary and confidential information; (vi) industrial designs and registrations thereof and applications therefor; (vii) renewals, modifications, developments and extensions of any of the items listed in clauses (i) through (vi) above; and (viii) patterns, plans, designs, research data, other proprietary know-how, processes, drawings, technology, inventions, formulae, specifications, performance data, quality control information, unpatented blue prints, flow sheets, equipment and parts lists, instructions, manuals, records and procedures, and all licenses, agreements and other contracts and commitments relating to any of the foregoing;



- 5 -

  1.1.32

Knowledge of the Corporation ” means information to the best of the knowledge, after due inquiry, of the following individuals: James Parsons and Niclas Stiernholm, in each case in their respective capacities as officers and/or directors of the Corporation;

     
  1.1.33

Lead Agent ” has the meaning given to it above;

     
  1.1.34

lien ” means any mortgage, charge, pledge, prior claim, security interest, assignment lien (statutory or otherwise), charge, title retention agreement or arrangement, restrictive covenant or other encumbrance of any nature, including any arrangement or condition which, in substance, secures payment or performance of an obligation;

     
  1.1.35

Material Adverse Effect ” or “ Material Adverse Change ” means any effect or change in the affairs of the Corporation, its Subsidiaries or the Business, taken as a whole, that is or is reasonably likely to be materially adverse to the results of operations, financial condition, assets, properties, capital, liabilities (contingent or otherwise), obligations, cash flow, income, affairs, business operations or prospects of the Corporation and its Subsidiaries or the Business, taken as a whole and as a going concern, or that is materially adverse to the completion of the transactions contemplated by this Agreement, taken as a whole;

     
  1.1.36

Material IP ” is defined in Section 9.1.52 ;

     
  1.1.37

Maximum Offering ” ” has the meaning given to it above;

     
  1.1.38

Minimum Offering ” ” has the meaning given to it above;

     
  1.1.39

Offered Securities ” has the meaning given to it above;

     
  1.1.40

Offered Units ” has the meaning given to it above;

     
  1.1.41

Offering ” means the offering of the Offered Securities on a “private placement” basis and pursuant to the terms of this Agreement;



- 6 -

  1.1.42

Offering Jurisdictions ” means the Provinces of Ontario and Alberta and the United States;

     
  1.1.43

Offshore Transaction ” means an “offshore transaction” as that term is defined in Rule 902(h) of Regulation S;

     
  1.1.44

Ontario Act ” means the Securities Act (Ontario) and the regulations thereunder, together with the instruments, policies, rules, orders, codes, notices and interpretation notes of the Ontario Securities Commission, as amended, supplemented or replaced from time to time;

     
  1.1.45

Non-U.S. Subscription Agreement ” means the form of subscription agreement for persons offered or purchasing Offered Units outside of the United States;

     
  1.1.46

person ” means any individual, partnership, limited partnership, limited liability company, joint venture, syndicate, sole proprietorship, company or corporation with or without share capital, unincorporated association, trust, trustee, executor, administrator or other legal personal representative, regulatory body or agency, government or governmental agency, authority or any other entity however designated or constituted;

     
  1.1.47

Preferred Shares ” means the series I non-voting convertible first preferred shares in the capital of the Corporation;

     
  1.1.48

Preferred Units ” has the meaning given to it above;

     
  1.1.49

Preferred Unit Common Share ” has the meaning given to it above;

     
  1.1.50

Preferred Unit Share ” has the meaning given to it above;

     
  1.1.51

Purchase Price ” has the meaning given to it above;

     
  1.1.52

Purchasers ” means the purchasers of the Offered Units, collectively;

     
  1.1.53

QEF Election ” is defined in Section 4.4.5 ;

     
  1.1.54

Regulation D ” means Regulation D under the 1933 Act;

     
  1.1.55

Regulation D Securities ” is defined in Section 4.3.4 ;

     
  1.1.56

Regulation S ” means Regulation S under the 1933 Act;

     
  1.1.57

Related Person ” means (i) with respect to the Corporation, any predecessor of the Corporation, any affiliated issuer, any director, executive officer, other officer of the Corporation participating in the offering of the Offered Units, any general partner or managing member of the Corporation, any beneficial owner of 20% or more of the Corporation’s outstanding voting equity securities, calculated on the basis of voting power, any “promoter” (as defined in Rule 405 under the 1933 Act) connected with the Corporation in any capacity, and (ii) with respect to an Agent and any member of the Selling Dealer Group, any person associated with that Agent or any member of the Selling Dealer Group, as applicable, that has been or will be paid (directly or indirectly) remuneration for solicitation of Purchasers in connection with the sale of the Offered Units; any general partner or managing member of any such solicitor; or any director, executive officer or other officer participating in the offering of the Offered Units of any such solicitor or general partner or managing member of such solicitor;



- 7 -

  1.1.58

Reporting Jurisdictions ” means the Provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia, collectively;

     
  1.1.59

Rights Plan ” means the rights agreement dated as of September 16, 2013 between the Corporation and Computershare Trust Company of Canada, as such agreement may be amended, restated, supplemented and/or replaced from time to time;

     
  1.1.60

Rule 144A ” means Rule 144A under the 1933 Act;

     
  1.1.61

SEC ” means the United States Securities and Exchange Commission;

     
  1.1.62

Securities Commissions ” means the securities regulatory authorities of the Offering Jurisdictions or Reporting Jurisdictions collectively, as the case may be, including, without limitation, the SEC;

     
  1.1.63

Securities Laws ” means the securities legislation and regulations of, and the instruments, policies, rules, orders, codes, notices and interpretation notes of the securities regulatory authorities (including the Stock Exchange) of, the applicable jurisdiction or jurisdictions collectively;

     
  1.1.64

Selling Dealer Group ” means the dealers and brokers other than the Agents who participate in the offer and sale of the Offered Units pursuant to this Agreement;

     
  1.1.65

Stock Exchange ” means the TSX Venture Exchange;

     
  1.1.66

Subscription Agreements ” means the Non-U.S. Subscription Agreement or the U.S. Subscription Agreement to be entered into between the Corporation and each Purchaser, as applicable, with respect to the purchase of the Offered Units, collectively;

     
  1.1.67

Subsidiaries ” means Stem Cell Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, and Trillium Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, collectively;

     
  1.1.68

Substantial U.S. Market Interest ” means “substantial U.S. market interest” as that term is defined in Rule 902(j) of Regulation S;



- 8 -

1.1.69

Transfer Agent ” means Computershare Trust Company of Canada as duly appointed as the transfer agent and registrar for the Common Shares of the Corporation;

     
1.1.70

United States ” means the United States of America, its territories and possessions, any state of the United States and the District of Columbia;

     
1.1.71

Units ” has the meaning given to it above;

     
1.1.72

Unit Shares ” has the meaning given to it above;

     
1.1.73

U.S. Affiliate ” means the Agent, if it is a United States registered broker-dealer, or if the Agent is not a United States registered broker-dealer, then it means the United States registered broker-dealer affiliate of the Agent, if any;

     
1.1.74

U.S. Person ” means a U.S. person as defined in Rule 902(k) of Regulation S under the 1933 Act;

     
1.1.75

U.S. Securities Laws ” means all applicable securities legislation in the United States, including without limitation, the 1933 Act, the 1934 Act and the rules and regulations promulgated thereunder, and any applicable state securities laws;

     
1.1.76

U.S. Subscription Agreement ” means the form of subscription agreement for persons offered or purchasing Offered Units that are in the United States or U.S. Persons, or purchasing for the account or benefit of persons in the United States or U.S. Persons;

     
1.1.77

Warrant ” has the meaning given to it above;

     
1.1.78

Warrant Agent ” has the meaning given to it above;

     
1.1.79

Warrant Common Share ” has the meaning given to it above; and

     
1.1.80

Warrant Indenture ” has the meaning given to it above.

     
1.2

Other Defined Terms : Whenever used in this Agreement, the words and terms “distribution”, “material fact”, “material change”, “misrepresentation”, “officer” and “subsidiary” shall have the meaning given to such word or term in the Ontario Act unless specifically provided otherwise herein.

     
1.3

Plural and Gender : Whenever used in this Agreement, words importing the singular number only shall include the plural and vice versa and words importing the masculine gender shall include the feminine gender and neuter. Every use of the words “including” or “includes” in this Agreement is to be construed as meaning “including, without limitation” or “includes, without limitation”, respectively.

     
1.4

Reference and Headings : The words “Agreement”, “hereof”, “herein”, “hereunder”, “hereto” and similar phrases mean and refer to this Agreement. The division of this Agreement into Sections and the insertion of headings is for convenience of reference only and shall not affect the construction or interpretation hereof. Any reference in this Agreement to a Section will refer to a section of this Agreement.



- 9 -

1.5

Currency : All references to monetary amounts in this Agreement are to lawful money of Canada.

   
1.6

Appendices and Schedules : The following appendices and schedules are attached to this Agreement and are deemed to be a part of and incorporated in this Agreement:


  Appendix Title
  A Form of U.S. Certificate
  B Form of Opinion of Corporation’s Canadian Counsel
  C Form of Officers’ Certificate
     
  Schedule Title
  9.1.5 Securities Convertible into Common Shares

Section 2. The Offering

2.1

Offered Units : The Offering is for Offered Units to raise gross proceeds in an amount in excess of the Minimum Offering and equal to or less than the Maximum Offering.


Section 3. The Agents

3.1

Sale on Exempt Basis : Each Agent shall offer for sale and sell the Offered Units in the Offering Jurisdictions in which it is so registered to do under applicable Securities Laws and, subject to applicable law, outside Canada and the United States in compliance with Securities Laws and only to such persons and in such manner so that, pursuant to the provisions of the Securities Laws of the Offering Jurisdictions, no prospectus, offering memorandum, registration statement or other similar document need be filed with, or delivered to, any Securities Commission or other similar regulatory authority in connection therewith.

   
3.2

Selling Dealer Group : The Corporation agrees that, subject to the prior consent of the Corporation, such consent not to be unreasonably withheld, the Agents have the right to invite one or more registered securities dealers to form a Selling Dealer Group to participate in finding purchasers for the Offered Units. The Agents shall have the exclusive responsibility for, and the right to control, all compensation arrangements with the members of the Selling Dealer Group and the Corporation shall have no obligation whatsoever to compensate the Selling Dealer Group members. The Corporation grants all of the rights and benefits of this Agreement to any securities dealer who is a member of any Selling Dealer Group formed by the Agents and appoints the Agents as trustees of such rights and benefits for all such securities dealers, and the Agents hereby accept such trust and agree to hold such rights and benefits for and on behalf of all such securities dealers. The Agents shall ensure that any securities dealer who is a member of any Selling Dealer Group formed by the Agents pursuant to the provisions of this Section 3.2 or with whom an Agent has a contractual relationship with respect to the Offering, if any, agrees with that Agent to comply with the covenants and obligations of that Agent herein.



- 10 -

3.3

Covenants, Representations and Warranties of the Agents : Each Agent covenants with the Corporation that it (a) will comply with the Securities Laws of the Offering Jurisdictions in which it solicits or procures subscriptions for Offered Units in connection with the Offering, (b) will not solicit or procure subscriptions for Offered Units so as to require that any prospectus, offering memorandum, registration statement or other similar document to be filed with, or delivered to, any Securities Commission or other similar regulatory authority in connection therewith, (c) will obtain from each Purchaser an executed Subscription Agreement in a form acceptable to the Corporation and the Agents, acting reasonably, (d) is acquiring any securities of the Corporation which it is entitled to receive hereunder as principal and an “accredited investor” as defined in National Instrument 45-106 of the Canadian Securities Administrators; (e) and any of its Related Persons is not subject to any Bad Actor Disqualification; and (f) has complied with the disclosure requirements of Rule 506(e) of Regulation D, to the extent applicable. Each Agent represents and warrants to the Corporation that it is, and, to the best of its knowledge, the members invited by it to any Selling Dealer Group are, qualified to so act in the Offering Jurisdictions that it, or such members, solicited or procured subscriptions for the Offered Units and that it, and to the best of its knowledge after due inquiry, each member invited by it to any such Selling Dealer Group, is registered under the Ontario Act, if applicable, and is registered or exempt from registration under the Securities Laws of any jurisdiction in which it solicited or procured subscriptions, as applicable, as a dealer in an appropriate category. Notwithstanding any other provision of this Agreement, the parties agree that the Agents’ acknowledgments, covenants, representations, warranties, rights and obligations under this Agreement are several and not joint and several.

   
3.4

Filings : The Corporation undertakes to file or cause to be filed all forms and undertakings required to be filed by the Corporation in connection with the Offering so that the distribution of the Offered Units may lawfully occur in the Offering Jurisdictions without the necessity of filing a prospectus, an offering memorandum, registration statement or other similar document with, or delivered to, any Securities Commission or other regulatory authority in connection therewith, and each Agent undertakes to use its commercially-reasonable efforts to cause the Purchasers of the Offered Units to complete (and it shall be a condition of closing in favour of the Corporation that the Purchasers complete and deliver to the Corporation) any forms and undertakings required by the Securities Laws of the Offering Jurisdictions or by the Stock Exchange. All fees payable in connection with such filings shall be at the expense of the Corporation.

   
3.5

No Offering Memorandum : Neither the Corporation nor any Agent shall (g) provide to prospective purchasers of Offered Units any document or other material that would constitute an offering memorandum or prospectus within the meaning of the Securities Laws of the Offering Jurisdictions or (h) engage in any form of general solicitation or general advertising in connection with the offer and sale of the Offered Units, including, causing the sale of the Offered Units to be advertised in any newspaper, magazine, printed public media, printed media or similar medium of general and regular paid circulation, broadcast over radio, television or telecommunications, including electronic display or the internet, or otherwise, or conduct any seminar or meeting relating to any offer and sale of the Offered Units whose attendees have been invited by a general solicitation or general advertising.



- 11 -

Section 4. United States Offers and Sales

4.1

Each Agent agrees that it will not offer or sell any of the Offered Units within the United States or to, or for the account or benefit of, any person in the United States or a U.S. Person except, if applicable, for offers and sales of the Offered Units in the United States or to, or for the account or benefit of, any person in the United States or a U.S. Person in accordance with this Section 4 .

     
4.2

Defined Terms : For the purposes of this Section 4 and Appendix A only, “affiliate” means “affiliate” as that term is defined in Rule 405 under the 1933 Act.

     
4.3

Acknowledgments, Representations, Warranties and Covenants of the Agents : Each Agent acknowledges, represents, warrants and covenants to the Corporation that:

     
4.3.1

the Offered Securities have not been and will not be registered under the 1933 Act or under any applicable securities laws of any state of the United States;

     
4.3.2

it has not offered or sold, and will not offer or sell, any of the Offered Units except (A) in accordance with this Section 4 , or (B) outside the United States in Offshore Transactions in compliance with Rule 903 of Regulation S. Accordingly, except in connection with offers and sales as described in this Section 4 or as permitted by Rule 903 of Regulation S, it has not made and will not make (i) any offer to sell Offered Units to or solicitation of an offer to buy Offered Units from a person in the United States or a U.S. Person, or a person acting for the account or benefit of a person in the United States or a U.S. Person, or (ii) any sale of Offered Units to any other purchaser unless at the time the purchaser’s buy order was or will be originated, the purchaser was outside the United States or it and its affiliates reasonably believed that the purchaser was outside the United States;

     
4.3.3

neither it nor any of its affiliates, nor any persons acting on its or their behalf, have engaged or will engage in any Directed Selling Efforts with respect to the Offered Units offered and sold pursuant to Rule 903 of Regulation S;

     
4.3.4

neither it, nor its U.S. Affiliates, nor any member of the Selling Dealer Group participating in the offering of the Offered Units to be offered and sold hereunder in reliance on Rule 506(b) of Regulation D (the “ Regulation D Securities ”) nor any Related Person of the foregoing is subject to any Bad Actor Disqualification;

     
4.3.5

it has complied with the disclosure requirements of Rule 506(e) of Regulation D, to the extent applicable;

     
4.3.6

neither it, nor its U.S. Affiliates, nor any member of the Selling Dealer Group participating in the offering of the Offered Units to be offered and sold in reliance on Rule 506(b) has paid or will pay, nor is it aware of any person that has paid or will pay, directly or indirectly, any remuneration to any person (other than the Agents and their respective U.S. Affiliates) for solicitation of purchasers of Regulation D Securities;



- 12 -

  4.3.7

it has not entered and will not enter into any contractual arrangement with respect to the distribution of the Offered Units, except with any Selling Dealer Group members or with the prior written consent of the Corporation;

     
  4.3.8

it shall require each Selling Dealer Group member to agree, for the benefit of the Corporation, to comply with, and shall use its best efforts to ensure that each Selling Dealer Group member complies with, the applicable provisions of this Section 4 as if such provisions applied to such Selling Dealer Group member;

     
  4.3.9

all offers and sales of the Offered Units in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person have been and will be effected through one or more of the U.S. Affiliates in accordance with all applicable U.S. broker-dealer requirements (or in the case of a foreign broker or dealer relying on Rule 15a-6 of the 1934 Act, by that foreign broker or dealer in accordance with all applicable requirements of Rule 15a-6 of the 1934 Act);

     
  4.3.10

each U.S. Affiliate is and on the date of each offer and sale of Offered Units in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person was and will be duly registered as a broker-dealer pursuant to Section 15(b) of the 1934 Act and under the laws of each state in which such offer or sale is made (unless exempted from the respective state’s broker-dealer registration requirements), and is a member of, and in good standing with, the Financial Industry Regulatory Authority, Inc.;

     
  4.3.11

it will not, either directly or through a U.S. Affiliate, solicit offers for, or offer to sell, the Offered Units in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person, nor has it done so, by means of any form of General Solicitation or General Advertising or in any manner involving a public offering within the meaning of Section 4(a)(2) of the 1933 Act;

     
  4.3.12

it will solicit, and will cause each U.S. Affiliate to solicit, offers for the Offered Units from persons in the United States or U.S. Persons, or persons acting for the account or benefit of a person in the United States or a U.S. Person only if it has reasonably grounds to believe and reasonably believes such persons to be Accredited Investors;

     
  4.3.13

it will offer, and will cause each U.S. Affiliate to offer the Offered Units to persons in the United States or U.S. Persons, or persons acting for the account or benefit of a person in the United States or a U.S. Person only if it has reasonable grounds to believe and reasonably believes such persons to be Accredited Investors;



- 13 -

4.3.14

it will inform, or cause each U.S. Affiliate to inform, all purchasers of the Offered Units that are in the United States or U.S. Persons, or purchasers acting for the account or benefit of a person in the United States or a U.S. Person that the Offered Securities have not been and will not be registered under the 1933 Act or any applicable securities laws of any state of the United States and are being sold to them without registration under the 1933 Act in reliance on an exemption from the registration requirements of the U.S. Securities Act provided by Rule 506(b) of Regulation D, as applicable, and in accordance with exemptions from any applicable securities laws of any state of the United States;

     
4.3.15

prior to completion of any sale of Offered Units in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person, each such purchaser thereof will be required to execute a U.S. Subscription Agreement;

     
4.3.16

it has not provided any written material other than a U.S. Subscription Agreement to each person in the United States or U.S. Person to which it has offered the Offered Units;

     
4.3.17

neither it nor its U.S. Affiliates nor any person acting on their behalf has engaged or will engage in any violation of Regulation M under the 1934 Act in connection with its offers or sales of the Offered Units in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person;

     
4.3.18

it shall cause each U.S. Affiliate to agree, for the benefit of the Corporation, to the same provisions as are contained in this Section 4.3 ;

     
4.3.19

at least one (1) Business Day prior to each closing, it shall cause each U.S. Affiliate to provide the Corporation with a list of all purchasers of the Offered Units that are in the United States or U.S. Persons, or acting for the account or benefit of a person in the United States or a U.S. Person;

     
4.3.20

it and its U.S. Affiliates acknowledge that until 40 days after the commencement of the Offering, an offer or sale of Offered Securities within the United States by any dealer (whether or not participating in the Offering) may violate the registration requirements of the 1933 Act if such offer or sale is made otherwise than in accordance with an exemption from the registration requirements of the 1933 Act; and

     
4.3.21

at Closing, it and, if applicable, its U.S. Affiliates will either (i) provide a certificate, substantially in the form of Appendix A to this Agreement, or (ii) be deemed to have represented and warranted to the Corporation as of the Closing Time that neither it nor they offered or sold any Offered Units in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person.

     
4.4

Representations, Warranties and Covenants of the Corporation : The Corporation represents, warrants and covenants to the Agents that:



- 14 -

  4.4.1

it is, and at Closing will be, a Foreign Issuer and it reasonably believes that there is no Substantial U.S. Market Interest in any Offered Securities;

     
  4.4.2

it is not, and after giving effect to the offering and sale of the Offered Units and the application of the proceeds thereof as described herein, will not be registered or required to register as an “investment company” pursuant to the provisions of the United States Investment Company Act of 1940, as amended;

     
  4.4.3

neither it, nor any of its Related Persons are subject to a Bad Actor Disqualification;

     
  4.4.4

it has complied with the disclosure requirements of Rule 506(e) of Regulation D, to the extent applicable;

     
  4.4.5

if the Corporation is a “passive foreign investment company” within the meaning of section 1297(a) of the Internal Revenue Code of 1986, as amended (the “ Code ”), during any calendar year following the purchase of the Offered Units by an Accredited Investor, the Corporation will make available to the U.S. purchaser, upon written request, after the end of such year, within a commercially reasonable time period after such written request, all information that would be required for income tax reporting purposes by a United States shareholder making an election to treat the Corporation as a “qualified electing fund” (the “ QEF Election ”) for the purposes of section 1295 of the Code and a “PFIC Annual Information Statement” as described in Treasury Regulation section 1.1295(1)(g)(1) (or any successor regulation). With regard to the PFIC Annual Information Statement, the Corporation shall calculate and report the amount and category of each type of long term capital gain as provided in section 1(h) of the Code that was recognized by the Corporation. Upon written request, the Corporation shall also use commercially reasonable efforts to make available as promptly as reasonably possible any other information that a U.S. purchaser is required to obtain in connection with maintaining such QEF Election with regard to the Corporation;

     
  4.4.6

none of it, its affiliates or any person acting on its or their behalf (other than the Agents, their respective affiliates or any person acting on their behalf, in respect of which no representation, warranty or covenant is made) has offered or will offer to sell the Offered Units in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person by means of any form of General Solicitation or General Advertising or has made or will make offers and sales of the Offered Units in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person in any manner involving a public offering within the meaning of Section 4(a)(2) of the 1933 Act;

     
  4.4.7

none of it, its affiliates or any person acting on its or their behalf (other than the Agents, their respective affiliates or any person acting on their behalf, in respect of which no representation, warranty or covenant is made) has engaged or will engage in any Directed Selling Efforts with respect to any of the Offered Securities or has taken any action in a manner involving a public offering within the meaning of Section 4(a)(2) of the 1933 Act with respect to the Offered Securities that were offered or sold in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person,, or has taken or will take any action that would cause the exemption from the registration requirements of the 1933 Act afforded by Rule 506 of Regulation D or the exclusion from registration requirements afforded by Regulation S to be unavailable for offers and sales of the Offered Securities pursuant to this Agreement;



- 15 -

  4.4.8

none of the Corporation, its affiliates or any persons acting on its or their behalf (other than the Agents, their respective affiliates or any person acting on their behalf, in respect of which no representation, warranty or covenant is made) (i) has offered or sold or will offer or sell the Offered Units except through the Agents and any U.S. Affiliates in compliance with this Section 4 , or (ii) has taken or will take any action that would cause the exemptions or exclusions from registration provided by Rule 903 of Regulation S or Rule 506 of Regulation D to be unavailable with respect to offers and sales of the Offered Units pursuant to this Section 4 ;

     
  4.4.9

if required by the Transfer Agent or Warrant Agent, subject to applicable law, the Corporation will use its commercially reasonable efforts to deliver an opinion, memorandum or such other document as may be required to permit the removal of resale restrictions in connection with the resale of any Offered Units in reliance on Rule 904 of Regulation S subject to delivery of customary declarations by the investors and, if applicable, their respective broker-dealers satisfactory to the Corporation;

     
  4.4.10

neither the Corporation nor any of its predecessors or affiliates has been subject to any order, judgment or decree of any court of competent jurisdiction temporarily, preliminarily, or permanently enjoining such person for failure to comply with applicable Securities Laws;

     
  4.4.11

neither the Corporation nor any person acting on its behalf has sold, offered for sale or solicited any offer to buy, and will not sell, offer for sale or solicit any offer to buy, any of its securities in the United States or to, or for the account or benefit of, a person in the United States or a U.S. Person in a manner that would be integrated with the offer and sale of the Offered Securities and would cause the exemptions from registration set forth in Rule 506(b) of Regulation D to become unavailable with respect to offers and sales of the Offered Securities contemplated hereby; and

     
  4.4.12

neither the Corporation nor any person acting on its behalf has engaged or will engage in any general solicitation or general advertising (within the meaning of Rule 502(c) of Regulation D) in connection with any offer or sale of its securities in reliance upon Rule 506(c) of Regulation D or otherwise in a manner that would be integrated with the offer and sale of the Offered Securities and would cause the exemption from registration set forth in Rule 506(b) of Regulation D to become unavailable with respect to the offer and sale of the Offered Securities.



- 16 -

Section 5. Due Diligence

The Corporation shall allow the Agents to conduct all due diligence investigations, including meeting with senior management of the Corporation and the Auditor, as the Agents shall consider appropriate in connection with the Offering.

Section 6. Deliveries by Closing Time

By the Closing Time:

6.1

all actions required to be taken by or on behalf of the Corporation including, the filing of articles of amendment creating the Preferred Shares, the passing of all required resolutions of the directors, including committees of the directors, and shareholders of the Corporation, shall have occurred in order to complete the transactions contemplated by this Agreement and the Ancillary Documents, including to create, if applicable, and issue the Preferred Unit Shares, the Unit Shares, the Warrants and the Compensation Options, and to allot and reserve for issuance the Preferred Unit Common Shares, the Warrant Common Shares and the Compensation Option Shares, and a certified copy of all such resolutions shall have been delivered by the Corporation to the Agents;

     
6.2

the Corporation shall have delivered or caused to be delivered to the Agents:

     
6.2.1

a favourable legal opinion dated the Closing Date of corporate counsel to the Corporation, substantially in the form set out in Appendix B . In connection with this opinion, corporate counsel to the Corporation may rely on the opinions of local counsel, dated the Closing Date and in form and substance reasonably satisfactory to the Agents and their counsel (signed copies of which shall be addressed to and delivered to the Agents and their counsel) with respect to those matters governed by laws other than those of British Columbia, Alberta and Ontario or the federal laws of Canada;

     
6.2.2

favourable legal opinions from intellectual property counsel to the Corporation dated as of the Closing Date, which shall cover, among other things, matters relating to the Material IP, addressed to the Agents and their counsel, in form and content to the satisfaction of their counsel, acting reasonably;

     
6.2.3

if any of the Offered Units are sold in the United States, receipt by the Agents of an opinion of U.S. counsel to the Corporation, dated the Closing Date, to the effect that no registration is required under the 1933 Act of, the Offered Units, Preferred Unit Shares or Unit Shares sold in the United States in accordance with this Agreement;

     
6.2.4

a certificate dated the Closing Date signed by an appropriate officer of the Corporation and addressed to the Agents and their counsel with respect to the articles and by-laws of the Corporation, the resolutions of the directors relating to this Agreement and the Ancillary Documents and with respect to such other matters as the Agents may reasonably request and including specimen signatures of the signing officers of the Corporation;



- 17 -

6.2.5

a certificate dated the Closing Date addressed to the Agents and their counsel signed by the chief executive officer and the chief financial officer of the Corporation or any two (2) other officers of the Corporation acceptable to the Agents substantially in the form set out in Appendix C ;

     
6.2.6

a fully executed copy of the Warrant Indenture;

     
6.2.7

counterparts to the Subscription Agreements; and

     
6.2.8

such further documents as may be contemplated by this Agreement or as the Agent may reasonably require,

     

all in form and substance satisfactory to the Agents; and

     
6.3

the Agents shall have delivered or caused to be delivered to the Corporation:

     
6.3.1

executed copies of the Subscription Agreements; and

     
6.3.2

such further documents as may be contemplated by this Agreement or as the Corporation may reasonably require,

all in form and substance satisfactory to the Corporation.

Section 7. Closing

7.1

Closing : The Closing shall be completed at the offices of Borden Ladner Gervais LLP, 40 King Street West, 44th floor, Toronto, Ontario M5H 3Y4 at the Closing Time on the Closing Date. At the Closing Time,

     
7.1.1

the Corporation shall deliver to the Agents definitive certificates representing the Offered Units in accordance with the instructions contained in the Subscription Agreements or shall cause the Transfer Agent to issue electronically and register through the non-certificated inventory process the Offered Units issued and sold by the Corporation pursuant to this Agreement, such electronic issuance being registered in the name of “CDS & Co.” (or in such other name as the Agent may direct), as CDS’ nominee, to be held by CDS as a book-entry only security in accordance with CDS’ rules and procedures; provided , however , that the Offered Units offered and sold pursuant to Rule 506 of Regulation D under the U.S. Securities Act and the Offered Preferred Units shall be represented by definitive certificates only;

     
7.1.2

the Agents will cause to be delivered to the Corporation a certified cheque, bank draft or wire transfer in an amount equal to the aggregate Purchase Price for the Offered Units net of the Agents’ Fee and the expenses of the Agents payable by the Corporation pursuant to Section 13 with respect to Offering;

     
7.1.3

the Corporation will deliver to the Agents (or in such other name as the Agents may direct) one or more Compensation Option certificates representing the Compensation Options that the Agents are entitled to receive pursuant to this Agreement; and



- 18 -

7.1.4

the Corporation will provide all further documentation as may be contemplated in this Agreement or as counsel to the Agent may reasonably require.

     
7.2

Conditions of Closing : The following are conditions precedent to the obligation of the Agents to complete the Offering, which conditions the Corporation hereby covenants and agrees to use its best efforts to fulfill within the time set out herein therefor, and which conditions may be waived in writing in whole or in part by the Agents:

     
7.2.1

the Corporation shall have received all necessary approvals and consents, including all necessary regulatory approvals and consents (including those of the Stock Exchange) required for the completion of the transactions contemplated by this Agreement, all in a form satisfactory to the Agents and the Stock Exchange shall have conditionally accepted the Offering (including listing of the Unit Shares, Preferred Unit Common Shares, Warrant Common Shares and Compensation Option Shares), subject to the fulfillment of standard listing conditions;

     
7.2.2

receipt by the Agents of the documents set forth in Section 6 of this Agreement to be delivered to the Agents;

     
7.2.3

the representations and warranties of the Corporation contained herein being true and correct as of the Closing Time with the same force and effect as if made at and as of the Closing Time after giving effect to the transactions contemplated hereby; and

     
7.2.4

the Corporation having complied with all covenants, and satisfied all terms and conditions, contained herein to be complied with and satisfied by the Corporation at or prior to the Closing Time.

     

The Corporation acknowledges and agrees that it is holding all funds wired directly to it

     

by Purchasers in trust pending the confirmation by the Agents of the completion of the Closing. The Corporation further acknowledges and agrees that in the event of a failure to meet the foregoing conditions precedent set out in this Section 7 it will immediately wire all such funds to the Lead Agent in trust for the Purchasers.


Section 8. Agents’ Fee

8.1

Commission : In consideration of the Agents agreeing to act as agents of the Corporation in respect of the Offering, and in consideration of the services performed and to be performed by the Agents in connection therewith, the Corporation shall pay to the Agents or as the Agents may otherwise direct an amount (the “ Agents’ Fee ”) equal to 6% of the aggregate Purchase Price for the Offered Units sold by the Agents, except for the Purchase Price for Offered Units acquired by Purchasers identified on the Exempt List. No commission shall be payable to the Agents for Purchasers identified on the Exempt List.



- 19 -

8.2

Compensation Options : In addition to the Agents’ fee payable to the Agents pursuant to Section 8.1 , as additional consideration for the services performed and to be performed by the Agents hereunder, the Corporation shall issue to the Agents or as the Agents may otherwise direct non-transferable options (the “ Compensation Options ”) equal to up to 6% of the number of Offered Units sold by the Agents in the Offering (excluding Offered Units sold to Purchasers identified on the Exempt List). Each Compensation Option will entitle the holder thereof to acquire one Common Share (a “ Compensation Option Share ”) at a price equal to the Purchase Price during the period ending 24 months after the Closing Date. Each Agent acknowledges and agrees that the Compensation Options are non-transferable. Each Agent acknowledges that the Compensation Options and the Compensation Option Shares have not been registered under the 1933 Act or the securities laws of any state of the United States. In connection with the issuance of the Compensation Options, each Agent represents, warrants and covenants that it is acquiring the Compensation Options as principal for its own account and not for the benefit or account of any other person. Each Agent acknowledges and agrees that the Compensation Options may not be exercised in the United States or by or on behalf of a person in the United States, unless such exercise is not subject to registration under the 1933 Act or the applicable securities laws of any state of the United States.

     
8.2.1

In connection with the issuance of the Compensation Options, Bloom Burton & Co. Inc. further acknowledges, represents, warrants and covenants to the Corporation that: (i) it is not a U.S. Person and it was not offered the Compensation Options in the United States; (ii) it did not execute or deliver this Agreement in the United States; and (iii) it will not engage in any Directed Selling Efforts with respect to any Compensation Options or Compensation Option Shares; and (iv) it will not offer, sell or transfer any Compensation Options or Compensation Option Shares unless in compliance with an exemption or an exclusion from the registration requirements of the 1933 Act and any applicable state securities laws.

     
8.2.2

In connection with the issuance of the Compensation Options, ROTH Capital Partners, LLC further acknowledges, represents, warrants and covenants to the Corporation that: (i) it is an Accredited Investor; (ii) it is acquiring the Compensation Options as principal for its own account, for investment purposes, and not with a view to any resale, distribution or other disposition of the Compensation Options or the Compensation Option Shares in violation of United States federal or state securities laws; (iii) it is not acquiring the Compensation Options or Compensation Option Shares as a result of any General Solicitation or General Advertising with respect to such securities; (iv) it understands and acknowledges that the Compensation Options and the Compensation Option Shares will be “restricted securities” within the meaning of Rule 144 under the 1933 Act; and (v) it will not offer, sell or transfer any Compensation Options or Compensation Option Shares unless in compliance with an exemption or an exclusion from the registration requirements of the 1933 Act and any applicable state securities laws.



- 20 -

8.3

No Finder’s Fees : Except as set forth in Section 8.1 and Section 8.2 , the Corporation is not obliged to pay any finder’s fees or make any similar payments, whether in cash, securities or otherwise, to any third party in connection with the Offering.


Section 9. Representations and Warranties of Corporation

9.1

Representations and Warranties : The Corporation represents and warrants as follows to the Agent, and acknowledges that the Agent is relying upon such representations and warranties in connection with its execution and delivery of this Agreement and the completion of the Offering:

     
9.1.1

each of the Corporation and its Subsidiaries is, and will be at the Closing Date, duly incorporated, validly subsisting, and in good standing under the laws of its governing jurisdiction, and has and will at the Closing Date have all requisite corporate power and authority to own, lease and operate its properties and assets and conduct its business as currently conducted; the Corporation has and will have at the Closing Date all requisite corporate power and authority to enter into this Agreement and the Ancillary Documents and carry out its obligations hereunder and thereunder, and to issue, sell and deliver the Offered Securities and the Compensation Option Securities, in accordance with the provisions of this Agreement and the Ancillary Documents; each of the Corporation and its Subsidiaries is current with all material filings required to be made under the laws of Canada and the Province of Ontario and all other jurisdictions in which it exists or carries on any material business and has all necessary licences, leases, permits, authorizations and other approvals necessary to permit it to conduct its business as it is currently conducted or as planned to be conducted as described in the Information Record, except where the absence of such power and authority or failure to make any filing or obtain any license, lease, permit, authorization or other approval would not have a Material Adverse Effect, and all such licences, leases, permits, authorizations and other approvals are in full force and effect in accordance with their terms except where the failure to so maintain such licences, leases, permits, authorizations or other approvals would not have a Material Adverse Effect;

     
9.1.2

except as contemplated by this Agreement or the Ancillary Documents or as otherwise disclosed in the Information Record, there are no other agreements, options, warrants, rights of conversion or other rights pursuant to which the Corporation is, or may become obligated to issue or transfer any securities (including debt securities) or any securities convertible or exchangeable, directly or indirectly, into any of its securities;

     
9.1.3

there are no agreements, options, warrants, rights of conversion or other rights pursuant to which any Subsidiary is, or may become obligated to issue or transfer any securities (including debt securities) or any securities convertible or exchangeable, directly or indirectly, into any of its securities;



- 21 -

  9.1.4

except as contemplated by this Agreement or as otherwise disclosed in the Information Record, to the Knowledge of the Corporation, no agreement, will be in force or effect at the Closing Date which in any manner affects the voting or control of any of the securities of the Corporation;

     
  9.1.5

the authorized capital of the Corporation consists of an unlimited number of Class B Shares, First Preferred Shares and Common Shares of which, as of the date hereof, no Class B Shares, no First Preferred Shares and 42,504,687 Common Shares are issued and outstanding as fully paid and non-assessable shares in the capital of the Corporation, and except as set out in Schedule 9.1.5 , as of the date hereof, no options to acquire Common Shares are issued and outstanding and no person has any agreement, option, right or privilege (whether pre-emptive, contractual or otherwise) capable of becoming an agreement for purchase, acquisition, subscription or issuance of any unissued Common Shares or other securities of the Corporation; the issuance and sale of the Offered Securities will not obligate the Corporation to issue shares of Common Shares or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Corporation securities to adjust the exercise, conversion, exchange, or reset price under any such securities;

     
  9.1.6

the Corporation has no subsidiaries other than the Subsidiaries. The Corporation does not beneficially own, or exercise control or direction over, outstanding securities of any person other than the Subsidiaries. The Corporation exercises control or direction over all of the outstanding securities of the Subsidiaries. The Corporation beneficially owns, directly or indirectly all of the issued and outstanding shares in the capital of the Subsidiaries and such shares are free and clear of all liens. All shares of the Subsidiaries have been duly authorized and validly issued and are outstanding as fully paid and non-assessable shares and, except as described in the Information Record or as contemplated by this Agreement or the Ancillary Documents, no person has any right, agreement or option, present or future, contingent or absolute, or any right capable of becoming a right, agreement or option, for the purchase from the Corporation or any Subsidiary of any interest in any of such shares or for the issue of any unissued shares in the capital of any Subsidiary or any other security convertible into or exchangeable for any such shares;

     
  9.1.7

neither the Corporation nor any Subsidiary is: (i) in breach or violation of any of the terms or provisions of, or in default under (whether after notice or lapse of time or both) any indenture, mortgage, deed of trust, loan agreement or other agreement (written or oral) or instrument to which it is a party or by which it is bound or to which any of its property or assets is subject (whether or not such default or violation has been waived), which breach or violation or the consequences thereof would, alone or in the aggregate, have a Material Adverse Effect; or (j) in violation of the provisions of its articles, by-laws or resolutions or any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over it or any of its properties, which violation or the consequences thereof would, alone or in the aggregate, have a Material Adverse Effect;



- 22 -

  9.1.8

other than such agreements or instruments which will terminate or be discharged, as applicable, or for such agreements pursuant to which the consent of the other contracting party will be obtained simultaneously with or prior to the Closing, the execution and delivery of this Agreement, the issue, sale and delivery of the Offered Securities and Compensation Option Securities, do not and will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under (whether after notice or lapse of time or both), any indenture, mortgage, deed of trust, loan agreement, lease or other agreement (written or oral) or instrument to which the Corporation or any Subsidiary is a party or by which it is bound or to which any of its property or assets is subject, other than any breach or violation or the consequences thereof which would, alone or in the aggregate, not have a Material Adverse Effect, nor will such action conflict with or result in any violation of the provisions of the articles, by-laws or resolutions of the Corporation or any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over it or any of its properties which violation or the consequences thereof would, alone or in the aggregate, have a Material Adverse Effect;

     
  9.1.9

except for the required consent and approval of the Stock Exchange, no consent, approval, authorization, order, registration or qualification of or with any person, court or governmental agency or body is required in connection with the execution and delivery by the Corporation of this Agreement or any Ancillary Document and the consummation of the transactions contemplated hereby and thereby, including the issuance, sale and delivery of the Offered Securities and Compensation Option Securities;

     
  9.1.10

the Business has not been, is not being, and will not be, immediately following Closing, conducted in violation of any laws, except for violations and possible violations that would not, individuals or in the aggregate be reasonably likely to have a Material Adverse Effect or materially impair the ability of the Corporation to complete the transactions contemplated by this Agreement and the Ancillary Documents;

     
  9.1.11

no order ceasing or suspending trading of the securities of the Corporation (except at the request of the Corporation and as approved by the Agent), prohibiting the sale of such securities has been issued to the Corporation and is outstanding and, no investigations or proceedings for such purposes of which the Corporation has been notified are pending or threatened;

     
  9.1.12

the Corporation is a reporting issuer or the equivalent in good standing under the Securities Laws of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia;



- 23 -

  9.1.13

the Corporation is in compliance, in all material aspects, with its timely and continuous disclosure obligations under Securities Laws of each of the Reporting Jurisdictions;

     
  9.1.14

the Corporation has not filed any confidential material change report with any Securities Commission, the Stock Exchange or any other self-regulatory authority which remains confidential;

     
  9.1.15

except with respect to Offered Units sold to purchasers that are in the United States or U.S. Persons, or acting for the account or benefit of persons in the United States or U.S. Persons, none of the Offered Securities will be subject to a statutory hold period under the Securities Laws of the Offering Jurisdictions or to any hold period under the policies of the Stock Exchange which extends beyond four months and one day after the Closing Date;

     
  9.1.16

there is not, in the constating documents of the Corporation or in any material agreement, mortgage, note, debenture, indenture or other instrument or document to which the Corporation is a party, any restriction upon or impediment to the declaration or payment of dividends by the directors of the Corporation or the payment of dividends by the Corporation to the holders of its Common Shares;

     
  9.1.17

neither the issuance of the securities comprising the Offered Units, nor the conversion or exchange thereof into Common Shares by the Purchaser thereof, will trigger a “Flip-in Event” or cause such Purchaser to become an “Acquiring Person” pursuant to the Rights Plan;

     
  9.1.18

there are no legal or governmental actions, proceedings or investigations pending or, to the Knowledge of the Corporation, contemplated or threatened against the Corporation or any Subsidiary, at law or in equity or before or by any federal, provincial, municipal or other governmental department, commission, board or agency, domestic or foreign, which: (k) would, in any way, have a Material Adverse Effect; or (l) questions the validity of the issuance, sale or delivery of the Offered Securities or the Compensation Option Securities or the validity of any action taken or to be taken by the Corporation pursuant to or in connection with this Agreement or the Ancillary Documents;

     
  9.1.19

all necessary corporate action has been taken by the Corporation to authorize the execution, delivery and performance of this Agreement and the Ancillary Agreements ;

     
  9.1.20

none of the Corporation, any Subsidiary or any other party to any agreement or instrument is in material default in the observance or performance of any term or obligation to be performed by it under any such agreement or instrument to which the Corporation or any Subsidiary is a party and no event has occurred which with notice or lapse of time or both would constitute such a default on the part of the Corporation or any Subsidiary, in any such case which default or event would have a Material Adverse Effect;



- 24 -

  9.1.21

subject to the conditions precedent contained therein, this Agreement has been duly and validly executed and delivered by the Corporation, constitutes a valid and binding obligation of the Corporation enforceable against it in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium and other laws relating to or affecting the rights of creditors generally, and except as limited by the application of equitable principles when equitable remedies are sought and by the fact that rights to indemnity, contribution and waiver, and the ability to sever unenforceable terms, may be limited by applicable law;

     
  9.1.22

each of the Corporation and its Subsidiaries is the beneficial owner of all its respective properties, business and assets or of the interests in its respective properties, business or assets, in each case free and clear of all material liens, and all agreements under which the Corporation or any Subsidiary holds an interest in a property, business or asset are in good standing according to their terms except where the failure to be in such good standing does not and will not have a Material Adverse Effect;

     
  9.1.23

the Corporation will use the net proceeds from the issue and sale of the Offered Units primarily to advance the Corporation’s SIRPα program and secondarily for the Corporation’s other research and development programs from time to time and for general corporate purposes;

     
  9.1.24

neither the Corporation nor any Subsidiary has received notice from any governmental or regulatory authority of any jurisdiction in which it carries on a material part of its business, or owns or leases any material property, of any restriction on its ability to or of a requirement for it to qualify to, nor is it otherwise aware of any restriction on its ability to or of a requirement for it to qualify to, conduct its business in such jurisdiction, except such qualifications as have been satisfied or that would not result in a Material Adverse Effect;

     
  9.1.25

Stem Cell Therapeutics Inc. has no material assets or material liabilities;

     
  9.1.26

Computershare Trust Company of Canada at its principal office in Toronto has been duly appointed as the Transfer Agent for the Common Shares;

     
  9.1.27

at the Closing Time, Computershare Trust Company of Canada at its principal office Toronto will have been duly appointed as the Warrant Agent for the Warrants;

     
  9.1.28

since December 31, 2012, except as disclosed in the Information Record: (m) there has not been any material change or change in material fact (whether actual, proposed, threatened or contemplated) in the Business; (n) there has not been any adverse material change in the consolidated financial position of the Corporation; and (o) there has been no material transaction entered into by the Corporation or any Subsidiary, other than those in the ordinary course of business;



- 25 -

  9.1.29

the Corporation maintains a system of internal accounting controls sufficient to provide reasonable assurance that (p) transactions are executed in accordance with management’s general or specific authorizations; (q) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; and (r) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;

     
  9.1.30

the Financial Statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and the Securities Laws and present fairly in all material respects the consolidated financial position of the Corporation as at their respective dates;

     
  9.1.31

except as disclosed in the Information Record, there are no material off-balance sheet transactions, arrangements, obligations (including contingent obligations) or other relationships of the Corporation or any of its Subsidiaries with unconsolidated entities or other persons that could reasonably be expected to have a Material Adverse Effect;

     
  9.1.32

except as disclosed in the Information Record, none of the Corporation or any of its Subsidiaries has any contingent liabilities in excess of the liabilities that are either reflected or reserved against in the financial statements of the Corporation that could reasonably be expected to have a Material Adverse Effect;

     
  9.1.33

the Auditor who provided its audit report on the Financial Statements is a firm of independent public accountants as required under Securities Laws, are a “participating audit firm” (within the meaning of National Instrument 52-108 – Auditor Oversight of the Securities Commission ) and is in compliance with any restriction or sanction imposed by the Canadian Public Accountability Board;

     
  9.1.34

there has never been a reportable event (within the meaning of National Instrument 51-102 – Continuous Disclosure Obligations ) between the Corporation and its present or former auditors;

     
  9.1.35

each of the Corporation and the Subsidiaries has accurately and timely filed all federal, provincial, state, local and foreign tax returns that are required to be filed at such time or have requested extensions thereof (except in any case in which the failure so to file would not have a Material Adverse Effect) and has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such assessment, fine or penalty that is currently being contested in good faith;

     
  9.1.36

each of the Corporation and the Subsidiaries has established on its books and records reserves that are adequate for the payment of all taxes not yet due and payable and to the Knowledge of the Corporation, there are no liens for taxes on the assets of the Corporation or any Subsidiary and there are no audits to the Knowledge of the Corporation to be pending on the tax returns of the Corporation or any Subsidiary (whether federal, state, provincial, local or foreign) and there are no claims which have been asserted relating to any such tax returns, which audits and claims, if determined adversely, would result in the assertion by any governmental agency of any deficiency that would have a Material Adverse Effect;



- 26 -

  9.1.37

no domestic or foreign taxation authority has asserted or, to the Knowledge of the Corporation, threatened to assert any assessment, claim or liability for taxes due or to become due in connection with any review or examination of the tax returns of the Corporation or any Subsidiary (including, without limitation, any predecessor companies) filed over the last three (3) years which would have a Material Adverse Effect;

     
  9.1.38

to the Knowledge of the Corporation, the minute books and records of the Corporation and its Subsidiaries, for the periods from their dates of incorporation to the date of examination thereof are all of the minute books and records of the Corporation and its Subsidiaries and contain copies of all material proceedings of the shareholders, the boards of directors and all committees of the boards of directors of the Corporation and each Subsidiary to the date of review of such corporate records and minute books and there have been no other material meetings, resolutions or proceedings of the shareholders, board of directors or any committees of the boards of directors of the Corporation or any Subsidiary to the date of review of such corporate records and minute books not reflected in such minute books and other records. True and complete copies of all such minutes and proceedings have been provided to the Agent or the Agent’s representatives;

     
  9.1.39

other than the Subsidiaries, the Corporation does not own, directly or indirectly, or exercise control or direction over, and has not agreed to acquire outstanding securities of any other corporation or options to acquire securities of any other corporation, other than marketable securities held in the ordinary course of business, or a participating interest in any person;

     
  9.1.40

other than as disclosed in the Information Record with respect to their respective security holdings in the Corporation, none of the directors or officers of the Corporation or any associate or affiliate of the foregoing has, or to the Knowledge of the Corporation, intends to have, any interest, direct or indirect, in any transaction or any proposed transaction with the Corporation which would materially affect, is material to or will materially affect the Corporation;

     
  9.1.41

the Corporation is not aware of any legislation, or proposed legislation (published by a legislative body), which it anticipates will have a Material Adverse Effect;

     
  9.1.42

each of the Corporation and the Subsidiaries is in compliance with all laws respecting employment and employment practices, terms and conditions of employment, pay equity and wages, except where such non-compliance would not have a Material Adverse Effect;



- 27 -

  9.1.43

neither the Corporation nor any Subsidiary has any loans or other indebtedness outstanding, outside the normal course of business, which has been made to any of its shareholders, officers, directors or employees, past or present, or any person not dealing at arm’s length with it;

     
  9.1.44

all material accruals for unpaid vacation pay, premiums for unemployment insurance, health premiums, federal or provincial pension plan premiums, accrued wages, salaries and commissions and payments for any plan for any officer, director, employee or consultant of the Corporation or its Subsidiaries have been accurately reflected in the books and records of the Corporation.

     
  9.1.45

each material plan for retirement, bonus, stock purchase, profit sharing, stock option, deferred compensation, severance or termination pay, insurance, medical, hospital, dental, vision care, drug, sick leave, disability, salary continuation, legal benefits, unemployment benefits, vacation, pension, incentive or otherwise contributed to, or required to be contributed to, by the Corporation or its Subsidiary for the benefit of any current or former officer, director, employee or consultant of the Corporation or its Subsidiary has been maintained in material compliance with the terms thereof and with the requirements prescribed by any and all statutes, orders, rules, policies and regulations that are applicable to any such plan. True and complete copies of all such plans have been provided to the Agent;

     
  9.1.46

no labour dispute exists or, to the Knowledge of the Corporation, is imminent with respect to any of the employees of the Corporation, which could reasonably be expected to result in a Material Adverse Effect; none of the Corporation’s employees is a member of a union that relates to such employee’s relationship with the Corporation, and the Corporation is not party to a collective bargaining agreement; to the Knowledge of the Corporation, no executive officer of the Corporation is, or is now expected to be, in violation of any material term of any employment agreement, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favour of any third party, and the continued employment of each such executive officer does not subject the Corporation to any liability with respect to any of the foregoing matters;

     
  9.1.47

except as disclosed in the Information Record, none of the directors, officers or employees of the Corporation, any known holder of more than ten percent (10%) of any class of securities of the Corporation, or any known associate or affiliate of any of the foregoing persons, has had any material interest, direct or indirect, in any material transaction within the previous two (2) years or any proposed material transaction which, as the case may be, is material to or will materially affect the Corporation;

     
  9.1.48

with respect to the premises which the Corporation or any Subsidiary occupies as tenant, the Corporation or such Subsidiary, as the case may be, occupies such leased premises and has the exclusive right to occupy and use the leased premises and the leases pursuant to which the Corporation or such Subsidiary, as the case may be, occupies the leased premises are in good standing in all material respects and in full force and effect;



- 28 -

  9.1.49

to the Knowledge of the Corporation, no person who is a related party (as such term is defined in National Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ) to the Corporation, together with that persons’ associates, beneficially owns or exercises control or direction over 10% or more of the outstanding securities of each class of equity securities of the Corporation;

     
  9.1.50

each of the Corporation and the Subsidiaries is insured against such losses and risks and in such amount as are customary in the business in which it is engaged or as are required to be kept in place pursuant to its Intellectual Property licenses, credit agreements and material contracts. All policies of insurance insuring the Corporation, the Subsidiaries or any of their respective businesses, assets, employees, officers and directors are in full force and effect, and the Corporation and the Subsidiaries are in compliance with the terms of such policies in all material respects. There are no material claims by the Corporation or any Subsidiary under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause and that would result in a Material Adverse Effect;

     
  9.1.51

each of the Corporation and the Subsidiaries, in all material respects: (s) is in compliance with any and all applicable federal, provincial and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“ Environmental Laws ”); (t) has received all permits, licences or other approvals required under applicable Environmental Laws to conduct its business; and (u) is in compliance with all terms and conditions of any such permit, license or approval, and there have been no past, and there are no pending or, to the Knowledge of the Corporation, threatened claims, complaints, notices or requests for information received by the Corporation or any Subsidiary with respect to any alleged material violation of any Environmental Law and no conditions exist which, with the passage of time, or the giving of notice or both, would give rise to liability under any Environmental Law; except, in each case, other than those that would not have a Material Adverse Effect;



- 29 -

 

  9.1.52 the Corporation or a Subsidiary owns, or has obtained valid and enforceable licences for, or other rights to use, all the Intellectual Property that is material to the conduct of its Business as presently conducted or as intended to be conducted following Closing (collectively, the “ Material IP ”). The Material IP is described in a disclosure letter that was delivered to the Agents concurrently with the execution of this Agreement. The Corporation (to the Knowledge of the Corporation) has no knowledge that it will be unable to obtain any rights or licences to use all Intellectual Property necessary for the conduct of the Business. The execution and delivery by the Corporation of this Agreement and the Ancillary Agreements will not result in the breach of, or create on behalf of any third party the right to terminate, impair, modify or demand a payment under (v) any license, sublicense or other agreement relating to any Material IP, or (w) any license, sublicense and other agreement as to which the Corporation or any Subsidiary is a party and pursuant to which the Corporation or a Subsidiary is authorized to use any third party Material IP, or (x) any right of the Corporation or any Subsidiary to develop, use, sell, or dispose of, or to bring any action for the infringement of any Intellectual Property. Except as disclosed in the Information Record, all such licenses are in good standing and there is no dispute with any licensor or licensee regarding the terms thereof. To the Knowledge of the Corporation, there is no infringement by third parties of any of the Material IP. To the Knowledge of the Corporation, all Material IP is enforceable and there is no pending or, to the Knowledge of the Corporation, threatened action, suit, proceeding or claim by others challenging the Corporation or any Subsidiary’s rights in or to any Intellectual Property, and the Corporation is unaware of any facts which form a reasonable basis for any such claim. There is no pending or, to the Knowledge of the Corporation, threatened action, suit, proceeding or claim by others challenging the validity or enforceability of any Material IP, and the Corporation is unaware of any finding of unenforceability or invalidity of the Material IP nor, to the Knowledge of the Corporation, does it know of any facts that would support such a claim of invalidity. There is no pending, or to the Knowledge of the Corporation, threatened action, suit, proceeding or claim by others that the Corporation infringes, misappropriates or otherwise violates (or would infringe, misappropriate or otherwise violate upon commercialization of the Corporation or any Subsidiary’s product or product candidates) any patent, trademark, copyright, trade secret, confidential information, know how or other proprietary or Intellectual Property rights of others. To the Knowledge of the Corporation, there is no patent or patent application by others that contains claims that interfere with the issued or pending claims of any of the Material IP. To the Knowledge of the Corporation, there is no prior art that necessarily renders any patent application owned by the Corporation or any Subsidiary unpatentable that has not been disclosed to the United States Patent and Trademark Office and the international equivalents;
     
  9.1.53

the Corporation or any Subsidiary (or parties under contractual obligation to the Corporation or a Subsidiary) holds and is in compliance with all licences, certificates, approvals and permits from all provincial, federal, state, United States, foreign and other regulatory authorities that are material to the conduct of the Business as currently conducted, all of which are valid and in full force and effect, and there is no proceeding pending or, to the Knowledge of the Corporation, threatened, which may cause any such license, certificate, approval or permit to be withdrawn, cancelled, suspended or not renewed. To the Knowledge of the Corporation, it is not in violation of any material law, order, rule, regulation, writ, injunction or decree of any court or governmental agency or body applicable to the investigation of new drugs in humans or animals or the cultivation, growing or processing of genetically modified organisms;



- 30 -

  9.1.54

the clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Corporation or any Subsidiary or in which the Corporation or any Subsidiary or their respective products or product candidates that are described in the Information Record have participated or the results of which are referred to in the Information Record were, to the Knowledge of the Corporation, and if still pending are, to the Knowledge of the Corporation, being, conducted in accordance with, in the judgment of senior management of the Corporation, as applicable, good clinical practice, good laboratory practices or scientific standards as appropriate for each particular study type. Neither the Corporation nor any Subsidiary has received any notices or other correspondence from any such agency requiring the termination, suspension or material modification or clinical hold of any clinical or pre-clinical studies or tests that are described in the Information Record or the results of which are referred to in the Information Record. Neither the Corporation, nor any Subsidiary, nor any of their respective employees or consultants has been debarred by the United Stated Food and Drug Administration nor, to the Knowledge of the Corporation, is any of them under investigation (and there are no facts that would warrant same);

     
  9.1.55

neither the Corporation nor any Subsidiary is currently pursuing any litigation against any person for any infringement, misappropriation or misuse of the Material IP;

     
  9.1.56

no proceedings have been taken, instituted or, to the Knowledge of the Corporation, are pending, for the dissolution or liquidation of the Corporation or the Subsidiary;

     
  9.1.57

there are no outstanding claims, actions, suits, litigation, arbitration, investigations or proceedings, whether or not purportedly on behalf of the Corporation or any Subsidiary, or, to the Knowledge of the Corporation, proposed or threatened in writing against the Corporation or any Subsidiary which, if determined adversely to the Corporation or such Subsidiary would have a Material Adverse Effect or which may restrict or prohibit the ability of the Corporation to perform its obligations hereunder;

     
  9.1.58

the attributes of each of the Offered Securities and Compensation Option Securities conforms in all material respects to the description thereof contained in the Ancillary Documents;

     
  9.1.59

each Ancillary Document will, at the Closing Time, be duly authorized, executed and delivered by the Corporation and will constitute a valid and binding obligation of the Corporation enforceable against it in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium and other laws relating to or affecting the rights of creditors generally, and except as limited by the application of equitable principles when equitable remedies are sought and by the fact that rights to indemnity, contribution and waiver, and the ability to sever unenforceable terms, may be limited by applicable law;



- 31 -

  9.1.60

for tax purposes, the Corporation is allocating the Purchase Price (y) for each Unit as to Cdn.$0.2025 for the underlying Unit Share and Cdn.$0.0075 for the underlying three-quarters of a Warrant and (z) for each Preferred Unit as to Cdn.$0.2025 for the underlying Preferred Unit Share and Cdn.$0.0075 for the underlying three-quarters of a Warrant;

       
  9.1.61

all outstanding Common Shares of the Corporation have been duly authorized for issuance and were validly issued as fully paid and non-assessable Common Shares and were not issued in violation of or subject to any pre-emptive rights or other contractual rights to purchase securities issued by the Corporation;

       
  9.1.62

the Corporation has taken all necessary corporate action to authorize the creation, issue and sale, as applicable, of:

       
  (a)

the Unit Shares comprising the Units and, upon payment for the Units, the Unit Shares will be validly issued as fully paid and non-assessable Common Shares;

       
  (b)

the Preferred Unit Shares comprising the Preferred Units and, upon payment for the Preferred Units, the Preferred Unit Shares will be validly issued as fully paid and non-assessable Preferred Shares;

       
  (c)

the Warrants comprising the Offered Units and, upon payment for the Offered Units, the Warrants will be validly created and issued;

       
  (d)

the Warrant Common Shares and, upon payment of the Exercise Price therefor in accordance with the terms of the Warrant Indenture, the Warrant Common Shares will be validly issued as fully paid and non- assessable Common Shares;

       
  (e)

the Preferred Unit Common Shares and, upon conversion of the Preferred Unit Shares in accordance with the articles of the Corporation, the Preferred Unit Common Shares will be validly issued as fully paid and non-assessable Common Shares;

       
  (f)

the Compensation Options, and upon issue thereof in accordance with the terms of this Agreement, the Compensation Options will be validly created and issued; and

       
  (g)

the Compensation Option Shares and, upon payment of the exercise price therefor in accordance with the terms of the Compensation Options, the Compensation Option Shares will be validly issued as fully paid and non- assessable Common Shares;

       
  9.1.63

the definitive forms of certificates representing the Common Shares and Preferred Shares are in proper form under the laws of Ontario and comply in all material respects with the requirements of the Stock Exchange and do not conflict with the constating documents of the Corporation;



- 32 -

  9.1.64

the definitive form of certificate representing the Compensation Options will not conflict with the constating documents of the Corporation;

     
  9.1.65

all agreements required to be filed under the Corporation’s timely and continuous disclosure obligations under Securities Laws of each of the Offering Jurisdictions (other than agreements which have terminated since the time of such filing obligation) are valid and enforceable against the Corporation in accordance with their respective terms, except (aa) as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, or moratorium or similar laws affecting creditors’ and contracting parties’ right generally; and (bb) as enforceability may be subject to general principles of equity and except as right to indemnity and contribution may be limited by state or federal securities laws or public policy underlying such laws;

     
  9.1.66

the Corporation has taken no action that would give rise to any claim by any Person for brokerage commissions, placement agent’s fees, or similar payments relating to this Agreement or the transaction contemplated hereby, except for dealings with the Agents, whose commissions and fees will be paid by the Corporation;

     
  9.1.67

there are no disagreements of any kind presently existing, or reasonably anticipated by the Corporation to arise between the Corporation and the accountants, lawyers and patent agents formerly or presently employed by the Corporation and the Corporation is current with respect to any fees owed to its accountants and lawyers which could affect the Corporation’s ability to perform any of its obligations under this Agreement;

     
  9.1.68

based on the consolidated financial condition of the Corporation as of the Closing Date, immediately after giving effect to the receipt by the Corporation of the proceeds from the sale of the Offered Units hereunder: (a) the fair saleable value of the Corporation’s assets exceeds the amount that will be required to be paid on or in respect of the Corporation’s existing debts and other liabilities (including known contingent liabilities) as they mature; (b) the Corporation’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Corporation, consolidated and projected capital requirements and capital availability thereof; and (c) the current cash flow of the Corporation, together with the proceeds the Corporation would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid; the Corporation has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date;



- 33 -

9.1.69

the Corporation is not required by applicable laws, Stock Exchange rules, or its constating documents to obtain the approval of its shareholders in order to issue any of the Offered Securities or Compensation Option Securities; and

     
9.1.70

no class of the Corporation’s securities is registered, or required to be registered, pursuant to section 12 of the 1934 Act, and the Corporation does not have a reporting obligation pursuant to Section 15(d) of the 1934 Act.

     
9.2

The Agent will be entitled to rely on the respective representations and warranties of the Corporation contained in this Agreement or any certificate delivered pursuant to this Agreement notwithstanding investigations which the Agent may undertake or may have undertaken or which may be undertaken or may have been undertaken on the Agent’s behalf.


Section 10. Covenants of the Corporation

10.1

Consents and Approvals : The Corporation covenants and agrees with the Agent, and acknowledges that such covenants are also being provided for the benefit of the Purchasers, that the Corporation will:

     
10.1.1

obtain, to the extent not already obtained, the necessary regulatory consents from the Stock Exchange and, to the extent necessary, from the Securities Commissions of the Offering Jurisdictions for the Offering on such terms as are mutually acceptable to the Agent and the Corporation, acting reasonably;

     
10.1.2

arrange for the listing of the Unit Shares, Preferred Unit Common Shares, Warrant Common Shares and the Compensation Option Shares on the Stock Exchange upon issuance of such securities; and

     
10.1.3

make all necessary filings and obtain all other necessary regulatory and other consents and approvals required in connection with the transactions contemplated by this Agreement.

     
10.2

General : The Corporation hereby covenants and agrees with the Agent, and acknowledges that such covenants are also being provided for the benefit of the Purchasers, that the Corporation will:

     
10.2.1

fulfill all legal requirements to permit the issue, offering and sale of the Offered Units and the issue of the Compensation Options, including compliance with the Securities Laws of the Offering Jurisdictions to enable the Offered Units to be offered for sale and sold without the necessity of filing a prospectus in the Offering Jurisdictions;

     
10.2.2

use commercially reasonable efforts to maintain the listing of the Common Shares on the Stock Exchange (or on the Toronto Stock Exchange) and the status of the Corporation as a reporting issuer not in default under the securities legislation of each of the Reporting Jurisdictions for a period of twenty-four (24) months after the Closing Date;



- 34 -

  10.2.3

in a timely manner following the Closing Date, file such documents as may be required under the Securities Laws of the Offering Jurisdictions relating to the offering of the Offered Units and Compensation Options which, without limiting the generality of the foregoing, shall include a Form 45-106F1 as prescribed by National Instrument 45-106 – Prospectus and Registration Exemptions of the Canadian Securities Administrators;

     
  10.2.4

until the date that is six (6) months after the Closing Date, not undertake a reverse or forward stock split or reclassification of the Common Shares without the prior written consent of the Lead Agent, provided , however , that no consent shall be required for a reverse stock split of the Common Shares that the board of directors of the Corporation, in the good faith exercise of its business judgment, determines to be necessary or advisable to list the Common Shares on the Stock Exchange or another trading market;

     
  10.2.5

reserve and keep available at all times during which the Warrants and Compensation Options remain exercisable and the Preferred Unit Shares remain convertible, free of pre-emptive rights and liens, other than restrictions on transfer provided for in this Agreement or any Ancillary Document or imposed by Securities Laws, a sufficient number of Common Shares for the purpose of enabling the Corporation to issue Warrant Common Shares, Compensation Option Shares and Preferred Unit Common Shares; and

     
  10.2.6

use the net proceeds from the issue and sale of the Offered Units primarily to advance the Corporation’s SIRPα program and secondarily for the Corporation’s other research and development programs from time to time and for general corporate purposes.


Section 11. Termination

11.1

Non-Compliance Out : If the Corporation does not comply in all material respects with the conditions of this Agreement, and such non-compliance does or would reasonably be expected to prevent, restrict or otherwise adversely affect the distribution of the Offered Units in accordance with the terms of this Agreement or would reasonably be expected to impact adversely on the market price of the Common Shares or marketability of the Offered Units in any of the Offering Jurisdictions, the Agents may terminate their obligations under this Agreement by written notice to that effect given to the Corporation on or prior to the Closing Time and in such event the Agents’ obligations shall be at an end. It is understood that the Agents may waive in whole or in part non-compliance therewith without prejudice to such rights in respect of any other condition or conditions or any other or subsequent breach or non-compliance, provided that any such waiver or extension shall be binding upon the Agents only if the same is in writing.

   
11.2

Due Diligence Out : If at any time prior to the Closing Time the Agents and their representatives shall, in their sole discretion, acting reasonably, not be satisfied with the results of their due diligence investigations and examinations of the Corporation and its Subsidiaries, then the Agents shall be entitled, at their option, to terminate their obligations under this Agreement by written notice to that effect given to the Corporation at or prior to the Closing Time;



- 35 -

11.3

Material Change Out : If at any time prior to the Closing Time there shall occur any adverse material change in the business, affairs, operations, assets, liabilities (contingent or otherwise), capital or control of the Corporation and its Subsidiaries, taken as a whole, or change in material fact, or the Agent becomes aware of any undisclosed adverse material fact relating to the Corporation or its Subsidiaries, or other adverse material development which, in the opinion of the Agents, acting reasonably, would have a material adverse effect on the market price of the Common Shares or the marketability of the Offered Units, then the Agents shall be entitled, at their option, to terminate its obligations under this Agreement by written notice to that effect given to the Corporation at or prior to the Closing Time.

   
11.4

Disaster Out : If at any time prior to the Closing Time there should develop, occur or come into effect or existence any event, action, state, condition or occurrence of national or international consequence, including any act of terrorism, war or like event, or any law or regulation, which in the opinion of the Agents, acting reasonably, seriously adversely affects, or would seriously adversely affect the Canadian, United States or international financial markets or the business, affairs, operations, assets, liabilities (contingent or otherwise), capital or control of the Corporation and its Subsidiaries, taken as a whole, the market price of the Common Shares or the marketability of the Offered Units, the Agents shall be entitled, at their option, to terminate its obligations under this Agreement by written notice to that effect given to the Corporation at or prior to the Closing Time.

   
11.5

Market Out : If at any time prior to the Closing Time, the state of financial markets in Canada or elsewhere where it is planned to market the Offered Units is such that, in the reasonable opinion of the Agents, the Offered Units cannot be marketed profitably, the Agents shall be entitled, at their option, to terminate its obligations under this Agreement by written notice to that effect given to the Corporation at or prior to the Closing Time.

   
11.6

Regulatory and Litigation Out : If at any time prior to the Closing Time there shall occur any change in any of the Securities Laws, or if any enquiry, action, suit, investigation or other proceeding, whether formal or informal, in relation to the Corporation, its Subsidiaries or the distribution of the Offered Units should be instituted or any order under or pursuant to any laws or regulations of any of the Offering Jurisdictions or by the Stock Exchange or any other regulatory or governmental authority should be made or issued (except for any such order based upon the activities or alleged activities of the Agent and not of the Corporation) which, in the reasonable opinion of the Agents, operates to prevent or restrict the trading of the Common Shares or the distribution of the Offered Units or materially adversely affects or will materially adversely affect the market price of the Common Shares or the marketability of the Offered Units, the Agents shall be entitled, at their option, to terminate its obligations under this Agreement by written notice to that effect given to the Corporation at or prior to the Closing Time.

   
11.7

Termination Mechanics : Any termination by the Agents pursuant to the provisions of this Agreement shall be effected by notice in writing delivered or sent via fax or email to the Corporation as set forth in Section 16 . The rights of termination contained in Sections 11.1 through 11.6 are in addition to any other rights or remedies the Agents may have in respect of any default, misrepresentation, act or failure to act of the Corporation in respect of any matters contemplated by this Agreement. In the event of any such termination, there shall be no further liability on the part of the Corporation or the Agents except for any liability provided for in Sections 12 and 13 .



- 36 -

Section 12. Indemnity and Contribution

12.1

Indemnity : The Corporation hereby covenants and agrees to protect, indemnify and save harmless the Agents and each securities dealer which is a member of any Selling Dealer Group formed by the Agents in connection with the Offering, each of the associates and affiliates of each of them and the respective directors, officers, employees, shareholders, partners, advisors and agents of the Agents and each securities dealer which is a member of any Selling Dealer Group formed by the Agents in connection with the Offering and of each of the associates and affiliates of each of them (each an “ Indemnified Person ” and collectively the “ Indemnified Persons ”) from and against all losses (other than a loss of profits), claims, damages, payments, liabilities, costs, fines, penalties and expenses (including the amount paid in settlement of any claim, action, suit or proceeding and the fees and expenses of counsel on a solicitor and his own client basis incurred obtaining advice in respect of, or in investigating, defending or settling, any such claim, action, suit or proceeding), joint or several, of whatsoever nature or kind to which an Indemnified Person may become subject or otherwise involved in any capacity under statute or common law or otherwise caused or incurred by reason of or in any way arising, directly or indirectly, from, by virtue of, or related to, enforcing the provisions of this Agreement, or:

     
12.1.1

the Agents having acted as agents in respect of the Offering or the Selling Dealer Group members having acted as Selling Dealer Group members in respect of the Offering (other than by reason of the fraud, gross negligence or wilful misconduct of the Agents or the Selling Dealer Group members, provided that this exception shall only apply to the applicable Agent or Selling Dealer Group member or Selling Dealer Group members which have acted fraudulently, been grossly negligent or committed wilful misconduct);

     
12.1.2

any statement or information contained in the Information Record which at the time and in light of the circumstances under which it was made containing or being alleged to contain a misrepresentation or being or being alleged to be untrue, false or misleading;

     
12.1.3

the omission or alleged omission to state in the Information Record any material fact required to be stated therein or necessary to make any statement therein not misleading in light of the circumstances under which it was made;

     
12.1.4

any order made or inquiry, investigation or proceeding commenced or threatened by any officer or official of the Stock Exchange, any securities commission or authority or any other competent authority, not based upon the activities or the alleged activities of the applicable Agent or member of any Selling Dealer Group formed by the Agents in connection with the Offering;



- 37 -

  12.1.5

the non-compliance or alleged non-compliance by the Corporation with any of the Securities Laws of the Offering Jurisdictions or any other applicable law in connection with the transactions contemplated herein;

     
  12.1.6

any fraud, gross negligence or wilful misconduct by the Corporation relating to or connected with the sale by the Corpo ration of the Offered Units;

     
  12.1.7

any misrepresentation or alleged misrepresentation (except any made by the Agents or Selling Dealer Group members and for which the Agents did not rely on any information provided by the Corporation or anyone acting on its behalf, provided that this exception shall only apply to the applicable Agent or Selling Dealer Group member or Selling Dealer Group members who have made such misrepresentation or alleged misrepresentation) relating to the Offering or the Offered Units, whether oral or written and whether made during and in connection with the Offering or in respect of the trading of the Offered Units in the secondary market after the completion of the Offering, where such misrepresentation or alleged misrepresentation may give or gives rise to any other liability under any statute in any jurisdiction which is in force on the date of this Agreement or which comes into force after that date;

     
  12.1.8

any failure or alleged failure to make timely disclosure of a material change by the Corporation, whether such failure or alleged failure occurs during the Offering or after the completion of the Offering, where such failure relates to the Offering or the Offered Units and may give or gives rise to any liability under any statute in any jurisdiction which is in force on the date of this Agreement or which comes into force after that date; or

     
  12.1.9

the breach of, or default under, any representation, warranty, term, condition, covenant or agreement of the Corporation made or contained herein or in any other document of the Corporation delivered pursuant hereto or made by the Corporation in connection with the sale of the Offered Units or any representation or warranty of the Corporation made or contained herein or in any other document of the Corporation delivered pursuant hereto or in connection with the sale of the Offered Units being or being alleged to be untrue, false or misleading.

If any matter or thing contemplated by this Section 12 shall be asserted against any Indemnified Person in respect of which indemnification is or might reasonably be considered to be provided hereunder, such Indemnified Person shall notify the Corporation as soon as possible of the nature of such claim and the Corporation shall be entitled, but not required, to assume the defence of any action, suit or proceeding brought to enforce such claim; provided , however , that the defence shall be through legal counsel reasonably acceptable to the Indemnified Person and that no settlement may be made by the Corporation or the Indemnified Person without the prior written consent of the other of them and the Corporation shall not be liable for any settlement of any such claim unless it has consented in writing to such settlement.


- 38 -

12.2

Counsel : In any claim referred to in Section 12 , the Indemnified Person shall have the right to retain separate legal counsel to act on behalf of such Indemnified Person provided that the fees and disbursements of such separate legal counsel shall be paid by the Indemnified Person unless:

     
12.2.1

the Corporation fails to assume the defence of such claim on behalf of the Indemnified Person within ten (10) days of receiving notice of such claim;

     
12.2.2

the Corporation and the Indemnified Person shall have mutually agreed to the retention of such separate legal counsel; or

     
12.2.3

the named parties to such claim (including any added, third or impleaded parties) include both the Corporation and the Indemnified Person and the Indemnified Person has been advised by legal counsel that representation of both the Corporation and the Indemnified Person by the same legal counsel would be inappropriate due to actual or potential differing interests between them;

     

in which event or events the reasonable fees and disbursements of such separate legal counsel shall be paid by the Corporation. Where more than one Indemnified Person is entitled to retain separate counsel in the circumstances described in this Section 12.2 , all Indemnified Persons shall be represented by one separate legal counsel and the fees and disbursements of only one separate legal counsel for all Indemnified Persons shall be paid by the Corporation, unless:

     
12.2.4

the Corporation and the Indemnified Persons have mutually agreed to the retention of more than one legal counsel for the Indemnified Persons; or

     
12.2.5

the Indemnified Persons have or any of them has been advised in writing by legal counsel that representation of all of the Indemnified Persons by the same legal counsel would be inappropriate due to actual or potential differing interests between them.

     
12.3

Waiver of Right : The Corporation hereby waives its right to recover contribution from the Agents and the other Indemnified Persons with respect to any liability of the Corporation by reason of or arising out of the indemnity provided by the Corporation in this Section 12 ; provided , however , that such waiver shall not apply in respect of any Agent for any liability directly caused or incurred by reason or arising out of any fraud, gross negligence or wilful misconduct of that Agent or information or statements relating solely to, and provided by, that Agent or any failure by that Agent in connection with the Offering to provide to Purchasers any document which the Corporation is required to provide to the Purchasers and which the Corporation has provided or made available to that Agent to forward to the Purchasers.



- 39 -

12.4

Contribution :

       
12.4.1

In order to provide for just and equitable contribution in circumstances in which the indemnity contained in this Section 12 is, for any reason of policy or otherwise, held to be unavailable to or unenforceable by, in whole or in part, an Indemnified Person other than in accordance with the provisions of this Section 12 , the Corporation shall contribute forthwith to the aggregate losses (other than a loss of profit), claims, damages, payments, liabilities, costs, fines, penalties and expenses (including the amount paid in settlement of any claim, action, suit or proceeding and the fees and expenses of counsel on a solicitor and his own client basis incurred obtaining advice in respect of, or in investigating, defending or settling, any such claim, action, suit or proceeding) of the nature contemplated by such indemnity incurred or paid by the Indemnified Person in such proportion as is appropriate to reflect not only the relative benefits received by the Corporation on the one hand and the Indemnified Person on the other hand in connection with the Offering but also the relative fault of the Corporation on the one hand and the Indemnified Person on the other hand in connection with the matters, things and actions which resulted in such losses, claims, damages, payments, liabilities, costs, fines, penalties or expenses as well as any other relevant equitable considerations or, if such allocation is not permitted by applicable law, in such proportion so that the Indemnified Person shall be responsible for the proportion represented by the percentage that the Agent’s Fee per Offered Unit bears to the Purchase Price and the Corporation shall be responsible for the balance, whether or not they are a party to the same or separate claims; provided , however , that no person who has engaged in any fraud, gross negligence or wilful misconduct shall be entitled to contribution from any person who has not engaged in any fraud, gross negligence or wilful misconduct and further provided that in no event shall any Agent be responsible for any amount in excess of the portion of Agent’s Fee, however paid, actually received from the Corporation under this Agreement and retained by that Agent. For purposes of this Section 12.4 , relative fault shall be determined by reference to, among other things, whether any untrue or alleged untrue statement of a material fact or any omission or alleged omission to state a material fact relates to information supplied by the Corporation on the one hand or an Agent on the other hand and the relevant intent, knowledge, access to information and opportunity to correct or prevent any such untrue statement or omission of the Corporation and the Indemnified Person.

       
12.4.2

In the event that the Corporation is held to be entitled to contribution from an Agent under the provisions of any statute or law, the Corporation shall be limited to such contribution in an amount not exceeding the lesser of:

       
(a)

the portion of the amount of the loss or liability giving rise to such contribution for which that Agent is responsible as determined in accordance with Section 12.4.1 ; and



- 40 -

  (b)

the amount of the Agent’s Fee actually received from the Corporation under this Agreement and retained by that Agent.


12.4.3

For purposes of this Section 12.4 , each party hereto shall give prompt notice to the other parties hereto of any claim, action, suit or proceeding threatened or commenced in respect of which a claim for contribution may be made under this Section 12.4 .

     
12.5

Held in Trust : To the extent that the indemnity and right to contribution contained in Section 12 is given in favour of a person who is not a party to this Agreement, the Corporation hereby constitutes the Lead Agent as trustee for such person for such indemnity, right to contribution and the covenants given by Corporation to such person in this Agreement. The Lead Agent hereby accepts such trust and holds such indemnity, right to contribution and covenants for the benefit of such persons. The benefit of such indemnity, right to contribution and covenants shall be held by the Lead Agent in trust for the persons in favour of whom such indemnities, right to contribution and covenants are given and may be enforced directly by such persons.

     
12.6

Indemnity re Investigations : The Corporation agrees that, if any investigation is commenced in respect of the Corporation and/or an Indemnified Person and an Indemnified Person or its personnel are required to testify in connection therewith or shall be required to respond to procedures designed to discover information regarding, in connection with or by reason of the Offering, the Indemnified Person shall have the right to employ its own counsel in connection therewith, and the reasonable fees and expenses of such counsel as well as the reasonable costs (including an amount to reimburse the Indemnified Person for time spent by its personnel in connection therewith at their normal per diem rates together with such disbursements and out-of-pocket expenses incurred by the personnel in connection therewith) shall be paid by the Corporation as they occur.

     
12.7

Survival : The obligations under Section 12 shall apply whether or not the transactions contemplated by this Agreement are completed and shall survive the completion of the transactions contemplated under this Agreement and the termination of this Agreement.


Section 13. Expenses

Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, all expenses of or incidental to the issue, sale, distribution and delivery of the Offered Units and Compensation Options and of or incidental to all matters in connection with the transactions herein set out shall be borne by the Corporation including, all printing costs, filing fees, the reasonable fees and disbursements of legal counsel for the Agents (plus applicable taxes) and the reasonable out-of-pocket expenses (plus applicable taxes) of the Agents, including road show and travel expenses.

Section 14. Restrictions on Further Issues or Sales

During the period commencing the date of this Agreement and ending on the day which is ninety (90) days following the Closing Date, the Corporation will not, directly or indirectly, without the prior written consent of the Lead Agent (which consent will not be unreasonably withheld), issue, offer, sell, contract to sell, grant any option to purchase, transfer, assign or otherwise dispose of any Common Shares or any securities convertible into or exchangeable for any Common Shares, except in conjunction with: (cc) the exercise or grant in the normal course of stock options and other similar issuances pursuant to the share incentive plan of the Corporation and other share compensation arrangements outstanding as of the date hereof; or (dd) outstanding warrants, the Warrants, the Preferred Unit Shares or the Compensation Options.


- 41 -

Section 15. No Fiduciary Duty

The Corporation: (ee) acknowledges and agrees that the Agents have certain statutory obligations as registrants under applicable Securities Laws and have fiduciary relationships with their respective clients; and (ff) consents to the Agents acting hereunder while continuing to act for their respective clients. To the extent that the Agents’ statutory obligations as registrants under applicable Securities Laws or fiduciary relationships with their respective clients conflicts with their obligations hereunder, the Agents shall be entitled to fulfill their statutory obligations as registrants under applicable Securities Laws and their duties to their respective clients. Nothing in this Agreement shall be interpreted to prevent the Agents from fulfilling their statutory obligations as registrants under applicable Securities Laws or to act as fiduciaries of their respective clients.

Section 16. Notices

Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be personally delivered or sent by facsimile on a Business Day to the following addresses:

16.1

in the case of the Corporation:


  Stem Cell Therapeutics Corp.
  96 Skyway Avenue
  Toronto, Ontario M9W 4Y9
  Attention: Dr. Niclas Stiernholm, President & CEO
  E-mail: niclas@stemcellthera.com
     
  with a copy (which copy shall not constitute notice) to:
     
  Borden Ladner Gervais LLP
  Scotia Plaza  
  40 King Street West, 44th Floor
  Toronto, Ontario M5H 3Y4
     
  Attention: Manoj Pundit
  Email: mpundit@blg.com
  Fax: 416-682-2841


- 42 -

(b)

in the case of the Agents:


  Bloom Burton & Co. Inc.
  65 Front Street East
  Suite 300  
  Toronto, Ontario M5E 1B5
     
  Attention: Jolyon Burton, CEO & Head of Investment Banking
  Email: jburton@bloomburton.com
  Fax: 416-640-7580
     
  ROTH Capital Partners, LLC
  888 San Clemente Drive
  Suite 400  
  Newport Beach, CA 92660
     
  Attention: Michael Margolis, R.Ph., Managing Director
  Email: mmargolis@roth.com
  Fax: 949-720-7227
     
  with a copy (which copy shall not constitute notice) to:
     
  Gowling Lafleur Henderson LLP
  Suite 1600,  
  100 King Street West
  1 First Canadian Place
  Toronto, Ontario M5X 1G5
     
  Attention: Vanessa Grant
  Email: vanessa.grant@gowlings.com
  Fax: 416-862-7661

The parties may change their respective addresses for notices by notice given in the manner set out above. Any notice or other communication will be in writing, and unless delivered personally to the addressee or to a responsible officer of the addressee, as applicable, will be given by fax or email and will be deemed to have been given when (i) in the case of a notice delivered personally to a responsible officer of the addressee, when so delivered; and (ii) in the case of a notice delivered or given by fax, on the first (1st) Business Day following the day on which it is sent.

Section 17. Miscellaneous

17.1

Governing Law : This Agreement shall be governed by and be interpreted in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein and the parties hereto irrevocably attorn to the jurisdiction of the courts of such province.

   
17.2

Time of Essence : Time shall be of the essence of this Agreement.



- 43 -

17.3

Survival : Except for as expressly provided herein, all representations, warranties, covenants and agreements of the Corporation herein contained or contained in any documents contemplated by, or delivered pursuant to, this Agreement or in connection with the purchase and sale of the Offered Units shall survive the purchase and sale of the Offered Units and the termination of this Agreement and shall continue in full force and effect for the benefit of the Agents, regardless of any subsequent disposition of Offered Units or any investigation by or on behalf of the Agents with respect thereto.

   
17.4

Counterparts : This Agreement may be executed by any one or more of the parties to this Agreement by fax, email or in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement.

   
17.5

Entire Agreement : This Agreement and all agreements, documents and instruments delivered in connection herewith constitutes the entire agreement between the Corporation and the Agents in connection with the issue and sale of the Offered Units by the Corporation and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, including, but not limited to, the Engagement Letter.

   
17.6

Severability : If any provision of this Agreement is determined to be void or unenforceable in whole or in part, it shall be deemed not to affect or impair the validity of any other provision of this Agreement and such void or unenforceable provision shall be severed from this Agreement.

   
17.7

Assignment and Enurement : The terms and provisions of this Agreement will be binding upon and enure to the benefit of the Corporation and the Agents and their respective successors and assigns; provided that , except as otherwise provided in this Agreement, this Agreement will not be assignable by any party without the written consent of the other and any purported assignment without that consent will be invalid and of no force and effect.

   
17.8

Reference to Agents : Upon the request of any Agent, the Corporation will include a reference to that Agent and its role in any press release or other public communication issued by the Corporation relating to the Offering. If the Offering is successfully completed, the Agents will be permitted to publish, at their own expense, such advertisements or announcements relating to the services provided hereunder in such newspaper or other publications as the Agents consider appropriate.

[signature pages follow]


- S-1 -

If the foregoing is in accordance with your understanding and is agreed to by you, please signify your acceptance by executing the enclosed copies of this letter where indicated below and returning them to the Lead Agent, upon which this letter as so accepted shall constitute an agreement among us.

Yours very truly,

  BLOOM BURTON & CO. INC.
     
     
  Per: Jolyon Burton ” (Signed)
    Authorized Signatory
       
   
  ROTH CAPITAL PARTNERS, LLC
     
     
  Per: Aaron Gurewitz ” (Signed)
    Authorized Signatory


- S-2 -

The foregoing is accepted and agreed to as of the date first above written.

Yours very truly,

  STEM CELL THERAPEUTICS CORP.
       
       
  Per: Niclas Stiernholm ” (signed)
    Name: Dr. Niclas Stiernholm
    Title: President & CEO


APPENDIX A
FORM OF U.S. CERTIFICATE

In connection with the private placement in the United States or to, or for the account or benefit of, persons in the United States or U.S. Persons of the Offered Units of Stem Cell Therapeutics Corp. (the “ Issuer ”) pursuant to the agency agreement dated as of December 13, 2013, between the Issuer and the Agents named therein (the “ Agency Agreement ”), the undersigned • (the “ U.S. Agent ”) does hereby certify that:

1.1

the Offered Securities have been offered in the United States or to, or for the account or benefit of, persons in the United States or U.S. Persons only by the U.S. Agent which (i) is, and was on the date of each offer and sale of Offered Securities in the United States or to, or for the account or benefit of, persons in the United States or U.S. Persons, duly registered as a broker-dealer pursuant to Section 15(b) of the 1934 Act and under the laws of each state in which such offer or sale was made (unless exempted from the respective state’s broker-dealer registration requirements), and is a member of, and in good standing with, the Financial Industry Regulatory Authority, Inc., and (ii) effected all offers and sales of such Offered Securities in accordance with all U.S. federal and state broker-dealer requirements;

   
1.2

it acknowledges the Offered Securities have not been and will not be registered under the 1933 Act or any applicable state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, persons in the United States or U.S. Persons except pursuant to an available exemption from the registration requirements of the 1933 Act and applicable state securities laws and as permitted under the terms and conditions of the Agency Agreement;

   
1.3

neither it nor its representatives have utilized, and neither it nor its representatives will utilize, any form of General Solicitation or General Advertising in connection with the offer and sale of the Offered Securities in the United States to, or for the account or benefit of, persons in the United States or U.S. Persons;

   
1.4

neither it nor any Related Person is subject to any Bad Actor Disqualification;

   
1.5

it has complied with the disclosure requirements of Rule 506(e) of Regulation D, to the extent applicable;

   
1.6

each purchaser of the Offered Securities that was offered the Offered Securities in the United States or is a U.S. Person, or acting for the account or benefit of a person in the United States or a U.S. Person, has executed a U.S. Subscription Agreement, and each other purchaser has executed a Non-U.S. Subscription Agreement and it has not used and will not use any written material other than the Subscription Agreements;

   
1.7

immediately prior to transmitting any of the foregoing materials to offerees, it had reasonable grounds to believe and did believe that each offeree purchasing Offered Units that was in the United States or a U.S. Person, or acting for the account or benefit of a person in the United States or a U.S. Person, was an Accredited Investor and, on the date hereof, it continues to believe that each such offeree is an Accredited Investor; and



-A-2-

1.8

the offering of the Offered Securities has been conducted by it in accordance with the Agency Agreement.

Terms used in this certificate have the meanings given to them in the Agency Agreement unless otherwise defined herein.

DATED as of this ___ day of December, 2013.

Per:  
  Name:  
  Title:  


APPENDIX B
FORM OF OPINION OF CORPORATION’S CANADIAN COUNSEL

Section 1 Form of Opinion

The opinion of the Corporation’s corporate counsel shall be in respect of the following matters, in a form satisfactory to the Agents and their counsel, acting reasonably:

1.1

The Corporation is continued under the laws of the Province of Ontario and has not been dissolved.

     
1.2

The Corporation has the corporate power and capacity to carry on its business, to own and lease its property and assets, in each case as described in its annual information form dated September 19, 2013 (the “ Annual Information Form ”), to enter into and perform its obligations under the Agreement and Ancillary Documents and to create and issue the Offered Securities as contemplated by the Agreement.

     
1.3

The execution and delivery by the Corporation of each of the Agreement and the Ancillary Documents and the performance by it of its obligations thereunder have been duly authorized by all necessary corporate action on the Corporation’s part.

     
1.4

The Corporation has duly executed and delivered each of the Agreement and the Ancillary Documents. Each of the Agreement and Ancillary Documents constitutes a legal, valid and binding obligation of the Corporation, enforceable against it in accordance with its terms.

     
1.5

The execution and delivery by the Corporation of each of the Agreement and Ancillary Documents and the performance by it of its obligations thereunder do not and will not breach any provisions of, or constitute a default under:

     
1.5.1

its articles or by-laws;

     
1.5.2

any law of the Province of Ontario or federal law of Canada applicable therein to which it is subject; or

     
1.5.3

the Rights Agreement dated as of September 16, 2013 between the Corporation and Computershare Trust Company of Canada as Rights Agent.

     
1.6

Trillium Therapeutics Inc. is a corporation that is incorporated under the laws of the Province of Ontario and has not been dissolved. Trillium Therapeutics Inc. has the corporate power and capacity to carry on its business and to own and lease its property and assets, in each case as described in the Annual Information Form.

     
1.7

All of the issued and outstanding shares in the capital of Trillium Therapeutics Inc. are registered in the name of the Corporation.

     
1.8

The authorized capital of the Corporation consists of an unlimited number of Common Shares, an unlimited number of Class B Shares and an unlimited number of First Preferred Shares, of which • Common Shares, no Class B Shares and no First Preferred Shares were outstanding as of the close of business on [insert date prior to Closing Date] .



-B-2-

1.9

The Corporation has taken all necessary corporate action to authorize the issue of the Unit Shares and, upon receipt by the Corporation of the consideration for the Units, the Unit Shares will be validly issued as fully paid Common Shares.

   
1.10

The Corporation has taken all necessary corporate action to authorize the issue of the Preferred Unit Shares and, upon receipt by the Corporation of the consideration for the Preferred Units, the Preferred Unit Shares will be validly issued as fully paid Preferred Shares.

   
1.11

The Corporation has taken all necessary corporate action to authorize the creation and issue of the Warrants and, upon receipt by the Corporation of the consideration for the Offered Units, the Warrants will be validly created and issued.

   
1.12

The Corporation has taken all necessary corporate action to authorize the issue of the Warrant Common Shares and, upon payment of the exercise price therefor, in accordance with their terms and the Warrant Indenture, the Warrant Common Shares will be validly issued as fully paid Common Shares.

   
1.13

The Corporation has taken all necessary corporate action to authorize the issue of the Preferred Unit Common Shares and, upon conversion of the Preferred Unit Shares, in accordance with their terms and the articles of the Corporation, the Preferred Unit Common Shares will be validly issued as fully paid Common Shares.

   
1.14

The Corporation has taken all necessary corporate action to authorize the creation and issue of the Compensation Options and, upon issue thereof in accordance with the terms of the Agreement, the Compensation Options will be validly created and issued to the Agents.

   
1.15

The Corporation has taken all necessary corporate action to authorize the issue of the Compensation Option Shares and, upon payment of the exercise price therefor in accordance with the terms of the Compensation Options, the Compensation Option Shares will be validly issued as fully paid Common Shares.

   
1.16

The issue and sale of the Offered Securities by the Corporation through the Lead Agent to the Purchasers in the Offering Jurisdictions in Canada and the issue of the Compensation Options by the Corporation to the Lead Agent in the Offering Jurisdictions in Canada is exempt from the prospectus requirements of securities laws and the only filing, proceeding, authorization, consent, permit or approval required to be obtained, taken or made under securities laws is the filing by the Corporation with the applicable Securities Commissions of a report prepared in accordance with Form 45-106F1 (or in British Columbia, a Form 45-106F6) to National Instrument 45-106 – Prospectus and Registration Exemptions and completed, executed and filed in accordance with securities laws within 10 days after the date hereof together with the payment of applicable fees.



-B-3-

1.17

No prospectus is required nor are any other documents, proceedings, or approvals, permits, consents or authorizations of regulatory authorities required to be filed, taken or obtained (other than those which have been filed, taken or obtained) under the securities laws to permit the issuance by the Corporation of the Preferred Unit Common Shares, Warrant Common Shares and Compensation Option Shares in the Offering Jurisdictions in Canada upon the conversion of the Preferred Unit Shares or exercise of the Warrants or Compensation Options, respectively, in accordance with their respective terms and in accordance with Subscription Agreements and the TSXV Approval Letter, and the articles of the Corporation, the Warrant Indenture or the Compensation Options, as applicable.

     
1.18

The first trade in the Unit Shares, Preferred Unit Shares, Warrants, Preferred Unit Common Shares, Warrant Common Shares and Compensation Option Shares, other than a trade that is otherwise exempt from the prospectus requirements of applicable securities laws, will be a distribution and subject to the prospectus requirements of applicable securities laws unless:

 
1.18.1

at the time of the trade, the Corporation is and has been a “reporting issuer”, as defined in the securities laws, in a jurisdiction of Canada for the four months immediately preceding the trade;

     
1.18.2

at the time of the trade, at least four months have elapsed from the date hereof;

     
1.18.3

the certificate representing the Unit Shares, Preferred Unit Shares, Warrants, Preferred Unit Common Shares, Warrant Common Shares, the Compensation Options and Compensation Option Shares, as applicable, carries a legend, or if the security is entered into a direct registration system or other electronic book-entry system, or if the purchaser did not directly receive a certificate representing the security, the purchaser received written notice containing a legend restriction notation as set out in Section 2.5(2)3(i) of National Instrument 45-102 – Resale of Securities (“ NI 45-102 ”);

     
1.18.4

such trade is not a “control distribution” within the meaning of NI 45-102;

     
1.18.5

no unusual effort is made to prepare the market or create a demand for the Unit Shares, Preferred Unit Shares, Warrants, Preferred Unit Common Shares, Warrant Common Shares, Compensation Options or Compensation Option Shares that are the subject of the trade;

     
1.18.6

no extraordinary commission or consideration is paid to a person or company in respect of the trade; and

     
1.18.7

if the selling security holder is an insider or officer of the Corporation, the selling security holder has no reasonable grounds to believe that the Corporation is in default of applicable securities legislation.



-B-4-

1.19

Subject to satisfying the conditions set out in the TSXV Approval Letter issued by the Exchange on December •, 2013, the Unit Shares, Preferred Unit Common Shares, Warrant Common Shares and Compensation Option Shares have been conditionally approved for listing on the Exchange.



APPENDIX C
FORM OF OFFICERS’ CERTIFICATE

Section 1 Form of Officers’ Certificate

The undersigned, Niclas Stiernholm, Chief Executive Officer of Stem Cell Therapeutics Corp. (the “ Corporation ”), and James Parsons, Chief Financial Officer of the Corporation, hereby certify, for and on behalf of the Corporation in their capacity as officers of the Corporation and not in their personal capacity, after having made due inquiry, that the following facts, matters and information are true and accurate and not misleading in any material respect:

1.1

The facts, matters and information certified herein are based on one or more of knowledge and information available or provided to us and our honest belief and all statements made in this certificate represent our reasonably held honest belief as to the facts, matters, information and belief possessed by us. We have used our best efforts to become informed of and about the facts, matters and information certified to herein and have sought the advice of counsel for the Corporation on those matters certified to herein which involve matters of law and have relied upon such advice to the extent that those matters involve matters of law.

   
1.2

The Corporation has complied with all covenants and agreements contained in, and has satisfied all of the terms and conditions of, the Agency Agreement to be complied with and satisfied by the Corporation at or prior to the Closing Time.

   
1.3

The representations and warranties of the Corporation contained in the Agency Agreement are true and correct as of the Closing Time with the same force and effect as if made at and as of the Closing Time after giving effect to the transactions contemplated thereby.

   
1.4

Since December 31, 2012, except as disclosed in the Information Record, there has been no material adverse change (whether actual, anticipated, proposed, prospective or threatened) in the financial condition, assets, liabilities (contingent or otherwise), business, affairs, operations, prospects or capital of the Corporation.

   
1.5

Except as disclosed in the Information Record, no transaction of a nature material to the Corporation has been entered into by the Corporation.

   
1.6

Except as disclosed in the Information Record, there are no contingent liabilities affecting the Corporation which are material to the Corporation.

   
1.7

No order, ruling or determination having the effect of ceasing or suspending the sale or ceasing, suspending or restricting trading in the Offered Units, the Common Shares or any other securities of the Corporation has been issued or made by any stock exchange, securities commission or other regulatory authority and is continuing in effect and no proceedings, investigations or enquiries for such purpose have been instituted or are pending, or are contemplated or threatened under any of the Securities Laws of the Offering Jurisdictions or by any stock exchange (including the Stock Exchange), securities commission or other regulatory authority.



-C-2-

1.8

There are no actions, suits, proceedings or enquiries pending or, to the best of our knowledge, threatened, against or affecting the Corporation or to which any property or assets of the Corporation is subject, at law or in equity, or before or by any federal, provincial, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, which may, in any way, materially and adversely affect the Corporation.

   
1.9

No failure or default on the part of the Corporation exists under any law or regulation applicable to the Corporation or under any licence, permit, contract, agreement or other instrument to which the Corporation is a party or by which the Corporation is bound, which may in any way materially and adversely affect the Corporation and the execution, delivery and performance of the Agency Agreement and the performance by the Corporation of its obligations thereunder will not result in any such default.

   
1.10

This certificate is being made and delivered pursuant to Section 6.2.5 of the Agency Agreement and we acknowledge that the addressees hereof will be relying on this certificate.

   
1.11

Unless otherwise defined herein, all words and terms with the initial letter or letters thereof capitalized in this certificate and not defined herein but defined in the Agency Agreement shall have the meanings given to such capitalized words and terms in the Agency Agreement. The undersigned acknowledge that they are familiar with the definitions given to the capitalized words and terms in the Agency Agreement and such definitions are hereby incorporated by reference.



SCHEDULE 9.1.5
SECURITIES CONVERTIBLE INTO COMMON SHARES

Warrants Number of securities
outstanding
Exercise Price Expiration
Common Share Purchase Warrants 909,091 $1.60 March 24, 2014
Compensation Warrants 814,050 $0.25 March 16, 2015
Common Share Purchase Warrants 17,215,000 $0.40 March 15, 2018
Common Share Purchase Warrants 420,000 $0.40 March 28, 2018
Total Warrants 19,358,141  

Options Number of securities
outstanding
Weighted Average
Exercise Price
Common Share Options 2,921,097 $0.33



Exhibit 15.1

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” and to the use of our reports dated March 27, 2014 and April 29, 2013 with respect to the financial statements of Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) in the Registration Statement on Form 20-F for the registration of common shares of Trillium Therapeutics Inc.

 

  /s/ Ernst & Young LLP
Toronto, Canada Chartered Accountants
August 12, 2014 Licensed Public Accountants
 



Exhibit 15.2

Consent of Independent Auditors

We consent to the reference to our firm under the caption “Experts” and to the use of our report dated September 27, 2012 (except Note 16 as to which the date is August 12, 2014) with respect to the financial statements of Trillium Therapeutics Inc. in the Registration Statement on Form 20-F for the registration of common shares of Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.).

 

  /s/ Ernst & Young LLP
Toronto, Canada Chartered Accountants
August 12, 2014 Licensed Public Accountants